<SEC-DOCUMENT>0001641172-25-000208.txt : 20250324
<SEC-HEADER>0001641172-25-000208.hdr.sgml : 20250324
<ACCEPTANCE-DATETIME>20250324083038
ACCESSION NUMBER:		0001641172-25-000208
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250324
DATE AS OF CHANGE:		20250324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39717
		FILM NUMBER:		25762332

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:LIXT="http://lixte.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_LIXT_lixte.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001335105 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001335105</ix:nonNumeric>
  <ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2024-12-31" id="xdx2ixbrl0083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0119" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781" id="xdx2ixbrl0701" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781" id="xdx2ixbrl0703" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781" id="xdx2ixbrl0705" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781" id="xdx2ixbrl0707" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812" id="xdx2ixbrl0713" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812" id="xdx2ixbrl0715" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812" id="xdx2ixbrl0717" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812" id="xdx2ixbrl0719" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812" id="xdx2ixbrl0721" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812" id="xdx2ixbrl0723" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl1161" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl1162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1193" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1195" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember" id="xdx2ixbrl1400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember" id="xdx2ixbrl1420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member" id="xdx2ixbrl1432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lixt-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-022023-06-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-02</xbrli:startDate>
        <xbrli:endDate>2023-06-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-19_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PurchasersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-11</xbrli:startDate>
        <xbrli:endDate>2025-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VendorAndConsultantMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ClinicalAndRelatedOversightCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalAndRelatedOversightCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PreclinicalResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PreclinicalResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RegulatoryServiceCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RegulatoryServiceCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LIXT:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LIXT:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-03-16</xbrli:startDate>
        <xbrli:endDate>2015-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UndesignatedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_UndesignatedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember24649234">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember24649234">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-092023-03-10_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-09</xbrli:startDate>
        <xbrli:endDate>2023-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-092023-03-10_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-09</xbrli:startDate>
        <xbrli:endDate>2023-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-10_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-192023-07-20_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-19</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-07_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-242023-08-07_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-24</xbrli:startDate>
        <xbrli:endDate>2023-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-19</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_PlacementAgentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-192023-07-20_custom_PlacementAgentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-19</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-07_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-07_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-02_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SchellensMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NewIndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_DirectorMember24650984">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_DirectorMember24650984">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-13</xbrli:startDate>
        <xbrli:endDate>2020-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-06</xbrli:startDate>
        <xbrli:endDate>2022-10-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-26</xbrli:startDate>
        <xbrli:endDate>2023-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-13</xbrli:startDate>
        <xbrli:endDate>2020-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-10</xbrli:startDate>
        <xbrli:endDate>2021-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-282021-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-28</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-28</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-16</xbrli:startDate>
        <xbrli:endDate>2022-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-302022-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-30</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-30</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-302023-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-30</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-30</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-252023-09-26_custom_MrvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-25</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-302024-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-30</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-302024-06-30_custom_FourNonOfficerDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-30</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-30</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-07-01_custom_SchellensMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-07-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-01_custom_SchellensMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SchellensMember24651765">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-302024-09-30_custom_FourNonOfficerDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-30</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-30</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-202025-01-20_custom_FourNonOfficerDirectorMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-20</xbrli:startDate>
        <xbrli:endDate>2025-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-20</xbrli:startDate>
        <xbrli:endDate>2025-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialMonitoringAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-072024-07-08_custom_ClinicalResearchSupportAgreementMember_custom_CityOfHopeNationalMedicalCenterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-07</xbrli:startDate>
        <xbrli:endDate>2024-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-11_us-gaap_SubsequentEventMember_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ClinicalTrialResearchMonitoringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember_custom_MDAndersonCancerCenterClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MDAndersonCancerCenterClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ClinicalTrialMonitoringAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-04</xbrli:startDate>
        <xbrli:endDate>2021-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-252023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-25</xbrli:startDate>
        <xbrli:endDate>2023-08-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-232024-02-23_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-23</xbrli:startDate>
        <xbrli:endDate>2024-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-23_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2030-01-31_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2030-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-30_custom_LicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-12-23</xbrli:startDate>
        <xbrli:endDate>2013-12-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-09-12</xbrli:startDate>
        <xbrli:endDate>2015-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-04_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-14</xbrli:startDate>
        <xbrli:endDate>2025-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-14</xbrli:startDate>
        <xbrli:endDate>2025-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-14</xbrli:startDate>
        <xbrli:endDate>2025-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-14</xbrli:startDate>
        <xbrli:endDate>2025-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialRandomizedPhaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-14</xbrli:startDate>
        <xbrli:endDate>2025-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialRandomizedPhaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseMD1b2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-14</xbrli:startDate>
        <xbrli:endDate>2025-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseMD1b2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-06_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:WallachBethCapitalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-062025-01-06_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:WallachBethCapitalLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-06</xbrli:startDate>
        <xbrli:endDate>2025-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-072025-03-07_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:WallachBethCapitalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-07</xbrli:startDate>
        <xbrli:endDate>2025-03-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PurchasersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-11</xbrli:startDate>
        <xbrli:endDate>2025-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PurchasersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PurchasersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-11</xbrli:startDate>
        <xbrli:endDate>2025-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>LIXT:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>LIXT:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl1400" toRefs="Footnote001435"/>
  <ix:relationship fromRefs="xdx2ixbrl1420" toRefs="Footnote001435"/>
  <ix:relationship fromRefs="xdx2ixbrl1432" toRefs="Footnote001435"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20240101__20241231_zu0UmZOWuuMc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000014" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--DocumentAnnualReport_c20240101__20241231_zR9a3N3WdbD7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the fiscal year ended <span id="xdx_909_edei--DocumentPeriodEndDate_c20240101__20241231_zc8hBj9ugf11"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate"><span id="xdx_906_edei--CurrentFiscalYearEndDate_c20240101__20241231_zx9TqSX4Htl2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000017" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90D_edei--DocumentFiscalYearFocus_c20240101__20241231_z556Gh1AMnS5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--DocumentTransitionReport_c20240101__20241231_z5hBuOIomyKe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the transition period from ______ to ______</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityFileNumber_c20240101__20241231_zVLZNbhYDsnj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000020" name="dei:EntityFileNumber">001-39717</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20240101__20241231_zUtWPIpOS6sk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityRegistrantName">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zYYR26O8iDUf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000022" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20240101__20241231_zDHM568YMvZ1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityTaxIdentificationNumber">20-2903526</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20240101__20241231_zMybxxAY7Ls4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressAddressLine1">680
    East Colorado Boulevard</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20240101__20241231_zJ4ukTRZUgTf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressAddressLine2">Suite 180</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20240101__20241231_z4qZYiGD82vd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressCityOrTown">Pasadena</ix:nonNumeric></span>,
    <span id="xdx_903_edei--EntityAddressStateOrProvince_c20240101__20241231_zUJ1kBU6cJgf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000027" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressPostalZipCode_c20240101__20241231_zE0AxRrcLnH2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">91101</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number: <b><span style="text-decoration: underline">(<span id="xdx_904_edei--CityAreaCode_c20240101__20241231_z643Y8H39dtd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:CityAreaCode">631</ix:nonNumeric></span>) <span id="xdx_906_edei--LocalPhoneNumber_c20240101__20241231_zm58nwImiZx1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:LocalPhoneNumber">830-7092</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act: Common Stock, $0.0001 par value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zHG2zTSI0gw8"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember" id="Fact000031" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zY0OkcTtJRt5"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember" id="Fact000032" name="dei:TradingSymbol">LIXT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_907_edei--SecurityExchangeName_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zICsvewrvmP7"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000033" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zS45okWWIwu8"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" id="Fact000034" name="dei:Security12bTitle">Warrants
    to Purchase Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_z19CC758G1ai"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" id="Fact000035" name="dei:TradingSymbol">LIXTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_908_edei--SecurityExchangeName_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zIgLuXRPV2v"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000036" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_90E_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zeng6T7vxy97"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000037" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes &#9744; <span id="xdx_903_edei--EntityVoluntaryFilers_c20240101__20241231_zItfIeIcjbE9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000038" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90D_edei--EntityCurrentReportingStatus_c20240101__20241231_zHll2vDOrpD4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000039" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20240101__20241231_zaaGztoI3FS1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000040" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting,
or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityFilerCategory_c20240101__20241231_z9FAiWGsygJ1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000041" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntitySmallBusiness_c20240101__20241231_zifKKvJe0I1l"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000042" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20240101__20241231_z4hW0RLYrdjb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90F_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zqRciAAAQJHi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_909_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zDazLQpCxDEc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000045" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; No <span id="xdx_903_edei--EntityShellCompany_dbF_c20240101__20241231_zBdNqCcJPVth"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000046" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2024 was approximately $<span id="xdx_904_edei--EntityPublicFloat_iI_c20240630_zBX4AS2twZ8g"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-30" id="Fact000047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,195,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20250314_z1O0lGprX5Zk"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-14" id="Fact000048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,684,074</ix:nonFraction></span> shares of common stock issued and outstanding as of March 14, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents
incorporated by reference: <span id="xdx_90D_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_z7E4FGlvZuia"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000049" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">TABLE
OF CONTENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page
    Number</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">BUSINESS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">RISK FACTORS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">16</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">UNRESOLVED STAFF COMMENTS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">CYBERSECURITY</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">PROPERTIES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">LEGAL PROCEEDINGS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">54</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">MINE SAFETY DISCLOSURES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">54</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">PART II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">RESERVED</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">76</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">76</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">CONTROLS AND PROCEDURES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">76</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">OTHER INFORMATION</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">78</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9C. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">78</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">PART III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">EXECUTIVE COMPENSATION</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">84</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">95</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">96</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">97</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">PART IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">98</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">98</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_027">FORM 10-K SUMMARY</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">98</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_028">INDEX TO EXHIBITS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">99</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_029">SIGNATURES</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">103</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_030">CONSOLIDATED FINANCIAL STATEMENTS</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-1</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introductory
Comment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Annual Report on Form 10-K, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; &#8220;Lixte,&#8221;
the &#8220;Company&#8221; and the &#8220;Registrant&#8221; refer to Lixte Biotechnology Holdings, Inc., a Delaware corporation, and Lixte
Biotechnology, Inc., a Delaware corporation, our wholly-owned subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (the &#8220;Report&#8221;) contains certain forward-looking statements. For example, statements regarding
our financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about
future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements
are generally accompanied by words such as &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;potential(ly),&#8221; &#8220;continue,&#8221; &#8220;forecast,&#8221; &#8220;predict,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect&#8221; or the negative of such terms
or other comparable terminology. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable,
based on information available to us on the date hereof, but we cannot assure you that these assumptions and expectations will prove
to have been correct or that we will take any action that we may presently be planning. However, these forward-looking statements are
inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected
or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
to, regulatory policies, competition from other similar businesses, and market and general policies, competition from other similar businesses,
and market and general economic factors. This discussion should be read in conjunction with the consolidated financial statements and
notes thereto included in this Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results
may vary materially from what we project. Any forward-looking statement you read in this Report reflects our current views with respect
to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations,
growth strategy, and liquidity. All subsequent forward-looking statements attributable to us or individuals acting on our behalf are
expressly qualified in their entirety by this paragraph. You should specifically consider the factors identified in this Report, which
would cause actual results to differ before making an investment decision. We are under no duty to update any of these forward-looking
statements after the date of this Report or to conform these statements to actual results.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and
commercializing cancer therapies. The Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A,
which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company believes that
inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The Company is focusing on the
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that the mechanism by which LB-100 affects cancer cell growth is different from cancer agents currently approved for
clinical use. LB-100 is currently being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable
(MSS) Colon Cancer, and Advanced Soft Tissue Sarcoma. LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme,
neuroblastoma, and medulloblastoma, all cancers of neural tissue. LB-100 has also been shown to enhance the effectiveness of commonly
used anti-cancer drugs in animal models of melanoma, breast cancer and sarcoma. The enhancement of anti-cancer activity of these anti-cancer
drugs occurs at doses of LB-100 that do not significantly increase toxicity in animals. It is therefore hoped that, when combined with
standard anti-cancer regimens against many tumor types, LB-100 will improve therapeutic benefit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment
at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, the Company has allocated resources
to expand the breadth and depth of its patent portfolio. The Company&#8217;s approach has been to operate with a minimum of overhead,
moving compounds forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain
milestones are reached. The Company&#8217;s longer-term objective is to secure one or more strategic partnerships or licensing agreements
with pharmaceutical companies with major programs in cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic access to equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
cancer patients are treated with either chemotherapy or immunotherapy or both. These therapies often have limited benefit and there is
a high unmet medical need to enhance their effects. In many preclinical models we have shown that LB-100 enhances the effect of both
chemotherapy and Immunotherapy</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: Red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-100,
a small molecule potent inhibitor of PP2A, was designed and developed by us. Numerous preclinical studies have documented that LB-100
potentiates most if not all anti-cancer drugs that damage DNA. LB-100 is not associated with any increase in cytotoxicity when given
with cytotoxic drugs. This synergy involves transient interruption of several DNA damage repair pathways by LB-100 and an increase in
cell division rate. LB-100 has FDA Investigational New Drug status in the US and Investigational Medicinal Product Dossier approval in
the European Union.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its initial Phase 1 clinical trial, LB-100 given alone daily for 3 days was non-toxic, except for a transient increase in serum creatinine
believed to be caused by inhibition of PP2A in the renal tubules. In the Phase 1 clinical trial, the Maximum Tolerated Dose (&#8220;MTD&#8221;)
was 2.33mg/m2 daily for 3 days every 3 weeks. Of the 25 patients with heavily-treated advanced solid tumors with measurable disease,
3 patients had stable disease for 2 cycles, 3 patients had stable disease for 4 cycles, and 3 patients had stable disease for 6 cycles.
One patient with pancreatic cancer had a partial response after 12 cycles lasting 534 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
doses of LB-100 have now been shown to enhance immune checkpoint inhibition (&#8220;ICI&#8221;) by several different mechanisms affecting
the tumor compartment and immune T-cell compartment. LB-100 increases CD8+T-cell infiltration and CD8-Treg ratio, CD8+T-cell proliferation,
and cytokine production induces microsatellite instability, neoantigen production and immune responsiveness, converting immunologically
&#8220;cold&#8221; to &#8220;hot&#8221; cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt="" style="height: 398px; width: 400px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ovarian
clear cell carcinoma patients with inactivating mutations in PPP2R1A, a gene coding for a scaffold component of PP2A, and treated with
immune checkpoint inhibitors, were recently found to have markedly longer survival than patients without the mutation in their cancers.
Retrospective reviews of patients with a variety of cancers treated with ICI or chemotherapy show much longer survival of ICI-treated
patients with a PPP2R1A mutation in their tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt="" style="height: 339px; width: 450px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the observations in ovarian clear cell carcinoma, we have initiated a clinical trial in this disease combining LB-100 with a monoclonal
antibody blocking PD-1, a protein found on T-cells (NCT06065462).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
these preclinical and clinical observations, it is likely that LB-100 may be a general way to enhance immunotherapy responses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: Red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt="" style="height: 204px; width: 800px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research on the LB-100 series was initiated in 2006 under a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with
the National Institute of Neurologic Disorders and Stroke or NINDS of the National Institutes of Health or NIH dated March 22, 2006 that
was subsequently extended through a series of amendments until it terminated on April 1, 2013.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also designed and developed the LB-200 series, which consists of histone deacetylase inhibitors (HDACi). LB-200 has not advanced
to the clinical stage and would require additional capital to fund further development. Accordingly, because of our focus on the clinical
development of LB-100 and analogs for cancer therapy as described below in more detail, we have decided not to actively pursue the preclinical
development of our LB-200 series of compounds at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trial Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spanish
Sarcoma Group Collaboration Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 31, 2019, we entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group
(Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a study entitled &#8220;Randomized
phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma&#8221;. The purpose of
this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined with doxorubicin in soft tissue
sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;). Doxorubicin
alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. We agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as well as to
provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over a period of
two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended Phase 2 dose
of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase 2 portion of
the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from any cause)
of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a
statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, we announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos y Productos
Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, our lead clinical compound, plus doxorubicin,
versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS). Consequently, this clinical
trial commenced during the quarter ended June 30, 2023 and to be completed and a report prepared by December 31, 2026. In April 2023,
GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n Jim&#233;nez D&#237;az University
Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment phase of the Phase 1b portion of the protocol
was completed during the quarter ended September 30, 2024. We expect to have data on toxicity and preliminary efficacy from this portion
of the clinical trial during the quarter ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, the Company entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved
the Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $3,095,000. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
Research Support Agreement Relating to Small Cell Lung Cancer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had executed a Clinical Research Support Agreement with the City of Hope National Medical Center to carry out a Phase 1b clinical trial
of LB-100 combined with an FDA-approved standard regiment for treatment of untreated extensive-stage disease small cell lung cancer.
The clinical trial was initiated on March 9, 2021. However, due to the lack of patient accrual, the Company provided notice to the City
of Hope National Medical Center of the Company&#8217;s intent to terminate the Clinical Research Support Agreement effective as of July
8, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MD
Anderson Cancer Center Clinical Trial</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2023, we announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to
a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab-gxly, may enhance
the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). The clinical trial is being
sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and is being conducted at The University of
Texas - MD Anderson Cancer Center. We are providing LB-100 and GSK is providing dostarlimab-gxly and financial support for the clinical
trial. On January 29, 2024, we announced the entry of the first patient into this clinical trial. We currently expect that this clinical
trial will be completed by December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, we announced that we had added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&#8217;s proprietary compound LB-100 with GSK&#8217;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands
Cancer Institute Clinical Trial</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 10, 2024, we entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (&#8220;NKI&#8221;) to conduct a Phase
1b clinical trial of the Company&#8217;s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary
molecule of F. Hoffman-La Roche Ltd. (&#8220;Roche&#8221;), for patients with microsatellite stable metastatic colon cancer. Under the
agreement, we will provide our lead clinical compound, LB-100, and under a separate agreement between NKI and Roche, Roche will provide
atezolizumab and financial support for the clinical trial. We have no obligation to and will not provide any reimbursement of clinical
trial costs. Pursuant to the agreement and the protocol set forth in the agreement, the clinical trial will be conducted by NKI at NKI&#8217;s
site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and NKI will be responsible for the recruitment of patients. The
agreement provides for the protection of the respective intellectual property rights of each of Lixte, NKI and Roche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&#8217;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. Patient accrual is expected to take up to 24 months, with a maximum
of 37 patients with advanced colorectal cancer to be enrolled in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&#8220;SAEs&#8221;) observed in the clinical trial that was launched in August 2024. The Investigational Review Board
(IRB) of the Netherlands Cancer Institute has requested additional information with respect to these SAEs and the study has been paused
for enrollment until the IRB&#8217;s questions have been, as more fully discussed at &#8220;Item 7. Management&#8217;s Discussion and
Analysis of Financial Condition and Results of Operations &#8211; Specific Risks Associated with the Company&#8217;s Business Activities
&#8211; Serious Adverse Events&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Cancer Institute Pharmacologic Clinical Trial</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic clinical trial. This study was being conducted
and funded by the NCI under a Cooperative Research and Development Agreement, with the Company being required to provide the LB-100 clinical
compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Institute of Health</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 23, 2024, we entered into a Patent License Agreement (the &#8220;License Agreement&#8221;) with the National Institute of Neurological
Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;), each an institute or center of the
National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, we have licensed exclusively NIH&#8217;s intellectual
property rights claimed for a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) subject invention co-developed with
the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer
drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis, until the expiration
of the last-to-expire valid claim of the jointly owned licensed patent rights in each such country in the licensed territory, unless
sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that we will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, we would be expected to commercialize the licensed products in markets where regulatory approval has been
obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
                                            Significant Agreements and Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands
Cancer Institute</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2021, we entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (&#8220;NKI&#8221;),
one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center,
for a term of three years. The Development Collaboration Agreement was subsequently modified by Amendment No. 1 thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. We agreed to fund the preclinical study, at an approximate cost of 391,000 Euros and provide a sufficient
supply of LB-100 to conduct the preclinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, we entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional research
activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added 500,000
Euros to the operating budget being funded by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, we entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment No. 2
and provided for a new study term of one year and starts upon the dosing of the first patient in the clinical trial at a project cost
of 100,000 Euros.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to our Board of Directors as an independent director. Dr. Bernards is a leader
in the field of molecular carcinogenesis and is employed by NKI.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property includes proprietary know-how, proprietary methodologies and extensive clinical validation data and publications.
To provide legal protection of our intellectual property, we rely on a combination of patents, licenses, trade secrets, trademarks, confidentiality
and non-disclosure clauses and agreements, and other forms of intellectual property protection to define and protect our rights to our
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are expected to be covered by our patents. These patents now cover sole rights to the composition and synthesis of our LB-100
series of drugs, which is the Company&#8217;s lead clinical compound in development. Lixte has filed patent applications covering the
treatment of cancer with LB-100. Lixte has also filed joint patent applications with the NIH and the Netherlands Cancer Institute for
the treatment of cancer using LB-100 in combination with other drugs like immune checkpoint inhibitors and WEE1 inhibitors (a class of
drugs that target and inhibit the WEE1 kinase enzyme that plays a crucial role in regulating cell division).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
applications for the LB-100 series (oxabicycloheptanes and oxabicycloheptenes) have been filed in the United States and internationally
under the Patent Cooperation Treaty. Patents for composition of matter and for several uses of the LB-100 series have been issued in
the United States, Mexico, Australia, Japan, China, Hong Kong, Canada, and by the European Patent Office</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company strives to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the
development of its business, including seeking, maintaining, and defending its patent rights, which are owned solely by our wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc., except in several instances jointly with one of many of our collaborators. The Company
also relies on trade secrets relating to its proprietary pipeline of product candidates and on know-how and continuing technological
innovation to develop and strengthen its pipeline. The Company intends to rely on regulatory protection afforded by regulatory agencies
through data exclusivity, market exclusivity, and patent term extensions, where available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company&#8217;s success will depend in large part on its ability to obtain and maintain patent and other proprietary protection for commercially
important technology, inventions and know-how related to its business; defend and enforce its patents; preserve the confidentiality of
its trade secrets; and operate without infringing valid and enforceable patents or proprietary rights of third parties. The Company&#8217;s
ability to stop third parties from making, using, selling, offering to sell, or importing our technology may depend on the extent to
which the Company has rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases,
enforcement of these rights may depend on cooperation of the joint owners of our jointly owned patents and patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">With
respect to both the Company&#8217;s solely and jointly owned intellectual property, the Company cannot be sure that patents will be granted
on any of its pending patent applications or on any patent applications filed solely or jointly by the Company in the future; we cannot
be sure that any of the Company&#8217;s existing patents or any patents that may be granted to us in the future will be commercially
useful in protecting the Company&#8217;s intended commercial products or therapeutic methods; and the Company cannot be sure that an
agency or court would determine that the Company&#8217;s solely or jointly owned patents are valid and enforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent portfolios for the Company&#8217;s most important programs involving the development of the LB-100 series are summarized and presented
below, along with related information, as of March 10, 2025, followed by a detailed listing of U.S. and non-U.S. patents that have been
issued. The projected patent expiration dates noted below assume that that all required maintenance or annuity fees for the patents are
timely paid and that a court or agency does not determine that the patents are invalid or unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100</i></b>.
The Company&#8217;s lead compound LB-100 is covered by U.S. Patent Nos. 8,822,461 and 7,998,957, which are solely owned by Lixte Biotechnology,
Inc. These patents are projected to expire in 2030 or 2028, exclusive of any available patent term extension. Counterpart non-U.S. patents
are projected to expire in 2028. Pharmaceutical compositions of LB-100 are covered by U.S. Patent Nos. 10,532,050, 10,023,587 and 8,822,461,
which are solely owned by Lixte Biotechnology, Inc. These patents and their non-U.S. counterparts are projected to expire in 2034 or
2028, exclusive of any available patent term extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
Combination Therapy with a Checkpoint Inhibitor</i></b>. LB-100 combination therapy with a checkpoint inhibitor for treating cancer is
covered by U.S. Patent No. 12,168,008 and a pending U.S. patent application, as well as by non-U.S. patents and patent applications.
These patents and patent applications are jointly owned by Lixte Biotechnology, Inc., and The United States of America, as represented
by the Secretary, Department of Health and Human Services. These patents and patents issuing from these patent applications are projected
to expire in 2037, exclusive of any patent term extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
Combination Therapy with Carboplatin, Etoposide and Atezolizumab</i></b>. LB-100 combination therapy with carboplatin, etoposide and
atezolizumab for treating small-cell lung cancer is covered by pending U.S. and non-U.S. patent applications that are solely owned by
Lixte Biotechnology, Inc. Patents issuing from these patent applications are projected to expire in 2041, exclusive of any patent term
extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
Combination Therapy with Another Investigational Compound</i></b>. LB-100 combination therapy with one of several other investigational
compounds for treating cancer, or preventing, inhibiting or reducing risk of metastasis of cancer, is covered by pending U.S. and non-U.S.
patent applications that are jointly owned by Lixte Biotechnology, Inc., and Stichting Het Nederlands Kanker Instituut &#8211; Antoni
Van Leeuwenhoek Ziekenhuis. Patents issuing from these patent applications are projected to expire in 2043, exclusive of any patent term
extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
for Treating Cancer</i></b>. LB-100 for treating breast cancer, colon cancer, large cell lung cancer, adenocarcinoma of the lung, small
cell lung cancer, stomach cancer, liver cancer, ovary adenocarcinoma, pancreas carcinoma, prostate carcinoma, promyelocytic leukemia,
chronic myelocytic leukemia or acute lymphocytic leukemia, is covered by U.S. Patent No. 9,079,917, which is solely owned by Lixte Biotechnology,
Inc. LB-100 for treating glioblastoma multiforme, medulloblastoma, ovarian cancer, kidney cancer and colorectal cancer is covered by
U.S. Patent No. 10,399,993. These patents and their non-U.S. counterparts are projected to expire in 2028, exclusive of any patent term
extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LB-100
Prodrugs and Analogs</i></b>. LB-100 prodrugs and analogs are covered by U.S. Patent Nos. 11,866,444, 10,618,908, 10,364,252, 9,988,394,
8,822,461, 8,541,458, 8,426,444, 8,227,473 and 7,998,957, which are solely owned by Lixte Biotechnology, Inc. These patents and their
non-U.S. counterparts are projected to expire in 2036, 2030 or 2028, exclusive of any patent term extension. Pharmaceutical compositions
of LB-100 prodrugs or analogs are covered by U.S. Patent Nos. 11,931,354, 11,236,102, 10,532,050, 10,023,587, 8,822,461, 8,227,473 and
7,998,957, which are solely owned by Lixte Biotechnology, Inc. These patents and their non-U.S. counterparts are projected to expire
in 2034, 2030 or 2028, exclusive of any patent term extension.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
portfolio of solely or jointly owned U.S. and non-U.S. issued patents is summarized below. We have additional U.S. and non-U.S. patent
applications pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxabicycloheptanes
and Oxabicycloheptenes, Their Preparation and Use</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue/Grant
    Date</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU
    2008214299</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/19/2014</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA
    2,676,422</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/16/2018</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN
    101662939</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/25/2015</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN
    103788108</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/12/2017</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    21245501</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/19/2017</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP
    5693850</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/1/2015</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP
    5666443</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/19/2014</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/19/2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX
    324705</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/21/2014</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/19/2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    7,998,957</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/16/2011</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/20/2030</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    8,227,473</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/24/2012</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/11/2030</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    8,426,444</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/23/2013</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    8,541,458</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/24/2013</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/17/2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    8,822,461</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/2/2014</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    9,079,917</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/14/2015</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    10,023,587</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/17/2018</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    10,399,993</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/3/2019</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/6/2028</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>EP
2124550 validated and pending in Germany, Spain, France, United Kingdom and Italy</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulations
of Oxabicycloheptanes and Oxabicycloheptenes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue/Grant
    Date</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU
    2014251087</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/2/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/8/2034</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA
    2909160</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/25/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/8/2034</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN
    105209036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/26/2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/8/2034</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    2983661<sup>1</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/8/2034</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL
    241945</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/30/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/8/2034</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    10,532,050</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/14/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/5/2034</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    11,931,354</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/19/2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/8/2034</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<sup>&#160;</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>EP
2983661 validated and pending as Unitary Patent, and in Spain, United Kingdom and Switzerland</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Process
of Synthesizing 3-(4-Methylpiperazine-1-Carbonyl)-7-Oxabicyclo [2.2.1] Heptane-2-Carboxylic Acid</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue/Grant
    Date</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    9,994,584</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/12/2018</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/14/2035</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxabicycloheptane
Prodrugs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue/Grant
                                            Date</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU
    2016263079</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/15/2019</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    3294287<sup>1</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/8/2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    3736275<sup>2</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/3/2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK
    1247576</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/5/2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL
    255516</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/27/2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL
    272027</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22/1/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
    394963</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/19/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP
    7187023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/2/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX
    386975</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/12/2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX
    393461</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/28/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TW
    I693226</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/11/2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TW
    I757720</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/11/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    9,988,394</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/5/2018</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    10,364,252</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/30/2019</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    10,618,908</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/14/2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    11,236,102</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/1/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2036</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    11,866,444</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/9/2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2036</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>EP
3294287 validated and pending in Austria, Switzerland, Czechia, Germany, Denmark, Spain, France, United Kingdom, Hungary, Ireland, Italy,
Netherlands, and Sweden</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup>EP
3736275 validated and pending as Unitary Patent, and in Spain, United Kingdom and Switzerland</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxabicycloheptanes
for Modulation of Immune Response</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue/Grant
    Date</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU
    2017370731</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/15/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/8/2037</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN
    110234647</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/23/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/8/2037</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    3551629<sup>1</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/15/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/8/2037</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK
    40015901</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/12/2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/8/2037</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL
    267134</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/2/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/8/2037</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL
    290857</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/2/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/8/2037</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP
    7246309</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/8/2037</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX
    396386</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/12/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/8/2037</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    12,168,008</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/17/2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/8/2037</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>EP
3551629 validated and pending in Belgium, Germany, Denmark, Spain, France, United Kingdom, Ireland, Iceland, Italy, Netherlands, Norway,
Sweden and Switzerland</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Market</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Cancer
Drugs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the mechanism by which compounds of the LB-100 series affects cancer cell growth is different from cancer agents currently
approved for clinical use. Lead compounds of the LB-100 series have activity against a broad spectrum of common and rarer human cancers
in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma
multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Lead compounds of the LB-100 series also have activity
against melanoma, breast cancer and sarcoma in animal models and enhance the effectiveness of commonly used anti-cancer drugs in animal
models. The enhancement of anti-cancer activity of these commonly-used anti-cancer drugs occurs at doses of LB-100 that do not significantly
increase toxicity in animals. It is therefore hoped that when combined with standard anti-cancer regimens against many tumor types, LB-100
will improve therapeutic benefit without unacceptable toxicity in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-100
is part of a pioneering effort in an entirely new field of cancer biology &#8211; activation lethality &#8211; that is advancing a new
treatment paradigm. The Company is the only company that has a drug in clinical trials with demonstrated capacity to over-activate oncogenic
signaling. The pre-clinical data obtained with LB-100 were recently posted online in a paper titled &#8220;Paradoxical Activation of
Oncogenic Signaling as a Cancer Treatment Strategy&#8221; in the scientific journal <i>Cancer Discovery</i>, and were published in the
July 2024 issue of <i>Cancer Discovery</i>. This study showed that LB-100 triggers hyper-activation of the signals that are responsible
for the deregulated proliferation of cancer cells, thus leading to cell death. This approach is the opposite of most of the current generation
of cancer therapies and opens potentially new treatment strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary goal to date has been to take our primary compound, LB-100, through Phase 2 clinical trials evaluating whether LB-100 will enhance
anti-cancer therapies. Because of the novelty and spectrum of activity of LB-100, we believe it is reasonably likely we may find a partner
in the pharmaceutical industry with interest in this compound at some stage of its clinical development. However, we would prefer to
delay the partnering/licensing decision until the potential value of our products are augmented by demonstrating there is no impediment
to clinical evaluation and a therapeutic dose level is determined in clinical trials. Demonstration of clinical usefulness would be expected
to substantially increase the value of our product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to FDA regulations as it conducts clinical trials. Additionally, any product for which we obtain marketing approval, along
with the manufacturing processes, post-approval clinical data and promotional activities for such product, will be subject to continual
review and periodic inspections by the FDA and other regulatory bodies. Even if regulatory approval of a product is granted, the approval
may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for costly post-marketing
testing and surveillance to monitor the safety or efficacy of the product. Later discovery of previously unknown problems with our products,
including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturer or manufacturing processes,
or failure to comply with regulatory requirements, may result in restrictions on such products or manufacturing processes, withdrawal
of the products from the market, voluntary or mandatory recall, fines, suspension of regulatory approvals, product seizures, injunctions
or the imposition of civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
life sciences industry is highly competitive and subject to rapid and profound technological change. Our present and potential competitors
include major pharmaceutical companies, as well as specialized biotechnology and life sciences firms in the United States and in other
countries. Most of these companies have considerably greater financial, technical and marketing resources than we do. Additionally, mergers
and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated in our competitors.
Our existing or prospective competitors may develop processes or products that are more effective than ours or be more effective at implementing
their technologies to develop commercial products faster. Our competitors may succeed in obtaining patent protection and/or receiving
regulatory approval for commercializing products before we do. Developments by our competitors may render our product candidates obsolete
or non-competitive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also experience competition from universities and other research institutions, and we are likely to compete with others in acquiring
technology from those sources. There can be no assurance that other organizations will not develop technologies with significant advantages
over those that we are seeking to develop. Any such development could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compete with universities and other research institutions engaged in research in these areas. Many of our competitors have greater technical
and financial resources than we do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete successfully is based on numerous factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost-effectiveness of any product that we ultimately commercialize relative to competing products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ease of use and ready availability of any product that we bring to market; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative speed with which we are able to bring any product resulting from its research to market in our target markets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to distinguish our products from competing products, or if competing products reach the market first, we may be unable
to compete successfully with current or future competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees
and Human Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 14, 2025, we had two officer/employees, our Chief Executive Officer and our Chief Financial Officer, and one consultant, our
Chief Medical Officer. The Company relies to a significant extent on outside consultants and advisors with various technical skills and
expertise that the Company can draw on as necessary to conduct its research and development and clinical trial programs. We consider
our relationship with our employees to be good. Our future performance depends significantly upon the continued service of our key personnel
and our ability to attract highly skilled employees. We provide our officer/employees and consultants with opportunities for equity ownership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 14, 2025, we do not operate or lease any facilities. We contract out research and development activities, drug production, and
drug storage to various commercial laboratories, drug manufacturers and storage facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to the regulations of the FDA as it conducts clinical trials. Clinical trials are research studies to answer specific
questions about new therapies or new ways of using known treatments. Clinical trials determine whether new drugs or treatments are both
safe and effective and the FDA has determined that carefully conducted clinical trials are the fastest and safest way to find treatments
that work in people.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also requires that an independent review body consider the benefits and risks of a clinical trial and grant approval for the proposed
study including selecting of initial doses, plans for escalation of dose, plans for modification of dose if toxicity is encountered,
plans for monitoring the wellbeing of individuals participating in the study, and for defining and measuring, to the extent possible,
any untoward effects related to drug administration. Serious adverse effects, such as life-threatening toxicities and death, are immediately
reportable to the review body and to the FDA. To minimize risk when studying a new drug, the initial dose is well below that expected
to cause any toxicity. No more than three patients are entered at a given dose. In general, a dose is not escalated within an individual
patient. Once safety is established by the absence of toxicity or low toxicity in a group of three patients, a planned higher dose is
then evaluated in a subsequent group of three individuals and so on until dose-limiting toxicity is encountered. The dose level producing
acceptable toxicity is then selected as the dose level to be evaluated in Phase 2 trials. Thus, the goal of Phase 1 studies is to determine
the appropriate dose level for evaluation of drug efficacy in patients with cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations imposed by the FDA, depending on our future activities, we may become subject to regulation under various federal
and state statutes and regulations, such as the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances
Control Act, the Research Conservation and Recovery Act, national restrictions on technology transfer, and import, export and customs
regulations. From time to time, other federal agencies and congressional committees have indicated an interest in implementing further
regulation of biotechnology applications. We are not able to predict whether any such regulations will be adopted or whether, if adopted,
such regulations will apply to our business, or whether we or our collaborators would be able to comply with any applicable regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as we intend to market our products in international markets, we will be required to obtain separate regulatory approvals from
the European Union and many other foreign jurisdictions. Approval by the FDA does not ensure approval by regulatory authorities in other
countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries
or by the FDA. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products
in any market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. We are not currently subject
to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following risk factors, together with the other information presented in this document, including the financial statements and the notes
thereto, should be considered by investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Resources and Capital Needs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are engaged in early-stage research and as such might not be successful in our efforts to develop a portfolio of commercially viable
products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of our strategy is to develop LB-100 in combination with other anti-cancer therapies to treat cancer. We are seeking to do
so through our internal research programs or strategic partnerships. A significant portion of the research and development that we are
conducting involves new and unproven technologies. Research programs to identify new disease targets and product candidates or to develop
them require substantial technical, financial and human resources whether or not any candidates or technologies are ultimately identified
or proven successful. Our research programs might initially show promise in identifying potential product candidates, yet fail to yield
product candidates for clinical development for the following reasons:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    research methodology used might not be successful in identifying potential product candidates; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    candidates for drugs might on further study be shown to have harmful side effects or other characteristics that indicate they are
    unlikely to be effective drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to discover suitable potential product candidates, develop additional delivery technologies through internal research programs
or strategic partnerships, or in-license suitable products or delivery technologies on acceptable business terms, our business prospects
will suffer. Even if we discover additional product candidates, new clinical trials of one or more additional drug candidates may show
that these product candidates are unsafe or ineffective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses
for the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common
diseases and then design novel compounds to attack those threats. We do not have any products approved by a regulatory authority and
have not generated any revenue from collaboration or licensing agreements or product sales to date, and have incurred significant research,
development and other expenses related to our ongoing operations and expect to continue to incur such expenses. As a result, we have
not been profitable and have incurred significant operating losses since our inception. For the years ended December 31, 2024 and 2023,
we reported a net loss of $3,585,965 and $5,087,029, respectively. As of December 31, 2024 and 2023, we had an accumulated deficit of
$52,067,693 and $48,481,728, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to generate revenues for many years, if at all. We expect to continue to incur significant expenses and operating losses
for the foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals
for one or more of our product candidates and any additional product candidates we might acquire, and potentially begin to commercialize
product candidates that might achieve regulatory approval. We might also encounter unforeseen expenses, difficulties, complications,
delays and other unknown factors that could adversely affect our business. The size of our future net losses will depend, in part, on
the rate of future growth of our expenses and our ability to generate revenues. Our expenses will further increase as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
    clinical trials of our lead product candidate, LB-100;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in-license
    or acquire rights to, and pursue development of, other products, product candidates or technologies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, administrative, manufacturing, quality control, quality assurance and scientific personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    marketing approval for any product candidates that successfully complete clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    our outsourced manufacturing and commercial activities and establish sales, marketing and distribution capabilities, if we receive,
    or expect to receive, marketing approval for any product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
    operational, financial and management information systems and personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception, and management has determined that substantial doubt exists about
the Company&#8217;s ability to continue as a going concern. As a result, our independent registered public accounting firm has included
an explanatory paragraph in their report with respect to this uncertainty that accompanies our audited consolidated financial statements
as of and for the year ended December 31, 2024. This going concern opinion could materially limit our ability to raise additional funds
through the sale of equity securities in the future, and subsequent reports by our independent registered public accounting firm on our
consolidated financial statements may also include an explanatory paragraph with respect to our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
need significant additional financing to fund our operations and complete the development and, if approved, the commercialization of
our lead product candidate, LB-100. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our
product development programs or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our existing cash resources as of December 31, 2024 will provide sufficient working capital resources to fund our operations,
including our clinical trial programs with respect to the development of our lead anti-cancer clinical compound LB-100, through approximately
September 30, 2025. Our existing cash resources will not be sufficient to complete development of and obtain regulatory approval for
our lead product candidate, and we will need to raise significant additional capital to be able to continue our efforts in this regard.
The Company estimates that it will need to raise additional capital to fund its operations by mid-2025, including its various clinical
trial commitments, to be able to proactively manage its current business plan during the remainder of 2025 and during 2026. In addition,
our operating plan might change as a result of many factors currently unknown to us, including possible additional clinical trials, and
we might need additional funds sooner than planned. The Company is considering various strategies and alternatives to obtain the required
additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to expend substantial resources for the foreseeable future to continue the clinical development and production of our lead product
candidate. These expenditures will include costs associated with research and development, potentially acquiring new product candidates
or technologies, conducting preclinical studies and clinical trials and potentially obtaining regulatory approvals and manufacturing
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Budgets
and future capital requirements depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
scope, progress, results and costs of our ongoing and planned development programs for our lead product candidate, as well as any additional
clinical trials we undertake to obtain data sufficient to seek marketing approval for our lead product candidate;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of, and the costs involved in, obtaining regulatory approvals for our lead drug candidate if our clinical trials are successful;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of commercialization activities for our lead product candidate, if it is approved for sale, including marketing, sales and distribution
    costs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost of manufacturing our lead product candidate for clinical trials in preparation for regulatory approval, including the cost and timing
of process development, manufacturing scale-up and validation activities;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs to in-license future product candidates or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation
    costs and the outcome of such litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs in defending and resolving future derivative and securities class action litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    operating expenses; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    emergence of competing technologies or other adverse market developments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
funds might not be available when we need them on terms that are acceptable to us, or at all. We have no committed source of additional
capital. If adequate funds are not available to us on a timely basis, we might not be able to continue as a going concern or we might
be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our product
candidates or target indications, or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other
activities that may be necessary to commercialize our lead product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have no source of revenues. We might never generate revenues or achieve profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we do not generate any revenues from product sales or otherwise. Even if we are able to successfully achieve regulatory approval for
our lead product candidate, we do not know when we will generate revenues or become profitable, if at all. Our ability to generate revenues
from product sales and achieve profitability will depend on our ability to successfully commercialize products, including our lead product
candidate, LB-100, and any other product candidates that we might develop, in-license or acquire in the future. Our ability to generate
revenues and achieve profitability also depends on a number of additional factors, including our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    complete development activities, including the necessary clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    and submit a New Drug Application (&#8220;NDA&#8221;) to the FDA and obtain U.S. regulatory approval for an indication for which
    there is a commercial market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    and submit applications to foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    regulatory approval in territories with viable market sizes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    coverage and adequate reimbursement from third parties, including government and private payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">set
    commercially viable prices for our intended product, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    and maintain supply and manufacturing relationships with reliable third parties and/or build our own manufacturing facility and ensure
    adequate, legally and globally compliant manufacturing of bulk drug substances and drug products to maintain that supply;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    distribution processes for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    commercial quantities of our lead product candidate, once approved, at acceptable cost levels;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    additional funding, if required to develop and commercialize our lead product candidate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves, in the markets
    in which we choose to commercialize on our own;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve
    market acceptance of one or more of our intended products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract,
    hire and retain qualified personnel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protect
    our rights in our intellectual property portfolio.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenues for any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets
in the territories for which it gains regulatory approval, the accepted price for the product, the ability to get reimbursement at any
price, and whether we own the commercial rights for that territory. If the number of our addressable-disease patients is not as significant
as our estimates, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population
for treatment is narrowed by competition, physician choice or treatment guidelines, we might not generate significant revenues from sales
of such products, even if approved. In addition, we anticipate incurring significant costs associated with commercializing any approved
product candidate. As a result, even if we generate revenues, we might not become profitable and might need to obtain additional funding
to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we might be
unable to continue our operations at planned levels and might be forced to reduce our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to use net operating losses to offset future taxable income might be subject to limitations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately
$31,067,000 and $35,836,000, respectively. Federal net operating losses from tax years preceding 2018, if not utilized earlier, expire
through 2038. Federal net operating losses generated in a tax year beginning after 2017 have an indefinite carryforward period. The utilization
of federal net operating loss carryforwards is subject to various limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
state net operating loss carryovers include approximately $19,141,000 that were incurred in the State of New York and approximately $16,695,000
that were incurred in the State of California, which are subject to various restrictions and limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and certain corresponding provisions of state law, if a
corporation undergoes an &#8220;ownership change&#8221;, which is generally defined as a greater than 50% change, by value, in the ownership
of its equity over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income might be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Development and Regulatory Approval of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical-stage
biopharmaceutical companies with product candidates in clinical development face a wide range of challenging activities which might entail
substantial risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company with a lead product candidate in clinical development. The success of our lead product
candidate will depend on several factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designing,
    conducting and successfully completing preclinical development activities, including preclinical efficacy and IND-enabling studies,
    for our lead product candidate or product candidates that we might, in the future, in-license or acquire;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designing,
    conducting and completing clinical trials with positive results for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
                                            of regulatory approvals from applicable authorities;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent and trade secret protection and regulatory exclusivity for our lead product candidate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    arrangements with third party manufacturers, receiving regulatory approval of our manufacturing processes and our third party manufacturers&#8217;
    facilities from applicable regulatory authorities and ensuring adequate supply of drug product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    our lead product candidate at an acceptable cost;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
    launching commercial sales of our lead product candidate, if approved, whether alone or in collaboration with others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    acceptance of our lead product candidate, if approved, by patients, the medical community and third party payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
    competing with other therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    our lead product candidate is approved, obtaining and maintaining coverage and adequate reimbursement by third party payors, including
    government payors, for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying
    with all applicable regulatory requirements, including FDA current Good Clinical Practices (&#8220;GCP&#8221;), Current Good Manufacturing
    Practices (&#8220;CGMP&#8221;), and standards, rules and regulations governing promotional and other marketing activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of the lead product candidate during development and following approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to
successfully develop and commercialize our lead product candidate, which could materially harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might find it difficult to enroll patients in our clinical trials which could delay or prevent the start of clinical trials for our product
candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in clinical trials of our lead product candidate is essential to our success. The timing of our
clinical trials depends in part on the rate at which we can recruit patients to participate in clinical trials of our lead product candidate,
and we might experience delays in our clinical trials if we encounter difficulties in enrollment. If we experience delays in our clinical
trials, the timeline for obtaining regulatory approval of our lead product candidate will most likely be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
factors might affect our ability to identify, enroll and maintain qualified patients, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eligibility
    criteria of our ongoing and planned clinical trials with specific characteristics appropriate for inclusion in our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">design
    of the clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
    and nature of the patient population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients&#8217;
    perceptions as to risks and benefits of the lead product candidate under study and the participation in a clinical trial generally
    in relation to other available therapies, including any new drugs that might be approved for the indications we are investigating;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability and efficacy of competing therapies and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pendency
    of other trials underway in the same patient population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">willingness
    of physicians to participate in our planned clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
    of the disease under investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    of patients to clinical sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    who are noncompliant or do not otherwise complete the trials; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues
    with a contract research organization (a &#8220;CRO&#8221;) and/or with other vendors that are involved with our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might not be able to initiate or continue to support clinical trials of LB-100, our lead product candidate, for one or more indications,
or any future product candidates if we are unable to locate and enroll a sufficient number of eligible participants in these trials as
required by the FDA or one or more other regulatory authorities. Even if we are able to enroll a sufficient number of patients in our
clinical trials, if the pace of enrollment is slower than we expect, the development costs for our lead product candidate might increase
and the completion of our trials might be delayed or our trials could become too expensive to complete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion of, or termination of, any clinical trials of our lead product candidate, the commercial prospects
of our lead product candidate could be harmed, and our ability to generate product revenue from any of our product candidates could be
delayed or prevented. In addition, any delays in completing our clinical trials would likely increase our overall costs, impair product
candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences
might harm our business, financial condition, and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our lead product candidate
in clinical trials, and any other product candidates that might advance into clinical trials, might not have favorable results in later
clinical trials or receive regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Success
in preclinical studies and early clinical trials does not ensure that later clinical trials will generate adequate data to demonstrate
the efficacy and safety of an investigational drug. A number of companies in the pharmaceutical and biotechnology industries, including
those with greater resources and experience than we have, have suffered significant setbacks in clinical trials, even after seeing promising
results in earlier preclinical studies or clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the results reported in earlier preclinical studies or clinical trials for our lead product candidate, we do not know whether the clinical
trials that we might conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our lead product
candidate for a particular indication, in any particular jurisdiction. Efficacy data from prospectively designed trials might differ
significantly from those obtained from retrospective subgroup analyses. If later-stage clinical trials do not produce favorable results,
our ability to achieve regulatory approval for our lead product candidate might be adversely impacted. Even if we believe that we have
adequate data to support an application for regulatory approval to market our lead product candidate or any future product candidates,
the FDA or other regulatory authorities might not agree and might require that we conduct additional clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
drug development involves a lengthy and expensive process with an uncertain outcome.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive and can take many years to complete, with the outcome inherently uncertain. Failure can occur at any time during
the clinical trial process. Before obtaining approval from regulatory authorities for the sale of our lead product candidate, we must
conduct extensive clinical trials to demonstrate the safety and efficacy of our lead product candidate in humans. Prior to initiating
clinical trials, a sponsor must complete extensive preclinical testing of a product candidate, including, in most cases, preclinical
efficacy experiments as well as IND-enabling toxicology studies. These experiments and studies might be time-consuming and expensive
to complete. The necessary preclinical testing might not be completed successfully for a preclinical product candidate and a potentially
promising product candidate might therefore never be tested in humans. Once it commences, clinical testing is expensive, difficult to
design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur
at any stage of testing. The outcome of preclinical testing and early clinical trials might not be predictive of the success of later
clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical
data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed
satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We
might experience numerous unforeseen events during drug development that could delay or prevent our ability to receive marketing approval
or commercialize our lead product candidate. In particular, clinical trials of our lead product candidate might produce inconclusive
or negative results. We have limited data regarding the safety, tolerability and efficacy of our lead product candidate. Clinical trials
also require the review and oversight of an institutional review board (&#8220;IRB&#8221;). An inability or delay in obtaining IRB approval
could prevent or delay the initiation and completion of clinical trials, and the FDA might decide not to consider any data or information
derived from a clinical investigation not subject to initial and continuing IRB review and approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might experience delays in our ongoing or future clinical trials, and we do not know whether planned clinical trials will begin or enroll
subjects on time, will need to be redesigned or will be completed on schedule, if at all. There can be no assurance that the FDA or another
regulatory agency will not put clinical trials of our lead product candidate on hold in the future. Clinical trials might be delayed,
suspended or prematurely terminated for a variety of reasons, such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in reaching agreement with the FDA or a foreign regulatory authority on a clinical trial design that we are able to execute;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority
    regarding the scope or design of a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject
    to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in obtaining IRB approval or the approval of other reviewing entities, including comparable foreign regulatory authorities,
    to conduct a clinical trial at each site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial sites from our clinical trials or the ineligibility of a site to participate in our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in recruiting and enrolling suitable subjects to participate in a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in subjects completing a trial or returning for post-treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or
    dropping out of a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs,
    including some that may be for the same indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our third party clinical trial managers, CROs, clinical trial sites, contracted laboratories or other third party vendors to satisfy
    their contractual duties, meet expected deadlines or return trustworthy data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure in adding new trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interim
    results or data that are ambiguous or negative or are inconsistent with earlier results or data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">alteration
    of trial design necessitated by re-evaluation of design assumptions based upon observed data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">feedback
    from the FDA, the IRB or a foreign regulatory authority, or results from earlier stage or concurrent preclinical studies and clinical
    trials, that might require modification to the protocol for a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decision by the FDA, the IRB, a foreign regulatory authority, or us to suspend or terminate clinical trials at any time for safety
    issues or for any other reason;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unacceptable
    risk-benefit profile, unforeseen safety issues or adverse side effects;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to demonstrate a benefit from using a product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in manufacturing, obtaining, from one or more third parties, or qualifying sufficient quantities of a product candidate to start
    or to use in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of adequate funding to continue a trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct
    additional studies or increased expenses associated with the services of our CROs and other third parties; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in governmental regulations or administrative actions or lack of adequate funding to continue a clinical trial.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion or termination of any clinical trial of our lead product candidate, the approval and commercial
prospects of our lead product candidate will be harmed, delaying our ability to generate product revenues from such product candidate
and our costs will most likely increase. The required regulatory approvals may also be delayed, thereby jeopardizing our ability to commence
product sales and generate revenues and the period of commercial exclusivity for our intended product may be shortened. Regulatory approval
of our lead product candidate may be denied for the same reasons that caused the delay.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
associated with operating in foreign countries could materially adversely affect our product development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently conducting clinical trials in Spain and the Netherlands. Consequently, we will also be subject to risks related to operating
in foreign countries. Risks associated with conducting operations in foreign countries include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    regulatory requirements for drug approvals and regulation of approved drugs in foreign countries; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">more
    stringent privacy requirements for data to be supplied to our operations in the United States, but generated outside of the United
    States, e.g., General Data Protection Regulation in the European Union;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
    changes in tariffs, trade barriers and regulatory requirements; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    weakness, including inflation, or political instability in particular foreign countries, economies or markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    taxes, including withholding or payroll taxes;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to
    doing business or operating in another country;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
    uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
    shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from geopolitical actions or events, including civil or political unrest (such as the ongoing conflict between
    Ukraine and Russia), sanctions, war and terrorism.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects or
have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result
in significant negative consequences following any regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our current or future product candidates, their delivery methods or dosage levels could cause us, our collaborators
or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial
of regulatory approval or termination of clinical trials by the FDA or other foreign regulatory authorities; or an IRB, that approves
and, monitors biomedical research to protect the rights and welfare of human subjects. As a result of safety or toxicity issues that
we might experience in our clinical trials, or negative or inconclusive results from the clinical trials of others for drug candidates
that might be similar to our own, we might not receive approval to market our current lead product candidate or any product candidates
we may pursue, which could prevent us from ever generating revenues or achieving profitability. Results of our trials could reveal an
unacceptably high severity or incidence of side effects. In such an event, our trials or those or our collaborators could be suspended
or terminated, and the FDA or foreign regulatory authorities could order us or our collaborators to cease further development of or deny
approval of our current or any future product candidates for any or all targeted indications. Any drug-related side effects could also
affect patient recruitment or the ability of enrolled subjects to complete clinical trials or result in potential product liability claims.
Any of these occurrences could have a material adverse effect on our business, results of operations, financial condition, cash flows
and future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if our lead product candidate receives regulatory approval, and we or others later identify undesirable side effects caused by such product,
a number of potentially significant negative consequences could result, including that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be forced to suspend marketing of such product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities might withdraw their approvals of such product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities might require additional warnings on the label that could diminish the usage or otherwise limit the commercial success
    of such product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to conduct post-marketing studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to subjects or patients; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of our lead product candidate, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product development program might not uncover all possible adverse events that patients who take our lead product candidate may experience.
The number of subjects exposed to our lead product candidate and the average exposure time in the clinical development program might
be inadequate to detect rare adverse events or chance findings that might only be detected once the product is administered to more patients
and for greater periods of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials by their nature utilize a sample of the potential patient population. However, with a limited number of subjects and limited duration
of exposure, we cannot be fully assured that rare and severe side effects of our lead product candidate will be uncovered. Such rare
and severe side effects might only be uncovered with a significantly larger number of patients exposed to our lead product candidate.
If such safety problems occur or are identified after our lead product candidate reaches the market, the FDA might require that we amend
the labeling of the product or recall the product, or might even withdraw approval for the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is a risk that one or more of our clinical trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs)
related to our drug candidate or to another company&#8217;s drug used in combination in one of our clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that the SAEs could be attributable to our drug candidate and could include, but not be limited to, unexpected severe side
effects, treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined
as dose-limiting toxicity (DLT). When two DLTs occur at the same dose-level that dose-level is considered too high and unsafe. Further
treatment is only allowed at lower dose-levels that have previously been found safe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Institutional Review Board of the Netherlands Cancer Institute
has put the colorectal cancer study on hold, as more fully discussed at &#8220;Item 7. Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations &#8211; Specific Risks Associated with the Company&#8217;s Business Activities &#8211;
Serious Adverse Events&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success is dependent on the regulatory approval of our lead product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is dependent on our ability to obtain regulatory approval for our lead product candidate in a timely manner. We cannot commercialize
our lead product candidate in the United States without first obtaining regulatory approval for the product from the FDA. Similarly,
we cannot commercialize our lead product candidate outside of the United States without obtaining regulatory approval from one or more
foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our lead product candidate for a target
indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, that the product candidate
is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate with
respect to such product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval by the FDA and foreign regulatory authorities is unpredictable but typically takes many years following
the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of
the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval
may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product candidate were to successfully obtain approval from the FDA and one or more foreign regulatory authorities, any approval
might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications,
or may be subject to burdensome post-approval study or risk management requirements. Also, any regulatory approval of our lead product
candidate or any future product candidates we may pursue, once obtained, may be withdrawn.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
lead product candidate and future product candidates could fail to receive regulatory approval from the FDA.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not obtained regulatory approval for our lead product candidate, and it is possible that our lead product candidate or any future
product candidates will not obtain regulatory approval, for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    with the regulatory authorities regarding the scope, design or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to demonstrate that a product candidate is safe and effective for our proposed indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of clinical trials to meet the level of statistical significance required for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    with our interpretation of data from preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    insufficiency of data collected from clinical trials of our lead product candidate to support the submission and filing of an NDA
    or other submission or to obtain regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to obtain approval of our manufacturing processes or facilities of third party manufacturers with whom we contract for clinical and
    commercial supplies or our own manufacturing facility; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the approval policies or regulations that render our preclinical and clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or a foreign regulatory authority might require more information, including additional preclinical or clinical data, to support approval
or additional studies, which might delay or prevent approval or our commercialization plans, or we might decide to abandon the development
program. The FDA or a foreign regulatory authority might also require the manufacture of a new lead product candidate in accordance with
new or revised standards. If we were to obtain approval, regulatory authorities might approve our lead product candidate and any future
product candidates we might pursue for fewer or more limited indications than we request (including failing to approve the most commercially
promising indications), might grant approval contingent on the performance of costly post-marketing clinical trials, or might approve
a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization
of that product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain regulatory approval for our lead product candidate in one or more jurisdictions, or if any approval contains
significant limitations, we might not be able to obtain sufficient funding to continue the development of that product or generate revenues
attributable to that product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to obtain regulatory approval in international jurisdictions would prevent our lead product candidate from being marketed abroad.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, to market and sell our lead product candidate in the European Union, in the United Kingdom,
in many Asian countries and in other jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying
regulatory requirements. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions,
and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries
or jurisdictions or by the FDA. The regulatory approval process outside the United States generally includes all of the risks associated
with obtaining FDA approval as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. The approval
procedure varies among countries and can require additional data or involve additional testing. The time required to obtain foreign approval
may differ substantially from that required to obtain FDA approval. We might not be able to obtain approvals from regulatory authorities
outside the United States on a timely basis, if at all. Clinical trials accepted in one country might not be accepted by regulatory authorities
in other countries. In addition, many countries outside the United States require that a product be approved for reimbursement before
it can be approved for sale in that country. A product candidate that has been approved for sale in a particular country might not receive
reimbursement approval in that country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might not be able to file for regulatory approvals and might not receive necessary approvals to commercialize our intended product in
any market. If we are unable to obtain approval of any of our current product candidate or any future product candidates we might pursue
by regulatory authorities in the European Union, United Kingdom, Asia or elsewhere, the commercial prospects of that product candidate
might be significantly diminished, our business prospects could decline and this could materially adversely affect our business, results
of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our current primary product candidate received regulatory approval, it might still face future development and regulatory difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for our lead product candidate, LB-100, that approval would be subject to ongoing requirements by the
FDA and foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage,
distribution, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety
and other post-marketing information. These requirements can include submissions of safety and other post-marketing information and reports,
registration, as well as continued compliance by us and/or our CMOs and CROs for any post-approval clinical trials that we or our collaborators
might conduct. The safety profile of any product will continue to be closely monitored by the FDA and foreign regulatory authorities
after approval. If the FDA or foreign regulatory authorities become aware of new safety information after approval of our lead product
candidate, they might require labeling changes or establishment of a risk evaluation and mitigation strategy, impose significant restrictions
on such product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies or post-market
surveillance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and
other regulatory authorities for compliance with CGMP, GCP, and other regulations. If we, a collaborator or a regulatory agency discover
previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility
where the product is manufactured, a regulatory agency might impose restrictions on that product, the manufacturing facility or us, including
requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our lead product candidate or the
manufacturing facilities for our lead product candidate fail to comply with applicable regulatory requirements, a regulatory agency might:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    warning letters or untitled letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandate
    modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due
    dates for specific actions and penalties for noncompliance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to applications filed by us or a collaborator;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above might inhibit our ability to successfully commercialize our intended product and generate
revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotion of any product candidate that obtains approval in the United States is heavily scrutinized by the FDA, the Department of
Justice, the Office of Inspector General of Health and Human Services, state attorneys general, members of Congress and the public. A
company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance
with the provisions of the approved label. Additionally, advertising and promotion of any product candidate that obtains approval outside
of the United States is heavily scrutinized by foreign regulatory authorities. Violations, including actual or alleged promotion of our
intended product for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal
sanctions by the FDA, as well as prosecution under the federal False Claims Act. Any actual or alleged failure to comply with labeling
and promotion requirements can have a negative impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Dependence on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on certain key scientific personnel for our success who do not work full time for us. The loss of any such personnel could adversely
affect our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bas van der Baan, a director of the Company since June 17, 2022, replaced the Company&#8217;s founder, Dr. John S.
Kovach, as President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023. Effective October 6, 2023, Mr. van der Baan
was appointed as Chairman of the Board of Directors. Dr. Kovach was also the Company&#8217;s Chief Scientific Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our success depended, in part, on the continued availability and contributions of Dr. Kovach, we were able to replace Dr. Kovach on a
timely basis with a qualified replacement in Mr. van der Baan. Furthermore, recruiting and retaining qualified scientific personnel to
perform future research and development work is critical to our success. Our inability to attract or retain qualified personnel or advisors
in the future could significantly weaken our management, harm our ability to compete effectively, and harm our business. The competition
for qualified personnel in the pharmaceutical field is intense and, as a result, we might be unable to attract and retain qualified personnel
necessary for the development of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we replaced our previous Chief Medical Officer, Dr. James S. Miser, with Dr. Jan Schellens during 2024, and we have reallocated the responsibilities
of Eric J. Forman, our Vice President and Chief Operating Officer, who resigned on December 31, 2024. We believe that Mr. Van der Baan
and Dr. Schellens are capable of managing the Company&#8217;s research and clinical activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to rely heavily on third parties for the conduct of clinical trials of our product candidates. If these clinical trials are not
successful, or if we or our collaborators are not able to obtain the necessary regulatory approvals, we will not be able to commercialize
our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to obtain regulatory approval for the commercial sale of our product candidates, we or our collaborators will be required to complete
extensive preclinical studies as well as clinical trials in humans to demonstrate to the FDA and foreign regulatory authorities that
our product candidates are safe and effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Miser is experienced in the design and conduct of early stage clinical trials. However, we expect to rely on collaborative partners and
CROs for their performance and management of clinical trials of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intended products under development might not be effective in treating any of our targeted disorders or might prove to have undesirable
or unintended side effects, toxicities or other characteristics that might prevent or limit their commercial use. Institutional review
boards or regulators, including the FDA, might hold, suspend or terminate our clinical research or the clinical trials of our product
candidates for various reasons, including non-compliance with regulatory requirements or if, in their opinion, the participating subjects
are being exposed to unacceptable health risks. Additionally, failure of third parties conducting or overseeing the operation of the
clinical trials to perform their contractual or regulatory obligations in a timely fashion could delay the clinical trials. Failure of
clinical trials can occur at any stage. Any of these events would adversely affect our ability to market a product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development process necessary to obtain regulatory approval is lengthy, complex and costly. If we or our collaborative partners do not
obtain necessary regulatory approvals, then our business would not be successful, and the market price of our common stock could decline
substantially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we, or our collaborative partners, are able to successfully advance a product candidate through the clinic, we, or such
partner, will be required to obtain regulatory approval prior to marketing and selling such product. The process of obtaining FDA and
other required regulatory approvals is costly and lengthy. The time required for FDA and other approvals is uncertain and can typically
take several or many years, depending on the complexity and novelty of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approval to market a product might be subject to limitations on the indicated uses for which we, or our collaborative partners,
may market the product. These limitations might restrict the size of the market for the product and affect reimbursement by third party
payors. In addition, regulatory agencies might not grant approvals on a timely basis or might revoke or significantly modify previously
granted approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
or our collaborative partners, also are subject to numerous foreign regulatory requirements governing the manufacturing and marketing
of our potential future products outside of the United States. The approval procedure varies among countries, additional testing might
be required in some jurisdictions, and the time required to obtain foreign approvals often differs from that required to obtain FDA approvals.
Moreover, approval by the FDA does not ensure approval by regulatory authorities in other countries, and vice versa.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, we, or our collaborative partners, might not successfully complete clinical trials in the time periods estimated,
if at all. Moreover, if we, or our collaborative partners, incur unanticipated costs and/or delays in development programs or if we fail
to successfully develop and commercialize products based upon our technologies, we might not be able to generate significant operating
revenues or sustainable profitability, as a result of which our stock price could decline substantially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
interruptions could adversely affect future operations, revenues, and financial conditions, and might increase our costs and expenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations, and those of our directors, advisors, contractors, consultants, CROs, and collaborators, could be adversely affected by earthquakes,
floods, hurricanes, typhoons, extreme weather conditions, fires, water shortages, power failures, business systems failures, medical
epidemics and other natural and man-made disaster or business interruptions. Our phones, electronic devices and computer systems and
those of our directors, advisors, contractors, consultants, CROs, and collaborators are vulnerable to damages, theft and accidental loss,
negligence, unauthorized access, terrorism, war, electronic and telecommunications failures, and other natural and man-made disasters.
Operating as a virtual company, our employees conduct business outside of our headquarters and leased or owned facilities. These locations
might be subject to additional security and other risk factors due to the limited control of our employees. If such an event as described
above were to occur in the future, it might cause interruptions in our operations, delay research and development programs, clinical
trials, regulatory activities, manufacturing and quality assurance activities, sales and marketing activities, hiring, training of employees
and persons within associated third parties, and other business activities. For example, the loss of clinical trial data from completed
or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likewise,
we will rely on third parties to manufacture our product candidates and conduct clinical trials, and similar events as those described
previously relating to their business systems, equipment and facilities could also have a material adverse effect on our business. To
the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or misappropriation
or disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization
of our lead product candidate could be delayed or altogether terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to find third party collaborators to assist or share in the costs of product development could materially harm our business,
financial condition or results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy for the development and commercialization of our proprietary product candidates might include the formation of collaborative
arrangements with third parties. We have entered into a number of agreements with third parties as described elsewhere in this document.
Existing and future collaborators have significant discretion in determining the efforts and resources they apply and might not perform
their obligations as expected. Potential third party collaborators include biopharmaceutical, pharmaceutical and biotechnology companies,
academic institutions, government agencies and other entities. Third party collaborators may assist us in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">funding
    research, preclinical development, clinical trials and manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
    and obtaining regulatory approvals; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    commercializing any future product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to establish further collaboration agreements, we might be required to undertake product development and commercialization
at our own expense. Such an undertaking might limit the number of product candidates that we will be able to develop, significantly increase
our capital requirements and place additional strain on our internal resources. Our failure to enter into additional collaborations could
materially harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our dependence on licensing, collaboration and other agreements with third parties might subject us to a number of risks. If
we fail to comply with our obligations under these agreements, of if one or more third parties allege that we fail to comply, then one
or more third parties might terminate the agreements. In this event, we might not be able to develop, manufacture or market our product
candidates. This would materially adversely affect our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
agreements might not be on terms that prove favorable to us and might require us to relinquish certain rights in our product candidates.
To the extent we agree to work exclusively with one collaborator in a particular territory, research area, or therapeutic field of use,
our opportunities to collaborate with other entities could be curtailed. Lengthy negotiations with potential new collaborators might
lead to delays in the research, development or commercialization of product candidates. The decision by our collaborators to pursue alternative
technologies or the failure of our collaborators to develop or commercialize successfully any product candidate to which they have obtained
rights from us could materially harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our agreements might not be assignable by us without the consent of the respective other party or parties, which might limit
or delay our ability to consummate transactions, adversely impact the value of those transactions, or limit our ability to pursue research,
development or other activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might be subject to claims by third parties asserting that our employees, consultants, collaborators contractors or we have misappropriated
their intellectual property, or claiming ownership of what we regard as our own intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees, consultants, collaborators or contractors have been previously employed at universities or third party pharmaceutical companies,
including our actual or possible competitors, and received confidential and proprietary information from them. Although we try to ensure
that our employees, consultants, collaborators or contractors do not use the proprietary information or know-how of others in their work
for us, we may be subject to claims that these employees, consultants, collaborators or contractors, or we, have used or disclosed intellectual
property, including trade secrets or other proprietary information, of any former employer. We might also be subject to claims that former
employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims.
We might not be successful in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages,
we could lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property.
Even if we are successful, litigation could result in substantial cost and reputational loss and be a distraction to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees, consultants, collaborators and contractors who may be involved in the development
of intellectual property to execute agreements assigning such intellectual property to us, we might be unsuccessful in executing such
an agreement with each party who in fact develops intellectual property that we regard as our own. Such assignment agreements might not
be self-executing or may be breached, and we might be forced to bring claims against third parties, or defend claims that third parties
might bring against us, to determine the ownership of what we regard as our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
cannot be certain we will be able to obtain patent protection to protect our product candidates and technology.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patents and patent applications are owned solely by our wholly-owned subsidiary, Lixte Biotechnology, Inc., except in several instances
where they are jointly owned with one of our collaborators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive and time-consuming, and we might not be able to file or prosecute all necessary or desirable
patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects
of our research or development before it is too late to obtain patent protection. Therefore, these patents and applications might not
be prosecuted and enforced in a manner consistent with the best interests of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent
years been the subject of much litigation. In addition, the laws of foreign countries might not protect our rights to the same extent
as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and
patent applications in the United States and other jurisdictions are typically not published until after filing, or in some cases not
at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our solely owned or jointly
owned patents or pending patent applications, or that we were the first inventors to file for patent protection of such inventions. As
a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and
future patent applications might not result in patents being issued that protect our technology or products, in whole or in part, or
that effectively prevent others from commercializing competitive technologies and products. Changes in the patent laws or their interpretation
by courts or patent offices might diminish the value of our patents or patent applications, or narrow their scope.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, term, validity or enforceability, and our solely or jointly owned
patents might be challenged in a U.S. or non-U.S. court or patent office. Such challenges might result in loss of exclusivity or in patent
claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using
or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and
products. Given the amount of time required for research, development, testing or regulatory review of product candidates, patents protecting
such candidates might expire before or shortly after such candidates are approved or commercialized. As a result, our solely or jointly
owned patents might not provide us with sufficient rights to exclude others from commercializing intended products similar or identical
to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that all patents applied for will be issued. If a third party has also filed a patent application relating to an invention
claimed by us, solely or jointly with one of our collaborators, we might be required to participate in an interference or derivation
proceeding declared or instituted by the United States Patent and Trademark Office, which could result in substantial uncertainties and
cost for us, even if the eventual outcome is favorable to us. The degree of future protection for our proprietary rights is uncertain.
For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    solely or jointly with our collaborators, might not have been the first to make the inventions covered by our pending or future patent
    applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    solely or jointly with our collaborators, might not have been the first to file patent applications for these inventions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    might independently develop identical, similar or alternative technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
is possible that our patent applications will not result in an issued patent or patents, or that the scope of protection granted by any
patents arising from our patent applications will be significantly narrower than expected;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    might be unaware of prior art that renders one or more of our patent applications unpatentable or one or more of our patents invalid;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court might determine that we failed to disclose to a patent office prior art that we were aware of and that is material to patentability
    and, therefore, conclude that one or more of our patents are unenforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    patents under which we hold rights might not cover commercially viable products, might not provide us with any competitive advantages
    or might be challenged by one or more third parties as being not infringed, being invalid, or being unenforceable under United States
    or foreign laws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court or patent office might determine that two or more of our patents claim patentably indistinct subject matter, which could adversely
    affect one or more of the patents&#8217; term, validity or enforceability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court or patent office might determine that one or more patents issued to us in the future or under which we hold rights are invalid
    or unenforceable; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    might develop additional proprietary technologies that are not patentable and which might not be adequately protected through trade
    secrets or know-how.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we solely or jointly own patents or patent applications in jurisdictions having, or that might in the future have, geopolitical
disputes, including over sovereignty. We cannot guarantee that patents granted in these jurisdictions will be enforceable. An inability
to enforce patents in these jurisdictions could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain patent term extension in the United States under the Hatch-Waxman Act or in foreign countries under similar legislation,
our business might be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the term of a patent that covers an FDA-approved drug, its method for use or method for manufacture, can be eligible
for patent term extension. U.S. law provides a patent term extension of up to five years beyond the expiration of the patent for time
during which the drug is under regulatory review. Patent term extension cannot extend the term of a patent beyond a total of 14 years
from the date of regulatory approval; only one patent can be extended for the same regulatory review period; and the scope of a patent&#8217;s
enforceability during a patent term extension is limited to the scope of FDA approval. There is no guarantee that the relevant agencies,
including the United States Patent and Trademark Office (&#8220;USPTO&#8221;), will agree with our assessment of whether such extensions
should be granted, and even if granted, the term of these extensions. We might not be granted patent term extension in the United States
or in any foreign country because of, for example, expiration of our patents before obtaining regulatory approval, failing to exercise
due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior
to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the length of a patent term extension,
as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request.
If we are unable to obtain any patent term extension or if the term of any such extension is less than we request, our competitors might
obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of
operations and prospects could be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering any of our product candidates
that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a
shorter period than we had sought.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations in agreements under which we have licensed or, might license, intellectual property rights from
third parties, or if we otherwise experience disruptions to our business relationships with our licensors, we could lose rights that
are important to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into, and might in the future enter into, one or more intellectual property license agreements that are important to our
business. These license agreements might impose various diligence, milestone payment, royalty and other obligations on us. For example,
we might be required to use commercially reasonable efforts to engage in various development and commercialization activities with respect
to licensed products, and might need to satisfy specified milestone and royalty payment obligations. If we fail to comply with any obligations
under our agreements with any of these licensors, we might be subject to termination of the license agreement in whole or in part, increased
financial obligations to our licensors or loss of exclusivity in a particular field or territory, in which case our ability to develop
or commercialize products covered by the license agreement will be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, disputes might arise regarding intellectual property subject to a license agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    our technology, product candidates or processes infringe intellectual property rights that are owned by the licensor, but that are
    not subject to the licensing agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and the activities that satisfy those obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are required to sublicense to a third party rights that the license grants to us, but that we do not commercially pursue; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ownership of inventions, data and know-how resulting from joint creation or use of intellectual property by our licensors and us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
disputes over intellectual property that we have licensed, or might in the future license, prevent or impair our ability to maintain
our licensing arrangements on acceptable terms, we may be unable to successfully develop or commercialize the affected product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may
fail to obtain any of these licenses at a commercially reasonable cost or on commercially reasonable terms, if at all. Other companies
might have a competitive advantage over us due to their larger size or cash resources or greater clinical development and commercialization
capabilities. We might be unable to further develop or commercialize one or more of our product candidates, which could harm our business
significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from
commercializing or increase the costs of commercializing our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on our ability to operate without infringing the proprietary rights of third parties. We cannot guarantee
that our intended products or our product candidates, or manufacture or use of our intended products or our product candidates, will
not infringe third party patents. Furthermore, a third party might claim that we are using without permission one or more inventions
covered by the third party&#8217;s patent rights and might go to court to stop us from engaging in our normal operations and activities,
including making, offering to sell or selling our product candidates. Still further a third party might go to court seeking judgment
that our patents are invalid or unenforceable. These lawsuits are costly and could affect our results of operations and divert the attention
of managerial and scientific personnel. Some of these third parties might be better capitalized and have more resources than us. There
is a risk that a court would decide that we are infringing the third party&#8217;s patents and would order us to stop the activities
covered by the patents. In that event, we might not have a viable way around the patent and might need to halt commercialization of the
relevant product candidate. In addition, there is a risk that a court will order us to pay the other party damages for having violated
the other party&#8217;s patents. There is also a risk that a court would decide that one or more of our patents are invalid or unenforceable.
In addition, we might be obligated to indemnify our licensors and collaborators against intellectual property infringement claims brought
by third parties, which could require us to expend additional resources. The pharmaceutical and biotechnology industries have produced
a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products
or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that we have identified all third party patents or pending patent applications that are or might be necessary for the
commercialization of our intended products and technologies in any jurisdiction. Patent applications in the United States and elsewhere
are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date
being commonly referred to as the priority date. Therefore, patent applications covering our technologies and intended products could
have been filed by others without our knowledge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover
our technologies or intended products. The scope of a patent claim is determined by the interpretation of the law, the words of a patent
claim, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope
of a patent or a pending patent application may be incorrect, which may negatively impact our ability to market our intended products.
We might incorrectly determine that our technologies or intended products are not covered by a third party patent or might incorrectly
predict whether a third party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United States or abroad that we consider relevant might be incorrect, and we might incorrectly conclude that
a third party patent does not cover our technology or intended products, is invalid or is unenforceable. Our inability to identify or
correctly interpret relevant patents might negatively impact our ability to develop or market our technologies or intended products.
If we fail to identify or correctly interpret relevant patents, we might be subject to infringement claims. We cannot guarantee that
we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to
being liable for damages, we might be temporarily or permanently enjoined or otherwise prohibited from commercializing any of technologies
or intended products that are held to be infringing. We might, if possible, also be forced to redesign intended products or product formulations
so that we no longer infringe the third party intellectual property rights. Any of these events, even if we were ultimately to prevail,
could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the pharmaceutical or biotechnology industry expands and more patents are issued, the risk increases that our product candidates or intended
products give rise to claims of infringement of the patent rights of others. There may be third party patents of which we are currently
unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of
our product candidates. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not
infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, negotiate and obtain a license
under reasonable terms to us or discontinue performing the allegedly infringing activities. We might not be able to do any of these.
Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence
to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we might incur substantial
costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us.
If we are unable to avoid infringing the patent rights of others, we might be required to seek a license, which might not be available,
and then we will have to defend an infringement action, challenge the validity of the patents in the USPTO or in court, or discontinue
performing the allegedly infringing activities. Patent litigation is costly and time consuming. We might not have sufficient resources
to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology,
fail to defend an infringement action successfully or fail to have infringed patents declared invalid or unenforceable, we might incur
substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing
or selling our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that others have not filed patent applications for technology covered by our pending applications, that we were the
first to invent the technology or that we were the first to file patent applications covering our technology, because:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">some
    patent applications in the United States are maintained in secrecy until the patents are issued;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patent
    applications in the United States are typically not published until 18 months after their earliest claimed priority date; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publications
    in the scientific literature often lag behind actual discoveries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors might have filed, and might in the future file, patent applications covering technology similar or identical to ours. Any
such patent applications might dominate our patent applications, which could further require us to obtain rights to issued patents covering
such technologies. If another party has filed US patent applications that cover inventions similar or identical to ours and claim priority
to any applications filed prior to the priority dates of our applications, we might have to participate in an interference proceeding
declared or a derivation proceed instituted by the USPTO to determine priority of invention in the United States. The costs of these
proceedings could be substantial, and it is possible that such efforts would be unsuccessful if the other party had independently arrived
at the same or similar inventions before us, possibly resulting in a loss of our U.S. patent position with respect to such inventions.
Other countries might have similar laws that permit secrecy of patent applications. Either way, the third party&#8217;s patents or patent
applications might be entitled to priority over our applications in such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors might be able to sustain the costs of a patent challenge more effectively than we can because they have substantially
greater resources. In addition, uncertainties regarding the outcome of the challenge could have a material adverse effect on our ability
to raise the funds necessary to continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade
secrets of one or more third parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the biotechnology and pharmaceutical industries, we employ, and might employ in the future, individuals who were previously
employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure
that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work
for us, we might be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise
used or disclosed trade secrets or other proprietary information of their former employers. Litigation might be necessary to defend against
these claims. If we fail in defending any such claims, in addition to paying monetary damages, we could lose valuable intellectual property
rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation
could result in substantial costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
intellectual property might not be sufficient to protect our intended products from competition, which might negatively affect our business
as well as limit our partnership or acquisition appeal.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might be subject to competition despite the existence of intellectual property we license or own. We can give no assurance that our intellectual
property claims will be sufficient to prevent third parties from designing around patents we own or license and developing and commercializing
competitive products. The existence of competitive products that avoid our intellectual property could materially adversely affect our
operating results and financial condition. Furthermore, any actual or perceived limitations, in our intellectual property might lessen
the interest of third parties to partner, collaborate or otherwise transact with us, if third parties perceive a higher than acceptable
risk to commercialization of our intended products or future products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
approach includes filing patent applications covering combination therapy with known, studied and/or marketed drugs. Although the protection
afforded by our patent applications might be significant, when looking at our patents&#8217; ability to block competition, the protection
offered by our patents might be, to some extent, more limited than protection provided by patents claiming a composition of matter that
is entirely new and previously unknown. If a competitor were able to successfully design around any combination therapy patents we have
or might have in the future, our business and competitive advantage could be significantly affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might elect to sue a third party, or otherwise make a claim, alleging infringement or other violation of patents, trademarks, trade dress,
copyrights, trade secrets, domain names or other intellectual property rights that we either own or license. We might alternatively elect
to sue a third party, or otherwise make a claim, alleging that we don&#8217;t infringe a third party&#8217;s patents or that the third
party&#8217;s patents are invalid or unenforceable. Any claims that we assert against a third party could provoke the third party to
assert one or more counterclaims against us, for example, alleging that we infringe their patents. In addition, in a patent infringement
proceeding, a court might decide that a patent of ours is invalid or unenforceable, in whole or in part; construe the patent&#8217;s
claims narrowly; or refuse to stop the other party from using the technology at issue. Any litigation proceeding could put one or more
of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Even if we prevail in a lawsuit, a court might
not award remedies that sufficiently compensate us for our losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not prevail in either type of litigation, we might be subject to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">paying
    monetary damages related to the legal expenses of the third party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facing
    additional competition that might have a significant adverse effect on our intended-product pricing, market share, business operations,
    financial condition, and the commercial viability of our intended products; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restructuring
    our company or delaying or terminating select business opportunities, including, but not limited to, research and development, clinical
    trials, and commercialization activities, due to a potential deterioration of our financial condition or market competitiveness.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third party might also challenge the validity, enforceability or scope of the intellectual property rights that we license or own, and
the result of these challenges might narrow the scope or claims of or invalidate patents that are integral to our product candidates
in the future. There can be no assurance that we will be able to successfully defend patents we own in an action against third parties
due to the unpredictability of litigation and the high costs associated with intellectual property litigation, among other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations of the
United States, and many companies have encountered significant difficulties in protecting and defending such rights in non-U.S. jurisdictions.
The legal systems of some countries are less supportive of enforcement of patents, trade secrets and other intellectual property protection,
than the United States. This could make it difficult for us to enforce our patents or market competing products outside the United States,
in violation of our proprietary rights generally. Proceedings to enforce our patent rights in non-U.S. jurisdictions, whether or not
successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our
patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third
parties to assert claims against us. We might not prevail in any lawsuits that we initiate, and the damages or other remedies awarded,
if any, might not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights in all jurisdictions
where we have the rights might be inadequate to obtain a significant commercial advantage from the intellectual property that we develop
or license. Furthermore, while we seek to protect our intellectual property rights in significant markets, we cannot ensure that we will
be able to initiate or maintain similar efforts in all jurisdictions in which we might wish to market our intended products or our product
candidates. Accordingly, our efforts to protect our intellectual property rights in such countries might be inadequate, which might have
an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets.
If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual
property rights important for our business in such jurisdictions, the value of these rights might be diminished, and we might face additional
competition from others in those jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to patent law, for example the Leahy-Smith America Invests Act, AIA or Leahy-Smith Act, of 2011 and the Patent Reform Act of 2009 and
other future article of legislation in the U.S., might substantially change the regulations and procedures surrounding patent applications,
issuance of patents, prosecution of patents, challenges to patent validity, and patent enforcement. We can give no assurance that our
patents or those of our licensor(s) can be defended or will protect us against future intellectual property challenges, particularly
as they pertain to changes in patent law and future patent law interpretations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, enforcing and maintaining our intellectual property protection depends on compliance with various procedural, document-submission,
fee-payment and other requirements imposed by the U.S. Patent and Trademark Office and courts, and foreign government patent agencies
and courts, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some jurisdictions outside the United States can be less extensive than those in the United States.
And filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates
might be prohibitively expensive or impractical. Competitors might use our technologies in jurisdictions where we have not obtained patent
protection to develop their own products or technologies and, further, may export otherwise infringing products or technologies to territories
where we and have patent protection, but where enforcement is not as strong as that in the United States. These third party products
or technologies might compete with our product candidates, and our intellectual property rights may not be effective or sufficient to
prevent third parties from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we might decide to abandon national or regional patent applications while they are still pending or to abandon granted patents.
This might invite or encourage third parties to develop their products or technologies in jurisdictions where we abandon patent applications
or patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not able to protect and control our unpatented trade secrets, know-how and other technological innovation, we might suffer competitive
harm.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on proprietary trade secrets and unpatented know-how to protect our research and development activities, particularly when
we do not believe that patent protection is appropriate or available. However, trade secrets are difficult to protect. We will attempt
to protect our trade secrets and unpatented know-how by requiring our employees, consultants, collaborators, and advisors to execute
a confidentiality and non-use agreement. We cannot guarantee that these agreements will provide meaningful protection; that these agreements
will not be breached, by, e.g., a misappropriating or disclosing our confidential information; that we will have an adequate remedy for
any such breach; or that our trade secrets will not otherwise become known or independently developed by a third party. Our trade secrets,
and those of our present or future collaborators that we utilize by agreement, might become known or might be independently discovered
by others, which could adversely affect the competitive position of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might incur substantial costs prosecuting our patent applications, maintaining our patents and patent applications, enforcing our patents,
defending against third party patent infringement suits, seeking invalidation of third party patents or in-licensing third party intellectual
property, as a result of litigation or other proceedings relating to patent and other intellectual property rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might be unaware of or unfamiliar with prior art and/or interpretations of prior art that could potentially impact the validity or scope
of our patents or pending patent applications, or patent applications that we will file. We might have elected, or elect now or in the
future, not to maintain or pursue intellectual property rights that, at some point in time, might be considered relevant to or enforceable
against a competitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
take efforts and enter into agreements with employees, consultants, collaborators, and advisors to confirm ownership of and chain of
title in intellectual property rights. However, an inventorship or ownership dispute could arise that might permit one or more third
parties to practice our intellectual property rights, including possible efforts to enforce rights against us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might not have rights under some patents or patent applications that cover technologies that we use in our research, drug targets that
we select, product candidates and particular uses thereof that we seek to develop and commercialize, as well as synthesis of our product
candidates. Third parties might own or control these patents and patent applications in the United States and elsewhere. These third
parties could bring claims against us or our collaborators that would cause us to incur substantial expenses and, if successful against
us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us or our collaborators, we
or they could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the
subject of the suit. We or our collaborators therefore might choose to seek, or be required to seek, a license from the third party and
would most likely be required to pay license fees or royalties or both. These licenses might not be available on acceptable terms, or
at all. Even if we or our collaborators were able to obtain a license, the rights might be nonexclusive, which would give our competitors
access to the same intellectual property. Ultimately, we could be prevented from commercializing a product or product candidate, or forced
to cease some aspect of our business operations, as a result of patent infringement claims, which could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees on issued U.S. patents are due to be paid to the USPTO, and periodic maintenance fees on issued non-U.S. patents and
pending non-U.S. patent applications are due to be paid to non-U.S. patent offices. Patent offices require compliance with many procedural,
documentary, fee payment and other requirements during the patent application process and after a patent issues or grants. While an inadvertent
lapse can in some cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations
in which non-compliance, for example, caused by geopolitical events such as civil or political unrest (including the ongoing conflict
between Ukraine and Russia), can result in abandonment or lapse of the patent or patent application, resulting in partial or complete
loss of a patent or patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a
patent or patent application include, but are not limited to, failure to respond to patent office actions within prescribed time limits,
non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to
enter the market, which would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
USPTO and various non-U.S. government agencies require compliance with certain foreign filing requirements during the patent application
process. For example, in some countries, including the United States, a foreign filing license is required before certain patent applications
are filed outside that country. The foreign filing license requirements can vary by country. In some cases, a foreign filing license
may be obtained retroactively in accordance with the applicable rules. There are situations, however, in which non-compliance can result
in abandonment of a pending patent application or can be grounds for revoking or invalidating an issued patent, resulting in the loss
of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the relevant markets with
similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results
of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been substantial litigation and other legal proceedings regarding patent and other intellectual property rights in the pharmaceutical
and biotechnology industries. Although we are not currently a party to any patent litigation or any other adversarial proceeding, including
any interference or derivation proceeding declared or instituted before the United States Patent and Trademark Office, regarding intellectual
property rights with respect to our intended products, our product candidates and our technology, it is possible that we might become
one in the future. We are not currently aware of any actual or reasonably foreseeable third party infringement claim involving our product
candidates. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. The outcome
of patent litigation is subject to uncertainties that cannot be adequately quantified in advance, including the dispute forum, demeanor
and credibility of witnesses and the identity of the adverse party, especially in pharmaceutical and biotechnology related patent cases
that might turn on the testimony of experts as to technical facts upon which experts might reasonably disagree. Some of our competitors
might be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater
financial resources. If a patent or other proceeding is resolved against us, we might be enjoined from researching, developing, manufacturing
or commercializing our intended products or our product candidates without a license from the other party and we might be held liable
for significant damages. We might not be able to obtain any required license on commercially acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainties
resulting from the initiation and continuation of patent litigation or other proceedings could harm our ability to compete in the marketplace.
Patent litigation or other proceedings might also absorb significant management time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect our intellectual property rights, our competitors might develop and market products with similar or identical
features that might reduce demand for our potential products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following factors are important to our success:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving
    patent protection for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preventing
    others from infringing our intellectual property rights; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    our patent rights and trade secrets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be able to protect our intellectual property rights in patents and trade secrets from unauthorized use by third parties only to
the extent that such intellectual property rights are covered by valid and enforceable patents or are effectively maintained as trade
secrets and we enforce these rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
issues of patentability involve complex legal and factual questions, the issuance, scope or enforceability of patents cannot be predicted
with certainty. Patents can be challenged, invalidated, found unenforceable, or circumvented. United States patents and patent applications
can be subject to interference or derivation proceedings. United States patents can also be subject to post grant proceedings, including
re-examination, derivation, <i>Inter Partes</i> Review and Post Grant Review, in the United States Patent and Trademark Office. Foreign
patents can be subject to opposition or comparable proceedings in corresponding foreign patent offices. Any of these challenges might
result in loss of the patent, rejection of the patent application or loss or reduction in the scope of one or more of the claims of the
patent or patent application. In addition, these proceedings can be costly. Thus, any patents that we own or license from others might
not provide any protection against competitors. Furthermore, an adverse decision in an interference or derivation proceeding can result
in a third party receiving the patent rights sought by us, which in turn could affect our ability to market a potential product to which
that patent filing was directed. Our pending patent applications, those that we might file in the future, or those that we might license
from third parties might not result in patents being issued. If issued, they might not provide us with proprietary protection or competitive
advantages against competitors with similar or identical technology. Furthermore, others might independently develop similar technologies
or duplicate any technology that we have developed. Some countries have compulsory licensing laws under which a patent owner might be
compelled to grant licenses to third parties. For example, compulsory licenses might be required in cases such as where the patent owner
has failed to &#8220;work&#8221; the invention in that country or where a third party has patented improvements. In addition, some countries
might limit the enforceability of patents against government agencies or government contractors. In these countries, we might have limited
infringement remedies, which could materially diminish the value of our patents. Moreover, the legal systems of some countries are less
supportive of enforcement of patents, trade secrets and other intellectual property protection, than the United States, which might make
it difficult to stop infringement in these countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers
who do not advertise or otherwise promote the compounds that are used in their products. Any litigation to enforce or defend our patent
rights, even if we prevail, could be costly and time-consuming and would divert the attention of management and key personnel from business
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will also rely on trade secrets, know-how and technology, which are not protected by patents, to maintain our competitive position. We
will seek to protect this information by entering into confidentiality agreements with parties that have access to it, such as strategic
partners, collaborators, employees, contractors and consultants. Any of these parties might breach these agreements and misappropriate
or disclose our confidential information or our competitors might learn of the information in some other way. If any trade secret, know-how
or other technology not protected by a patent were disclosed to, or independently developed by, a competitor, our business, financial
condition and results of operations could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization of Our Current Product Candidate and Future Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
commercial success depends upon attaining significant market acceptance of our current product candidate and future product candidates,
if approved, among physicians, patients, healthcare payors and cancer treatment centers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for our lead product candidate or any future product candidates, the products might not gain market
acceptance among physicians, healthcare payors, patients or the medical community, including cancer treatment centers. Market acceptance
of any product candidates for which we receive approval depends on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy and safety of such product candidates as demonstrated in clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications and patient populations for which the product candidate is approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    by physicians, major cancer treatment centers and patients of the drug as a safe and effective treatment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    adoption of novel immunotherapies by physicians, hospitals and third party payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential and perceived advantages of product candidates over alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    safety of product candidates seen in a broader patient group, including our use outside the approved indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    restrictions on use together with other medications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    labeling or product insert requirements of the FDA or other regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of our intended product as well as competitive products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    development of manufacturing and distribution processes for commercial scale manufacturing for our lead product candidate and any
    future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment in relation to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement from third party payors and government authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience and ease of administration; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our sales and marketing efforts and those of our collaborators.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our lead product candidate and any future product candidates are approved but fail to achieve market acceptance among physicians, patients,
healthcare payors or cancer treatment centers, we will not be able to generate significant revenues, which would compromise our ability
to become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we are able to commercialize our lead product candidate or any future product candidates, the products might not receive coverage
or adequate reimbursement from third party payors in the United States and in other countries in which we seek to commercialize our intended
products, which could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for
such product and related treatments will be available from third party payors, including government health administration authorities,
private health insurers and other organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
party payors determine which medications they will cover and establish reimbursement levels. A primary trend in the healthcare industry
is cost containment. Third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular
medications. Increasingly, third party payors are requiring that drug companies provide them with predetermined discounts from list prices
and are challenging the prices charged for medical products. Third party payors might also seek additional clinical evidence, beyond
the data required to obtain regulatory approval, demonstrating clinical benefit and value in specific patient populations before covering
our intended product for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product
that we commercialize and, if coverage is available, what the level of reimbursement will be. Coverage and reimbursement might impact
the demand for, or the price of, any product candidate for which we obtain regulatory approval. If reimbursement is not available or
is available only at limited levels, we might not be able to successfully commercialize any product candidate for which we obtain regulatory
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
might be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage might be more limited than
the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage
and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, might also not be sufficient
to cover our costs and might only be temporary. Reimbursement rates might vary according to the use of the drug and the clinical setting
in which it is used, might be based on reimbursement levels already set for lower cost drugs and might be incorporated into existing
payments for other services. Net prices for drugs might be reduced by mandatory discounts or rebates required by third party payors and
by any future relaxation of laws that presently restrict imports of drugs from countries where they might be sold at lower prices than
in the United States. No uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can
differ significantly from payor to payor. Third party payors can rely upon Medicare coverage policy and payment limitations in setting
their own reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Our inability
to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved product
that we develop could have a material adverse effect on our operating results, ability to raise capital needed to commercialize our intended
product and overall financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
legislative measures aimed at reducing healthcare costs might have a material adverse effect on our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling
healthcare costs. In both the United States and certain international jurisdictions, there have been a number of legislative and regulatory
changes to the health care system that could impact our ability to sell our intended product profitably. In particular, in 2010, the
Affordable Care Act (&#8220;ACA&#8221;) was enacted, which, among other things, subjected biologic products to potential competition
by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by
most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions
of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded
prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at
containing or lowering the cost of healthcare. We cannot predict the initiatives that might be adopted in the future. The continuing
efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce
costs of healthcare and/or impose price controls might adversely affect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    demand for our lead product candidate, if we obtain regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to receive or set a price that we believe is fair for our intended product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to generate revenue and achieve or maintain profitability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of taxes that we are required to pay; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of capital.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the ACA, as well as other healthcare reform measures that might be adopted in the future, might result in additional reductions
in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could
lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other
government-funded programs might result in a similar denial or reduction in payments from private payors, which might prevent us from
being able to generate sufficient revenue, attain profitability or commercialize our product candidate, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Price
controls might be imposed in foreign markets, which might adversely affect our future profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some countries, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental
authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure
by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political,
economic and regulatory developments might further complicate pricing negotiations, and pricing negotiations might continue after reimbursement
has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced
and high-priced member states, can further reduce prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some countries, we or our collaborators might be required to conduct a clinical trial or other studies that compare the cost-effectiveness
of our product candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of
discounts by third party payors or authorities might lead to further pressure on the prices or reimbursement levels within the country
of publication and other countries. If reimbursement of our intended product is unavailable or limited in scope or amount, or if pricing
is set at unsatisfactory levels, our business could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Healthcare Compliance Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers and third party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare
laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished
profits and future earnings. If we or they are unable to comply with these provisions, we might become subject to civil and criminal
investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and third party payors will play a primary role in the recommendation and prescription of any product candidates
for which we obtain regulatory approval. Our current and future arrangements with healthcare providers, healthcare entities, third party
payors and customers might expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that might constrain
the business or financial arrangements and relationships through which we research, develop and will market, sell and distribute our
intended product. As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly
to Medicare, Medicaid or other third party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and
patients&#8217; rights are applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations
that might affect our ability to operate include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal healthcare Anti-Kickback Statute which prohibits, among other things, individuals and entities from knowingly and willfully
    soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce
    or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service,
    for which payment might be made under a federal healthcare program such as Medicare and Medicaid;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims laws, including the federal False Claims Act that can be enforced through civil whistleblower or
    qui tam actions, and civil monetary penalty laws, prohibit individuals or entities from knowingly presenting, or causing to be presented,
    to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent
    or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) which imposes criminal and civil liability
    for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and
    willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the
    delivery of or payment for healthcare benefits, items or services, as amended by the Health Information Technology for Economic and
    Clinical Health Act of 2009 (&#8220;HITECH&#8221;) which imposes obligations, including mandatory contractual terms, with respect
    to safeguarding the privacy, security and transmission of individually identifiable health information on entities subject to the
    law, such as certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, and their respective
    business associates that perform services for them that involve the creation, use, maintenance or disclosure of, individually identifiable
    health information;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal physician sunshine requirements under the ACA which requires certain manufacturers of drugs, devices, biologics and medical
    supplies, with certain exceptions, to report annually to HHS information related to payments and other transfers of value to physicians,
    other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare
    providers and their immediate family members and applicable group purchasing organizations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, which might apply to sales or marketing
    arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private
    insurers; some state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance
    guidelines and the relevant compliance guidance promulgated by the federal government and might require drug manufacturers to report
    information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures
    or pricing information; and certain state and local laws which require the registration of pharmaceutical sales representatives;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign laws govern the privacy and security of health information in specified circumstances, many of which differ from each
    other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices might not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that might apply to us, we might be subject to
significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded
healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring
of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be
in compliance with applicable laws, they might be subject to criminal, civil or administrative sanctions, including exclusions from government
funded healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees might engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could cause significant liability for us and harm our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar
regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities,
comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations
and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information
or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information
obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity might not be effective
in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits
stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are
not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results
of operations, including the imposition of significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion
from government funded healthcare programs, such as Medicare and Medicaid, and integrity oversight and reporting obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we
might develop.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability exposure related to the testing of our lead product candidate or future product candidates
in human clinical trials and will face an even greater risk if we commercially sell any products that we might develop. Product liability
claims might be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering
or selling our intended product. If we cannot successfully defend ourselves against claims that our lead product candidate or product
caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims might result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for any product candidates or products that we might develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of clinical trial sites or entire clinical trial programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation and significant negative media attention;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    costs to defend the related litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial subjects or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management and scientific resources from our business operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any products that we might develop.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to engaging in clinical trials, we obtain product liability insurance coverage at a level that we believe is customary for similarly
situated companies and adequate to provide us with insurance coverage for foreseeable risks; however, we might be unable to obtain such
coverage at a reasonable cost, if at all. If we are able to obtain product liability insurance, we might not be able to maintain insurance
coverage at a reasonable cost or in an amount adequate to satisfy any liability that might arise and such insurance might not be adequate
to cover all liabilities that we might incur. Furthermore, we intend to expand our insurance coverage for products to include the sale
of commercial products if we obtain regulatory approval for our lead product candidate in development, but we might be unable to obtain
commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded
in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims
brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Business Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face substantial competition, which might result in others discovering, developing or commercializing products before or more successfully
than we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies
and private and public research institutions for our lead product candidate. Our commercial opportunities will be reduced or eliminated
if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than
any products that we might develop. Competition could result in reduced sales and pricing pressure on our lead product candidate, if
approved, which in turn would reduce our ability to generate meaningful revenues and have a negative impact on our results of operations.
In addition, significant delays in the development of our lead product candidate could allow our competitors to bring products to market
before we do and impair our ability to commercialize our lead product candidate. The biotechnology industry, including the cancer immunotherapy
market, is intensely competitive and involves a high degree of risk. We compete with other companies that have far greater experience
and financial, research and technical resources than us. Potential competitors in the United States and worldwide are numerous and include
pharmaceutical and biotechnology companies, educational institutions and research foundations, many of which have substantially greater
capital resources, marketing experience, research and development staffs and facilities than ours. Some of our competitors might develop
and commercialize products that compete directly with those incorporating our technology or might introduce products to market earlier
than our intended product or on a more cost-effective basis. Our competitors compete with us in recruiting and retaining qualified scientific
and management personnel as well as in acquiring technologies complementary to our technology. We might face competition with respect
to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing
and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent position, including the potentially
dominant patent positions of others. An inability to successfully complete our product development or commercializing our lead product
candidate could result in our having limited prospects for establishing market share or generating revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors or potential competitors have significantly greater established presence in the market, financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved products than we do, and as a result might have a competitive advantage over us. Mergers and acquisitions in the pharmaceutical
and biotechnology industries might result in even more resources being concentrated among a smaller number of our competitors. Smaller
or early-stage companies might also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses
complementary to our programs or potentially advantageous to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, these competitors might obtain regulatory approval of their products before we are able to obtain patent protection
or other intellectual property rights, which will limit our ability to develop or commercialize our lead product candidate. Our competitors
might also develop drugs that are safer, more effective, more widely used and cheaper than ours, and might also be more successful than
us in manufacturing and marketing their products. These appreciable advantages could render our lead product candidate obsolete or non-competitive
before we can recover the expenses of development and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business might be adversely affected by the coronavirus or other pandemics.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout the world
as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak has subsided,
the extent to which the coronavirus pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital raising
efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
disruptions of information technology systems, computer system failures or breaches of information and cyber security could adversely
affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely to a large extent upon sophisticated information technology systems to operate our business. In the ordinary course of business,
we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual
property). The size and complexity of our information technology and information security systems, and those of our third party vendors
with whom we might contract, make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent
or intentional actions by our employees or vendors, or from malicious attacks by third parties. Such attacks are of ever-increasing levels
of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage
and market manipulation) and expertise. While we intend to invest in the protection of data and information technology, there can be
no assurance that our efforts will prevent service interruptions or security breaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal computer systems, and those of our CROs, our CMOs, and other business vendors on which we might rely, are vulnerable to damage
from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. We
exercise little or no control over these third parties, which increases our vulnerability to problems with their systems. If such an
event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs.
Any interruption or breach in our systems could adversely affect our business operations and/or result in the loss of critical or sensitive
confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us or allow
third parties to gain material, inside information that they use to trade in our securities. For example, the loss of clinical trial
data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data
or applications, or misappropriation or disclosure of confidential or proprietary information, we could incur liability, the further
development of our lead and future product candidates could be delayed and our business could be otherwise adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might need to grow the size of our organization in the future, and we might experience difficulties in managing this growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 14, 2025, we had two officer/employees, our Chief Executive Officer and our Chief Financial Officer, and one consultant, our
Chief Medical Officer. The Company relies to a significant extent on outside consultants and advisors with various technical skills and
expertise that the Company can draw on as necessary to conduct its research and development and clinical trial programs. We might need
to grow the size of our organization in order to support our continued development and potential commercialization of our lead product
candidate. As our development and commercialization plans and strategies continue to develop, our need for additional managerial, operational,
manufacturing, sales, marketing, financial and other resources might increase. Our management, personnel and systems currently in place
might not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our clinical trials effectively;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, maintaining, motivating and integrating additional employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors
    and other third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our managerial, development, operational, information technology, and finance systems; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanding
    our facilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations expand, we will likely also need to manage additional relationships with various strategic partners, suppliers and other
third parties. Our future financial performance and our ability to commercialize our lead product candidate and to compete effectively
will depend, in part, on our ability to manage any future growth effectively, as well as our ability to develop a sales and marketing
force when appropriate for our company. To that end, we must be able to manage our development efforts and preclinical studies and clinical
trials effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales
and marketing personnel. The failure to accomplish any of these tasks could prevent us from successfully growing our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inadequate
funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel,
prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from
performing normal business functions on which the operation of our business might rely, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other
government agencies on which our operations might rely, including those that fund research and development activities is subject to the
political process, which is inherently fluid and unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies might also slow the time necessary for new drugs to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several
times for various periods of time, and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC
and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact
the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and
obtain necessary capital in order to properly capitalize and continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unstable
market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have
serious adverse consequences on our business, financial condition and stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity
and credit availability, declines in consumer confidence, declines in economic growth, inflationary pressures and interest rate changes,
increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely
affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, between Israel
and Gaza, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts,
including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures
by the affected countries or others could exacerbate market and economic instability. Future adverse developments with respect to financial
institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies
to access near-term working capital needs, and create additional market and economic uncertainty. There can be no assurance that future
credit and financial market instability and a deterioration in confidence in economic conditions will not occur. Our general business
strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment or continued unpredictable
and unstable market conditions. If the equity markets deteriorate, or if adverse developments are experienced by financial institutions,
it may cause short-term liquidity risk and also make any necessary equity financing more difficult, more costly and more dilutive. Failure
to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our business plans
and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of
our current service providers, financial institutions, manufacturers and other partners may be adversely affected by the foregoing risks,
which could directly affect our ability to conduct our business plans on schedule and on budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Owning our Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;smaller reporting company&#8221; and we have elected to comply with certain reduced reporting and disclosure requirements
which could make its common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company,&#8221; as defined in the Regulation S-K of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), which allows us to take advantage of certain exemptions from various reporting requirements that are applicable to other
public companies that are not smaller reporting companies, including (1) not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act of 2002, and (2) reduced disclosure obligations regarding executive compensation in our periodic
reports and proxy statements. In addition, as an emerging growth company, we are only required to provide two years of audited financial
statements in this document. As a result of these reduced reporting and disclosure requirements our financial statements might not be
comparable to SEC registrants not classified as emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our common stock less attractive because we might rely on these exemptions. If some investors find
our common stock less attractive as a result, there might be a less active trading market for our common stock and our stock price might
be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm is not required to formally attest to the effectiveness of our internal control over financial
reporting until we are no longer a &#8220;smaller reporting company&#8221;. We cannot assure you that there will not be material weaknesses
or significant deficiencies in our internal controls in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
might find our common stock less attractive as a result of our election to utilize these exemptions, which could result in a less active
trading market for our common stock and/or the market price of our common stock might be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
publicly-traded warrants that we issued in our November 2020 public offering are speculative in nature.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants issued in our November 2020 public offering do not confer any rights of common stock ownership on their holders, such as voting
rights or the right to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically,
holders of the warrants may exercise their right to acquire the common stock and pay an effective exercise price of $57.00 per share,
which is substantially in excess of the current market price of the Company&#8217;s common stock. Furthermore, each warrant will expire
five years from the original issuance date, which is November 20, 2025. In the event our common stock price does not exceed the exercise
price of the warrants during the period when the warrants are exercisable, the warrants may not have any value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders
of the warrants have no rights as a common stockholder until they acquire our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
the acquisition of shares of our common stock upon exercise of the warrants, a holder has no rights with respect to shares of our common
stock issuable upon exercise of the warrant. Upon exercise of a warrant, a holder will be entitled to exercise the rights of a common
stockholder as to the security exercised only as to matters for which the record date occurs after the exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is a limited market for the warrants to purchase shares of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the warrants are currently trading on The Nasdaq Capital Market, there can be no assurance that an active trading market for the warrants
will develop. Without an active trading market, the liquidity of the warrants will continue to be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of certain warrants could discourage a change-in control transaction involving a third party.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our warrants contain provisions that could make it more difficult or expensive for a third party to make an investment in us acquire
us in a change-in-control transaction. Under certain transactions constituting a &#8220;fundamental transaction&#8221;, the Company could
be required to redeem the warrants for a cash payment calculated pursuant to the Black-Scholes option-pricing model. These and other
provisions of the warrants could prevent or deter a third party from acquiring us or investing in us in a change-in control transaction,
even where the acquisition could be beneficial to you.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>July
20, 2023 sale of common stock and warrants.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, we sold 583,334 shares of common stock at a price of $6.00 per share to an institutional investor and raised gross proceeds
of approximately $3,500,000. As part of this financing, the Company sold warrants to the institutional investor to purchase 583,334 shares
of common stock. The common warrants had an initial exercise price of $6.00 per share, were immediately exercisable upon issuance, and
expire five years thereafter on July 20, 2028. The Company also issued warrants to the placement agent to purchase 35,000 shares of common
stock at an exercise price of $6.60 per share and expiring on July 20, 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investor and to the placement agent are subject to customary adjustments
for stock splits, stock dividends, stock combinations, reclassifications, reorganizations, or similar events affecting the Company&#8217;s
common stock. In addition, the warrants issued to the institutional investor contain a &#8220;fundamental transaction&#8221; provision
whereby in the event of a fundamental transaction (including a sale or transfer of assets or ownership of the Company as defined in the
warrant agreement) within the Company&#8217;s control, the holder of the unexercised common stock warrants would be entitled to receive,
in exchange for extinguishment of the warrants, cash consideration equal to a Black-Scholes valuation, as defined in the warrant agreement.
If such fundamental transaction is not within the Company&#8217;s control, the warrant holder would only be entitled to receive the same
form of consideration (and in the same proportion) as the holders of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
in the event of a change in control of the Company or a sale or transfer of all or substantially all of the Company&#8217;s assets, as
defined in the warrants, to the extent that the warrants issued to the institutional investor are outstanding at the effective date that
such a transaction is closed, this &#8220;fundamental transaction&#8221; provision would entitle the holder to substantial cash consideration,
thus reducing the amounts to be retained by the Company or potentially distributable to the Company&#8217;s stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>February
13, 2025 sale of common stock and warrants.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2025, we sold 434,784 shares of common stock at a price of $2.415 per share to two institutional investors and raised gross
proceeds of approximately $1,050,000. As part of this financing, the Company sold warrants to the institutional investors to purchase
434,784 shares of common stock. The common warrants had an initial exercise price of $2.29 per share, were immediately exercisable upon
issuance, and expire five years thereafter on February 13, 2030. The Company also issued warrants to the placement agent to purchase
32,609 shares of common stock at an exercise price of $3.0188 per share and expiring on February 13, 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investors and to the placement agent are subject to customary adjustments
for stock splits, stock dividends, stock combinations, reclassifications, reorganizations, or similar events affecting the Company&#8217;s
common stock. In addition, the warrants issued to the institutional investors contain a &#8220;fundamental transaction&#8221; provision
whereby in the event of a fundamental transaction (including a sale or transfer of assets or ownership of the Company as defined in the
warrant agreement) within the Company&#8217;s control, the holders of the unexercised common stock warrants would be entitled to receive,
in exchange for extinguishment of the warrants, cash consideration equal to a Black-Scholes valuation, as defined in the warrant agreement.
If such fundamental transaction is not within the Company&#8217;s control, the warrant holders would only be entitled to receive the
same form of consideration (and in the same proportion) as the holders of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
in the event of a change in control of the Company or a sale or transfer of all or substantially all of the Company&#8217;s assets, as
defined in the warrants, to the extent that the warrants issued to the institutional investors are outstanding at the effective date
that such a transaction is closed, this &#8220;fundamental transaction&#8221; provision would entitle the holders to substantial cash
consideration, thus reducing the amounts to be retained by the Company or potentially distributable to the Company&#8217;s stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management has broad discretion over the use of the proceeds from any stock offerings we may conduct in the future and we may apply it
to uses that do not improve our operating results or the value of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the application of the net proceeds from any stock offerings, and investors will be relying
solely on the judgment of our management regarding the application of these proceeds. Although we expect to use the net proceeds from
an offering for working capital and general corporate purposes, including the ongoing clinical development of our lead compound LB-100,
we have not allocated these net proceeds for specific purposes. Investors will not have the opportunity, as part of their investment
decision, to assess whether the proceeds are being used appropriately. Our use of the proceeds may not improve our business prospects
or increase the value of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
part of the Company&#8217;s ongoing process of evaluating various alternatives to obtain the capital required to fund its operations
and maintain its listing on Nasdaq, management may decide to consider a wide variety of strategic alternatives, and there can be no assurances
that any such transaction, if implemented, would enhance stockholder value, and could be highly dilutive to existing stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is evaluating various alternatives to obtain the capital required to fund its operations and maintain its listing on Nasdaq,
including merger or acquisition opportunities (including reverse mergers) and funding transactions involving a change in control. There
can be no assurances that the evaluation process will result in the identification of an appropriate transaction, the negotiation and
execution of a definitive agreement to effect such a transaction, or that any such transaction will ultimately be approved by the Company&#8217;s
stockholders and then be consummated. Depending on various factors, many of which are outside the control of the Company, our failure
to enter into and consummate a strategic transaction could have a material adverse effect on our ability to continue to operate and finance
our business, and on the market price of our common stock. Even if such a strategic transaction is consummated, there can be no assurances
that it will enhance stockholder value, and it may result in substantial dilution to existing stockholders. Any potential transaction
would be dependent on a number of factors that may be outside of our control, including, among other things, market conditions, industry
trends, the interest of third parties in a potential transaction with the Company, and the availability of appropriate financing for
such a transaction. If we are unable to raise the required capital to fund our operations, or to enter into a strategic transaction in
the near future, we may need to curtail or cease operations, which could result in a total loss of stockholders&#8217; investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our common stock or warrants might fluctuate substantially.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consider an investment in our common stock and warrants to be risky. Some factors that might cause the market price of our common
stock or warrants to fluctuate, in addition to the other risks mentioned in this &#8220;Risk Factors,&#8221; are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of our common stock by our stockholders, executives, and directors and our stockholders;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of our shares of common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financings to conduct and complete research and development activities including, but not limited to, our clinical
    trials, and other business activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and success of introductions of new products by us or our competitors or any other change in the competitive dynamics of our
    industry, including consolidation among competitors, customers or strategic partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">network
    outages or security breaches;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure resources and the necessary personnel to conduct clinical trials on our desired schedule;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement,
    enrollment or results of our clinical trials for our lead product candidate or any future clinical trials we might conduct;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the development status of our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays or adverse developments or perceived adverse developments with respect to the FDA&#8217;s review of our planned preclinical
    and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our submission for studies or product approvals or adverse regulatory decisions, including failure to receive regulatory
    approval for our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    safety concerns related to the use of our lead product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures
    to meet external expectations or management guidance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    and events surrounding financing efforts, including debt and equity securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to enter into new markets or develop new products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reputational
    issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing technologies and products or new technologies and products that might emerge;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in general economic, political and market conditions in or any of the regions in which we conduct our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in industry conditions or perceptions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in valuations of similar companies or groups of companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst
    research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures
    and additions of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    and litigations related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which might be out of our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences
a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition
and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and might expose us to lawsuits that,
even if unsuccessful, could be costly to defend and a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Company&#8217;s Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Compliance. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock in order to remain in compliance
with the $1.00 minimum closing bid price requirement of Nasdaq. However, there can be no assurances that the Company will be able to
remain in compliance with the $1.00 minimum closing bid price requirement of Nasdaq over time. In addition, Nasdaq has other continued
listing requirements, one of which is maintaining a minimum net stockholders&#8217; equity of $2,500,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2024, the Company received a letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock
Market LLC (&#8220;Nasdaq&#8221;) on August 19, 2024 indicating that the Company was not in compliance with the minimum stockholders&#8217;
equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &#8220;Stockholders&#8217;
Equity Requirement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders&#8217; Equity Requirement, which
outlined the Company&#8217;s proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2024, the Staff provided notice (the &#8220;Notice&#8221;) to the Company that it had granted an extension through February
18, 2025 to regain compliance with the Stockholders&#8217; Equity Requirement, which required that the Company complete its capital raising
initiatives and evidence compliance with the Stockholders&#8217; Equity Requirement through filing a Current Report on Form 8-K with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) providing certain required information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 18, 2025, the Company had not gained compliance with the Stockholders&#8217; Equity Requirement. Accordingly, on February
19, 2025, the Company received a Staff determination letter from the Staff stating that the Company did not meet the terms of the extension
because it did not complete its proposed financing initiatives to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company timely filed an appeal and requested a Hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;), which has been granted.
The Hearing request automatically stayed Nasdaq&#8217;s delisting of the Company&#8217;s common shares and warrants pending the Panel&#8217;s
decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension through no
later than August 18, 2025. At the upcoming hearing, the Company will present its plan for regaining and sustaining compliance with the
Stockholders&#8217; Equity Requirement for continued listing. However, there can be no assurances that the Hearings Panel will grant
the Company an extension of time to regain compliance, or that the Company will be able to regain compliance during any extension period.
During the appeal process the Company&#8217;s common shares and warrants will continue to trade on The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to take reasonable measures available to regain compliance under Nasdaq&#8217;s listing rules and to remain listed on
Nasdaq. However, there can be no assurances that the Company will ultimately regain compliance with the Stockholders&#8217; Equity Rule,
or be able to maintain compliance with all other applicable requirements for continued listing on Nasdaq. If the Company does not regain
compliance with Nasdaq&#8217;s continued listing requirements within the time period permitted by Nasdaq, then the Company&#8217;s securities
will be delisted from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company were to be delisted from Nasdaq, its common stock and warrants may be eligible for trading on an over-the-counter market.
If the Company is not able to obtain a listing on another stock exchange or quotation service for its common stock and warrants, it may
be extremely difficult or impossible for stockholders to sell their shares of common stock and warrants. Moreover, if the Company is
delisted from Nasdaq, but obtains a substitute listing for its common stock and warrants, it will likely be on a market with less liquidity,
and therefore experience potentially more price volatility than experienced on Nasdaq. Stockholders may not be able to sell their shares
of common stock and warrants on any such substitute market in the quantities, at the times, or at the prices that could potentially be
available on a more liquid trading market. As a result of these factors, if the Company&#8217;s common stock is delisted from Nasdaq,
the value and liquidity of the Company&#8217;s common stock and warrants would likely be significantly adversely affected. A delisting
of the Company&#8217;s common stock from Nasdaq could also adversely affect the Company&#8217;s ability to obtain financing for its operations
and/or could result in a loss of confidence by investors, employees and/or business partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
sale or perceived sale of a substantial number of shares of our common stock might cause the price of our common stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our stockholders sell substantial amounts of our common stock in the public market, the market price of our common stock could fall.
Moreover, the perceived risk of this potential dilution could cause stockholders to attempt to sell their shares and investors to short
our common stock. These sales also might make it more difficult for us to sell equity or equity-related securities in the future at a
time and price that we deem reasonable or appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
and economic conditions might negatively impact our business, financial condition and share price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concerns
over medical epidemics, energy costs, geopolitical issues, the U.S. mortgage market and a deteriorating real estate market, unstable
global credit markets and financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished
liquidity and credit availability, declines in consumer confidence and discretionary spending, diminished expectations for the global
economy and expectations of slower global economic growth, increased unemployment rates, and increased credit defaults in recent years.
Our general business strategy might be adversely affected by any such economic downturns (including the impact related to the recent
COVID-19 pandemic), volatile business environments and continued unstable or unpredictable economic and market conditions. If these conditions
continue to deteriorate or do not improve, it might make any necessary debt or equity financing more difficult to complete, more costly,
and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse
effect on our growth strategy, financial performance, and share price and could require us to delay or abandon development or commercialization
plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our
stock price and trading volume might decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us,
our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our common stock,
the lack of research coverage might adversely affect the market price of our common stock. Furthermore, if one or more of the analysts
who do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business, our stock price
would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose
visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading volume to decline
and might also impair our ability to expand our business with existing customers and attract new customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales and issuances of our common stock could result in additional dilution of the percentage ownership of our stockholders and could
cause our share price to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we will need to issue additional authorized but previously unissued equity securities, resulting in the dilution of the ownership
interests of our stockholders. We may also issue additional common stock, warrants or other securities that are convertible into or exercisable
for common stock in connection with future mergers or acquisitions, future sales of securities for capital raising purposes, or for other
business purposes, in one or more transactions at prices and in a manner that we determine from time to time. The future issuance of
any such additional shares of common stock may create downward pressure on the trading price of the common stock. There can be no assurances
that we will not be required to issue additional shares, warrants or other convertible securities in the future in conjunction with any
capital raising efforts, and the new investors could gain rights superior to our existing stockholders in any such transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate
declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase,
if any, of our share price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might be at risk of securities class action litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might be at risk of securities class action litigation. In the past, biotechnology and pharmaceutical companies have experienced significant
stock price volatility, particularly when associated with binary events such as clinical trials and product approvals. If we face such
litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our
business and results in a decline in the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation and our Amended and Restated Bylaws, and Delaware law might have anti-takeover effects that could discourage,
delay or prevent a change in control, which might cause our stock price to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and our Amended and Restated Bylaws, and Delaware law could make it more difficult for a third party to
acquire us, even if closing such a transaction would be beneficial to our stockholders. We are authorized to issue up to 10,000,000 shares
of preferred stock. This preferred stock might be issued in one or more series, the terms of which might be determined at the time of
issuance by our Board of Directors without further action by stockholders. The terms of any series of preferred stock might include voting
rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption
rights and sinking fund provisions. We have designated 350,000 shares of preferred stock as Series A Convertible Preferred Stock, all
of which are issued and outstanding. The issuance of any preferred stock could materially adversely affect the rights of the holders
of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights granted to future holders of
preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control
by the present management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our Certificate of Incorporation and our Amended and Restated Bylaws and Delaware law also could have the effect of discouraging potential
acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider
favorable. Such provisions might also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular,
the certificate of incorporation and bylaws and Delaware law, as applicable, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    the Board of Directors with the ability to alter the bylaws without stockholder approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">place
    limitations on the removal of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    advance notice requirements for nominations for election to the Board of Directors or for proposing matters that can be acted upon
    at stockholder meetings; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that vacancies on the Board of Directors might be filled by a majority of directors in office, although less than a quorum.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be required
to devote substantial time to compliance matters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly traded company we incur significant additional legal, accounting and other expenses. The obligations of being a public company
in the United States require significant expenditures and will place significant demands on our management and other personnel, including
costs resulting from public company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance
practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and the listing
requirements of the stock exchange on which our securities are listed. These rules require the establishment and maintenance of effective
disclosure and financial controls and procedures, internal control over financial reporting and changes in corporate governance practices,
among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Moreover, despite recent
reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations will make some activities more time-consuming
and costly, particularly after we are no longer an &#8220;emerging growth company&#8221;. In addition, we expect these rules and regulations
to make it more difficult and more expensive for us to obtain director and officer liability insurance. Our management and other personnel
will need to devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with new regulations,
otherwise we might fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the rules under Sarbanes-Oxley related to accounting controls and procedures in the future, or, if we discover
material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
and raising capital could be more difficult.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404 of Sarbanes-Oxley requires annual management assessments of the effectiveness of our internal control over financial reporting. If
we fail to comply with the rules under Sarbanes-Oxley related to disclosure controls and procedures in the future, or, if we discover
material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
and raising capital could be more difficult. If material weaknesses or significant deficiencies are discovered or if we otherwise fail
to achieve and maintain the adequacy of our internal control, we might not be able to ensure that we can conclude on an ongoing basis
that we have effective internal controls over financial reporting in accordance with Section 404 of Sarbanes-Oxley. Moreover, effective
internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud. If
we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose
confidence in our reported financial information, and the trading price of our common stock could drop significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>ITEM
1C. CYBERSECURITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_981_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-OOESUXFV_zsEWecyJu6gi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000052-01" escape="true" id="Fact000052" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Management and Strategy</b></span></ix:nonNumeric></p>

<div id="xdx_C09_gBFCRMPFAIAMT-OOESUXFV_zCdo4JemS9Wc"><ix:continuation continuedAt="ConU000052-02" id="ConU000052-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zJXUajnDerac" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000053" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">We
have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have <span id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z2cccSJvoRY3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">integrated</ix:nonNumeric></span>
these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats,
including any potential unauthorized occurrence on or conducted through our information and email systems that may result in adverse
effects on the confidentiality, integrity, or availability of our information and email systems or any information residing therein.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zb8js64TZvA7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000055" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">We
conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our
business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include
identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such
risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
these risk assessments, we intend to take any steps necessary to redesign, implement, and maintain reasonable safeguards to minimize
identified risks; to reasonably address any identified gaps in existing safeguards; and to regularly monitor the effectiveness of our
safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with an IT consultant, who reports
to our Chief Executive Officer and Chief Financial Officer, to manage the risk assessment and mitigation process. As part of our overall
risk management system, we monitor and periodically evaluate our safeguards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may engage consultants, or other <span id="xdx_900_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zDtwoLnAn6sl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third parties</ix:nonNumeric></span> in connection with our risk assessment processes. These service providers can assist us
to design and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have <span id="xdx_908_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zVBe9V9MMel6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000057" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">not</ix:nonNumeric></span> encountered cybersecurity challenges that have materially impaired our operations or financial condition. Additional
information regarding risks from cybersecurity threats is provided at &#8220;Item 1A. Risk Factors&#8221;.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C09_gBFCRMPFAIAMT-OOESUXFV_zk7LBl9qV3ih"><ix:continuation id="ConU000052-02">&#160;</ix:continuation></span></span></p>

<p id="xdx_98B_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_gBFCRBODOTB-UQKBFT_z7VEcwaA64F" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000060-01" escape="true" id="Fact000060" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span></ix:nonNumeric></p>

<div id="xdx_C08_gBFCRBODOTB-UQKBFT_zQdwHybDukah"><ix:continuation continuedAt="ConU000060-02" id="ConU000060-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zNsi1iNNlH3k" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000061" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">One
of the functions of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats.
Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible
for the day-to-day management of the material risks that we face. Our Board of Directors administers its cybersecurity risk oversight
function directly as a whole, as well as through the audit committee.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_z9c24LgH3xW9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000062" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our
Chief Executive Officer and Chief Financial Officer are primarily responsible to assess and manage our material risks from cybersecurity
threats with assistance from third-party service providers.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zDME1MjQBUV" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000063" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">Our
Chief Executive Officer and Chief Financial Officer interact with our IT consultant and oversee our cybersecurity policies and processes,
including those described above at &#8220;Risk Management and Strategy&#8221;. The cybersecurity risk management program includes tools
and activities to prevent, detect, and analyze current and emerging cybersecurity threats, and plans and strategies to address threats
and incidents.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_z1pZM2QgKpL9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000064" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">Our
Chief Executive Officer and Chief Financial Officer provide periodic briefings to the audit committee regarding the Company&#8217;s cybersecurity
risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of
third parties, and similar issues.</ix:nonNumeric></span></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C09_gBFCRBODOTB-UQKBFT_ztob4sKdtcj6"><ix:continuation id="ConU000060-02">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of December 31, 2024, the
Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and warrants have traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively, since November 25, 2020. The stock market in general has experienced significant price fluctuations in the past few years.
In some cases, these fluctuations have been unrelated to the operating performance of the affected companies. Many companies have experienced
dramatic volatility in the market prices of their common stock. The Company believes that a number of factors, both within and outside
its control, could cause the price of the Company&#8217;s common stock to fluctuate, perhaps substantially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the range of reported closing prices of the Company&#8217;s common stock during the periods presented, and
have been retroactively adjusted for all periods presented to reflect the 1-for-10 reverse split of the Company&#8217;s outstanding shares
of common stock effected on June 2, 2023. Such quotations reflect prices between dealers in securities and do not include any retail
mark-up, markdown, or commissions, and may not necessarily represent actual transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Low</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">High</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Year Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">First Quarter</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.90</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Second Quarter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Third Quarter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fourth Quarter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.30</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Low</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>High</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Quarter</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Quarter</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    Quarter</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth
    Quarter</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had 35 stockholders of record holding 2,249,290 shares of the Company&#8217;s common stock outstanding,
including 2,117,561 shares of common stock held by an indeterminate number of beneficial owners of securities whose shares are held in
the names of various depository accounts, brokerage firms and clearing agencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s dividend policy is determined by its Board of Directors and will depend upon a number of factors, including the Company&#8217;s
financial condition and performance, its cash needs and expansion plans, income tax consequences, and the restrictions that applicable
laws and any credit or other contractual arrangements may then impose. The Company has not paid any cash dividends on its common stock
to date and at the current time the Company does not anticipate paying a cash dividend on its common stock in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized For Issuance Under Equity Incentive Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth in the table below is information regarding awards made through compensation plans or arrangements through December 31, 2024, the
most recently completed fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan
    Category</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    securities to<br/>
    be issued upon<br/>
    exercise of<br/>
    outstanding<br/>
    options, warrants<br/>
    and rights</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    average<br/>
    price of<br/>
    outstanding<br/>
    options, warrants<br/>
    and rights</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    securities<br/>
    remaining<br/>
    available for<br/>
    future issuance<br/>
    under&#160;compensation<br/>
    plans (excluding<br/>
    securities reflected<br/>
    in column 1)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    Compensation Plans Approved by Security Holders</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">567,815</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.858</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">182,185</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    Compensation Plans Not Approved by Security Holders</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not include 45,417 shares issuable that were not issued pursuant to a plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    182,185 shares that remain available are pursuant to the Company&#8217;s 2020 Stock Incentive Plan, which was adopted on July 14,
    2020 and amended on October 7, 2022 and on November 27, 2023 (see &#8220;ITEM 11. EXECUTIVE COMPENSATION&#8221;).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>ITEM
6. RESERVED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the following discussion and analysis of our financial condition and results of operations together with and our consolidated
financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information,
this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results
may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited
to, those identified below, and those discussed in the section titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report
on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and
commercializing cancer therapies. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents,
radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase
inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic access to equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Significant Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
of News Releases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
25, 2025 - :</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company announced that it had added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University
as a second site in a clinical trial combining the Company&#8217;s proprietary compound LB-100 with GSK&#8217;s dostarlimab to treat
ovarian clear cell cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
10, 2025 &#8211;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company announced online publication of new pre-clinical data in BioXriv and International Journal of Pharmaceutics demonstrating how
the Company&#8217;s lead clinical compound, LB-100, is converted into its active form, endothall, a protein phosphatase (PP2A) inhibitor
that has been found to be effective in cancer treatment in combination with immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
published in BioXriv, scientists at the Netherlands Cancer Institute have discovered an enzyme that mediates the conversion of LB-100
into the active metabolite endothall. Accordingly, this protein represents a potential biomarker to identify patients who are most likely
to respond to LB100. The biomarker discovery study was performed in the laboratories of Professor Rene Bernards, group leader at the
Netherlands Cancer Institute and LIXTE board member.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
published in the International Journal of Pharmaceutics, Dr. Hans Rollema and colleagues, medicinal chemists and biochemists at BioPharmaWorks
LLC, a consultant to LIXTE, studied how LB-100 can spontaneously convert into the active metabolite endothall by hydrolysis. Their data
indicate that this conversion is slow under physiological conditions. The enzymatic conversion of LB-100 identified by the Bernards laboratory
expedites the activation of LB-100 inside the cell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Significant Developments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 11, 2025, the Company entered into Amendment No. 1 to the Collaboration Agreement between the Company and GEIS that relieved the
Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $3,095,000, as more fully described below at Principal Commitments &#8211; Clinical Trial Agreements - GEIS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, the Company recorded a net loss of $3,585,965 and used cash in operations of $3,164,536. At December
31, 2024, the Company had cash of $1,038,952 available to fund its operations. Subsequently, the Company completed a securities offering
that generated gross proceeds of $1,050,003 during February 2025 before deducting the placement agent&#8217;s fees and related offering
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time
and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At March 14, 2025, the Company&#8217;s
remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred
aggregated approximately $526,000, which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements also
do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary if the Company is unable
to continue as a going concern. The Company has no recurring source of revenues and has experienced negative operating cash flows since
inception. The Company has financed its working capital requirements through the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the consolidated financial statements are being issued. The Company&#8217;s consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2024, and the funds raised subsequent
to December 31, 2024, will provide sufficient working capital to fund the current clinical trial program with respect to the development
of the Company&#8217;s lead anti-cancer clinical compound LB-100 through approximately&#160;September 30, 2025. However, existing cash
resources will not be sufficient to complete the development of and obtain regulatory approval for the Company&#8217;s product candidate,
which will require that the Company raise significant additional capital. The Company estimates that it will need to raise additional
capital to fund its operations by mid-2025 to be able to proactively manage its current business plan during the remainder of 2025 and
during 2026. In addition, the Company&#8217;s operating plans may change as a result of many factors that are currently unknown and/or
outside of the control of the Company, and additional funds may be needed sooner than planned. The Company is considering various strategies
and alternatives to obtain the required additional capital. However, as market conditions present uncertainty as to the Company&#8217;s
ability to secure additional funds, there can be no assurance that the Company will be able to secure additional financing on acceptable
terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reverse Stock Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">On June 2, 2023, the Company effected a 1-for-10 reverse split
of its outstanding shares of common stock. The authorized number of shares of common stock and the par value per share were not affected
by the reverse stock split. No fractional shares were issued in connection with the reverse stock split, with all fractional shares being
rounded up to the next whole share. All share and per share amounts and information presented herein have been retroactively adjusted
to reflect the reverse stock split for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Compliance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on the Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock in order to remain in compliance
with the $1.00 minimum closing bid price requirement of Nasdaq. However, there can be no assurances that the Company will be able to
remain in compliance with the $1.00 minimum closing bid price requirement of Nasdaq over time. In addition, Nasdaq has other continued
listing requirements, one of which is maintaining a minimum net stockholders&#8217; equity of $2,500,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2024, the Company received a letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock
Market LLC (&#8220;Nasdaq&#8221;) on August 19, 2024 indicating that the Company was not in compliance with the minimum stockholders&#8217;
equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &#8220;Stockholders&#8217;
Equity Requirement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders&#8217; Equity Requirement, which
outlined the Company&#8217;s proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2024, the Staff provided notice (the &#8220;Notice&#8221;) to the Company that it had granted an extension through February
18, 2025 to regain compliance with the Stockholders&#8217; Equity Requirement, which required that the Company complete its capital raising
initiatives and evidence compliance with the Stockholders&#8217; Equity Requirement through filing a Current Report on Form 8-K with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) providing certain required information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 18, 2025, the Company had not gained compliance with the Stockholders&#8217; Equity Requirement. Accordingly, on February
19, 2025, the Company received a Staff determination letter from the Staff stating that the Company did not meet the terms of the extension
because it did not complete its proposed financing initiatives to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company timely filed an appeal and requested a Hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;), which has been granted.
The Hearing request automatically stayed Nasdaq&#8217;s delisting of the Company&#8217;s common shares and warrants pending the Panel&#8217;s
decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension through no
later than August 18, 2025. At the upcoming hearing, the Company will present its plan for regaining and sustaining compliance with the
Stockholders&#8217; Equity Requirement for continued listing. However, there can be no assurances that the Hearings Panel will grant
the Company an extension of time to regain compliance, or that the Company will be able to regain compliance during any extension period.
During the appeal process the Company&#8217;s common shares and warrants will continue to trade on The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to take reasonable measures available to regain compliance under Nasdaq&#8217;s listing rules and to remain listed on
Nasdaq. However, there can be no assurances that the Company will ultimately regain compliance with the Stockholders&#8217; Equity Rule,
or be able to maintain compliance with all other applicable requirements for continued listing on Nasdaq. If the Company does not regain
compliance with Nasdaq&#8217;s continued listing requirements within the time period permitted by Nasdaq, then the Company&#8217;s securities
will be delisted from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
description of recently issued accounting pronouncements that may potentially impact the Company&#8217;s consolidated financial statements,
including their presentation and related disclosures, is provided in Note 2 to consolidated financial statements included elsewhere in
this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration
of Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented 10% or more of general and administrative costs or research and development costs for the years ended December 31, 2024 and
2023 are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the years ended December 31, 2024 and 2023 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing 8.6% and 23.3% of total general
and administrative costs, respectively. General and administrative costs for the year ended December 31, 2024 also include charges from
two vendors and consultants representing 15.0% and 13.1%, respectively, of total general and administrative costs. General and administrative
costs for the year ended December 31, 2023 also include charges from a vendor and consultant representing 10.4% of total general and
administrative costs. General and administrative costs for the years ended December 31, 2024 and 2023 also included charges for the fair
value of stock options granted to directors and corporate officers representing 14.7% and 18.4%, respectively, of total general and administrative
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the year ended December 31, 2024 include charges from three vendors and consultants representing 39.2%, 29.0%
and 15.4%, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2023
include charges from three vendors and consultants representing 29.9%, 25.2% and 13.7%, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following critical accounting policies affect the more significant judgements and estimates used in the preparation of the Company&#8217;s
consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s President and Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) and evaluates
performance and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis.
Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates in a single reportable
segment, which consists of the development of a drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated
financial results of the Company. The CODM uses consolidated net income (loss) as the sole measure of segment profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure.&#160; ASU 2023-07 amends the FASB Accounting Standards
Codification to require additional reportable segment disclosures of a public entity by requiring disclosure of significant segment expenses
that are regularly provided to the chief operating decision maker, requiring other new disclosures, and requiring enhanced interim disclosures.&#160;
ASU 2023-07 requires public entities with a single reportable segment to provide all the disclosures required by ASU 2023-07 and all
existing segment disclosures in Topic 280 on an interim and annual basis.&#160; The Company adopted ASU 2023-07 effective January 1,
2024 for the 2024 annual period on a retrospective basis.&#160;The adoption of ASU 2023-07 resulted in additional required segment-related
disclosures in the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and Licensing Legal and Filing Fees and Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">In
September 2023, the Company appointed a new President and Chief Executive Officer, who, with the assistance of the Company&#8217;s management,
Board of Directors and patent legal counsel, conducted a comprehensive review and analysis of the Company&#8217;s extensive patent portfolio
in order to implement a program to balance patent prosecution costs with intellectual property protection benefits. As a result of such
review and analysis, the Company identified certain patent filings that it decided not to continue to support in 2024 and thereafter.&#160;
In addition, the Company changed patent legal counsel in mid-2024. The Company expects that patent and licensing legal and filing fees
and costs will continue to be a significant continuing cost in 2025 and thereafter as the&#160;Company continues to develop and expand
its patent portfolio related to the clinical development of LB-100.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">As
a result of such review and analysis, patent and licensing legal and filing fees and costs related to the development and protection
of the Company&#8217;s intellectual property, primarily related to LB-100, decreased to $243,186 for the year ended December 31, 2024,
as compared to $978,244 for the year ended December 31, 2023, a decrease of $735,058, or 75.1%. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
descriptive summary of the patent portfolio for the Company&#8217;s most important clinical programs involving the development of LB-100,
as well as a detailed listing of each domestic and international patent that has been issued, is presented at &#8220;ITEM 1. BUSINESS
&#8211; Intellectual Property&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#8217;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of the Company&#8217;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing meet the requirements for equity classification. This assessment, which requires the use
of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants
are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to
be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all
of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair value
on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the
warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance sheet
date. At December 31, 2024 and 2023, the Company did not have any liability-classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Business Activities and Plans </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and
commercializing cancer therapies. The Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A,
which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company believes that
inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The Company is focusing on the
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that the mechanism by which LB-100 affects cancer cell growth is different from cancer agents currently approved for
clinical use. LB-100 is currently being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable
(MSS) Colon Cancer, and Advanced Soft Tissue Sarcoma. LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme,
neuroblastoma, and medulloblastoma, all cancers of neural tissue. LB-100 has also been shown to enhance the effectiveness of commonly
used anti-cancer drugs in animal models of melanoma, breast cancer and sarcoma. The enhancement of anti-cancer activity of these anti-cancer
drugs occurs at doses of LB-100 that do not significantly increase toxicity in animals. It is therefore hoped that, when combined with
standard anti-cancer regimens against many tumor types, LB-100 will improve therapeutic benefit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment
at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, the Company has allocated resources
to expand the breadth and depth of its patent portfolio. The Company&#8217;s approach has been to operate with a minimum of overhead,
moving compounds forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain
milestones are reached. The Company&#8217;s longer-term objective is to secure one or more strategic partnerships or licensing agreements
with pharmaceutical companies with major programs in cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Specific
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serious
Adverse Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of
these trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to the Company&#8217;s drug
candidate or to another company&#8217;s drug used in combination in one of the Company&#8217;s clinical trials. It is possible that the
SAEs could be attributable to the Company&#8217;s drug candidate and could include, but not be limited to, unexpected severe side effects,
treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting
toxicity (DLT). When two DLTs occur at the same dose-level, that dose-level is considered too high and unsafe. Further treatment is only
allowed at lower dose-levels that have previously been found safe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving the Company&#8217;s drug candidate, the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring
the Company to pause or discontinue further enrollment and dosing in its clinical trial. It is also possible that the clinical trial
could be terminated. Any of these actions could delay or halt the development of the Company&#8217;s drug candidate, increase development
costs, and negatively impact the Company&#8217;s ability to ultimately achieve regulatory approval. Additionally, if an SAE is confirmed
to be drug-related, the Company may be required to conduct additional studies, modify the study design, or abandon further development
of the drug candidate altogether, which could materially impact the Company&#8217;s business, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of an SAE and any resulting clinical hold could also harm the Company&#8217;s reputation with patients, physicians, health
institutions, and investors, diminish its ability to attract clinical trial participants, and damage its ability to interest investors
and obtain financing in the future. There can be no assurance that the Company will not experience such SAEs in the future or that any
related clinical hold will be lifted in a timely manner, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Institutional Review Board (the &#8220;IRB&#8221;) of the
Netherlands Cancer Institute (&#8220;NKI&#8221;) has put the colorectal cancer study on hold. The adverse reactions that developed in
the two patients were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and
atezolizumab in one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second
patient. The patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea.
The patient with fever and aphasia fully recovered from the adverse events with supportive medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator is preparing a response to the IRB
detailing the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab.
Doxorubicin is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related
to that of atezolizumab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through February 2025, a total of 78 patient have received or are receiving experimental treatment
with LB-100. It is expected that it will take at least two months to prepare a detailed response to the IRB, during which time the Company
intends to update the safety overview of LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks Associated with the Company&#8217;s Business Activities </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although Covid-19 outbreak has
subsided, the extent to which the coronavirus pandemic may reappear and impact the Company&#8217;s clinical trial programs and capital
raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates have had a material effect on its
operations to date, other than their impact on the general economy. However, there is a risk that the Company&#8217;s operating costs
could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs (including, specifically, clinical trial costs), and which would put additional stress on the Company&#8217;s working
capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear
at this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital could all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risks. </b>The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity
threats, and has integrated these processes into its overall risk management systems and processes. The Company routinely assesses material
risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through its information and email systems
that may result in adverse effects on the confidentiality, integrity, or availability of the Company&#8217;s information and email systems
or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as assessments
in the event of a material change in the Company&#8217;s business practices that may affect information systems that are vulnerable to
such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the
likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems and
safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges to date that have materially impaired
its operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company had not yet commenced any revenue-generating operations, does not have any positive cash flows from operations,
and is dependent on its ability to raise equity capital to fund its operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated statements of operations as discussed herein are presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Research and development costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">726,232</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">898,100</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,846,557</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,192,136</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total costs and expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,572,789</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,090,236</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,572,789</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,090,236</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,486</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,821</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,233</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency gain (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,403</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,954</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,585,965</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,087,029</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.59</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.66</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,249,290</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,915,838</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span>.
The Company did not have any revenues for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development Costs</span>. For the year ended December 31, 2024, research and development costs were $726,232, which consisted of clinical
and related oversight costs of $377,958, regulatory service costs of $18,836, and preclinical research focused on development of additional
novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $329,438.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in clinical and related oversight costs for the year ended December 31, 2024 is $207,004 for the cost of patients enrolled in the City
of Hope clinical trial prior to its termination on July 8, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, research and development costs were $898,100, which consisted of clinical and related oversight costs
of $416,269, regulatory service costs of $18,738, and preclinical research focused on development of additional novel anti-cancer compounds
to add to the Company&#8217;s clinical pipeline of $463,093.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (&#8220;NKI&#8221;) to conduct
a Phase 1b/2 clinical trial of the Company&#8217;s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor,
the proprietary molecule of F. Hoffman-La Roche Ltd. (&#8220;Roche&#8221;), for patients with metastatic colon cancer. NKI employs Dr.
Ren&#233; Bernards, a director of the Company since June 15, 2022. The Company has no financial contractual commitment associated with
this clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in preclinical research costs for the years ended December 31, 2024 and 2023 were $210,362 and $226,150, respectively, of costs paid
to the Netherlands Cancer Institute, On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potential LB-100 analogues, to be used to
treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with the Netherlands Cancer Institute,
which provided for additional research activities, extended the termination date of the Development Collaboration Agreement by two years
to October 8, 2026, and added 500,000 Euros to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year commencing upon the dosing of the first patient in the clinical trial at a project
cost of 100,000 Euros (see &#8220;Principal Commitments &#8211; Other Significant Agreements and Contracts &#8211; Netherlands Cancer
Institute&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs decreased by $171,868, or 19.1%, in 2024 as compared to 2023, primarily as a result of a decrease in preclinical
research focused on development of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $133,655.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative Costs</span>. For the year December 31, 2024, general and administrative costs were $2,846,557, which consisted of the
fair value of vested stock options issued to directors and officers of $418,422 (including quarterly director and board committee fees
of $55,000), patent and licensing legal and filing fees and costs of $243,186, other consulting and professional fees of $735,021, insurance
expense of $434,444, officer salaries and related costs of $691,244, cash-based director and board committee fees of $38,819, licensing
and royalties of $75,643, shareholder reporting costs of $41,488, listing fees of $49,500, filing fees of $28,012, investor relations
of $59,588, rent of $16,435, conference fees of $14,475 and other operating costs of $45,830, offset by a state franchise tax credits
of $45,550.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, general and administrative costs were $4,192,136, which consisted of the fair value of vested stock
options issued to directors and officers of $773,203, patent and licensing legal and filing fees and costs of $978,244, other consulting
and professional fees of $655,854, insurance expense of $442,976, officer salaries and related costs of $841,709, cash-based director
and board committee fees of $163,479, shareholder reporting costs of $93,860, listing fees of $62,000, filing fees of $17,125, taxes
and licenses of $73,877, investor relations of $59,238, rent of $15,571 and other operating costs of $24,109, offset by a credit to licensing
fees of $9,109 relating to the termination of the Moffitt agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs decreased by $1,345,579, or 32.1%, in 2024 as compared to 2023, primarily as a result of a decrease in the fair
value of vested stock options issued to directors and officers of $354,781, a decrease in patent and licensing legal and filing fees
and costs of $735,058, a decrease in officer salaries and related costs of $150,465, a decrease in shareholder reporting costs of $52,372,
a decrease in taxes and licenses of $119,427, and a decrease in cash-based director and board committee fees of $124,660, offset by increases
in licensing and royalties of $84,752, and in other consulting and professional fees of $79,167.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Income</span>. For the year ended December 31, 2024, the Company had interest income of $7,048, as compared to interest income of $17,486
for the year ended December 31, 2023, related to the investment of the Company&#8217;s cash resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Expense</span>. For the year ended December 31, 2024, the Company had interest expense of $16,821, as compared to interest expense of $16,233
for the year ended December 31, 2023, related to the financing of the premium for the Company&#8217;s directors and officers liability
insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Foreign
Currency Gain (Loss)</span>. For the year ended December 31, 2024, the Company had a foreign currency loss of $3,403, as compared to a foreign
currency gain of $1,954 for the year ended December 31, 2023, from foreign currency transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span>. For the year ended December 31, 2024, the Company incurred a net loss of $3,585,965, as compared to a net loss of $5,087,029
for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources &#8211; December 31, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated statements of cash flows as discussed herein are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,164,536</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,293,265</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,143,361</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net decrease in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,164,536</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,146,904</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company had working capital of $827,219, as compared to working capital of $3,994,762 at December 31, 2023, reflecting
a decrease in working capital of $3,167,543 for the year ended December 31, 2024. The decrease in working capital during the year ended
December 31, 2024 was primarily the result of the funding of the Company&#8217;s ongoing research and development activities and other
ongoing operating expenses, including maintaining and developing the Company&#8217;s patent portfolio. At December 31, 2024, the Company
had cash of $1,038,952 available to fund its operations. Subsequently, the Company completed a securities offering that generated gross
proceeds of $1,050,003 during February 2025 before deducting the placement agent&#8217;s fees and related offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going
Concern</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements also
do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary if the Company is unable
to continue as a going concern. The Company has no recurring source of revenues and has experienced negative operating cash flows since
inception. The Company has financed its working capital requirements through the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the consolidated financial statements are being issued. In addition, the Company&#8217;s independent
registered public accounting firm has included an explanatory paragraph in their report with respect to this uncertainty that accompanies
the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2024. The Company&#8217;s independent
registered public accounting firm, in their report on the Company&#8217;s December 31, 2024 audited consolidated financial statements,
has expressed substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The Company&#8217;s consolidated
financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design, and results of the Company&#8217;s clinical trial program, which, in turn, depends on
the availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2024, and the funds raised subsequent
to December 31, 2024, will provide sufficient working capital to fund the current clinical trial program with respect to the development
of the Company&#8217;s lead anti-cancer clinical compound LB-100 through approximately&#160;September 30, 2025. However, existing cash
resources will not be sufficient to complete the development of and obtain regulatory approval for the Company&#8217;s product candidate,
which will require that the Company raise significant additional capital. The Company estimates that it will need to raise additional
capital to fund its operations by mid-2025 to be able to proactively manage its current business plan during the remainder of 2025 and
during 2026. In addition, the Company&#8217;s operating plans may change as a result of many factors that are currently unknown and/or
outside of the control of the Company, and additional funds may be needed sooner than planned. The Company is considering various strategies
and alternatives to obtain the required additional capital. However, as market conditions present uncertainty as to the Company&#8217;s
ability to secure additional funds, there can be no assurance that the Company will be able to secure additional financing on acceptable
terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 14, 2025, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial
monitoring agreements not yet incurred aggregated $526,000, which are currently scheduled to be incurred through approximately December
31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet
arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
Activities</span>. For the year ended December 31, 2024, operating activities utilized cash of $3,164,536, as compared to utilizing cash
of $4,293,265 for the year ended December 31, 2023, to fund the Company&#8217;s ongoing research and development activities and to fund
its other ongoing operating expenses, including maintaining and developing its patent portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investing
Activities</span>. For the years ended December 31, 2024 and 2023, the Company had no investing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Financing
Activities</span>. For the year ended December 31, 2024, the Company had no financing activities. For the year ended December 31, 2023,
financing activities consisted primarily of the gross proceeds from the sale of securities in the Company&#8217;s registered direct offering
of $3,499,964, reduced by offering costs of $362,925, and $6,281 from the exercise of common stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 14, 2025, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial
monitoring agreements not yet incurred, as described below, aggregated $526,000, including clinical trial agreements of $264,000 and
clinical trial monitoring agreements of $262,000, which, based on current estimates, are currently scheduled to be incurred through approximately
December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely availability
of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds to the Company&#8217;s
current or future clinical trial programs. The Company expects that the full amount of these expenditures will be incurred only if such
clinical trial programs are conducted as originally designed and their respective enrollments and duration are not modified or reduced.
Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently involve a series
of changes and modifications over time as clinical data is obtained and analyzed, and is frequently modified, suspended or terminated,
in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial endpoint is reached.
Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current clinical assumptions
and conditions and are typically subject to significant modifications and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information with respect to the conduct of the Company&#8217;s clinical trial programs is provide at &#8220;ITEM 1A. RISK FACTORS - Risks
Related to the Development and Regulatory Approval of Our Product Candidates&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s ongoing contractual clinical trials described below as of March 14, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Description
    of Clinical Trial</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Institution</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Start
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Projected
    End Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number
                                            of Patients</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>in
    Trial</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Study
    Objective</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Clinical
    Update</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Expected</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Date
    of Preliminary Efficacy</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Signal</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>NCT
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Remaining</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Financial</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Contractual</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Commitment</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">LB-100
    combined with atezolizumab in microsatellite stable metastatic colorectal cancer (Phase 1b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Netherlands
    Cancer Institute (NKI)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">August
    2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">December
    2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Determine
    RP2D with atezolizumab</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">First
    patient entered August 2024, in total two patients entered</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">June
    2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">NCT06012734</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">LB-100
    combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">GEIS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">June
    2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Recruitment
    completed September 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">9
    to 18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Determine
    MTD and RP2D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fourteen
    patients entered</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">December
    2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">NCT05809830</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">264,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Doxorubicin
    with or without LB-100 in advanced soft tissue sarcoma (Randomized Phase 2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">GEIS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">TBD</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">TBD</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">150</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Determine
    efficacy: PFS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Clinical
    trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">TBD</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">NCT05809830</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">LB-100
    combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">MD
    Anderson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">January
    2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">December
    2027</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Determine
    the OS of patients with recurrent ovarian clear cell carcinoma</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Nine
    patients entered</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">December
    2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">NCT06065462</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">264,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute
(&#8220;NKI&#8221;) to conduct a Phase 1b clinical trial of the Company&#8217;s protein phosphatase inhibitor, LB-100, combined with
atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (&#8220;Roche&#8221;), for patients with microsatellite
stable metastatic colorectal cancer. Under the agreement, the Company will provide its lead compound, LB-100, and under a separate agreement
between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to
and will not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement,
the clinical trial will be conducted by NKI at NKI&#8217;s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and
NKI will be responsible for the recruitment of patients. The agreement provides for the protection of the respective intellectual property
rights of each of the Company, NKI and Roche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&#8217;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. A total of two patients have been enrolled to date. Patient accrual
is expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&#8220;SAEs&#8221;) observed in the clinical trial (see &#8220;Specific Risks Associated with the Company&#8217;s Business
Activities &#8211; Serious Adverse Events&#8221; above for additional information).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no financial contractual commitment associated with this clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the &#8220;Agreement&#8221;) with
the City of Hope National Medical Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively,
&#8220;City of Hope&#8221;), to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase
inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;).
LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously
untreated ED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#8220;RP2D&#8221;). Patient entry was to be expanded so that a total of 12 patients would be evaluable at the RP2D to
confirm the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration
of overall response, progression-free survival, and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient
accrual was slower than expected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (&#8220;SCRI&#8221;),
Nashville, Tennessee, to the ongoing Phase 1b clinical trial. The Company and City of Hope continued efforts to increase patient accrual
by adding additional sites and by modifying the protocol to increase the number of patients eligible for the clinical trial. The impact
of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms
of the Agreement, the Company provided notice to City of Hope of the Company&#8217;s intent to terminate the Agreement effective as of
July 8, 2024. Upon closure, the Company incurred a prorated charge of $207,004 for the cost of patients enrolled to date, which is included
in accounts payable and accrued expenses at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024 and 2023, the Company incurred costs of $285,019 and $69,001, respectively, pursuant to this Agreement.
As of December 31, 2024, total costs of $732,532 had been incurred pursuant to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the
anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause, of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practice (GMP) of the active pharmaceutical ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $1,144,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of ASTS. Consequently, this
clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report prepared by December 31,
2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n Jim&#233;nez
D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b
portion of the protocol was extended with two patients and was completed during the quarter ended September 30, 2024. The Company expects
to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, the Company entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved
the Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $3,095,000. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provided for various payments based on achieving specific milestones over the term of the agreement.
During the years ended December 31, 2024 and 2023, the Company incurred costs of $0 and $268,829, respectively, pursuant to this agreement.
Through December 31, 2024, the Company has incurred charges of $684,652 for work done under this agreement through the fourth milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $264,000
for the Phase 1b portion of this clinical trial as of March 14, 2025, which is scheduled to be incurred through December 31, 2025. As
the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations between the
United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign currency gain
or loss, as appropriate, and have not been significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc
(&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#8220;OCCC&#8221;). The study objective is to determine the overall survival (&#8220;OS&#8221;) of patients with OCCC. The clinical
trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and is being conducted at The
University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial
support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical trial. The
Company currently expects that this clinical trial will be completed by December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, the Company announced that it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&#8217;s proprietary compound LB-100 with GSK&#8217;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida (&#8220;Moffitt&#8221;), effective for a term of five years. Pursuant to the Clinical Trial Research
Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s
lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic
syndrome (&#8220;MDS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (&#8220;IND&#8221;)
Application to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and
intermediate-1 risk MDS who had failed or were intolerant of standard treatment. This Phase 1b/2 clinical trial utilized LB-100 as a
single agent in the treatment of patients with low and intermediate-1 risk MDS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the
year ended December 31, 2023, the clinical trial was closed. Although the maximum tolerated dose (&#8220;MTD&#8221;) was not achieved,
there was no dose-limiting toxicity noted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company incurred costs of $0 and $16,165, respectively, pursuant to this agreement. As
of December 31, 2024, total costs of $147,239 had been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
September 2023, the Company decided not to pursue further studies in MDS, as other, more promising, opportunities had become available
(see &#8220;Patent and License Agreements - Moffitt&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (&#8220;NCI&#8221;) initiated a glioblastoma
(&#8220;GBM&#8221;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen
investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1
(&#8220;PD-1&#8221;) blocking antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy
in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). On August 19, 2024, the Company signed a work order agreement
with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this letter of intent and related work order agreement are estimated to be approximately $95,000. During the year ended December
31, 2024, the Company incurred costs of $26,763 pursuant to this letter of intent and subsequent work order. As of December 31, 2024,
total costs of $26,763 have been incurred pursuant to this letter of intent and subsequent work order.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $70,000
as of December 31, 2024, which is expected to be incurred through December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement were estimated to be approximately $335,000. During the years December 31, 2024 and 2023, the Company incurred costs
of $10,642 and $20,240, respectively, pursuant to this work order. As of December 31, 2024, total costs of $89,323 had been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see &#8220;Clinical Trial Agreements &#8211; City
of Hope&#8221; above), the work order agreement with Theradex to monitor this clinical trial was concurrently terminated, although nominal
oversight trailing costs subsequent to July 8, 2024 are expected to be incurred relating to the closure of this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study
oversight is expected to be completed by December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $153,000, with such payments expected to be allocated approximately
72% to Theradex for services and approximately 28% for payments for pass-through software costs. During the years ended December 31,
2024 and 2023, the Company incurred costs of $34,593 and $14,862, respectively, pursuant to this work order. As of December 31, 2024,
total costs of $49,455 have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $104,000 as of December 31, 2024, which is expected to be incurred through December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>On August 27, 2024, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical
trial of LB-100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colorectal cancer.
The study oversight is expected to be completed by May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $106,380, with such payments expected to be allocated approximately
47% to Theradex for services and approximately 53% for payments for pass-through software costs. During the year ended December 31, 2024,
the Company incurred costs of $20,191 pursuant to this work order. As of December 31, 2024, total costs of $20,191 have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $88,000 as of December 31, 2024, which is expected to be incurred through May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Institute of Health.</b> Effective February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;)
with the National Institute of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;),
each an institute or center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has
licensed on an exclusive basis the NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement
(&#8220;CRADA&#8221;) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer
activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors,
immunotherapy, and radiation for the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product,
licensed process, and country basis, until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights
in each such country in the licensed territory, estimated at twenty years, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $50,000 and a first minimum annual royalty
within sixty days from the effective date of the Agreement. The first minimum annual royalty of $25,643 was prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $30,000 is due each January
1 and may be credited against any earned royalties due for sales made in that year. The license issue royalty of $50,000 and the first
minimum annual royalty of $25,643, were paid in April 2024. The second minimum annual royalty for 2025 of $30,000, was paid in December
2024 and is included in other prepaid expenses at December 31, 2024 in the accompanying consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#8217;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, which the Company is required to pursue based on &#8220;commercially reasonable
efforts&#8221; as defined in the License Agreement, with deadlines of October 1, 2024, 2027, 2029 and 2031, respectively, each with a
different specified benchmark payment amount payable within thirty days of achieving such benchmark. The October 1, 2024 benchmark of
$100,000 was defined as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product
in the licensed fields of use. The Company had not commenced a Phase 2 clinical study as of December 31, 2024. The total of all such
benchmark payments is $1,225,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to provide annual reports to the NIH on its progress toward the development and commercialization of products under
the licensed patents. These reports, due within sixty days following the end of each calendar year, must include updates on research
and development activities, regulatory submissions, manufacturing efforts, sublicensing, and sales initiatives. If any deviations from
the established commercial development plan or agreed-upon benchmarks occur, the Company is obligated to provide explanation and may
amend the commercial development plan and the benchmarks, which, subject to certain conditions, the NIH shall not unreasonably withhold,
condition, or delay approval of any request of the Company to amend the commercial development plan and/or the benchmarks and to extend
the time periods of the benchmarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH sublicensing royalties of 5% on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company incurred costs of $75,643 in connection with its obligations under the License Agreement.
Such costs when incurred have been included in general and administrative costs in the Company&#8217;s consolidated statement of operations.
As of December 31, 2024, total costs of $75,643 have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment
pursuant to this agreement, less amounts previously paid to date, totaled approximately $1,795,000 as of December 31, 2024, which is
expected to be incurred over approximately the next twenty years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee was due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded a credit to operations of $9,109 representing the reversal of obligations previously
recorded with respect to the Exclusive License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into a consulting agreement with NDA Consulting Corp. for consultation
and advice in the field of oncology research and drug development. As part of the consulting agreement, NDA also agreed to cause its
president, Dr. Daniel D. Von Hoff, M.D., to serve on the Company&#8217;s Scientific Advisory Committee during the term of such consulting
agreement. The term of the consulting agreement was for one year and provided for a quarterly cash fee of $4,000. The consulting agreement
had been automatically renewed for additional one-year terms on its anniversary date, most recently on December 24, 2023, but was subsequently
terminated effective September 30, 2024. Consulting and advisory fees charged to operations pursuant to this consulting agreement were
$12,000 and $16,000 for the years ended December 31, 2024 and 2023, respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly fee. Effective March 1, 2024, the compensation payable under the Collaboration Agreement was converted to an hourly
rate structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded charges to operations pursuant to this Collaboration Agreement of $39,200 and $120,000 during the years ended December
31, 2024 and 2023, respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht,
a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently modified
by Amendment No. 1 thereto. The Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs
to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific
molecular mechanisms underlying the identified combinations. The Company agreed to fund the preclinical study, at an approximate cost
of 391,000 Euros and provide a sufficient supply of LB-100 to conduct the preclinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added
500,000 Euros to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year and starts upon the dosing of the first patient in the clinical trial at a project
cost of 100,000 Euros.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company incurred charges in the amount of $210,362 and $226,150, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
As of December 31, 2024, total costs of $695,918 have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment
pursuant to this agreement, less amounts previously paid to date, totaled approximately $104,000 as of December 31, 2024, which is expected
to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to
foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>As amended, the Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical
trials in the United States. During the years ended December 31, 2024 and 2023, the Company incurred costs of $23,308 and $32,307, respectively,
pursuant to this contract. As of December 31, 2024, total costs of $340,522 have been incurred pursuant to this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $118,000
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trends,
Events and Uncertainties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development of new pharmaceutical compounds is, by its nature, unpredictable. Although we will undertake research and development
efforts with commercially reasonable diligence, there can be no assurance that our cash position will be sufficient to enable us to develop
our pharmaceutical compounds to the extent needed to create future sales to sustain operations as contemplated herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that our pharmaceutical compound will obtain the regulatory approvals and market acceptance to achieve sustainable
revenues sufficient to support our operations. Even if we are able to generate revenues, there can be no assurance that we will be able
to achieve operating profitability or positive operating cash flows. There can be no assurance that we will be able to secure additional
financing, to the extent required, on acceptable terms or at all. If cash resources are insufficient to satisfy our ongoing cash requirements,
we would be required to reduce or discontinue our research and development programs, or attempt to obtain funds, if available, through
strategic alliances, joint ventures or other transaction structures that could require the Company to relinquish rights to and/or control
of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as discussed above, we are not currently aware of any trends, events or uncertainties that are likely to have a material effect
on our financial condition in the near term, although it is possible that new trends or events may develop in the future that could have
a material effect on our financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements and notes thereto and the related report of its independent registered public accounting
firm are attached to this Annual Report on Form 10-K beginning on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_016"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined
in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) that is designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized, and reported, within the time periods specified in the rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the
reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its
principal executive officer(s) and principal financial officer(s), or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Exchange Act Rules 13a-15 and 15d-15, an evaluation was completed under the supervision and with the participation of
the Company&#8217;s management, including its Chief Executive Officer and its Chief Financial Officer, of the effectiveness of the design
and operation of the Company&#8217;s disclosure controls and procedures as of the fiscal year ended December 31, 2023, the end of the
most recent fiscal year covered by this report. Based on that evaluation, the Company&#8217;s management concluded that the Company&#8217;s
disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the
Company&#8217;s reports filed or submitted under the Exchange Act was recorded, processed, summarized, and reported within the time periods
specified in the rules and forms of the Securities and Exchange Commission (&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management, including its Chief Executive Officer and its Chief Financial Officer, is responsible for establishing and
maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act). Internal
control over financial reporting is a process, including policies and procedures, designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with
U.S. generally accepted accounting principles. The Company&#8217;s internal control over financial reporting is designed to ensure that
material information regarding the Company&#8217;s operations is made available to management and the Board of Directors to provide them
reasonable assurance that the published financial statements are fairly presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management assessed the Company&#8217;s internal control over financial reporting based on the Internal Control&#8212;Integrated
Framework (2013 Framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). The Company&#8217;s
system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those
systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Furthermore, smaller
reporting companies face additional limitations. Smaller reporting companies employ fewer individuals and can find it more difficult
to properly segregate duties. Smaller reporting companies also tend to utilize general accounting software packages that lack a rigorous
set of software controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is
a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented
or deterred on a timely basis. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&#8217;s evaluation under the framework in COSO, the Company&#8217;s management, with the participation of its Chief Executive
Officer and its Chief Financial Officer, concluded that the Company&#8217;s internal control over financial reporting was effective as
of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the consolidated financial statements included in this report fairly present, in all material respects, the Company&#8217;s
financial condition, results of operations and cash flows as of and for the period ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Auditor&#8217;s
Report on Internal Control Over Financing Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report does not include an attestation report of the Company&#8217;s independent registered public accounting firm regarding internal
control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s independent registered
public accounting firm pursuant to rules of the SEC that permit the Company to provide only management&#8217;s report in this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management, including its Chief Executive Officer and its Chief Financial Officer, has determined that no change in the
Company&#8217;s internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities
Exchange Act of 1934) occurred during or subsequent to the period ended December 31, 2024 that has materially affected, or is reasonably
likely to materially affect, the Company&#8217;s internal control over financial reporting.&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule
10b5-1 Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the quarter ended December 31, 2024, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company <span id="xdx_900_eecd--Rule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zg88MiUyVxnb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_901_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zp8l4W1gUBJ8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000065" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000066" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>
or <span id="xdx_900_eecd--Rule10b51ArrTrmntdFlag_dbF_c20241001__20241231_z87euXUThkSg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90E_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20241001__20241231_zlOYmlU4F2xd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000067" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000068" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; as such term is defined in Item 408(a) of Regulation S-K. As of December
31, 2024, the Company did not have a &#8220;Rule 10b5-1 trading arrangement&#8221; in effect with respect to its securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted insider trading policies and procedures governing the purchase, sale, and other disposition of its securities, which
has been included as an exhibit to this report and has been posted to the investor information/governance section of the Company&#8217;s
corporate website (www.lixte.com).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_020"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table and text set forth the names of all of our directors and executive officers as of March 14, 2025. The Board of Directors
is comprised of only one class. All of the directors will serve until the next annual meeting of stockholders and until their successors
are elected and qualified, or until their earlier death, retirement, resignation or removal. The brief descriptions of the business experience
of each director and executive officers and an indication of directorships held by each director in other companies subject to the reporting
requirements under the Federal securities laws are provided herein below. Also provided are the biographies of the members of the Scientific
Advisory Committee and our consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and executive officers are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 53%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s)
    Held with Company</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer, and Chairman of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Jan H.M. Schellens</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consultant
    and Chief Medical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President and Chief Financial Officer, Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Stephen J. Forman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regina
    Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Yun Yen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ren&#233; Bernards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Biographies
of Directors and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bastiaan
van der Baan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
(&#8220;Bas&#8221;) van der Baan was appointed to the Company&#8217;s Board of Directors effective June 17, 2022.&#160;&#160;Effective
September 26, 2023, Mr. van der Baan replaced the Company&#8217;s founder, Dr. John S. Kovach, as President and Chief Executive Officer.
Dr. Kovach passed away on October 5, 2023. Effective October 6, 2023, as a result of the passing of Dr. Kovach, Mr. van der Baan was
appointed as Chairman of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
van der Baan has over 20 years of experience in the biotechnology industry, with a key focus on oncology and diagnostics. He has extensive
knowhow in the process of managing a compound from clinical development to reimbursement and commercialization, as well as the establishment
of partnerships with the pharmaceutical industry, academic collaborators, distributors, insurance companies and governments to successfully
launch new oncology products. Mr. van der Baan was most recently the Chief Clinical Officer of Agendia, an oncology molecular diagnostic
company based in Irvine, California and Amsterdam, Netherlands through July 15, 2023. Mr. van der Baan is an independent director of
Tethis S.p.A., a Milan, Italy-based developer of a novel platform for liquid biopsy testing. Mr. van der Baan was co-founder of ThromboDx,
a liquid biopsy company that was acquired in 2016, Qameleon Therapeutics, a company developing synthetic lethal drug combinations for
cancer&#160;treatment, and Oncosence, an oncology drug development company using senescence as target for drug development. Mr. van der
Baan started his career in 1997 at a&#160;specialty chemicals division of Unilever that was acquired by ICI. In 2002, Mr. van der Baan
joined&#160;Kreatech, a biotechnology company acquired by Leica that&#160;specialized in&#160;life science reagents for gene expression,
DNA and protein analysis. Mr. van der Baan holds a Master&#8217;s Degree in Molecular Sciences from the Wageningen University in the
Netherlands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Jan H.M. Schellens, M.D., Ph.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Schellens was appointed as our Chief Medical Officer effective August 1, 2024. Dr. Schellens has more than 25 years of clinical experience
as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs
to market. Co-author of more than 900 publications in peer-reviewed scientific journals, Dr. Schellens has held leadership positions
at the Netherlands Cancer Institute in Amsterdam and the Dr. Daniel den Hoed Clinic-Erasmus University in Rotterdam. He was professor
of clinical pharmacology at Utrecht University in the Netherlands, where he earned his M.D. degree, and he served as a board member and
Chief Medical Officer of Byondis B.V. from January 2019 through September 2023. He also earned a Ph.D. degree in Pharmaceutical Sciences
from Leiden University in Leiden, Netherlands. Dr. Schellens served for 17 years as a board member of the Dutch Medicines Evaluation
Board and for 12 years as a member and chairperson of the Scientific Advisory Board Oncology of the EMA. From 2016 to the present, he
has served as a part-time Chief Medical Officer of Modra Pharmaceuticals B.V., an Amsterdam-based company that successfully completed
a Phase 2b clinical study of ModraDoc006/r, a boosted oral taxane therapeutic, in contrast to the standard-of-care IV chemotherapy docetaxel,
in patients with prostate cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Schellens plays a leadership role in the planning, implementation and oversight of the Company&#8217;s clinical trials and is responsible
for assisting in the development of strategic clinical goals and the implementation and safety monitoring of investigational studies.
Dr. Schellens is the primary medical monitor for all clinical investigational studies, and for the oversight of third party CRO monitors.
He is responsible for the regulatory strategy and implementation of the strategy and the primary contact for regulators. Dr. Schellens
works closely with the Company&#8217;s Chief Executive Officer on the development of strategic goals needed to ensure the timely implementation
of appropriate clinical studies needed for the successful registration of therapeutics products. Dr. Schellens services are principally
rendered in the Netherlands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Robert
N. Weingarten</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Weingarten was appointed to serve as our Vice President and Chief Financial Officer effective August 12, 2020. Mr. Weingarten is an experienced
business consultant and advisor with a consulting practice focusing on accounting and SEC compliance issues. Mr. Weingarten was familiar
with the financial and business operations of the Company, as he had provided accounting and financial consulting services to the Company
for a number of years prior to his appointment as Vice President and Chief Financial Officer with respect to the preparation of the Company&#8217;s
consolidated financial statements and certain other financial and compliance matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
1979, Mr. Weingarten has provided such financial consulting and advisory services, has acted as chief financial officer, and has served
on the boards of directors of numerous public companies in various stages of development, operation or reorganization. Mr. Weingarten
has experience in a variety of industries, including the pharmaceutical industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Weingarten was a Director of Guardion Health Sciences, Inc. since June 2015 and was Chairman of its Board of Directors from July 2020
through October 2024. Mr. Weingarten also served on the audit, compensation, and nominating and corporate governance committees of Guardion
Health Sciences, Inc. during such period. Previously, Mr. Weingarten served as Lead Director on Guardion&#8217;s Board of Directors from
January 2017 through March 2020. Mr. Weingarten received a B.A. in Accounting from the University of Washington in 1974, an M.B.A. in
Finance from the University of Southern California in 1975, and is a Certified Public Accountant (inactive) in the State of California.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Stephen J. Forman</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
J. Forman, M.D., was appointed to our Board of Directors effective May 13, 2016. Dr. Forman is an internationally recognized expert in
hematologic malignancies and bone marrow transplantation, and is a leader in preclinical and clinical cancer research. Dr. Forman was
appointed to our Board of Directors on May 13, 2016. He is co-editor of Thomas&#8217; Hematopoietic Cell Transplantation, a definitive
textbook for clinicians, scientists and health care professionals. Dr. Forman is the Francis and Kathleen McNamara Distinguished Chair
in Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center, a position he has held since 1987.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
nearly 40 years at the City of Hope, Dr. Forman has been instrumental in advancing the survival rates for patients suffering from cancers
of the blood and immune system such as leukemia, lymphoma and myeloma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Director of the T Cell Immunotherapy Research Laboratory, his current research is focused on cancer immunotherapy, using the body&#8217;s
own immune system to attack cancer. Pharmacological enhancement of patients&#8217; immune responses to their cancers is of special interest
to the Company, as the enzyme target of its lead clinical compound, LB-100, has been reported to be critical to immune function. Much
of Dr. Forman&#8217;s current work centers on T-cells and their cancer-fighting potential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Yun Yen</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yun
Yen, M.D., Ph.D., F.A.C.P., was appointed to our Board of Directors effective August 4, 2018. Dr. Yen is a physician, scientist, innovator,
and philanthropist. Dr. Yen was appointed to our Board of Directors on August 4, 2018. He is widely regarded as an expert in ribonucleotide
reductase, a critical target in cancer therapy and diagnostics. He is President Emeritus of Taipei Medical University (TMU) and Chair
Professor of the Ph.D. Program for Cancer Biology and Drug Discovery. Prior to TMU, Dr. Yen was the Allen and Lee Chao Endowed Chair
in Developmental Cancer Therapeutics, Chair of Molecular Pharmacology Department, Associate Director for Translational Research, and
Co-Director of the Developmental Cancer Therapeutics Program at the City of Hope NCI-designated Comprehensive Cancer Center, Duarte California.
He has published more than 300 peer-reviewed articles, holds over 60 patents, and has commercialized multiple methodologies involving
nanoparticles, small and large molecule drugs, biomarkers, stem cells, and medical devices. Dr. Yen has also founded philanthropic organizations
aimed at serving the global cancer community and holds membership in numerous professional societies. He serves on the boards of Fulgent
Genetics and Tanvex BioPharma Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regina
Brown, CPA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regina
Brown was appointed to our Board of Directors effective May 11, 2021. Ms. Brown has been a practicing accountant for over thirty years.
Her practice has a wide range of clients, varying in size, industry and geographic locations, including large national corporations listed
on the New York Stock Exchange, as well as Southern California businesses. Other clients consist of professionals, wholesalers and high
net worth individuals. Many of her clients have international and cross-border operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a consequence of her depth of experience, she regularly assists other professionals with their client&#8217;s issues and performs tax
research and analysis in connection with litigation and other matters, including marital dissolution, tax and accounting with respect
to mergers and acquisitions, implementation of internal controls, and extensive work in the area of trusts and estates. International
tax matters and compliance are also a significant part of her practice. Ms. Brown is a member in good standing of the California Society
of CPAs and the American Institute of Certified Public Accountants and has appeared as a speaker before both organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Ren&#233; Bernards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Ren&#233; Bernards was appointed to our Board of Directors effective June 15, 2022. Dr. Bernards is a leader in the field of molecular
carcinogenesis, working at the Netherlands Cancer Institute in Amsterdam. His research focuses on identifying effective new drug combinations,
new drug targets, and mechanisms of resistance to anti-cancer drugs. He has also co-founded four biotechnology companies to bring his
scientific discoveries to clinical oncology practice. He is a member of the Royal Netherlands Academy of Sciences, an International Honorary
Member of the American Academy of Arts and Sciences and an International Member of the National Academy of Sciences (USA). Additionally,
he is a fellow of the American Association for Cancer Research (AACR). Dr. Bernards has presented new data on the unexpected effectiveness
of the Company&#8217;s lead clinical compound, LB-100, when given with a variety of standard and investigational anti-cancer compounds
that have only modest activity on their own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
Forman, the Company&#8217;s Vice President and Chief Operating Officer during the years ended December 31, 2024, 2023 and 2022 was the
son of board member Dr. Stephen Forman and the son-in-law of former board member Gil Schwartzberg, who passed away on October 30, 2022.
Julie Forman, the wife of Eric Forman and the daughter of the late Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management,
where the Company&#8217;s cash is deposited and managed, and the Company maintains a continuing banking relationship. Eric Forman resigned
as Vice President and Chief Operating Officer of the Company effective December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of Our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors directs the management of our business and affairs, as provided by Delaware law, and conducts its business through
meetings of the Board of Directors and its standing committees. We have a standing audit committee and compensation committee. The Board
of Directors serves in place of a nominating and corporate governance committee. In addition, from time to time, special committees may
be established under the direction of the Board of Directors when necessary to address specific issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
    and retaining the independent auditors to conduct the annual audit of our financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the proposed scope and results of the audit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and pre-approving audit and non-audit fees and services;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    accounting and financial controls with the independent auditors and our financial and accounting staff;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving transactions between us and our directors, officers and affiliates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for complaints received by us regarding accounting matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    internal audit functions, if any; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the audit committee that the rules of the SEC require to be included in our annual meeting proxy statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee currently consists of Regina Brown, Dr. Yun Yen and Dr. Ren&#233; Bernards, with Ms. Brown serving as chair. Our Board
of Directors has determined that each of the committee members meet the definition of an &#8220;independent director,&#8221; as defined
under Nasdaq rules, and that they each meet the independence standards under Rule 10A-3 of the Exchange Act. Each member of our audit
committee meets the financial literacy requirements of the Nasdaq rules. In addition, our Board of Directors has determined that Ms.
Brown qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K. Our
Board of Directors has adopted a written charter for the audit committee, which is available on our corporate website at www.lixte.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending the compensation arrangements for executive management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and reviewing general compensation policies with the objective to attract and retain superior talent, to reward individual performance
    and to achieve our financial goals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our stock incentive plans; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the compensation committee that the rules of the SEC require to be included in our annual meeting proxy statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee currently consists of Dr. Yun Yen, Regina Brown and Dr. Ren&#233; Bernards, with Dr. Yen serving as chair. Our
Board of Directors has determined that each of the three committee members meet the definition of an &#8220;independent director&#8221;,
as defined under Nasdaq rules. Our Board of Directors has adopted a written charter for the compensation committee, which is available
on our corporate website at www.lixte.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our Board of Directors serves in place of a nominating and corporate governance committee, our independent directors on the Board of
Directors are responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nominating
    members of the Board of Directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    a set of corporate governance principles applicable to the Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the evaluation of our Board of Directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors may adopt resolutions addressing, among other things, the nomination process, as may be necessary in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has adopted a code of ethics covering all of our executive officers and key employees. A copy of our code of ethics
will be furnished without charge to any person upon written request. Requests should be sent to: Secretary, Lixte Biotechnology Holdings,
Inc., 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
on Liability and Indemnification Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation contains provisions that limit the liability of our current and former directors for monetary damages to
the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for
monetary damages for any breach of fiduciary duties as directors, except liability for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful
    payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation
    Law; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction from which the director derived an improper personal benefit.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable
remedies such as injunctive relief or rescission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation provides that we are authorized to indemnify our directors and officers to the fullest extent permitted
by Delaware law. Our Amended and Restated Bylaws provide that we are required to indemnify our directors and executive officers to the
fullest extent permitted by Delaware law. Our Amended and Restated Bylaws also provide that, upon satisfaction of certain conditions,
we are required to advance expenses incurred by a director or executive officer in advance of the final disposition of any action or
proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out
of their actions in that capacity, regardless of whether we would otherwise be permitted to indemnify them under the provisions of Delaware
law. Our Amended and Restated Bylaws also provide our Board of Directors with discretion to indemnify our other officers and employees
when determined appropriate by our Board of Directors. We have entered into agreements to indemnify our directors, executive officers
and other employees as determined by the Board of Directors. With certain exceptions, these agreements provide for indemnification for
related expenses, including, among other things, attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any of these
individuals in any action or proceeding. We believe that these provisions and agreements are necessary to attract and retain qualified
persons as directors and officers. We have obtained customary directors and officers liability insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation of liability and indemnification provisions in our Certificate of Incorporation and Amended and Restated Bylaws may discourage
stockholders from bringing a lawsuit against our directors for an alleged breach of their fiduciary duty. These provisions may also reduce
the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and
other stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement
and damage awards against directors and officers as required by these indemnification provisions. At present, there is no pending litigation
or proceeding involving any of our directors, officers or employees for which indemnification is sought, and we are not aware of any
threatened litigation that may result in claims for indemnification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compliance
with Section 16(a) of the Securities Exchange Act of 1934, as Amended</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Securities Exchange Act of 1934, as amended, requires the Company&#8217;s directors and executive officers and persons who
own more than 10% of a registered class of the Company&#8217;s equity securities to file various reports with the Securities and Exchange
Commission concerning their holdings of, and transactions in, securities of the Company. Copies of these filings are required to be furnished
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Company&#8217;s knowledge, based solely on its review of the copies of the Section 16(a) reports furnished to the Company and any
written representations to the Company that no other reports were required, the Company believes that all individual filing requirements
applicable to a director, officer, or beneficial owner of more than 10% of the Company&#8217;s common stock were complied with under
Section 16(a) of the Exchange Act during the year ended December 31, 2023, except as follows: Rene Bernards was late in filing his Form
4 in connection with the grant of stock options on June 30, 2024, and Rene Bernards, Yun Yen, Regina Brown and Stephen Forman were late
in filing their Form 4&#8217;s in connection with the grant of stock options on September 30, 2024. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_021"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OFFICER
AND DIRECTOR COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table set forth below presents the compensation awarded to, earned by, or paid to our named executive officers for the years ended December
31, 2024, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OFFICER
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary<br/>
($)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus<br/>
($)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
    Awards<br/>
($)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
    Awards<br/>
($)(1)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Equity
    Incentive Plan Compensation<br/>
($)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Qualified
    Deferred Compensation Earnings<br/>
($)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
    Other Compensation<br/>
($)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
($)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bas
    van der Baan (6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">153,495</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">153,495</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,639</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">403,066</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">443,705</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Kovach (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">190,860</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">190,860</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,640</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">315,640</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    S. Miser (3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,083</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,083</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,640</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">240,640</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten (4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,640</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">240,640</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    J. Forman (5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">178,819</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,640</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">244,459</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jan
    H.M. Schellens (7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,226</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,074</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85,300</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Consists of grant date fair value of option award calculated pursuant to the Black-Scholes option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
John S. Kovach was the President and Chief Executive Officer from inception through September 26, 2023. Effective July 15, 2020, the
Company entered into an employment agreement with Dr. Kovach. On November 6, 2022, Dr. Kovach was awarded an option grant for 20,000
shares of common stock, exercisable for a period of five years at $20.00 per share and valued at $3.282 per share. The employment agreement
with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
James S. Miser was appointed as Chief Medical Officer on August 1, 2020. In connection with his employment agreement, Dr. Miser was awarded
an option grant for 8,334 shares of common stock, exercisable for a period of five years at $71.40 per share and valued at $68.718 per
share. On November 6, 2022, Dr. Miser was awarded an option grant for 20,000 shares of common stock, exercisable for a period of five
years at $20.00 per share and valued at $3.282 per share. On May 29, 2024, the Company elected not to renew its employment agreement
with Dr. Miser, as a result of which such employment agreement expired on July 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Robert N. Weingarten was appointed as Vice President and Chief Financial Officer on August 12, 2020. In connection with his employment
agreement, Mr. Weingarten was awarded an option grant for 5,833 shares of common stock, exercisable for a period of five years at $71.40
per share and valued at $68.718 per share. On November 6, 2022, Mr. Weingarten was awarded an option grant for 20,000 shares of common
stock, exercisable for a period of five years at $20.00 per share and valued at $3.282 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Eric J. Forman was Chief Administrative Officer from July 15, 2020 through November 6, 2020. In connection with his employment agreement,
Mr. Forman was awarded an option grant for 5,833 shares of common stock, exercisable for a period of five years at $71.40 per share and
valued at $68.718 per share. Effective November 6, 2022, Mr. Forman was appointed as Vice President and Chief Operating Officer. On November
6, 2022, Mr. Forman was awarded an option grant for 20,000 shares of common stock, exercisable for a period of five years at $20.00 per
share and valued at $3.282 per share. The employment agreement with Mr. Forman terminated upon his resignation as an officer of the Company
effective December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Bas van der Baan was appointed as President and Chief Executive Officer on September 26, 2023. In connection with his employment agreement,
Mr. van der Baan was awarded an option grant for 250,000 shares of common stock exercisable for a period of five years at $1.95 per share
and valued at $1.612 per share. The compensation information provided herein excludes compensation as a Director received before his
appointment as President and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
On May 31, 2024, the Company entered into a consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D., Pursuant to the agreement,
effective July 1, 2024, the Company engaged Dr. Schellens as a consultant, and, effective August 1, 2024, as the Company&#8217;s Chief
Medical Officer. In connection with his employment agreement, Mr. Schellens was awarded an option grant for 15,000 shares of common stock
exercisable for a period of five years at $2.39 per share and valued at $1.938 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no option exercises by officers during the years ended December 31, 2024, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at December 31, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table set forth below presents information regarding outstanding stock options held by our named executive officers as of December 31,
2024.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NAME</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GRANT </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DATE</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VESTING</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMMENCEMENT</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DATE</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER OF</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDERLYING</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNEXERCISED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTIONS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISABLE</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER OF</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDERLYING</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNEXERCISED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTIONS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNEXERCISABLE</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRICE</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DATE</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 19%; text-align: left">Bas van der Baan</td><td style="width: 2%">&#160;</td>
    <td style="width: 13%; text-align: center">June 17, 2022 (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 13%; text-align: center">June 17, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">7.40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 13%; text-align: center">June 17, 2027</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">June 30, 2023 (1)</td><td>&#160;</td>
    <td style="text-align: center">September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">June 30, 2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">September 26, 2023</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,835</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">September 26, 2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Jan H.M. Schellens</td><td>&#160;</td>
    <td style="text-align: center">July 1, 2024</td><td>&#160;</td>
    <td style="text-align: center">September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">July 1, 2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. James S. Miser</td><td>&#160;</td>
    <td style="text-align: center">August 1, 2020</td><td>&#160;</td>
    <td style="text-align: center">August 1, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">July 31, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">July 31, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert N. Weingarten</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2020</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2027</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eric J. Forman</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2020</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">August 12, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: center">November 6, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2025</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Granted in his capacity as a Director before date of officer appointment on September 26, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $2.03 per share on December 31, 2024, the intrinsic value attributed to exercisable but unexercised common
stock options held by our named executive officers was approximately $8,000 at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements; Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S.
Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. The employment agreements
were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice prior to the
end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically renewed
for additional one-year periods in July and August 2021, 2022, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
John Kovach</b>. On July 15, 2020, the Company entered into an employment agreement with Dr. John Kovach to continue to act as the Company&#8217;s
President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $250,000, payable monthly. His responsibilities
included the oversight of the Company&#8217;s entire operations and strategic planning, and to act as the primary contact between the
Company&#8217;s executive team and the Board of Directors, to whom he reported. Dr. Kovach supervised all scientific endeavors, providing
guidance to the Chief Medical Officer. He was the principal spokesperson for the Company. The effective date of the agreement was October
1, 2020 and remained in effect until the earlier of (i) one year from the effective date, automatically renewable for additional one-year
periods unless terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, (ii) his death,
or (iii) termination for cause. The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Eric
Forman.</b> On July 15, 2020, as amended on August 12, 2020, the Company entered into an employment agreement with Eric Forman, to act
as the Company&#8217;s Chief Administrative Officer, reporting directly to the Company&#8217;s Chief Executive Officer, with an annual
salary of $120,000, payable monthly. Effective May 1, 2021, Mr. Forman&#8217;s annual salary was increased to $175,000. Effective November
6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $200,000. Mr. Forman&#8217;s
primary function was to oversee the Company&#8217;s internal operations, including IT, licensing, legal, personnel, marketing, and corporate
governance. Mr. Forman was also granted stock options to acquire 5,833 shares of the Company&#8217;s common stock. The effective date
of the employment agreement was October 1, 2020 and remained in effect until the earlier of (i) one year from the effective date, automatically
renewable for additional one-year periods unless terminated by either party upon 60 days written notice prior to the end of the applicable
one-year period, (ii) his death, or (iii) termination for cause. The employment agreement with Mr. Forman terminated upon his resignation
as an officer of the Company effective December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
James Miser</b>. On August 1, 2020, the Company entered into an employment agreement with Dr. James Miser, M.D., pursuant to which Dr.
Miser was appointed as the Company&#8217;s Chief Medical Officer, with an annual salary of $150,000. Effective May 1, 2021, Dr. Miser&#8217;s
annual salary was increased to $175,000. Dr. Miser was required to devote at least 50% of his business time to the Company&#8217;s activities.
Dr. Miser was also granted stock options to acquire 8,334 shares of the Company&#8217;s common stock. The effective date of the agreement
was August 1, 2020 and remained in effect until the earlier of (i) one year from the effective date, automatically renewable for additional
one-year periods unless terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, (ii)
his death, or (iii) termination for cause. On May 29, 2024, the Company elected not to renew its employment agreement with Dr. Miser,
as a result of which such employment agreement expired on July 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Jan H.M. Schellens, M.D., Ph.D. </b>On May 31, 2024, the Company entered into a consulting agreement with Dr. Jan H.M. Schellens, M.D.,
Ph.D. Pursuant to the agreement, effective July 1, 2024, the Company engaged Dr. Schellens as a consultant, and, effective August 1,
2024, as the Company&#8217;s Chief Medical Officer. The term of the agreement is in effect from July 1, 2024 until the earliest of (i)
termination by either party upon sixty days&#8217; notice, (ii) Dr. Schellens&#8217; death or disability, or (iii) termination by the
Company for breach as provided in the agreement. Under the agreement, Dr. Schellens provides his services for two days per week with
the specific days in each week based on arrangements agreed to from time to time between Dr. Schellens and the Company&#8217;s Chief
Executive Officer. The Company pays Dr. Schellens an annual compensation of 104,000 Euros (approximately $108,000 as of December 31,
2024), payable on a monthly basis. On July 1, 2024, in connection with the consulting agreement, Dr. Schellens was granted stock options
to purchase 15,000 shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Robert
N. Weingarten</b>. On August 12, 2020, the Company entered into an employment agreement with Robert N. Weingarten pursuant to which Mr.
Weingarten was appointed as the Company&#8217;s Vice-President and Chief Financial Officer, with an annual salary of $120,000. Effective
May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased to $175,000. Mr. Weingarten was also granted stock options to acquire
5,833 shares of the Company&#8217;s common stock. The effective date of the agreement was August 12, 2020 and remained in effect until
the earlier of (i) one year from the effective date, automatically renewable for additional one-year periods unless terminated by either
party upon 60 days written notice prior to the end of the applicable one-year period, (ii) his death, or (iii) termination for cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bas
van der Baan</b>. Effective September 26, 2023, the Company entered into an employment agreement with Bas van der Baan to act as the
Company&#8217;s President and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $150,000.
Effective October 6, 2023, Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October
5, 2023. Mr. van der Baan&#8217;s annual salary may be increased from time to time at the sole discretion of the Board of Directors.
In addition, Mr. van der Baan will be eligible to receive an annual bonus as determined at the sole discretion of the Board of Directors.
Mr. van der Baan was also granted stock options to acquire 250,000 shares of the Company&#8217;s common stock. The term of the employment
agreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject
to early termination provisions as described in the employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and Practices &#8211; Option Grants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors.
</b>The Company has a comprehensive compensation program for its non-officer directors for their service on the Board of Directors. This
program, as amended, has been in place since April 9, 2021. The Company, with the input and advice of its Compensation Committee, has
issued only stock options to its officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for directors under this compensation program is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new directors &#8211; The Company grants options to purchase 25,000 shares of common stock, exercisable for a period of five years,
at the closing market price on the date of grant, vesting 50% on the grant date and the remaining 50% vesting 12.5% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $100,000 to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to directors &#8211; Effective on the last business day of the month of June, the Company grants options to purchase
10,000 shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting 12.5%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $40,000 to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Officers.
</b>The Company has no specific policy or program with respect to the discretionary grant of options to its officers. The Company granted
options to its officers concurrent with their respective appointments during the year ended December 31, 2020. The Company also granted
discretionary stock options to its officers during the year ended December 31, 2022. It is the Company&#8217;s policy that any such option
grants take into account the existence of material non-public information when determining the timing of such a grant and the specific
terms of such award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Clawback Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that
emphasizes integrity and accountability and that reinforces the Company&#8217;s pay-for-performance compensation philosophy. The Board
of Directors has therefore adopted a compensation recoupment policy, which provides for the recovery of erroneously awarded incentive
compensation from the Company&#8217;s executive officers in the event of a triggering event, and which has been filed as an exhibit to
this report and has been posted to the investor information/governance section of the Company&#8217;s corporate website (www.lixte.com).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase 25,000 shares of the Company&#8217;s common stock, exercisable for a period of five years
at an exercise price of $28.00 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($2.6335 per
share), of which $329,188 was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
May 11, 2021 through June 30, 2023. During the years ended December 31, 2023, 2022 and 2021, the Company recorded charges to general
and administrative costs in the consolidated statement of operations of $76,388, $154,042 and $427,944, respectively, with respect to
these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total
of 50,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $30.30 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $1,421,095 ($28.4225 per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023.
During the years ended December 31, 2023, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $211,413, $638,915 and $358,200, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors. As a new director, in lieu of
a grant of stock options, Dr. Bernards received a one-time cash board fee of $100,000, payable immediately, and an annual cash board
fee of $40,000, payable quarterly. During the years ended December 31, 2023 and 2022, the Company recorded charges to general and administrative
costs in the consolidated statement of operations of $62,500 and $133,873, respectively, with respect to his cash board compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase 25,000 shares of the Company&#8217;s common stock, exercisable for a period of five years
at an exercise price of $7.40 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($6.341 per share),
of which $79,263 was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations
on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June
17, 2022 through June 30, 2024. During the years ended December 31, 2023 and 2022, the Company recorded charges to general and administrative
costs in the consolidated statement of operations of $38,885 and $100,249, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total
of 50,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $7.40 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $316,700 ($6.334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
For the years ended December 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $94,881 and $63,777, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase 10,000 shares (a total
of 40,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $5.88 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $192,593 ($4.8131 per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
For the year ended December 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated statement
of operations of $48,464 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase 10,000 shares (a total
of 40,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $2.37 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $73,976 ($1.8494 per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2026.
During the year ended December 31, 2024, the Company record a charge general and administrative costs in the consolidated statement of
operations of $18,648 with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of 16,598 stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of five years at an exercise price of $2.37 per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of five years and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $27,500 ($1.6570 per share), which was charged to operations on June 30, 2024, the date on which the
stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of 21,217 stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of five years at an exercise price of $1.87 per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of five years and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended September 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $27,500 ($1.2961 per share), which was charged to operations on September 30, 2024, the date on which
the stock options were fully vested.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2025, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of 16,665 stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of five years at an exercise price of $2.33 per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of five years and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended December 31, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $27,500 ($1.65002 per share). The grant date value of the stock options of $27,500 was accrued at December
31, 2024 and charged to operations at that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table set forth below presents the compensation awarded to, earned by or paid to our named directors for the years ended December 31,
2024, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTOR
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Principal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position (2)</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards<br/>
($)(1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Qualified Deferred Compensation Earnings<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Philip F. Palmedo</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (8)</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 5%; text-align: center">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">63,340</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">21,148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">84,408</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stephen J. Forman (9)</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,494</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,989</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,631</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,840</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yun Yen (3)</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,494</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,994</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,131</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gil Schwartzberg</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (4)</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,970</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Regina Brown</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,374</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (5)</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,131</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ren&#233; Bernards</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,244</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,438</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (6)</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,873</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bas van der Baan</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Director (7)</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,609</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,394</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Consists of grant date fair value of option award calculated pursuant to the Black-Scholes option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Dr. John S. Kovach, the founder of the Company, served as Chairman of the Board of Directors until his death on October 5, 2023. Prior
to September 26, 2023, Dr. Kovach was also the President, Chief Executive Officer and Chief Scientific Officer of the Company. Dr. Kovach
did not receive any separate compensation for his services as a member of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Appointed as a director of the Company effective August 4, 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Appointed as a director of the Company effective April 9, 2021 and died on October 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Appointed as a director of the Company effective May 11, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Appointed as a director of the Company effective June 15, 2022. Dr. Bernards received all of his compensation from June 15, 2022 through
March 31, 2024 in the form of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
Appointed as a director of the Company effective June 17, 2022, and as Chairman of the Board of Directors on October 6, 2023. Excludes
compensation received after appointment as President and Chief Executive Officer on September 26, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
Did not stand for re-election at the annual meeting of stockholders. Accordingly, his term as a director of the Company ended effective
October 7, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
Appointed as a director of the Company effective May 13, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Committee; Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Scientific Advisory Committee was established to advise the Company&#8217;s management in three areas: human molecular pathology; the
clinical management of human brain tumors; and medicinal chemistry. Members of the Scientific Advisory Committee do not serve in any
management capacity with the Company. During the years ended December 31, 2024, 2023 and 2022, the Scientific Advisory Committee consisted
of one member, Dr. Daniel D. Von Hoff, M.D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 24, 2013, the Company entered into a consulting agreement with NDA Consulting Corp. for consultation and advice in the field
of oncology research and drug development. As part of the consulting agreement, NDA also agreed to have its president, Dr. Daniel D.
Von Hoff, M.D., serve on the Company&#8217;s Scientific Advisory Committee during the term of such consulting agreement. The term of
the consulting agreement was for one year and provided for a quarterly cash fee of $4,000. The consulting agreement had been automatically
renewed for additional one-year terms on its anniversary date, most recently on December 24, 2023, but was subsequently terminated by
mutual agreement effective September 30, 2024. As a result of the termination of the consulting agreement effective September 30, 2024,
Dr. Von Hoff also ceased to be a member of the Scientific Advisory Committee at that time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
and advisory fees charged to operations pursuant to this consulting agreement were $12,000, $16,000 and $16,000 for the years ended December
31, 2024, 2023 and 2022, respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020
Stock Incentive Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Summary</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of 233,333 shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by 180,000 shares, to a total of 413,333 shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by 336,667 shares, to a total of 750,000 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, unexpired stock options for 613,232 shares were issued and outstanding under the 2020 Plan and 136,768 shares were
available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Having
an adequate number of shares available for future equity compensation grants is necessary to promote our long-term success and the creation
of stockholder value by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enabling
    us to continue to attract and retain the services of key service providers who would be eligible to receive grants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aligning
    the interests of participants with the interests of stockholders through incentives that are based upon the performance of our common
    stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motivating
    participants, through equity incentive awards, to achieve long-term growth in our business, in addition to short-term financial performance;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing
    a long-term equity incentive program that is competitive as compared to other companies with whom we compete for talent.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2020 Plan permits the discretionary award of incentive stock options (&#8220;ISOs&#8221;), non-statutory stock options (&#8220;NQSOs&#8221;),
restricted stock, restricted stock units (&#8220;RSUs&#8221;), stock appreciation rights (&#8220;SARs&#8221;), other equity awards and/or
cash awards to selected participants. The 2020 Plan will remain in effect until July 14, 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2020 Plan provides for the reservation of 750,000 shares of common stock for issuance thereunder (the &#8220;Share Limit&#8221;), and
provides that the maximum number of shares that may be issued pursuant to the exercise of ISOs is 750,000 shares (the &#8220;ISO Limit&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Key
Features of the 2020 Plan</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
key features of the 2020 Plan are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    not terminated earlier by our Board of Directors, the 2020 Plan will terminate on July 14, 2030.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to a maximum aggregate of 750,000 shares of common stock may be issued under the 2020 Plan. &#160;The maximum number of shares that
    may be issued pursuant to the exercise of ISOs is also 750,000.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2020 Plan is administered by the Compensation Committee, which is comprised solely of independent members of our Board of Directors.
    &#160;The Board of Directors may designate a separate committee to make awards to employees who are not officers subject to the reporting
    requirements of Section 16 of the Exchange Act.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees,
    consultants and board members are eligible to receive awards, provided that the Compensation Committee has the discretion to determine
    (i) who shall receive any awards, and (ii) the terms and conditions of such awards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
    may consist of ISOs, NQSOs, restricted stock, RSUs, SARs, other equity awards and/or cash awards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    options and SARs may not be granted at a per share exercise price below the fair market value of a share of our common stock on the
    date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    options and SARs may not be repriced or exchanged without stockholder approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    maximum exercisable term of stock options and SARs may not exceed ten years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
    are subject to recoupment of compensation policies adopted by us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Eligibility
to Receive Awards</span>.</i> Employees, consultants and members of our Board of Directors are eligible to receive awards under the 2020
Plan. The Compensation Committee determines, in its discretion, the selected participants who will be granted awards under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Shares
Subject to the 2020 Plan</span>. </i>The maximum number of shares of common stock that can be issued under the 2020 Plan is 750,000 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares underlying forfeited or terminated awards (without payment of consideration), or unexercised awards become available again for
issuance under the 2020 Plan. No fractional shares may be issued under the 2020 Plan. No shares will be issued with respect to a participant&#8217;s
award unless applicable tax withholding obligations have been satisfied by the participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Administration
of the 2020 Plan</span>.</i> The 2020 Plan is administered by the Compensation Committee of the Board of Directors, which consists of independent
board members. With respect to certain awards issued under the 2020 Plan, the members of the Compensation Committee also must be &#8220;Non-Employee
Directors&#8221; under Rule 16b-3 of the Exchange Act. Subject to the terms of the 2020 Plan, the Compensation Committee has the sole
discretion, among other things, to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Select
    the individuals who will receive awards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    the terms and conditions of awards (for example, performance conditions, if any, and vesting schedule);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Correct
    any defect, supply any omission, or reconcile any inconsistency in the 2020 Plan or any award agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerate
    the vesting, extend the post-termination exercise term or waive restrictions of any awards at any time and under such terms and conditions
    as it deems appropriate, subject to the limitations set forth in the 2020 Plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permit
    a participant to defer compensation to be provided by an award; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpret
    the provisions of the 2020 Plan and outstanding awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee may suspend vesting, settlement, or exercise of awards pending a determination of whether a selected participant&#8217;s
service should be terminated for cause (in which case outstanding awards would be forfeited). Awards may be subject to any policy that
the Board of Directors may implement on the recoupment of compensation (referred to as a &#8220;compensation clawback&#8221; policy).
The members of the Board of Directors, the Compensation Committee and their delegates shall be indemnified by us to the maximum extent
permitted by applicable law for actions taken or not taken regarding the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Types
of Awards</span>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock
Options</span></i>. A stock option is the right to acquire shares at a fixed exercise price over a fixed period of time. The Compensation
Committee determines, among other terms and conditions, the number of shares covered by each stock option and the exercise price of the
shares subject to each stock option, but such per share exercise price cannot be less than the fair market value of a share of our common
stock on the date of grant of the stock option. The exercise price of each stock option granted under the 2020 Plan must be paid in full
at the time of exercise, either with cash, or through a broker-assisted &#8220;cashless&#8221; exercise and sale program, or net exercise,
or through another method approved by the Compensation Committee. Stock options granted under the 2020 Plan may be either ISOs or NQSOs.
In order to comply with Treasury Regulation Section 1.422-2(b), the 2020 Plan provides that no more than 750,000 shares may be issued
pursuant to the exercise of ISOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">SARs</span></i>.
A SAR is the right to receive, upon exercise, an amount equal to the difference between the fair market value of the shares on the date
of the SAR&#8217;s exercise and the aggregate exercise price of the shares covered by the exercised portion of the SAR. The Compensation
Committee determines the terms of SARs, including the exercise price (provided that such per share exercise price cannot be less than
the fair market value of a share of our common stock on the date of grant), the vesting and the term of the SAR. Settlement of a SAR
may be in shares of common stock or in cash, or any combination thereof, as the Compensation Committee may determine. SARs may not be
repriced or exchanged without stockholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Restricted
Stock</span></i>. A restricted stock award is the grant of shares of our common stock to a selected participant and such shares may be subject
to a substantial risk of forfeiture until specific conditions or goals are met. The restricted shares may be issued with or without cash
consideration being paid by the selected participant as determined by the Compensation Committee. The Compensation Committee also will
determine any other terms and conditions of an award of restricted stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">RSUs</span></i>.
RSUs are the right to receive an amount equal to the fair market value of the shares covered by the RSU at some future date after the
grant. The Compensation Committee will determine all of the terms and conditions of an award of RSUs. Payment for vested RSUs may be
in shares of common stock or in cash, or any combination thereof, as the Compensation Committee may determine. RSUs represent an unfunded
and unsecured obligation for us, and a holder of a stock unit has no rights other than those of a general creditor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Other
Awards</span></i>. The 2020 Plan also provides that other equity awards, which derive their value from the value of our shares or from increases
in the value of our shares, may be granted. In addition, cash awards may also be issued. Substitute awards may be issued under the 2020
Plan in assumption of or substitution for or exchange for awards previously granted by an entity which we may acquire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Limited
Transferability of Awards</span></i>. Awards granted under the 2020 Plan generally are not transferrable other than by will or by the laws
of descent and distribution. However, the Compensation Committee may in its discretion permit the transfer of awards other than ISOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Change
in Control</span></i>. In the event that we are a party to a merger or other reorganization or similar transaction, outstanding 2020 Plan
awards will be subject to the agreement pertaining to such merger or reorganization. Such agreement may provide for (i) the continuation
of the outstanding awards by us if we are a surviving corporation, (ii) the assumption or substitution of the outstanding awards by the
surviving entity or its parent, (iii) full exercisability and/or full vesting of outstanding awards, or (iv) cancellation of outstanding
awards either with or without consideration, in all cases with or without consent of the selected participant. The Compensation Committee
will decide the effect of a change in control of us on outstanding awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Amendment
and Termination of the 2020 Plan</span></i>. The Board of Directors generally may amend or terminate the 2020 Plan at any time and for any
reason, except that it must obtain stockholder approval of material amendments to the extent required by applicable laws, regulations
or rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_022"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table set forth below presents certain information regarding beneficial ownership of our common stock (the only class of our voting equity
securities issued and outstanding) as of March 14, 2025 by (i) each person or entity who is known by us to own beneficially more than
5% of our outstanding shares of common stock, (ii) each of our directors, and (iii) all of our directors and executive officers as a
group. As of March 14, 2025, there were 2,684,074 shares of our common stock issued and outstanding. In computing the number and percentage
of shares beneficially owned by a person, shares of common stock that a person has a right to acquire within sixty (60) days of March
14, 2025 pursuant to stock options, warrants, convertible preferred stock or other rights are counted as outstanding, while these shares
are not counted as outstanding for computing the percentage ownership of any other person. This table is based upon information supplied
by our directors, officers and principal stockholders and reports filed with the Securities and Exchange Commission. Except as noted,
the Company&#8217;s executive office is reflected as the address of all officers, directors and other stockholders owning more than 5%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Name and Address of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount and Nature <br/> of Beneficial<br/> Ownership</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent of Class</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Officers and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bas van der Baan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Pasadena, California 91101</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">168,498</td><td style="width: 1%; text-align: left"><sup>(2)</sup>&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">5.9</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dr. Stephen J. Forman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,711</td><td style="text-align: left"><sup>(3)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dr. Yun Yen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,089</td><td style="text-align: left"><sup>(4)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dr. Ren&#233; Bernards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,203</td><td style="text-align: left"><sup>(5)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Regina Brown</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,053</td><td style="text-align: left"><sup>(10)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Robert N. Weingarten</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,833</td><td style="text-align: left"><sup>(6)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dr. Jan H.M. Schellens</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,750</td><td style="text-align: left"><sup>(8)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">All officers and directors as a group (9 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other Stockholders Owning More Than 5%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">John S. Kovach Trust</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,128</td><td style="text-align: left"><sup>(1)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Barbara C. H. Kovach</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,128</td><td style="text-align: left"><sup>(1)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Alexandra E. Kovach</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,128</td><td style="text-align: left"><sup>(1)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Arthur and Jane Riggs 1990 Irrevocable Trust</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Jane Riggs, Trustee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">4852 Saint Andres Avenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">La Verne, California 91750</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,750</td><td style="text-align: left"><sup>(7)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Glenn L. Krinsky</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">680 East Colorado Boulevard, Suite 180</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Pasadena, California 91101</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147,499</td><td style="text-align: left"><sup>(9)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Includes 154,018 shares of common stock and stock warrants to purchase 2,110 shares of common stock owned by the John S. Kovach Trust
dated September 22, 2015. The primary beneficiary of the trust is Barbara C. H. Kovach. Barbara C. H. Kovach and Alexandra E. Kovach
are co-trustees of the trust and have the exclusive right to control the investment of the assets of the trust.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Includes 11,000 shares of common stock and stock options to purchase 157,498 shares of common stock owned by Bas van der Baan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Includes 375 shares of common stock and stock options to purchase 43,126 shares of common stock owned by Dr. Stephen Forman. Also includes
7,105 shares of common stock and stock warrants to purchase 2,105 shares of common stock owned by the Stephen Forman Living Trust dated
12/16/98. Stephen Forman is trustee of the trust and holds voting and dispositive power over the common stock and common stock warrants
owned by the trust.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Includes 5,263 shares of common stock, stock warrants to purchase 5,263 shares of common stock and stock options to purchase 46,563 shares
of common stock.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Includes 25,000 shares of common stock and stock options to purchase 13,203 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Consists of stock options to purchase 20,833 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
Includes 101,833 shares of common stock and 72,917 shares of common stock issuable upon conversion of 350,000 shares of Series A Convertible
Preferred Stock owned by the Arthur and Jane Riggs 1990 Irrevocable Trust dated November 18, 1990. Jane Riggs is the trustee of the Arthur
and Jane Riggs 1990 Irrevocable Trust. The shares of Series A Convertible Preferred Stock were acquired on March 17, 2015 and January
15, 2016, are non-voting, and are immediately convertible into common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
Consists of stock options to purchase 3,750 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
Includes 14,166 shares of common stock owned by Glenn L. Krinsky. Also includes 133,333 shares of common stock owned by the John and
Barbara Kovach 2015 Trust, as to which Glenn L. Krinsky, as trustee, has voting, dispositive and investment control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
Includes 630 shares of common stock and stock options to purchase 67,423 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_023"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024, 2023,and 2022, there were no transactions, either directly or indirectly, between the Company and
any of its officers, directors or affiliates, including their family members, except as described elsewhere in this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers that Dr. Yun Yen, Regina Brown and Dr. Ren&#233; Bernards are each an &#8220;independent director,&#8221; as defined
under Nasdaq rules and by Rule 10A-3 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_024"></span>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weinberg
&amp; Company, P.A. acted as the Company&#8217;s independent registered public accounting firm for the fiscal years ended December 31,
2024 and 2023 and for the interim periods in such fiscal years. The following table shows the fees that were incurred by the Company
for audit and other services provided by Weinberg &amp; Company, P.A. for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">104,205</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120,640</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related Fees<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Fees<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,718</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,860</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Fees<sup>(4)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,695</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">143,618</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">153,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    fees represent fees for professional services provided in connection with the audit of the Company&#8217;s annual financial statements
    included in its Annual Reports on Form 10-K and the review of its interim financial statements included in its Quarterly Reports
    on Form 10-Q and services that are normally provided in connection with statutory or regulatory filings, excluding those fees included
    in Other Fees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related
    fees represent fees for assurance and related services that are reasonably related to the performance of the audit or review of the
    Company&#8217;s financial statements and not reported above under Audit Fees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    fees represent fees for professional services related to tax compliance, tax advice and tax planning.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    fees represent fees incurred with respect to the Company&#8217;s Registration Statements on Form S-1 and Form S-3. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
audit and audit-related services, tax services and other services rendered by Weinberg &amp; Company, P.A. during the fiscal years ended
December 31, 2024 and 2023 were pre-approved by either the Company&#8217;s Audit Committee or by the Company&#8217;s Board of Directors.
The Board of Directors has adopted a pre-approval policy that provides for the pre-approval of all services performed for the Company
by its independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_025"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_026"></span>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of documents filed as part of this report:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to the Index to Consolidated Financial Statements on page F-1, where these documents are listed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statement Schedules</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statement schedules have been omitted because the required information is not applicable, or not present in amounts sufficient
to require submission of the schedules, or because the information is included in the financial statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
(b) below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
list of exhibits required to be filed as part of this Annual Report on Form 10-K is set forth in the Index to Exhibits, which is presented
elsewhere in this document, and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_027"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 98; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_028"></span>INDEX
TO EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; width: 0.1in; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Document</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: bottom; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220022628/ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated as of November 25, 2020, between the Company and WestPark Capital, Inc. and WallachBeth, LLC, filed as Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 27, 2020 and incorporated herein by reference. </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420406027818/v047035_ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Exchange Agreement dated as of June 8, 2006 among the Company, John S. Kovach and Lixte Biotechnology, Inc., filed as Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 7, 2006 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420405023652/v022460_ex3-1.txt" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation, as filed with the Delaware Secretary of State on May 24, 2005, f<span style="text-decoration: underline">iled as Exhibit 3.1 to the Company&#8217;s Registration Statement on Form 10-SB, as filed with the Securities and Exchange Commission on August 3, 2005 and incorporated herein by reference.</span></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420406039012/v053105_pre14c.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment of Certificate of Incorporation, filed as Appendix A to the Company&#8217;s Information Statement, as filed with the Securities and Exchange Commission on September 19, 2006 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315215000869/ex4-01.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designations for the Company&#8217;s Series A Convertible Preferred Stock, filed as Exhibit 4.01 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on March 18, 2015 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315216008321/ex3-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment of Certificate of Designations of the Series A Convertible Preferred Stock, filed as Exhibit 3.4 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the Securities and Exchange Commission on March 28, 2016 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315222031348/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws, filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 10, 2022 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220022628/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment of Certificate of Incorporation, filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 27, 2020 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223020163/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Certificate of Incorporation of Lixte Biotechnology Holdings, Inc., filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 6, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220004697/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, filed as Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission on March 25, 2020 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220022628/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Public Warrant included in Unit, filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 27, 2020 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023 and incorporated herein by reference.</span></a></td></tr>
</table>

<p style="margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 99; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; width: 0.1in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315225006285/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2025 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant, filed as Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315225006285/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant, filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2025 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420413015451/v336103_ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master Agreement between Lixte Biotechnology Holdings, Inc. and Theradex Systems, Inc. dated January 12, 2010, f<span style="text-decoration: underline">iled as Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as filed with the Securities and Exchange Commission on March 15, 2013 and incorporated herein by reference.</span></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000114420414017092/v369493_ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Materials Cooperative Research and Development Agreement between Lixte Biotechnology Holdings, Inc. and the National Institute of Neurological Disorders and Stroke dated October 18, 2013, filed as Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 21, 2014 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315224023798/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Trial Agreement dated as of June 10, 2024 between the Company and the Netherlands Cancer Institute, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 14, 2024 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315215004422/ex10-01.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration Agreement between Lixte Biotechnology Holdings, Inc. and BioPharmaWorks LLC effective September 14, 2015, filed as Exhibit 10.01 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on September 18, 2015 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315219011717/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration Agreement for an Investigator-Initiated Clinical Trial between Lixte Biotechnology Holdings, Inc. and the Spanish Sarcoma Group as of July 31, 2019 (certain portions of this exhibit have been omitted based on a request for confidential treatment filed by the Company with the Securities and Exchange Commission that was granted on September 19, 2019), filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on August 6, 2019 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315225010282/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Collaboration Agreement dated March 11, 2025 for an Investigator-Initiated Clinical Trial between Lixte Biotechnology Holdings, Inc. and the Spanish Sarcoma Group as of July 31, 2019, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on March 14, 2025 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement between the Company and Dr. Jan Schellens, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on June 5, 2024 and incorporated herein by reference.+</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220016207/ex10-02.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between the Company and Robert N. Weingarten, filed as Exhibit 10.02 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on August 18, 2020 and incorporated herein by reference.+</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315220013545/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan, filed as Exhibit 10.1 to the Company Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 17, 2020 and incorporated herein by reference.+</span></a></td></tr>
</table>

<p style="margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 100; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; width: 0.1in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223042954/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan (as amended), filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 28, 2023 and incorporated herein by reference.+ </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315221001630/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigator-Initiated Clinical Research Support Agreement between City of Hope National Medical Center and City of Hope Medical Foundation and Lixte Biotechnology Holdings, Inc., filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on January 22, 2021 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315221027755/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute, Amsterdam, and Oncode Institute, Utrecht, entered into on October 8, 2021 (certain portions of this Exhibit have been omitted), filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission on November 10, 2021 and incorporated herein by reference.&#160;&#160;</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223009386/ex10-21.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy, filed as Exhibit 10.21 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 29, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315224010427/ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Clawback Policy, filed as Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 19, 2024, and incorporated herein by reference.+</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223016069/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Contract between Lixte Biotechnology Holdings, Inc. and MRI Global effective April 17, 2022, filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 10, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 20, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315225006285/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2025 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223033825/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between the Company and Bastiaan van der Baan effective September 26, 2023, &#160;filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on September 27, 2023 and incorporated herein by reference. </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223040115/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute, Amsterdam, and the Oncode Institute, Utrecht, entered into on October 8, 2021, filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, as filed with the Securities and Exchange Commission on November 9, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute, Amsterdam, and the Oncode Institute, Utrecht, entered into on October 13, 2023 (certain portions of this Exhibit have been omitted), filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on October 17, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315224048292/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 3 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc. and the Netherlands Cancer Institute, Amsterdam, and the Oncode Institute, Utrecht, entered into on November 29, 2024, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on December 2, 2024 and incorporated herein by reference.</span></a></td></tr>
</table>

<p style="margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 101; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; width: 0.1in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223040115/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination letter between H. Lee Moffitt Cancer Center and Research Institute, Inc. and the Company dated October 4, 2023 and effective as of September 30, 2023, filed as Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, as filed with the Securities and Exchange Commission on November 9, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315224007784/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive Patent License Agreement between Lixte Biotechnology, Inc. and the National Institute of Neurological Disorders and Stroke and the National Cancer Institute, each a component of the National Institute of Health, effective as of February 23, 2024, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 26, 2024 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="https://www.sec.gov/Archives/edgar/data/1335105/000149315223009386/ex21-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of the Registrant, filed as Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 29, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Weinberg &amp; Company, P.A., Independent Registered Public Accounting Firm*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document (does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Scheme Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101.INS)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.4in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or any compensatory plan, contract or arrangement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24pt; text-align: justify; text-indent: -24pt"></p>

<!-- Field: Page; Sequence: 102; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_029"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 13 and 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 50%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 24, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 5%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
    BIOTECHNOLOGY HOLDINGS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    BASTIAAN VAN DER BAAN</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant
in the capacity and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 30%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 46%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 2%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 20%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    BASTIAAN VAN DER BAAN</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
                                            S. Kovach</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    ROBERT N. WEINGARTEN</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President and Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
                                            N. Weingarten</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    STEPHEN J. FORMAN</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    J. Forman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    RENE BERNARDS</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ren&#233;
    Bernards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    YUN YEN </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yun
    Yen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    REGINA BROWN </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regina
    Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 103; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence -->-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_030"></span>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(INCLUDING
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
    Number</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#v_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID NO. <span id="xdx_90E_edei--AuditorFirmId_c20240101__20241231_zsYQZRTGXGH8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000069" name="dei:AuditorFirmId">572</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#v_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets &#8211; December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#v_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations &#8211; Years Ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#v_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Stockholders&#8217; Equity &#8211; Years Ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#v_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows &#8211; Years Ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#v_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements &#8211; Years Ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 104; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="v_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Opinion
on the Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_982_edei--AuditorOpinionTextBlock_c20240101__20241231_zTam1RmY0uzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000070" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Lixte Biotechnology Holdings, Inc. and subsidiary (the &#8220;Company&#8221;)
as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders&#8217; equity and cash flows for
the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023,
and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted
in the United States of America.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going
Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company has no recurring source of revenue and has experienced negative operating cash flows since
inception. The Company has financed its working capital requirements through the recurring sale of its equity securities. These matters
raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these
matters are also described in Note 1 to the financial statements. These financial statements do not include any adjustments that might
result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis
for Opinion</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Critical
Audit Matter</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 6 to the financial statements, the Company recognized $418,422 of compensation expense related to stock-based awards
to certain officers, employees and consultants. Management accounts for stock-based compensation based on the estimated fair value of
each award granted, which is amortized as expense over the requisite service period of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditing
management&#8217;s estimate of the valuation of stock-based compensation was complex and highly judgmental due to the subjectivity of
the inputs and assumptions that management utilized in determining the fair value of the stock-based awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit procedures related to the stock-based awards, including the valuation methodology and related assumptions such as the risk-free
interest rate, volatility, and dividend yield, consisted of the following, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    obtained and read the stock-based award agreements, and obtained board minutes and board resolutions related to the stock-based awards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    evaluated the option price model management selected to determine the fair value, and evaluated the reasonableness of management&#8217;s
    significant valuation assumptions, and tested the mathematical accuracy of management&#8217;s valuation analyses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    developed independent estimates for the fair values of the stock-based awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2008.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_90B_edei--AuditorName_c20240101__20241231_zHbPsv8SaGZ8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000071" name="dei:AuditorName">Weinberg &amp; Company, P.A</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--AuditorLocation_c20240101__20241231_zX4maIMd4iLe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000072" name="dei:AuditorLocation">Los
Angeles, California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
24, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="v_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zCzjlcCZIcSk" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zcWmmZ53Ox1i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zdTOSa2S9wnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Cash_i02I_maAzoqT_zhktpPxXpN38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,038,952</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,203,488</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AdvancesOnResearchAndDevelopmentContractServices_i02I_maAzoqT_zXGm7ekLDKS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advances on research and development contract services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0083">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2023-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,016</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidInsurance_i02I_maAzoqT_zSW1MWBO0J97" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,898</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,116</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_i02I_maAzoqT_zlHWdWsDmERk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,653</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_iTI_mtAzoqT_zuZP8KCC458c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,145,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,308,620</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzJLV_zPBO9pKrtKzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable and accrued expenses, including $<span id="xdx_90D_eus-gaap--AccountsPayableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zl8FjRWPQw38" title="Related parties accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,500</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--AccountsPayableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zG8AJ7pBJVl2" title="Related parties accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,250</ix:nonFraction></span> to related parties at December 31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,758</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ResearchAndDevelopmentContractLiabilitiesCurrent_i02I_maLCzJLV_zW7KBDxftvjb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Research and development contract liabilities, including $<span id="xdx_900_ecustom--ResearchAndDevelopmentContractLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztksCwEvcO6" title="Related parties research and development contract liabilities"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilities" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_901_ecustom--ResearchAndDevelopmentContractLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zZg38e7EJzTi" title="Related parties research and development contract liabilities"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilities" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,768</ix:nonFraction></span> to related parties at December 31, 2024 and 2023, respectively</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,078</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,100</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzJLV_maLASEzUP3_zS5vmmWJ8JQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,284</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">313,858</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzUP3_zsY4KF4BCoq6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0118">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0119">-</span></span>&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i02I_maSEzpkD_zNs4d24EEZqi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preferred Stock, $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zmydRAP6cPaj" title="Preferred stock, par value"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zzqt9MXDk9Yb" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zx3y3tTS6F6g" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zs5a74FFSN1b" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; issued and outstanding &#8211; <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zhmTkxoT1W0b" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zHH8AkjGaCs6" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zOyNbyNdZAF5" title="Preferred stock, shares outstanding"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zjFW4AzmOcAj" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of Series A Convertible Preferred Stock, $<span id="xdx_908_eus-gaap--PreferredStockLiquidationPreference_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zwmguIwsO8l" title="Preferred stock liquidation preference per share"><span id="xdx_902_eus-gaap--PreferredStockLiquidationPreference_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_pdd" title="Preferred stock liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></ix:nonFraction></span></span> per share stated value, liquidation preference based on assumed conversion into common shares &#8211; <span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zMDlfPjpaSu6" title="Preferred stock, issuable upon conversion"><span id="xdx_909_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zFpqSOy3Eba6" title="Preferred stock, issuable upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></ix:nonFraction></span></span> shares at December 31, 2024 and 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_i02I_maSEzpkD_zHif1vrDllm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock, $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zYFr0EU16ZM8" title="Common stock, par value"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zxDjjtoTyfMf" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zKw5TAr4b6M2" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20231231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; issued and outstanding &#8211; <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20241231_z9TKjjGnvKTj" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20231231_ztaWdka8otu5" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zdF2EbMQv6p6" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zOck6gUnVVy5" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares at December 31, 2024 and 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_i02I_maSEzpkD_zPaydFQCHc3h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,394,687</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,976,265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzpkD_z34SfoLoJigi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,067,693</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,481,728</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquity_i02TI_mtSEzpkD_maLASEzUP3_ztAMNRS6MWYc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">827,219</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,994,762</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzUP3_zxyAWw2z5HJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,145,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,308,620</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="v_003"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_zCLmBxVUAgf6" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_za5pYlNvZrYl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zJeXtGWD98zk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maOILzpTl_zFCnYBBNxmH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0183">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zQhd2zJF24f1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzKmU_z6GyQxZ8zFR7" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Research and development costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726,232</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">898,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzKmU_zxyL2zQjPvfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,846,557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,192,136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpenses_i01T_mtOEzKmU_msOILzpTl_zdL8BqYcK2Jd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total costs and expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,572,789</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,090,236</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_maNILz3k4_mtOILzpTl_znO5afWdoQH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,572,789</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,090,236</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--InvestmentIncomeNonoperating_maNILz3k4_zNHKnKgfJ07a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2024-01-01to2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2023-01-012023-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,486</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestExpense_iN_di_msNILz3k4_z8aCC8wjOzak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,821</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,233</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_maNILz3k4_z6aPAQR1WQO8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency gain (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-01to2024-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,403</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-012023-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,954</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_iT_mtNILz3k4_z3HBU150tUP1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,585,965</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,087,029</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zitnjNQujmS4" title="Net loss per common share basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zdg9gLJ4ndIh" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.59</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z62AylN0bI63" title="Net loss per common share basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zSSk9hdVJnM2" title="Net loss per common share diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.66</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zmTYXQGoG4C1" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zFNYWlIhl8ea" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zVDAdncdO1rd" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zHJ0Wn3kCZV3" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,915,838</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="v_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_114_zwbLA6pf7es6" summary="xdx: Statement - Consolidated Statements of Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesAConvertiblePreferredStockMember_zwJsXsu25crh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zlhO2sWlOwm2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Par&#160;Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zVVYNF5J4djd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zzddOTVeOgGg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B9_zxhM8GDbr4gh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Equity</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Series
                                            A Convertible</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Preferred
                                            Stock</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Common
    Stock</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 9pt">Additional Paid-in</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 9pt">Total Stockholders&#8217;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Par&#160;Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Equity</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_439_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zd7iCG9Ttpda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%"><span style="font-size: 9pt">Balance, December 31, 2022</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_ztbAHkeyQpn7" title="Balance, shares" style="width: 6%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9DaJY7fVQuh" title="Balance, shares" style="width: 6%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000236" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,706</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,059,760</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,394,699</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,165,227</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z4BnVgirmu7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Proceeds from sale of securities in registered direct equity offering,
    net of offering costs</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcHzoInOcDcj" title="Proceeds from sale of securities in registered direct equity offering, net of offering costs, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,137,021</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0241">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,137,039</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_zBOOZnU9Vn21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Exercise of pre-funded common stock warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zehp0niUZfVi" title="Exercise of pre-funded common stock warrants, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0248">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zUV90kv3cLIe" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">Exercise of common stock options</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTIS4ZeDdUZb" title="Exercise of common stock options, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0257">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zCK898KvZljb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Stock-based compensation</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">773,203</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0265">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">773,203</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zV5h5yyfE6V6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000271" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,087,029</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,087,029</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zvmoUHWIcUgd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance, December 31, 2023</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zhzVDYRUvRrc" title="Balance, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFCpAL54nf15" title="Balance, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000282" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,976,265</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000277" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,481,728</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,994,762</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_43E_c20240101__20241231_eus-gaap--StockholdersEquity_iS_znqTxONFm9ae" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z22QkGol0ZY1" title="Balance, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrtLjdYetL9j" title="Balance, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,976,265</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000287" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,481,728</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,994,762</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zCDSHD52n8u" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Stock-based compensation</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,422</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,422</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zgvNnUFo2o7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000303" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,585,965</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,585,965</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_439_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zTYvPzr65y2e" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">Balance, December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmzRf9ZrnF67" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfwDminGybO5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000314" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,394,687</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000309" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,067,693</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">827,219</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_438_c20240101__20241231_eus-gaap--StockholdersEquity_iE_z5AFshG0f8H9" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">Balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zqwHqY168Zw5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoVhHuYILumg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,394,687</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,067,693</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">827,219</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="v_005"></span><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zymuUMAihBi7" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_z0p3OVDaKZt2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zqi8KPEkO00g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z57HroCx1Pue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maNCPBUz0eM_zAYxHAEYCqgl" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000329" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,585,965</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000330" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,087,029</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zEhMZNRrhoBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensationAbstract_i02B_znLSc9CwYe3f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense included in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_i03_maNCPBUz0eM_z7C6jfGdJOgh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" contextRef="From2024-01-01to2024-12-31" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,422</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" contextRef="From2023-01-012023-12-31" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">773,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ShareBasedCompensationIncludedInResearchAndDevelopmentCost_i03_maNCPBUz0eM_zzhGHopNwUZg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i03B_zOEsUof7ZcN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i04B_zP301vniun99" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Increase) decrease in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_i05N_di_msNCPBUz0eM_zl1E4ydqEcE2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Advances on research and development contract services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2024-01-01to2024-12-31" id="Fact000350" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,016</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2023-01-012023-12-31" id="Fact000351" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidInsurance_i05N_di_msNCPBUz0eM_znyzSGxKUbma" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2024-01-01to2024-12-31" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,782</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2023-01-012023-12-31" id="Fact000354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,108</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_i05N_di_msNCPBUz0eM_zrvRJDl47gJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2024-01-01to2024-12-31" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,653</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2023-01-012023-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,350</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i04B_zsfz1ju0JKc8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase (decrease) in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i05_maNCPBUz0eM_zkuiNvH6UiI8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,552</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000363" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,976</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_i05_maNCPBUz0eM_zHB2ZIvftCjg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Research and development contract liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,978</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000366" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,922</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUz0eM_maCCERCzMHB_z7gAAwbyrQU3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000368" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,164,536</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000369" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,293,265</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zZEzcnULt14f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUz4w7_zdPYfT2VdSU6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from sale of securities in registered direct offering, net of <br/> offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,137,039</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUz4w7_zWz8djzLkPye" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercise of pre-funded common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-012023-12-31" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUz4w7_zdAoMIr0g9s5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Exercise of common stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUz4w7_maCCERCzMHB_zS5TbWlbMpX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,143,361</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_iB_zftKXaTxlqD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cash:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_i01T_mtCCERCzMHB_zT8gOq1l4YX5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net decrease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000389" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,164,536</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000390" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,149,904</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_z2DpjiRty347" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,203,488</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,353,392</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_zqJAwXw7zR2g" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,038,952</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,203,488</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zhVKmU5Ogjy9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationRelatedText_i01_zIZDi30ie3j9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPaidNet_i01_zWHnlDzlwEM8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,821</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxesPaidNet_i01_zvQIiqCPwDOf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="v_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000410" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z8O7RSmNuSJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82B_z0atKDIVjeI3">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc., a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (collectively,
the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development
and developing and commercializing cancer therapies. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents,
radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase
inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic access to equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 2, 2023, the Company effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztceidAmV8wa" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" id="Fact000412" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> reverse split of
its outstanding shares of common stock. The authorized number of shares of common stock and the par value per share were not affected
by the reverse stock split. No fractional shares were issued in connection with the reverse stock split, with all fractional shares being
rounded up to the next whole share. All share and per share amounts and information presented herein have been retroactively adjusted
to reflect the reverse stock split for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Compliance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on the Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF9lnpadEeQb" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" id="Fact000414" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> reverse split of its outstanding shares of common stock in order to remain in compliance
with the $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zYaEmCqxk1w7" title="Bid price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact000416" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> minimum closing bid price requirement of Nasdaq. However, there can be no assurances that the Company will be able to
remain in compliance with the $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zSfQVo5UkKQd" title="Bid price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact000418" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> minimum closing bid price requirement of Nasdaq over time. In addition, Nasdaq has other continued
listing requirements, one of which is maintaining a minimum net stockholders&#8217; equity of $<span id="xdx_90E_ecustom--NasdaqListingMaintainingMinimumNetStockholdersEquity_iI_c20230602_zdhgrYF8ztb9" title="Minimum net stockholders equity maintaining in nasdaq"><ix:nonFraction name="LIXT:NasdaqListingMaintainingMinimumNetStockholdersEquity" contextRef="AsOf2023-06-02" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2024, the Company received a letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock
Market LLC (&#8220;Nasdaq&#8221;) on August 19, 2024 indicating that the Company was not in compliance with the minimum stockholders&#8217;
equity requirement of $<span id="xdx_90D_eus-gaap--StockholdersEquity_iNI_di_c20240819__srt--RangeAxis__srt--MinimumMember_z5EJ6mu2gCf5" title="Stock holders' equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-08-19_srt_MinimumMember" id="Fact000422" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,500,000</ix:nonFraction></span> for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &#8220;Stockholders&#8217;
Equity Requirement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders&#8217; Equity Requirement, which
outlined the Company&#8217;s proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2024, the Staff provided notice (the &#8220;Notice&#8221;) to the Company that it had granted an extension through February
18, 2025 to regain compliance with the Stockholders&#8217; Equity Requirement, which required that the Company complete its capital raising
initiatives and evidence compliance with the Stockholders&#8217; Equity Requirement through filing a Current Report on Form 8-K with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) providing certain required information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 18, 2025, the Company had not gained compliance with the Stockholders&#8217; Equity Requirement. Accordingly, on February
19, 2025, the Company received a Staff determination letter from the Staff stating that the Company did not meet the terms of the extension
because it did not complete its proposed financing initiatives to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company timely filed an appeal and requested a Hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;), which has been granted.
The Hearing request automatically stayed Nasdaq&#8217;s delisting of the Company&#8217;s common shares and warrants pending the Panel&#8217;s
decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension through no
later than August 18, 2025. At the upcoming hearing, the Company will present its plan for regaining and sustaining compliance with the
Stockholders&#8217; Equity Requirement for continued listing. However, there can be no assurances that the Hearings Panel will grant
the Company an extension of time to regain compliance, or that the Company will be able to regain compliance during any extension period.
During the appeal process the Company&#8217;s common shares and warrants will continue to trade on The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to take reasonable measures available to regain compliance under Nasdaq&#8217;s listing rules and to remain listed on
Nasdaq. However, there can be no assurances that the Company will ultimately regain compliance with the Stockholders&#8217; Equity Rule,
or be able to maintain compliance with all other applicable requirements for continued listing on Nasdaq. If the Company does not regain
compliance with Nasdaq&#8217;s continued listing requirements within the time period permitted by Nasdaq, then the Company&#8217;s securities
will be delisted from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, the Company recorded a net loss of $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20240101__20241231_zawoyi7IHt16" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000424" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,585,965</ix:nonFraction></span> and used cash in operations of $<span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zzy26qFGPpwd" title="Net cash used in operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,164,536</ix:nonFraction></span>. At December
31, 2024, the Company had cash of $<span id="xdx_90A_eus-gaap--Cash_iI_pp0p0_c20241231_zhtTYjk1UZtl" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000428" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,038,952</ix:nonFraction></span> available to fund its operations. Subsequently, the Company completed a securities offering
that generated gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember_z3yZNr8Wi3Bk" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember" id="Fact000430" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,050,003</ix:nonFraction></span> during February 2025 before deducting the placement agent&#8217;s fees and related offering
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time
and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At March 14, 2025, the Company&#8217;s
remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred
aggregated approximately $<span id="xdx_90A_eus-gaap--ContractualObligation_iI_pp0p0_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_zGsjk7dkI0H7" title="Contractual obligation"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-12-31_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" id="Fact000432" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">526,000</ix:nonFraction></span> (see Note 8), which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements also
do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary if the Company is unable
to continue as a going concern. The Company has no recurring source of revenues and has experienced negative operating cash flows since
inception. The Company has financed its working capital requirements through the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the consolidated financial statements are being issued. In addition, our independent registered public
accounting firm has included an explanatory paragraph in their report with respect to this uncertainty that accompanies our audited consolidated
financial statements as of and for the year ended December 31, 2024. The Company&#8217;s consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2024, and the funds raised subsequent
to December 31, 2024, will provide sufficient working capital to fund the current clinical trial program with respect to the development
of the Company&#8217;s lead anti-cancer clinical compound LB-100 through approximately&#160;September 30, 2025. However, existing cash
resources will not be sufficient to complete the development of and obtain regulatory approval for the Company&#8217;s product candidate,
which will require that the Company raise significant additional capital. The Company estimates that it will need to raise additional
capital to fund its operations by mid-2025 to be able to proactively manage its current business plan during the remainder of 2025 and
during 2026. In addition, the Company&#8217;s operating plans may change as a result of many factors that are currently unknown and/or
outside of the control of the Company, and additional funds may be needed sooner than planned. The Company is considering various strategies
and alternatives to obtain the required additional capital. However, as market conditions present uncertainty as to the Company&#8217;s
ability to secure additional funds, there can be no assurance that the Company will be able to secure additional financing on acceptable
terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000434" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z3Dj4EoSrzlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_828_zCRrJMw2c0r1">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000436" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zcsIdVU2V1Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zEuemcl2zLm9">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000438" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zYvjq1FPqv17" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zoX5utclQqPk">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s President and Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) and evaluates
performance and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis.
Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates in a single reportable
segment, which consists of the development of a drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated
financial results of the Company. The CODM uses consolidated net income (loss) as the sole measure of segment profit or loss. The required
segment information, including significant segment expenses, is presented at Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000440" name="us-gaap:UseOfEstimates"><p id="xdx_840_eus-gaap--UseOfEstimates_zmvnkG6QTX85" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zUoSEeUK3TB8">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000442" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zG0A1VClo8q1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zOSF5nRCfQi3">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20241231_zuPcV34pXhV8" title="Cash FDIC insurance"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span> and $<span id="xdx_903_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_zZmG3YrZbOKd" title="Cash SIPC insurance"><ix:nonFraction name="LIXT:CashSIPCInsuredAmount" contextRef="AsOf2024-12-31" id="Fact000446" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000448" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOkDrS9BPgeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zbpnMn2tEvs1">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000450" name="LIXT:PrepaidInsurancePolicyTextBlock"><p id="xdx_845_ecustom--PrepaidInsurancePolicyTextBlock_z3h6e4ZR1uuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zBPYZfM44O72">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000452" name="LIXT:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_84C_ecustom--DeferredOfferingCostsPolicyTextBlock_zmXv6jpx1Dw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z5vbovG3uAmb">Offering
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000454" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFKb0Ge7Xzcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zkvflM1oU2r9">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20240101__20241231_z8kzl53Ud9r7" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-01to2024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">243,186</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--LegalFees_pp0p0_c20230101__20231231_z5i9qWOZxyQb" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-12-31" id="Fact000458" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">978,244</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively. Patent and licensing legal and
filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000460" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zLGgas8MCWyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zGdRUYxAvfhl">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9cCd0QpT6ze"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zD825rhACgR9"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="Fact000461" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="Fact000462" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction>%</span></span> or more of general and administrative costs or research and development costs for the years ended December 31, 2024 and
2023 are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the years ended December 31, 2024 and 2023 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwUSECDxAlwj" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000464" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.6</ix:nonFraction>%</span> and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQXrAfWQzf68" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000466" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23.3</ix:nonFraction>%</span> of total general
and administrative costs, respectively. General and administrative costs for the year ended December 31, 2024 also include charges from
two vendors and consultants representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRJHqxTpIgMk" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_SalesRevenueNetMember" id="Fact000468" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction>%</span> and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyddusgTwf8k" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_SalesRevenueNetMember" id="Fact000470" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.1</ix:nonFraction>%</span>, respectively, of total general and administrative costs. General and administrative
costs for the year ended December 31, 2023 also include charges from a vendor and consultant representing <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z30MQm4Fjg0k" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember" id="Fact000472" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.4</ix:nonFraction>%</span> of total general and
administrative costs. General and administrative costs for the years ended December 31, 2024 and 2023 also included charges for the fair
value of stock options granted to directors and corporate officers representing <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_z9paTxDZXXX1" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember" id="Fact000474" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14.7</ix:nonFraction>%</span> and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_zbM2PsTnRHK2" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember" id="Fact000476" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.4</ix:nonFraction>%</span>, respectively, of total general and administrative
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the year ended December 31, 2024 include charges from three vendors and consultants representing <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zHjn8TgPM1eh" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000478" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39.2</ix:nonFraction>%</span>, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zoCCNC5i5Ujg" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000480" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">29.0</ix:nonFraction>%</span>
and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVdSOUKz5uX2" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000482" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.4</ix:nonFraction>%</span>, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2023
include charges from three vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNvRjDIHroyd" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000484" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">29.9</ix:nonFraction>%</span>, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zKJgDKbflNyh" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000486" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25.2</ix:nonFraction>%</span> and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5iMhCrmN43g" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000488" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.7</ix:nonFraction>%</span>, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000490" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_z4Stpixsnnd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_z8gALVTKeQ5h">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#8217;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at December 31, 2024 and 2023. In the event the Company was to determine that it would be able
to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be
credited to operations in the period such determination was made. Should the Company determine that it would not be able to realize all
or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period
such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2024 or 2023
and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.
Subsequent to December 31, 2024, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000492" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJ2AhX4EeRW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_znLUEeLScyNc">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#8217;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000494" name="LIXT:WarrantsPolicyTextBlock"><p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zArJkAjk1hQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zh6QqgtvV183">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of the Company&#8217;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance
sheet date. At December 31, 2024 and 2023, the Company did not have any liability-classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000496" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zbaux3PEnad8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zonN5FB7w03a">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000498" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkOy0A0pBYfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024 and 2023, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zHPj4DF7oZe6" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z4VI50AUQvL9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zNebEdGefqK9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zSbnaTJ2wWQe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000501" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z3WBLs00WJ0a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember" id="Fact000503" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember" id="Fact000504" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zmgHoDjTCpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_CommonStockOptionsMember" id="Fact000506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">613,232</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_CommonStockOptionsMember" id="Fact000507" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">552,083</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zywad6fWeD06" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,494,514</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,433,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z3OYOmZ6i7Sh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000512" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzjL7LzueeNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z6jwXI0Q6Frk">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of <span id="xdx_906_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20241231_zqKinyWzaDg6" title="Foreign currency average rate"><ix:nonFraction name="LIXT:ForeignCurrencyExchangeRateTranslation" contextRef="From2024-01-01to2024-12-31" id="Fact000514" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.0823</ix:nonFraction></span> and <span id="xdx_905_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20230101__20231231_z5eezjnOYcmf" title="Foreign currency average rate"><ix:nonFraction name="LIXT:ForeignCurrencyExchangeRateTranslation" contextRef="From2023-01-012023-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.0820</ix:nonFraction></span> Euros per United States dollar, respectively. As of December 31,
2024 and 2023, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was not a party
to any foreign currency forward or exchange contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000518" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzbdSNTg8JPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zr6DQNoj1sf6">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments, which consists of accounts payable and accrued expenses is considered to be representative of
their respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000520" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWV5z0CNHuEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zoYAQW06qCIj">Recent
Accounting Pronouncements</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-03,
Presentation of Financial Statements (Topic 205), Income Statement &#8212; Reporting Comprehensive Income (Topic 220), Distinguishing
Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#8212; Stock Compensation (Topic 718) (&#8220;ASU 2023-03&#8221;).
ASU 2023-03 amends the FASB Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting
Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting
Series Release 280 &#8212; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide
any new guidance, there was no transition or effective date associated with its adoption. The Company adopted ASU 2023-03 immediately
upon its issuance in July 2023. The adoption of ASU 2023-03 did not have any impact on the Company&#8217;s consolidated financial statement
presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure.&#160; ASU 2023-07
amends the FASB Accounting Standards Codification to require additional reportable segment disclosures of a public entity by requiring
disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, requiring other new disclosures,
and requiring enhanced interim disclosures.&#160; ASU 2023-07 requires public entities with a single reportable segment to provide all
the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280 on an interim and annual basis.&#160; ASU 2023-07
is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, and is applied
retrospectively.&#160;The Company adopted ASU 2023-07 effective January 1, 2024 for the 2024 annual period on a retrospective basis.&#160;The
adoption of ASU 2023-07 resulted in additional required segment-related disclosures (see Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures
(Subtopic 220-40). ASU 2024-03 amends the FASB Accounting Standards Codification to require specified information about certain costs
and expenses in the notes to the financial statements at each interim and annual reporting period, including disclosure of the amounts
of purchases of inventory; employee compensation; depreciation; intangible asset amortization; and depreciation, depletion, and amortization
included in each relevant expense caption on the face of the income statement within continuing operations that contains any of the expense
categories previously listed. Disclosure will also be required of the total amount of selling expenses and an entity&#8217;s definition
of selling expenses in annual reporting periods. ASU 2024-03 does not change or remove current expense disclosure requirements, but does
affect where and how this information is presented in the notes to the financial statements. ASU 2024-03 is effective for annual reporting
periods beginning January 1, 2027, and interim periods within annual reporting periods beginning January 1, 2028. Early adoption is permitted.
The Company is in the process of evaluating ASU 2024-03 to determine its impact on the Company&#8217;s consolidated financial statement
presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000522" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5bzgaVIIWQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zu3j216Ka7K9">Reclassifications</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the adoption of ASU 2023-07 effective January 1, 2024, certain reclassifications have been made to the prior year statement
of operations to conform it to the current year presentation. In presenting general and administrative costs on the Company&#8217;s consolidated
statement of operations for the year ended December 31, 2023, $<span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zeb3o5LTx6ah" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" id="Fact000524" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,718,180</ix:nonFraction></span> of compensation to related parties, $<span id="xdx_902_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zPz4cLHRxZo1" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-12-31" id="Fact000526" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">978,244</ix:nonFraction></span> of patent and licensing
legal and filing fees and costs, and $<span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSvkEDE7wNU9" title="Legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember" id="Fact000528" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,495,712</ix:nonFraction></span> of other costs and expenses were shown separately. In presenting the Company&#8217;s
consolidated statement of operations for the year ended December 31, 2024, the Company has combined these categories into general and
administrative costs in the accompanying consolidated statement of operations for the year ended December 31, 2023. These reclassifications
had no effect on the reported results of operations, including loss from operations and net loss.</span></p>
</ix:nonNumeric><p id="xdx_858_zyhV3J125Fw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000530" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zkaepRb4dZIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_825_zU5STFEyee65">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Company&#8217;s President and Chief Executive Officer
(&#8220;CEO&#8221;).&#160; The Company&#8217;s CODM evaluates performance and makes operating decisions about allocating resources based on financial
data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined
that it has a single operating segment composed of the consolidated financial results of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000532" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zP5EFrePXqoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM and included in general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPIJcxJyNOLl">Schedule
of Information by segment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zETcYSt7bFzi" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_z8UO2HUZbS84" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Compensation to related parties:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CashBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_zCLm9UfEApc" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; text-indent: 13.5pt">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="LIXT:CashBasedCompensationToRelatedParties" contextRef="From2024-01-01to2024-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">753,124</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="LIXT:CashBasedCompensationToRelatedParties" contextRef="From2023-01-012023-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">944,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_z46vrHQtW378" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 13.5pt">Stock-based</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:StockBasedCompensationToRelatedParties" contextRef="From2024-01-01to2024-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,422</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:StockBasedCompensationToRelatedParties" contextRef="From2023-01-012023-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">773,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maOEzto3_maGAAEzrRU_zbZOsPQhxxmd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Patent and licensing legal and filing fees and costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:LegalFeesRelatingToPatentsAndLicensing" contextRef="From2024-01-01to2024-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,186</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:LegalFeesRelatingToPatentsAndLicensing" contextRef="From2023-01-012023-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">978,244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherConsultingAndProfessionalFees_i02_maOEzto3_maGAAEzrRU_zJT7l41PW0Q1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other consulting and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:OtherConsultingAndProfessionalFees" contextRef="From2024-01-01to2024-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">735,021</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:OtherConsultingAndProfessionalFees" contextRef="From2023-01-012023-12-31" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_zq1M5KBNuWJh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,444</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2023-01-012023-12-31" id="Fact000547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">442,976</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherCostAndExpenseOperating_i02_maOEzto3_maGAAEzrRU_zjykiRH4hWb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other costs and expenses, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2024-01-01to2024-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,360</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2023-01-012023-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,882</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02_mtGAAEzrRU_zzKr2726wAD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total general and administrative costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,846,557</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,192,136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM, and included in research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zULItvwWvFu6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zDe9RiimY82h" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zXVQc8HCrOXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Clinical and related oversight costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_ClinicalAndRelatedOversightCostsMember" id="Fact000555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">377,958</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ClinicalAndRelatedOversightCostsMember" id="Fact000556" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,269</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zT0k6nIKot1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preclinical research focused on development of additional novel anti-cancer compounds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_PreclinicalResearchMember" id="Fact000558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">329,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_PreclinicalResearchMember" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,093</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_zmyzxwrGY0c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Regulatory service costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_RegulatoryServiceCostsMember" id="Fact000561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,836</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_RegulatoryServiceCostsMember" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,738</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zlssANikio66" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total research and development costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726,232</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000565" format="ixt:numdotdecimal" decimals="0" unitRef="USD">898,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of research and development costs for the years ended December 31, 2024 and 2023 based on the respective
geographical regions where such costs were incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zgS3gpVgf6ac" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zQuUutuOvKPh" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zhI62rfIJFwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_country_US" id="Fact000567" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,566</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_country_US" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,589</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zi2qV338Hpf9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_country_ES" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,022</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_country_ES" id="Fact000571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,163</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zO57OxTVorqb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_country_CN" id="Fact000573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_country_CN" id="Fact000574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,198</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zBd5NB5odKhd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Netherlands</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_country_NL" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,362</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_country_NL" id="Fact000577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_z4TX9qz5HvAh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726,232</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">898,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s total assets by segment at December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zgNLEZyDoDz1" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20231231_zAtd3ap42RPc" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zKvNy7KVPQK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Research and development assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_ResearchAndDevelopmentMember" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,298</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31_custom_ResearchAndDevelopmentMember" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,369</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zXnyYYYbrMg9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Corporate assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_us-gaap_CorporateMember" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,106,205</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31_us-gaap_CorporateMember" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,230,251</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_iI_zIs5kCZrKhMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,145,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,308,620</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_znCrEZGWeial" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000591" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zTRFqv7VKJWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82E_z46kftVfLe16">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zt9egMKEwHuf" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_z03YNqldrtk6" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000595" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total of <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zW0XETcgPNP4" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The
holders of each tranche of <span id="xdx_903_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zvAAN9XOS7Kd" title="Principal cash obligations and commitments"><ix:nonFraction name="LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" id="Fact000599" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span> shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20150316__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYUIr7kuHtga" title="Preferred stock dividend, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember" id="Fact000601" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% of the annual net revenue of the Company divided by <span id="xdx_90B_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3UNnUqr0kpc" title="Annual net revenue"><ix:nonFraction name="LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" id="Fact000603" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span>, until converted or redeemed. As of December 31, 2024 and 2023, the
Company had <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zFQDS2gcNL9a" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zHAlDEbStNb2" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_custom_UndesignatedPreferredStockMember" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_UndesignatedPreferredStockMember" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,650,000</ix:nonFraction></ix:nonFraction></span></span> shares of undesignated preferred stock, which may be issued with such rights and powers as the Board of Directors
may designate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PreferredStockConversionBasis_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJAcJwmQyHrb" title="Preferred stock, conversion description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember" id="Fact000609" name="us-gaap:PreferredStockConversionBasis">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2EKqeiLVeIl" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.20833</ix:nonFraction></span> shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zmvtyj5pRgvd" title="Gross proceeds from sale of transaction"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember24649234" id="Fact000613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,875,000</ix:nonFraction></span>.</ix:nonNumeric></span> The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have any cash liquidation preference rights or any registration rights. The <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zD0Ks7ts2Or2" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zohvtACnVNij" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></ix:nonFraction></span></span> outstanding shares of Series A Convertible
Preferred Stock were convertible into a total of <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z2ODX8a4jrmj" title="Preferred stock convertible into common stock"><span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5qWdPOnMqi1" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember24649234" id="Fact000619" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember24649234" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,917</ix:nonFraction></ix:nonFraction></span></span> shares of common stock at December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_z0SfTXUb0D76" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z3wqLIwKIVpk" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000623" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zz3FLLUJ7Kf" title="Common stock, par value"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zmERsWlDAFP5" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000629" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. As of December 31, 2024 and
2023, the Company had <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zCGsbj7NBPV7" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zuKbOVAYKe17" title="Common stock, shares outstanding"><span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zQktoFsLzCsc" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zgn7d56TjOX5" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,249,290</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRDCcoGwncCh" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" id="Fact000639" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse
split of its outstanding shares of common stock. The authorized number of shares of common stock and the par value per share were
not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split, with all
fractional shares being rounded up to the next whole share. All share and per share amounts and information presented herein have
been retroactively adjusted to reflect the reverse stock split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 10, 2023, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkhwuyPbYqi" title="Stock issued new issue shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-092023-03-10_us-gaap_CommonStockMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span> shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpTexyi45nZf" title="Stock issued new issue shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span> shares exercisable at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9tBU7eNrWI6" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-10_us-gaap_WarrantMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.025</ix:nonFraction></span> per share for total cash proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBLbiKUrHHPb" title="Proceeds from warrant exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember" id="Fact000647" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 20, 2023, the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH3jFAxKmBS2" title="Number of common stock shares issued during period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-192023-07-20_us-gaap_CommonStockMember" id="Fact000649" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span> shares of common stock at a price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5fwlwYHLffd" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember" id="Fact000651" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share and pre-funded warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWNhmqskRhT2" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember" id="Fact000653" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span>
shares of common stock at a price of $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmbWyUkapLKa" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember" id="Fact000655" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.9999</ix:nonFraction></span> per pre-funded warrant to an institutional investor in a registered direct offering. The
pre-funded warrants had an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z237LfrOg3Ji" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_us-gaap_CommonStockMember" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, were immediately exercisable upon issuance, and were valid and exercisable
until all pre-funded warrants were exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 24, 2023 through August 7, 2023, the <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6WAhVcMlkL8" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-07_us-gaap_CommonStockMember" id="Fact000659" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span> pre-funded warrants, exercisable at $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkyko0IIWk53" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-07_us-gaap_CommonStockMember" id="Fact000661" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per common share, were
exercised for total cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXwf5tWjImw3" title="Exercise of common stock options"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember" id="Fact000663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41</ix:nonFraction></span>, resulting in the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqD0OkpYR6u3" title="Issuance of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">403,334</ix:nonFraction></span> shares of common stock. The pre-funded warrants were determined
to be common stock equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement to the institutional investor, the Company also sold warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zAYsELifG5R3" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">583,334</ix:nonFraction></span> shares of common stock.
Each common warrant had an initial exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z8S4pRkbHWn8" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share, was immediately exercisable upon issuance, and expires <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmhg1yYQWJP3" title="Warrants term"><ix:nonNumeric contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember" format="ixt-sec:durwordsen" id="Fact000671" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span>
thereafter on <span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsHaPvGtWCOg" title="Warrant expires date"><ix:nonNumeric contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" format="ixt:datemonthdayyearen" id="Fact000673" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">July 20, 2028</ix:nonNumeric></span>. The common warrants and the shares of common stock issuable upon exercise of the common warrants were not
registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon
exercise of the warrants were registered for resale on a registration statement on Form S-3 declared effective by the SEC on May 2, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registered direct offering and the concurrent private placement generated gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zI0I8arUkIAb" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" id="Fact000675" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,499,964</ix:nonFraction></span>. The total cash costs of the registered
direct offering and the private placement were $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDnN1ImGPIZd" title="Costs of public offering"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" id="Fact000677" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">362,925</ix:nonFraction></span>, resulting in net proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNLHdqAgpA0g" title="Net proceeds from issuance of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember" id="Fact000679" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,137,039</ix:nonFraction></span>. Pursuant to the placement agent agreement,
the Company granted the placement agent warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zG8Ie7H25qfg" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-20_custom_PlacementAgentsMember" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zQa5gEyPWks6" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-20_custom_PlacementAgentsMember" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.60</ix:nonFraction></span> per share and
expiring on <span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zAaUw4R95965" title="Warrant expires date"><ix:nonNumeric contextRef="From2023-07-192023-07-20_custom_PlacementAgentsMember" format="ixt:datemonthdayyearen" id="Fact000685" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">July 20, 2028</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investor (exercisable at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230807__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z9YpXokFexdf" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-07_us-gaap_InvestorMember" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share) and to the placement agent (exercisable
at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230807__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVJLwNN69Udi" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-07_us-gaap_PrivatePlacementMember" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.60</ix:nonFraction></span> per share) are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications, reorganizations,
or similar events affecting the Company&#8217;s common stock. In addition, the warrants issued to the institutional investor contain
a &#8220;fundamental transaction&#8221; provision which provides that if any defined fundamental transactions are within the Company&#8217;s
control and are consummated, the holder of the unexercised common stock warrants would be entitled to receive, at its option, in exchange
for extinguishment of such warrants, cash consideration equal to a Black-Scholes valuation amount, as defined in the warrant agreement.
The fundamental transaction provision includes (i) a sale, lease, assignment, transfer, conveyance or other disposition of all or substantially
all of the assets of the Company in one or a series of related transactions, or (ii) a change in control of the Company by which it,
directly or indirectly, in one or more related transactions, consummates a stock or share purchase agreement or other business combination
with another person or group, whereby such other person or group acquires more than 50% of the voting power of the common equity of the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
such fundamental transaction is not within the Company&#8217;s control, including not being approved by the Company&#8217;s Board of
Directors, the warrant holder would only be entitled to receive the same type or form of consideration (and in the same proportion) equal
to the Black-Scholes valuation amount of the remaining unexercised portion of the warrant on the date of consummation of such fundamental
transaction as the holders of the Company&#8217;s common stock receive. Accordingly, these warrants are classified as a component of
permanent stockholders&#8217; equity. The Company will account for any cash payment for a warrant redemption as a distribution from stockholders&#8217;
equity, as and when a fundamental transaction is consummated and such cash payment is required to be made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000691" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhcIZXlq9Czh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s
public offering, during the years ended December 31, 2024 and 2023 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zA0LzxTe39m8" style="display: none">Schedule
of Warrants Outstanding</span>&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Warrants outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvHUu21qIy06" title="Number of Shares, Warrants Outstanding, Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">190,031</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcSRgPR6Frqf" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning" style="width: 14%; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">50.161</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEZAjyDTOxd1" title="Number of Shares, Issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">618,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxMIT1R6kws8" title="Weighted Average Exercise Price, Issued" style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781" id="Fact000699" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqUPaLqudB04" title="Number of Shares, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3w2UWFqXbO9" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHUVxVlSkml9" title="Number of Shares, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWqXzT6yUnuh" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhtKS7HDS22" title="Number of Shares, Warrants Outstanding, Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember" id="Fact000709" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOBaUP6LtZg" title="Weighted Average Exercise Price, Warrants Outstanding, Ending" style="text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHRl5Z2KGZP7" title="Number of Shares, Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdBlxcAjvoWb" title="Weighted Average Exercise Price, Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOztlHckLpi8" title="Number of Shares, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpnGHNQtUagf" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0719">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqGSfEZcfqFb" title="Number of Shares, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYX1oEXjnIh" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0723">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXeuv9vUD975" title="Number of Shares, Warrants Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPW2Yq38twX1" title="Weighted Average Exercise Price, Warrants Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXLrtH3fCSbe" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812" format="ixt-sec:duryear" id="Fact000729" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">2.99</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGs6rbVFADM5" title="Number of Shares, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember" id="Fact000731" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zB8XJIi0ChUa" title="Weighted Average Exercise Price, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjX90tWAUER5" title="Number of Shares, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember" id="Fact000735" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAxpK8s0Bnv2" title="Weighted Average Exercise Price, Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwQvuPayTsh" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812" format="ixt-sec:duryear" id="Fact000739" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm">2.99</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zuJwvDR6Wpk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000741" name="LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zJW3jkC8sjVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zlNz7iDJy66f" style="display: none">Schedule of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants <br/> Outstanding (Shares)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 2%; text-align: left">$</td><td style="width: 46%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BLW3JZyeU6" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.000</ix:nonFraction></span></td><td style="width: 2%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAv0MNL8T0Va" title="Warrants Outstanding Shares" style="width: 45%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact000745" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">583,334</ix:nonFraction></td><td style="width: 2%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxcR0ejaDVdh" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.600</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7JUSpnp3An2" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOveWcXkvlOc" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zJfWm6ToHzy6" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact000753" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zZYsk5xZFzP" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact000755" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvZQLxqzHFYb" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zDjqAiGL4Xsg" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zg9Z0wMJ1m7g" title="Warrants Outstanding Shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,700</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231_zCEMOz6bI6Ha" title="Warrants Outstanding Shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">808,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zh1iXQquaTbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants exercisable at $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrf3uLcQTI52" title="Warrants exercisable"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.00</ix:nonFraction></span> per share at December 31, 2024 consist of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyYYovZIwzWf" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,497,000</ix:nonFraction></span> publicly-traded warrants, described herein on a pre-split
<span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF2HT8ouHQFj" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember" id="Fact000769" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> basis, that were issued as part of the Company&#8217;s November 2020 public offering of units, and are exercisable for a period
of five years thereafter. As a result of the 1-for-10 reverse split of the Company&#8217;s common stock effective June 2, 2023, each
such publicly-traded warrant currently now represents the right to purchase 1/10th of a share of common stock at the original exercise
price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfw68oB2krba" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-02_us-gaap_CommonStockMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.70</ix:nonFraction></span> per share. Accordingly, the exercise of 10 warrants, each exercisable at $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4GkiwIoNwzf" title="Warrants exercisable"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-02_us-gaap_WarrantMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.70</ix:nonFraction></span>, are required to acquire one share of post-split
common stock, which is equivalent to a purchase price of $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyJ17QWMjMJ8" title="Warrants and rights outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-06-02_us-gaap_WarrantMember" id="Fact000775" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">57.00</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the closing fair market value of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEMybhi9NBei" title="Fair market value of stock"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.03</ix:nonFraction></span> per share on December 31, 2024, there was no intrinsic value attributed to exercisable but
unexercised common stock warrants at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000779" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFqZGgdkYFwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82E_zQhu5H8QRTr7">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. Except as noted below, these employment
agreements were automatically renewed for additional one-year periods in July and August 2021, 2022, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_903_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zW9TkZvKIlTc" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember" id="Fact000781" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.
The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023. During the year ended December 31, 2023, the Company
paid $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ziKxBrQLEGEg" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000783" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,860</ix:nonFraction></span> to Dr. Kovach under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s
consolidated statement of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020, to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember_zQn1R3EceS9e" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember" id="Fact000785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zb47GQ3wa3Mb" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" id="Fact000787" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>.
Dr. Miser was required to devote at least 50% of his business time to the Company&#8217;s activities. On May 29, 2024, the Company elected
not to renew its employment agreement with Dr. Miser, as a result of which such employment agreement expired on July 31, 2024. During
the years ended December 31, 2024 and 2023, the Company paid $<span id="xdx_900_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zhbwHRsbKls2" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,083</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z9UDO1Trlt4g" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000791" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>, respectively, to Dr. Miser under this employment
agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations
for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zrXKmKSzmK8a" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember" id="Fact000793" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_901_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zaXTh3eb5yMg" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember" id="Fact000795" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_902_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zFsiOp3dbLX3" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember" id="Fact000797" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>. Effective October 1, 2022, Mr. Forman was provided a monthly office rent allowance,
pursuant to which the Company paid $<span id="xdx_90B_eus-gaap--PaymentsForRent_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zpX57SQlVGZk" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,435</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zF30Nql6zjN6" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,571</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively, on Mr. Forman&#8217;s
behalf. The employment agreement with Mr. Forman terminated upon his resignation as an officer of the Company effective December 31,
2024. During the years ended December 31, 2024 and 2023, the Company paid $<span id="xdx_903_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAFmPNuuaDp2" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000803" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z13pky0hmBs4" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>, respectively, to Mr. Forman under this
employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of
operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_905_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zWhgFA4Tr6G6" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" id="Fact000807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_90A_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_z8H0NhtRJfth" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" id="Fact000809" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>. During the years ended December 31, 2024 and 2023, the Company paid $<span id="xdx_90D_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWa0gxkPCAAd" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqGD2IbxApRd" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $<span id="xdx_904_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z4Oae3txdtd8" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember" id="Fact000815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>. Effective October 6, 2023,
Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023. Mr. van der Baan&#8217;s
annual salary may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan is eligible
to receive an annual bonus as determined at the sole discretion of the Board of Directors. The term of the employment agreement is for
three years and is automatically renewable for additional one-year periods unless terminated by either party, subject to early termination
provisions as described in the employment agreement. During the years ended December 31, 2024 and 2023, the Company paid $<span id="xdx_904_eus-gaap--OfficersCompensation_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0V0iOHZR8s8" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000817" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,495</ix:nonFraction></span> and
$<span id="xdx_903_eus-gaap--OfficersCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zOq4r0L3xQwl" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,639</ix:nonFraction></span>, respectively, to Mr. van der Baan under this employment agreement, which costs are included in general and administrative costs
in the Company&#8217;s consolidated statement of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, the Company entered into a consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D. Pursuant to the agreement, effective
July 1, 2024, the Company engaged Dr. Schellens as a consultant, and, effective August 1, 2024, as the Company&#8217;s Chief Medical
Officer. The term of the agreement is in effect from July 1, 2024 until the earliest of (i) termination by either party upon sixty days&#8217;
notice, (ii) Dr. Schellens&#8217; death or disability, or (iii) termination by the Company for breach as provided in the agreement. Under
the agreement, Dr. Schellens provides his services for two days per week with the specific days in each week based on arrangements agreed
to from time to time between Dr. Schellens and the Company&#8217;s Chief Executive Officer. The Company pays Dr. Schellens an annual
compensation of <span id="xdx_90B_eus-gaap--ShareBasedCompensation_uEUR_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zaBAXretHULa" title="Annual compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_SchellensMember" id="Fact000821" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">104,000</ix:nonFraction></span> Euros (approximately $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zHlqimYpTB59" title="Annual compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_SchellensMember" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,000</ix:nonFraction></span> as of December 31, 2024), payable on a monthly basis. During the year ended December
31, 2024, the Company paid $<span id="xdx_908_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zuto7JslNzs" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-12-31_custom_SchellensMember" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,226</ix:nonFraction></span> to Dr. Schellens under this consulting agreement, which costs are included in general and administrative
costs in the Company&#8217;s consolidated statement of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. Upon
his appointment, it was agreed that Dr. Bernards would receive annual compensation for his services on the Board only in the form of
cash, in lieu of the annual June 30 grant of stock options as provided to the Company&#8217;s other non-officer directors. During the
years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement
of operations of $<span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_zWHf65OHqPsc" title="General administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_srt_DirectorMember" id="Fact000827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zL73ks6RIMkb" title="General administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_srt_DirectorMember" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span>, respectively, with respect to his annual cash board compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the Company&#8217;s efforts to preserve cash, effective with the quarter ended June 30, 2024, Dr. Bernards agreed to
receive equity-based compensation for his services on the Board, for the quarters ended June 30, 2024, September 30, 2024 and December
31, 2024. In order to reconcile his Board compensation with that of the other non-officer directors, Dr. Bernards has agreed to receive
the same Board compensation, both in form and amount, as the other non-officer directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for
their services on the Board of Directors (the &#8220;Board Plan&#8221;), which was subsequently amended effective May 25, 2022 and July
9, 2024. Officers who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_901_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zualF1oz72h4" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_srt_DirectorMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span> per year (except for Dr. Bernards, who was paid an additional annual cash fee of $<span id="xdx_90C_eus-gaap--Cash_iI_c20210409_zBw7KjuliqO7" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-04-09" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span>, in lieu of
the annual June <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_znivQYyz6Fkc" title="Stock option grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30</ix:nonFraction></span> grant of stock option as described below, through March 31, 2024)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee &#8211; additional $<span id="xdx_903_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_z58VxW5ZvtVl" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember" id="Fact000837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees &#8211; additional $<span id="xdx_904_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zT083QGWGz6d" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember" id="Fact000839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee &#8211; additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zbHC4xLPQtb1" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember" id="Fact000841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees &#8211; additional $<span id="xdx_907_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_z9KzKYYgZmyg" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember" id="Fact000843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the Company&#8217;s efforts to preserve cash, the Board approved an amendment to the Board Plan, such that for the quarters
ended June 30, 2024, September 30, 2024 and December 31, 2024, the non-officer directors (including Dr. Bernards) received, in lieu of
cash compensation, stock options exercisable for a period of five years, vesting immediately, to purchase common stock at an exercise
price based on the closing market price upon issuance, with the amount of such stock options equal to the cash payment such director
would otherwise have been entitled to receive for such quarter, divided by their quarterly value as determined pursuant to the Black-Scholes
option-pricing model. The Board may extend this amendment to the Board Plan for additional quarterly periods subsequent to December 31,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new directors &#8211; The Company grants options to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zZjbuZOTbD8" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_custom_NewIndependentDirectorMember" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zCDT3JB8W5wb" title="Options exercisable period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember" format="ixt-sec:durwordsen" id="Fact000847" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">five years</ix:nonNumeric></span>,
at the closing market price on the date of grant, vesting 50% on the grant date and the remaining <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_z3fzU7LrDJXi" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2024-01-012024-12-31_custom_NewIndependentDirectorMember" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% vesting <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20240101__20241231_zt4jYsjxTIi7" title="Award vesting rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2024-01-01to2024-12-31" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $<span id="xdx_90C_eus-gaap--ManagementFeePayable_iI_c20241231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_z2FvsVsl72b1" title="Cash fee payable"><ix:nonFraction name="us-gaap:ManagementFeePayable" contextRef="AsOf2024-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember" id="Fact000853" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to directors &#8211; Effective on the last business day of the month of June, the Company grants options to purchase
<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zCqqL8u4SMV7" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_znEBEdBWU0u1" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember" id="Fact000857" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_907_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_za6dyUtxOLUl" title="Annual cash fee"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember" id="Fact000859" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to non-officer directors was $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zKYwGrzOEVCh" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_IndependentDirectorMember" id="Fact000861" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,819</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_z783IsZNd8Mf" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_IndependentDirectorMember" id="Fact000863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,479</ix:nonFraction></span>, respectively, for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000865" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zCkUAaQ2qT4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2024 and 2023, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_z0855uu1EIeb" style="display: none">Summary
of Related Party Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zqFSlMulDgNa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20230101__20231231_zV6VaY1AgAHb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zawWesLCRlSe" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-01-012024-12-31_srt_DirectorMember24650984" id="Fact000867" format="ixt:numdotdecimal" decimals="0" unitRef="USD">753,124</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-12-31_srt_DirectorMember24650984" id="Fact000868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">944,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zl3IsGzqtrfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Stock-based</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_srt_DirectorMember24650984" id="Fact000870" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,422</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_srt_DirectorMember24650984" id="Fact000871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">773,203</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zcTgqVL3cSRg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_srt_DirectorMember24650984" id="Fact000873" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,171,546</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_srt_DirectorMember24650984" id="Fact000874" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,718,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zBGjUe6mo7u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000876" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zAS0EvzUnC36" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_821_z5QSJ2YgHftl">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_z5GuizCV97Fi" title="Number of restricted stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">233,333</ix:nonFraction></span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zTSz8EKwHV1c" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span> shares, to a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zE4A1Cd4OWN8" title="Shares total"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">413,333</ix:nonFraction></span> shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zbEgVAQBJBbd" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">336,667</ix:nonFraction></span> shares, to a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231126__20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zmDhV4NvBWMg" title="Shares total"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, unexpired stock options for <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zKgsl5FF78e7" title="Shares outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">613,232</ix:nonFraction></span> shares were issued and outstanding under the 2020 Plan and <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zDvSZPRmRuh9" title="Shares were available for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136,768</ix:nonFraction></span> shares were
available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000892" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zavaGoiujWQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2024, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zNrDkvVspYj8" style="display: none">Schedule
of Fair Value of Each Option Award Estimated Assumption</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zClvD3qZD5I6" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_srt_MinimumMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.550</ix:nonFraction></span>%
    to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zUtnvCVi5V68" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_srt_MaximumMember" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.290</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20241231_zpklP1HcI7Y8" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-01to2024-12-31" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zD3o1Bin2H01" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_srt_MinimumMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125.59</ix:nonFraction></span>%
    to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zWMs3o2xMUVa" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_srt_MaximumMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">126.45</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zaKQpP0zrOp5" title="Expected life"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000904" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.5</ix:nonNumeric></span>
    to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zMg6pH8a5QH" title="Expected life"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000906" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.5</ix:nonNumeric></span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zEV5Y5uG5HB8" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_srt_MinimumMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.565</ix:nonFraction></span>%
    to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z08wtOj4FW7f" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_srt_MaximumMember" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.843</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_z9iTTxDtBjG1" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zlA1ii6t9nk3" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">138.05</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zsz1Kn08Z9bl" title="Expected life"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact000916" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.0</ix:nonNumeric></span>
    years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zPslbr6NUISf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement with Eric J. Forman, Mr. Forman was granted
stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zMyTuv7VS1Y1" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,833</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4G2aMjjXozc" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" id="Fact000920" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4pV6DzAFmV8" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" id="Fact000922" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">71.40</ix:nonFraction></span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zgTKt8iooZE9" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" id="Fact000924" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zkuoPl0FLrZ" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" id="Fact000926" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400,855</ix:nonFraction></span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVcsG7G5wyy1" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" id="Fact000928" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">68.718</ix:nonFraction></span> per share), of which $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zqdb3DKObyTj" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember" id="Fact000930" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,214</ix:nonFraction></span> was attributable to the portion of the stock options fully vested
on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock
options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded a charge to general and
administrative costs in the consolidated statement of operations for the year ended December 31, 2023 of $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbAo5RYKuya1" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember" id="Fact000932" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,501</ix:nonFraction></span> with respect to these
stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2020, in connection with an employment agreement with Dr. James S. Miser, M.D., Dr. Miser was granted stock options to purchase
<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zACfU2SfE6Wc" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" id="Fact000934" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,333</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable for a
period of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRJ9nhBgNAte" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" id="Fact000936" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z70Ro5BHCZ15" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" id="Fact000938" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">71.40</ix:nonFraction></span> per share, which was equal to the closing market price of the Company&#8217;s common
stock on the effective date of the employment agreement. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zm28jaOS3r2" title="Stock options description"><ix:nonNumeric contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" id="Fact000940" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The options vested 25% on August 1, 2020, 2021 and 2022, respectively, with
the final 25% vesting on August 1, 2023.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zmK0KxNHtiHj" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" id="Fact000942" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">572,650</ix:nonFraction></span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zotTW5RlPWy8" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" id="Fact000944" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">68.718</ix:nonFraction></span> per share), of which $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKieuDW6iOC" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" id="Fact000946" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,163</ix:nonFraction></span> was attributable to the portion of the stock options fully
vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company recorded a charge to general
and administrative costs in the consolidated statement of operations for the year ended December 31, 2023 of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zvPSOWfDCLhc" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember" id="Fact000948" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,544</ix:nonFraction></span> with respect to
these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, in connection with the employment agreement with Robert N. Weingarten, Mr. Weingarten was granted stock options to purchase
<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVsW0NWHhm51" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" id="Fact000950" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,833</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable for a
period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zvISUkkFWlC3" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" id="Fact000952" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zCiUPBIwy8sc" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" id="Fact000954" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">71.40</ix:nonFraction></span> per share, which was equal to the closing market price of the Company&#8217;s common
stock on the grant date. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z8m4schk1qAc" title="Stock options description"><ix:nonNumeric contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" id="Fact000956" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August
12, 2023.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to
be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0Pzdq0hflf1" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" id="Fact000958" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400,855</ix:nonFraction></span> ($<span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrRIMcEAWTe1" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" id="Fact000960" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">68.718</ix:nonFraction></span> per share), of which $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zE7V0Ey14iub" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" id="Fact000962" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,214</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on August 12, 2020
and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged
to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded a charge to general and administrative costs
in the consolidated statement of operations for the year ended December 31, 2023 of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0ug49ODV8jc" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" id="Fact000964" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,501</ix:nonFraction></span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zzh6JhtbRQK3" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z1xkGjQa3fv9" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt-sec:durwordsen" id="Fact000968" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span>
at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zeogJ2T3kR1e" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" id="Fact000970" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">28.00</ix:nonFraction></span> per share (the closing market price on the grant date), <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_za37kSpZdctd" title="Stock options description"><ix:nonNumeric contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" id="Fact000972" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.</ix:nonNumeric></span> The fair value of these stock options, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_ztzMK6qv9hjl" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" id="Fact000974" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">658,363</ix:nonFraction></span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z9fgbPAnBtm4" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" id="Fact000976" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">26.335</ix:nonFraction></span> per share), of which $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zM1RVyhmbw31" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" id="Fact000978" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">329,188</ix:nonFraction></span> was attributable
to the portion of the stock options fully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining
unvested portion of the fair value of the stock options was charged to operations ratably from May 11, 2021 through June 30, 2023. The
Company recorded a charge to general and administrative costs in the consolidated statement of operations for the year ended December
31, 2023 of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zrvzJ6LDjU1l" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_MsReginaBrownMember_srt_DirectorMember" id="Fact000980" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,388</ix:nonFraction></span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zwOHHv1bIhF5" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-06-282021-06-30_srt_DirectorMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zMlcx5RYY0S6" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" id="Fact000984" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zfygF6b8UFc2" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact000986" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zMSYmHmSxYQb" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.30</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zxhvTON12Tne" title="Stock options description"><ix:nonNumeric contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" id="Fact000990" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.</ix:nonNumeric></span>
The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zin5rP0MyYVb" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" id="Fact000992" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,421,095</ix:nonFraction></span>
($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zMsdvsDDo0z1" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember" id="Fact000994" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">28.423</ix:nonFraction></span> per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded a charge to
general and administrative costs in the consolidated statement of operations for the year ended December 31, 2023 of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z8jzQPKUfMUg" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsMember" id="Fact000996" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">211,413</ix:nonFraction></span> with respect
to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. van der Baan was granted stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zIE3nq5lOfMc" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of
<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z7hpvadKEowh" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" format="ixt-sec:durwordsen" id="Fact001000" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zsAaB0CFkOx2" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" id="Fact001002" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">7.40</ix:nonFraction></span> per share (the closing market price on the grant date), <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zRZQNRPemM1l" title="Stock options description"><ix:nonNumeric contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" id="Fact001004" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</ix:nonNumeric></span> The
fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zJiFnELwH7y4" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" id="Fact001006" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">158,525</ix:nonFraction></span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z1nn1O4rlXfj" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" id="Fact001008" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">6.341</ix:nonFraction></span>
per share), of which $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zPfqCoQheYTc" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,263</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
June 17, 2022 through June 30, 2024. During the years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative
costs in the consolidated statement of operations of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zeTkbZxU9gsg" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_BasvanderBaanMember" id="Fact001012" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,390</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zj0OTRT68Mii" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember" id="Fact001014" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,885</ix:nonFraction></span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zhGWiPw0bW5g" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-302022-06-30_srt_DirectorMember" id="Fact001016" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp5d_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z2ADy4wM81gd" title="Stock price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001018" format="ixt:numdotdecimal" decimals="5" unitRef="Shares">50,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zG5wpfh4aXq9" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" format="ixt-sec:durwordsen" id="Fact001020" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z6ahBUqJVBCi" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.40</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z9vLLybWDl5c" title="Stock options description"><ix:nonNumeric contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001024" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zeNHdbd3Njw3" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001026" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">316,700</ix:nonFraction></span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zWZPbCZ69Vd2" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember" id="Fact001028" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">6.334</ix:nonFraction></span> per share), which was charged to operations ratably from July 1, 2022 through June 30, 2024. During
the years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement
of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zPbQ2VaJBnM5" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_FiveNonOfficerDirectorsOneMember" id="Fact001030" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,310</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zxZbwBXmbDF9" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsOneMember" id="Fact001032" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">94,881</ix:nonFraction></span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zNzhFeiDs7G1" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> shares
(a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zx7DjRwuqfx7" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-11-06_custom_FourOfficersMember" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zd9I7E8Ermw6" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt-sec:durwordsen" id="Fact001038" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zf0lZSyktps4" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_srt_DirectorMember" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span>
per share, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zP6s0urCCtu4" title="Stock options description"><ix:nonNumeric contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" id="Fact001042" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.</ix:nonNumeric></span> The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zmjp9j9IwPJ1" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_znEf26e1q3Rd" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" id="Fact001046" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">262,560</ix:nonFraction></span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z6yEW44TiIGb" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_custom_FourOfficersMember" id="Fact001048" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">3.282</ix:nonFraction></span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the
years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement
of operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zUJV4XJcERx8" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_FourOfficersMember" id="Fact001050" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,565</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zhkFQvPLdmAd" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_FourOfficersMember" id="Fact001052" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,448</ix:nonFraction></span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zUVmBb1944ac" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-06-302023-06-30_srt_DirectorMember" id="Fact001054" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z66LSaKS7KYk" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zCg5ynPtkov9" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001058" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zUCPAZNtCWqc" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.88</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zxgGWCzODHLh" title="Share based compensation vesting rights, percentage"><ix:nonNumeric contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001062" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zHbluKpuIore" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001064" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,593</ix:nonFraction></span> ($<span id="xdx_90F_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zvnHSF4cmcR6" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001066" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">4.8131</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
During the years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z2N2fdJcahqb" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember" id="Fact001068" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">96,532</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zsTC1wZp8nmg" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_FourNonOfficerDirectorsMember" id="Fact001070" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,464</ix:nonFraction></span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted stock
options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zra8WHrxR603" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001072" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrnnqKn9guA6" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" format="ixt-sec:durwordsen" id="Fact001074" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z6JFikwDG9Y7" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJ2jJ1RO191k" title="Options vesting term"><ix:nonNumeric contextRef="From2023-09-252023-09-26_custom_MrvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service.</ix:nonNumeric></span> The fair value of these stock options,
as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_904_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKATwL4QezPd" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001080" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">403,066</ix:nonFraction></span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zAuqBnWIHYLl" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001082" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.612</ix:nonFraction></span> per share), which is being charged
to operations ratably from September 26, 2023 through September 30, 2026. During the years ended December 31, 2024 and 2023, the Company
recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zIsz7mX8F6Aa" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001084" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">134,114</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRanRFYcfPV4" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember" id="Fact001086" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,178</ix:nonFraction></span>, respectively,
with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zIcLW1DcpXff" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-06-302024-06-30_srt_DirectorMember" id="Fact001088" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares (a total
of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zY05fABykAe7" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-06-302024-06-30_srt_DirectorMember" id="Fact001090" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_z9uginQJ5ym4" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-06-302024-06-30_srt_DirectorMember" format="ixt-sec:durwordsen" id="Fact001092" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zdAow8K7fJzg" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_srt_DirectorMember" id="Fact001094" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.37</ix:nonFraction></span> per share
(the closing market price on the grant date), <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zmoEUrdG4Kt7" title="Share based compensation vesting rights, percentage"><ix:nonNumeric contextRef="From2024-06-302024-06-30_srt_DirectorMember" id="Fact001096" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zB463LtqCsJ2" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-06-302024-06-30_srt_DirectorMember" id="Fact001098" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,976</ix:nonFraction></span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zkI1jrMrewl1" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_srt_DirectorMember" id="Fact001100" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.8494</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2026.
During the year ended December 31, 2024, the Company record a charge general and administrative costs in the consolidated statement of
operations of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_zpoC8URmx8J4" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_srt_DirectorMember" id="Fact001102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,648</ix:nonFraction></span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_z2wpVDiIz68d" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorMember" id="Fact001104" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">16,598</ix:nonFraction></span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zY6AOdCPTgD3" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001106" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z9fiqbloed59" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.37</ix:nonFraction></span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_ziKDphPSejHf" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001110" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zrGK7aE3H0y2" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001112" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> ($<span id="xdx_905_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zqU48oqYeWP" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember" id="Fact001114" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.6570</ix:nonFraction></span> per share), which was charged to operations on June 30, 2024, the date on which the
stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2024, in connection with the consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D., Dr. Schellens was granted stock options
to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zniZHl3nv6a1" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-07-012024-07-01_custom_SchellensMember" id="Fact001116" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">15,000</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zwpIisoII6s7" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-07-012024-07-01_custom_SchellensMember" format="ixt-sec:durwordsen" id="Fact001118" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise e price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zXVyoKcihSA9" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-07-01_custom_SchellensMember" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.39</ix:nonFraction></span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the grant date. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zoIJuGIjF7te" title="Share based compensation vesting rights, percentage"><ix:nonNumeric contextRef="From2024-07-012024-07-01_custom_SchellensMember" id="Fact001122" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The options vest quarterly over a three-year period commencing on the last day of each calendar quarter
commencing September 30, 2024.</ix:nonNumeric></span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_z53mJUW80PCh" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-07-012024-07-01_custom_SchellensMember" id="Fact001124" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,074</ix:nonFraction></span> ($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_z4EBCzcjLuVi" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-07-01_custom_SchellensMember" id="Fact001126" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.9382</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2027.
During the year ended December 31, 2024, the Company record a charge general and administrative costs in the consolidated statement of
operations of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zfRHcERCYs68" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_SchellensMember24651765" id="Fact001128" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,863</ix:nonFraction></span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zf3hl42bOGB" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorMember" id="Fact001130" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">21,217</ix:nonFraction></span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zLTWU4TpCZJf" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001132" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zIsLNLDLwf29" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001134" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.87</ix:nonFraction></span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zWPM7wwnj2Df" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember" format="ixt-sec:durwordsen" id="Fact001136" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended September 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zZ61bb60kkW5" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001138" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zkO5iVOtult7" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember" id="Fact001140" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">1.2961</ix:nonFraction></span> per share), which was charged to operations on September 30, 2024, the date on which
the stock options were fully vested.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2025, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCT6jE6OTBNc" title="Fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorMember_us-gaap_SubsequentEventMember" id="Fact001142" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">16,665</ix:nonFraction></span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSOKuGRsLkcc" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen" id="Fact001144" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> at an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsw1EgAHQWXb" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.33</ix:nonFraction></span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpqM61ZhgShj" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen" id="Fact001148" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">five years</ix:nonNumeric></span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended December 31, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJ7qnbKysjw9" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember" id="Fact001150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp5d_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfvM0U1tg9g5" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember" id="Fact001152" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">1.65002</ix:nonFraction></span> per share). The grant date value of the stock options of $<span id="xdx_907_ecustom--FairValueOfStockOptions_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zp2wV1mNfFc2" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember" id="Fact001154" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> was accrued at December
31, 2024 and charged to operations at that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#8217;s Board of Directors at the
Company&#8217;s annual meeting of stockholders held on October 7, 2022. Gil Schwartzberg, a former director of the Company, died on October
30, 2022. Dr. John S. Kovach, the Chairman of the Board of Directors and the Company&#8217;s President and Chief Executive Officer, and
Chief Scientific Officer, died on October 5, 2023, the employment agreement of the Company&#8217;s Chief Medical Officer, Dr. James S.
Miser expired on July 31, 2024, and the employment agreement of the Company&#8217;s Vice President and Chief Operating Officer, Eric
J. Forman, terminated upon his resignation from the Company on December 31, 2024. Accordingly, the unvested stock options for each such
person ceased vesting effective as of the respective dates that their services to the Company terminated. Furthermore, the expiration
date of all vested stock options owned by each such person contractually expire one year from the respective dates that their services
to the Company terminate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001156" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zLmHfiQDu9Vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the years ended December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zgC3DbVUULNd" style="display: none">Summary
of Stock-based Compensation Costs</span>&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20240101__20241231_zCPUK4slL2Rf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zD7ueh03xcgj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zw41nmCfHsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember" id="Fact001158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,422</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" id="Fact001159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">773,203</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zRIWM6L1xRA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Non-related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1161">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_zC9hb6zYcjhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,422</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact001165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">773,203</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zNtVSvWUGJ02" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001167" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWFBvOWESuj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2024 and 2023
is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z8jCAeDDOI2f" style="display: none">Summary
of Stock Option Activity Including Options Form of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                                                                                                                                                                                                                                                               Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Contractual Life</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(in Years)</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zEqJTGSvK8w6" title="Number of shares, stock options outstanding, at the beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" id="Fact001169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">389,479</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zFVS6abLMYZj" title="Weighted average exercise price, stock options outstanding, at the beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" id="Fact001171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zNz0eVZiNNlb" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31" id="Fact001173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zhUt0lVuxo7f" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31" id="Fact001175" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zyMcabLTWXEj" title="Number of shares, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="Fact001177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zoZSsYFi1C96" title="Weighted average exercise price, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31" id="Fact001179" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvzjbhKsNVA4" title="Number of shares, expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-012023-12-31" id="Fact001181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,146</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z3eDmD362pL5" title="Weighted average exercise price, expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31" id="Fact001183" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.687</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zNsZKEOEHbQ3" title="Number of shares, stock options outstanding, at the end" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">552,083</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zdAC1ThDecti" title="Weighted average exercise price, stock options outstanding, at the end" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231_z5nJTobYUYk5" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">92,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zUaVZz4zovPa" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact001191" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.259</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_ziyRLtF7njf2" title="Number of shares, exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zgg5FRnlwTeb" title="Weighted average exercise price, exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1195">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231_zmUY0rVkgze3" title="Number of shares, expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,666</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_z2fVu7X2tNAd" title="Weighted average exercise price, expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact001199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.368</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zisLJpd1Xp63" title="Number of shares, stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">613,232</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zniAOJtrgp25" title="Weighted average exercise price, stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.317</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_z3FMT0xDwTD1" title="Weighted average remaining contractual life (in years), stock options outstanding"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001205" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.08</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_zrlZMuvw59Tf" title="Number of shares, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31" id="Fact001207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">252,292</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zW8Vuv6cQ5Pc" title="Weighted average exercise price, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001209" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.387</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zcFNdfHDkKz9" title="Number of shares, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">409,897</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z4GpV6jBnfXd" title="Weighted average exercise price, stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001213" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zqqRxBwPm26a" title="Weighted average remaining contractual life (in years), stock options exercisable"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001215" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.75</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zp7zS8mJVt6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_909_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20240101__20241231_zNusLmbTe0Ca" title="Deferred compensation expense for unvested stock options"><ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375,000</ix:nonFraction></span> at December 31, 2024, which
will be recognized subsequent to December 31, 2024 over a weighted-average period of approximately <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20240101__20241231_z7hrdWB2apc1" title="Weighted-average recognition period"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:durmonth" id="Fact001219" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">19</ix:nonNumeric></span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001221" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxCENmtaZDP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zATPZYEZtqe7" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options <br/> Outstanding (Shares)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable (Shares)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 2%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zUdjPHIoTpU1" title="Exercise Prices" style="width: 29%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceOneMember" id="Fact001223" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.870</ix:nonFraction></td><td style="width: 2%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zPLnqMyc8LC8" title="Options Outstanding (Shares)" style="width: 29%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact001225" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,217</ix:nonFraction></td><td style="width: 2%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhfjeM9xS2H" title="Options Exercisable (Shares)" style="width: 28%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact001227" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,217</ix:nonFraction></td><td style="width: 2%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zMlBOsmIQWDe" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceTwoMember" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbGfTIdPEjzj" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact001231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zJPf0fapi55a" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact001233" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">104,165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zDZKuhgTEYV5" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceThreeMember" id="Fact001235" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zMS7bvdTvIjg" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact001237" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,598</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWJIZmt3Iha" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact001239" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,598</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zoKtlMKICBRg" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceFourMember" id="Fact001241" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z4184IydkpKj" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3CYfCHKP3ml" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z6BAhCpDtVil" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceFiveMember" id="Fact001247" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4oo7pdUWGwd" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z9F94HjKKxe" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zDUtY0ROnTQc" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceSixMember" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z9gkiVfuIA9i" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceSixMember" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSwKjUz8Ptra" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceSixMember" id="Fact001257" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zINl9Gix6yWk" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceSevenMember" id="Fact001259" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqvBQe5D6csj" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceSevenMember" id="Fact001261" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zopgLrWifA3d" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceSevenMember" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zYxWTpuH3XF1" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceEightMember" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zeIU5jit3mTj" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceEightMember" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8G91Hl00Zx4" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceEightMember" id="Fact001269" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zXocKwlCnDA3" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceNineMember" id="Fact001271" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zTIFtFO3b0O5" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceNineMember" id="Fact001273" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO5FIkIDEdge" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceNineMember" id="Fact001275" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zhKpThSwUhSg" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceTenMember" id="Fact001277" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zk8fo0MKpFw5" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceTenMember" id="Fact001279" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zC7NtmxlyU4" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceTenMember" id="Fact001281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zIDrWpTVGmDl" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceElevenMember" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSZ3Uzb1Lduk" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceElevenMember" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1sfqEiGkF5a" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceElevenMember" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z4XC1cRXhEk6" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceTwelveMember" id="Fact001289" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZRbvYz7Twhf" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceTwelveMember" id="Fact001291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zPbAT7QuotZe" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceTwelveMember" id="Fact001293" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zm8x6BwcAAul" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceThirteenMember" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zGbd8qGCO71i" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceThirteenMember" id="Fact001297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zJRDC1T6atcg" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceThirteenMember" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zbIZs6lY2Ai1" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceFourteenMember" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">71.400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPm1YGFhbvp" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceFourteenMember" id="Fact001303" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zAjXdDdK80Ec" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceFourteenMember" id="Fact001305" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_ziws5S9oXQ66" title="Exercise Prices" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceFifteenMember" id="Fact001307" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">120.000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj7QDC3nkmzh" title="Options Outstanding (Shares)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceFifteenMember" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,334</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zylMGmJKZVg5" title="Options Exercisable (Shares)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceFifteenMember" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,334</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_z7BBJromCTEi" title="Options Outstanding (Shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31" id="Fact001313" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">613,232</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231_zUWwimlEsfRh" title="Options Exercisable (Shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31" id="Fact001315" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">409,897</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zOAlgQxtv9Og" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the closing fair market value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20240101__20241231_zipOr7b9aRXa" title="Fair market value, per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001317" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">2.03</ix:nonFraction></span> per share on December 31, 2024, the intrinsic value attributed to exercisable but unexercised
common stock options was approximately $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_do_c20241231_zJYMgeKnJRM2" title="Intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31" id="Fact001319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span> at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231_zLAN0yFnJN0a" title="Outstanding stock options to acquire shares of common stock not vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-12-31" id="Fact001321" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">203,334</ix:nonFraction></span> shares of the Company&#8217;s common stock had not vested at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the exercise of such stock options, the Company expects to satisfy the related stock obligations through the issuance of authorized but
unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001323" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zXcWy9o7k9f9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82C_zgjKmYjldi0i">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets as
of December 31, 2024 and 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001325" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhcMrKCfMEyg" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z6Mg4awZE5Fl" style="display: none">Schedule of Components of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zhZf6zsba7ub" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20231231_zP1AFuQVBBm9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_zELyJMLaS4Gk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research credits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2024-12-31" id="Fact001327" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">652,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" id="Fact001328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">612,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zBwHgXQtF5a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001330" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">900,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact001331" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">844,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_z8HjiCuxMNK9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001333" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,550,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001334" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,631,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zA3UrvyNPuE6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net operating loss carryforwards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001336" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,515,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001337" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,601,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_z8A2JzUUu7g5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001339" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,617,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001340" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,688,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_zVRTtLd8PKe1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001342" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,617,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001343" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,688,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zzXX3BLEty3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zZdrcyd8uN54" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining
future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2024 and 2023, management
was unable to determine if it is more likely than not that the Company&#8217;s deferred tax assets will be realized and has therefore
recorded an appropriate valuation allowance against deferred tax assets at such dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_do_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zvlPonMVROy"><span id="xdx_90C_eus-gaap--IncomeTaxExpenseBenefit_do_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zd0wseKP9f2f"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="Fact001347" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="Fact001348" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span>
federal tax provision has been provided for the years ended December 31, 2024 and 2023 due to the losses incurred during such periods.
The reconciliation below presents the difference between the income tax rate computed by applying the U.S. federal statutory rate and
the effective tax rate for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001350" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zO7KRmwRQbIa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zIdAW3X8Ite7" style="display: none">Schedule of Effective Income Tax Rate</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20241231_zgAhkbWfYUrj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zodb6ZAgqzS2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zOUdJUJqc2rl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">U. S. federal statutory tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001352" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_zEJojD5OZill" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001355" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_z43h5lMrnr7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expirations related to stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2024-01-01to2024-12-31" id="Fact001358" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.8</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2023-01-012023-12-31" id="Fact001359" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">10.4</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_za0dRVJpsqI9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustment to deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" contextRef="From2024-01-01to2024-12-31" id="Fact001361" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.1</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" contextRef="From2023-01-012023-12-31" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.8</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zADWTP1AqVjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001364" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">24.3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">17.4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_z9DPi7jgTpSj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="Fact001368" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zKZ6frVnfgA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately
$<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20241231_z7q5FhRzD8Uk" title="Operating loss carryforwards, federal"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2024-12-31" id="Fact001370" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,067,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20241231_zXCk9xyKQbWk" title="Operating loss carryforwards, state"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact001372" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,836,000</ix:nonFraction></span>, respectively. Federal net operating losses from tax years preceding 2018, if not utilized earlier, expire
through 2038. Federal net operating losses generated in a tax year beginning after 2017 have an indefinite carryforward period. The utilization
of federal net operating loss carryforwards is subject to various limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
state net operating loss carryovers include approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zipZCELoHTRh" title="Net operating loss carryovers"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2022-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" id="Fact001374" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,141,000</ix:nonFraction></span> that were incurred in the State of New York. New York tax law requires
New York net operating loss carryovers from years prior to 2015 to be converted, by applying a formula, into a Prior Net Operating Loss
Conversion (PNOLC) subtraction pool. <span id="xdx_909_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zYvJkk1ZDO1a" title="Prior net operating loss conversion utilization"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" id="Fact001376" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse">The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.</ix:nonNumeric></span> The state net
operating loss carryovers also include approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zACcJVv1fc7i" title="Operating loss carryforwards, state"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember" id="Fact001378" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,695,000</ix:nonFraction></span> that was incurred in the State of California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and certain corresponding provisions of state law, if a
corporation undergoes an &#8220;ownership change&#8221;, which is generally defined as a greater than 50% change, by value, in the ownership
of its equity over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income might be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company&#8217;s net operating losses have yet to be utilized, all previous tax years since 2006 remain subject to adjustment by Federal
authorities and other jurisdictions in which the Company currently operates or has operated in the past.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001380" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zDBhwmoYf2Ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_822_zuyoCltX3Ayc">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of December 31, 2024 and
2023, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 14, 2025, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial
monitoring agreements not yet incurred, as described below, aggregated $<span id="xdx_908_eus-gaap--ContractualObligation_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_z1tqH4drcJU3" title="Clinical trial contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" id="Fact001382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,000</ix:nonFraction></span>, including clinical trial agreements of $<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsMember_zqWnh1Y3vhH4" title="Contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialAgreementsMember" id="Fact001384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,000</ix:nonFraction></span> and
clinical trial monitoring agreements of $<span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_zJvmGUJ4tmLb" title="Contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialMonitoringAgreementsMember" id="Fact001386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,000</ix:nonFraction></span>, which, based on current estimates, are currently scheduled to be incurred through approximately
December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely availability
of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds to the Company&#8217;s
current or future clinical trial programs. The Company expects that the full amount of these expenditures will be incurred only if such
clinical trial programs are conducted as originally designed and their respective enrollments and duration are not modified or reduced.
Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently involve a series
of changes and modifications over time as clinical data is obtained and analyzed, and is frequently modified, suspended or terminated,
in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial endpoint is reached.
Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current clinical assumptions
and conditions and are typically subject to significant modifications and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001388" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock"><p id="xdx_89A_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zbNYDSNxOP0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s ongoing contractual clinical trials described below as of March 14, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zyV50Cq5DUUh" style="display: none">Schedule
of Contractual Clinical Trials</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="font-size: 8pt">Description
    of Clinical Trial</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Institution</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Start Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Projected End Date</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number
                                            of Patients</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>in
                                            Trial</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Study Objective</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Clinical Update</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Expected</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Date
                                            of Preliminary Efficacy</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Signal</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">NCT No.</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Financial</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Commitment</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 19%; text-align: left"><span style="font-size: 8pt"><span id="xdx_906_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zXixyQiSU8ni" title="Clinical trial, description"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember" id="Fact001390" name="LIXT:ClinicalTrialDescription">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer</ix:nonNumeric></span> (Phase 1b)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 8pt">Netherlands Cancer Institute (NKI)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zuV8mTERxdwj" title="Estimated Start Date"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember" id="Fact001392" name="LIXT:ContractualClinicalTrialPeriodStartDate">August 2024</ix:nonNumeric></span></span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 8pt"><span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zDj9IIabnRz1" title="Estimated End Date"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember" id="Fact001394" name="LIXT:ContractualClinicalTrialPeriodEndDate">December 2026</ix:nonNumeric></span></span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 6%; text-align: center"><span style="font-size: 8pt"><span id="xdx_902_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zrh1OR2gLFo2" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember" id="Fact001396" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">37</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 8pt">Determine RP2D with atezolizumab</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 8pt">First patient entered August 2024, in total two patients entered</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 8pt"><span id="xdx_904_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zS25rgjPU17f" title="Expected Date"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember" id="Fact001398" name="LIXT:ExpectedDateOfPreliminaryEfficacySignal">June 2026</ix:nonNumeric></span></span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 8pt">NCT06012734</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zcorFI7OWv78" title="Remaining financial contractual commitment"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></span></span><span style="font-size: 8pt">(1</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 8pt"><span id="xdx_901_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z7i2OWVQ7vk8" title="Clinical trial, description"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember" id="Fact001402" name="LIXT:ClinicalTrialDescription">LB-100 combined with doxorubicin in advanced soft
    tissue sarcoma</ix:nonNumeric></span> (Phase 1b)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">GEIS</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zdJjLV15myt" title="Estimated Start Date"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember" id="Fact001404" name="LIXT:ContractualClinicalTrialPeriodStartDate">June 2023</ix:nonNumeric></span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_901_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zHVmg7al70x1" title="Estimated End Date"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember" id="Fact001406" name="LIXT:ContractualClinicalTrialPeriodEndDate">Recruitment completed September 2024</ix:nonNumeric></span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zCffF5jNIjjh" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember" id="Fact001408" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">9</ix:nonFraction></span>
                                            to <span id="xdx_90B_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zUGXB7TkRXY8" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember" id="Fact001410" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">18</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Determine MTD and RP2D</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Fourteen patients entered</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zT0RXnmH1cL1" title="Expected Date"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember" id="Fact001412" name="LIXT:ExpectedDateOfPreliminaryEfficacySignal">December 2025</ix:nonNumeric></span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">NCT05809830</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td id="xdx_982_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zs1b7zL5Cn61" title="Remaining financial contractual commitment" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember" id="Fact001414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDIp_zaK0ldzzzrnk" title="Clinical trial, description"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember" id="Fact001416" name="LIXT:ClinicalTrialDescription">Doxorubicin with or without LB-100 in advanced soft
    tissue sarcoma</ix:nonNumeric> </span>(Randomized Phase 2)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">GEIS</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">TBD</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">TBD</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zTQUm6J8wsGk" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember" id="Fact001418" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">150</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Determine efficacy: PFS</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical
    trial)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">TBD</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">NCT05809830</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zCxDdXQeHIvi" title="Remaining financial contractual commitment"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></span></span><span style="font-size: 8pt">(1</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_903_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDIp_zj2xTKkOQkK" title="Clinical trial, description"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member" id="Fact001422" name="LIXT:ClinicalTrialDescription">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma</ix:nonNumeric></span> (Phase 1b/2)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">MD Anderson</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_903_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zQMbpJSy59Lj" title="Estimated Start Date"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member" id="Fact001424" name="LIXT:ContractualClinicalTrialPeriodStartDate">January 2024</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zzCWNGur0Zk7" title="Estimated End Date"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member" id="Fact001426" name="LIXT:ContractualClinicalTrialPeriodEndDate">December 2027</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zSwqRcECedGi" title="Number of Patients in Trial"><ix:nonFraction name="LIXT:NumberOfPatientInTrial" contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member" id="Fact001428" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">21</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">Determine the OS of patients with recurrent ovarian
    clear cell carcinoma</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt">Nine patients entered</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zUMEVM22olN7" title="Expected Date"><ix:nonNumeric contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member" id="Fact001430" name="LIXT:ExpectedDateOfPreliminaryEfficacySignal">December 2026</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt">NCT06065462</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zhxbiG9B0Ac5" title="Remaining financial contractual commitment"><span style="-sec-ix-hidden: xdx2ixbrl1432">-</span></span></span><span style="font-size: 8pt">(1</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"><span style="font-size: 8pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td id="xdx_98A_eus-gaap--OtherCommitment_iI_c20250314_zokjzbaUrqnj" title="Remaining financial contractual commitment" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-03-14" id="Fact001434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span id="xdx_F06_zXGwjXEDSFLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zndBSHdtJAg4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001435" xml:lang="en-US">The
    Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A7_zA6RA5e8Ptxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute
(&#8220;NKI&#8221;) (see Note 5) to conduct a Phase 1b clinical trial of the Company&#8217;s protein phosphatase inhibitor, LB-100, combined
with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (&#8220;Roche&#8221;), for patients with microsatellite
stable metastatic colorectal cancer. Under the agreement, the Company will provide its lead compound, LB-100, and under a separate agreement
between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to
and will not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement,
the clinical trial will be conducted by NKI at NKI&#8217;s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and
NKI will be responsible for the recruitment of patients. The agreement provides for the protection of the respective intellectual property
rights of each of the Company, NKI and Roche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&#8217;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. A total of two patients have been enrolled to date. Patient accrual
is expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&#8220;SAEs&#8221;) observed in the clinical trial. The Investigational Review Board (IRB) of the Netherlands Cancer
Institute has requested additional information with respect to these SAEs and the study has been paused for enrollment until the IRB&#8217;s
questions have been satisfactorily addressed (see &#8220;Specific Risks Associated with the Company&#8217;s Business Activities - Serious
Adverse Events&#8221; below for additional information).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no financial contractual commitment associated with this clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the &#8220;Agreement&#8221;) with
the City of Hope National Medical Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively,
&#8220;City of Hope&#8221;), to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase
inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;).
LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously
untreated ED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#8220;RP2D&#8221;). Patient entry was to be expanded so that a total of 12 patients would be evaluable at the RP2D to
confirm the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration
of overall response, progression-free survival, and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient
accrual was slower than expected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (&#8220;SCRI&#8221;),
Nashville, Tennessee, to the ongoing Phase 1b clinical trial. The Company and City of Hope continued efforts to increase patient accrual
by adding additional sites and by modifying the protocol to increase the number of patients eligible for the clinical trial. The impact
of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms
of the Agreement, the Company provided notice to City of Hope of the Company&#8217;s intent to terminate the Agreement effective as of
July 8, 2024. Upon closure, the Company incurred a prorated charge of $<span id="xdx_90D_eus-gaap--LitigationSettlementExpense_c20240707__20240708__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_z5acQ9n9FrKd" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2024-07-072024-07-08_custom_ClinicalResearchSupportAgreementMember_custom_CityOfHopeNationalMedicalCenterMember" id="Fact001437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,004</ix:nonFraction></span> for the cost of patients enrolled to date, which is included
in accounts payable and accrued expenses at December 31, 2024 .</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024 and 2023, the Company incurred costs of $<span id="xdx_901_eus-gaap--LitigationSettlementExpense_c20240101__20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zerFstXrgqWh" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2024-01-012024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" id="Fact001439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,019</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--LitigationSettlementExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zWPnrIWmoQ0j" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" id="Fact001441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,001</ix:nonFraction></span>, respectively, pursuant to this Agreement.
As of December 31, 2024, total costs of $<span id="xdx_90A_eus-gaap--DeferredCosts_iI_c20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zhtmO9ywpI37" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" id="Fact001443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">732,532</ix:nonFraction></span> had been incurred pursuant to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the
anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause, of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practice (GMP) of the active pharmaceutical ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_907_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zrrPgDwaZoHa" title="Inventory costs"><ix:nonFraction name="us-gaap:InventoryPartsAndComponentsNetOfReserves" contextRef="AsOf2024-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" id="Fact001445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of ASTS. Consequently, this
clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report prepared by December 31,
2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n Jim&#233;nez
D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b
portion of the protocol was extended with two patients and was completed during the quarter ended September 30, 2024. The Company expects
to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, the Company entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved
the Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $<span id="xdx_905_eus-gaap--OtherCommitment_iI_uEUR_c20250311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zfFDQYq8Va3k" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-03-11_us-gaap_SubsequentEventMember_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" id="Fact001447" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">3,095,000</ix:nonFraction></span>. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provided for various payments based on achieving specific milestones over the term of the agreement.
During the years ended December 31, 2024 and 2023, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zaia5Nyr86Kc" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" id="Fact001449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zfaifKZ1ugng" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" id="Fact001451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,829</ix:nonFraction></span>, respectively, pursuant to this agreement.
Through December 31, 2024, the Company has incurred charges of $<span id="xdx_902_ecustom--AmountRelatedToMilestonePayment_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zPbDmT63fws6" title="Amount related to milestone payment"><ix:nonFraction name="LIXT:AmountRelatedToMilestonePayment" contextRef="From2024-01-012024-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" id="Fact001453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">684,652</ix:nonFraction></span> for work done under this agreement through the fourth milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_z3ayU8lepmxg" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" id="Fact001455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,000</ix:nonFraction></span>
for the Phase 1b portion of this clinical trial as of March 14, 2025, which is scheduled to be incurred through December 31, 2025. As
the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations between the
United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign currency gain
or loss, as appropriate, and have not been significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc
(&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#8220;OCCC&#8221;). The study objective is to determine the overall survival (&#8220;OS&#8221;) of patients with OCCC. The clinical
trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and is being conducted at The
University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial
support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical trial. The
Company currently expects that this clinical trial will be completed by December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, the Company announced that it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&#8217;s proprietary compound LB-100 with GSK&#8217;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida (&#8220;Moffitt&#8221;), effective for a term of five years. Pursuant to the Clinical Trial Research
Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s
lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic
syndrome (&#8220;MDS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (&#8220;IND&#8221;)
Application to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and
intermediate-1 risk MDS who had failed or were intolerant of standard treatment. This Phase 1b/2 clinical trial utilized LB-100 as a
single agent in the treatment of patients with low and intermediate-1 risk MDS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the
year ended December 31, 2023, the clinical trial was closed. Although the maximum tolerated dose (&#8220;MTD&#8221;) was not achieved,
there was no dose-limiting toxicity noted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company incurred costs of $<span id="xdx_90F_eus-gaap--LitigationSettlementExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zob6CNqPjDLa" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2024-01-012024-12-31_custom_ClinicalResearchSupportAgreementMember" id="Fact001457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--LitigationSettlementExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zqwFN48l7781" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2023-01-012023-12-31_custom_ClinicalResearchSupportAgreementMember" id="Fact001459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,165</ix:nonFraction></span>, respectively, pursuant to this agreement. As
of December 31, 2024, total costs of $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zq3iBSb06mGk" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-12-31_custom_ClinicalTrialResearchAgreementMember" id="Fact001461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,239</ix:nonFraction></span> had been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
September 2023, the Company decided not to pursue further studies in MDS, as other, more promising, opportunities had become available
(see &#8220;Patent and License Agreements - Moffitt&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (&#8220;NCI&#8221;) initiated a glioblastoma
(&#8220;GBM&#8221;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen
investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1
(&#8220;PD-1&#8221;) blocking antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy
in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). On August 19, 2024, the Company signed a work order agreement
with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this letter of intent and related work order agreement are estimated to be approximately $<span id="xdx_90D_ecustom--WorkOrderAgreementCosts_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zwEqjo3bJZ4i" title="Work order agreement costs"><ix:nonFraction name="LIXT:WorkOrderAgreementCosts" contextRef="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember" id="Fact001463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,000</ix:nonFraction></span>. During the year ended December
31, 2024, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zJXSCxsY3QLl" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_ClinicalTrialResearchMonitoringMember" id="Fact001465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,763</ix:nonFraction></span> pursuant to this letter of intent and subsequent work order. As of December 31, 2024,
total costs of $<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MDAndersonCancerCenterClinicalMember_z6u3aHzZVgW9" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember_custom_MDAndersonCancerCenterClinicalMember" id="Fact001467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,763</ix:nonFraction></span> have been incurred pursuant to this letter of intent and subsequent work order.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $<span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_z7s91UCce1F1" title="Remaining financial contractual commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-12-31_custom_ClinicalTrialMonitoringAgreementsMember" id="Fact001469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span>
as of December 31, 2024, which is expected to be incurred through December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement were estimated to be approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zuwqhvVoEij5" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact001471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,000</ix:nonFraction></span>. During the years December 31, 2024 and 2023, the Company incurred costs
of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zxUpJtMbc5Me" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact001473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,642</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zoWlzMGxETc8" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact001475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,240</ix:nonFraction></span>, respectively, pursuant to this work order. As of December 31, 2024, total costs of $<span id="xdx_908_eus-gaap--DeferredCosts_iI_c20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zy7awQEgtZC5" title="Total costs incurred"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" id="Fact001477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,323</ix:nonFraction></span> had been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see &#8220;Clinical Trial Agreements &#8211; City
of Hope&#8221; above), the work order agreement with Theradex to monitor this clinical trial was concurrently terminated, although nominal
oversight trailing costs subsequent to July 8, 2024 are expected to be incurred relating to the closure of this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study
oversight is expected to be completed by December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_908_ecustom--EstimatedWorkCost_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zHPObUbzIjvl" title="Work cost"><ix:nonFraction name="LIXT:EstimatedWorkCost" contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact001479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,000</ix:nonFraction></span>, with such payments expected to be allocated approximately
<span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zSs29Oasw99d" title="Percentage of payment through services"><ix:nonFraction name="LIXT:ExpectedPaymentinServices" contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact001481" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">72</ix:nonFraction>%</span> to Theradex for services and approximately <span id="xdx_909_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zVJsW386BqG1" title="Percentage of payment through software"><ix:nonFraction name="LIXT:ExpectedPaymentThroughSoftware" contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact001483" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction>%</span> for payments for pass-through software costs. During the years ended December 31,
2024 and 2023, the Company incurred costs of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zvrFtEs5QRhl" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact001485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,593</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zt7Etgvjyxx8" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact001487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,862</ix:nonFraction></span>, respectively, pursuant to this work order. As of December 31, 2024,
total costs of $<span id="xdx_905_eus-gaap--DeferredCosts_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zosVXaEv71r8" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31_custom_WorkOrderAgreementMember" id="Fact001489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,455</ix:nonFraction></span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90F_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zYMs96711Ewa" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-12-31_custom_WorkOrderAgreementMember" id="Fact001491" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,000</ix:nonFraction></span> as of December 31, 2024, which is expected to be incurred through December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>On August 27, 2024, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical
trial of LB-100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colorectal cancer.
The study oversight is expected to be completed by May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_90B_ecustom--EstimatedWorkCost_c20230825__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zTDQMn6kiTjj" title="Work cost"><ix:nonFraction name="LIXT:EstimatedWorkCost" contextRef="From2023-08-252023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact001493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,380</ix:nonFraction></span>, with such payments expected to be allocated approximately
<span id="xdx_90D_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230825__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zPhBSyHe1mcb" title="Percentage of payment through services"><ix:nonFraction name="LIXT:ExpectedPaymentinServices" contextRef="From2023-08-252023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact001495" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">47</ix:nonFraction>%</span> to Theradex for services and approximately <span id="xdx_908_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230825__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zEtdN6DvHa5i" title="Percentage of payment through software"><ix:nonFraction name="LIXT:ExpectedPaymentThroughSoftware" contextRef="From2023-08-252023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact001497" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">53</ix:nonFraction>%</span> for payments for pass-through software costs. During the year ended December 31, 2024,
the Company incurred costs of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zAWEsj9qaw03" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember" id="Fact001499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,191</ix:nonFraction></span> pursuant to this work order. As of December 31, 2024, total costs of $<span id="xdx_90B_eus-gaap--DeferredCosts_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zWv2GVZIyMpi" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" id="Fact001501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,191</ix:nonFraction></span> have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_z6OTPaC8QIS7" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember" id="Fact001503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,000</ix:nonFraction></span> as of December 31, 2024, which is expected to be incurred through May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Institute of Health.</b> Effective February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;)
with the National Institute of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;),
each an institute or center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has
licensed on an exclusive basis the NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement
(&#8220;CRADA&#8221;) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer
activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors,
immunotherapy, and radiation for the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product,
licensed process, and country basis, until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights
in each such country in the licensed territory, estimated at twenty years, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zptXwdPPvFr4" title="Non refundable license issue royalty"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember" id="Fact001505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> and a first minimum annual royalty
within sixty days from the effective date of the Agreement. The first minimum annual royalty of $<span id="xdx_902_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zCqN7oWazy69" title="Minimum annual royalty payable"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2024-02-23_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember" id="Fact001507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,643</ix:nonFraction></span> was prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $<span id="xdx_90F_ecustom--RoyaltyPayable_iI_c20300131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_z3Gc6lfxHH3i" title="Minimum annual royalty payable"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2030-01-31_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember" id="Fact001509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> is due each January
1 and may be credited against any earned royalties due for sales made in that year. The license issue royalty of $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z0r7EDgcW52d" title="Non refundable license issue royalty"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-04-012024-04-30_custom_LicenseAgreementMember_srt_MinimumMember" id="Fact001511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> and the first
minimum annual royalty of $<span id="xdx_907_ecustom--RoyaltyPayable_iI_c20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_z5XWMqrKPmve" title="Minimum annual royalty payable"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2024-04-30_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember" id="Fact001513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,643</ix:nonFraction></span>, were paid in April 2024. The second minimum annual royalty for 2025 of $<span id="xdx_909_ecustom--RoyaltyPayable_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zTsgb8AqqnTa" title="Minimum annual royalty payable"><ix:nonFraction name="LIXT:RoyaltyPayable" contextRef="AsOf2024-12-31_custom_LicenseAgreementMember" id="Fact001515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span>, was paid in December
2024 and is included in other prepaid expenses at December 31, 2024 in the accompanying consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#8217;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, which the Company is required to pursue based on &#8220;commercially reasonable
efforts&#8221; as defined in the License Agreement, with deadlines of October 1, 2024, 2027, 2029 and 2031, respectively, each with a
different specified benchmark payment amount payable within thirty days of achieving such benchmark. The October 1, 2024 benchmark of
$<span id="xdx_90B_eus-gaap--HealthCareOrganizationHealthCareCostsGross_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zmWKH5089rna" title="Dosing of product"><ix:nonFraction name="us-gaap:HealthCareOrganizationHealthCareCostsGross" contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember" id="Fact001517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> was defined as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product
in the licensed fields of use. The Company had not commenced a Phase 2 clinical study as of December 31, 2024. The total of all such
benchmark payments is $<span id="xdx_90F_eus-gaap--PaymentsForRoyalties_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zDrlkfevcfV6" title="Payment for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember" id="Fact001519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,225,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to provide annual reports to the NIH on its progress toward the development and commercialization of products under
the licensed patents. These reports, due within sixty days following the end of each calendar year, must include updates on research
and development activities, regulatory submissions, manufacturing efforts, sublicensing, and sales initiatives. If any deviations from
the established commercial development plan or agreed-upon benchmarks occur, the Company is obligated to provide explanation and may
amend the commercial development plan and the benchmarks, which, subject to certain conditions, the NIH shall not unreasonably withhold,
condition, or delay approval of any request of the Company to amend the commercial development plan and/or the benchmarks and to extend
the time periods of the benchmarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH sublicensing royalties of <span id="xdx_90D_ecustom--RoyatiesPercentage_pid_dp_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zmpeM7Wasmi7" title="Royalty percentage"><ix:nonFraction name="LIXT:RoyatiesPercentage" contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember" id="Fact001521" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span> on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company incurred costs of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zKLGUFOwBJmj" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember" id="Fact001523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,643</ix:nonFraction></span> in connection with its obligations under the License Agreement.
Such costs when incurred have been included in general and administrative costs in the Company&#8217;s consolidated statement of operations.
As of December 31, 2024, total costs of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zR0X46ULC2v9" title="Research and development process costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember" id="Fact001525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,643</ix:nonFraction></span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment
pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zBK6C61HFLq4" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-12-31_us-gaap_LicensingAgreementsMember" id="Fact001527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,795,000</ix:nonFraction></span> as of December 31, 2024, which is
expected to be incurred over approximately the next twenty years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee was due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded a credit to operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zYQRKdDADNGl" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_LicensingAgreementsMember" id="Fact001529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,109</ix:nonFraction></span> representing the reversal of obligations previously
recorded with respect to the Exclusive License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into a consulting agreement with NDA Consulting Corp. for consultation
and advice in the field of oncology research and drug development. As part of the consulting agreement, NDA also agreed to have its president,
Dr. Daniel D. Von Hoff, M.D., serve on the Company&#8217;s Scientific Advisory Committee during the term of such consulting agreement.
The term of the consulting agreement was for one year and provided for a quarterly cash fee of $<span id="xdx_908_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zZZVADBV9pRa" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember" id="Fact001531" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span>. The consulting agreement had been
automatically renewed for additional one-year terms on its anniversary date, most recently on December 24, 2023, but was subsequently
terminated by mutual agreement effective September 30, 2024. Consulting and advisory fees charged to operations pursuant to this consulting
agreement were $<span id="xdx_906_ecustom--ConsultingAndAdvisoryCashFee_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_z46HHK3xWhk8" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2024-01-012024-12-31_custom_NDAConsultingCorpMember" id="Fact001533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zw8m0P3OayKc" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2023-01-012023-12-31_custom_NDAConsultingCorpMember" id="Fact001535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_90A_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zkwYA3IcTSi9" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" id="Fact001537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly fee. Effective March 1, 2024, the compensation payable under the Collaboration Agreement was converted to an hourly
rate structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_90A_ecustom--ReimbursementExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_ziEGFH02FsQd" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2024-01-012024-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" id="Fact001539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,200</ix:nonFraction></span> and $<span id="xdx_905_ecustom--ReimbursementExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zKkEIJpFnvAl" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2023-01-012023-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" id="Fact001541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> during the years ended December
31, 2024 and 2023, respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;) (see Note 5), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. The Company agreed to fund the preclinical study, at an approximate cost of <span id="xdx_903_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zoVVWKBXOnP7" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact001543" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">391,000</ix:nonFraction></span> Euros and provide a
sufficient supply of LB-100 to conduct the preclinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added
<span id="xdx_902_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zxvXEhvSBEni" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact001545" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">500,000</ix:nonFraction></span> Euros to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year and starts upon the dosing of the first patient in the trial at a project cost of
<span id="xdx_90C_eus-gaap--OtherCommitment_iI_uEUR_c20241004__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zvjNsJGVi2Z6" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-10-04_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact001547" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">100,000</ix:nonFraction></span> Euros.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company incurred charges in the amount of $<span id="xdx_908_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zuma1q5Sg1rl" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2024-01-012024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact001549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,362</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zklbAAnirwS1" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-01-012023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact001551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,150</ix:nonFraction></span>, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
As of December 31, 2024, total costs of $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zAdVNb4vM5Nj" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact001553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,918</ix:nonFraction></span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment
pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_902_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zlf9PRipJmid" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" id="Fact001555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,000</ix:nonFraction></span> as of December 31, 2024, which is expected
to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to
foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>As amended, the Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical
trials in the United States. During the years ended December 31, 2024 and 2023, the Company incurred costs of $<span id="xdx_907_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zCMROx1V97V2" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2024-01-012024-12-31_custom_MRIGlobalMember" id="Fact001557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,308</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zgRbDfMAeETe" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-01-012023-12-31_custom_MRIGlobalMember" id="Fact001559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,307</ix:nonFraction></span>, respectively,
pursuant to this contract. As of December 31, 2024, total costs of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zbFiOeixeyIc" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_MRIGlobalMember" id="Fact001561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,522</ix:nonFraction></span> have been incurred pursuant to this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_906_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zPHuGQJrNYj4" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-12-31_custom_MRIGlobalMember" id="Fact001563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,000</ix:nonFraction></span>
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Specific
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serious
Adverse Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of
these trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to the Company&#8217;s drug
candidate or to another company&#8217;s drug used in combination in one of the Company&#8217;s clinical trials. It is possible that the
SAEs could be attributable to the Company&#8217;s drug candidate and could include, but not be limited to, unexpected severe side effects,
treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting
toxicity (DLT). When two DLTs occur at the same dose-level, that dose-level is considered too high and unsafe. Further treatment is only
allowed at lower dose-levels that have previously been found safe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving the Company&#8217;s drug candidate, the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring
the Company to pause or discontinue further enrollment and dosing in its clinical trial. It is also possible that the clinical trial
could be terminated. Any of these actions could delay or halt the development of the Company&#8217;s drug candidate, increase development
costs, and negatively impact the Company&#8217;s ability to ultimately achieve regulatory approval. Additionally, if an SAE is confirmed
to be drug-related, the Company may be required to conduct additional studies, modify the study design, or abandon further development
of the drug candidate altogether, which could materially impact the Company&#8217;s business, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of an SAE and any resulting clinical hold could also harm the Company&#8217;s reputation with patients, physicians, health
institutions, and investors, diminish its ability to attract clinical trial participants, and damage its ability to interest investors
and obtain financing in the future. There can be no assurance that the Company will not experience such SAEs in the future or that any
related clinical hold will be lifted in a timely manner, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Netherlands Cancer Institute (&#8220;NKI&#8221;) Institutional
Review Board (the &#8220;IRB&#8221;) has put the colorectal cancer study on hold. The adverse reactions that developed in the two patients
were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and atezolizumab in
one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second patient. The
patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea. The patient
with fever and aphasia fully recovered from the adverse events with supportive medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator is preparing a response to the IRB
detailing the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab.
Doxorubicin is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related
to that of atezolizumab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through February 2025, a total of 78 patient have received or are receiving experimental treatment
with LB-100. It is expected that it will take at least two months to prepare a detailed response to the IRB, during which time the Company
intends to update the safety overview of LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Business Risks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus or any other pandemics may reappear and impact the Company&#8217;s clinical trial programs
and capital raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates have had a material effect on its
operations to date, other than their impact on the general economy. However, there is a risk that the Company&#8217;s operating costs
could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs (including, specifically, clinical trial costs), and which would put additional stress on the Company&#8217;s working
capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear
at this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital could all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risks. </b>The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity
threats, and has integrated these processes into its overall risk management systems and processes. The Company routinely assesses material
risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through its information and email systems
that may result in adverse effects on the confidentiality, integrity, or availability of the Company&#8217;s information and email systems
or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as assessments
in the event of a material change in the Company&#8217;s business practices that may affect information systems that are vulnerable to
such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the
likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems and
safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges to date that have materially impaired
its operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001565" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zvgSFNEAHlnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_82A_zoBAb5jgYfWe">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
Other than as described below, there were no material subsequent events which affected, or could affect, the amounts or disclosures in
the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Compliance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2024, the Company received a letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock
Market LLC (&#8220;Nasdaq&#8221;) on August 19, 2024 indicating that the Company was not in compliance with the minimum net stockholders&#8217;
equity requirement of $<span id="xdx_903_eus-gaap--StockholdersEquity_iNI_di_c20240823__srt--RangeAxis__srt--MinimumMember_ziiVLvi279f4" title="Stock holders' equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-08-23_srt_MinimumMember" id="Fact001567" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,500,000</ix:nonFraction></span> for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &#8220;Stockholders&#8217;
Equity Requirement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders&#8217; Equity Requirement, which
outlined the Company&#8217;s proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2024, the Staff provided notice (the &#8220;Notice&#8221;) to the Company that it had granted an extension through February
18, 2025 to regain compliance with the Stockholders&#8217; Equity Requirement, which required that the Company complete its capital raising
initiatives and evidence compliance with the Stockholders&#8217; Equity Requirement through filing a Current Report on Form 8-K with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) providing certain required information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 18, 2025, the Company had not gained compliance with the Stockholders&#8217; Equity Requirement. Accordingly, on February
19, 2025, the Company received a Staff determination letter from the Staff stating that the Company did not meet the terms of the extension
because it did not complete its proposed financing initiatives to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company timely filed an appeal and requested a Hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;), which has been granted.
The Hearing request automatically stayed Nasdaq&#8217;s delisting of the Company&#8217;s common shares and warrants pending the Panel&#8217;s
decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension through no
later than August 18, 2025. At the upcoming hearing, the Company will present its plan for regaining and sustaining compliance with the
Stockholders&#8217; Equity Requirement for continued listing. However, there can be no assurances that the Hearings Panel will grant
the Company an extension of time to regain compliance, or that the Company will be able to regain compliance during any extension period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to take reasonable measures available to regain compliance under Nasdaq&#8217;s listing rules and to remain listed on
Nasdaq. However, there can be no assurances that the Company will ultimately regain compliance with the Stockholders&#8217; Equity Rule,
or be able to maintain compliance with all other applicable requirements for continued listing on Nasdaq. If the Company does not regain
compliance with Nasdaq&#8217;s continued listing requirements within the time period permitted by Nasdaq, then the Company&#8217;s securities
will be delisted from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination
of At-the-Market Sales Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WallachBeth
Capital, LLC.</b> Effective January 6, 2025, the Company entered into an At-the-Market Sales Agreement (the &#8220;Sales Agreement&#8221;)
with WallachBeth Capital, LLC (the &#8220;Agent&#8221;) pursuant to which the Company may offer and sell from time to time through the
Agent, acting as agent, shares of its common stock, $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_zLWWLbiydgya" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-01-06_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember" id="Fact001569" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share, having an aggregate offering price of up to $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20250106__20250106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember__srt--RangeAxis__srt--MaximumMember_zPx8pQU8fwx8" title="Aggregate offering price"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-01-062025-01-06_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember_srt_MaximumMember" id="Fact001571" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,700,000</ix:nonFraction></span>,
subject to the terms and conditions of the Agreement. The issuance and sale, if any, of shares of common stock through the Agent under
the Sales Agreement was to be made pursuant to the Company&#8217;s effective shelf registration statement on Form S-3 (File No. 333-278874)
(the &#8220;Registration Statement&#8221;) filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 23, 2024,
and declared effective on May 2, 2024.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of shares of the Company&#8217;s common stock pursuant to the Sales Agreement was scheduled to terminate upon the earliest of
(i) the sale of the maximum dollar amount of shares of common stock subject to the Sales Agreement, (ii) the termination of the Sales
Agreement by the Company or the Agent, and (iii) the expiration of the shelf registration statement on Form S-3 (File No. 333-278874)
on the third anniversary of the initial effective date of such registration statement. <span id="xdx_90F_eus-gaap--SaleOfStockDescriptionOfTransaction_pid_c20250307__20250307__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_zGF1KYdEYA0g" title="Description of stock transaction"><ix:nonNumeric contextRef="From2025-03-072025-03-07_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember" id="Fact001573" name="us-gaap:SaleOfStockDescriptionOfTransaction">On March 7, 2025, the Company provided a notice
of termination of the Sales Agreement to the Agent, which, pursuant to the terms of the Sales Agreement, will become effective 10 days
after issuance, or March 18, 2025. No shares of common stock were sold under this Sales Agreement.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sale
of Securities Pursuant to Securities Purchase Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers
named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, (a) in a registered direct offering
(the &#8220;Registered Offering&#8221;), an aggregate of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zh9s9g5sJ1ib" title="Number of shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember" id="Fact001575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">434,784</ix:nonFraction></span> shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock,
par value $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zDoTMOUdUI4f" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember" id="Fact001577" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (the &#8220;Common Stock&#8221;), at an offering price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zD18FKAYQFy8" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_PrivatePlacementMember" id="Fact001579" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.415</ix:nonFraction></span> per share, and (b) in a concurrent private
placement (the &#8220;Private Offering&#8221;), warrants (the &#8220;Common Stock Warrants&#8221;) to purchase an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzki4rINDy5h" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember" id="Fact001581" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">434,784</ix:nonFraction></span>
shares of Common Stock. The Common Stock Warrants were immediately exercisable for a term of <span id="xdx_905_ecustom--ClassOfWarrantOrRightExercisableTerm_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zXGCQqEqDC1a" title="Class of warrant or right exercisable term"><ix:nonNumeric contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember" format="ixt-sec:durwordsen" id="Fact001583" name="LIXT:ClassOfWarrantOrRightExercisableTerm">five years</ix:nonNumeric></span> from issuance at an exercise
price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zm7giliVbI3g" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember" id="Fact001585" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Warrants and the shares of Common Stock underlying the Common Stock Warrants have not been registered under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and have been issued in reliance on an exemption from the registration requirements
of the Securities Act afforded by Section 4(a)(2) thereof. The Common Stock Warrants and the shares of the Company&#8217;s Common Stock
underlying the Common Stock Warrants may not be offered or sold in the United States in the absence of an effective registration statement
or exemption from applicable registration requirements. The Company has agreed to file a registration statement to cover the resale of
any share of Common Stock issuable upon the exercise of the Common Stock Warrants by April 4, 2025. The Registered Offering and Private
Offering are referred to herein as the &#8220;Offering&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></p>

<ix:exclude><!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering resulted in gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember_zIxauiAYnN4l" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember" id="Fact001587" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,050,003</ix:nonFraction></span> before deducting the placement agent&#8217;s fees and related offering expenses. The
Shares were offered by the Company pursuant to a prospectus supplement to the Company&#8217;s effective shelf registration statement
on Form S-3 (Registration No. 333-278874), which was initially filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;)
on April 23, 2024, and was declared effective by the Commission on May 2, 2024. The Offering closed on February 13, 2025 (the &#8220;Closing
Date&#8221;). H.C. Wainwright &amp; Co., LLC acted as the exclusive placement agent for the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Fundamental Transaction (as defined in the Common Stock Warrants) occurs, then the successor entity will succeed to, and be substituted
for the Company, and may exercise every right and power that the Company may exercise and will assume all of the Company&#8217;s obligations
under the Common Stock Warrants with the same effect as if such successor entity had been named in the Common Warrant itself. If holders
of shares of the Company&#8217;s Common Stock are given a choice as to the securities, cash or property to be received in such a Fundamental
Transaction, then the holder of the Common Stock Warrants shall be given the same choice as to the consideration it would receive upon
any exercise of the Common Stock Warrants following such a Fundamental Transaction. Additionally, as more fully described in the Common
Stock Warrants, in the event of certain Fundamental Transactions, the holders of such Common Stock Warrants will be entitled to receive
cash consideration in an amount equal to the Black-Scholes value of the Common Stock Warrants on the date of consummation of such Fundamental
Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued to the Placement Agent, or its designees, warrants (the &#8220;Placement Agent&#8217;s Warrants&#8221;)
to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSOkkSC5AQS6" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember" id="Fact001589" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,609</ix:nonFraction></span> shares of Common Stock, which represents <span id="xdx_909_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlWEAF5LECRi" title="Percentage of shares sold"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember" id="Fact001591" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction>%</span> of the Shares sold in the Registered Offering. The Placement Agent&#8217;s
Warrants have an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zI6NXxN1Imbk" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember" id="Fact001593" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.0188</ix:nonFraction></span> per share, and a term of five years form the commencement of the sales pursuant to the Offering
and otherwise have the same terms as the Common Stock Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent&#8217;s Warrants and the shares of Common Stock underlying the Placement Agent&#8217;s Warrants have not been registered
under the Securities Act and have been issued in reliance on an exemption from the registration requirements of the Securities Act afforded
by Section 4(a)(2) thereof. The Placement Agent&#8217;s Warrants and the shares of the Company&#8217;s Common Stock underlying the Placement
Agent&#8217;s Warrants may not be offered or sold in the United States in the absence of an effective registration statement or exemption
from applicable registration requirements. As soon as practicable (and in any event by April 4, 2025), the Company has agreed to file
a registration statement on Form S-1 providing for the resale by the Purchasers of the Common Warrant Shares issued and issuable upon
exercise of the Common Warrants. The Company is obligated to use commercially reasonable efforts to cause such registration statement
to become effective within 120 days following the Closing Date and to keep such registration statement effective at all times until no
Purchaser owns any Common Warrants or Common Warrant Shares issuable upon exercise thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Significant Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 11, 2025, the Company entered into Amendment No. 1 to the Collaboration Agreement between the Company and GEIS that relieved the
Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $<span id="xdx_90D_eus-gaap--OtherCommitment_iI_uEUR_c20250311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zQVvdMliOe9j" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2025-03-11_us-gaap_SubsequentEventMember_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" id="Fact001595" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">3,095,000</ix:nonFraction></span> (see Note 8).</span></p>

</ix:nonNumeric><p id="xdx_81D_zYQQOwhbOisj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 144; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-248588), Form S-3 (No. 333-278874), and
Form S-8 (333-255407 and No. 333-268860) of our report dated March 24, 2025, relating to the consolidated financial statements of Lixte
Biotechnology Holdings, Inc. as of and for the years ended December 31, 2024 and 2023 (which report includes an explanatory paragraph
relating to substantial doubt about the Company&rsquo;s ability to continue as a going concern), included in Lixte Biotechnology Holdings,
Inc.&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission.
We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in such Registration Statements and related Prospectuses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 45.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Weinberg &amp; Company, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
24, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Bastiaan van der Baan, Chief Executive Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Registrant&rdquo;), certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2024 of Lixte Biotechnology Holdings, Inc. (the
&ldquo;Annual Report&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all
material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented
in this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant
and I have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision,
to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to me by others
within those entities, particularly during the period in which this Annual Report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this Annual Report my conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
most recent fiscal quarter (the Registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the Registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant&rsquo;s auditors
and the audit committee of the Registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 24, 2025</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    BASTIAAN VAN DER BAAN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
    van der Baan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
and Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert N. Weingarten, Chief Financial Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Registrant&rdquo;), certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2024 of Lixte Biotechnology Holdings, Inc. (the
&ldquo;Annual Report&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all
material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented
in this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant
and I have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision,
to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to me by others
within those entities, particularly during the period in which this Annual Report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this Annual Report my conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
most recent fiscal quarter (the Registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the Registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant&rsquo;s auditors
and the audit committee of the Registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 51%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 24, 2025</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    ROBERT N. WEINGATEN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
N. Weingarten</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
President and Chief Financial Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the filing by Lixte Biotechnology Holdings, Inc. (the &ldquo;Registrant&rdquo;) of its Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 (the &ldquo;Annual Report&rdquo;) with the Securities and Exchange Commission, I, Bastiaan van
der Baan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Annual Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act
of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations
of the Registrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 24, 2025</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    BASTIAAN VAN DER BAAN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bastiaan
van der Baan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF THE CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the filing by Lixte Biotechnology Holdings, Inc. (the &ldquo;Registrant&rdquo;) of its Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 (the &ldquo;Annual Report&rdquo;) with the Securities and Exchange Commission, I, Robert N. Weingarten,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Annual Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act
of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations
of the Registrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Date:
    March 24, 2025</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    ROBERT N. WEINGARTEN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
N. Weingarten</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
President and Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "F E@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'0,,,/H15B.%(8TC10J( JJ.P%#KJSLM6.."E=*4M%MWWO\ \#T./TA=0O\
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M*_2OW_!XG#J$:,(J"6R6B^1^:8BC4<G4D^;SZGA &*,TBL& P=V>!CG->H^
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M$&'MRTH72M\7G?\ ,^IK9[E5:_-.5F[[>5OR/$K.ZMX#)B$PYM98L[BV]F7
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M=-T8).44V^K;7<CF_P!4WT-?&5U_Q^7'_75_YFOLV?\ U3?0U\977_'Y<?\
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MM(Q]FN2H+'S(N "<?>7!]<U^8NGZM;ZI;A[=\MCE#]Y?PK]P/%O_ "*NL_\
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M4U@Z3^S%\+="M;ZWL/!6FVL-\D4=PB*V)$CF6>-3\WW5D564#@8 ''%>H44
M<-XB^"'@7Q9%K$>K^&K*^&KW<5]>O(&#R7$<8CCE# @HZH H92#CCO2'X'>
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M%U(C!N1&-WU^OOUK;HK&I1IU;>TBG;575[,N%2<+\C:OO80<"EHHK8@****
M$ZBN%T+X$_#SPQXYOO&6D^#-&T_Q1>C$^J6]HJS-ZD''RD]R,$]\UW=% ""E
MHHH **** "BBB@ HHHH **** *Z6%M'>27:V\2W4BA'G" .RC.%+=2!D\>]4
M%\*:2NI:AJ L8C>WX5;BX(R[ )L !ZCY>.*UZ* .6G^&7AVXGLY'L6VVT4,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 4B!2@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***0$&@!:*3--<X(H ?14>X^]&XYZ&@"2BH]Q]#
M1N/H: )**CW'T-&X^AH DHJ/<?0T;C[T 244S>1UI=XH =13-_M3@<T +111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 44A;%)O% #J8[[306SP*:3CKUH 4MGUHP1
M32])NH ?R>](3FF9-#GI0!)NH+8J/?[T;_K0 [S/:CS/:F[Q1O% #O,]J/,]
MJ;O%&\4 /#YI=U1EZ-V#0!)D&EXJ+=0' (H D YHR5XIN_ZTX$'F@ W?6G*V
M:8<MTI3G&!UH DHJ-6VGFGAMU "T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]1G(_"G(<B@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M63Y: &ORU7;*VZ,PJO90F=\GH*V%4*H'84 .IH'K3J* "BBB@ HHHH ****
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M(X9<I84KW:?\2NX';8?Y5^17[0B;OBWJT2LPW2XZU^O-Y@:5<_[C?R-?D/\
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M*>$,GX<>&QT'V=1^E>4?M;_$_P#X5?X"DAC;9<7:$(1P>:]7\'9;X<^&L_\
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M_P#PL#XI?] ,?]\4?\+ ^*7_ $ Q_P!\5] 44 ?/_P#PL#XI?] ,?]\4?\+
M^*7_ $ Q_P!\5] 44 ?/_P#PL#XI?] ,?]\4?\+ ^*7_ $ Q_P!\5] 44 ?/
M_P#PL#XI?] ,?]\4?\+ ^*7_ $ Q_P!\5] 44 ?/_P#PL#XI?] ,?]\4?\+
M^*7_ $ Q_P!\5] 44 ?/_P#PL#XI?] ,?]\4?\+ ^*7_ $ Q_P!\5] 44 ?/
M_P#PL#XI?] ,?]\4?\+ ^*7_ $ Q_P!\5] 44 ?/_P#PL#XI?] ,?]\4?\+
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MHK2;(5"C>Z2%D_UA;]!TINTO\W3U% =&ZL/SI2Z#^(?G7(U)N[39T:)6B)M
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M169XDL)]0T>:*V?9+C(->2^%/B5?^%-<DTKQ"K+"[829^GYU:VN%[GMP3/S
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MGIQ6K_P4AFM?^&BO#Z:P#]@\^,*K'Y3R,5^F_P )E@'PU\.BW14@^Q1[%4<
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MCYII';C&37X[Q/Q))2>%P;O(^VR?)XSMB,3I$2^U";6+IKB=R9&.<'M4>&0
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M@1N4@EDY& >/TK]%U/DH%50H' 'I51]$TZ:Z^TO91&YZ^85&[\Z /S2_:<^
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M444 %%%)C- "T4E+0 4444 %%)C%+2U ****8!1128H 6BBB@ HHHH ****
M"BBBD W:"<XYKPGXS)_Q<CP^YZ BO>*\0^-$7_%::-)Z%?Z4P/:;5MUM$1W4
M?RJ:J>D-OTZW/^P*N4 %%%% "  =JS=?T&S\2:=)97L0EB<8P:TZ80-V: /G
MR^LM:^#&K^?:A[K2&;)49(4'_"O9/"'C&P\9:;'<VDJF3&60'E:U-1TZWU6T
MDM+N-9(I!@@CM7AGB#PCJWPIUAM4T1G?3G8EXEYP._% 'OKDL<=*;NVL!C/O
M7,^!O'=CXSL%>-U2[ P\)/S#WQ72Y\O@T 3T4U?NBG4 %%%% !1110 4444
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M)V4??8 GB@"]@$ U%U)VG-".'0%6RA&0PY!JM%J=@)FB2ZB,O=0X)_*@"T"
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MA2CC!->DLO//3UH >AW<T^HXB.0*DH 0G%+110 4444 %%%% !1110 4444
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MMT&.HKT'1?"MKI!!6,&3KNQTKY[%8J*D['VV R^I.*YMC+\$>%!I-E'/,O\
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M:$AB^$.AQP(L<:PK@+TZ"O@#_@JK<_V=\2_#=W?1&:P62,8(X'- '/\ @?\
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MC80WT[E0_&037VC%!#&<1Q(G^ZH%2+$L?W$ ^@H _.#]KK]BGQ!9_$B+XB^
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M **** "BBB@ HHHH **** $SSBO,_C=%_P 2(R=QBO2R.<UYQ\;T)\+2MV%
M&W\+'W^"[%O4&NNKC/A&V[P-8'US79T %%%% !1110 4444 %%%% $9 )S37
M)"@KG-2X [48% '$^/OAO9>,[$MM$%XH++*HYR.E>=^$?'NJ_#[5!HOB)&%H
M#MBE8=1ZYKWEFQ[5S7C7P/8^,]->*>,"?'R2]UH WK&]@U"V2X@</&XR"*LU
M\_Z'XBU?X2:O_9NIAI],+$+*>0*]RTC5[;6[)+JTE$L3#.0<T 7J*C)(!.:<
MIR* '444@&* %HHHH **** "F2"GTA&: & \4PC /O4K  5&W8T 0LNUJ9(.
M,^M6" 1DBH&&5_&@"K(F3G-5905<&KI7%02 <Y&: -&REWQ<]:L(:RM/DVO@
MGBM88 H 4\4$\4G)-#_=H 53FF$XI@4[2*$ZX/-.Q'-9V8\XXYJ%V6(EF; '
MKQ2E27]!UKS[X@>(95?[%;2;)#P<5K3IN<K(YL776'AS,T?$'Q#L]/9X+5_-
MNAT4<BN>3XF:HLH,EOB,=3BL[2= CMX_/N1YEPW.XUKO%#@!DR.F*]>.'I0C
M[RU/E:F+Q%65Z<K(Z'PWX\M]=E:(G8X]>*ZQ&!Z<BO%M<T0QH+G33Y#KR=O>
MNT^'OB&34+$07+YN%X.>]<E?#**YXGH8#,)2E[.KN=J[+M.T9-1[NQ%*F%?D
M4<,W/:O)4I-Z'TKLT17%G!<\20J_U%-@TVVM3NCA2,^H&*LJ^6(/&*C(9O2M
M;SMH8<E-RNT.$AR0PP*;C=G/2E0%FRP%/PH[<5G[RW-O=>PV(8'6G21';Q4D
M:J5Z4[;S[5730:2/-_BEIAG6"["Y\KG-9>BWT=[9A@PW#C&:]/U/38M0MGAD
M4%6&.:\KUSPC=^&IS<6>98W;[@YQ7L8:NN509\GCL'/VKK+4T @QAZ5G$/S.
M1Y>.IKG_ .U;^'"O;,QQG..E$5EJGBE3$(V@4'&<8KO;C%7;/+M.K[B5AVF6
MLVO>(PT<?F0(<Y(R!7LD(6&)%[A0*P_"?AQ?#VGHA&^4_>;O71!$89*UXF)K
M<[T/JLOPRHQO(%D!%.C0*<BA4!Z#%.48)KC1Z[0ZBBBF 4444 %%%% "4@^\
M:4CBF$[%)/6@"GJ+X.*HHG<<T^Z<O*>:(CZT 2Q(<5808 J.+O4JC(QWH D'
M4>_^-.8$@A>]( "/>I0* &QL N">:&W+SU]J<JC.<<T^@!JDE13J** (SG?S
MTIJJ-^1T]*EQF@ #I0 TM@]*0GGY1S3R :,4 -VDCT-(>1@C'O4E(0#0 P#8
M,&C&*>1FC&: (RP4]*%^7J>*D*@]J"H/:@!B\<YZTH7\J=@4M ##C.1VHR1S
MCBG;1Z48H :BCK3Z3&*6@!&^Z<4P$#&>OO4E-V@]J &N,GIS3DZ4N*6@ HHH
MH 0G%(Q^0FG4F,TMP(U^84H %/V@=J#2MV'Z##AJ;PGXU+M .<4A0'J*=B;#
M$8%JEIH0#H*=0E884444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &[OFQ7G_P <8_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4A&:6B@!A.7QVK@OCL=OPSU7']T"N^XW>]<'
M\<5W_#;5!["@"M^S\2WPPTPGU:O1Z\Y^ :>7\---7L,UZ-0 4444 %%%% !1
M110 4444 %%%% !1110 UQQ30%<^].89%1-$0VY: ([ZRM]2@:VN8EEB?@JP
MR*\0\2^#-3^&>JMK&C.TEFQW/ N2%&>>*]W*EE]#45Q;Q7EN\$R;XV&&!Z4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% #=OS9KAOC8N_X<ZH!_=KNF^Z:XKX
MP8?X>ZEG^[0!2^ Y_P"+<Z>.XSFO0Z\Y^ Y_XH.V7T)KT:@ HI.M+0 4444
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M0$1SZUE4K2GNSKP^#I45=+4LITIU-3[M.KGW.X****+ %%%%, HHHH ****
M$(S1QBEII^[0 $A:4'--">M+G'2@!&PIR3@5EW]T97V#I3]2N_X%/-4X_G!S
MUH <D6 .*GB0@X[T1#"X-2HN#UH ?R1SP:E484>IIIP,"I  !F@ 52:D VK3
M5R!SWIW3@T .3I3J9&,"GT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH#UIX.*:1DT((Z!MW#%(%]13@,#-(3G&.O>@+=4/7I2TB]*6@84444 %%%%
M!1110 4U@21BG4G2@ IJL6ZT[.:BED6$9SB@"1F"C)K.O;S'"&F7-Z7&U?TJ
MNL1DY- "("QW-R?>I40 Y%$<9(JPL6WF@!$7J:E3KTS0%(I\<>: '!><TYCV
MI*<$P,F@!RY YIRC(YI N>M/H 3&*6BB@ HHHH **** "BBB@ HHHH ****
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M4<<"E5=M !M"=Z>%YS^-&SWIW2@!:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K'%8/C92?#%X/]FN@K$\8
M+O\ #UV/]D_RH \\^"AQ-<K[FO7J\>^"[8U*\7TS7L- !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4)$:B3(W]LUZBSDL#GY.Q% $]%1,=_0\4Y?FY!H 4C--8%3QTJ2F.P Q0 A
M*]!3,9X-.(*KQ^5,/7/Z4 #?+3'&!P.:>!NZTUO2@"-UR/0U&R<X[5,RD#UI
MA./K0!$5Q49C&>>:L$;@>V:B/!H B=1Z"F^4#R<5*RE?>D(W?X4 0;5]/TI#
M&">@Q4^P9--[8QB@"N4YI/*'K5@14>4/2@"#RN/:E6)<<]*F9<G HVYX[4 1
MQPAR1BE,6QL8S3]FP\5(JYY- $*QYXQ3A%M-3*,#&/QI<9/K0 T+@=!2B/<.
M>#4FW;[FG;>] #5C'M3]NW'I2@'(SZ4\'!YH %0#M3P@6@' ]C3@E ";!FG[
M0!2;<'.:4T )@*:<JYY-"C<.:?0 4444 %%%% !1110 4444 %%%% !1110
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M=] #Z*13NI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ4 /5LTM,08S3LYH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQZU#&^?J:?'D-0!.>5H#<\]*8#D8I=QZ&@"4'-+4:\#VI^<T +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 W!+9H
M;E2/:ES29W T >)Z/A?B5=#U8U[8GW1]*\1L?W?Q*N/=C7MT?W%^E #J***
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M$'H?PH MJ34JOD55$P/%31N!0!8R3S3@V<"HPP-.R#T[4 3*2*7=@TQ,8IV
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ML<=:4<U&H!10 !WIN%SPPJTW;85EW'44#CCTI,\U+OV!6%(STI,&@MSCUH)
MH2'<<F<<TZFJ<CBEJK !-(!M^E+C--=2WTI@4+^T$F6 ]ZSDE*2;2/:NA90R
MD5B7ULT<NX4 2KPU3;L<"J:N6P!UJ</A1GK0!9!(J="2*K(PX)J9#SGM0!(/
ME/UIQ&.:C#;B*EQF@!PYI:;N XIU !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 W;\V:%&,TZDZF@#Q+QNNSQO;'U<5[1:_\>T7^Z/Y5
MXS\01L\96AZ?./YU[+9'-I"?]@?RH E/WLTZFG[PIU !1110 4444 %%%% !
M1110 4444 %%%% !1110!&1EC03M%'\?YTUN6H :S$CFHQR.:<_S9&>E1$G!
MYZ4 ,8<]:A<TKL<U [T 1NQ#8'>M33[8(H;O6?9IY\HW?G6VB[4 % #N#131
MPU.QBE8!:***8!43\,*EJ-\#YF. .YI7[ 5[RX6SMI9G. BYYKY5^*_Q+N_$
M^IRV4$ACMD;:2.E=_P#'GX@2V5L;+3Y\.>& -> Q/NW/)R[<MGN:^FRW \]I
MR/'Q=?E7*AL<:P ?QO\ WJEVX^8<DFE#*>,4FQEY!XKZNT8*R/'NY:L#EJ-M
M+G-(<BDFP388(HP2:3=FE)XQWIIMBLP.11D$8HW9XHR$''7Z4G?9CW5F)DH2
M:9/:*0)@/F!R/:I@ U1X<S8'"55X\K4D*$7%WN>N_!?XH-IEU'IM_*?*/ 9N
M@KZ0BN([B%)8R'C89!'>OA"9'3#PL4D4@[@<5]'_  +^(;:Q9+IUT^9(Q@$]
MZ^0S+!V?M8H]S#8E2]UL]C'"C%*#EN*104)STH5@S<5\[YGJDE-W4N<5#->0
MPG#R*I]Z$F]D)M(FP*,"J3:S9)]ZXC'XU+'J%O*,K*K#VI\LNPN9=RS134D6
M094@_2AFQ2*&R':M01J[<Y %+?WT-A;M+.XCC49))Q7@7Q(^/+J\NGZ6=K@X
M$BUT4</.N[11C.O&EHSV37/'.D>'W$=W<JLGH.?ZUP>O_'JQL)62V(D&.#UK
MYRO]9O\ 6'+W\S2R'G.:J>0&.7SFOH\/E*:O,\NKC?Y3UZ\_:!OGE<HAV'IB
MLI_CQK"W *HQ0UYT$SQCBE4\$#CWKT_[/HQLK'%]8J/4]>M?V@KR$9D0],G-
M=/X=_:!L[M/]*PG/)(KYX\O.0_('7WIC01-\R H!V%93RNE-72+CBI)ZGVQH
M/BS3?$T(DLKA7/IGI6Q(C;"<Y-?#FF:WJV@N'T^Y>%,Y(SUKUWP-^T#+#)!8
MZD"[,0#(:^>Q&65*;O$].EC(M:GT-!GR\G@U,*HZ5J=OJEHDT$BR(XSE:O;N
M:\=KE=F=ZDI*Z%HHHH*"J]W#YD1]:GS3><\]*5^P&"I\AB&]ZE0_*":EU&UR
MV\#@56C8D8I@74/ X%3QO^E54) ZU-%UH G&.M2YR.E0*<FI"2#UXH ?MXZT
MY>E-S\G^?6G+TH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 T\&D7J:?28Q0!XM\2AM\6V1_P!L?SKV&R_X\8/]Q?Y5Y!\5AL\2:>?^
MF@_G7KFFDMIMN?\ IF* ++#.*?3$/6GT %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3+@X%5E8DXJ= <]?U- $Q)'2@9(]Z!Q0O4T 2*<BG4V/[HIU !1110 4444
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MJLH(ZU9E^[55LD@9H U-,7$>:N!LMWQ4-BN(!FIF^44 /HIB9QDT^@ HHHH
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MBH1+@XQ3V)*Y% #Z*8AI] !1110 4444 %%%% !1110 4444 %%%% !1110
M4W)S3J0M2 !S32O-/J%\]J8F[#L8/%!XYZT \>]*J\]:375#3ON*O*T$9(I5
MZ49&<5*?1@+1115( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %(1FEHH **** /'?C_ ![AI!])/ZUZ1X1?=X?M3_L"O/\
MX\)NBTP^CUWG@QO-\/6W;Y!0!MIW-/IC#:F!S3E^Z* %HHHH **** "BBB@
MHHHH **** "BBB@"->M1L<9Q4@ZFF.FT9]J (BV"3ZU%)Q]*EQD5#*^.,4 0
M2]*K*-T@%3R,64YJO%S,@]Z -VW&U%'M3V&6%"+\HYI2N6!H =1110 4444
M%)2T4 (1FHFQNYXJ6FLF3SS28&=K6C0:W92V]Q&KJRD#(Z5\E?%'P1-X7U2>
M$1$VDF<$#@"OL78>.O%<]XQ\%V?B_3W@G4!R,!Z]+!8MX:HI/8XJ]!55L?F+
MXW\*RZ9=/<PKF-B2=HSBN4AD5QP3D=C7VC\1_@?+X:1BB&\@?G@9Q7SEXO\
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M,FS_ ."J/C6]E@*?#^5K>5@!((CC%?>WP3^(EW\3O ]IK=Y9&PGF +0D8(H
M] I*:7]*56S0 M+2<TA) YH =36H7)ZT<X.>E $:'>QSVIPX^7%?+G[=W[3=
M_P#LS^$=*U73[<SO=3>60!G'.*[OX)?&2Z^(WP1D\830E+@6IFV'U"Y_I0![
M3C%(<CI7Q]^R+^USJ7QX\>>(]'N;=HH].G:($CJ :^P\?-UH %%.I@3'>GT
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MPW$YY+.H)K\R?V_/ GAW0_CIX?MK"QC@C9T#JJ@#MFOUCC)R1VK\N_\ @H>
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M !=WQZ?^GM_YU^G)(!H =112 YH 6BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!YQ\9TW:-&>N#6G\*'W^%X_8XJC\8DW:"3Z U-\
M'6SX3![[OZ4 =V>10.*;'TYIW6@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M(^S]V!S2!BQXZ5QG@+XAV?C*S7:ZK.!RE=BI ?%?+U*<J;LSUH5%+8DVTX'
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M0BO0/V>M;/AG]BO3-20;S!9%L?@*\C_X*".TO[(GA)W),C1PEB>YVK7I7P<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&^$OA^TNT*3QVRAE/7.!7=7VD66I@?:K:.XVG(WC.*LPPI;QJD:!$'0*, 4
M.P12TM% #0#BN6\4^ M/\58-VF<=P.:ZH<>U(037)B,-2Q,>2JKHTA4E2?-!
MZF!H?ANT\-6BPV:8 [UKJ&*CUJ?8#Q2A0!6E&C"A#D@K(SE*4Y<TGJ-Z@>M&
MT]:>!BEK:P/4:O2EI:0<4P%HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#F_B,N[P/K0_Z=FKSW]EN/R_ EP/\
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M,,0)H  -_44J9Q1C\J7&* %HHHH *3I2TG6@!@)(.*8%(;)-3!0O2FF,$YH
M0]>*-A%/[TM #3PM-#?*>:?VI!&,YH 8I !..:D4Y%(RYI>E "TUEW4ZD- "
M9&.E!/&:4*!2% ?I0 TL3TY'K1NPV!TIRJ%&!1M .: %!S2TW&.E.H 2EHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_F28'2F(O3'2@":%<#!J9$YYJ.,#CUJ=,Y/% #@N.G6IE&T<U&HYS4I.1B@
M0=Z<,DT=!C%.08H =1110 4444 %%%% "$9I:** "BBB@ HHHH 0'-'6EHH
M**** "D Q2T4 %)2T4 %%%% !1110 4@XI:* "BBB@!.E+110 4444 %%%%
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M9-P\+$&O//C:7_LVT49QQTK]0PC55Q9\?B+Q;/+(D,>?XLG-24Q1B, >E.!
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MX% $Y;WI"V!5?)'!.:"QH ;JS!M$O,\C817DGPFD"^++E!_>->KWISI-RO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %-+ "E/2HP,T *?F.:&^Z:"=M-+$@T )&
M".:'.ZFEL#%,,E "D_+BHV;  I&DP*C:0$YH >S\5$[]^U,DDIC-_%VH >7
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M?Y0E 'WR?O"G5YO\&_'.H>/M*DU"]A,*MR@QC@UZ/UH 6BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2EH
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MN2#BEEDP<BI+2W:X.2#B@!+*V,\F6'%;$2!5P*;%$L(PHJ0#O0 @!#4^BB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM#( P+9P,U^G/PR\>V'Q(\)V>I6D@D+1@O@YP:_'"ZB$ME+D?,JY!]*^Y/\
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M&5.?:GD\8%!.X@4X* * !.E.HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[9["@+@]* $V4H7%.HH 0*!2T44 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% #"V0:3M^%'\1/O2B@",' -1-U..U./#$4PG.?>@"*9MN#4+MD#MF
MI+@]JKR'Y1[4 1R#,H4>M:]I#Y<8..<5E6JF2<5N+\N![4 -)(84YL\8IU%
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M@F;@5-*<_6JY.Y@#[4 :.FPC&ZKV>:BM4\N,5+CYLB@!U%%% !1110 4444
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M++4K74H]]K.DP]5;.* +=%1@%3D]Z?UH 6BBB@ HHHH **** "BBB@ HHHH
M*:S8IU-89H 9. T1XSFL)4\MCV-=!C(P:Q]10)-P.* !#N7!ZFIXR> >E5HV
MPHJRAP@- $Z')Q3P<U%$>>:E4CO0!*.E*AY(IBL<XIW0YH DHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ ILGW:7I32=PH :P^6F,V!3G/04C=* (N<$U7<'DY
MJ5FVU$WS<YQ0!7F)&*;;(991]:2:3/-6-)7<Y:@#3"D(*5#R:?28H 6BBB@
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MBF'CFG]@: )***04 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44F:6@ HHHH **** "BBB@ HHHH ****
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M=1\+?^"?C+?0ZCK5P=N=QB;_  H @_8%^$%Z;^Y\0:E&T=NPW1!AC)K[] P
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MC4^6W/.>AI8U82$GH: )J3&*6B@ HHHH **** $I:** "BBB@ HHHH ****
M"BBB@ HHHH **** $;I2*,+BG4E &+?'$X!]:2+[U.U0 7 ]Z2$?** )PN<5
M,O"XIB]*E'W1F@"1>%-2 945&H^7ZU(!@4 )C%2#I4;'@4\=!0 ZBDS2T %%
M%% !124M !1110 44F<TM !1110 AXI:3.*6@ HHHH ***3.* %HI,T9Q0 M
M%(?6C(- "T44A/I0 =*.HI:0#% $1C!;)IQ&:&)W^U!/I47;?D)*P @=J;LS
M3]V.](Q/:A25[(=KC6<*<=30>,<=:0@ Y-&_<>E*ZN%TM!=PQ0Q'2D55W=J1
MW^;%$;/X1O78<.O!J1??K42<XQ3PPS[T7;=D))]22BBBM "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5^2'[,_Q N/AI\1+2.%V*7D@4)D]S7VIXV_;+LO 'C"RT34[=4$ZJ2S#L>]
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MSVI[?+R3Q7(?%'Q@?!7@;4-;B&_[/"9!CZ9KQ+]C?]J&3]HF+6_.A\LV,IC
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ML./O.R'7#K"A=V"J.3FN>/Q#T07WV,W $V<;<UYY\4/BDMNCZ?9/NF/!(KQ
MFYDO/MAE83YSG/O7Y3G?&T,OK*C2U/K\OX>GBJ3G/0^TH72= \;;@>1S4S+N
MZUX=\,?BBQ"65Y)EQP":]LMKA;F$2*<@C/%?:9+F]'-:*G%ZG@XW U<#-QDM
M"4 @^@IRKSGM3 =W!IZ<?X5],HI:H\M2N2T445904444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(P.?04GWCAOSKYYM?VY_ART8^T7C1N3C Y%=8O[2_@_5?#]Q?6-\KD1DJ&8
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ML]N[!4,ASS7Z$6MPEW;13QD%)%# CWH ?MROO0L8%/HH 0#!]J6BB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML)+%I9#L20<XS7W]-;QW,>R6-9$/\+#(J.STZVL%*V\"0 ]0BXH _.+]M/\
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M@!L<2QQA5P&ZFGYR11MYI<4 %%%% !1110 444=J #&**** "BBB@ HHHS0
M=*BD@>5MPD9!ZKP:EI"">,D#TH AM9KJP<R6][.''^UUKMO#?QN\7>#I(I[*
M\ED*$$!F-<?G'04W;ALG[O<4 ?H)^SI^VA9>-S%I'B*00ZD<+N8\>E?6<,T=
MS DD+B2-AE67D&OQ$B,MA>1WMC(;>6,A@Z<$D5]W?LB_M2OKTMMX8UR;%Q@*
MDDAZ^E 'VDO"BG5&9%50<Y!Z>]+D\GM0 [.:6HT&34E !1110 4444 %%%%
M!1110 4444 %%%% !1110 A.!56ZFQ":MUGZDP2/% &: 2VZK48^7G\*K1\I
M5M%R@S0!)$N#Q5E!@XJO .<5.JL>U #V/&*<#P*84+L!V%*TB)PTBCV) H G
MHIB.KCY7#?0YJ-\N<*X^F>: )3D4U4RV[--#J,#S%SZ9I6;;R6"#W/% "@'=
M2L^.M,\Z-S@2J?;<#04VC YH ",$%:< <Y--,L:#!D0'W(I-Z2M\LJGV# T
M2%<GVIP&*SM;NVT[1KJY#JCPQL^6/' S7S%^S'^U7=_&;XG>)O#ERT:1Z4S
M$MUP<<<T ?5Q8 9)Q2*ZOT(/TKCOBQ>:M;^!M2E\/@2ZFL1,*@@Y;M7C_P"R
M/KWQ)U2PU$^/[802"4B+'=>U 'TG2'/:FN=N26 'O4:S(QP)D)]-PH ?D,U)
MG#BAQGC//K1D 8WC\30 CD;ACK5>YTVROOENK."8]_,C5OYBITDCSCS$+?44
MD_&TY_&@"K;:+IED?]&T^VB/7]W"H_7%6UD64XQC'%/0<"G! #D"@!J@ ^U.
M*XYH*@FEZT ,!;/:G*#WZT*NVG4 %%%% !1110!$W+FFN.>#4I4&F>0,DYI6
MON U0!VH?"\_C4NP4UHMU*.C"R,3Q3_R!IC_ +)KY%O\-XEG([2=,U]>>*H@
M-(F&?X37R!>J5\4S@<CS/ZU^'<=)?6(/T/T'AK2$TCZS\ '/A>T(_NC^5="V
M,"N>\"*!X5L\9^Z*Z,)@8[U^M93I@:/H?$8O7$5/4:6# "G1X%)M(!XIR#!%
M>Q;5LY"6BBBF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'!45+HCXW%)>WFUW'G[N*$Y-##-"<'%>LGJ<:)****L84444 %%%% !1110
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M ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** (P"*/XN*DJ/!4\4 1N"3Q3
M&SMY-2OU]Z:R[OPH KN 1Q43QL>.U66_2HWR0: *+H>G:HX6,$@;M5MQP159
MDH VK>=9T!%35AVUP86 [5L1N)4&#0 KG\J15P_L::3V-.Y(]Q0!\$_\%!/A
M_<2:M;:W:V[21(H+,HR!P*^-[*8W,0/0]_:OV1^*'@:V\>^$KS39H5DDD4A2
MPZ&OR9^+7@+4/A7XQN[.[@9+9G(4[2!UH YIB%&.II1],5'"4/SJ<@\T_)8Y
M;K0 M%%%  #F@C%%% !1110 4444 %% SB@]?:@ HHZT <4 %(6P<4'I05##
M;WH ,\X]:KZF?)L9B>H&:F(*K@<FG6NGS:SJ-M9P(97D8!E'/>@#[W_X)]>%
MI8O!;:O(@"N< D<U]@/E@V.U>1_LN^%W\)?"RSM)(S&Y 8@C':O6E;((7F@"
M6,$*,TZD7[M+0 4444 %%%% !1110 4444 %%%% #=W.*4G I!^M!X- #0P(
MRU9>HW.X[1TJQ?W.T84BLZ%3(V6% #XX\)Q4T:]*:!TQTJ8#I0 X*3CTJ9>&
MQVIJC@5(%!.: '+P"#_^JI,!1CN:1>>:7^*@!5&#3Z** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"-A\V<4U@.N:D?D5'U XH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M! <GVIP7N:%.>/QIZKN7F@!P4'!I6.XT 8X%."XH 4# I:** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.^E #57')_6E+<<&G;,GFE" 4 "C(%*1Z48I: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D(R*6B@",#!HSS4E-*]: &,N333P<=J>O7%!3<: (<#MV
MI)!@#UJ81@4C+D4 0%3MYI/+R*F W#^E&W!H KF,KUIA3%62IZGZTUDW=J *
M_E<?XTUDQU__ %U9"Y[4TIG% %<QT>614Y3':C'M0! T>33-AJUCVIH3 Y%
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /C!2@# 2(  A$! Q$!_\0
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M2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I**
M(_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I
M:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I
M:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B
M@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_
M*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/
M*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:D
MHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"
M/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6
MCREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6
MI** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH
M C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/R
MEH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CR
MEJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C\I:/*6I*
M* (_*6CREJ2B@"/REH\I:DHH C\I:/*6I** (_*6CREJ2B@"/REH\I:DHH C
M\I:/*6I** (_*%((0#Q4AZ<4#I0!"P#2"BGL/WE% $E%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #
M#]\44'[XHH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1132<=* %S32_!(Z^E!;C%<OX\^(NA?#C2'U'6KQ+:)>
M@)&3]*FZ[AN=2G(S2G/:L/P=XLL?&>@0:OIS%K.<;D8]Q6TSC%4 C$@_2EW9
M7UKB_B3\5] ^%FCOJ.M7.Q "0@/S'Z"O,_AQ^VGX"^)&M?V7:-<64Q.U6N5V
MJWTH6NP'OY8@X%&3C)%4;_6+33M/>_N+A(K5%W&5FPN*^?-:_;P^'NA^)&T:
M07<K+)Y9F1<H#TZT=; M=CZ2SQ0&R*QO"OBO3?&6C6^IZ7<+<6TPR"I_0UL"
M08) Z4/3<$)(?+1FZ[03BO(M+^.<6I?%3_A$EA(8 G=]*]:G?=;R?[IKY&\*
MJ!^U.2 !\AI: ?7X%.HIKN$&33 =14(ER<8[U(6 H%<7I29W+3/.!)&.E.5P
M!0,<.!2TSS!GH?RH\P$]#0 ^BHQ*.>#3BW'% #J*:#QDTNZ@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPH\U/[PJC_9S?WS^=']G-_?/YT!<O>:G]X4>:G]X51_LYO[Y_.C^SF_OG\Z
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MXJ6E8 HHHI@,/WQ10?OBB@!]%%% !1110 4444 %%%% !1110 4444 %%%%
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MCS%O"NAKG'^E*?UK[2 XKXL_X*/@CPQH9'_/RH_6NW!:54<>+U@>Y?LKMO\
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MVT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10
MW;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% ##]\44'[XHH ?1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD/2C..] "T4W?SBE!!H 6BBB@ HHHH **** "BBB@ HI,XI: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHI,XH 6BDS36?!Q0 ^BF;\?6EW8 S0 ZBF%P!2[N1B@!U%%% !1110 4444
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MBP NHO\ OL5\H_&J]5OBNFR_55*]%?BI;2&H2>ECZ=M/&.GWFH)9QS1M,PR
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MO\O[4S]_E- SZ^HHHH **** (F//%?"?_!1<$P:?V^9?_0J^[&&6_'-?"/\
MP4=E2&SL7D;8H9<G/O79@T_:'!B]8'U3^S^,?"+PYG_GU3G\*]&1NW6OG[X(
M?''P;8?"O0+>76;6.6*U165I!D'%>F^'?BWX9\27/V>QU6VGE/14<$FIK4JB
MDW;0NC5IN*5]3MBN:-M)O##CZT$X!KC21UW% QWIU-0Y6G50QC'G%.%+12L
M44446 ****8!1110 4F.<TM% !1110 4444 %%%%*P!28/K2T4P"BBB@!" :
M6BB@ HHHH **** "BBBE8 HHHI@%%%% !1110 4444 %%%% "<_A2T44 %%%
M% !3<C=CO3J* "BBB@ HHHI6 *;MIU%%@$(XI,<TZBF 4444 %%%% !1110
M4444 %%%%*P!11118 HHHHL 44446 ****8!1112L 4444P"BBB@ HHHH **
M** "BBB@ HHHH ****5@"BBBBP!1113 **** "BBB@ HHHH ****5@"BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 ,/WQ10?OBB@!]%%% !1110
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M&[+Q);F&]C$L70J1FGJEJ2G[S1X??_MK^"[2"1GMKPA<]4KR7X*?$;3?B?\
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MQ?W: U&?V@G>C^T(STIWV2/^[1]EC!^[0)$L4H=<T_.:15$8P*4#%!0M%%%
M##]\44'[XHH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,/WQ1
M0?OBB@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(Q
MP* %HJ,.,G'%.^;VH =13&W8ZBD .,DB@"2BFJ<T \T .HHHH **** "BBB@
M HHHH *8X R>]/II SS0!YK\8?B5??#[2_/L[)KR0KG:O-?,/P+\:77Q _:&
M.H7EO]DEV']VPK[6UG1+'5[=EO(%F3!^\,U\G>#-/M-+_:A:*RB$,>T_*!0!
M]B"EHHH **** "BBB@ J-OO'-24QE!-)[ ?-W[<,4<GPGN=ZAC@X)[<5F_\
M!/>,)\$H@.OG-S6G^W$,?"6Y_O8-9G_!/E_^+(PK_P!-FKU=?JIY=TL0?4J_
M=%+4:-P!4E>3<]0**:33JH HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &'[XHH/WQ10 ^BBB@ HHHH **** "BBB@ HHHH
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MNDU\C^%E!_:E)'=#7US=?\>TG^Z:^2/"W_)TG_ #0!]>4444 %%%% !1110
MG2F,WSX[4_/I439W@XJ;!ZGSE^W&0/A-<D],&L']@77-,LO@G"DMY$DGG$E6
M;!%>M?M"_#*X^*?@BYTFT;;,ZD*?0U\1^&OV0_C%X+MWL=+U*2.VWE@%8@8-
M>Q15.='DE*QY%;GA5YHQN?HW!XHTJ=PD=["S9Q@,*UE8,,J00>17Y->,[_XI
M_ WQ?IL&KWDL@FG12"Y((S7ZA_#_ %&35/!FDW<P_>RVZLWXBN.O05*S3NCK
MH5_:Z-'0YQ3NM(OTIU<B.L****8PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 8?OBB@_?%% #Z*** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &'
M[XHH/WQ10 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F
MM@CZ4ZFLN010 TM@]J\M^+7QD\ >!8OL/BV\MU:0'$$H!+5-\5OC';_#%8//
MMVF,KA!M'2OFK]HG5O VI>)-&UOQ9HC:C'-'O6/L*Q:YM"XI;L\X^+?B[PQ\
M2TFM/A]X'62]8D)=Q+W]>*ZC]BGX _%3P9XGFU;Q-JERNFR-O2SD8X4>E;OA
M?]J;X<> %"Z#X4%KM7 (CY_.O8/@]^UEI_Q5U<V%OISVY#;<D8KHB[*QFY7/
MH'=PN/I3]P'4TF,'\,TUUSSUJ.HQQ;C@_C65J'BC3=*N$BN;J..1S@*3S7'?
M'/XG0?"?P'=ZS*=I"E4SZXKXP\!?"GXI_'Z#4O%,OB2>QM)&:6S3<0,=@*E7
M=[#TL?HI#.DT2O&0R,,@BG,^T5\:?LE_&K7[/Q?J?@/Q?=M<7=FQ2*:0_>[5
M]C@;^#T/(-.6BN2GK8225$B,DA"HHR23TK.T[Q3I>J7#6]K=QR2H>5!KY"_:
M<^,OB?Q+X]3X<>#;J2SO=P$LL?8$UP_C3X%_%CX36>G:_H?B2?5;MV7[1:Q,
M6/OQ1&\F-Z'Z$GD]JRKCQ5I=I>+9RW<:7!X"9YKY^^+7QWU/P#^SPNKSJ]MX
MB,:1>6PPVXBO!]$^!'Q7\?>#/^$Z7Q/,EY<1_:88=W('7%/J-JR/T/60$ @@
M@\Y'>EWBOEG]CKXX:EXW_M/PGK\K3ZSI)V22N>6Q7U$J!=V/7UHEHU8A-]0N
M&S;R<_PFODGPHW_&4I'^P:^LYD+0.!QQBODOPO'M_:I(YSL-"&MM3Z]HR*#0
M0 .E,89%&129'I1D>E*X"[AZT9%- Q11<5Q2P!H# TE%%PN.R*0GB@'%&ZBX
MS\[O^"A%]'8^--&FF(2))T+-[9K[.^!OC#2O%GP\TA]-N5G$=NBL!V.*\I_;
M)^">F?$+P=<ZA.BBXMT9P_?.*\V_X)OW%W'I&J64LS2102,B[CG@&O6FE4PZ
MDNAY,&X8AKN?< Y-/R*C8X(%/R/2O)N>L+D49%)D>E&1Z47 "P%&\4E%%Q7%
MWBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*
M2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7
M%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>
M*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX
M7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC
M>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BB
MX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WB
MC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2B
MBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%WBC>*2BBX7%W
MBC>*2BBX7%WBC>*2BBX7' YI:0"EIC"BBB@ HHHH 8?OBB@_?%% #Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1NAI::PR* .6\5?#[1
M_&.P:C;B4J=RY[$5\J_M+^+O#OP[\7:7::SX>N=3TZ*/ :&+> *^S\8X)ZUY
M[\4?$_@?P[:&7Q3':3':<1RJ"Q'MFL]G9%*]CP#X=ZO\#_B/L4VL6ERL/N7(
M"\_C7NG@+X3^"?#EU]L\/"!G/S;HB#_*OAGXS:Y\+O',UQ#X+M=0MM9)/EFW
M0A,_45VG[#?@'XS^&O$ES<>)9WD\.NW[GS2=VVM:=W<SEH?H"<CTZ4I(VTG0
M8]J:1DYJ.K*Z'RO_ ,%#BW_"E6 Z&5>_O7IW[,D"0_ _P]L !-DN<?2LG]KW
MX>7?Q'^$UWI]DI:9"9  .>*\9_9J_:GT#PIX"G\.Z^);6\T=##AQC<0.E$':
M+3%)7M)'!7@-A^UM!]GX+SX<#ZU^AI8BT5^0=G;UQ7P/^SGX>N_C+\=-7\7M
M"\.EV\K/#)(N"1FOK&'X]>&Y/&LGA,-)]OB^4DCCTK26M-1"]YGYX^-_%?B>
M;]MK5=,\.QG[9* I=ATYZUZUX^7XR_L]O;>*-2U!=4TR25?,M\[]@)]*S_BW
MIEQ\"/VJC\0+VP>XTJ\V_O N>]=M^U3^T?H'C?X>V.E:%%)?7UXZGR@N=N:F
M+]RRW-)-2E8YS]ICXAVWQ7\%:)?PA4W&)ID'3/&:^O/A!&D?P@TI$QL^R 8'
M3[M?(GCOX&ZMX?\ V8SJD<!DU(B.81*,LHZUW/PO_:Z\,:!\$HK.]6:/5K&V
M\F2 KR6QC@4K^ZX]29:R78XO]E>+[+^U%XW\D_*TQW+^-?7WQ6U_5/#VBM-I
M4+23]P!FOES]A_P9J.J_$'Q3XXNH7ALM1D+0!Q@XK[9F@2==LJ"1?1AFF](I
M,G>39\<:M\>/B+8VTQ739R1G&$-<C^S;XJU;Q?\ M F\UB%H+G8?E<8-?=<^
MBZ>T+LUE"W!X*"OE7PLD2?M38M[=+=!&>$&!2L,^K[BXE2=@N=OTJ/[5/_=K
M1(]LT #'04Q6* NI>ZFD-U+V4UH;1Z4;1Z55T3;S,[[5-_=-'VJ;^Z:T2H'1
M0:3'^R*5UV*L9_VJ7T-'VJ7T-:&/]D48_P!D4778+&?]JD[+2_:Y2/NU?_X"
M*1NGW11==AGD_P"T3(X^&6HD9#&%L_E7S=_P3KD91K?4_OG_ )U],?M% ?\
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M &11C_9%%PL41<R?W:3[5)C[E7\?[(HQ_LB@+% 7,O=:/M,O=:OX_P!D4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4A/%+36&1Q0 QS@>^.*^$?V@/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME;YR23BMX:ZF<M#[-(S],<5(O;Z4S'&!QQ3HSN&:SZC'T444P"BBB@ HHHH
M**** "BBB@"&ZXMI?]TU\C^$Q_QE(3_L&OKFZ_X]I/\ =-?(_A48_:C/^X:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCZ*9Y@]11Y@]10%Q]%,\P>HH\P>HH"X^BF>8/44>8/44!<?13/,'J*/,'J*
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MHP?0T!8K?8'_ +YH^P/_ 'S5G!]#1@^AH"Q6^P/_ 'S1]@?^^:LX/H:,'T-
M6*WV!_[YH^P/_?-6<'T-&#Z&@+%;[ _]\T?8'_OFK.#Z&C!]#0%BM]@?^^:/
ML#_WS5G!]#1@^AH"Q6^P/_?-'V!_[YJS@^AHP?0T!8K?8'_OFC[ _P#?-6<'
MT-&#Z&@+%;[ _P#?-'V!_P"^:LX/H:,'T- 6*WV!_P"^:/L#_P!\U9P?0T8/
MH: L5OL#_P!\T?8'_OFK.#Z&C!]#0%BM]@?^^:/L#_WS5G!]#1@^AH"Q6^P/
M_?-(=/<_\M#5K!]#1@^AH"Q5_L]\?ZPTU;&1&^_5U5YY%/VCTH&101LBX:I
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M+<V,$T@YWN@)K5HIV'T*\-NEN@2*-8T7HJC JN-)M//\[[*GFG^/;S^=:%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% ##]\44'[XHH ?1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !3)<A>.M/IDG2I>P'SW^U_\ &"Z^'/P]D@T;+ZQ=N(8PIY7/>O%/
M@U^Q=JOC+24\1>--<GNY=0_?+;2.3L!YQ74_ML:?/H=QIGB&=2VG13J&R,@5
M]%_!SQ7IOBWP!I-YIUS%*GDJK*C#Y3CI1"*2YNII-V243YX\;?L!:9J6FR-H
M&H/I.H*-R2Q,0<BLC]D7XC>(O!_C?4OAYXLN9;@V;&**XG.=WT-?9U]>6^FV
MLEQ<3)#"@+,[-@"OAGPE?Q_$W]IR_DT9A+;VMQNDFCZ'!]:NF[MIF36A]X8%
M*.*:@VJHZX '-/6H6XQ>M+115 %%%% !2=:6B@ HHHH **** (KK_CVD_P!T
MU\D^%O\ DZ+_ ( U?6UU_P >TG^Z:^2?"W_)T7_ &H ^NZ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!.E YI:*5@"BBBF U
MA\IK\X_VFF$?[2&DL2,&9>OUK]'&.,_2O@/]L;X*>+-=\?VNN>'K62=XVWAH
MQG'->A@FE-W9PXJZA=(^XO#4T;>'=.^< >2G.?:M1'# ;3N'KFOS+U'Q7\<O
M#FA++-;WD4%NF,\\ 5[]^P_\;M=^)<6I6>N.SW%L<?-U%%7"VBYWT(HXCF:@
MUJ?7U%(O2D(.:\\]$=1110 444C'% "T4T-SBD#\T@'T4F<FEHN 44T@F@-G
M/M3 =12$\9II>DW8!]%1^9@\]*#(>..M%]+@245'YF!T/%'F$#-,5R2BHO-/
MI2B0D?2E<9)148D)[4>8<XQ1<"2BF;\8SQGI2&0CK3 DHI@;C-*K;J5P'444
M4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^^9(P"WX5L1]>M#LI-$IW1+1110,**** "BBB@ HHHH **** "BBB@ HHHH
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M(@,$\FOAS]I]9-&_:,\(W,HVQ-*N6/0<U[O\9(OB"WQ-T8^';6631%($[(>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M,/WQ10?OBB@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MP_?%%!^^** 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%(6 ZF@'-*X"T4F:,BF M%("#THS0 M%)F@'-
M"T4FX#J:,B@".Z_X]I/]TU\D^%O^3HO^ -7UK<G]Q)S_  FODCPID?M1G/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ##]\44'[XHH ?1110
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MO_?%+_PJSPF/^8':_P#?L5TWVV*D^VQ4N>7<.2/8YK_A5GA/_H"6O_?L4?\
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M'A?IY9H S_\ AJ/PZ/X'H_X:B\._W'J__P ,X>&!U0TO_#-_A?\ YYF@#/\
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MZ#-+0 4444 ,/WQ10?OBB@!]%%% !1110 4444 %%%% !1110 4444 %%%%
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M>>&M0M-3B-KK=K&3Y+##$BKY4R'T/JC<O>11^-*KKG =3^(K\TV^/_Q/\?\
MQ U#2=#MKEHH9BF8_K71:O\ $CXR_#()J=_IMY-:1X+E@2,4ME=E6N['Z%;A
MSGC'<T&:,#)D4?C7S%IG[4'_  EWP9U#6[50NJ6L1,D2_>!Q7S7\//C%\6_B
MS?WK:;;7C01L<$=.M"CKRATN?IBKACPRG\:4YQZ#UKX#TGXX?$WX6>(K;_A*
M]/N8M-D<(99<XZU[E\3_ -J*VT3P=!>:0#<WLZ#")R<FAK30+ZGT.64<;E!]
M,\T[.!@]/>OS[;XN?&"U@_X2:XTB[_LL'?TXVU[_ ."?VB_^$O\ AE?ZD0(]
M1MHCF,'G.*3LD-*[L?09=!UD4?C2JZ,<!U/T.:_.#0OBW\5_B3XCOH=(M+MX
M(7(&S.,9K9UKQ[\9?AR8]1O=/O)+93E]P) %*VQ-]6NQ^A(&% H(!ZBO&?V>
M/CBOQ:T+?./*O(Q\Z>A%<]^TA^U9H?P<TB5([H-J ;:$!ZFG-6:01U5SZ&4@
M-C(/TJ2O"OV7OB_=?&'PY-J=PC+D_+GM7NU4U8$[A1112&%1M_%]*DJ-NK_2
M@#Y,F_Y+2_\ UWKZQM?^/>/Z"ODZ;_DM+_\ 7>OK&V_X]X_H* )J*** "BBB
M@!A^^**#]\44 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FEL-CM3J8P^84 1
MW!W6\HQ_":^2/"GR_M38Z?(U>]?%?XI+\.M.,WV"6])!XC&<5\N_!/QLOQ _
M:+.H"V>T.P_)(,-0!]S4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4;?<;Z&I*B<XC;Z4 ?
M)^JD_P#"\E_W_P"M?5$4ODZ>C]=J9KY6U?\ Y+F!_M_UKZKM$$EE&C#(*@&D
MGKJ#M;0^9?C!^V2GPOU]=-.EO<Y.-RK7$_\ #PZ('_D"R_\ ?-?2GBGX$^$O
M%]Z+O4=/6:8?Q$5D_P##,/@/_H%1_P#?->A&=!+WD<,HUF_=9X"?^"AT.?\
MD"R_]\FC_AX?#_T!9/\ ODU[]_PS#X"_Z!4?_?-'_#,7@//_ ""H_P#OFJ]I
MA^Q')7[G@/\ P\.B[Z+)_P!\FD/_  4/BS_R!9/^^37T!_PS%X#/_,)C_*C_
M (9@\!_] F/\J/:8?L+DK]SY_P#^'A\6?^0+)_WR:/\ AX?%G_D"R?\ ?)KW
M_P#X9A\!_P#0)C_*C_AF'P'_ - F/\J/:8?L')7[G@'_  \/BS_R!9/^^30?
M^"A\7_0%D_[Y->__ /#,/@/_ *!,?Y4']F#P&?\ F$Q_E1[3#]@Y*_<\ _X>
M'Q?] 63_ +Y-+_P\.BQ_R!9?^^37OP_9@\!_] F/\J4_LP^ \8.DQ_E1[3#]
M@Y*_<\ _X>'PX_Y TO\ WR:/^'A\/_0%D_[XKWX_LP^ _P#H$I_WR*/^&8?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ IC\$4^D(S0!EZSH=CJ]LZWL*S+C^(5\G>"M.M-)_:B:"SC6.+
M:>%&*^P+G MY/3::^2/"N#^U(W^X30!]>T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4,G"
M-]#4U1M]QOH: /DW503\<Q_O_P!:^K;/BTB]=HKY4U<9^.?_  /^M?5ED/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J)ON/]*EJ-_N-]* /E#5?^2Y_P# _P"M?5EE_P >L7^Z*^4M4;_B^G_
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M"N3_ &;/$&L>)?CU]IUR$PWNT_*13M8#[YHHHH **** "BBB@ HHHH ****
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MUN(Y\'S.F#7MN/I^=)CZ?G3B^2Z0GJK,8, 5\L_M6?LV:]\:KF*73IO+1#D
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M]]"C^V['_GX0_C0!>W4;JI#6K$C_ (^$_.@ZW8_\_"?G0!=W4;JI_P!LV/\
MS\1_]]"F_P!N6/\ S\1_]]"@"]NHW51_MRQ_Y^(_^^A1_;EC_P _$?\ WT*
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MT4;: /EK_A1'Q$_Z#7_CQH_X41\1/^@U_P"/&OJ7;1MH ^6O^%$?$3_H-?\
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MK_A1'Q$_Z#7_ (\:/^%$?$3_ *#7_CQKZEVT;: /EK_A1'Q$_P"@U_X\:/\
MA1'Q$_Z#7_CQKZEVT;: /EK_ (41\1/^@U_X\:/^%$?$3_H-?^/&OJ7;1MH
M^6C\"/B)VUK_ ,>K,\3?!OXB:+H=S>_VVQ>)=V ]?7&VN>\=PF;POJ"(,LT9
M&/6@#X7^%&G_ !(\>Z[=6)U9P(FQDL<5[')\"/B*?NZUCZ/5S]GC0KC2O%%^
M[PM&&8XR/>OIA@ ,B@#Y</P'^(F?^0W_ ./4?\*(^(G_ $&O_'J^I<4;: /E
MK_A1'Q$_Z#7_ (\:/^%$?$3_ *#7_CQKZEVT;: /EK_A1'Q$_P"@U_X\:/\
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M%OB5>BUM91'.3M4,<$G\:]C 4@8Z>M,!]%)D4M !1110 4444 %(1GMFEHH
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MFW,NF3JS_P!PGD5WA'(IO17"Y*#FEJ-!P:DH&%%%% !1110 W;SUI#G=3Z*
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M.9OM0G?!DZ]:_0>SN1=VD,ZCY9%#?F*<E>"9GM)HN(/EIU,C.5%/H*"BBB@
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M($/C#P] ]Q%$,%(P<X%?:]M9P62%+>)($]$&!3KBUBNHBD\:RH>SKFJ;L0?
M'B?Q#XQ_:0N+/26TNYL[=2%<RJ<9K[8^%W@]? _@S3-)P/-@B"N5]:W[71M/
MLGW6]G#"W]Y$ JZBC/%.ZL)JY+1112*"BBB@ HHHH **** "BBB@ HHHH *1
MONFEI#TH %Z"F,F<CUZTH! HX/6EN!P'C'X'>%/'5R+C5K!)Y1R&(&17RK^T
M]^R7H+QP'1-/E9R03M&0*^ZF(%5YK."?_6Q)*#SR,U.UK#3W/F_P+\ ;2+X$
MC2K:W,6H20X.\=\5XGX0\8>-OV=9KK07TJYO+5W)1H5.!FOOU(HX4"HH51T
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M3J** "BBB@ HHHH **** "BBB@ HHHH **** &LN:39[T^B@!FSWI!'S4E%
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MDD9I@.HJ(.<^U)O)Z=J3=A$U%0&X5>KKGTS2LY(R#P>E,9-14(DYZCZ4KLP
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MR13<MFBX$M%(IR*6F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,/WQ10?OBB@!]%%%
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MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &'[XHH/WQ10 ^BBB@ HHHH **** "BBB@ HHHH
M**** "BD Q2T %%%% !112 YH 6BBB@ HHHH **3'.:6@ HHHH **** "D)Q
M2T4 %%%% !2$XI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,4_%&*BP$:@[#D4*<#!J6DQ3MI8")CGM1C@C'7FI<48H2L!$"<]*0*<DXJ;
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MI3EY(E)-=6ASDTI*S%%W5QY."*6F'FGU104444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(!BEHH ****
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M3>!?VI/#?C'54T\L+2X<@*K\9KR']D7X'^%-<^%EK=:B!<7#@98GFO*_VT_
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M6JN/HHHJAB$XI,X%!I* #?U[5Q?C_P"*ND> +8R7LJEP/N9YKK+VX%O:32G
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M67_C#7X=C3MNA1AC&:^OU(  ';BM6DDD9W;=Q>Y'I2KTH"BEQBI&+2'I2T4
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M,G =M5+L;?[*RFX_:&UJ9/FC\MQN'3K5S]ML#3]:TNZC^27[0H_45Z1^R?\
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MB@ HHHH :3Q2,< 4#!-<A\5O'UO\-/!E[X@N@##;#)!-0]-0.IN;6*[A:&5
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MK91Q,>X7%:W(7WKR#PQ^T9H?B_Q1)H^GNDLB-@LI]Z]?5MP&>,\U5M-0)%&
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MZ'X_T/Q%K=R[&6\7"%NVZOU"\)7,=OX)T>:1MJ"TC))_W17QY^WTP.L^&%'
M-R@P/K7UIH>GMJ7PVTNV5L,]E& 1_NUG!W@;35VFSR3]J']H'2O!?PROKO3+
M]'OXY%4*K<CUK=^ WQPT?QAX#TJ:ZU!/MLJ#*EN<U\J?M=_LV:IH7P[U/5_M
M3R(TP.P-GJ:ZK]F']FO5&\%Z%K#7KI'M5]A.*NGJ]3*HN5:'W3%<)<1*\9RI
MYR*E&<YSQ5+2;-K#3X(&.YD7!/K5X# I@&,T@.*=3,8I,!DJAT*G'->?^+?
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M(S(P]JQOV,OB/-X\^'&V\F\RZMG,94GG XKU?XK*'^'/B$./E-I)G\J^3/\
M@G_<3"[U:%,FW$S_ $ZU,%=M"E*R1]Q!13J0"EI@%%%% !4;C)Q4E12L5/%
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M\O\ "/P.2'Q]=>(-4_>OO+Q;AG;7N"@,/:DGI9 ]00@BEZ&E"XI:2 ****H
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MVU[_ *^%)1_M+3ENF2NMSX^^"?P/UOQ/XY'BGQ-&2 =RJ_.#7HG[6OB6+2/
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MH5DW",!O7%6,9%4W=)"ZW$0Y44ZD' I:0!1110 4444 %%%% !1110 4444
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M44 %%%% !1110 @&*6BB@ HHHH **** $(S0!BEHH **** "BBB@ I",TM%
M"8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "D Q2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !12$XIOF#% ".,N**0-EQ10 E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
610 4444 *.M(_4444 '\0HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %M!98# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7G^*,4!8] \U/[P_.E#!NA!^AKS[%='X3_U=S_O"@+'04444""BBB@ HHHH
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M7J'_ "#KO_KB_P#Z":Y3X,?\D?\  _\ V [+_P!$)0!V5%%% !1110 4444
M%%%% !1110 4444 %*.HI*4=10!POP9_Y$RZ_P"PYJ__ *<;BNYKAO@S_P B
M9=?]AS5__3C<5W- !1110 4444 %%%% !1110 4444 %<1\6/^0;X:_[&73/
M_1XKMZXCXL?\@WPU_P!C+IG_ */% ';T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5T?A+_5W/^\*YRNC\)?ZNY_WA0)G04444$A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'&0&&:T5^\OUKF/A?_R3+P=_V!;+_P!)TKIU^\OUKDEH[&ZV.!^"7_(C3_\
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M?6O2/VH- \%Z?X\\ ?"BQLO'OCOQ3I^D"UL]&TW6ULTD0L[B2XG9"7DP#R%
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M;NW_ "G=]P8_&O5:*GF=^;J.RM8\.^#?[''P\^!.N7VJ^%SK8N+RRDL)4O\
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M_P 51_PF&A?]!K3O_ N/_P"*H V**Q_^$PT+_H-:=_X%Q_\ Q5'_  F&A?\
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M_H,Z=_X&1_\ Q5 &E16;_P )/HO_ $&=._\  R/_ .*H_P"$GT7_ *#.G?\
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M\._^"J#_ .(H_P"%1>!?^A*\._\ @J@_^(KK:* .2_X5%X%_Z$KP[_X*H/\
MXBC_ (5%X%_Z$KP[_P""J#_XBNMHH Y+_A47@7_H2O#O_@J@_P#B*/\ A47@
M7_H2O#O_ (*H/_B*ZVB@#DO^%1>!?^A*\._^"J#_ .(H_P"%1>!?^A*\._\
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M-X/T"::30K%WDDTN!F=C A))*\DUZQJG_(,N_P#KB_\ Z":Y'X&?\D5\ _\
M8 L/_2=* +?_  J+P+_T)7AW_P %4'_Q%'_"HO O_0E>'?\ P50?_$5UM% '
M)?\ "HO O_0E>'?_  50?_$4?\*B\"_]"5X=_P#!5!_\176T4 <E_P *B\"_
M]"5X=_\ !5!_\11_PJ+P+_T)7AW_ ,%4'_Q%=;10!R7_  J+P+_T)7AW_P %
M4'_Q%'_"HO O_0E>'?\ P50?_$5UM% ')?\ "HO O_0E>'?_  50?_$4?\*B
M\"_]"5X=_P#!5!_\176T4 <E_P *B\"_]"5X=_\ !5!_\11_PJ+P+_T)7AW_
M ,%4'_Q%=;10!R7_  J+P+_T)7AW_P %4'_Q%'_"HO O_0E>'?\ P50?_$5U
MM% 'BOP6^%G@J[\&W3S>#] F<:YK";GTN D*-2N !RG0  #T KO?^%1>!?\
MH2O#O_@J@_\ B*R_@;_R)%W_ -A[6O\ TYW->@T <E_PJ+P+_P!"5X=_\%4'
M_P 11_PJ+P+_ -"5X=_\%4'_ ,176T4 <E_PJ+P+_P!"5X=_\%4'_P 11_PJ
M+P+_ -"5X=_\%4'_ ,176T4 <E_PJ+P+_P!"5X=_\%4'_P 11_PJ+P+_ -"5
MX=_\%4'_ ,176T4 <E_PJ+P+_P!"5X=_\%4'_P 11_PJ+P+_ -"5X=_\%4'_
M ,176T4 <E_PJ+P+_P!"5X=_\%4'_P 11_PJ+P+_ -"5X=_\%4'_ ,176T4
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MW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\
MQ%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+
MP+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW
M_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q
M%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7
M_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\
MT)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P5
M0?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_
M  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T
M)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %
M4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;1
M0!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO
M O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7A
MW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\
MQ%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+
MP+_T)7AW_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW
M_P %4'_Q%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q
M%=;10!R7_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7
M_"HO O\ T)7AW_P50?\ Q%'_  J+P+_T)7AW_P %4'_Q%=;10!R7_"HO O\
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MIRDX*2;70'&27,UH34445L2%%%% !1110 4444 %%%% !1110 4444 %%%%
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M^8?ZG8;_ )^R_ ^K_P#A:?A3_H.6G_?='_"T_"G_ $'+3_ONOE#/THS]*/\
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MJ@=<GH,<YJ+2]6LM<L(K[3KRWU"RF&8[FUE66-QG&5920><]#0!<HI,YHS0
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MM_0/V3_B/-\*?VA-&\5^)?#FH^*OB:S207FGPS6]I [6JP[70J6501@8+$@
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M<\!?L4VC_LD6GP>\?7-K>W]M<75W;:OI!?=8W+W$DL,\#,%973>,\#/S#H:
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MP#SG'&#Z'X)^"?Q1\;?'#P]\2?B_J'ABW?PK97%KH>A^%//DB\Z=0DMS-),
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MO*X.>JX.1FJ^I._*Y:W:7R_(2Q":ND?>L/Q]\(S_ !GF^%JW5U_PET5O]I:
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MS_#O3OVL?VLOBOH/Q U#5I_#'@&'3+32/#=CJ4]E$7N8#-)=R>2ZL[9&%.<
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MSF><9C"O@Z?-%12W2UN^_J?HW#>;83 865/$3LW*^S[(\<P:,&O9/^&<+O\
MZ#D7_@,?_BJ/^&;[O_H.1?\ @,?_ (JOS7_4//O^?'XK_,^M_P!9,L_Y^_@S
MQO!HP:]D_P"&;[O_ *#D7_@,?_BJ/^&;[O\ Z#D7_@,?_BJ/]0L^_P"?'XK_
M ##_ %DRS_G[^#/&\&C!KV3_ (9ON_\ H.1?^ Q_^*H_X9ON_P#H.1?^ Q_^
M*H_U#S[_ )\?BO\ ,/\ 63+/^?OX,\;P:,&O9/\ AF^[_P"@Y%_X#'_XJC_A
MF^[_ .@Y%_X#'_XJC_4+/O\ GQ^*_P P_P!9,L_Y^_@SQO!HP:]D_P"&;[O_
M *#D7_@,?_BJ/^&;[O\ Z#D7_@,?_BJ/]0\^_P"?'XK_ ##_ %DRS_G[^#/&
M\&C!KV3_ (9ON_\ H.1?^ Q_^*H_X9ON_P#H.1?^ Q_^*H_U"S[_ )\?BO\
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MXK_,/]9,L_Y^_@SQO!HP:]D_X9ON_P#H.1?^ Q_^*H_X9ON_^@Y%_P" Q_\
MBJ/]0\^_Y\?BO\P_UDRS_G[^#/&\&C!KV3_AF^[_ .@Y%_X#'_XJC_AF^[_Z
M#D7_ (#'_P"*H_U#S[_GQ^*_S#_63+/^?OX,\;P:,&O7[G]G:ZM[:64ZY$?+
M0OC[,><#/]ZLKP7\%+CQGX/T+7X]5CM8]5L8+Y8&A+F,21J^TG<,XW8SCM1_
MJ%GW_/C\5_F'^LF6?\_?P9YK@T8->R?\,WW?_0<B_P# 8_\ Q5'_  S?=_\
M0<B_\!C_ /%4?ZAY]_SX_%?YA_K)EG_/W\&>-X-&#7LG_#-]W_T'(O\ P&/_
M ,51_P ,WW?_ $'(O_ 8_P#Q5'^H>??\^/Q7^8?ZR99_S]_!GC>#1@U[)_PS
M?=_]!R+_ ,!C_P#%4?\ #-]W_P!!R+_P&/\ \51_J'GW_/C\5_F'^LF6?\_?
MP9XW@T8->R?\,WW?_0<B_P# 8_\ Q5'_  S?=_\ 0<B_\!C_ /%4?ZAY]_SX
M_%?YA_K)EG_/W\&>-X(KN/AM\-KGQM?":8/!I438DE P9#_=7^I[5V5E^SFT
M=W"UWK"S6P;,D<<)5F'H#N.*]CTW3+?2;**TM(4@MXE"I&@X K[;ACP_Q"Q/
MM\VCRPCM&][^MNA\_F_$]+V7L\"[R?7:W_!$TW3;?2;**TM(E@MXEVHB#  J
M[28%+TK^B(0C3BH05DC\M<G)W8M%%%:"//O@;_R)%W_V'M:_].=S7H->?? W
M_D2+O_L/:U_Z<[FO0: "BBB@ HHHH **** "BBB@ HHHH *\\^-/_(*\+_\
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MUX=TSXD^+/'$(NQKOB:QMM/ORTV8C% K+'L7'RG#G)SS7=T4 <%\$_@QX=^
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M?\@_P?\ ]C5I7_I0*]'KSCXW#_B7>$.,X\5:5_Z4"@#T>BBB@ HHHH ****
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M% 'G7_#/_@C_ *!^H?\ @ZOO_CU'_#/_ ((_Z!^H?^#J^_\ CU>BT4 >=?\
M#/\ X(_Z!^H?^#J^_P#CU'_#/_@C_H'ZA_X.K[_X]7HM% 'G7_#/_@C_ *!^
MH?\ @ZOO_CU'_#/_ ((_Z!^H?^#J^_\ CU>BT4 >=?\ #/\ X(_Z!^H?^#J^
M_P#CU'_#/_@C_H'ZA_X.K[_X]7HM% 'G7_#/_@C_ *!^H?\ @ZOO_CU'_#/_
M ((_Z!^H?^#J^_\ CU>BT4 >=?\ #/\ X(_Z!^H?^#J^_P#CU'_#/_@C_H'Z
MA_X.K[_X]7HM% 'G7_#/_@C_ *!^H?\ @ZOO_CU'_#/_ ((_Z!^H?^#J^_\
MCU>BT4 >=?\ #/\ X(_Z!^H?^#J^_P#CU'_#/_@C_H'ZA_X.K[_X]7HM% 'G
M7_#/_@C_ *!^H?\ @ZOO_CU'_#/_ ((_Z!^H?^#J^_\ CU>BT4 >=?\ #/\
MX(_Z!^H?^#J^_P#CU'_#/_@C_H'ZA_X.K[_X]7HM% 'G7_#/_@C_ *!^H?\
M@ZOO_CU>?_&+X&^#K&Q\*&*PO@9/$VF1-NU>\;*M. >LIQ]>M?0M><?&[_D'
M^#_^QJTK_P!*!0 'X ^"!_RX:A_X.K[_ ./4?\*!\$?\^%__ .#J^_\ CU:?
MQ;U"YTOP'J-S9SR6UPC1;98FVL,R*#S]*^>/^$_\2?\ 0<OO^_S5^><0<9X7
MA[$QPU>G*3:OI;S7Z'TV69#7S2DZU*223MK\O\SW7_A0/@C_ )\+_P#\'=[_
M /'J/^% ^"/^?"__ /!W>_\ QZO"O^$_\2?]!R^_[_-1_P )_P")/^@Y??\
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MXD_Z#E]_W^:C_B*67?\ /F?X?YA_J?B_^?D?Q/=?^% ^"/\ GPO_ /P=WO\
M\>H_X4#X(_Y\+_\ \'=[_P#'J\*_X3_Q)_T'+[_O\U'_  G_ (D_Z#E]_P!_
MFH_XBEEW_/F?X?YA_J?B_P#GY'\3W7_A0/@C_GPO_P#P=WO_ ,>H_P"% ^"/
M^?"__P#!W>__ !ZO"O\ A/\ Q)_T'+[_ +_-1_PG_B3_ *#E]_W^:C_B*67?
M\^9_A_F'^I^+_P"?D?Q/=?\ A0/@C_GPO_\ P=WO_P >H_X4#X(_Y\+_ /\
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M0!X!\&O@9X-OO!UU)+87Q8:WJ\8*ZQ>+\JZC<*.!-Z ?7J>:[K_AG_P1_P!
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M]:^@*\\^-/\ R"O"_P#V,VE_^E"T -_X9_\ !'_0/U#_ ,'5]_\ 'J/^&?\
MP1_T#]0_\'5]_P#'J]%HH \Z_P"&?_!'_0/U#_P=7W_QZC_AG_P1_P! _4/_
M  =7W_QZO1:* /.O^&?_  1_T#]0_P#!U??_ !ZC_AG_ ,$?] _4/_!U??\
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M ,>KT6B@#SK_ (9_\$?] _4/_!U??_'J/^&?_!'_ $#]0_\ !U??_'J]%HH
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M /.O^&?_  1_T#]0_P#!U??_ !ZC_AG_ ,$?] _4/_!U??\ QZO1:* /.O\
MAG_P1_T#]0_\'5]_\>H_X9_\$?\ 0/U#_P '5]_\>KT6B@#SK_AG_P $?] _
M4/\ P=7W_P >H_X9_P#!'_0/U#_P=7W_ ,>KT6B@#SK_ (9_\$?] _4/_!U?
M?_'J/^&?_!'_ $#]0_\ !U??_'J]%HH \Z_X9_\ !'_0/U#_ ,'5]_\ 'J/^
M&?\ P1_T#]0_\'5]_P#'J]%HH \Z_P"&?_!'_0/U#_P=7W_QZC_AG_P1_P!
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M@<RP>5G&\% 21GC@&K5I\2?"][>^'[.+7+(WGB"U:]TJV:4++>0*H9GC0X)
M5E)XXS7P3\&=#\7_  P_X)W7_P 0K#XDZ[=A?!\\EAH-U;VK66GR^;E9(_W6
M]B-I'SLP^<\=,:_Q+\&>)/B)^TW^SA<0?$37/#=]K'A&\E6YTV&V+6;K;Q-(
M8@\;#]Z6&[<#C:-N* /T%K(\4^*M'\$:#=ZWX@U.UT?2+0!I[V\E$<48)"@L
MQX&20/QKP+X7^+?%>G_M;>)OAWJ?BB^\0:)HO@W3+B,WL<2O-<L[K)</L5?G
M?;D@87T KYP_:*\5^*OB=^R_^U%#JOBF^6V\,>.)+.SACCBVM9H\ 6U;Y<[
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M><?&[_D'^#_^QJTK_P!*!7H]><?&[_D'^#_^QJTK_P!*!0!<^-?_ "3C4O\
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M]W<M>SQRW,0E$EPX4D'+9.3[\UN^._B#>^.[FW>>%;6&W4A($8L,GJW;FG^
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M ?+UQ^P=XLL_#'BOP'X>^-^K>'OA?KLMY,= AT6VEN8OM)8R1&Z8[FB+,<C
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M!$D@8EMHE^5L C8.]2>$OV7/BGX2BT30;?\ :&UR3P/I$L7D:<=$M1?R6\;
MK;O>YW%=JA2P4$C(KZ#T/QGX?\3Z*^L:-KFFZMI*!BU_8W<<T"[1ELR*2O Z
M\\50A^*'@VYU>RTJ'Q;H4NJ7J"2UL4U*%I[A2,AHT#;F!'((% 'DZ_LT>(O#
MGQWUSX@>#?B3<^&])\2W=I>>(/#LNDPW:7CP*$_=RN0T.]!AL GDD=L;WPV_
M9WM_AUX$^(GAJ/7);Z/QAJVJ:J]PUL$-J;T8*!0QW!.Q)&?:O1?%/CSPUX&A
MAF\2>(=*\/PSG;%)JM[%;+(WHI=AD_2IIO%VA6^@?V]+K.GQZ'L\W^TWNHQ;
M!/[WFYVX]\T > 7W[%EK_P *L^&.@:1XTU+P_P",?AW$8]#\86-M'YJ[EV2K
M) Q*O&Z@90GL.>H.[H/P"^(%[HOC*R\??&&]\9_\)!HT^C0V\.C06%I8"564
MS+%&29'YZLW3(KU_0O&GA_Q1HSZOHVNZ;J^DIN+7]C>1S0+M&6S(I*\#D\\4
MMIXRT"_O+.TM=<TVYNKV+[1:P0W<;O/%C.]%!RRXYR,B@#A=*^!<.E?LUQ?"
M(:Q+) GAP^'O[6-N Y4P&'S?+W8SSG;N]LUYCKO[&VLV2_#/5/ GQ)N?"'C#
MP7X>7PP-6DTF*\AOK,!<AX';"-N7<"&/7%>^V7Q)\):EXDE\/6GBC1;KQ!%G
MS-*@U"%[I,=<Q!MPQ]*7Q5\1O"W@A[>+Q!XET?0I[K/V>+5+^*V:8^B!V!;G
MTH \ \.?L476G>%/C+INN_$K4_%.J_$RSBMK[6;_ $^));=EA:+<J(P4CYN$
M 4*% R>M=Q\1/V;+;X@?"'P-X#DUZ6RB\+7NE7J7RVH=K@V6W"E-P"[\<G)Q
MGO5_]EOXTW?[07P:TKQM?:;;Z3<7MQ=PFUM93+&!%<21 AB 3D(#^->N4 ?-
MWCK]E/Q+<?%K7?'?PW^*FH?#6Y\3000^(+.#2X+^.[:)=D<T?F_ZJ4)\N[!]
M:C\'?LD>(?AO\&D\&>$_B[KFC:W%KT^NKXE^PPS2SF5F9H;B%B4E4[LD\9(!
MP.E?2M% '@WP?_9LU;P=\5=4^)GCGQS)X\\;WFF)HT5S%I<.FVUM:*_F;%BC
M)W,6YWLQ..*] ^,_P>\.?'CX=ZIX,\5023:5?!3YD#;)H)%.Y)8VP=KJ0"#C
MV.0:[FB@#Y3?]D[XN:EI,7AK5/VF/$D_A!%$3Q6>BVMMJ<T(_P"6;7H)?IQO
M R><U>US]D?Q=8_$SQ?XD^'WQ@U'P%I7C"6.XUO3HM(M[R5IDC"&2WGDYB++
M['!.1VQ]/44 ?,'AO]B.T\/?"/X:>!O^$QNKJ/P5XI3Q.FH2V2^9>LLTLOE.
MN_"Y\T@N">F<<UZ?XF^"<'B3X\>$/B6^JO#+X>TR\TU=-\@,EP+@KEB^<KC;
MTP<YKU"B@#Y5T_\ 8X\9>!8M4T#X;_&[6/ W@#4+R6[&A1:1;W4]AYKEY([2
MZ<[HE)+8^4E<Y&3DGH?&O[+7B"/XFZQX]^&/Q.OOASKNO00PZW!)ID.I66H-
M$NR.8Q2%=DH7(W \^G7/T310!\^W/[+NKZ_IGP['BGXDZGXIUGPGXF'B:35+
MVQB0WCA77R%C0A88P&XQG&*^@>W2EHH ^=_CI^S)XL^+WQ7\(>--,^*4GA5?
M"CO/I6G+H$-VL4TD9CF<R-(I;<O&""!VKM_#7P2C\/?'GQ7\33K$ES<^(-*L
MM,DT\VX58?L^[YP^XD[MW3 QZUZC10!\]6W[+.L^'O#WCNU\*?$S5/"NM>)O
M&5QXPCU:SL8W-LTH4&U>)V*S1<<YQGCCBE^&_P"R[JNE_$^]^(GQ%\>2_$#Q
M7-HSZ!;O#I4.F6UO9NV]U\N,DNQ(^\QXY %?0E% 'RAX;_8J\2:#\*/%/PME
M^+=WJ'PZU'2[G3-+TN?1(/.TT2R!PYG#AI=@W*%.T$/VP!75_$W]EF_\5K\-
M-5\*>.KGP;XR\!VCV5CK*Z?'=QSPR1+%*DD#L <A >O&3UX(^A** /F;QE^R
MEXSU/QSHOCOPO\7[OPMX[70HM!US5AH=O<Q:K&C;O-^SL0D4FXDC&0.!ZY9X
M6_8@T_2O@Q\4/A[KOC75_%,?CS4)=2N]9O(HTO(IG$>&)&5<AXPV<*#TP*^G
M** /FRZ_9-U_QQ\*I/"/Q%^*-_XIU"QO+:_\/^(+#2H=.NM&GMQB*5-A;S'Z
M[BW7) QUKH/AM\&?BGX>\9:?J_C3XX7_ (RTO3XWCBT:WT*VTZ&X+)M#SM&6
M9R,Y X&1FO<Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH X_XMZ=XRU;X=ZU:?#[5;'0_&,L2C3M0U*+S;>%]ZDEUVMD%
M=P^Z>2*_+WQ)X,_:<C_;X\)Z9>?$'PI+\4Y/"TTEEK26 %E'99FW1M'Y(RYP
M_.T]1S7ZY5R-U\*/"5[\2++Q_/H5K)XRL[,V%OK+ ^=' =V8QSC'SMV_B- &
M5\#-'^(NB?#RTM/BGKNF>(_%ZS2F>_TB#R8&C+'RP%V)R%P#\M?/7_!3KQ-I
M$/P&70'U.T37)M1M;J+3FF7SWA#.#($ZE001G&*^Q^U>>?$3]G_X>?%K5[?4
M_&'A.PU^_MH/LT,]T&+)%N+;1@CC+,?QK>A4C3J*<NAG4BYQ<4?(W[1GB;1_
M$W_!.CPV-*U*TU+[#'H]I="UE63R)EC3=&^#PPXRIYYKQ3XX_!#PG\/_  M^
MSEJ^@6EQINH^*K6!M5N([N3?,S+:DL#NRA_?./EQ@$>E?HU;_LU?#"T\$W7@
M^'P9IL?AF[NEO9]-56\IYP  YYSD!1W[5H>(/@3X"\5V/AJSU?PO97]KX:54
MT>*4-BR"A  F#V$:=?[HKMAC%3TC>UV_O.>5!RW['Q5X=^&V@_ [_@I%X8\.
M^#;5])T>XTDRR6HF>0$O;S;@2Q)()C4X)ZBO-?A)\%O"7Q0MOVF-6\0:>]WJ
M&@27MQITJS.@@EWW3[]JD!CE%Z@\9K]++SX1^#[_ .(5KXYN- M)?%UM%Y$.
MKL#YR)AEVCG'1V'3N:J>'_@;X#\*P>)8=)\,V5C%XDWC5UB5L7F[?NWY/?S'
MZ?WC36-25[.]DON8O8/Y:GY<CX0^&=0_8+_X6+<6DTOBV#6A8Q7LES(RQVXE
M">4J$[57DG@=:]/_ &E]<^SZ'^R-XAUF=O(BL;2YNKV7)QM^QN[$^PR37W<G
M[/?PZC^'K>!5\):>/"33_:3I.&\GS=V[=USG//6I_%7P+\!>-_!FE^%-<\+V
M.H>']+6-+&RD4@6RHNQ0C AEPHQP>1UI_78N:E)/=_<T+V#M9/HOP/CB_P#&
MOA_Q]_P4T\&ZGX;U>SURP321 ;JQD$L?F+!<$KN'!(#+GZUPWP:^"'A#XS_&
M[]HU/%6G-?\ ]EW%U/9E9WC\F5IKCY\*1N(VC&<CKZU]X^%_V:_AAX*\0Z9K
MNA>"M*TK5M-B,-I=VT11XE(8'OR2&;).2<]:U_#7P;\%>#]8\0:IHWAVST[4
M/$!)U2XA!W7>2Q._)[EV/'J:CZW&*M!/9+[F5[%MWEW/RWT3Q%XCL_\ @GCK
M]IIES<C3_P#A,Q;78B8X6V:W1]AQT1I=F1P,GWKIOC7H'PX^'\'P(U?X+7=N
MOC6XD@:9M)NC-/,2(L-,H)VN7+J5(&<L","OT>\+_ _P'X,\):CX8T;PMIUE
MX>U)VDO--$6^&=BH4EE;.>%7\A6'X&_9;^%/PW\1)KOASP1IFF:M'DQ785I'
MB)[IO)"GW&#R:T^NPNW9[M^M^Y/L):*Y\1^+?AM\-8_^"B&M:%XRT_3+/PC>
MV;7\\.HW)AMWNI;996<N7&"TA<]<9) K8^(OPT\)_$S_ (*&^'_"NI6B7_A.
M;P];^7;03LL<D4=K(T0#J<E>%[\@5]I?$?\ 9V^&_P 7=4@U+Q?X0T_7-0AC
M\E+J=6639G(4E2"P&3@'/6M"V^"O@BR\:6/BZ#PW91>);&U6RMM24'S8H%3R
MU0<XP$)7ITJ%C$K/6_+;_@E>QOIYW/SS^$UIJ7PI\;_M6>'O 9N;5-)TF[&G
MP0NS/'Y4Y567J2RHSX/7@5Y;X&^&D/Q&^!RO#JGPNT&XANGN)]:UC59K?7$=
M6)PX)(*D$8VJ<\8^:OUD\.?"'P;X1\7:WXGT?P_:6&OZT6.HW\0/F7.YMQW9
M..6YZ5Q6K?L<_!?7-:DU6\^'>CO>2N9'9$:-&;KDHK!?TK2..BKZ=OP1+P[T
M1\8?'7PI'\3?CK^S5H7B'4VU*/6/#5C!>:GITS*UP&9\R1NP#?..<D _,>*Z
M[]J'PE\.OV==!^'GPTT?P-9^)GU'4KF_L'\5ZC*MC9R2&*)WD*LI;G;]XX4
MGO7V=>_!+P+J/B+P[KT_ABP;5_#L*6^DW00J;*-,[$C (  R<#%3?$KX.^#/
MC#IUM8^,O#UGKUM:R&2 7((:)CP=K*0PSQG!YP*Q6*5X73LO^"5[%V?=GY]?
MLH:7-X)_;M?2()O#D23Z5/\ :8/!\\DFF\PJ^Q2[,20P!/)PV<8KA/@CX/\
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M@?+$BLP4D!1GH.6:LGBHRIS=M;Z>CW*]DU.*Z=?D>_ 8I:0#%+7DG<%?)OQ
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M/7G'QN_Y!_@__L:M*_\ 2@4 7/C5_P DXU/_ 'HO_1JU\P9.*^I?B[8W.I>
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M^$(\0_\ 0$U#_P !G_PH_LK,/^?$O_ 7_D'UW"?\_8_>C%R:3-;?_"#^(?\
MH!ZA_P" S_X4?\(1XA_Z FH?^ S_ .%']EYA_P ^9?\ @+_R#Z]A/^?L?O1B
M49/K6W_PA'B'_H":A_X#/_A1_P (1XA_Z FH?^ S_P"%']EYA_SXE_X"_P#(
M/KV%_P"?L?O1BDYI,YK;_P"$'\0_] /4/_ 9_P#"C_A"/$/_ $!-0_\  9_\
M*/[+S#_GS+_P%_Y!]>PO_/V/WHQ,T5IV/AC5]4@,]EIMW=PB1XC)#"S*'1BC
MKD#JK*P([$8JQ_P@_B'_ * >H?\ @,_^%']EYA_SYE_X"_\ (/KN%_Y^Q^]&
M)G-&:V_^$(\0_P#0$U#_ ,!G_P */^$(\0_] 34/_ 9_\*/[+S#_ )\2_P#
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MW_@K3_X[0!Z117F__"Z)/^B?^-O_  5I_P#':/\ A=$G_1/_ !M_X*T_^.T
M>D45YO\ \+HD_P"B?^-O_!6G_P =H_X71)_T3_QM_P""M/\ X[0!Z117F_\
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MY\%OBW)9>"IHQX&\8S@ZSJS[XM,0K\VHW!Q_K.HS@^A!KO/^%T2?]$_\;?\
M@K3_ ..T<J[ >C[1Z"C:/05YQ_PNB3_HG_C;_P %:?\ QVC_ (71)_T3_P ;
M?^"M/_CM'*NP'H^T>@HVCT%><?\ "Z)/^B?^-O\ P5I_\=H_X71)_P!$_P#&
MW_@K3_X[1RKL!Z/M'H*-H]!7G'_"Z)/^B?\ C;_P5I_\=H_X71)_T3_QM_X*
MT_\ CM'*NP'H^T>@HVCT%><?\+HD_P"B?^-O_!6G_P =H_X71)_T3_QM_P""
MM/\ X[1RKL!Z/M'H*-H]!7G'_"Z)/^B?^-O_  5I_P#':/\ A=$G_1/_ !M_
MX*T_^.T<J[ >C;1Z"C;Z<5YS_P +HD_Z)_XV_P#!6G_QVC_A=$G_ $3_ ,;?
M^"M/_CM.R0'HP%.KS?\ X71)_P!$_P#&W_@K3_X[1_PNB3_HG_C;_P %:?\
MQVF!WVJ?\@R[_P"N+_\ H)KD?@9_R17P#_V +#_TG2L;4?C+(^GW2_\ " >-
M0#$XS_9:?W3_ --:Y;X-?%Z2S^$7@B#_ (07QE.(M$LD\V+3$*/B!!N4^9R#
MVH ]ZHKS?_A=$G_1/_&W_@K3_P".T?\ "Z)/^B?^-O\ P5I_\=H ](HKS?\
MX71)_P!$_P#&W_@K3_X[1_PNB3_HG_C;_P %:?\ QV@#TBBO-_\ A=$G_1/_
M !M_X*T_^.T?\+HD_P"B?^-O_!6G_P =H ](HKS?_A=$G_1/_&W_ (*T_P#C
MM'_"Z)/^B?\ C;_P5I_\=H ](HKS?_A=$G_1/_&W_@K3_P".T?\ "Z)/^B?^
M-O\ P5I_\=H ](HKS?\ X71)_P!$_P#&W_@K3_X[1_PNB3_HG_C;_P %:?\
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M^I^+_P"?D?Q_R/K/CVHX]J^3/^%D>*?^@Y=?]]#_  H_X61XI_Z#EU_WT/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC"W*H-2U]Z^Y[&.GO2T@Z4M?K!\:%%%% !1110 4444 %%%% !1110 4444
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M5"^MYK"]Q<$QB)58R999">5 &PYY.*^J** "BBB@ HHHH *\X^-W_(/\'_\
M8U:5_P"E KT>O./C=_R#_!__ &-6E?\ I0* +GQJ'_%N-3X_BB_]&K7S!DU]
M/_&K_DF^I_[T7_HU:^8,=*_E[Q/O_:].W\B_.1^O\'_[E/\ Q?H@Y]Z,'WKU
M#P9\%D\6^%K?5AJCV\LV\"'R@0"K$#G/M6+X-^&DOB+Q+J.C7L[Z?/9J2Y";
MLD$#OVYSGZ5\5_JOFS5"7L]*WPZK72_RT[GO?VU@E[1<_P##^+1Z:V^>O8XC
M)]:7-=7H'P[O?$OBB\TFSD BM)&66Y<<* Q .!W.#@5VLWP4T.*Y%@?%"#42
M.(6"9S_NYS_6KPG"N:XR#J0A9)VNVE=KM=ZBKYW@L/)0G+6U]$WIYV/'^:.?
M>O5]/^"^E7$@MI_%,$=^':-K= N=P.. 3GGC\ZL:E\$-'TAMEWXICMY2NX1R
MJB$CUP6KK7!><NFZO(K+^_'3\3#_ %AR]2Y>9W_PO_(\@S1S7HW@_P"$J:UH
M+:WJNJ+IFG\E&*C)4'&XD\ &H/'OPL/A728=6L;X:EIKD R!0"N>AXX(/K[U
MQ3X6S:&%^N.G[MK[J]N]M['0LZP,J_U=3]Z]MG:_:^QP'-'->JZ3\&+"\\-V
M.KWNO_V?'<QJY\Q%"J2.F2:P/&7@32_#]K:OIFO1:Q<33"+R8]N1D'G@GO@?
MC3K\*YKAZ"Q%2"46D_B5[/;2]Q4L[P5:K[&$FW>VSM]]K'$\TF:]:_X4UI>C
M6EH=?\1)I]U<\)&%4+GT!/7&1S7.>./A=>>$=4L;:&87T5\_EP,%VMNR!@C\
M>OUJL3PIFV%H^WJ4]-+I--J^UU>^HJ.>8&O4]G"?>VC2=M[/8XC-+S7L4/P+
MTZV^S6VH>(E@U*X7*0*JC<0.=H)R:XS4/AEJEGXTB\.H4EEE >.?!"E.['Z8
MHQ7"F;X2$95*?Q-+1IN[V3MM\PHYY@:\I1A/97U36BW>IQ^:7\:]>_X4?I9O
M#IB^)E.L+'YAM_+'3Z9SBN/TKX9:GJ/C";P^[);S09:65AE0G&"/7.12Q'"F
M;X:4(RI7YWRJS3U[.ST?J.EG>!K*4HSMRJ[NFM.^JU.1R:.:]@7X*Z)>WEQI
MMGXG$NJ6ZY> QJ2OU .?_P!=<OX;^&G]IZ]JVG:EJ,>FKIN/-E(!!SG&"2!C
MC//K6E?A+-J%2%.4%[SLGS*UUNF[Z$4\]P-2,I*7PZO1WL_*VIP^329KUY_@
MAI^JZ?/-H7B-+^:(<J0K+GT)4\5ROP]^&ESXWNKKS+@65I:G;+(5W'=_= Z<
M<_I45>%,VI5Z>']G=U+\MFFG;?5.VA<,\P,Z4ZJG91WNFGKMH<9S1S7J>L_!
MBV.A7&I:#K"ZK]G#%XP =VWJ 0>H]*\KKR\TR;&Y1*,<5&W,KIIII^C1V8+'
MX?'IRH2O;?2S7R8O/O1S[TE%>%=GI"\^]'/O24478"\^]'/O24478!2CWR:2
ME#$4XO74#TSX4_%63PQ-'IFIR%])<X21CDP'_P")_E7T/!.ES#'+$ZR1N RL
MIR"/6OBP?TKTSX5?%5_"\L>F:I(TFE.<)(>3;G_XG^5?NW!7&KH..7YA+W-H
MR?3R?E^1^<<0</\ M4\7A5[W5=_-'T)JG_(,N_\ KB__ *":Y'X&?\D5\ _]
M@"P_])TKJ+VX2YTBXDC=9(W@9E93D$;3@BN7^!G_ "17P#_V +#_ -)TK^BH
MR4DG%W3/RUIIV9W%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH \^^!O\
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M+8Z.=0<G<%X$/^KSVQB@#]'OAY\;?A_\6I+R/P7XST/Q3+9X-Q'I5]'.T0/
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M63:6VJ7(!.U2<>@K"\'?&_P+\3M/U:?P3XOT3Q5)IJ$W"Z5>QW'E'!(WA22
M<=>_:OGW_@H+9^'M0O?@/;>+$L)/#DOCVV6^35"HM6B\B7(DW?+M]<\5S9M_
M!4W[=NB?\*JCT9;:S\$7Z>*&\-K&+549E^RI+Y7R>9NY /. * /3/V>OVT?!
M_P 0OAIX-O\ QSXO\*>&_&VO^8!HBWZ0L2)WCC"QNY8;@HZGDGBO7OB)\;?
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M]5T1R8C,H8!14YVYFEOU9W]UX,T*\N))[C2+.:9SN>1X%+,?4DBM"PTZTTJ
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M=Y'41KQG>>.5'4U+X'_;+\(>(?AMX[\5>(M.U3P/<^!)6@\1Z)K$:F[LGQE
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M]I^$_P 7-6^._P"Q8OCG7=-32M5U;PY?O<6\((C9D66/S$!R0C[-XY/##DT
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MCS;.2R[N<' =<\X*\UV'[)%U?7W[+WPHGU(NUX_AC3S(S_>;_1TP3GU&/SH
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M'_"NO$W_ $ [S_OW1_8N8_\ 0//_ ,!?^0?VA@_^?L?O1SE%='_PKKQ-_P!
M.\_[]T?\*Z\3?] .\_[]T?V+F/\ T#S_ / 7_D']H8/_ )^Q^]'.45T?_"NO
M$W_0#O/^_='_  KKQ-_T [S_ +]T?V+F/_0//_P%_P"0?VA@_P#G['[T<Y17
M1_\ "NO$W_0#O/\ OW1_PKKQ-_T [S_OW1_8N8_] \__  %_Y!_:&#_Y^Q^]
M'.45L:9X/UK6K5KFQTNXNH!+)"9(TRH>-VCD7ZJRLI]Q5O\ X5UXF_Z =Y_W
M[H_L7,?^?$__  %_Y!_:&$_Y^Q^]'.45T?\ PKKQ-_T [S_OW1_PKKQ-_P!
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MMM>&_'C_  P\6^#?!]EX.O=-BU#Q)9BW:>5KB-_F0%O+SSM#$%@"<8K[+HH
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MX1_%+XEQ?$+X3?$CQSIVO:_<ZWHFO^ K^^>*6*X(;[//#!<1B.56R-S#YO7
M&?TCHH \L_9G\.:9X4^"WA[3M(\%:A\/-.19I(O#FJ7!GN;0-*[?O&+,=S9W
MD;CMW8[5Y5_P4*UC6M9^ OB;X?>'O OBSQ9K/B2Q5;:XT'2VNK:!DGC8B:0'
MY"0I(&#7U110!Y_\$O'<GC_P+:W<OA?Q%X3EM-MHUEXET\V=PQ1%RZH2<H<X
M#=\&O-OVMO!VN^+/$/P+FT72;S4XM*\?V5_?O:1%Q;6ZQ3!I9"/NH"P!)XYK
MZ)HH ^<M7\&Z[+^WUH'BA-(O6\.1> KBPDU983]G6X-ZKK$7Z;RN2!UQ7BGQ
M2^$OC34_AY^V1:6?A75;FY\2ZG:RZ-%%:LS:BJQ0!FA&/G *MT]#7WQ10!\7
M>)9/%G[/?[1^G?$9_A]XE\;^%_$'@VST*X'ABS^UWNFWD#E@KPY!".&ZYQGZ
M5U'[%MAXLN?''QP\4>*/!.L>!E\2>(HKZQL=90"5H?LZJ#E<J>@SM) )QGBO
MJFB@#P_]KKXH?$+X7?#!;KX9>"[_ ,8^*+^Y%E']AM6NO[/1E8M<O$O+[<8"
MD@%B,G'!\H_8YUBQ\%:FV@M\*_BM#XI\22O>:_X[\9:$D"WMP%9B9I!*Q1.J
MH@! R!U))^QZ* /SW\+W_P 1/V?/@KX^^ \'PH\6>)-;N;G5+7PSK6E6:RZ5
M=6UX[E)9KC<!$4\UBRMTP!].J^+-Y\6?V<_V>/A9\*_A[X5U_6+U]*CT_6_%
M'AK33?S:4D:(LI@BRJF5RS;&9@!C/7I]O44 ?+7[*7B+1O!WA"]\&^$_@U\1
MO"J:?93:D]]XPTM+5M8NN-V^?S&WSR$CDC '3 &*\E_:#\8:Q^U1\+#\,_#W
M[/GC+P[XOU"ZMU&I>(-&CM+'1-LJL]RMT&P<*K ;,%@>G8_?V*6@"GI-K)8:
M9:6TLAFDAB2-I#U8@ $_C5RBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD(S7!7O@7Q?<7D\L'
MQ)U.TADD9D@32[%A$I/"@M$2<=,DYXH [ZBO//\ A7_C/_HJ.J_^"FP_^,T?
M\*_\9_\ 14=5_P#!38?_ !F@#T.BO//^%?\ C/\ Z*CJO_@IL/\ XS1_PK_Q
MG_T5'5?_  4V'_QF@#T.BO//^%?^,_\ HJ.J_P#@IL/_ (S1_P *_P#&?_14
M=5_\%-A_\9H ]#HKSS_A7_C/_HJ.J_\ @IL/_C-'_"O_ !G_ -%1U7_P4V'_
M ,9H ]#HKSS_ (5_XS_Z*CJO_@IL/_C-'_"O_&?_ $5'5?\ P4V'_P 9H ]#
MHKSS_A7_ (S_ .BHZK_X*;#_ .,T?\*_\9_]%1U7_P %-A_\9H ]#HKSS_A7
M_C/_ **CJO\ X*;#_P",T?\ "O\ QG_T5'5?_!38?_&: /0Z*\\_X5_XS_Z*
MCJO_ (*;#_XS1_PK_P 9_P#14=5_\%-A_P#&: /0Z*\\_P"%?^,_^BHZK_X*
M;#_XS1_PK_QG_P!%1U7_ ,%-A_\ &: /0Z3&:\]_X5_XS_Z*CJO_ (*;#_XS
M1_PK_P 9_P#14=5_\%-A_P#&: /0L"C%>>_\*_\ &?\ T5'5?_!38?\ QFC_
M (5_XS_Z*CJO_@IL/_C- 'H0&*6O//\ A7_C/_HJ.J_^"FP_^,T?\*_\9_\
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M1U7_ ,%-A_\ &:/^%?\ C/\ Z*CJO_@IL/\ XS0!Z'17GG_"O_&?_14=5_\
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M7_P4V'_QFC_A7_C/_HJ.J_\ @IL/_C- 'H=%>>?\*_\ &?\ T5'5?_!38?\
MQFC_ (5_XS_Z*CJO_@IL/_C- 'H=>>?&G_D%>%_^QFTO_P!*%H_X5_XS_P"B
MHZK_ ."FP_\ C-9/B'X.>)_$T-E%>_$[5V6TO(;Z/9I=@O[V)PZ9_<],CD4
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M?_&:/^%?^,_^BHZK_P""FP_^,T >AT5YY_PK_P 9_P#14=5_\%-A_P#&:/\
MA7_C/_HJ.J_^"FP_^,T >AT5YY_PK_QG_P!%1U7_ ,%-A_\ &:/^%?\ C/\
MZ*CJO_@IL/\ XS0!Z'17GG_"O_&?_14=5_\ !38?_&:/^%?^,_\ HJ.J_P#@
MIL/_ (S0!Z'17GG_  K_ ,9_]%1U7_P4V'_QFC_A7_C/_HJ.J_\ @IL/_C-
M'H=%>>?\*_\ &?\ T5'5?_!38?\ QFC_ (5_XS_Z*CJO_@IL/_C- 'H=%>>?
M\*_\9_\ 14=5_P#!38?_ !FC_A7_ (S_ .BHZK_X*;#_ .,T >AT5YY_PK_Q
MG_T5'5?_  4V'_QFC_A7_C/_ **CJO\ X*;#_P",T >AT5YY_P *_P#&?_14
M=5_\%-A_\9K5\,>%?$6C:D;C5/&M]K]L4*BTN+"UA4,2/FW11JW'/&<<T ==
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>lixt-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaKB2bP9z5Z8+ekhvWB8bfmKLyYnMsMj2Syezqb2wdEG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:LIXT="http://lixte.com/20241231" elementFormDefault="qualified" targetNamespace="http://lixte.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://lixte.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
          <link:definition>999014 - Disclosure - Organization and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999016 - Disclosure - Segment Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999017 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999018 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999019 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999020 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999021 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999022 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999023 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999024 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999025 - Disclosure - Segment Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999026 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>999027 - Disclosure - Related Party Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999028 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999029 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999030 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" id="OrganizationAndBasisOfPresentationDetailsNarrative">
          <link:definition>999031 - Disclosure - Organization and Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:definition>999032 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" id="ScheduleOfInformationBySegmentDetails">
          <link:definition>999034 - Disclosure - Schedule of Information by segment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" id="ScheduleOfWarrantsOutstandingDetails">
          <link:definition>999035 - Disclosure - Schedule of Warrants Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>999036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999037 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" id="SummaryOfRelatedPartyCostsDetails">
          <link:definition>999038 - Disclosure - Summary of Related Party Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999039 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" id="ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails">
          <link:definition>999040 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" id="SummaryOfStock-basedCompensationCostsDetails">
          <link:definition>999041 - Disclosure - Summary of Stock-based Compensation Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" id="SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails">
          <link:definition>999042 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" id="ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails">
          <link:definition>999043 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999044 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" id="ScheduleOfComponentsOfDeferredTaxAssetsDetails">
          <link:definition>999045 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" id="ScheduleOfEffectiveIncomeTaxRateDetails">
          <link:definition>999046 - Disclosure - Schedule of Effective Income Tax Rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999047 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" id="ScheduleOfContractualClinicalTrialsDetails">
          <link:definition>999048 - Disclosure - Schedule of Contractual Clinical Trials (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999049 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999050 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="LIXT_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PurchasersMember" name="PurchasersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" name="ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantOneMember" name="VendorAndConsultantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_GeneralAndAdministrativeMember" name="GeneralAndAdministrativeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantTwoMember" name="VendorAndConsultantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantMember" name="VendorAndConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DirectorsAndCorporateOfficersMember" name="DirectorsAndCorporateOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorAndConsultantThreeMember" name="VendorAndConsultantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockOptionsMember" name="CommonStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalAndRelatedOversightCostsMember" name="ClinicalAndRelatedOversightCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PreclinicalResearchMember" name="PreclinicalResearchMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RegulatoryServiceCostsMember" name="RegulatoryServiceCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PlacementAgentsMember" name="PlacementAgentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EmploymentAgreementMember" name="EmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrKovachMember" name="DrKovachMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrJamesSMiserMember" name="DrJamesSMiserMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EricJFormanMember" name="EricJFormanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RobertNWeingartenMember" name="RobertNWeingartenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BasvanderBaanMember" name="BasvanderBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SchellensMember" name="SchellensMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfAuditCommitteeMember" name="ChairmanOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfOtherCommitteesMember" name="ChairmanOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfAuditCommitteeMember" name="MemberOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfOtherCommitteesMember" name="MemberOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NewIndependentDirectorMember" name="NewIndependentDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AppointmentGrantsOfOptionsMember" name="AppointmentGrantsOfOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualGrantOfOptionsMember" name="AnnualGrantOfOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IndependentDirectorMember" name="IndependentDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MsReginaBrownMember" name="MsReginaBrownMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FiveNonOfficerDirectorsMember" name="FiveNonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FiveNonOfficerDirectorsOneMember" name="FiveNonOfficerDirectorsOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourOfficersMember" name="FourOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourNonOfficerDirectorsMember" name="FourNonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MrvanderBaanMember" name="MrvanderBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourNonOfficerDirectorMember" name="FourNonOfficerDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceNineMember" name="ExercisePriceNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTenMember" name="ExercisePriceTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwelveMember" name="ExercisePriceTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThirteenMember" name="ExercisePriceThirteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFourteenMember" name="ExercisePriceFourteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFifteenMember" name="ExercisePriceFifteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialAgreementsMember" name="ClinicalTrialAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialMonitoringAgreementsMember" name="ClinicalTrialMonitoringAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalResearchSupportAgreementMember" name="ClinicalResearchSupportAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CityOfHopeNationalMedicalCenterMember" name="CityOfHopeNationalMedicalCenterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CollaborationAgreementMember" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" name="GrupoEspanolDeInvestigacionEnSarcomasMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DevelopmentCollaborationAgreementMember" name="DevelopmentCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialResearchAgreementMember" name="ClinicalTrialResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialResearchMonitoringMember" name="ClinicalTrialResearchMonitoringMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MDAndersonCancerCenterClinicalMember" name="MDAndersonCancerCenterClinicalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WorkOrderAgreementMember" name="WorkOrderAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TheradexSystemsIncMember" name="TheradexSystemsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DueEachJanuaryOneMember" name="DueEachJanuaryOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NDAConsultingCorpMember" name="NDAConsultingCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BioPharmaWorksLLCMember" name="BioPharmaWorksLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NetherlandsCancerInstituteMember" name="NetherlandsCancerInstituteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MRIGlobalMember" name="MRIGlobalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase1bMember" name="ClinicalTrialPhase1bMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhase1bTwoMember" name="ClinicalTrialPhase1bTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialRandomizedPhaseTwoMember" name="ClinicalTrialRandomizedPhaseTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialPhaseMD1b2Member" name="ClinicalTrialPhaseMD1b2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AtTheMarketSalesAgreementMember" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WallachBethCapitalLLCMember" name="WallachBethCapitalLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AdvancesOnResearchAndDevelopmentContractServices" name="AdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" name="ResearchAndDevelopmentContractLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchAndDevelopmentContractLiabilities" name="ResearchAndDevelopmentContractLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" name="ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" name="ShareBasedCompensationIncludedInResearchAndDevelopmentCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" name="IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" name="IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PrepaidInsurancePolicyTextBlock" name="PrepaidInsurancePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity" name="NasdaqListingMaintainingMinimumNetStockholdersEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CashSIPCInsuredAmount" name="CashSIPCInsuredAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ForeignCurrencyExchangeRateTranslation" name="ForeignCurrencyExchangeRateTranslation" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CashBasedCompensationToRelatedParties" name="CashBasedCompensationToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockBasedCompensationToRelatedParties" name="StockBasedCompensationToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_LegalFeesRelatingToPatentsAndLicensing" name="LegalFeesRelatingToPatentsAndLicensing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_OtherConsultingAndProfessionalFees" name="OtherConsultingAndProfessionalFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" name="NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" name="AnnualNetRevenueDividedByConvertedOrRedeemedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FairValueOfStockOptions" name="FairValueOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" name="EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialDescription" name="ClinicalTrialDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractualClinicalTrialPeriodStartDate" name="ContractualClinicalTrialPeriodStartDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractualClinicalTrialPeriodEndDate" name="ContractualClinicalTrialPeriodEndDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NumberOfPatientInTrial" name="NumberOfPatientInTrial" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedDateOfPreliminaryEfficacySignal" name="ExpectedDateOfPreliminaryEfficacySignal" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AmountRelatedToMilestonePayment" name="AmountRelatedToMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WorkOrderAgreementCosts" name="WorkOrderAgreementCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EstimatedWorkCost" name="EstimatedWorkCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedPaymentinServices" name="ExpectedPaymentinServices" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExpectedPaymentThroughSoftware" name="ExpectedPaymentThroughSoftware" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RoyaltyPayable" name="RoyaltyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RoyatiesPercentage" name="RoyatiesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ConsultingAndAdvisoryCashFee" name="ConsultingAndAdvisoryCashFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ReimbursementExpense" name="ReimbursementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AdvanceAmountRelatedToMilestonePayment" name="AdvanceAmountRelatedToMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClassOfWarrantOrRightExercisableTerm" name="ClassOfWarrantOrRightExercisableTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrBernardMember" name="DrBernardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>lixt-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20241231.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SegmentInformation" xlink:href="lixt-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SegmentInformationTables" xlink:href="lixt-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20241231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesTables" xlink:href="lixt-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:href="lixt-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20241231.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" xlink:href="lixt-20241231.xsd#ScheduleOfInformationBySegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20241231.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20241231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20241231.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:href="lixt-20241231.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20241231.xsd#SummaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20241231.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20241231.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="lixt-20241231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="lixt-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:href="lixt-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:href="lixt-20241231.xsd#ScheduleOfContractualClinicalTrialsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:href="lixt-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="999014 - Disclosure - Organization and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformation" xlink:title="999016 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="999018 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="999019 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999024 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformationTables" xlink:title="999025 - Disclosure - Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="999027 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="999028 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesTables" xlink:title="999029 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="999030 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="999031 - Disclosure - Organization and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999032 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" xlink:title="999034 - Disclosure - Schedule of Information by segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CashBasedCompensationToRelatedParties" xlink:label="loc_LIXTCashBasedCompensationToRelatedParties" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_LIXTCashBasedCompensationToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_StockBasedCompensationToRelatedParties" xlink:label="loc_LIXTStockBasedCompensationToRelatedParties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_LIXTStockBasedCompensationToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:label="loc_LIXTLegalFeesRelatingToPatentsAndLicensing" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_LIXTLegalFeesRelatingToPatentsAndLicensing" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_OtherConsultingAndProfessionalFees" xlink:label="loc_LIXTOtherConsultingAndProfessionalFees" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_LIXTOtherConsultingAndProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapGeneralInsuranceExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="999035 - Disclosure - Schedule of Warrants Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="999037 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="999038 - Disclosure - Summary of Related Party Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999039 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="999040 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:title="999041 - Disclosure - Summary of Stock-based Compensation Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="999042 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="999043 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999044 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="999045 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="999046 - Disclosure - Schedule of Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:label="loc_LIXTEffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_LIXTEffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:title="999047 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="999048 - Disclosure - Schedule of Contractual Clinical Trials (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999049 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:title="999050 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>lixt-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20241231.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SegmentInformation" xlink:href="lixt-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SegmentInformationTables" xlink:href="lixt-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20241231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesTables" xlink:href="lixt-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:href="lixt-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20241231.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" xlink:href="lixt-20241231.xsd#ScheduleOfInformationBySegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20241231.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20241231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20241231.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:href="lixt-20241231.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20241231.xsd#SummaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20241231.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20241231.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="lixt-20241231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="lixt-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:href="lixt-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:href="lixt-20241231.xsd#ScheduleOfContractualClinicalTrialsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:href="lixt-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_60" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_60" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_60" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_60" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_60" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_60" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_60" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_60" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_60" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_60" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_60" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_60" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_60" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_60" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_60" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_60" xlink:type="arc" order="63" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilities_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="999014 - Disclosure - Organization and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformation" xlink:title="999016 - Disclosure - Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="999018 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="999019 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999024 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformationTables" xlink:title="999025 - Disclosure - Segment Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="999027 - Disclosure - Related Party Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="999028 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesTables" xlink:title="999029 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="999030 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="999031 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SecuritiesPurchaseAgreementMember" xlink:label="loc_LIXTSecuritiesPurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSecuritiesPurchaseAgreementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PurchasersMember" xlink:label="loc_LIXTPurchasersMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_LIXTPurchasersMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity" xlink:label="loc_LIXTNasdaqListingMaintainingMinimumNetStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTNasdaqListingMaintainingMinimumNetStockholdersEquity_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquity_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999032 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GeneralAndAdministrativeMember" xlink:label="loc_LIXTGeneralAndAdministrativeMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_LIXTGeneralAndAdministrativeMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTDirectorsAndCorporateOfficersMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_LIXTDirectorsAndCorporateOfficersMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="loc_LIXTVendorAndConsultantOneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantOneMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="loc_LIXTVendorAndConsultantTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantTwoMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantMember" xlink:label="loc_LIXTVendorAndConsultantMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="loc_LIXTVendorAndConsultantThreeMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantThreeMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ForeignCurrencyExchangeRateTranslation" xlink:label="loc_LIXTForeignCurrencyExchangeRateTranslation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTForeignCurrencyExchangeRateTranslation_210" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" xlink:title="999034 - Disclosure - Schedule of Information by segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalAndRelatedOversightCostsMember" xlink:label="loc_LIXTClinicalAndRelatedOversightCostsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTClinicalAndRelatedOversightCostsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PreclinicalResearchMember" xlink:label="loc_LIXTPreclinicalResearchMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTPreclinicalResearchMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RegulatoryServiceCostsMember" xlink:label="loc_LIXTRegulatoryServiceCostsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTRegulatoryServiceCostsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_ES" xlink:label="loc_countryES_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="loc_countryCN_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NL" xlink:label="loc_countryNL_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ResearchAndDevelopmentMember" xlink:label="loc_LIXTResearchAndDevelopmentMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_LIXTResearchAndDevelopmentMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaapCorporateMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CashBasedCompensationToRelatedParties" xlink:label="loc_LIXTCashBasedCompensationToRelatedParties_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTCashBasedCompensationToRelatedParties_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_StockBasedCompensationToRelatedParties" xlink:label="loc_LIXTStockBasedCompensationToRelatedParties_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTStockBasedCompensationToRelatedParties_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:label="loc_LIXTLegalFeesRelatingToPatentsAndLicensing_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTLegalFeesRelatingToPatentsAndLicensing_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_OtherConsultingAndProfessionalFees" xlink:label="loc_LIXTOtherConsultingAndProfessionalFees_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTOtherConsultingAndProfessionalFees_230" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapGeneralInsuranceExpense_230" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_230" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_230" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_230" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapAssets_230" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="999035 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="999037 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="loc_LIXTUndesignatedPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTUndesignatedPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares_310" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis_310" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_310" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_310" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_310" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_310" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_310" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_310" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_310" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_310" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_310" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_310" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_310" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_310" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_310" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_310" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_310" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_310" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_310" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_310" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_310" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_310" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_310" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_310" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_310" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="999038 - Disclosure - Summary of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtDirectorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999039 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SchellensMember" xlink:label="loc_LIXTSchellensMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTSchellensMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_IndependentDirectorMember" xlink:label="loc_LIXTIndependentDirectorMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTIndependentDirectorMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NewIndependentDirectorMember" xlink:label="loc_LIXTNewIndependentDirectorMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTNewIndependentDirectorMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="loc_LIXTAppointmentGrantsOfOptionsMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAppointmentGrantsOfOptionsMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages_380" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_380" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent_380" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation_380" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_380" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCash_380" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_380" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_380" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_380" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable_380" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue_380" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="999040 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:title="999041 - Disclosure - Summary of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="999042 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="999043 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="loc_LIXTExercisePriceFourteenMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourteenMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFifteenMember" xlink:label="loc_LIXTExercisePriceFifteenMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFifteenMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_320" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999044 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTEricJFormanMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrJamesSMiserMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRobertNWeingartenMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MsReginaBrownMember" xlink:label="loc_LIXTMsReginaBrownMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMsReginaBrownMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBasvanderBaanMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MrvanderBaanMember" xlink:label="loc_LIXTMrvanderBaanMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrvanderBaanMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SchellensMember" xlink:label="loc_LIXTSchellensMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSchellensMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FiveNonOfficerDirectorsOneMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsOneMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsOneMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FourNonOfficerDirectorsMember" xlink:label="loc_LIXTFourNonOfficerDirectorsMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorsMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FourNonOfficerDirectorMember" xlink:label="loc_LIXTFourNonOfficerDirectorMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_590" xlink:type="arc" order="592" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_650" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_650" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_650" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_650" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_650" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_650" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_650" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_650" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions_650" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_650" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_650" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_650" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_650" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_650" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_650" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_650" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_650" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_650" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_650" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_650" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="999045 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="999046 - Disclosure - Schedule of Effective Income Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:title="999047 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:label="loc_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="999048 - Disclosure - Schedule of Contractual Clinical Trials (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="loc_LIXTClinicalTrialPhase1bMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="loc_LIXTClinicalTrialPhase1bTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:label="loc_LIXTClinicalTrialRandomizedPhaseTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialRandomizedPhaseTwoMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialPhaseMD1b2Member" xlink:label="loc_LIXTClinicalTrialPhaseMD1b2Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhaseMD1b2Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialDescription" xlink:label="loc_LIXTClinicalTrialDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTClinicalTrialDescription_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodStartDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodStartDate_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodEndDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodEndDate_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NumberOfPatientInTrial" xlink:label="loc_LIXTNumberOfPatientInTrial_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTNumberOfPatientInTrial_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:label="loc_LIXTExpectedDateOfPreliminaryEfficacySignal_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTExpectedDateOfPreliminaryEfficacySignal_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitment_120" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999049 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialMonitoringAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialMonitoringAgreementsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="loc_LIXTClinicalTrialResearchAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchAgreementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialResearchMonitoringMember" xlink:label="loc_LIXTClinicalTrialResearchMonitoringMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchMonitoringMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_LicenseAgreementMember" xlink:label="loc_LIXTLicenseAgreementMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTLicenseAgreementMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLicensingAgreementsMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember_460" xlink:type="arc" order="462" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MDAndersonCancerCenterClinicalMember" xlink:label="loc_LIXTMDAndersonCancerCenterClinicalMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMDAndersonCancerCenterClinicalMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember_430" xlink:type="arc" order="432" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DueEachJanuaryOneMember" xlink:label="loc_LIXTDueEachJanuaryOneMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_LIXTDueEachJanuaryOneMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapContractualObligation_560" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense_560" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCosts_560" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:label="loc_us-gaapInventoryPartsAndComponentsNetOfReserves_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapInventoryPartsAndComponentsNetOfReserves_560" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment_560" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_560" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment_560" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WorkOrderAgreementCosts" xlink:label="loc_LIXTWorkOrderAgreementCosts_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTWorkOrderAgreementCosts_560" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EstimatedWorkCost" xlink:label="loc_LIXTEstimatedWorkCost_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTEstimatedWorkCost_560" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExpectedPaymentinServices" xlink:label="loc_LIXTExpectedPaymentinServices_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentinServices_560" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="loc_LIXTExpectedPaymentThroughSoftware_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentThroughSoftware_560" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_560" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RoyaltyPayable" xlink:label="loc_LIXTRoyaltyPayable_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTRoyaltyPayable_560" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:label="loc_us-gaapHealthCareOrganizationHealthCareCostsGross_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapHealthCareOrganizationHealthCareCostsGross_560" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_560" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RoyatiesPercentage" xlink:label="loc_LIXTRoyatiesPercentage_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTRoyatiesPercentage_560" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_560" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation_560" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee_560" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTReimbursementExpense_560" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="loc_LIXTAdvanceAmountRelatedToMilestonePayment_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAdvanceAmountRelatedToMilestonePayment_560" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:title="999050 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AtTheMarketSalesAgreementMember" xlink:label="loc_LIXTAtTheMarketSalesAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTAtTheMarketSalesAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SecuritiesPurchaseAgreementMember" xlink:label="loc_LIXTSecuritiesPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSecuritiesPurchaseAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WallachBethCapitalLLCMember" xlink:label="loc_LIXTWallachBethCapitalLLCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTWallachBethCapitalLLCMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PurchasersMember" xlink:label="loc_LIXTPurchasersMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_LIXTPurchasersMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PlacementAgentMember" xlink:label="loc_LIXTPlacementAgentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_LIXTPlacementAgentMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_60" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquity_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClassOfWarrantOrRightExercisableTerm" xlink:label="loc_LIXTClassOfWarrantOrRightExercisableTerm_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_LIXTClassOfWarrantOrRightExercisableTerm_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOtherCommitment_120" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="loc_LIXTAppointmentGrantsOfOptionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAppointmentGrantsOfOptionsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>lixt-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockParValue0.0001PerShareMember" xlink:to="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SecuritiesPurchaseAgreementMember" xlink:label="LIXT_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SecuritiesPurchaseAgreementMember" xlink:to="LIXT_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PurchasersMember" xlink:label="LIXT_PurchasersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PurchasersMember" xlink:to="LIXT_PurchasersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PurchasersMember_lbl" xml:lang="en-US">Purchasers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="LIXT_VendorAndConsultantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantOneMember" xlink:to="LIXT_VendorAndConsultantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantOneMember_lbl" xml:lang="en-US">Vendor And Consultant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GeneralAndAdministrativeMember" xlink:label="LIXT_GeneralAndAdministrativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GeneralAndAdministrativeMember" xlink:to="LIXT_GeneralAndAdministrativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_GeneralAndAdministrativeMember_lbl" xml:lang="en-US">General And Administrative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="LIXT_VendorAndConsultantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantTwoMember" xlink:to="LIXT_VendorAndConsultantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantTwoMember_lbl" xml:lang="en-US">Vendor And Consultant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantMember" xlink:label="LIXT_VendorAndConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantMember" xlink:to="LIXT_VendorAndConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantMember_lbl" xml:lang="en-US">Vendor And Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DirectorsAndCorporateOfficersMember" xlink:label="LIXT_DirectorsAndCorporateOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DirectorsAndCorporateOfficersMember" xlink:to="LIXT_DirectorsAndCorporateOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DirectorsAndCorporateOfficersMember_lbl" xml:lang="en-US">Stock Options Granted to Directors and Corporate Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="LIXT_VendorAndConsultantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantThreeMember" xlink:to="LIXT_VendorAndConsultantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorAndConsultantThreeMember_lbl" xml:lang="en-US">Vendor and Consultant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="LIXT_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockOptionsMember" xlink:label="LIXT_CommonStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockOptionsMember" xlink:to="LIXT_CommonStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockOptionsMember_lbl" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalAndRelatedOversightCostsMember" xlink:label="LIXT_ClinicalAndRelatedOversightCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalAndRelatedOversightCostsMember" xlink:to="LIXT_ClinicalAndRelatedOversightCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalAndRelatedOversightCostsMember_lbl" xml:lang="en-US">Clinical And Related Oversight Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PreclinicalResearchMember" xlink:label="LIXT_PreclinicalResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PreclinicalResearchMember" xlink:to="LIXT_PreclinicalResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PreclinicalResearchMember_lbl" xml:lang="en-US">Preclinical Research [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RegulatoryServiceCostsMember" xlink:label="LIXT_RegulatoryServiceCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RegulatoryServiceCostsMember" xlink:to="LIXT_RegulatoryServiceCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RegulatoryServiceCostsMember_lbl" xml:lang="en-US">Regulatory Service Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_ES" xlink:label="country_ES" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_ES" xlink:to="country_ES_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_ES_lbl" xml:lang="en-US">SPAIN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl" xml:lang="en-US">CHINA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NL" xlink:label="country_NL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US">NETHERLANDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ResearchAndDevelopmentMember" xlink:label="LIXT_ResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentMember" xlink:to="LIXT_ResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchAndDevelopmentMember_lbl" xml:lang="en-US">Research And Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateMember" xlink:label="us-gaap_CorporateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateMember" xlink:to="us-gaap_CorporateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateMember_lbl" xml:lang="en-US">Corporate Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="LIXT_UndesignatedPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_UndesignatedPreferredStockMember" xlink:to="LIXT_UndesignatedPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_UndesignatedPreferredStockMember_lbl" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PlacementAgentsMember" xlink:label="LIXT_PlacementAgentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PlacementAgentsMember_lbl" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceOneMember" xlink:label="LIXT_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="LIXT_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="LIXT_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFourMember" xlink:label="LIXT_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="LIXT_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EmploymentAgreementMember" xlink:label="LIXT_EmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EmploymentAgreementMember_lbl" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DrKovachMember" xlink:label="LIXT_DrKovachMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrKovachMember_lbl" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DrJamesSMiserMember" xlink:label="LIXT_DrJamesSMiserMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMember" xlink:to="LIXT_DrJamesSMiserMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrJamesSMiserMember_lbl" xml:lang="en-US">Dr.James S. Miser [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EricJFormanMember" xlink:label="LIXT_EricJFormanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EricJFormanMember_lbl" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RobertNWeingartenMember" xlink:label="LIXT_RobertNWeingartenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RobertNWeingartenMember_lbl" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BasvanderBaanMember" xlink:label="LIXT_BasvanderBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BasvanderBaanMember_lbl" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SchellensMember" xlink:label="LIXT_SchellensMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SchellensMember" xlink:to="LIXT_SchellensMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SchellensMember_lbl" xml:lang="en-US">Schellens [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="LIXT_ChairmanOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_lbl" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="LIXT_ChairmanOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_lbl" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="LIXT_MemberOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfAuditCommitteeMember_lbl" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="LIXT_MemberOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfOtherCommitteesMember_lbl" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NewIndependentDirectorMember" xlink:label="LIXT_NewIndependentDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NewIndependentDirectorMember" xlink:to="LIXT_NewIndependentDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NewIndependentDirectorMember_lbl" xml:lang="en-US">New Independent Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="LIXT_AppointmentGrantsOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AppointmentGrantsOfOptionsMember" xlink:to="LIXT_AppointmentGrantsOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AppointmentGrantsOfOptionsMember_lbl" xml:lang="en-US">Appointment Grants of Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="LIXT_AnnualGrantOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualGrantOfOptionsMember_lbl" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_IndependentDirectorMember" xlink:label="LIXT_IndependentDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IndependentDirectorMember" xlink:to="LIXT_IndependentDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IndependentDirectorMember_lbl" xml:lang="en-US">Independent Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MsReginaBrownMember" xlink:label="LIXT_MsReginaBrownMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MsReginaBrownMember" xlink:to="LIXT_MsReginaBrownMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MsReginaBrownMember_lbl" xml:lang="en-US">Ms.Regina Brown [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="LIXT_FiveNonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsMember" xlink:to="LIXT_FiveNonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FiveNonOfficerDirectorsMember_lbl" xml:lang="en-US">Five Non Officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FiveNonOfficerDirectorsOneMember" xlink:label="LIXT_FiveNonOfficerDirectorsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsOneMember" xlink:to="LIXT_FiveNonOfficerDirectorsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FiveNonOfficerDirectorsOneMember_lbl" xml:lang="en-US">Five Non-Officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FourOfficersMember" xlink:label="LIXT_FourOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourOfficersMember_lbl" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FourNonOfficerDirectorsMember" xlink:label="LIXT_FourNonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorsMember" xlink:to="LIXT_FourNonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourNonOfficerDirectorsMember_lbl" xml:lang="en-US">Four Non-officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MrvanderBaanMember" xlink:label="LIXT_MrvanderBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrvanderBaanMember" xlink:to="LIXT_MrvanderBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MrvanderBaanMember_lbl" xml:lang="en-US">Mrvander Baan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FourNonOfficerDirectorMember" xlink:label="LIXT_FourNonOfficerDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorMember" xlink:to="LIXT_FourNonOfficerDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourNonOfficerDirectorMember_lbl" xml:lang="en-US">Four Non Officer Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceSixMember" xlink:label="LIXT_ExercisePriceSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceSevenMember" xlink:label="LIXT_ExercisePriceSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceEightMember" xlink:label="LIXT_ExercisePriceEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceNineMember" xlink:label="LIXT_ExercisePriceNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceNineMember_lbl" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTenMember" xlink:label="LIXT_ExercisePriceTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceElevenMember" xlink:label="LIXT_ExercisePriceElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="LIXT_ExercisePriceTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="LIXT_ExercisePriceThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThirteenMember_lbl" xml:lang="en-US">Exercise PriceThirteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="LIXT_ExercisePriceFourteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourteenMember" xlink:to="LIXT_ExercisePriceFourteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFourteenMember_lbl" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFifteenMember" xlink:label="LIXT_ExercisePriceFifteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFifteenMember" xlink:to="LIXT_ExercisePriceFifteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFifteenMember_lbl" xml:lang="en-US">Exercise Price Fifteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:label="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_lbl" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialAgreementsMember" xlink:label="LIXT_ClinicalTrialAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:label="LIXT_ClinicalTrialMonitoringAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialMonitoringAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialMonitoringAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="LIXT_ClinicalResearchSupportAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_lbl" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CollaborationAgreementMember" xlink:label="LIXT_CollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CollaborationAgreementMember_lbl" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xml:lang="en-US">GEIS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="LIXT_DevelopmentCollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_lbl" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="LIXT_ClinicalTrialResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchAgreementMember" xlink:to="LIXT_ClinicalTrialResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialResearchAgreementMember_lbl" xml:lang="en-US">Clinical Trial Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialResearchMonitoringMember" xlink:label="LIXT_ClinicalTrialResearchMonitoringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchMonitoringMember" xlink:to="LIXT_ClinicalTrialResearchMonitoringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialResearchMonitoringMember_lbl" xml:lang="en-US">Clinical Trial Research Monitoring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MDAndersonCancerCenterClinicalMember" xlink:label="LIXT_MDAndersonCancerCenterClinicalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MDAndersonCancerCenterClinicalMember" xlink:to="LIXT_MDAndersonCancerCenterClinicalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MDAndersonCancerCenterClinicalMember_lbl" xml:lang="en-US">MD Anderson Cancer Center Clinical [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WorkOrderAgreementMember" xlink:label="LIXT_WorkOrderAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WorkOrderAgreementMember_lbl" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_TheradexSystemsIncMember" xlink:label="LIXT_TheradexSystemsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TheradexSystemsIncMember_lbl" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_LicenseAgreementMember" xlink:label="LIXT_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LicenseAgreementMember" xlink:to="LIXT_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DueEachJanuaryOneMember" xlink:label="LIXT_DueEachJanuaryOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DueEachJanuaryOneMember" xlink:to="LIXT_DueEachJanuaryOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DueEachJanuaryOneMember_lbl" xml:lang="en-US">Due Each January 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US">Licensing Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NDAConsultingCorpMember" xlink:label="LIXT_NDAConsultingCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NDAConsultingCorpMember_lbl" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="LIXT_BioPharmaWorksLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BioPharmaWorksLLCMember_lbl" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="LIXT_NetherlandsCancerInstituteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NetherlandsCancerInstituteMember_lbl" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MRIGlobalMember" xlink:label="LIXT_MRIGlobalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MRIGlobalMember_lbl" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="LIXT_ClinicalTrialPhase1bMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bMember" xlink:to="LIXT_ClinicalTrialPhase1bMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase1bMember_lbl" xml:lang="en-US">Phase 1b [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bTwoMember" xlink:to="LIXT_ClinicalTrialPhase1bTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember_lbl" xml:lang="en-US">Phase 1b Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:label="LIXT_ClinicalTrialRandomizedPhaseTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:to="LIXT_ClinicalTrialRandomizedPhaseTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialRandomizedPhaseTwoMember_lbl" xml:lang="en-US">Randomized Phase 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialPhaseMD1b2Member" xlink:label="LIXT_ClinicalTrialPhaseMD1b2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhaseMD1b2Member" xlink:to="LIXT_ClinicalTrialPhaseMD1b2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialPhaseMD1b2Member_lbl" xml:lang="en-US">Clinical Trial Phase MD 1b 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AtTheMarketSalesAgreementMember" xlink:label="LIXT_AtTheMarketSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AtTheMarketSalesAgreementMember" xlink:to="LIXT_AtTheMarketSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AtTheMarketSalesAgreementMember_lbl" xml:lang="en-US">At The Market Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WallachBethCapitalLLCMember" xlink:label="LIXT_WallachBethCapitalLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WallachBethCapitalLLCMember" xlink:to="LIXT_WallachBethCapitalLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WallachBethCapitalLLCMember_lbl" xml:lang="en-US">Wallach Beth Capital LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PlacementAgentMember" xlink:label="LIXT_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentMember" xlink:to="LIXT_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses, including $27,500 and $36,250 to related parties at December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xml:lang="en-US">Research and development contract liabilities, including $0 and $120,768 to related parties at December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.0001 par value; authorized &#8211; 10,000,000 shares; issued and outstanding &#8211; 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares &#8211; 72,917 shares at December 31, 2024 and 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 2,249,290 shares at December 31, 2024 and 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Related parties accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ResearchAndDevelopmentContractLiabilities" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilities_lbl" xml:lang="en-US">Related parties research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock liquidation preference per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Preferred stock, issuable upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct equity offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct equity offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Exercise of pre-funded common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Exercise of pre-funded common stock warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Stock-based compensation expense included in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_lbl" xml:lang="en-US">General and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Increase (decrease) in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xml:lang="en-US">Research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of securities in registered direct offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of pre-funded common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xml:lang="en-US">Cash:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Balance at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Balance at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Cash paid for -</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xml:lang="en-US">Prepaid Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DeferredOfferingCostsPolicyTextBlock" xlink:label="LIXT_DeferredOfferingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DeferredOfferingCostsPolicyTextBlock" xlink:to="LIXT_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patent and Licensing Legal and Filing Fees and Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WarrantsPolicyTextBlock" xlink:label="LIXT_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsPolicyTextBlock" xlink:to="LIXT_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Information by segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Summary of Related Party Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Each Option Award Estimated Assumption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Summary of Stock-based Compensation Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Schedule of Contractual Clinical Trials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Bid price</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity" xlink:label="LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity" xlink:to="LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity_lbl" xml:lang="en-US">Minimum net stockholders equity maintaining in nasdaq</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stock holders' equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="LIXT_CashSIPCInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CashSIPCInsuredAmount_lbl" xml:lang="en-US">Cash SIPC insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal and filing fees and costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration of risk, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ForeignCurrencyExchangeRateTranslation" xlink:label="LIXT_ForeignCurrencyExchangeRateTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ForeignCurrencyExchangeRateTranslation" xlink:to="LIXT_ForeignCurrencyExchangeRateTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ForeignCurrencyExchangeRateTranslation_lbl" xml:lang="en-US">Foreign currency average rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xml:lang="en-US">Segment Reporting, Revenue from External Customer, Product and Service [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CashBasedCompensationToRelatedParties" xlink:label="LIXT_CashBasedCompensationToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashBasedCompensationToRelatedParties" xlink:to="LIXT_CashBasedCompensationToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CashBasedCompensationToRelatedParties_lbl" xml:lang="en-US">Cash-based</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_StockBasedCompensationToRelatedParties" xlink:label="LIXT_StockBasedCompensationToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockBasedCompensationToRelatedParties" xlink:to="LIXT_StockBasedCompensationToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockBasedCompensationToRelatedParties_lbl" xml:lang="en-US">Stock-based</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:label="LIXT_LegalFeesRelatingToPatentsAndLicensing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:to="LIXT_LegalFeesRelatingToPatentsAndLicensing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_LegalFeesRelatingToPatentsAndLicensing_lbl" xml:lang="en-US">Patent and licensing legal and filing fees and costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_OtherConsultingAndProfessionalFees" xlink:label="LIXT_OtherConsultingAndProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherConsultingAndProfessionalFees" xlink:to="LIXT_OtherConsultingAndProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_OtherConsultingAndProfessionalFees_lbl" xml:lang="en-US">Other consulting and professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="us-gaap_GeneralInsuranceExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Other costs and expenses, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Total general and administrative costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of Shares, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Warrants Outstanding Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:to="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_lbl" xml:lang="en-US">Principal cash obligations and commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock dividend, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:to="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_lbl" xml:lang="en-US">Annual net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xml:lang="en-US">Preferred stock, conversion description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Preferred stock convertible into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Gross proceeds from sale of transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock shares issued during period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrant expires date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs of public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Net proceeds from issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Fair market value of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and rights outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Cash-based</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_3_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Annual salary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_2_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Paid office rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, grants in period, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Options exercisable period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based payment award, award vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementFeePayable" xlink:label="us-gaap_ManagementFeePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeePayable_lbl" xml:lang="en-US">Cash fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Annual cash fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Total stock-based compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common shares avaliable for issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Fair value of stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares were available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average recognition period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Share based compensation vesting rights, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FairValueOfStockOptions" xlink:label="LIXT_FairValueOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FairValueOfStockOptions_lbl" xml:lang="en-US">Fair value of stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Stock options fully vested amount, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of fully vested option exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of fully vested option exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Deferred compensation expense for unvested stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair market value, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Outstanding stock options to acquire shares of common stock not vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U. S. federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Expirations related to stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:label="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:to="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_lbl" xml:lang="en-US">Adjustment to deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Operating loss carryforwards, federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Operating loss carryforwards, state</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Prior net operating loss conversion utilization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialDescription" xlink:label="LIXT_ClinicalTrialDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialDescription" xlink:to="LIXT_ClinicalTrialDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialDescription_lbl" xml:lang="en-US">Clinical trial, description</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodStartDate" xlink:to="LIXT_ContractualClinicalTrialPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate_lbl" xml:lang="en-US">Estimated Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodEndDate" xlink:to="LIXT_ContractualClinicalTrialPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate_lbl" xml:lang="en-US">Estimated End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NumberOfPatientInTrial" xlink:label="LIXT_NumberOfPatientInTrial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfPatientInTrial" xlink:to="LIXT_NumberOfPatientInTrial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NumberOfPatientInTrial_lbl" xml:lang="en-US">Number of Patients in Trial</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:label="LIXT_ExpectedDateOfPreliminaryEfficacySignal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:to="LIXT_ExpectedDateOfPreliminaryEfficacySignal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedDateOfPreliminaryEfficacySignal_lbl" xml:lang="en-US">Expected Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Remaining financial contractual commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligation_2_lbl" xml:lang="en-US">Contractual commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Litigation settlement expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Total costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:label="us-gaap_InventoryPartsAndComponentsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:to="us-gaap_InventoryPartsAndComponentsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPartsAndComponentsNetOfReserves_lbl" xml:lang="en-US">Inventory costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCommitment_2_lbl" xml:lang="en-US">Aggregate commitments expected</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="LIXT_AmountRelatedToMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AmountRelatedToMilestonePayment_lbl" xml:lang="en-US">Amount related to milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WorkOrderAgreementCosts" xlink:label="LIXT_WorkOrderAgreementCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementCosts" xlink:to="LIXT_WorkOrderAgreementCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WorkOrderAgreementCosts_lbl" xml:lang="en-US">Work order agreement costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EstimatedWorkCost" xlink:label="LIXT_EstimatedWorkCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedWorkCost" xlink:to="LIXT_EstimatedWorkCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EstimatedWorkCost_lbl" xml:lang="en-US">Work cost</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExpectedPaymentinServices" xlink:label="LIXT_ExpectedPaymentinServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentinServices" xlink:to="LIXT_ExpectedPaymentinServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedPaymentinServices_lbl" xml:lang="en-US">Percentage of payment through services</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="LIXT_ExpectedPaymentThroughSoftware" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentThroughSoftware" xlink:to="LIXT_ExpectedPaymentThroughSoftware_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExpectedPaymentThroughSoftware_lbl" xml:lang="en-US">Percentage of payment through software</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Non refundable license issue royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RoyaltyPayable" xlink:label="LIXT_RoyaltyPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyaltyPayable" xlink:to="LIXT_RoyaltyPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RoyaltyPayable_lbl" xml:lang="en-US">Minimum annual royalty payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:label="us-gaap_HealthCareOrganizationHealthCareCostsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:to="us-gaap_HealthCareOrganizationHealthCareCostsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationHealthCareCostsGross_lbl" xml:lang="en-US">Dosing of product</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payment for royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RoyatiesPercentage" xlink:label="LIXT_RoyatiesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyatiesPercentage" xlink:to="LIXT_RoyatiesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RoyatiesPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development process costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="LIXT_ConsultingAndAdvisoryCashFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_lbl" xml:lang="en-US">Consulting and advisory fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ReimbursementExpense" xlink:label="LIXT_ReimbursementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ReimbursementExpense_lbl" xml:lang="en-US">Reimbursed expense</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:to="LIXT_AdvanceAmountRelatedToMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment_lbl" xml:lang="en-US">Advance amount related to milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Aggregate offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Description of stock transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClassOfWarrantOrRightExercisableTerm" xlink:label="LIXT_ClassOfWarrantOrRightExercisableTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClassOfWarrantOrRightExercisableTerm" xlink:to="LIXT_ClassOfWarrantOrRightExercisableTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClassOfWarrantOrRightExercisableTerm_lbl" xml:lang="en-US">Class of warrant or right exercisable term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Percentage of shares sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Advances on research and development contract services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xml:lang="en-US">Research and development contract liabilities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilities_doc" xml:lang="en-US">Research and development contract liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:to="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_doc" xml:lang="en-US">Number of share tranche of the series a convertible preferred stock receive a per share dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:to="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_doc" xml:lang="en-US">Annual net revenue divided by converted or redeemed shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_UndesignatedPreferredStockMember" xlink:to="LIXT_UndesignatedPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_UndesignatedPreferredStockMember_doc" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PlacementAgentsMember_doc" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option weighted average exercise price exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule Of Warrants Outstanding And Exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EmploymentAgreementMember_doc" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrKovachMember_doc" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMember" xlink:to="LIXT_DrJamesSMiserMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrJamesSMiserMember_doc" xml:lang="en-US">Dr.James S. Miser [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EricJFormanMember_doc" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RobertNWeingartenMember_doc" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BasvanderBaanMember_doc" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SchellensMember" xlink:to="LIXT_SchellensMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SchellensMember_doc" xml:lang="en-US">Schellens [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DrBernardMember" xlink:label="LIXT_DrBernardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrBernardMember" xlink:to="LIXT_DrBernardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrBernardMember_doc" xml:lang="en-US">Dr Bernard [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_doc" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_doc" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfAuditCommitteeMember_doc" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfOtherCommitteesMember_doc" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NewIndependentDirectorMember" xlink:to="LIXT_NewIndependentDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NewIndependentDirectorMember_doc" xml:lang="en-US">New Independent Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AppointmentGrantsOfOptionsMember" xlink:to="LIXT_AppointmentGrantsOfOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AppointmentGrantsOfOptionsMember_doc" xml:lang="en-US">Appointment Grants of Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualGrantOfOptionsMember_doc" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IndependentDirectorMember" xlink:to="LIXT_IndependentDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IndependentDirectorMember_doc" xml:lang="en-US">Independent Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FairValueOfStockOptions_doc" xml:lang="en-US">Fair value of stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_doc" xml:lang="en-US">Clinical Trial Agreements And Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialAgreementsMember" xlink:to="LIXT_ClinicalTrialAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialAgreementsMember_doc" xml:lang="en-US">Clinical Trial Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:to="LIXT_ClinicalTrialMonitoringAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialMonitoringAgreementsMember_doc" xml:lang="en-US">Clinical Trial Monitoring Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialDescription" xlink:to="LIXT_ClinicalTrialDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialDescription_doc" xml:lang="en-US">Clinical trial description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bMember" xlink:to="LIXT_ClinicalTrialPhase1bMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase1bMember_doc" xml:lang="en-US">Phase 1b [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MsReginaBrownMember" xlink:to="LIXT_MsReginaBrownMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MsReginaBrownMember_doc" xml:lang="en-US">Ms.Regina Brown [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodStartDate" xlink:to="LIXT_ContractualClinicalTrialPeriodStartDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractualClinicalTrialPeriodStartDate_doc" xml:lang="en-US">Contractual clinical trial period start date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractualClinicalTrialPeriodEndDate" xlink:to="LIXT_ContractualClinicalTrialPeriodEndDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractualClinicalTrialPeriodEndDate_doc" xml:lang="en-US">Contractual clinical trial period end date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfPatientInTrial" xlink:to="LIXT_NumberOfPatientInTrial_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NumberOfPatientInTrial_doc" xml:lang="en-US">Number of patient in trial.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:to="LIXT_ExpectedDateOfPreliminaryEfficacySignal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedDateOfPreliminaryEfficacySignal_doc" xml:lang="en-US">Expected date of preliminary efficacy signal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhase1bTwoMember" xlink:to="LIXT_ClinicalTrialPhase1bTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhase1bTwoMember_doc" xml:lang="en-US">Phase 1b&#9;Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsMember" xlink:to="LIXT_FiveNonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FiveNonOfficerDirectorsMember_doc" xml:lang="en-US">Five Non Officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:to="LIXT_ClinicalTrialRandomizedPhaseTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialRandomizedPhaseTwoMember_doc" xml:lang="en-US">Randomized Phase 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialPhaseMD1b2Member" xlink:to="LIXT_ClinicalTrialPhaseMD1b2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialPhaseMD1b2Member_doc" xml:lang="en-US">Clinical Trial Phase MD 1b 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsOneMember" xlink:to="LIXT_FiveNonOfficerDirectorsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FiveNonOfficerDirectorsOneMember_doc" xml:lang="en-US">Five Non-Officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_doc" xml:lang="en-US">Stock based compensation expense included in research and development costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_doc" xml:lang="en-US">Stock based compensation expense included in general and administrative costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Increase decrease in advances on research and development contract services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xml:lang="en-US">Increase decrease in research and development contract liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourOfficersMember_doc" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity" xlink:to="LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity_doc" xml:lang="en-US">Nasdaq listing maintaining minimum net stockholders equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorsMember" xlink:to="LIXT_FourNonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourNonOfficerDirectorsMember_doc" xml:lang="en-US">Four Non-officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MrvanderBaanMember" xlink:to="LIXT_MrvanderBaanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MrvanderBaanMember_doc" xml:lang="en-US">Mrvander Baan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourNonOfficerDirectorMember" xlink:to="LIXT_FourNonOfficerDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourNonOfficerDirectorMember_doc" xml:lang="en-US">Four Non Officer Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CashSIPCInsuredAmount_doc" xml:lang="en-US">Cash SIPC insured amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_doc" xml:lang="en-US">Prepaid Insurance [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DeferredOfferingCostsPolicyTextBlock" xlink:to="LIXT_DeferredOfferingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DeferredOfferingCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred Offering Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_doc" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CollaborationAgreementMember_doc" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xml:lang="en-US">GEIS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DirectorsAndCorporateOfficersMember" xlink:to="LIXT_DirectorsAndCorporateOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DirectorsAndCorporateOfficersMember_doc" xml:lang="en-US">Stock Options Granted to Directors and Corporate Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AmountRelatedToMilestonePayment_doc" xml:lang="en-US">Amount related to milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantOneMember" xlink:to="LIXT_VendorAndConsultantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantOneMember_doc" xml:lang="en-US">Vendor And Consultant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantTwoMember" xlink:to="LIXT_VendorAndConsultantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantTwoMember_doc" xml:lang="en-US">Vendor And Consultant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchAgreementMember" xlink:to="LIXT_ClinicalTrialResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialResearchAgreementMember_doc" xml:lang="en-US">Clinical Trial Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantMember" xlink:to="LIXT_VendorAndConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantMember_doc" xml:lang="en-US">Vendor And Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorAndConsultantThreeMember" xlink:to="LIXT_VendorAndConsultantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorAndConsultantThreeMember_doc" xml:lang="en-US">Vendor and Consultant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsPolicyTextBlock" xlink:to="LIXT_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WarrantsPolicyTextBlock_doc" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSixMember_doc" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSevenMember_doc" xml:lang="en-US">Exercise Price Seven [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchMonitoringMember" xlink:to="LIXT_ClinicalTrialResearchMonitoringMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialResearchMonitoringMember_doc" xml:lang="en-US">Clinical Trial Research Monitoring [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MDAndersonCancerCenterClinicalMember" xlink:to="LIXT_MDAndersonCancerCenterClinicalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MDAndersonCancerCenterClinicalMember_doc" xml:lang="en-US">MD Anderson Cancer Center Clinical [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceEightMember_doc" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceNineMember_doc" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTenMember_doc" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceElevenMember_doc" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementCosts" xlink:to="LIXT_WorkOrderAgreementCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WorkOrderAgreementCosts_doc" xml:lang="en-US">Work order agreement costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwelveMember_doc" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThirteenMember_doc" xml:lang="en-US">Exercise PriceThirteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourteenMember" xlink:to="LIXT_ExercisePriceFourteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFourteenMember_doc" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFifteenMember" xlink:to="LIXT_ExercisePriceFifteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFifteenMember_doc" xml:lang="en-US">Exercise Price Fifteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ForeignCurrencyExchangeRateTranslation" xlink:to="LIXT_ForeignCurrencyExchangeRateTranslation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ForeignCurrencyExchangeRateTranslation_doc" xml:lang="en-US">Foreign currency exchange rate translation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WorkOrderAgreementMember_doc" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EstimatedWorkCost" xlink:to="LIXT_EstimatedWorkCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EstimatedWorkCost_doc" xml:lang="en-US">Estimated work cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TheradexSystemsIncMember_doc" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentinServices" xlink:to="LIXT_ExpectedPaymentinServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedPaymentinServices_doc" xml:lang="en-US">Expected payment in services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExpectedPaymentThroughSoftware" xlink:to="LIXT_ExpectedPaymentThroughSoftware_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExpectedPaymentThroughSoftware_doc" xml:lang="en-US">Percentage of expected paymen through software.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LicenseAgreementMember" xlink:to="LIXT_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyaltyPayable" xlink:to="LIXT_RoyaltyPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RoyaltyPayable_doc" xml:lang="en-US">Royalty payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DueEachJanuaryOneMember" xlink:to="LIXT_DueEachJanuaryOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DueEachJanuaryOneMember_doc" xml:lang="en-US">Due Each January 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RoyatiesPercentage" xlink:to="LIXT_RoyatiesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RoyatiesPercentage_doc" xml:lang="en-US">Royaties percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_doc" xml:lang="en-US">Consulting and advisory quarterly cash fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NDAConsultingCorpMember_doc" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BioPharmaWorksLLCMember_doc" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ReimbursementExpense_doc" xml:lang="en-US">Reimbursement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_doc" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NetherlandsCancerInstituteMember_doc" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:to="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_doc" xml:lang="en-US">Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:to="LIXT_AdvanceAmountRelatedToMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment_doc" xml:lang="en-US">Advance amount related to milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MRIGlobalMember_doc" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:to="LIXT_LegalFeesRelatingToPatentsAndLicensing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_LegalFeesRelatingToPatentsAndLicensing_doc" xml:lang="en-US">Legal fees relating to patents and licensing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherConsultingAndProfessionalFees" xlink:to="LIXT_OtherConsultingAndProfessionalFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_OtherConsultingAndProfessionalFees_doc" xml:lang="en-US">Other consulting and professional fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashBasedCompensationToRelatedParties" xlink:to="LIXT_CashBasedCompensationToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CashBasedCompensationToRelatedParties_doc" xml:lang="en-US">Cash based compensation to related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AtTheMarketSalesAgreementMember" xlink:to="LIXT_AtTheMarketSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AtTheMarketSalesAgreementMember_doc" xml:lang="en-US">At The Market Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WallachBethCapitalLLCMember" xlink:to="LIXT_WallachBethCapitalLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WallachBethCapitalLLCMember_doc" xml:lang="en-US">Wallach Beth Capital LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockBasedCompensationToRelatedParties" xlink:to="LIXT_StockBasedCompensationToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockBasedCompensationToRelatedParties_doc" xml:lang="en-US">Stock based compensation to related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalAndRelatedOversightCostsMember" xlink:to="LIXT_ClinicalAndRelatedOversightCostsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalAndRelatedOversightCostsMember_doc" xml:lang="en-US">Clinical And Related Oversight Costs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PreclinicalResearchMember" xlink:to="LIXT_PreclinicalResearchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PreclinicalResearchMember_doc" xml:lang="en-US">Preclinical Research [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RegulatoryServiceCostsMember" xlink:to="LIXT_RegulatoryServiceCostsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RegulatoryServiceCostsMember_doc" xml:lang="en-US">Regulatory Service Costs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentMember" xlink:to="LIXT_ResearchAndDevelopmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchAndDevelopmentMember_doc" xml:lang="en-US">Research And Development [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SecuritiesPurchaseAgreementMember" xlink:to="LIXT_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClassOfWarrantOrRightExercisableTerm" xlink:to="LIXT_ClassOfWarrantOrRightExercisableTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClassOfWarrantOrRightExercisableTerm_doc" xml:lang="en-US">Class of warrant or right exercisable term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PurchasersMember" xlink:to="LIXT_PurchasersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PurchasersMember_doc" xml:lang="en-US">Purchasers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentMember" xlink:to="LIXT_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GeneralAndAdministrativeMember" xlink:to="LIXT_GeneralAndAdministrativeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_GeneralAndAdministrativeMember_doc" xml:lang="en-US">General And Administrative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockOptionsMember" xlink:to="LIXT_CommonStockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockOptionsMember_doc" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_5_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:to="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost_3_lbl" xml:lang="en-US">ShareBasedCompensationIncludedInGeneralAndAdministrativeCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:to="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost_3_lbl" xml:lang="en-US">ShareBasedCompensationIncludedInResearchAndDevelopmentCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xml:lang="en-US">IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:to="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_3_lbl" xml:lang="en-US">Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>lixt-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20241231.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SegmentInformation" xlink:href="lixt-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SegmentInformationTables" xlink:href="lixt-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20241231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesTables" xlink:href="lixt-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:href="lixt-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20241231.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" xlink:href="lixt-20241231.xsd#ScheduleOfInformationBySegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20241231.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20241231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20241231.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:href="lixt-20241231.xsd#ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20241231.xsd#SummaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20241231.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20241231.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="lixt-20241231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="lixt-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:href="lixt-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:href="lixt-20241231.xsd#ScheduleOfContractualClinicalTrialsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:href="lixt-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaapShareBasedCompensationAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_LIXTShareBasedCompensationIncludedInGeneralAndAdministrativeCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:label="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_LIXTShareBasedCompensationIncludedInResearchAndDevelopmentCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="999014 - Disclosure - Organization and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformation" xlink:title="999016 - Disclosure - Segment Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="999018 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="999019 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="loc_LIXTPrepaidInsurancePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTPrepaidInsurancePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_LIXTDeferredOfferingCostsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTDeferredOfferingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WarrantsPolicyTextBlock" xlink:label="loc_LIXTWarrantsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTWarrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999024 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SegmentInformationTables" xlink:title="999025 - Disclosure - Segment Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="999027 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="999028 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesTables" xlink:title="999029 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesTables" xlink:title="999030 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="999031 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SecuritiesPurchaseAgreementMember" xlink:label="loc_LIXTSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PurchasersMember" xlink:label="loc_LIXTPurchasersMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_LIXTPurchasersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity" xlink:label="loc_LIXTNasdaqListingMaintainingMinimumNetStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTNasdaqListingMaintainingMinimumNetStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="999032 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GeneralAndAdministrativeMember" xlink:label="loc_LIXTGeneralAndAdministrativeMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_LIXTGeneralAndAdministrativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTDirectorsAndCorporateOfficersMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_LIXTDirectorsAndCorporateOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantOneMember" xlink:label="loc_LIXTVendorAndConsultantOneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantTwoMember" xlink:label="loc_LIXTVendorAndConsultantTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantMember" xlink:label="loc_LIXTVendorAndConsultantMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_VendorAndConsultantThreeMember" xlink:label="loc_LIXTVendorAndConsultantThreeMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorAndConsultantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ForeignCurrencyExchangeRateTranslation" xlink:label="loc_LIXTForeignCurrencyExchangeRateTranslation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTForeignCurrencyExchangeRateTranslation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfInformationBySegmentDetails" xlink:title="999034 - Disclosure - Schedule of Information by segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalAndRelatedOversightCostsMember" xlink:label="loc_LIXTClinicalAndRelatedOversightCostsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTClinicalAndRelatedOversightCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PreclinicalResearchMember" xlink:label="loc_LIXTPreclinicalResearchMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTPreclinicalResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RegulatoryServiceCostsMember" xlink:label="loc_LIXTRegulatoryServiceCostsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_LIXTRegulatoryServiceCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_ES" xlink:label="loc_countryES" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="loc_countryCN" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NL" xlink:label="loc_countryNL" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ResearchAndDevelopmentMember" xlink:label="loc_LIXTResearchAndDevelopmentMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_LIXTResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaapCorporateMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CashBasedCompensationToRelatedParties" xlink:label="loc_LIXTCashBasedCompensationToRelatedParties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTCashBasedCompensationToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_StockBasedCompensationToRelatedParties" xlink:label="loc_LIXTStockBasedCompensationToRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTStockBasedCompensationToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_LegalFeesRelatingToPatentsAndLicensing" xlink:label="loc_LIXTLegalFeesRelatingToPatentsAndLicensing" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTLegalFeesRelatingToPatentsAndLicensing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_OtherConsultingAndProfessionalFees" xlink:label="loc_LIXTOtherConsultingAndProfessionalFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_LIXTOtherConsultingAndProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapGeneralInsuranceExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="999035 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="999037 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="loc_LIXTUndesignatedPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTUndesignatedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="999038 - Disclosure - Summary of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999039 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SchellensMember" xlink:label="loc_LIXTSchellensMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTSchellensMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_IndependentDirectorMember" xlink:label="loc_LIXTIndependentDirectorMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTIndependentDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NewIndependentDirectorMember" xlink:label="loc_LIXTNewIndependentDirectorMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTNewIndependentDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AppointmentGrantsOfOptionsMember" xlink:label="loc_LIXTAppointmentGrantsOfOptionsMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTAppointmentGrantsOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails" xlink:title="999040 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:title="999041 - Disclosure - Summary of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="999042 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="999043 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="loc_LIXTExercisePriceFourteenMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExercisePriceFifteenMember" xlink:label="loc_LIXTExercisePriceFifteenMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFifteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999044 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DrJamesSMiserMember" xlink:label="loc_LIXTDrJamesSMiserMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrJamesSMiserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRobertNWeingartenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MsReginaBrownMember" xlink:label="loc_LIXTMsReginaBrownMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMsReginaBrownMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBasvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MrvanderBaanMember" xlink:label="loc_LIXTMrvanderBaanMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMrvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SchellensMember" xlink:label="loc_LIXTSchellensMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSchellensMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FiveNonOfficerDirectorsOneMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsOneMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FourNonOfficerDirectorsMember" xlink:label="loc_LIXTFourNonOfficerDirectorsMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FourNonOfficerDirectorMember" xlink:label="loc_LIXTFourNonOfficerDirectorMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourNonOfficerDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="999045 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="999046 - Disclosure - Schedule of Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:label="loc_LIXTEffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_LIXTEffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxesDetailsNarrative" xlink:title="999047 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:label="loc_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails" xlink:title="999048 - Disclosure - Schedule of Contractual Clinical Trials (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialPhase1bMember" xlink:label="loc_LIXTClinicalTrialPhase1bMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialPhase1bTwoMember" xlink:label="loc_LIXTClinicalTrialPhase1bTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhase1bTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialRandomizedPhaseTwoMember" xlink:label="loc_LIXTClinicalTrialRandomizedPhaseTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialRandomizedPhaseTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialPhaseMD1b2Member" xlink:label="loc_LIXTClinicalTrialPhaseMD1b2Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_LIXTClinicalTrialPhaseMD1b2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialDescription" xlink:label="loc_LIXTClinicalTrialDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTClinicalTrialDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ContractualClinicalTrialPeriodStartDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodStartDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ContractualClinicalTrialPeriodEndDate" xlink:label="loc_LIXTContractualClinicalTrialPeriodEndDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTContractualClinicalTrialPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NumberOfPatientInTrial" xlink:label="loc_LIXTNumberOfPatientInTrial" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTNumberOfPatientInTrial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExpectedDateOfPreliminaryEfficacySignal" xlink:label="loc_LIXTExpectedDateOfPreliminaryEfficacySignal" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_LIXTExpectedDateOfPreliminaryEfficacySignal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999049 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialAgreementsMember" xlink:label="loc_LIXTClinicalTrialAgreementsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialMonitoringAgreementsMember" xlink:label="loc_LIXTClinicalTrialMonitoringAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialMonitoringAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="loc_LIXTClinicalTrialResearchAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClinicalTrialResearchMonitoringMember" xlink:label="loc_LIXTClinicalTrialResearchMonitoringMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchMonitoringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_LicenseAgreementMember" xlink:label="loc_LIXTLicenseAgreementMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLicensingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_MDAndersonCancerCenterClinicalMember" xlink:label="loc_LIXTMDAndersonCancerCenterClinicalMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMDAndersonCancerCenterClinicalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DueEachJanuaryOneMember" xlink:label="loc_LIXTDueEachJanuaryOneMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_LIXTDueEachJanuaryOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPartsAndComponentsNetOfReserves" xlink:label="loc_us-gaapInventoryPartsAndComponentsNetOfReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapInventoryPartsAndComponentsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WorkOrderAgreementCosts" xlink:label="loc_LIXTWorkOrderAgreementCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTWorkOrderAgreementCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_EstimatedWorkCost" xlink:label="loc_LIXTEstimatedWorkCost" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTEstimatedWorkCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExpectedPaymentinServices" xlink:label="loc_LIXTExpectedPaymentinServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentinServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ExpectedPaymentThroughSoftware" xlink:label="loc_LIXTExpectedPaymentThroughSoftware" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTExpectedPaymentThroughSoftware" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RoyaltyPayable" xlink:label="loc_LIXTRoyaltyPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTRoyaltyPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationHealthCareCostsGross" xlink:label="loc_us-gaapHealthCareOrganizationHealthCareCostsGross" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapHealthCareOrganizationHealthCareCostsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_RoyatiesPercentage" xlink:label="loc_LIXTRoyatiesPercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTRoyatiesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTReimbursementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="loc_LIXTAdvanceAmountRelatedToMilestonePayment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_LIXTAdvanceAmountRelatedToMilestonePayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEventsDetailsNarrative" xlink:title="999050 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_AtTheMarketSalesAgreementMember" xlink:label="loc_LIXTAtTheMarketSalesAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTAtTheMarketSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_SecuritiesPurchaseAgreementMember" xlink:label="loc_LIXTSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_WallachBethCapitalLLCMember" xlink:label="loc_LIXTWallachBethCapitalLLCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTWallachBethCapitalLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtCounterpartyNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PurchasersMember" xlink:label="loc_LIXTPurchasersMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_LIXTPurchasersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_PlacementAgentMember" xlink:label="loc_LIXTPlacementAgentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_LIXTPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20241231.xsd#LIXT_ClassOfWarrantOrRightExercisableTerm" xlink:label="loc_LIXTClassOfWarrantOrRightExercisableTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_LIXTClassOfWarrantOrRightExercisableTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 14, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001335105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2903526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">680
    East Colorado Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">830-7092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,195,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,684,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Lixte Biotechnology Holdings, Inc. and subsidiary (the &#8220;Company&#8221;)
as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders&#8217; equity and cash flows for
the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023,
and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted
in the United States of America.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Weinberg & Company, P.A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los
Angeles, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember', window );">Warrants to Purchase Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants
    to Purchase Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXTW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,038,952<span></span>
</td>
<td class="nump">$ 4,203,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">20,898<span></span>
</td>
<td class="nump">17,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">85,653<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,145,503<span></span>
</td>
<td class="nump">4,308,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, including $27,500 and $36,250 to related parties at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">83,206<span></span>
</td>
<td class="nump">156,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent', window );">Research and development contract liabilities, including $0 and $120,768 to related parties at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">235,078<span></span>
</td>
<td class="nump">157,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">318,284<span></span>
</td>
<td class="nump">313,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value; authorized &#8211; 10,000,000 shares; issued and outstanding &#8211; 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares &#8211; 72,917 shares at December 31, 2024 and 2023</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 2,249,290 shares at December 31, 2024 and 2023</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">49,394,687<span></span>
</td>
<td class="nump">48,976,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(52,067,693)<span></span>
</td>
<td class="num">(48,481,728)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">827,219<span></span>
</td>
<td class="nump">3,994,762<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,145,503<span></span>
</td>
<td class="nump">$ 4,308,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances on research and development contract services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development contract liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, issuable upon conversion</a></td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Related parties accounts payable and accrued expenses</a></td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="nump">$ 36,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ResearchAndDevelopmentContractLiabilities', window );">Related parties research and development contract liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 120,768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ResearchAndDevelopmentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ResearchAndDevelopmentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">726,232<span></span>
</td>
<td class="nump">898,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="nump">2,846,557<span></span>
</td>
<td class="nump">4,192,136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">3,572,789<span></span>
</td>
<td class="nump">5,090,236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,572,789)<span></span>
</td>
<td class="num">(5,090,236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">7,048<span></span>
</td>
<td class="nump">17,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(16,821)<span></span>
</td>
<td class="num">(16,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency gain (loss)</a></td>
<td class="num">(3,403)<span></span>
</td>
<td class="nump">1,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,585,965)<span></span>
</td>
<td class="num">$ (5,087,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share basic</a></td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (2.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share diluted</a></td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (2.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding basic</a></td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">1,915,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding diluted</a></td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">1,915,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 45,059,760<span></span>
</td>
<td class="num">$ (43,394,699)<span></span>
</td>
<td class="nump">$ 5,165,227<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">1,664,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of securities in registered direct equity offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,137,021<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,137,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from sale of securities in registered direct equity offering, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Exercise of pre-funded common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Exercise of pre-funded common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,281<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">773,203<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 773,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,087,029)<span></span>
</td>
<td class="num">(5,087,029)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">48,976,265<span></span>
</td>
<td class="num">(48,481,728)<span></span>
</td>
<td class="nump">$ 3,994,762<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">418,422<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 418,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,585,965)<span></span>
</td>
<td class="num">(3,585,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 49,394,687<span></span>
</td>
<td class="num">$ (52,067,693)<span></span>
</td>
<td class="nump">$ 827,219<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,585,965)<span></span>
</td>
<td class="num">$ (5,087,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation expense included in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost', window );">General and administrative costs</a></td>
<td class="nump">418,422<span></span>
</td>
<td class="nump">773,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost', window );">Research and development costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Increase (decrease) in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="nump">78,016<span></span>
</td>
<td class="nump">69,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="num">(3,782)<span></span>
</td>
<td class="nump">32,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Other prepaid expenses</a></td>
<td class="num">(75,653)<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(73,552)<span></span>
</td>
<td class="num">(73,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities', window );">Research and development contract liabilities</a></td>
<td class="nump">77,978<span></span>
</td>
<td class="num">(7,922)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,164,536)<span></span>
</td>
<td class="num">(4,293,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of securities in registered direct offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,137,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of pre-funded common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,281<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,143,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract', window );"><strong>Cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease</a></td>
<td class="num">(3,164,536)<span></span>
</td>
<td class="num">(1,149,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at beginning of period</a></td>
<td class="nump">4,203,488<span></span>
</td>
<td class="nump">5,353,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at end of period</a></td>
<td class="nump">1,038,952<span></span>
</td>
<td class="nump">4,203,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">16,821<span></span>
</td>
<td class="nump">16,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in advances on research and development contract services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in research and development contract liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense included in research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expense included in general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,585,965)<span></span>
</td>
<td class="num">$ (5,087,029)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Management and Strategy</b></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zJXUajnDerac">We
have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z2cccSJvoRY3">integrated</span>
these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats,
including any potential unauthorized occurrence on or conducted through our information and email systems that may result in adverse
effects on the confidentiality, integrity, or availability of our information and email systems or any information residing therein.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zb8js64TZvA7">We
conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our
business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include
identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such
risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">-53-</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
these risk assessments, we intend to take any steps necessary to redesign, implement, and maintain reasonable safeguards to minimize
identified risks; to reasonably address any identified gaps in existing safeguards; and to regularly monitor the effectiveness of our
safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with an IT consultant, who reports
to our Chief Executive Officer and Chief Financial Officer, to manage the risk assessment and mitigation process. As part of our overall
risk management system, we monitor and periodically evaluate our safeguards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may engage consultants, or other <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zDtwoLnAn6sl">third parties</span> in connection with our risk assessment processes. These service providers can assist us
to design and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zVBe9V9MMel6">not</span> encountered cybersecurity challenges that have materially impaired our operations or financial condition. Additional
information regarding risks from cybersecurity threats is provided at &#8220;Item 1A. Risk Factors&#8221;.</span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We
have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z2cccSJvoRY3">integrated</span>
these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats,
including any potential unauthorized occurrence on or conducted through our information and email systems that may result in adverse
effects on the confidentiality, integrity, or availability of our information and email systems or any information residing therein.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zNsi1iNNlH3k">One
of the functions of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats.
Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible
for the day-to-day management of the material risks that we face. Our Board of Directors administers its cybersecurity risk oversight
function directly as a whole, as well as through the audit committee.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_z9c24LgH3xW9">Our
Chief Executive Officer and Chief Financial Officer are primarily responsible to assess and manage our material risks from cybersecurity
threats with assistance from third-party service providers.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zDME1MjQBUV">Our
Chief Executive Officer and Chief Financial Officer interact with our IT consultant and oversee our cybersecurity policies and processes,
including those described above at &#8220;Risk Management and Strategy&#8221;. The cybersecurity risk management program includes tools
and activities to prevent, detect, and analyze current and emerging cybersecurity threats, and plans and strategies to address threats
and incidents.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_z1pZM2QgKpL9">Our
Chief Executive Officer and Chief Financial Officer provide periodic briefings to the audit committee regarding the Company&#8217;s cybersecurity
risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of
third parties, and similar issues.</span></span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">One
of the functions of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats.
Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible
for the day-to-day management of the material risks that we face. Our Board of Directors administers its cybersecurity risk oversight
function directly as a whole, as well as through the audit committee.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our
Chief Executive Officer and Chief Financial Officer are primarily responsible to assess and manage our material risks from cybersecurity
threats with assistance from third-party service providers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our
Chief Executive Officer and Chief Financial Officer interact with our IT consultant and oversee our cybersecurity policies and processes,
including those described above at &#8220;Risk Management and Strategy&#8221;. The cybersecurity risk management program includes tools
and activities to prevent, detect, and analyze current and emerging cybersecurity threats, and plans and strategies to address threats
and incidents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our
Chief Executive Officer and Chief Financial Officer provide periodic briefings to the audit committee regarding the Company&#8217;s cybersecurity
risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of
third parties, and similar issues.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z8O7RSmNuSJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82B_z0atKDIVjeI3">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc., a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (collectively,
the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development
and developing and commercializing cancer therapies. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents,
radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase
inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic access to equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 2, 2023, the Company effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztceidAmV8wa" title="Reverse stock split">1-for-10</span> reverse split of
its outstanding shares of common stock. The authorized number of shares of common stock and the par value per share were not affected
by the reverse stock split. No fractional shares were issued in connection with the reverse stock split, with all fractional shares being
rounded up to the next whole share. All share and per share amounts and information presented herein have been retroactively adjusted
to reflect the reverse stock split for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Compliance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on the Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF9lnpadEeQb" title="Reverse stock split">1-for-10</span> reverse split of its outstanding shares of common stock in order to remain in compliance
with the $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zYaEmCqxk1w7" title="Bid price">1.00</span> minimum closing bid price requirement of Nasdaq. However, there can be no assurances that the Company will be able to
remain in compliance with the $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zSfQVo5UkKQd" title="Bid price">1.00</span> minimum closing bid price requirement of Nasdaq over time. In addition, Nasdaq has other continued
listing requirements, one of which is maintaining a minimum net stockholders&#8217; equity of $<span id="xdx_90E_ecustom--NasdaqListingMaintainingMinimumNetStockholdersEquity_iI_c20230602_zdhgrYF8ztb9" title="Minimum net stockholders equity maintaining in nasdaq">2,500,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2024, the Company received a letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock
Market LLC (&#8220;Nasdaq&#8221;) on August 19, 2024 indicating that the Company was not in compliance with the minimum stockholders&#8217;
equity requirement of $<span id="xdx_90D_eus-gaap--StockholdersEquity_iNI_di_c20240819__srt--RangeAxis__srt--MinimumMember_z5EJ6mu2gCf5" title="Stock holders' equity">2,500,000</span> for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &#8220;Stockholders&#8217;
Equity Requirement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders&#8217; Equity Requirement, which
outlined the Company&#8217;s proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2024, the Staff provided notice (the &#8220;Notice&#8221;) to the Company that it had granted an extension through February
18, 2025 to regain compliance with the Stockholders&#8217; Equity Requirement, which required that the Company complete its capital raising
initiatives and evidence compliance with the Stockholders&#8217; Equity Requirement through filing a Current Report on Form 8-K with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) providing certain required information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 18, 2025, the Company had not gained compliance with the Stockholders&#8217; Equity Requirement. Accordingly, on February
19, 2025, the Company received a Staff determination letter from the Staff stating that the Company did not meet the terms of the extension
because it did not complete its proposed financing initiatives to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company timely filed an appeal and requested a Hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;), which has been granted.
The Hearing request automatically stayed Nasdaq&#8217;s delisting of the Company&#8217;s common shares and warrants pending the Panel&#8217;s
decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension through no
later than August 18, 2025. At the upcoming hearing, the Company will present its plan for regaining and sustaining compliance with the
Stockholders&#8217; Equity Requirement for continued listing. However, there can be no assurances that the Hearings Panel will grant
the Company an extension of time to regain compliance, or that the Company will be able to regain compliance during any extension period.
During the appeal process the Company&#8217;s common shares and warrants will continue to trade on The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to take reasonable measures available to regain compliance under Nasdaq&#8217;s listing rules and to remain listed on
Nasdaq. However, there can be no assurances that the Company will ultimately regain compliance with the Stockholders&#8217; Equity Rule,
or be able to maintain compliance with all other applicable requirements for continued listing on Nasdaq. If the Company does not regain
compliance with Nasdaq&#8217;s continued listing requirements within the time period permitted by Nasdaq, then the Company&#8217;s securities
will be delisted from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, the Company recorded a net loss of $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20240101__20241231_zawoyi7IHt16" title="Net loss">3,585,965</span> and used cash in operations of $<span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zzy26qFGPpwd" title="Net cash used in operations">3,164,536</span>. At December
31, 2024, the Company had cash of $<span id="xdx_90A_eus-gaap--Cash_iI_pp0p0_c20241231_zhtTYjk1UZtl" title="Cash">1,038,952</span> available to fund its operations. Subsequently, the Company completed a securities offering
that generated gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember_z3yZNr8Wi3Bk" title="Gross proceeds">1,050,003</span> during February 2025 before deducting the placement agent&#8217;s fees and related offering
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time
and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At March 14, 2025, the Company&#8217;s
remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred
aggregated approximately $<span id="xdx_90A_eus-gaap--ContractualObligation_iI_pp0p0_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_zGsjk7dkI0H7" title="Contractual obligation">526,000</span> (see Note 8), which are currently scheduled to be incurred through approximately December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements also
do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary if the Company is unable
to continue as a going concern. The Company has no recurring source of revenues and has experienced negative operating cash flows since
inception. The Company has financed its working capital requirements through the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the consolidated financial statements are being issued. In addition, our independent registered public
accounting firm has included an explanatory paragraph in their report with respect to this uncertainty that accompanies our audited consolidated
financial statements as of and for the year ended December 31, 2024. The Company&#8217;s consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2024, and the funds raised subsequent
to December 31, 2024, will provide sufficient working capital to fund the current clinical trial program with respect to the development
of the Company&#8217;s lead anti-cancer clinical compound LB-100 through approximately&#160;September 30, 2025. However, existing cash
resources will not be sufficient to complete the development of and obtain regulatory approval for the Company&#8217;s product candidate,
which will require that the Company raise significant additional capital. The Company estimates that it will need to raise additional
capital to fund its operations by mid-2025 to be able to proactively manage its current business plan during the remainder of 2025 and
during 2026. In addition, the Company&#8217;s operating plans may change as a result of many factors that are currently unknown and/or
outside of the control of the Company, and additional funds may be needed sooner than planned. The Company is considering various strategies
and alternatives to obtain the required additional capital. However, as market conditions present uncertainty as to the Company&#8217;s
ability to secure additional funds, there can be no assurance that the Company will be able to secure additional financing on acceptable
terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z3Dj4EoSrzlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_828_zCRrJMw2c0r1">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zcsIdVU2V1Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zEuemcl2zLm9">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zYvjq1FPqv17" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zoX5utclQqPk">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s President and Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) and evaluates
performance and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis.
Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates in a single reportable
segment, which consists of the development of a drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated
financial results of the Company. The CODM uses consolidated net income (loss) as the sole measure of segment profit or loss. The required
segment information, including significant segment expenses, is presented at Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--UseOfEstimates_zmvnkG6QTX85" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zUoSEeUK3TB8">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zG0A1VClo8q1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zOSF5nRCfQi3">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20241231_zuPcV34pXhV8" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_903_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_zZmG3YrZbOKd" title="Cash SIPC insurance">500,000</span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOkDrS9BPgeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zbpnMn2tEvs1">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_ecustom--PrepaidInsurancePolicyTextBlock_z3h6e4ZR1uuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zBPYZfM44O72">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--DeferredOfferingCostsPolicyTextBlock_zmXv6jpx1Dw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z5vbovG3uAmb">Offering
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFKb0Ge7Xzcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zkvflM1oU2r9">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20240101__20241231_z8kzl53Ud9r7" title="Legal and filing fees and costs">243,186</span> and $<span id="xdx_90E_eus-gaap--LegalFees_pp0p0_c20230101__20231231_z5i9qWOZxyQb" title="Legal and filing fees and costs">978,244</span> for the years ended December 31, 2024 and 2023, respectively. Patent and licensing legal and
filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zLGgas8MCWyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zGdRUYxAvfhl">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9cCd0QpT6ze"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zD825rhACgR9">10%</span></span> or more of general and administrative costs or research and development costs for the years ended December 31, 2024 and
2023 are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the years ended December 31, 2024 and 2023 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwUSECDxAlwj" title="Concentration risk percentage">8.6%</span> and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQXrAfWQzf68" title="Concentration risk percentage">23.3%</span> of total general
and administrative costs, respectively. General and administrative costs for the year ended December 31, 2024 also include charges from
two vendors and consultants representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRJHqxTpIgMk" title="Concentration of risk, percentage">15.0%</span> and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyddusgTwf8k" title="Concentration of risk, percentage">13.1%</span>, respectively, of total general and administrative costs. General and administrative
costs for the year ended December 31, 2023 also include charges from a vendor and consultant representing <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z30MQm4Fjg0k" title="Concentration of risk, percentage">10.4%</span> of total general and
administrative costs. General and administrative costs for the years ended December 31, 2024 and 2023 also included charges for the fair
value of stock options granted to directors and corporate officers representing <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_z9paTxDZXXX1" title="Concentration risk percentage">14.7%</span> and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_zbM2PsTnRHK2" title="Concentration risk percentage">18.4%</span>, respectively, of total general and administrative
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the year ended December 31, 2024 include charges from three vendors and consultants representing <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zHjn8TgPM1eh" title="Concentration of risk, percentage">39.2%</span>, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zoCCNC5i5Ujg" title="Concentration of risk, percentage">29.0%</span>
and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVdSOUKz5uX2" title="Concentration of risk, percentage">15.4%</span>, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2023
include charges from three vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNvRjDIHroyd" title="Concentration of risk, percentage">29.9%</span>, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zKJgDKbflNyh" title="Concentration of risk, percentage">25.2%</span> and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5iMhCrmN43g" title="Concentration of risk, percentage">13.7%</span>, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_z4Stpixsnnd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_z8gALVTKeQ5h">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#8217;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at December 31, 2024 and 2023. In the event the Company was to determine that it would be able
to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be
credited to operations in the period such determination was made. Should the Company determine that it would not be able to realize all
or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period
such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2024 or 2023
and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.
Subsequent to December 31, 2024, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJ2AhX4EeRW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_znLUEeLScyNc">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#8217;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zArJkAjk1hQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zh6QqgtvV183">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of the Company&#8217;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance
sheet date. At December 31, 2024 and 2023, the Company did not have any liability-classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zbaux3PEnad8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zonN5FB7w03a">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkOy0A0pBYfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024 and 2023, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zHPj4DF7oZe6" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z4VI50AUQvL9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zNebEdGefqK9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zSbnaTJ2wWQe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z3WBLs00WJ0a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zmgHoDjTCpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">613,232</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">552,083</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zywad6fWeD06" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,494,514</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,433,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z3OYOmZ6i7Sh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzjL7LzueeNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z6jwXI0Q6Frk">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of <span id="xdx_906_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20241231_zqKinyWzaDg6" title="Foreign currency average rate">1.0823</span> and <span id="xdx_905_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20230101__20231231_z5eezjnOYcmf" title="Foreign currency average rate">1.0820</span> Euros per United States dollar, respectively. As of December 31,
2024 and 2023, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was not a party
to any foreign currency forward or exchange contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzbdSNTg8JPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zr6DQNoj1sf6">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments, which consists of accounts payable and accrued expenses is considered to be representative of
their respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWV5z0CNHuEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zoYAQW06qCIj">Recent
Accounting Pronouncements</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-03,
Presentation of Financial Statements (Topic 205), Income Statement &#8212; Reporting Comprehensive Income (Topic 220), Distinguishing
Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#8212; Stock Compensation (Topic 718) (&#8220;ASU 2023-03&#8221;).
ASU 2023-03 amends the FASB Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting
Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting
Series Release 280 &#8212; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide
any new guidance, there was no transition or effective date associated with its adoption. The Company adopted ASU 2023-03 immediately
upon its issuance in July 2023. The adoption of ASU 2023-03 did not have any impact on the Company&#8217;s consolidated financial statement
presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure.&#160; ASU 2023-07
amends the FASB Accounting Standards Codification to require additional reportable segment disclosures of a public entity by requiring
disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, requiring other new disclosures,
and requiring enhanced interim disclosures.&#160; ASU 2023-07 requires public entities with a single reportable segment to provide all
the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280 on an interim and annual basis.&#160; ASU 2023-07
is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, and is applied
retrospectively.&#160;The Company adopted ASU 2023-07 effective January 1, 2024 for the 2024 annual period on a retrospective basis.&#160;The
adoption of ASU 2023-07 resulted in additional required segment-related disclosures (see Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures
(Subtopic 220-40). ASU 2024-03 amends the FASB Accounting Standards Codification to require specified information about certain costs
and expenses in the notes to the financial statements at each interim and annual reporting period, including disclosure of the amounts
of purchases of inventory; employee compensation; depreciation; intangible asset amortization; and depreciation, depletion, and amortization
included in each relevant expense caption on the face of the income statement within continuing operations that contains any of the expense
categories previously listed. Disclosure will also be required of the total amount of selling expenses and an entity&#8217;s definition
of selling expenses in annual reporting periods. ASU 2024-03 does not change or remove current expense disclosure requirements, but does
affect where and how this information is presented in the notes to the financial statements. ASU 2024-03 is effective for annual reporting
periods beginning January 1, 2027, and interim periods within annual reporting periods beginning January 1, 2028. Early adoption is permitted.
The Company is in the process of evaluating ASU 2024-03 to determine its impact on the Company&#8217;s consolidated financial statement
presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5bzgaVIIWQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zu3j216Ka7K9">Reclassifications</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the adoption of ASU 2023-07 effective January 1, 2024, certain reclassifications have been made to the prior year statement
of operations to conform it to the current year presentation. In presenting general and administrative costs on the Company&#8217;s consolidated
statement of operations for the year ended December 31, 2023, $<span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zeb3o5LTx6ah" title="Legal and filing fees and costs">1,718,180</span> of compensation to related parties, $<span id="xdx_902_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zPz4cLHRxZo1" title="Legal and filing fees and costs">978,244</span> of patent and licensing
legal and filing fees and costs, and $<span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSvkEDE7wNU9" title="Legal and filing fees and costs">1,495,712</span> of other costs and expenses were shown separately. In presenting the Company&#8217;s
consolidated statement of operations for the year ended December 31, 2024, the Company has combined these categories into general and
administrative costs in the accompanying consolidated statement of operations for the year ended December 31, 2023. These reclassifications
had no effect on the reported results of operations, including loss from operations and net loss.</span></p>
<p id="xdx_858_zyhV3J125Fw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zkaepRb4dZIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_825_zU5STFEyee65">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Company&#8217;s President and Chief Executive Officer
(&#8220;CEO&#8221;).&#160; The Company&#8217;s CODM evaluates performance and makes operating decisions about allocating resources based on financial
data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined
that it has a single operating segment composed of the consolidated financial results of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zP5EFrePXqoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM and included in general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPIJcxJyNOLl">Schedule
of Information by segment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zETcYSt7bFzi" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_z8UO2HUZbS84" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Compensation to related parties:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CashBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_zCLm9UfEApc" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; text-indent: 13.5pt">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">753,124</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">944,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_z46vrHQtW378" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 13.5pt">Stock-based</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">418,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">773,203</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maOEzto3_maGAAEzrRU_zbZOsPQhxxmd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Patent and licensing legal and filing fees and costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">978,244</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherConsultingAndProfessionalFees_i02_maOEzto3_maGAAEzrRU_zJT7l41PW0Q1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other consulting and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">735,021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">655,854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_zq1M5KBNuWJh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">442,976</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherCostAndExpenseOperating_i02_maOEzto3_maGAAEzrRU_zjykiRH4hWb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other costs and expenses, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">262,360</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">396,882</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02_mtGAAEzrRU_zzKr2726wAD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total general and administrative costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,846,557</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,192,136</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM, and included in research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zULItvwWvFu6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zDe9RiimY82h" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zXVQc8HCrOXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Clinical and related oversight costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">377,958</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">416,269</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zT0k6nIKot1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preclinical research focused on development of additional novel anti-cancer compounds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329,438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463,093</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_zmyzxwrGY0c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Regulatory service costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,836</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,738</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zlssANikio66" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total research and development costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">726,232</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">898,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of research and development costs for the years ended December 31, 2024 and 2023 based on the respective
geographical regions where such costs were incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zgS3gpVgf6ac" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zQuUutuOvKPh" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zhI62rfIJFwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">462,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">359,589</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zi2qV338Hpf9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,163</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zO57OxTVorqb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,198</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zBd5NB5odKhd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Netherlands</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">210,362</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">226,150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_z4TX9qz5HvAh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">726,232</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">898,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s total assets by segment at December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zgNLEZyDoDz1" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20231231_zAtd3ap42RPc" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zKvNy7KVPQK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Research and development assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">39,298</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">78,369</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zXnyYYYbrMg9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Corporate assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,106,205</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,230,251</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_iI_zIs5kCZrKhMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,145,503</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,308,620</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_znCrEZGWeial" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zTRFqv7VKJWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82E_z46kftVfLe16">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zt9egMKEwHuf" title="Preferred stock, shares authorized">10,000,000</span> shares of preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_z03YNqldrtk6" title="Preferred stock, par value">0.0001</span> per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total of <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zW0XETcgPNP4" title="Preferred stock, shares authorized">350,000</span> shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The
holders of each tranche of <span id="xdx_903_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zvAAN9XOS7Kd" title="Principal cash obligations and commitments">175,000</span> shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20150316__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYUIr7kuHtga" title="Preferred stock dividend, percentage">1</span>% of the annual net revenue of the Company divided by <span id="xdx_90B_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3UNnUqr0kpc" title="Annual net revenue">175,000</span>, until converted or redeemed. As of December 31, 2024 and 2023, the
Company had <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zFQDS2gcNL9a" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zHAlDEbStNb2" title="Preferred stock, shares authorized">9,650,000</span></span> shares of undesignated preferred stock, which may be issued with such rights and powers as the Board of Directors
may designate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PreferredStockConversionBasis_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJAcJwmQyHrb" title="Preferred stock, conversion description">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2EKqeiLVeIl" title="Preferred stock convertible into common stock">0.20833</span> shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zmvtyj5pRgvd" title="Gross proceeds from sale of transaction">21,875,000</span>.</span> The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have any cash liquidation preference rights or any registration rights. The <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zD0Ks7ts2Or2" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zohvtACnVNij" title="Preferred stock, shares outstanding">350,000</span></span> outstanding shares of Series A Convertible
Preferred Stock were convertible into a total of <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z2ODX8a4jrmj" title="Preferred stock convertible into common stock"><span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5qWdPOnMqi1" title="Preferred stock convertible into common stock">72,917</span></span> shares of common stock at December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_z0SfTXUb0D76" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z3wqLIwKIVpk" title="Common stock, shares authorized">100,000,000</span></span> shares of common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zz3FLLUJ7Kf" title="Common stock, par value"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zmERsWlDAFP5" title="Common stock, par value">0.0001</span></span> per share. As of December 31, 2024 and
2023, the Company had <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zCGsbj7NBPV7" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zuKbOVAYKe17" title="Common stock, shares outstanding"><span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zQktoFsLzCsc" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zgn7d56TjOX5" title="Common stock, shares outstanding">2,249,290</span></span></span></span> shares of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRDCcoGwncCh" title="Reverse stock split">1-for-10</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse
split of its outstanding shares of common stock. The authorized number of shares of common stock and the par value per share were
not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split, with all
fractional shares being rounded up to the next whole share. All share and per share amounts and information presented herein have
been retroactively adjusted to reflect the reverse stock split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 10, 2023, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkhwuyPbYqi" title="Stock issued new issue shares">1,250</span> shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpTexyi45nZf" title="Stock issued new issue shares">1,250</span> shares exercisable at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9tBU7eNrWI6" title="Warrant exercise price">5.025</span> per share for total cash proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBLbiKUrHHPb" title="Proceeds from warrant exercises">6,281</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 20, 2023, the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH3jFAxKmBS2" title="Number of common stock shares issued during period">180,000</span> shares of common stock at a price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5fwlwYHLffd" title="Sale of stock price per share">6.00</span> per share and pre-funded warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWNhmqskRhT2" title="Warrants to purchase shares">403,334</span>
shares of common stock at a price of $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmbWyUkapLKa" title="Common Stock, Par or Stated Value Per Share">5.9999</span> per pre-funded warrant to an institutional investor in a registered direct offering. The
pre-funded warrants had an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z237LfrOg3Ji" title="Warrant exercise price">0.0001</span> per share, were immediately exercisable upon issuance, and were valid and exercisable
until all pre-funded warrants were exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from July 24, 2023 through August 7, 2023, the <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6WAhVcMlkL8" title="Warrants to purchase shares">403,334</span> pre-funded warrants, exercisable at $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkyko0IIWk53" title="Common stock, par value">0.0001</span> per common share, were
exercised for total cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXwf5tWjImw3" title="Exercise of common stock options">41</span>, resulting in the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqD0OkpYR6u3" title="Issuance of common stock">403,334</span> shares of common stock. The pre-funded warrants were determined
to be common stock equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement to the institutional investor, the Company also sold warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zAYsELifG5R3" title="Warrants to purchase shares">583,334</span> shares of common stock.
Each common warrant had an initial exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z8S4pRkbHWn8" title="Warrant exercise price">6.00</span> per share, was immediately exercisable upon issuance, and expires <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmhg1yYQWJP3" title="Warrants term">five years</span>
thereafter on <span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsHaPvGtWCOg" title="Warrant expires date">July 20, 2028</span>. The common warrants and the shares of common stock issuable upon exercise of the common warrants were not
registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon
exercise of the warrants were registered for resale on a registration statement on Form S-3 declared effective by the SEC on May 2, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registered direct offering and the concurrent private placement generated gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zI0I8arUkIAb" title="Proceeds from issuance initial public offering">3,499,964</span>. The total cash costs of the registered
direct offering and the private placement were $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDnN1ImGPIZd" title="Costs of public offering">362,925</span>, resulting in net proceeds of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNLHdqAgpA0g" title="Net proceeds from issuance of stock">3,137,039</span>. Pursuant to the placement agent agreement,
the Company granted the placement agent warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zG8Ie7H25qfg" title="Warrants to purchase shares">35,000</span> shares of common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zQa5gEyPWks6" title="Warrant exercise price">6.60</span> per share and
expiring on <span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zAaUw4R95965" title="Warrant expires date">July 20, 2028</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of the warrants issued to the institutional investor (exercisable at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230807__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z9YpXokFexdf" title="Warrant exercise price">6.00</span> per share) and to the placement agent (exercisable
at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230807__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVJLwNN69Udi" title="Warrant exercise price">6.60</span> per share) are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications, reorganizations,
or similar events affecting the Company&#8217;s common stock. In addition, the warrants issued to the institutional investor contain
a &#8220;fundamental transaction&#8221; provision which provides that if any defined fundamental transactions are within the Company&#8217;s
control and are consummated, the holder of the unexercised common stock warrants would be entitled to receive, at its option, in exchange
for extinguishment of such warrants, cash consideration equal to a Black-Scholes valuation amount, as defined in the warrant agreement.
The fundamental transaction provision includes (i) a sale, lease, assignment, transfer, conveyance or other disposition of all or substantially
all of the assets of the Company in one or a series of related transactions, or (ii) a change in control of the Company by which it,
directly or indirectly, in one or more related transactions, consummates a stock or share purchase agreement or other business combination
with another person or group, whereby such other person or group acquires more than 50% of the voting power of the common equity of the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
such fundamental transaction is not within the Company&#8217;s control, including not being approved by the Company&#8217;s Board of
Directors, the warrant holder would only be entitled to receive the same type or form of consideration (and in the same proportion) equal
to the Black-Scholes valuation amount of the remaining unexercised portion of the warrant on the date of consummation of such fundamental
transaction as the holders of the Company&#8217;s common stock receive. Accordingly, these warrants are classified as a component of
permanent stockholders&#8217; equity. The Company will account for any cash payment for a warrant redemption as a distribution from stockholders&#8217;
equity, as and when a fundamental transaction is consummated and such cash payment is required to be made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhcIZXlq9Czh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s
public offering, during the years ended December 31, 2024 and 2023 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zA0LzxTe39m8" style="display: none">Schedule
of Warrants Outstanding</span>&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Warrants outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvHUu21qIy06" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">190,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcSRgPR6Frqf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">50.161</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEZAjyDTOxd1" style="text-align: right" title="Number of Shares, Issued">618,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxMIT1R6kws8" style="text-align: right" title="Weighted Average Exercise Price, Issued">6.034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqUPaLqudB04" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3w2UWFqXbO9" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHUVxVlSkml9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWqXzT6yUnuh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhtKS7HDS22" style="text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOBaUP6LtZg" style="text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">16.407</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHRl5Z2KGZP7" style="text-align: right" title="Number of Shares, Issued"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdBlxcAjvoWb" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="-sec-ix-hidden: xdx2ixbrl0715">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOztlHckLpi8" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpnGHNQtUagf" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0719">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqGSfEZcfqFb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYX1oEXjnIh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0723">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXeuv9vUD975" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPW2Yq38twX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXLrtH3fCSbe" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">2.99</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGs6rbVFADM5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zB8XJIi0ChUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjX90tWAUER5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAxpK8s0Bnv2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwQvuPayTsh" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">2.99</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zuJwvDR6Wpk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zJW3jkC8sjVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zlNz7iDJy66f" style="display: none">Schedule of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants <br/> Outstanding (Shares)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 2%; text-align: left">$</td><td style="width: 46%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BLW3JZyeU6" title="Exercise Prices">6.000</span></td><td style="width: 2%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAv0MNL8T0Va" style="width: 45%; text-align: right" title="Warrants Outstanding Shares">583,334</td><td style="width: 2%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxcR0ejaDVdh" title="Exercise Prices">6.600</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7JUSpnp3An2" style="text-align: right" title="Warrants Outstanding Shares">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOveWcXkvlOc" title="Exercise Prices">20.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zJfWm6ToHzy6" style="text-align: right" title="Warrants Outstanding Shares">29,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zZYsk5xZFzP" title="Exercise Prices">37.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvZQLxqzHFYb" style="text-align: right" title="Warrants Outstanding Shares">11,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zDjqAiGL4Xsg" title="Exercise Prices">57.000</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zg9Z0wMJ1m7g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding Shares">149,700</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231_zCEMOz6bI6Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zh1iXQquaTbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants exercisable at $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrf3uLcQTI52" title="Warrants exercisable">57.00</span> per share at December 31, 2024 consist of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyYYovZIwzWf" title="Warrants outstanding">1,497,000</span> publicly-traded warrants, described herein on a pre-split
<span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF2HT8ouHQFj" title="Reverse stock split">1-for-10</span> basis, that were issued as part of the Company&#8217;s November 2020 public offering of units, and are exercisable for a period
of five years thereafter. As a result of the 1-for-10 reverse split of the Company&#8217;s common stock effective June 2, 2023, each
such publicly-traded warrant currently now represents the right to purchase 1/10th of a share of common stock at the original exercise
price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfw68oB2krba" title="Exercise price">5.70</span> per share. Accordingly, the exercise of 10 warrants, each exercisable at $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4GkiwIoNwzf" title="Warrants exercisable">5.70</span>, are required to acquire one share of post-split
common stock, which is equivalent to a purchase price of $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyJ17QWMjMJ8" title="Warrants and rights outstanding">57.00</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the closing fair market value of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEMybhi9NBei" title="Fair market value of stock">2.03</span> per share on December 31, 2024, there was no intrinsic value attributed to exercisable but
unexercised common stock warrants at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFqZGgdkYFwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82E_zQhu5H8QRTr7">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. Except as noted below, these employment
agreements were automatically renewed for additional one-year periods in July and August 2021, 2022, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_903_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zW9TkZvKIlTc" title="Annual salary">250,000</span>.
The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023. During the year ended December 31, 2023, the Company
paid $<span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ziKxBrQLEGEg" title="Compensation">190,860</span> to Dr. Kovach under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s
consolidated statement of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020, to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember_zQn1R3EceS9e" title="Annual salary">150,000</span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zb47GQ3wa3Mb" title="Increase in annual salary">175,000</span>.
Dr. Miser was required to devote at least 50% of his business time to the Company&#8217;s activities. On May 29, 2024, the Company elected
not to renew its employment agreement with Dr. Miser, as a result of which such employment agreement expired on July 31, 2024. During
the years ended December 31, 2024 and 2023, the Company paid $<span id="xdx_900_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zhbwHRsbKls2" title="Compensation">102,083</span> and $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z9UDO1Trlt4g" title="Compensation">175,000</span>, respectively, to Dr. Miser under this employment
agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations
for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zrXKmKSzmK8a" title="Annual salary">120,000</span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_901_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zaXTh3eb5yMg" title="Increase in annual salary">175,000</span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_902_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zFsiOp3dbLX3" title="Compensation">200,000</span>. Effective October 1, 2022, Mr. Forman was provided a monthly office rent allowance,
pursuant to which the Company paid $<span id="xdx_90B_eus-gaap--PaymentsForRent_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zpX57SQlVGZk" title="Paid office rent">16,435</span> and $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zF30Nql6zjN6" title="Paid office rent">15,571</span> for the years ended December 31, 2024 and 2023, respectively, on Mr. Forman&#8217;s
behalf. The employment agreement with Mr. Forman terminated upon his resignation as an officer of the Company effective December 31,
2024. During the years ended December 31, 2024 and 2023, the Company paid $<span id="xdx_903_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAFmPNuuaDp2" title="Compensation">200,000</span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z13pky0hmBs4" title="Compensation">200,000</span>, respectively, to Mr. Forman under this
employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of
operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_905_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zWhgFA4Tr6G6" title="Annual salary">120,000</span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_90A_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_z8H0NhtRJfth" title="Increase in annual salary">175,000</span>. During the years ended December 31, 2024 and 2023, the Company paid $<span id="xdx_90D_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWa0gxkPCAAd" title="Compensation">175,000</span> and $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqGD2IbxApRd" title="Compensation">175,000</span>, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company&#8217;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $<span id="xdx_904_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z4Oae3txdtd8" title="Annual salary">150,000</span>. Effective October 6, 2023,
Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023. Mr. van der Baan&#8217;s
annual salary may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan is eligible
to receive an annual bonus as determined at the sole discretion of the Board of Directors. The term of the employment agreement is for
three years and is automatically renewable for additional one-year periods unless terminated by either party, subject to early termination
provisions as described in the employment agreement. During the years ended December 31, 2024 and 2023, the Company paid $<span id="xdx_904_eus-gaap--OfficersCompensation_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0V0iOHZR8s8" title="Compensation">153,495</span> and
$<span id="xdx_903_eus-gaap--OfficersCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zOq4r0L3xQwl" title="Compensation">40,639</span>, respectively, to Mr. van der Baan under this employment agreement, which costs are included in general and administrative costs
in the Company&#8217;s consolidated statement of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, the Company entered into a consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D. Pursuant to the agreement, effective
July 1, 2024, the Company engaged Dr. Schellens as a consultant, and, effective August 1, 2024, as the Company&#8217;s Chief Medical
Officer. The term of the agreement is in effect from July 1, 2024 until the earliest of (i) termination by either party upon sixty days&#8217;
notice, (ii) Dr. Schellens&#8217; death or disability, or (iii) termination by the Company for breach as provided in the agreement. Under
the agreement, Dr. Schellens provides his services for two days per week with the specific days in each week based on arrangements agreed
to from time to time between Dr. Schellens and the Company&#8217;s Chief Executive Officer. The Company pays Dr. Schellens an annual
compensation of <span id="xdx_90B_eus-gaap--ShareBasedCompensation_uEUR_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zaBAXretHULa" title="Annual compensation">104,000</span> Euros (approximately $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zHlqimYpTB59" title="Annual compensation">108,000</span> as of December 31, 2024), payable on a monthly basis. During the year ended December
31, 2024, the Company paid $<span id="xdx_908_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zuto7JslNzs" title="Compensation">56,226</span> to Dr. Schellens under this consulting agreement, which costs are included in general and administrative
costs in the Company&#8217;s consolidated statement of operations for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. Upon
his appointment, it was agreed that Dr. Bernards would receive annual compensation for his services on the Board only in the form of
cash, in lieu of the annual June 30 grant of stock options as provided to the Company&#8217;s other non-officer directors. During the
years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement
of operations of $<span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_zWHf65OHqPsc" title="General administrative expense">10,000</span> and $<span id="xdx_909_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zL73ks6RIMkb" title="General administrative expense">40,000</span>, respectively, with respect to his annual cash board compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the Company&#8217;s efforts to preserve cash, effective with the quarter ended June 30, 2024, Dr. Bernards agreed to
receive equity-based compensation for his services on the Board, for the quarters ended June 30, 2024, September 30, 2024 and December
31, 2024. In order to reconcile his Board compensation with that of the other non-officer directors, Dr. Bernards has agreed to receive
the same Board compensation, both in form and amount, as the other non-officer directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for
their services on the Board of Directors (the &#8220;Board Plan&#8221;), which was subsequently amended effective May 25, 2022 and July
9, 2024. Officers who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_901_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zualF1oz72h4" title="Compensation">20,000</span> per year (except for Dr. Bernards, who was paid an additional annual cash fee of $<span id="xdx_90C_eus-gaap--Cash_iI_c20210409_zBw7KjuliqO7" title="Cash">40,000</span>, in lieu of
the annual June <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_znivQYyz6Fkc" title="Stock option grant">30</span> grant of stock option as described below, through March 31, 2024)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee &#8211; additional $<span id="xdx_903_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_z58VxW5ZvtVl" title="Compensation">10,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees &#8211; additional $<span id="xdx_904_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zT083QGWGz6d" title="Compensation">5,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee &#8211; additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zbHC4xLPQtb1" title="Compensation">5,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees &#8211; additional $<span id="xdx_907_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_z9KzKYYgZmyg" title="Compensation">2,500</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the Company&#8217;s efforts to preserve cash, the Board approved an amendment to the Board Plan, such that for the quarters
ended June 30, 2024, September 30, 2024 and December 31, 2024, the non-officer directors (including Dr. Bernards) received, in lieu of
cash compensation, stock options exercisable for a period of five years, vesting immediately, to purchase common stock at an exercise
price based on the closing market price upon issuance, with the amount of such stock options equal to the cash payment such director
would otherwise have been entitled to receive for such quarter, divided by their quarterly value as determined pursuant to the Black-Scholes
option-pricing model. The Board may extend this amendment to the Board Plan for additional quarterly periods subsequent to December 31,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new directors &#8211; The Company grants options to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zZjbuZOTbD8" title="Options, grants in period, gross">25,000</span> shares of common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zCDT3JB8W5wb" title="Options exercisable period">five years</span>,
at the closing market price on the date of grant, vesting 50% on the grant date and the remaining <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_z3fzU7LrDJXi" title="Share-based payment award, award vesting period">50</span>% vesting <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20240101__20241231_zt4jYsjxTIi7" title="Award vesting rights, percentage">12.5</span>% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $<span id="xdx_90C_eus-gaap--ManagementFeePayable_iI_c20241231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_z2FvsVsl72b1" title="Cash fee payable">100,000</span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to directors &#8211; Effective on the last business day of the month of June, the Company grants options to purchase
<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zCqqL8u4SMV7" title="Options, grants in period, gross">10,000</span> shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_znEBEdBWU0u1" title="Share-based payment award, award vesting period">12.5</span>%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_907_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_za6dyUtxOLUl" title="Annual cash fee">40,000</span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to non-officer directors was $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zKYwGrzOEVCh" title="Stock based compensation">38,819</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_z783IsZNd8Mf" title="Stock based compensation">163,479</span>, respectively, for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zCkUAaQ2qT4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2024 and 2023, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_z0855uu1EIeb" style="display: none">Summary
of Related Party Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zqFSlMulDgNa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20230101__20231231_zV6VaY1AgAHb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zawWesLCRlSe" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">753,124</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">944,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zl3IsGzqtrfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Stock-based</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">418,422</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">773,203</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zcTgqVL3cSRg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,171,546</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,718,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zBGjUe6mo7u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zAS0EvzUnC36" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_821_z5QSJ2YgHftl">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_z5GuizCV97Fi" title="Number of restricted stock issued">233,333</span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zTSz8EKwHV1c" title="Common shares avaliable for issuable">180,000</span> shares, to a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zE4A1Cd4OWN8" title="Shares total">413,333</span> shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zbEgVAQBJBbd" title="Common shares avaliable for issuable">336,667</span> shares, to a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231126__20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zmDhV4NvBWMg" title="Shares total">750,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, unexpired stock options for <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zKgsl5FF78e7" title="Shares outstanding">613,232</span> shares were issued and outstanding under the 2020 Plan and <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zDvSZPRmRuh9" title="Shares were available for issuance">136,768</span> shares were
available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zavaGoiujWQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2024, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zNrDkvVspYj8" style="display: none">Schedule
of Fair Value of Each Option Award Estimated Assumption</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zClvD3qZD5I6" title="Risk-free interest rate">3.550</span>%
    to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zUtnvCVi5V68" title="Risk-free interest rate">4.290</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20241231_zpklP1HcI7Y8" title="Expected dividend yield">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zD3o1Bin2H01" title="Expected volatility">125.59</span>%
    to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zWMs3o2xMUVa" title="Expected volatility">126.45</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zaKQpP0zrOp5" title="Expected life">2.5</span>
    to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zMg6pH8a5QH" title="Expected life">3.5</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zEV5Y5uG5HB8" title="Risk-free interest rate">4.565</span>%
    to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z08wtOj4FW7f" title="Risk-free interest rate">4.843</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_z9iTTxDtBjG1" title="Expected dividend yield">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zlA1ii6t9nk3" title="Expected volatility">138.05</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zsz1Kn08Z9bl" title="Expected life">4.0</span>
    years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p id="xdx_8A0_zPslbr6NUISf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement with Eric J. Forman, Mr. Forman was granted
stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zMyTuv7VS1Y1" title="Stock options granted to purchase common stock, issued">5,833</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4G2aMjjXozc" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4pV6DzAFmV8" title="Stock options are exercisable price per share">71.40</span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zgTKt8iooZE9" title="Stock option vested exercisable term">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zkuoPl0FLrZ" title="Fair value of stock options">400,855</span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVcsG7G5wyy1" title="Stock price per share">68.718</span> per share), of which $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zqdb3DKObyTj" title="Stock options fully vested amount, fair value">100,214</span> was attributable to the portion of the stock options fully vested
on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock
options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded a charge to general and
administrative costs in the consolidated statement of operations for the year ended December 31, 2023 of $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbAo5RYKuya1" title="Stock based compensation">61,501</span> with respect to these
stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2020, in connection with an employment agreement with Dr. James S. Miser, M.D., Dr. Miser was granted stock options to purchase
<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zACfU2SfE6Wc" title="Stock options granted to purchase common stock, issued">8,333</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable for a
period of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRJ9nhBgNAte" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z70Ro5BHCZ15" title="Stock options are exercisable price per share">71.40</span> per share, which was equal to the closing market price of the Company&#8217;s common
stock on the effective date of the employment agreement. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zm28jaOS3r2" title="Stock options description">The options vested 25% on August 1, 2020, 2021 and 2022, respectively, with
the final 25% vesting on August 1, 2023.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zmK0KxNHtiHj" title="Fair value of stock options">572,650</span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zotTW5RlPWy8" title="Stock price per share">68.718</span> per share), of which $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKieuDW6iOC" title="Stock options fully vested amount, fair value">143,163</span> was attributable to the portion of the stock options fully
vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company recorded a charge to general
and administrative costs in the consolidated statement of operations for the year ended December 31, 2023 of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zvPSOWfDCLhc" title="Stock based compensation">83,544</span> with respect to
these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, in connection with the employment agreement with Robert N. Weingarten, Mr. Weingarten was granted stock options to purchase
<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVsW0NWHhm51" title="Number of fully vested option exercisable">5,833</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable for a
period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zvISUkkFWlC3" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zCiUPBIwy8sc" title="Stock options are exercisable price per share">71.40</span> per share, which was equal to the closing market price of the Company&#8217;s common
stock on the grant date. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z8m4schk1qAc" title="Stock options description">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August
12, 2023.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to
be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0Pzdq0hflf1" title="Fair value of stock options">400,855</span> ($<span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrRIMcEAWTe1" title="Stock price per share">68.718</span> per share), of which $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zE7V0Ey14iub" title="Stock options fully vested amount, fair value">100,214</span> was attributable to the portion of the stock options fully vested on August 12, 2020
and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged
to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded a charge to general and administrative costs
in the consolidated statement of operations for the year ended December 31, 2023 of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0ug49ODV8jc" title="Stock based compensation">61,501</span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zzh6JhtbRQK3" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z1xkGjQa3fv9" title="Stock option vested exercisable term">five years</span>
at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zeogJ2T3kR1e" title="Stock options are exercisable price per share">28.00</span> per share (the closing market price on the grant date), <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_za37kSpZdctd" title="Stock options description">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.</span> The fair value of these stock options, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_ztzMK6qv9hjl" title="Fair value of stock options">658,363</span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z9fgbPAnBtm4" title="Stock price per share">26.335</span> per share), of which $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zM1RVyhmbw31" title="Stock options fully vested amount, fair value">329,188</span> was attributable
to the portion of the stock options fully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining
unvested portion of the fair value of the stock options was charged to operations ratably from May 11, 2021 through June 30, 2023. The
Company recorded a charge to general and administrative costs in the consolidated statement of operations for the year ended December
31, 2023 of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zrvzJ6LDjU1l" title="Stock based compensation">76,388</span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zwOHHv1bIhF5" title="Number of fully vested option exercisable">10,000</span> shares (a total
of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zMlcx5RYY0S6" title="Number of fully vested option exercisable">50,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zfygF6b8UFc2" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zMSYmHmSxYQb" title="Stock options are exercisable price per share">30.30</span> per share
(the closing market price on the grant date), <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zxhvTON12Tne" title="Stock options description">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.</span>
The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zin5rP0MyYVb" title="Fair value of stock options">1,421,095</span>
($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zMsdvsDDo0z1" title="Stock price per share">28.423</span> per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded a charge to
general and administrative costs in the consolidated statement of operations for the year ended December 31, 2023 of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z8jzQPKUfMUg" title="Stock based compensation">211,413</span> with respect
to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. van der Baan was granted stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zIE3nq5lOfMc" title="Number of fully vested option exercisable">25,000</span> shares of the Company&#8217;s common stock, exercisable for a period of
<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z7hpvadKEowh" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zsAaB0CFkOx2" title="Stock options are exercisable price per share">7.40</span> per share (the closing market price on the grant date), <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zRZQNRPemM1l" title="Stock options description">vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</span> The
fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zJiFnELwH7y4" title="Fair value of stock options">158,525</span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z1nn1O4rlXfj" title="Stock price per share">6.341</span>
per share), of which $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zPfqCoQheYTc" title="Stock options granted to purchase common stock, issued">79,263</span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
June 17, 2022 through June 30, 2024. During the years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative
costs in the consolidated statement of operations of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zeTkbZxU9gsg" title="Stock based compensation">19,390</span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zj0OTRT68Mii" title="Stock based compensation">38,885</span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zhGWiPw0bW5g" title="Fair value of stock options">10,000</span> shares (a total
of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp5d_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z2ADy4wM81gd" title="Stock price per share">50,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zG5wpfh4aXq9" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z6ahBUqJVBCi" title="Stock options are exercisable price per share">7.40</span> per share
(the closing market price on the grant date), <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z9vLLybWDl5c" title="Stock options description">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zeNHdbd3Njw3" title="Fair value of stock options">316,700</span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zWZPbCZ69Vd2" title="Stock price per share">6.334</span> per share), which was charged to operations ratably from July 1, 2022 through June 30, 2024. During
the years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement
of operations of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zPbQ2VaJBnM5" title="Stock based compensation">47,310</span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zxZbwBXmbDF9" title="Stock based compensation">94,881</span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zNzhFeiDs7G1" title="Number of fully vested option exercisable">20,000</span> shares
(a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zx7DjRwuqfx7" title="Number of fully vested option exercisable">80,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zd9I7E8Ermw6" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zf0lZSyktps4" title="Share price">20.00</span>
per share, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zP6s0urCCtu4" title="Stock options description">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.</span> The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zmjp9j9IwPJ1" title="Stock options granted to purchase common stock, issued">80,000</span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_znEf26e1q3Rd" title="Fair value of stock options">262,560</span> ($<span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z6yEW44TiIGb" title="Stock price per share">3.282</span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the
years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement
of operations of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zUJV4XJcERx8" title="Stock based compensation">42,565</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zhkFQvPLdmAd" title="Stock based compensation">61,448</span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2023, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zUVmBb1944ac" title="Number of fully vested option exercisable">10,000</span> shares (a total
of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z66LSaKS7KYk" title="Number of fully vested option exercisable">40,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zCg5ynPtkov9" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zUCPAZNtCWqc" title="Exercise price">5.88</span> per share
(the closing market price on the grant date), <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zxgGWCzODHLh" title="Share based compensation vesting rights, percentage">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zHbluKpuIore" title="Fair value of stock options">192,593</span> ($<span id="xdx_90F_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zvnHSF4cmcR6" title="Stock price per share">4.8131</span> per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
During the years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z2N2fdJcahqb" title="Stock based compensation">96,532</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zsTC1wZp8nmg" title="Stock based compensation">48,464</span>, respectively, with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted stock
options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zra8WHrxR603" title="Options, grants in period, gross">250,000</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrnnqKn9guA6" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z6JFikwDG9Y7" title="Stock options are exercisable price per share">1.95</span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJ2jJ1RO191k" title="Options vesting term">The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service.</span> The fair value of these stock options,
as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_904_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKATwL4QezPd" title="Fair value of stock options">403,066</span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zAuqBnWIHYLl" title="Stock price per share">1.612</span> per share), which is being charged
to operations ratably from September 26, 2023 through September 30, 2026. During the years ended December 31, 2024 and 2023, the Company
recorded charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zIsz7mX8F6Aa" title="Stock based compensation">134,114</span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRanRFYcfPV4" title="Stock based compensation">35,178</span>, respectively,
with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zIcLW1DcpXff" title="Number of fully vested option exercisable">10,000</span> shares (a total
of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zY05fABykAe7" title="Number of fully vested option exercisable">40,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_z9uginQJ5ym4" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zdAow8K7fJzg" title="Exercise price">2.37</span> per share
(the closing market price on the grant date), <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zmoEUrdG4Kt7" title="Share based compensation vesting rights, percentage">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zB463LtqCsJ2" title="Fair value of stock options">73,976</span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zkI1jrMrewl1" title="Stock price per share">1.8494</span> per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2026.
During the year ended December 31, 2024, the Company record a charge general and administrative costs in the consolidated statement of
operations of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_zpoC8URmx8J4" title="Stock based compensation">18,648</span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_z2wpVDiIz68d" title="Fair value of stock options">16,598</span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zY6AOdCPTgD3" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z9fiqbloed59" title="Exercise price">2.37</span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_ziKDphPSejHf" title="Stock option vested exercisable term">five years</span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zrGK7aE3H0y2" title="Fair value of stock options">27,500</span> ($<span id="xdx_905_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zqU48oqYeWP" title="Stock price per share">1.6570</span> per share), which was charged to operations on June 30, 2024, the date on which the
stock options were fully vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2024, in connection with the consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D., Dr. Schellens was granted stock options
to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zniZHl3nv6a1" title="Fair value of stock options">15,000</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zwpIisoII6s7" title="Stock option vested exercisable term">five years</span> at an exercise e price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zXVyoKcihSA9" title="Exercise price">2.39</span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the grant date. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zoIJuGIjF7te" title="Share based compensation vesting rights, percentage">The options vest quarterly over a three-year period commencing on the last day of each calendar quarter
commencing September 30, 2024.</span> The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_z53mJUW80PCh" title="Fair value of stock options">29,074</span> ($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_z4EBCzcjLuVi" title="Stock price per share">1.9382</span> per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2027.
During the year ended December 31, 2024, the Company record a charge general and administrative costs in the consolidated statement of
operations of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zfRHcERCYs68" title="Stock based compensation">4,863</span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zf3hl42bOGB" title="Fair value of stock options">21,217</span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zLTWU4TpCZJf" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zIsLNLDLwf29" title="Exercise price">1.87</span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zWPM7wwnj2Df" title="Stock option vested exercisable term">five years</span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended September 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zZ61bb60kkW5" title="Fair value of stock options">27,500</span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zkO5iVOtult7" title="Stock price per share">1.2961</span> per share), which was charged to operations on September 30, 2024, the date on which
the stock options were fully vested.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2025, the Board of Directors, in conjunction with the Company&#8217;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCT6jE6OTBNc" title="Fair value of stock options">16,665</span> stock options to purchase shares of the Company&#8217;s common stock, exercisable for a period
of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSOKuGRsLkcc" title="Stock option vested exercisable term">five years</span> at an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsw1EgAHQWXb" title="Exercise price">2.33</span> per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpqM61ZhgShj" title="Stock option vested exercisable term">five years</span> and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended December 31, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $<span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJ7qnbKysjw9" title="Fair value of stock options">27,500</span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp5d_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfvM0U1tg9g5" title="Stock price per share">1.65002</span> per share). The grant date value of the stock options of $<span id="xdx_907_ecustom--FairValueOfStockOptions_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zp2wV1mNfFc2" title="Fair value of stock options">27,500</span> was accrued at December
31, 2024 and charged to operations at that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#8217;s Board of Directors at the
Company&#8217;s annual meeting of stockholders held on October 7, 2022. Gil Schwartzberg, a former director of the Company, died on October
30, 2022. Dr. John S. Kovach, the Chairman of the Board of Directors and the Company&#8217;s President and Chief Executive Officer, and
Chief Scientific Officer, died on October 5, 2023, the employment agreement of the Company&#8217;s Chief Medical Officer, Dr. James S.
Miser expired on July 31, 2024, and the employment agreement of the Company&#8217;s Vice President and Chief Operating Officer, Eric
J. Forman, terminated upon his resignation from the Company on December 31, 2024. Accordingly, the unvested stock options for each such
person ceased vesting effective as of the respective dates that their services to the Company terminated. Furthermore, the expiration
date of all vested stock options owned by each such person contractually expire one year from the respective dates that their services
to the Company terminate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zLmHfiQDu9Vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the years ended December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zgC3DbVUULNd" style="display: none">Summary
of Stock-based Compensation Costs</span>&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20240101__20241231_zCPUK4slL2Rf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zD7ueh03xcgj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zw41nmCfHsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">418,422</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">773,203</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zRIWM6L1xRA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Non-related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1161">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_zC9hb6zYcjhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">418,422</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">773,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zNtVSvWUGJ02" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWFBvOWESuj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2024 and 2023
is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z8jCAeDDOI2f" style="display: none">Summary
of Stock Option Activity Including Options Form of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                                                                                                                                                                                                                                                               Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Contractual Life</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(in Years)</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zEqJTGSvK8w6" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning">389,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zFVS6abLMYZj" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">29.183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zNz0eVZiNNlb" style="text-align: right" title="Number of shares, granted">290,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zhUt0lVuxo7f" style="text-align: right" title="Weighted average exercise price, granted">2.492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zyMcabLTWXEj" style="text-align: right" title="Number of shares, exercised">(1,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zoZSsYFi1C96" style="text-align: right" title="Weighted average exercise price, exercised">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvzjbhKsNVA4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired">(126,146</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z3eDmD362pL5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired">28.687</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zNsZKEOEHbQ3" style="text-align: right" title="Number of shares, stock options outstanding, at the end">552,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zdAC1ThDecti" style="text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">15.330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231_z5nJTobYUYk5" style="text-align: right" title="Number of shares, granted">92,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zUaVZz4zovPa" style="text-align: right" title="Weighted average exercise price, granted">2.259</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_ziyRLtF7njf2" style="text-align: right" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zgg5FRnlwTeb" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1195">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231_zmUY0rVkgze3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired">(31,666</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_z2fVu7X2tNAd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired">35.368</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zisLJpd1Xp63" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end">613,232</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zniAOJtrgp25" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">12.317</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_z3FMT0xDwTD1" title="Weighted average remaining contractual life (in years), stock options outstanding">3.08</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_zrlZMuvw59Tf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable">252,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zW8Vuv6cQ5Pc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable">28.387</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zcFNdfHDkKz9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable">409,897</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z4GpV6jBnfXd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable">17.100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zqqRxBwPm26a" title="Weighted average remaining contractual life (in years), stock options exercisable">2.75</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zp7zS8mJVt6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_909_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20240101__20241231_zNusLmbTe0Ca" title="Deferred compensation expense for unvested stock options">375,000</span> at December 31, 2024, which
will be recognized subsequent to December 31, 2024 over a weighted-average period of approximately <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20240101__20241231_z7hrdWB2apc1" title="Weighted-average recognition period">19</span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxCENmtaZDP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zATPZYEZtqe7" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options <br/> Outstanding (Shares)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable (Shares)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 2%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zUdjPHIoTpU1" style="width: 29%; text-align: right" title="Exercise Prices">1.870</td><td style="width: 2%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zPLnqMyc8LC8" style="width: 29%; text-align: right" title="Options Outstanding (Shares)">21,217</td><td style="width: 2%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhfjeM9xS2H" style="width: 28%; text-align: right" title="Options Exercisable (Shares)">21,217</td><td style="width: 2%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zMlBOsmIQWDe" style="text-align: right" title="Exercise Prices">1.950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbGfTIdPEjzj" style="text-align: right" title="Options Outstanding (Shares)">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zJPf0fapi55a" style="text-align: right" title="Options Exercisable (Shares)">104,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zDZKuhgTEYV5" style="text-align: right" title="Exercise Prices">2.370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zMS7bvdTvIjg" style="text-align: right" title="Options Outstanding (Shares)">56,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWJIZmt3Iha" style="text-align: right" title="Options Exercisable (Shares)">26,598</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zoKtlMKICBRg" style="text-align: right" title="Exercise Prices">2.390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z4184IydkpKj" style="text-align: right" title="Options Outstanding (Shares)">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3CYfCHKP3ml" style="text-align: right" title="Options Exercisable (Shares)">2,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z6BAhCpDtVil" style="text-align: right" title="Exercise Prices">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4oo7pdUWGwd" style="text-align: right" title="Options Outstanding (Shares)">8,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z9F94HjKKxe" style="text-align: right" title="Options Exercisable (Shares)">8,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zDUtY0ROnTQc" style="text-align: right" title="Exercise Prices">5.880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z9gkiVfuIA9i" style="text-align: right" title="Options Outstanding (Shares)">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSwKjUz8Ptra" style="text-align: right" title="Options Exercisable (Shares)">30,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zINl9Gix6yWk" style="text-align: right" title="Exercise Prices">7.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqvBQe5D6csj" style="text-align: right" title="Options Outstanding (Shares)">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zopgLrWifA3d" style="text-align: right" title="Options Exercisable (Shares)">55,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zYxWTpuH3XF1" style="text-align: right" title="Exercise Prices">20.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zeIU5jit3mTj" style="text-align: right" title="Options Outstanding (Shares)">45,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8G91Hl00Zx4" style="text-align: right" title="Options Exercisable (Shares)">40,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zXocKwlCnDA3" style="text-align: right" title="Exercise Prices">20.600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zTIFtFO3b0O5" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO5FIkIDEdge" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zhKpThSwUhSg" style="text-align: right" title="Exercise Prices">28.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zk8fo0MKpFw5" style="text-align: right" title="Options Outstanding (Shares)">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zC7NtmxlyU4" style="text-align: right" title="Options Exercisable (Shares)">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zIDrWpTVGmDl" style="text-align: right" title="Exercise Prices">30.300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSZ3Uzb1Lduk" style="text-align: right" title="Options Outstanding (Shares)">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1sfqEiGkF5a" style="text-align: right" title="Options Exercisable (Shares)">30,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z4XC1cRXhEk6" style="text-align: right" title="Exercise Prices">32.100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZRbvYz7Twhf" style="text-align: right" title="Options Outstanding (Shares)">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zPbAT7QuotZe" style="text-align: right" title="Options Exercisable (Shares)">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zm8x6BwcAAul" style="text-align: right" title="Exercise Prices">60.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zGbd8qGCO71i" style="text-align: right" title="Options Outstanding (Shares)">8,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zJRDC1T6atcg" style="text-align: right" title="Options Exercisable (Shares)">8,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zbIZs6lY2Ai1" style="text-align: right" title="Exercise Prices">71.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPm1YGFhbvp" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zAjXdDdK80Ec" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_ziws5S9oXQ66" style="padding-bottom: 1pt; text-align: right" title="Exercise Prices">120.000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj7QDC3nkmzh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding (Shares)">8,334</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zylMGmJKZVg5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable (Shares)">8,334</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_z7BBJromCTEi" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)">613,232</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231_zUWwimlEsfRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)">409,897</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zOAlgQxtv9Og" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the closing fair market value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20240101__20241231_zipOr7b9aRXa" title="Fair market value, per share">2.03</span> per share on December 31, 2024, the intrinsic value attributed to exercisable but unexercised
common stock options was approximately $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_do_c20241231_zJYMgeKnJRM2" title="Intrinsic value">12,000</span> at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231_zLAN0yFnJN0a" title="Outstanding stock options to acquire shares of common stock not vested">203,334</span> shares of the Company&#8217;s common stock had not vested at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the exercise of such stock options, the Company expects to satisfy the related stock obligations through the issuance of authorized but
unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zXcWy9o7k9f9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82C_zgjKmYjldi0i">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets as
of December 31, 2024 and 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhcMrKCfMEyg" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z6Mg4awZE5Fl" style="display: none">Schedule of Components of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zhZf6zsba7ub" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20231231_zP1AFuQVBBm9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_zELyJMLaS4Gk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research credits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">652,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">612,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zBwHgXQtF5a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_z8HjiCuxMNK9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zA3UrvyNPuE6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net operating loss carryforwards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,515,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,601,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_z8A2JzUUu7g5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,617,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,688,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_zVRTtLd8PKe1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,617,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,688,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zzXX3BLEty3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zZdrcyd8uN54" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining
future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2024 and 2023, management
was unable to determine if it is more likely than not that the Company&#8217;s deferred tax assets will be realized and has therefore
recorded an appropriate valuation allowance against deferred tax assets at such dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_do_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zvlPonMVROy"><span id="xdx_90C_eus-gaap--IncomeTaxExpenseBenefit_do_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zd0wseKP9f2f">No</span></span>
federal tax provision has been provided for the years ended December 31, 2024 and 2023 due to the losses incurred during such periods.
The reconciliation below presents the difference between the income tax rate computed by applying the U.S. federal statutory rate and
the effective tax rate for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zO7KRmwRQbIa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zIdAW3X8Ite7" style="display: none">Schedule of Effective Income Tax Rate</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20241231_zgAhkbWfYUrj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zodb6ZAgqzS2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zOUdJUJqc2rl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">U. S. federal statutory tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_zEJojD5OZill" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_z43h5lMrnr7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expirations related to stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.4</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_za0dRVJpsqI9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustment to deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.8</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zADWTP1AqVjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24.3</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17.4</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_z9DPi7jgTpSj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A2_zKZ6frVnfgA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately
$<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20241231_z7q5FhRzD8Uk" title="Operating loss carryforwards, federal">31,067,000</span> and $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20241231_zXCk9xyKQbWk" title="Operating loss carryforwards, state">35,836,000</span>, respectively. Federal net operating losses from tax years preceding 2018, if not utilized earlier, expire
through 2038. Federal net operating losses generated in a tax year beginning after 2017 have an indefinite carryforward period. The utilization
of federal net operating loss carryforwards is subject to various limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
state net operating loss carryovers include approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zipZCELoHTRh" title="Net operating loss carryovers">19,141,000</span> that were incurred in the State of New York. New York tax law requires
New York net operating loss carryovers from years prior to 2015 to be converted, by applying a formula, into a Prior Net Operating Loss
Conversion (PNOLC) subtraction pool. <span id="xdx_909_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zYvJkk1ZDO1a" title="Prior net operating loss conversion utilization">The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.</span> The state net
operating loss carryovers also include approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zACcJVv1fc7i" title="Operating loss carryforwards, state">16,695,000</span> that was incurred in the State of California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and certain corresponding provisions of state law, if a
corporation undergoes an &#8220;ownership change&#8221;, which is generally defined as a greater than 50% change, by value, in the ownership
of its equity over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income might be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company&#8217;s net operating losses have yet to be utilized, all previous tax years since 2006 remain subject to adjustment by Federal
authorities and other jurisdictions in which the Company currently operates or has operated in the past.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zDBhwmoYf2Ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_822_zuyoCltX3Ayc">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of December 31, 2024 and
2023, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 14, 2025, the Company&#8217;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial
monitoring agreements not yet incurred, as described below, aggregated $<span id="xdx_908_eus-gaap--ContractualObligation_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_z1tqH4drcJU3" title="Clinical trial contractual commitment">526,000</span>, including clinical trial agreements of $<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsMember_zqWnh1Y3vhH4" title="Contractual commitment">264,000</span> and
clinical trial monitoring agreements of $<span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_zJvmGUJ4tmLb" title="Contractual commitment">262,000</span>, which, based on current estimates, are currently scheduled to be incurred through approximately
December 31, 2027. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely availability
of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds to the Company&#8217;s
current or future clinical trial programs. The Company expects that the full amount of these expenditures will be incurred only if such
clinical trial programs are conducted as originally designed and their respective enrollments and duration are not modified or reduced.
Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently involve a series
of changes and modifications over time as clinical data is obtained and analyzed, and is frequently modified, suspended or terminated,
in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial endpoint is reached.
Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current clinical assumptions
and conditions and are typically subject to significant modifications and revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zbNYDSNxOP0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s ongoing contractual clinical trials described below as of March 14, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zyV50Cq5DUUh" style="display: none">Schedule
of Contractual Clinical Trials</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="font-size: 8pt">Description
    of Clinical Trial</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Institution</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Start Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Projected End Date</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number
                                            of Patients</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>in
                                            Trial</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Study Objective</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Clinical Update</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Expected</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Date
                                            of Preliminary Efficacy</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Signal</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">NCT No.</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Financial</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Commitment</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 19%; text-align: left"><span style="font-size: 8pt"><span id="xdx_906_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zXixyQiSU8ni" title="Clinical trial, description">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer</span> (Phase 1b)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 8pt">Netherlands Cancer Institute (NKI)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zuV8mTERxdwj" title="Estimated Start Date">August 2024</span></span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 8pt"><span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zDj9IIabnRz1" title="Estimated End Date">December 2026</span></span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 6%; text-align: center"><span style="font-size: 8pt"><span id="xdx_902_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zrh1OR2gLFo2" title="Number of Patients in Trial">37</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 8pt">Determine RP2D with atezolizumab</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 8pt">First patient entered August 2024, in total two patients entered</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 8pt"><span id="xdx_904_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zS25rgjPU17f" title="Expected Date">June 2026</span></span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 8pt">NCT06012734</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zcorFI7OWv78" title="Remaining financial contractual commitment"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></span></span><span style="font-size: 8pt">(1</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 8pt"><span id="xdx_901_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z7i2OWVQ7vk8" title="Clinical trial, description">LB-100 combined with doxorubicin in advanced soft
    tissue sarcoma</span> (Phase 1b)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">GEIS</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zdJjLV15myt" title="Estimated Start Date">June 2023</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_901_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zHVmg7al70x1" title="Estimated End Date">Recruitment completed September 2024</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zCffF5jNIjjh" title="Number of Patients in Trial">9</span>
                                            to <span id="xdx_90B_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zUGXB7TkRXY8" title="Number of Patients in Trial">18</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Determine MTD and RP2D</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Fourteen patients entered</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zT0RXnmH1cL1" title="Expected Date">December 2025</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">NCT05809830</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td id="xdx_982_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zs1b7zL5Cn61" style="text-align: right" title="Remaining financial contractual commitment"><span style="font-size: 8pt">264,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDIp_zaK0ldzzzrnk" title="Clinical trial, description">Doxorubicin with or without LB-100 in advanced soft
    tissue sarcoma </span>(Randomized Phase 2)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">GEIS</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">TBD</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">TBD</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zTQUm6J8wsGk" title="Number of Patients in Trial">150</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Determine efficacy: PFS</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical
    trial)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">TBD</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">NCT05809830</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zCxDdXQeHIvi" title="Remaining financial contractual commitment"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></span></span><span style="font-size: 8pt">(1</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_903_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDIp_zj2xTKkOQkK" title="Clinical trial, description">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma</span> (Phase 1b/2)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">MD Anderson</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_903_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zQMbpJSy59Lj" title="Estimated Start Date">January 2024</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zzCWNGur0Zk7" title="Estimated End Date">December 2027</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zSwqRcECedGi" title="Number of Patients in Trial">21</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">Determine the OS of patients with recurrent ovarian
    clear cell carcinoma</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt">Nine patients entered</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zUMEVM22olN7" title="Expected Date">December 2026</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt">NCT06065462</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zhxbiG9B0Ac5" title="Remaining financial contractual commitment"><span style="-sec-ix-hidden: xdx2ixbrl1432">-</span></span></span><span style="font-size: 8pt">(1</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"><span style="font-size: 8pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td id="xdx_98A_eus-gaap--OtherCommitment_iI_c20250314_zokjzbaUrqnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Remaining financial contractual commitment"><span style="font-size: 8pt">264,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span id="xdx_F06_zXGwjXEDSFLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zndBSHdtJAg4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.</span></td></tr>
  </table>
<p id="xdx_8A7_zA6RA5e8Ptxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute
(&#8220;NKI&#8221;) (see Note 5) to conduct a Phase 1b clinical trial of the Company&#8217;s protein phosphatase inhibitor, LB-100, combined
with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (&#8220;Roche&#8221;), for patients with microsatellite
stable metastatic colorectal cancer. Under the agreement, the Company will provide its lead compound, LB-100, and under a separate agreement
between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to
and will not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement,
the clinical trial will be conducted by NKI at NKI&#8217;s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and
NKI will be responsible for the recruitment of patients. The agreement provides for the protection of the respective intellectual property
rights of each of the Company, NKI and Roche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&#8217;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. A total of two patients have been enrolled to date. Patient accrual
is expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&#8220;SAEs&#8221;) observed in the clinical trial. The Investigational Review Board (IRB) of the Netherlands Cancer
Institute has requested additional information with respect to these SAEs and the study has been paused for enrollment until the IRB&#8217;s
questions have been satisfactorily addressed (see &#8220;Specific Risks Associated with the Company&#8217;s Business Activities - Serious
Adverse Events&#8221; below for additional information).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no financial contractual commitment associated with this clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the &#8220;Agreement&#8221;) with
the City of Hope National Medical Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively,
&#8220;City of Hope&#8221;), to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase
inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#8220;ED-SCLC&#8221;).
LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously
untreated ED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#8220;RP2D&#8221;). Patient entry was to be expanded so that a total of 12 patients would be evaluable at the RP2D to
confirm the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration
of overall response, progression-free survival, and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient
accrual was slower than expected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (&#8220;SCRI&#8221;),
Nashville, Tennessee, to the ongoing Phase 1b clinical trial. The Company and City of Hope continued efforts to increase patient accrual
by adding additional sites and by modifying the protocol to increase the number of patients eligible for the clinical trial. The impact
of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms
of the Agreement, the Company provided notice to City of Hope of the Company&#8217;s intent to terminate the Agreement effective as of
July 8, 2024. Upon closure, the Company incurred a prorated charge of $<span id="xdx_90D_eus-gaap--LitigationSettlementExpense_c20240707__20240708__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_z5acQ9n9FrKd" title="Litigation settlement expense">207,004</span> for the cost of patients enrolled to date, which is included
in accounts payable and accrued expenses at December 31, 2024 .</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024 and 2023, the Company incurred costs of $<span id="xdx_901_eus-gaap--LitigationSettlementExpense_c20240101__20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zerFstXrgqWh" title="Litigation settlement expense">285,019</span> and $<span id="xdx_907_eus-gaap--LitigationSettlementExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zWPnrIWmoQ0j" title="Litigation settlement expense">69,001</span>, respectively, pursuant to this Agreement.
As of December 31, 2024, total costs of $<span id="xdx_90A_eus-gaap--DeferredCosts_iI_c20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zhtmO9ywpI37" title="Total costs">732,532</span> had been incurred pursuant to this Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the
anti-tumor activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#8220;PFS&#8221;), no evidence of disease progression or death from
any cause, of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practice (GMP) of the active pharmaceutical ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_907_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zrrPgDwaZoHa" title="Inventory costs">1,144,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of ASTS. Consequently, this
clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report prepared by December 31,
2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n Jim&#233;nez
D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b
portion of the protocol was extended with two patients and was completed during the quarter ended September 30, 2024. The Company expects
to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, the Company entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved
the Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $<span id="xdx_905_eus-gaap--OtherCommitment_iI_uEUR_c20250311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zfFDQYq8Va3k" title="Aggregate commitments expected">3,095,000</span>. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provided for various payments based on achieving specific milestones over the term of the agreement.
During the years ended December 31, 2024 and 2023, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zaia5Nyr86Kc" title="Research and development costs">0</span> and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zfaifKZ1ugng" title="Research and development costs">268,829</span>, respectively, pursuant to this agreement.
Through December 31, 2024, the Company has incurred charges of $<span id="xdx_902_ecustom--AmountRelatedToMilestonePayment_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zPbDmT63fws6" title="Amount related to milestone payment">684,652</span> for work done under this agreement through the fourth milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_z3ayU8lepmxg" title="Aggregate commitments expected">264,000</span>
for the Phase 1b portion of this clinical trial as of March 14, 2025, which is scheduled to be incurred through December 31, 2025. As
the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations between the
United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign currency gain
or loss, as appropriate, and have not been significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#8220;PD-1&#8221;) blocking antibody of GSK plc
(&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#8220;OCCC&#8221;). The study objective is to determine the overall survival (&#8220;OS&#8221;) of patients with OCCC. The clinical
trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;) and is being conducted at The
University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial
support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical trial. The
Company currently expects that this clinical trial will be completed by December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, the Company announced that it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&#8217;s proprietary compound LB-100 with GSK&#8217;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida (&#8220;Moffitt&#8221;), effective for a term of five years. Pursuant to the Clinical Trial Research
Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#8217;s
lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic
syndrome (&#8220;MDS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (&#8220;IND&#8221;)
Application to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and
intermediate-1 risk MDS who had failed or were intolerant of standard treatment. This Phase 1b/2 clinical trial utilized LB-100 as a
single agent in the treatment of patients with low and intermediate-1 risk MDS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the
year ended December 31, 2023, the clinical trial was closed. Although the maximum tolerated dose (&#8220;MTD&#8221;) was not achieved,
there was no dose-limiting toxicity noted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company incurred costs of $<span id="xdx_90F_eus-gaap--LitigationSettlementExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zob6CNqPjDLa" title="Litigation settlement expense">0</span> and $<span id="xdx_90C_eus-gaap--LitigationSettlementExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zqwFN48l7781" title="Litigation settlement expense">16,165</span>, respectively, pursuant to this agreement. As
of December 31, 2024, total costs of $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zq3iBSb06mGk" title="Research and development costs">147,239</span> had been incurred pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
September 2023, the Company decided not to pursue further studies in MDS, as other, more promising, opportunities had become available
(see &#8220;Patent and License Agreements - Moffitt&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (&#8220;NCI&#8221;) initiated a glioblastoma
(&#8220;GBM&#8221;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MD
Anderson Cancer Center Clinical Trial</b>. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen
investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1
(&#8220;PD-1&#8221;) blocking antibody of GSK plc (&#8220;GSK&#8221;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy
in the treatment of ovarian clear cell carcinoma (&#8220;OCCC&#8221;). On August 19, 2024, the Company signed a work order agreement
with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this letter of intent and related work order agreement are estimated to be approximately $<span id="xdx_90D_ecustom--WorkOrderAgreementCosts_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zwEqjo3bJZ4i" title="Work order agreement costs">95,000</span>. During the year ended December
31, 2024, the Company incurred costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zJXSCxsY3QLl" title="Research and development process costs">26,763</span> pursuant to this letter of intent and subsequent work order. As of December 31, 2024,
total costs of $<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MDAndersonCancerCenterClinicalMember_z6u3aHzZVgW9" title="Research and development costs">26,763</span> have been incurred pursuant to this letter of intent and subsequent work order.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $<span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_z7s91UCce1F1" title="Remaining financial contractual commitment">70,000</span>
as of December 31, 2024, which is expected to be incurred through December 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement were estimated to be approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zuwqhvVoEij5" title="Research and development expense">335,000</span>. During the years December 31, 2024 and 2023, the Company incurred costs
of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zxUpJtMbc5Me" title="Research and development expense">10,642</span> and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zoWlzMGxETc8" title="Research and development expense">20,240</span>, respectively, pursuant to this work order. As of December 31, 2024, total costs of $<span id="xdx_908_eus-gaap--DeferredCosts_iI_c20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zy7awQEgtZC5" title="Total costs incurred">89,323</span> had been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see &#8220;Clinical Trial Agreements &#8211; City
of Hope&#8221; above), the work order agreement with Theradex to monitor this clinical trial was concurrently terminated, although nominal
oversight trailing costs subsequent to July 8, 2024 are expected to be incurred relating to the closure of this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study
oversight is expected to be completed by December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_908_ecustom--EstimatedWorkCost_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zHPObUbzIjvl" title="Work cost">153,000</span>, with such payments expected to be allocated approximately
<span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zSs29Oasw99d" title="Percentage of payment through services">72%</span> to Theradex for services and approximately <span id="xdx_909_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zVJsW386BqG1" title="Percentage of payment through software">28%</span> for payments for pass-through software costs. During the years ended December 31,
2024 and 2023, the Company incurred costs of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zvrFtEs5QRhl" title="Research and development costs">34,593</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zt7Etgvjyxx8" title="Research and development costs">14,862</span>, respectively, pursuant to this work order. As of December 31, 2024,
total costs of $<span id="xdx_905_eus-gaap--DeferredCosts_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zosVXaEv71r8" title="Total costs">49,455</span> have been incurred pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_90F_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zYMs96711Ewa" title="Aggregate commitments expected">104,000</span> as of December 31, 2024, which is expected to be incurred through December 31, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute. </b>On August 27, 2024, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical
trial of LB-100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colorectal cancer.
The study oversight is expected to be completed by May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_90B_ecustom--EstimatedWorkCost_c20230825__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zTDQMn6kiTjj" title="Work cost">106,380</span>, with such payments expected to be allocated approximately
<span id="xdx_90D_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230825__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zPhBSyHe1mcb" title="Percentage of payment through services">47%</span> to Theradex for services and approximately <span id="xdx_908_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230825__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zEtdN6DvHa5i" title="Percentage of payment through software">53%</span> for payments for pass-through software costs. During the year ended December 31, 2024,
the Company incurred costs of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zAWEsj9qaw03" title="Research and development costs">20,191</span> pursuant to this work order. As of December 31, 2024, total costs of $<span id="xdx_90B_eus-gaap--DeferredCosts_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zWv2GVZIyMpi" title="Total costs">20,191</span> have been incurred
pursuant to this work order agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_z6OTPaC8QIS7" title="Aggregate commitments expected">88,000</span> as of December 31, 2024, which is expected to be incurred through May 31, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Institute of Health.</b> Effective February 23, 2024, the Company entered into a Patent License Agreement (the &#8220;License Agreement&#8221;)
with the National Institute of Neurological Disorders and Stroke (&#8220;NINDS&#8221;) and the National Cancer Institute (&#8220;NCI&#8221;),
each an institute or center of the National Institute of Health (&#8220;NIH&#8221;). Pursuant to the License Agreement, the Company has
licensed on an exclusive basis the NIH&#8217;s intellectual property rights claimed for a Cooperative Research and Development Agreement
(&#8220;CRADA&#8221;) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer
activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors,
immunotherapy, and radiation for the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product,
licensed process, and country basis, until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights
in each such country in the licensed territory, estimated at twenty years, unless sooner terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zptXwdPPvFr4" title="Non refundable license issue royalty">50,000</span> and a first minimum annual royalty
within sixty days from the effective date of the Agreement. The first minimum annual royalty of $<span id="xdx_902_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zCqN7oWazy69" title="Minimum annual royalty payable">25,643</span> was prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $<span id="xdx_90F_ecustom--RoyaltyPayable_iI_c20300131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_z3Gc6lfxHH3i" title="Minimum annual royalty payable">30,000</span> is due each January
1 and may be credited against any earned royalties due for sales made in that year. The license issue royalty of $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z0r7EDgcW52d" title="Non refundable license issue royalty">50,000</span> and the first
minimum annual royalty of $<span id="xdx_907_ecustom--RoyaltyPayable_iI_c20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_z5XWMqrKPmve" title="Minimum annual royalty payable">25,643</span>, were paid in April 2024. The second minimum annual royalty for 2025 of $<span id="xdx_909_ecustom--RoyaltyPayable_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zTsgb8AqqnTa" title="Minimum annual royalty payable">30,000</span>, was paid in December
2024 and is included in other prepaid expenses at December 31, 2024 in the accompanying consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#8217;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, which the Company is required to pursue based on &#8220;commercially reasonable
efforts&#8221; as defined in the License Agreement, with deadlines of October 1, 2024, 2027, 2029 and 2031, respectively, each with a
different specified benchmark payment amount payable within thirty days of achieving such benchmark. The October 1, 2024 benchmark of
$<span id="xdx_90B_eus-gaap--HealthCareOrganizationHealthCareCostsGross_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zmWKH5089rna" title="Dosing of product">100,000</span> was defined as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product
in the licensed fields of use. The Company had not commenced a Phase 2 clinical study as of December 31, 2024. The total of all such
benchmark payments is $<span id="xdx_90F_eus-gaap--PaymentsForRoyalties_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zDrlkfevcfV6" title="Payment for royalties">1,225,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to provide annual reports to the NIH on its progress toward the development and commercialization of products under
the licensed patents. These reports, due within sixty days following the end of each calendar year, must include updates on research
and development activities, regulatory submissions, manufacturing efforts, sublicensing, and sales initiatives. If any deviations from
the established commercial development plan or agreed-upon benchmarks occur, the Company is obligated to provide explanation and may
amend the commercial development plan and the benchmarks, which, subject to certain conditions, the NIH shall not unreasonably withhold,
condition, or delay approval of any request of the Company to amend the commercial development plan and/or the benchmarks and to extend
the time periods of the benchmarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is obligated to pay the NIH sublicensing royalties of <span id="xdx_90D_ecustom--RoyatiesPercentage_pid_dp_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zmpeM7Wasmi7" title="Royalty percentage">5%</span> on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company incurred costs of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zKLGUFOwBJmj" title="Research and development process costs">75,643</span> in connection with its obligations under the License Agreement.
Such costs when incurred have been included in general and administrative costs in the Company&#8217;s consolidated statement of operations.
As of December 31, 2024, total costs of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zR0X46ULC2v9" title="Research and development process costs">75,643</span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment
pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zBK6C61HFLq4" title="Aggregate commitments expected">1,795,000</span> as of December 31, 2024, which is
expected to be incurred over approximately the next twenty years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee was due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded a credit to operations of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zYQRKdDADNGl" title="Stock based compensation">9,109</span> representing the reversal of obligations previously
recorded with respect to the Exclusive License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into a consulting agreement with NDA Consulting Corp. for consultation
and advice in the field of oncology research and drug development. As part of the consulting agreement, NDA also agreed to have its president,
Dr. Daniel D. Von Hoff, M.D., serve on the Company&#8217;s Scientific Advisory Committee during the term of such consulting agreement.
The term of the consulting agreement was for one year and provided for a quarterly cash fee of $<span id="xdx_908_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zZZVADBV9pRa" title="Consulting and advisory fee">4,000</span>. The consulting agreement had been
automatically renewed for additional one-year terms on its anniversary date, most recently on December 24, 2023, but was subsequently
terminated by mutual agreement effective September 30, 2024. Consulting and advisory fees charged to operations pursuant to this consulting
agreement were $<span id="xdx_906_ecustom--ConsultingAndAdvisoryCashFee_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_z46HHK3xWhk8" title="Consulting and advisory fee">12,000</span> and $<span id="xdx_90F_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zw8m0P3OayKc" title="Consulting and advisory fee">16,000</span> for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_90A_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zkwYA3IcTSi9" title="Consulting and advisory fee">10,000</span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly fee. Effective March 1, 2024, the compensation payable under the Collaboration Agreement was converted to an hourly
rate structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded charges to operations pursuant to this Collaboration Agreement of $<span id="xdx_90A_ecustom--ReimbursementExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_ziEGFH02FsQd" title="Reimbursed expense">39,200</span> and $<span id="xdx_905_ecustom--ReimbursementExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zKkEIJpFnvAl" title="Reimbursed expense">120,000</span> during the years ended December
31, 2024 and 2023, respectively, which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#8220;NKI&#8221;) (see Note 5), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. The Company agreed to fund the preclinical study, at an approximate cost of <span id="xdx_903_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zoVVWKBXOnP7" title="Aggregate commitments expected">391,000</span> Euros and provide a
sufficient supply of LB-100 to conduct the preclinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added
<span id="xdx_902_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zxvXEhvSBEni" title="Aggregate commitments expected">500,000</span> Euros to the operating budget being funded by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year and starts upon the dosing of the first patient in the trial at a project cost of
<span id="xdx_90C_eus-gaap--OtherCommitment_iI_uEUR_c20241004__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zvjNsJGVi2Z6" title="Aggregate commitments expected">100,000</span> Euros.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company incurred charges in the amount of $<span id="xdx_908_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zuma1q5Sg1rl" title="Advance amount related to milestone payment">210,362</span> and $<span id="xdx_90C_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zklbAAnirwS1" title="Advance amount related to milestone payment">226,150</span>, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#8217;s consolidated statements of operations.
As of December 31, 2024, total costs of $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zAdVNb4vM5Nj" title="Research and development costs">695,918</span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment
pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_902_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zlf9PRipJmid" title="Aggregate commitments expected">104,000</span> as of December 31, 2024, which is expected
to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to
foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>As amended, the Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical
trials in the United States. During the years ended December 31, 2024 and 2023, the Company incurred costs of $<span id="xdx_907_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zCMROx1V97V2" title="Advance amount related to milestone payment">23,308</span> and $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zgRbDfMAeETe" title="Advance amount related to milestone payment">32,307</span>, respectively,
pursuant to this contract. As of December 31, 2024, total costs of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zbFiOeixeyIc" title="Research and development costs">340,522</span> have been incurred pursuant to this contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_906_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zPHuGQJrNYj4" title="Aggregate commitments expected">118,000</span>
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Specific
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serious
Adverse Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of
these trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to the Company&#8217;s drug
candidate or to another company&#8217;s drug used in combination in one of the Company&#8217;s clinical trials. It is possible that the
SAEs could be attributable to the Company&#8217;s drug candidate and could include, but not be limited to, unexpected severe side effects,
treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting
toxicity (DLT). When two DLTs occur at the same dose-level, that dose-level is considered too high and unsafe. Further treatment is only
allowed at lower dose-levels that have previously been found safe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving the Company&#8217;s drug candidate, the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring
the Company to pause or discontinue further enrollment and dosing in its clinical trial. It is also possible that the clinical trial
could be terminated. Any of these actions could delay or halt the development of the Company&#8217;s drug candidate, increase development
costs, and negatively impact the Company&#8217;s ability to ultimately achieve regulatory approval. Additionally, if an SAE is confirmed
to be drug-related, the Company may be required to conduct additional studies, modify the study design, or abandon further development
of the drug candidate altogether, which could materially impact the Company&#8217;s business, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of an SAE and any resulting clinical hold could also harm the Company&#8217;s reputation with patients, physicians, health
institutions, and investors, diminish its ability to attract clinical trial participants, and damage its ability to interest investors
and obtain financing in the future. There can be no assurance that the Company will not experience such SAEs in the future or that any
related clinical hold will be lifted in a timely manner, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Netherlands Cancer Institute (&#8220;NKI&#8221;) Institutional
Review Board (the &#8220;IRB&#8221;) has put the colorectal cancer study on hold. The adverse reactions that developed in the two patients
were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and atezolizumab in
one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second patient. The
patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea. The patient
with fever and aphasia fully recovered from the adverse events with supportive medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator is preparing a response to the IRB
detailing the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab.
Doxorubicin is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related
to that of atezolizumab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through February 2025, a total of 78 patient have received or are receiving experimental treatment
with LB-100. It is expected that it will take at least two months to prepare a detailed response to the IRB, during which time the Company
intends to update the safety overview of LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Business Risks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus or any other pandemics may reappear and impact the Company&#8217;s clinical trial programs
and capital raising efforts in the future is uncertain and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
and Interest Rate Risk. </b>The Company does not believe that inflation or increasing interest rates have had a material effect on its
operations to date, other than their impact on the general economy. However, there is a risk that the Company&#8217;s operating costs
could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#8217;s
operating costs (including, specifically, clinical trial costs), and which would put additional stress on the Company&#8217;s working
capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear
at this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geopolitical
Risk.</b> The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#8217;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#8217;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#8217;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital could all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#8217;s business, financial condition and results
of operations may differ from current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risks. </b>The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity
threats, and has integrated these processes into its overall risk management systems and processes. The Company routinely assesses material
risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through its information and email systems
that may result in adverse effects on the confidentiality, integrity, or availability of the Company&#8217;s information and email systems
or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as assessments
in the event of a material change in the Company&#8217;s business practices that may affect information systems that are vulnerable to
such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the
likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems and
safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges to date that have materially impaired
its operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zvgSFNEAHlnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_82A_zoBAb5jgYfWe">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
Other than as described below, there were no material subsequent events which affected, or could affect, the amounts or disclosures in
the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Compliance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2024, the Company received a letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock
Market LLC (&#8220;Nasdaq&#8221;) on August 19, 2024 indicating that the Company was not in compliance with the minimum net stockholders&#8217;
equity requirement of $<span id="xdx_903_eus-gaap--StockholdersEquity_iNI_di_c20240823__srt--RangeAxis__srt--MinimumMember_ziiVLvi279f4" title="Stock holders' equity">2,500,000</span> for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &#8220;Stockholders&#8217;
Equity Requirement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders&#8217; Equity Requirement, which
outlined the Company&#8217;s proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2024, the Staff provided notice (the &#8220;Notice&#8221;) to the Company that it had granted an extension through February
18, 2025 to regain compliance with the Stockholders&#8217; Equity Requirement, which required that the Company complete its capital raising
initiatives and evidence compliance with the Stockholders&#8217; Equity Requirement through filing a Current Report on Form 8-K with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) providing certain required information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 18, 2025, the Company had not gained compliance with the Stockholders&#8217; Equity Requirement. Accordingly, on February
19, 2025, the Company received a Staff determination letter from the Staff stating that the Company did not meet the terms of the extension
because it did not complete its proposed financing initiatives to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company timely filed an appeal and requested a Hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;), which has been granted.
The Hearing request automatically stayed Nasdaq&#8217;s delisting of the Company&#8217;s common shares and warrants pending the Panel&#8217;s
decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension through no
later than August 18, 2025. At the upcoming hearing, the Company will present its plan for regaining and sustaining compliance with the
Stockholders&#8217; Equity Requirement for continued listing. However, there can be no assurances that the Hearings Panel will grant
the Company an extension of time to regain compliance, or that the Company will be able to regain compliance during any extension period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to take reasonable measures available to regain compliance under Nasdaq&#8217;s listing rules and to remain listed on
Nasdaq. However, there can be no assurances that the Company will ultimately regain compliance with the Stockholders&#8217; Equity Rule,
or be able to maintain compliance with all other applicable requirements for continued listing on Nasdaq. If the Company does not regain
compliance with Nasdaq&#8217;s continued listing requirements within the time period permitted by Nasdaq, then the Company&#8217;s securities
will be delisted from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination
of At-the-Market Sales Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WallachBeth
Capital, LLC.</b> Effective January 6, 2025, the Company entered into an At-the-Market Sales Agreement (the &#8220;Sales Agreement&#8221;)
with WallachBeth Capital, LLC (the &#8220;Agent&#8221;) pursuant to which the Company may offer and sell from time to time through the
Agent, acting as agent, shares of its common stock, $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_zLWWLbiydgya" title="Sale of stock, price per share">0.0001</span> par value per share, having an aggregate offering price of up to $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20250106__20250106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember__srt--RangeAxis__srt--MaximumMember_zPx8pQU8fwx8" title="Aggregate offering price">1,700,000</span>,
subject to the terms and conditions of the Agreement. The issuance and sale, if any, of shares of common stock through the Agent under
the Sales Agreement was to be made pursuant to the Company&#8217;s effective shelf registration statement on Form S-3 (File No. 333-278874)
(the &#8220;Registration Statement&#8221;) filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 23, 2024,
and declared effective on May 2, 2024.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of shares of the Company&#8217;s common stock pursuant to the Sales Agreement was scheduled to terminate upon the earliest of
(i) the sale of the maximum dollar amount of shares of common stock subject to the Sales Agreement, (ii) the termination of the Sales
Agreement by the Company or the Agent, and (iii) the expiration of the shelf registration statement on Form S-3 (File No. 333-278874)
on the third anniversary of the initial effective date of such registration statement. <span id="xdx_90F_eus-gaap--SaleOfStockDescriptionOfTransaction_pid_c20250307__20250307__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_zGF1KYdEYA0g" title="Description of stock transaction">On March 7, 2025, the Company provided a notice
of termination of the Sales Agreement to the Agent, which, pursuant to the terms of the Sales Agreement, will become effective 10 days
after issuance, or March 18, 2025. No shares of common stock were sold under this Sales Agreement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sale
of Securities Pursuant to Securities Purchase Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers
named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, (a) in a registered direct offering
(the &#8220;Registered Offering&#8221;), an aggregate of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zh9s9g5sJ1ib" title="Number of shares issued">434,784</span> shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock,
par value $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zDoTMOUdUI4f" title="Sale of stock, price per share">0.0001</span> per share (the &#8220;Common Stock&#8221;), at an offering price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zD18FKAYQFy8" title="Sale of stock, price per share">2.415</span> per share, and (b) in a concurrent private
placement (the &#8220;Private Offering&#8221;), warrants (the &#8220;Common Stock Warrants&#8221;) to purchase an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzki4rINDy5h" title="Number of warrants issued">434,784</span>
shares of Common Stock. The Common Stock Warrants were immediately exercisable for a term of <span id="xdx_905_ecustom--ClassOfWarrantOrRightExercisableTerm_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zXGCQqEqDC1a" title="Class of warrant or right exercisable term">five years</span> from issuance at an exercise
price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zm7giliVbI3g" title="Exercise price per share">2.29</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Warrants and the shares of Common Stock underlying the Common Stock Warrants have not been registered under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and have been issued in reliance on an exemption from the registration requirements
of the Securities Act afforded by Section 4(a)(2) thereof. The Common Stock Warrants and the shares of the Company&#8217;s Common Stock
underlying the Common Stock Warrants may not be offered or sold in the United States in the absence of an effective registration statement
or exemption from applicable registration requirements. The Company has agreed to file a registration statement to cover the resale of
any share of Common Stock issuable upon the exercise of the Common Stock Warrants by April 4, 2025. The Registered Offering and Private
Offering are referred to herein as the &#8220;Offering&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering resulted in gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember_zIxauiAYnN4l" title="Gross proceeds">1,050,003</span> before deducting the placement agent&#8217;s fees and related offering expenses. The
Shares were offered by the Company pursuant to a prospectus supplement to the Company&#8217;s effective shelf registration statement
on Form S-3 (Registration No. 333-278874), which was initially filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;)
on April 23, 2024, and was declared effective by the Commission on May 2, 2024. The Offering closed on February 13, 2025 (the &#8220;Closing
Date&#8221;). H.C. Wainwright &amp; Co., LLC acted as the exclusive placement agent for the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Fundamental Transaction (as defined in the Common Stock Warrants) occurs, then the successor entity will succeed to, and be substituted
for the Company, and may exercise every right and power that the Company may exercise and will assume all of the Company&#8217;s obligations
under the Common Stock Warrants with the same effect as if such successor entity had been named in the Common Warrant itself. If holders
of shares of the Company&#8217;s Common Stock are given a choice as to the securities, cash or property to be received in such a Fundamental
Transaction, then the holder of the Common Stock Warrants shall be given the same choice as to the consideration it would receive upon
any exercise of the Common Stock Warrants following such a Fundamental Transaction. Additionally, as more fully described in the Common
Stock Warrants, in the event of certain Fundamental Transactions, the holders of such Common Stock Warrants will be entitled to receive
cash consideration in an amount equal to the Black-Scholes value of the Common Stock Warrants on the date of consummation of such Fundamental
Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued to the Placement Agent, or its designees, warrants (the &#8220;Placement Agent&#8217;s Warrants&#8221;)
to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSOkkSC5AQS6" title="Number of warrants issued">32,609</span> shares of Common Stock, which represents <span id="xdx_909_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlWEAF5LECRi" title="Percentage of shares sold">7.5%</span> of the Shares sold in the Registered Offering. The Placement Agent&#8217;s
Warrants have an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zI6NXxN1Imbk" title="Exercise price per share">3.0188</span> per share, and a term of five years form the commencement of the sales pursuant to the Offering
and otherwise have the same terms as the Common Stock Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent&#8217;s Warrants and the shares of Common Stock underlying the Placement Agent&#8217;s Warrants have not been registered
under the Securities Act and have been issued in reliance on an exemption from the registration requirements of the Securities Act afforded
by Section 4(a)(2) thereof. The Placement Agent&#8217;s Warrants and the shares of the Company&#8217;s Common Stock underlying the Placement
Agent&#8217;s Warrants may not be offered or sold in the United States in the absence of an effective registration statement or exemption
from applicable registration requirements. As soon as practicable (and in any event by April 4, 2025), the Company has agreed to file
a registration statement on Form S-1 providing for the resale by the Purchasers of the Common Warrant Shares issued and issuable upon
exercise of the Common Warrants. The Company is obligated to use commercially reasonable efforts to cause such registration statement
to become effective within 120 days following the Closing Date and to keep such registration statement effective at all times until no
Purchaser owns any Common Warrants or Common Warrant Shares issuable upon exercise thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Significant Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 11, 2025, the Company entered into Amendment No. 1 to the Collaboration Agreement between the Company and GEIS that relieved the
Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $<span id="xdx_90D_eus-gaap--OtherCommitment_iI_uEUR_c20250311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zQVvdMliOe9j" title="Aggregate commitments expected">3,095,000</span> (see Note 8).</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zcsIdVU2V1Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zEuemcl2zLm9">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zYvjq1FPqv17" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zoX5utclQqPk">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s President and Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) and evaluates
performance and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis.
Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates in a single reportable
segment, which consists of the development of a drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated
financial results of the Company. The CODM uses consolidated net income (loss) as the sole measure of segment profit or loss. The required
segment information, including significant segment expenses, is presented at Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_840_eus-gaap--UseOfEstimates_zmvnkG6QTX85" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zUoSEeUK3TB8">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zG0A1VClo8q1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zOSF5nRCfQi3">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20241231_zuPcV34pXhV8" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_903_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_zZmG3YrZbOKd" title="Cash SIPC insurance">500,000</span>, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOkDrS9BPgeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zbpnMn2tEvs1">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_PrepaidInsurancePolicyTextBlock', window );">Prepaid Insurance</a></td>
<td class="text"><p id="xdx_845_ecustom--PrepaidInsurancePolicyTextBlock_z3h6e4ZR1uuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zBPYZfM44O72">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_DeferredOfferingCostsPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><p id="xdx_84C_ecustom--DeferredOfferingCostsPolicyTextBlock_zmXv6jpx1Dw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z5vbovG3uAmb">Offering
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent and Licensing Legal and Filing Fees and Costs</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFKb0Ge7Xzcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zkvflM1oU2r9">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20240101__20241231_z8kzl53Ud9r7" title="Legal and filing fees and costs">243,186</span> and $<span id="xdx_90E_eus-gaap--LegalFees_pp0p0_c20230101__20231231_z5i9qWOZxyQb" title="Legal and filing fees and costs">978,244</span> for the years ended December 31, 2024 and 2023, respectively. Patent and licensing legal and
filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zLGgas8MCWyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zGdRUYxAvfhl">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9cCd0QpT6ze"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zD825rhACgR9">10%</span></span> or more of general and administrative costs or research and development costs for the years ended December 31, 2024 and
2023 are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the years ended December 31, 2024 and 2023 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwUSECDxAlwj" title="Concentration risk percentage">8.6%</span> and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQXrAfWQzf68" title="Concentration risk percentage">23.3%</span> of total general
and administrative costs, respectively. General and administrative costs for the year ended December 31, 2024 also include charges from
two vendors and consultants representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRJHqxTpIgMk" title="Concentration of risk, percentage">15.0%</span> and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyddusgTwf8k" title="Concentration of risk, percentage">13.1%</span>, respectively, of total general and administrative costs. General and administrative
costs for the year ended December 31, 2023 also include charges from a vendor and consultant representing <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z30MQm4Fjg0k" title="Concentration of risk, percentage">10.4%</span> of total general and
administrative costs. General and administrative costs for the years ended December 31, 2024 and 2023 also included charges for the fair
value of stock options granted to directors and corporate officers representing <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_z9paTxDZXXX1" title="Concentration risk percentage">14.7%</span> and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_zbM2PsTnRHK2" title="Concentration risk percentage">18.4%</span>, respectively, of total general and administrative
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the year ended December 31, 2024 include charges from three vendors and consultants representing <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zHjn8TgPM1eh" title="Concentration of risk, percentage">39.2%</span>, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zoCCNC5i5Ujg" title="Concentration of risk, percentage">29.0%</span>
and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVdSOUKz5uX2" title="Concentration of risk, percentage">15.4%</span>, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2023
include charges from three vendors and consultants representing <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNvRjDIHroyd" title="Concentration of risk, percentage">29.9%</span>, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zKJgDKbflNyh" title="Concentration of risk, percentage">25.2%</span> and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5iMhCrmN43g" title="Concentration of risk, percentage">13.7%</span>, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_z4Stpixsnnd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_z8gALVTKeQ5h">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#8217;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at December 31, 2024 and 2023. In the event the Company was to determine that it would be able
to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be
credited to operations in the period such determination was made. Should the Company determine that it would not be able to realize all
or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period
such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2024 or 2023
and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.
Subsequent to December 31, 2024, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJ2AhX4EeRW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_znLUEeLScyNc">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#8217;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zArJkAjk1hQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zh6QqgtvV183">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;), and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance
outside of the Company&#8217;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance
sheet date. At December 31, 2024 and 2023, the Company did not have any liability-classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zbaux3PEnad8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zonN5FB7w03a">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkOy0A0pBYfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024 and 2023, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zHPj4DF7oZe6" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z4VI50AUQvL9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zNebEdGefqK9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zSbnaTJ2wWQe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z3WBLs00WJ0a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zmgHoDjTCpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">613,232</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">552,083</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zywad6fWeD06" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,494,514</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,433,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z3OYOmZ6i7Sh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzjL7LzueeNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z6jwXI0Q6Frk">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of <span id="xdx_906_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20241231_zqKinyWzaDg6" title="Foreign currency average rate">1.0823</span> and <span id="xdx_905_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20230101__20231231_z5eezjnOYcmf" title="Foreign currency average rate">1.0820</span> Euros per United States dollar, respectively. As of December 31,
2024 and 2023, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was not a party
to any foreign currency forward or exchange contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzbdSNTg8JPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zr6DQNoj1sf6">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments, which consists of accounts payable and accrued expenses is considered to be representative of
their respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWV5z0CNHuEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zoYAQW06qCIj">Recent
Accounting Pronouncements</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-03,
Presentation of Financial Statements (Topic 205), Income Statement &#8212; Reporting Comprehensive Income (Topic 220), Distinguishing
Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#8212; Stock Compensation (Topic 718) (&#8220;ASU 2023-03&#8221;).
ASU 2023-03 amends the FASB Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting
Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting
Series Release 280 &#8212; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide
any new guidance, there was no transition or effective date associated with its adoption. The Company adopted ASU 2023-03 immediately
upon its issuance in July 2023. The adoption of ASU 2023-03 did not have any impact on the Company&#8217;s consolidated financial statement
presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure.&#160; ASU 2023-07
amends the FASB Accounting Standards Codification to require additional reportable segment disclosures of a public entity by requiring
disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, requiring other new disclosures,
and requiring enhanced interim disclosures.&#160; ASU 2023-07 requires public entities with a single reportable segment to provide all
the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280 on an interim and annual basis.&#160; ASU 2023-07
is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, and is applied
retrospectively.&#160;The Company adopted ASU 2023-07 effective January 1, 2024 for the 2024 annual period on a retrospective basis.&#160;The
adoption of ASU 2023-07 resulted in additional required segment-related disclosures (see Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures
(Subtopic 220-40). ASU 2024-03 amends the FASB Accounting Standards Codification to require specified information about certain costs
and expenses in the notes to the financial statements at each interim and annual reporting period, including disclosure of the amounts
of purchases of inventory; employee compensation; depreciation; intangible asset amortization; and depreciation, depletion, and amortization
included in each relevant expense caption on the face of the income statement within continuing operations that contains any of the expense
categories previously listed. Disclosure will also be required of the total amount of selling expenses and an entity&#8217;s definition
of selling expenses in annual reporting periods. ASU 2024-03 does not change or remove current expense disclosure requirements, but does
affect where and how this information is presented in the notes to the financial statements. ASU 2024-03 is effective for annual reporting
periods beginning January 1, 2027, and interim periods within annual reporting periods beginning January 1, 2028. Early adoption is permitted.
The Company is in the process of evaluating ASU 2024-03 to determine its impact on the Company&#8217;s consolidated financial statement
presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statements, including their presentation and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5bzgaVIIWQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zu3j216Ka7K9">Reclassifications</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the adoption of ASU 2023-07 effective January 1, 2024, certain reclassifications have been made to the prior year statement
of operations to conform it to the current year presentation. In presenting general and administrative costs on the Company&#8217;s consolidated
statement of operations for the year ended December 31, 2023, $<span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zeb3o5LTx6ah" title="Legal and filing fees and costs">1,718,180</span> of compensation to related parties, $<span id="xdx_902_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zPz4cLHRxZo1" title="Legal and filing fees and costs">978,244</span> of patent and licensing
legal and filing fees and costs, and $<span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSvkEDE7wNU9" title="Legal and filing fees and costs">1,495,712</span> of other costs and expenses were shown separately. In presenting the Company&#8217;s
consolidated statement of operations for the year ended December 31, 2024, the Company has combined these categories into general and
administrative costs in the accompanying consolidated statement of operations for the year ended December 31, 2023. These reclassifications
had no effect on the reported results of operations, including loss from operations and net loss.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_PrepaidInsurancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Insurance [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_PrepaidInsurancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkOy0A0pBYfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024 and 2023, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zHPj4DF7oZe6" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z4VI50AUQvL9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zNebEdGefqK9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zSbnaTJ2wWQe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">72,917</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z3WBLs00WJ0a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,365</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zmgHoDjTCpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">613,232</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">552,083</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zywad6fWeD06" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,494,514</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,433,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Information by segment</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zP5EFrePXqoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM and included in general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPIJcxJyNOLl">Schedule
of Information by segment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zETcYSt7bFzi" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_z8UO2HUZbS84" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Compensation to related parties:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CashBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_zCLm9UfEApc" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; text-indent: 13.5pt">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">753,124</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">944,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_z46vrHQtW378" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 13.5pt">Stock-based</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">418,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">773,203</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maOEzto3_maGAAEzrRU_zbZOsPQhxxmd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Patent and licensing legal and filing fees and costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">978,244</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherConsultingAndProfessionalFees_i02_maOEzto3_maGAAEzrRU_zJT7l41PW0Q1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other consulting and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">735,021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">655,854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_zq1M5KBNuWJh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">442,976</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherCostAndExpenseOperating_i02_maOEzto3_maGAAEzrRU_zjykiRH4hWb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other costs and expenses, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">262,360</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">396,882</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02_mtGAAEzrRU_zzKr2726wAD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total general and administrative costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,846,557</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,192,136</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#8217;s
CODM, and included in research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zULItvwWvFu6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zDe9RiimY82h" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zXVQc8HCrOXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Clinical and related oversight costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">377,958</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">416,269</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zT0k6nIKot1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preclinical research focused on development of additional novel anti-cancer compounds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329,438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463,093</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_zmyzxwrGY0c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Regulatory service costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,836</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,738</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zlssANikio66" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total research and development costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">726,232</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">898,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of research and development costs for the years ended December 31, 2024 and 2023 based on the respective
geographical regions where such costs were incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zgS3gpVgf6ac" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zQuUutuOvKPh" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zhI62rfIJFwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">462,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">359,589</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zi2qV338Hpf9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,163</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zO57OxTVorqb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,198</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zBd5NB5odKhd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Netherlands</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">210,362</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">226,150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_z4TX9qz5HvAh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">726,232</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">898,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s total assets by segment at December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zgNLEZyDoDz1" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20231231_zAtd3ap42RPc" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zKvNy7KVPQK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Research and development assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">39,298</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">78,369</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zXnyYYYbrMg9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Corporate assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,106,205</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,230,251</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_iI_zIs5kCZrKhMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,145,503</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,308,620</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhcIZXlq9Czh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#8217;s
public offering, during the years ended December 31, 2024 and 2023 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zA0LzxTe39m8" style="display: none">Schedule
of Warrants Outstanding</span>&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Warrants outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvHUu21qIy06" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">190,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcSRgPR6Frqf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">50.161</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEZAjyDTOxd1" style="text-align: right" title="Number of Shares, Issued">618,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxMIT1R6kws8" style="text-align: right" title="Weighted Average Exercise Price, Issued">6.034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqUPaLqudB04" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3w2UWFqXbO9" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHUVxVlSkml9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWqXzT6yUnuh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhtKS7HDS22" style="text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">808,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOBaUP6LtZg" style="text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">16.407</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHRl5Z2KGZP7" style="text-align: right" title="Number of Shares, Issued"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdBlxcAjvoWb" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="-sec-ix-hidden: xdx2ixbrl0715">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOztlHckLpi8" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpnGHNQtUagf" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0719">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqGSfEZcfqFb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYX1oEXjnIh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0723">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXeuv9vUD975" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPW2Yq38twX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXLrtH3fCSbe" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">2.99</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGs6rbVFADM5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zB8XJIi0ChUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjX90tWAUER5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAxpK8s0Bnv2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable">16.407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwQvuPayTsh" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">2.99</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zJW3jkC8sjVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zlNz7iDJy66f" style="display: none">Schedule of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants <br/> Outstanding (Shares)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 2%; text-align: left">$</td><td style="width: 46%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BLW3JZyeU6" title="Exercise Prices">6.000</span></td><td style="width: 2%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAv0MNL8T0Va" style="width: 45%; text-align: right" title="Warrants Outstanding Shares">583,334</td><td style="width: 2%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxcR0ejaDVdh" title="Exercise Prices">6.600</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7JUSpnp3An2" style="text-align: right" title="Warrants Outstanding Shares">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOveWcXkvlOc" title="Exercise Prices">20.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zJfWm6ToHzy6" style="text-align: right" title="Warrants Outstanding Shares">29,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zZYsk5xZFzP" title="Exercise Prices">37.000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvZQLxqzHFYb" style="text-align: right" title="Warrants Outstanding Shares">11,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zDjqAiGL4Xsg" title="Exercise Prices">57.000</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zg9Z0wMJ1m7g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding Shares">149,700</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231_zCEMOz6bI6Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares">808,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrants Outstanding And Exercisable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Related Party Costs</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zCkUAaQ2qT4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2024 and 2023, is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_z0855uu1EIeb" style="display: none">Summary
of Related Party Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zqFSlMulDgNa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20230101__20231231_zV6VaY1AgAHb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
Ended December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zawWesLCRlSe" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">753,124</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">944,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zl3IsGzqtrfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Stock-based</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">418,422</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">773,203</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zcTgqVL3cSRg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,171,546</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,718,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Each Option Award Estimated Assumption</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zavaGoiujWQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2024, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zNrDkvVspYj8" style="display: none">Schedule
of Fair Value of Each Option Award Estimated Assumption</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zClvD3qZD5I6" title="Risk-free interest rate">3.550</span>%
    to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zUtnvCVi5V68" title="Risk-free interest rate">4.290</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20241231_zpklP1HcI7Y8" title="Expected dividend yield">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zD3o1Bin2H01" title="Expected volatility">125.59</span>%
    to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zWMs3o2xMUVa" title="Expected volatility">126.45</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zaKQpP0zrOp5" title="Expected life">2.5</span>
    to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zMg6pH8a5QH" title="Expected life">3.5</span> years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zEV5Y5uG5HB8" title="Risk-free interest rate">4.565</span>%
    to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z08wtOj4FW7f" title="Risk-free interest rate">4.843</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_z9iTTxDtBjG1" title="Expected dividend yield">0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zlA1ii6t9nk3" title="Expected volatility">138.05</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zsz1Kn08Z9bl" title="Expected life">4.0</span>
    years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Stock-based Compensation Costs</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zLmHfiQDu9Vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the years ended December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zgC3DbVUULNd" style="display: none">Summary
of Stock-based Compensation Costs</span>&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20240101__20241231_zCPUK4slL2Rf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zD7ueh03xcgj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zw41nmCfHsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">418,422</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">773,203</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zRIWM6L1xRA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Non-related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1161">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_zC9hb6zYcjhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">418,422</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">773,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWFBvOWESuj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2024 and 2023
is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z8jCAeDDOI2f" style="display: none">Summary
of Stock Option Activity Including Options Form of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                                                                                                                                                                                                                                                               Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Contractual Life</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(in Years)</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zEqJTGSvK8w6" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning">389,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zFVS6abLMYZj" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">29.183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zNz0eVZiNNlb" style="text-align: right" title="Number of shares, granted">290,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zhUt0lVuxo7f" style="text-align: right" title="Weighted average exercise price, granted">2.492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zyMcabLTWXEj" style="text-align: right" title="Number of shares, exercised">(1,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zoZSsYFi1C96" style="text-align: right" title="Weighted average exercise price, exercised">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvzjbhKsNVA4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired">(126,146</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z3eDmD362pL5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired">28.687</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zNsZKEOEHbQ3" style="text-align: right" title="Number of shares, stock options outstanding, at the end">552,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zdAC1ThDecti" style="text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">15.330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231_z5nJTobYUYk5" style="text-align: right" title="Number of shares, granted">92,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zUaVZz4zovPa" style="text-align: right" title="Weighted average exercise price, granted">2.259</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_ziyRLtF7njf2" style="text-align: right" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zgg5FRnlwTeb" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1195">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231_zmUY0rVkgze3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired">(31,666</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_z2fVu7X2tNAd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired">35.368</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zisLJpd1Xp63" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end">613,232</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zniAOJtrgp25" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">12.317</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_z3FMT0xDwTD1" title="Weighted average remaining contractual life (in years), stock options outstanding">3.08</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_zrlZMuvw59Tf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable">252,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zW8Vuv6cQ5Pc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable">28.387</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zcFNdfHDkKz9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable">409,897</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z4GpV6jBnfXd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable">17.100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zqqRxBwPm26a" title="Weighted average remaining contractual life (in years), stock options exercisable">2.75</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxCENmtaZDP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zATPZYEZtqe7" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options <br/> Outstanding (Shares)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable (Shares)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 2%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zUdjPHIoTpU1" style="width: 29%; text-align: right" title="Exercise Prices">1.870</td><td style="width: 2%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zPLnqMyc8LC8" style="width: 29%; text-align: right" title="Options Outstanding (Shares)">21,217</td><td style="width: 2%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhfjeM9xS2H" style="width: 28%; text-align: right" title="Options Exercisable (Shares)">21,217</td><td style="width: 2%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zMlBOsmIQWDe" style="text-align: right" title="Exercise Prices">1.950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbGfTIdPEjzj" style="text-align: right" title="Options Outstanding (Shares)">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zJPf0fapi55a" style="text-align: right" title="Options Exercisable (Shares)">104,165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zDZKuhgTEYV5" style="text-align: right" title="Exercise Prices">2.370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zMS7bvdTvIjg" style="text-align: right" title="Options Outstanding (Shares)">56,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWJIZmt3Iha" style="text-align: right" title="Options Exercisable (Shares)">26,598</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zoKtlMKICBRg" style="text-align: right" title="Exercise Prices">2.390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z4184IydkpKj" style="text-align: right" title="Options Outstanding (Shares)">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3CYfCHKP3ml" style="text-align: right" title="Options Exercisable (Shares)">2,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z6BAhCpDtVil" style="text-align: right" title="Exercise Prices">5.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4oo7pdUWGwd" style="text-align: right" title="Options Outstanding (Shares)">8,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z9F94HjKKxe" style="text-align: right" title="Options Exercisable (Shares)">8,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zDUtY0ROnTQc" style="text-align: right" title="Exercise Prices">5.880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z9gkiVfuIA9i" style="text-align: right" title="Options Outstanding (Shares)">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSwKjUz8Ptra" style="text-align: right" title="Options Exercisable (Shares)">30,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zINl9Gix6yWk" style="text-align: right" title="Exercise Prices">7.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqvBQe5D6csj" style="text-align: right" title="Options Outstanding (Shares)">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zopgLrWifA3d" style="text-align: right" title="Options Exercisable (Shares)">55,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zYxWTpuH3XF1" style="text-align: right" title="Exercise Prices">20.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zeIU5jit3mTj" style="text-align: right" title="Options Outstanding (Shares)">45,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8G91Hl00Zx4" style="text-align: right" title="Options Exercisable (Shares)">40,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zXocKwlCnDA3" style="text-align: right" title="Exercise Prices">20.600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zTIFtFO3b0O5" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO5FIkIDEdge" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zhKpThSwUhSg" style="text-align: right" title="Exercise Prices">28.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zk8fo0MKpFw5" style="text-align: right" title="Options Outstanding (Shares)">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zC7NtmxlyU4" style="text-align: right" title="Options Exercisable (Shares)">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zIDrWpTVGmDl" style="text-align: right" title="Exercise Prices">30.300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSZ3Uzb1Lduk" style="text-align: right" title="Options Outstanding (Shares)">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1sfqEiGkF5a" style="text-align: right" title="Options Exercisable (Shares)">30,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z4XC1cRXhEk6" style="text-align: right" title="Exercise Prices">32.100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZRbvYz7Twhf" style="text-align: right" title="Options Outstanding (Shares)">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zPbAT7QuotZe" style="text-align: right" title="Options Exercisable (Shares)">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zm8x6BwcAAul" style="text-align: right" title="Exercise Prices">60.000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zGbd8qGCO71i" style="text-align: right" title="Options Outstanding (Shares)">8,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zJRDC1T6atcg" style="text-align: right" title="Options Exercisable (Shares)">8,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zbIZs6lY2Ai1" style="text-align: right" title="Exercise Prices">71.400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPm1YGFhbvp" style="text-align: right" title="Options Outstanding (Shares)">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zAjXdDdK80Ec" style="text-align: right" title="Options Exercisable (Shares)">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_ziws5S9oXQ66" style="padding-bottom: 1pt; text-align: right" title="Exercise Prices">120.000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj7QDC3nkmzh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding (Shares)">8,334</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zylMGmJKZVg5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable (Shares)">8,334</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_z7BBJromCTEi" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)">613,232</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231_zUWwimlEsfRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)">409,897</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhcMrKCfMEyg" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z6Mg4awZE5Fl" style="display: none">Schedule of Components of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zhZf6zsba7ub" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20231231_zP1AFuQVBBm9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_zELyJMLaS4Gk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research credits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">652,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">612,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zBwHgXQtF5a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_z8HjiCuxMNK9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zA3UrvyNPuE6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net operating loss carryforwards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,515,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,601,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_z8A2JzUUu7g5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,617,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,688,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_zVRTtLd8PKe1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,617,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,688,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zzXX3BLEty3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zO7KRmwRQbIa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zIdAW3X8Ite7" style="display: none">Schedule of Effective Income Tax Rate</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20241231_zgAhkbWfYUrj" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zodb6ZAgqzS2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zOUdJUJqc2rl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">U. S. federal statutory tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_zEJojD5OZill" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_z43h5lMrnr7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expirations related to stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.4</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_za0dRVJpsqI9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustment to deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.8</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zADWTP1AqVjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24.3</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17.4</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_z9DPi7jgTpSj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Contractual Clinical Trials</a></td>
<td class="text"><p id="xdx_89A_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zbNYDSNxOP0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s ongoing contractual clinical trials described below as of March 14, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zyV50Cq5DUUh" style="display: none">Schedule
of Contractual Clinical Trials</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><span style="font-size: 8pt">Description
    of Clinical Trial</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Institution</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Start Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Projected End Date</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number
                                            of Patients</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>in
                                            Trial</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Study Objective</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Clinical Update</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Expected</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Date
                                            of Preliminary Efficacy</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Signal</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">NCT No.</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Financial</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Commitment</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 19%; text-align: left"><span style="font-size: 8pt"><span id="xdx_906_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zXixyQiSU8ni" title="Clinical trial, description">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer</span> (Phase 1b)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 8pt">Netherlands Cancer Institute (NKI)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zuV8mTERxdwj" title="Estimated Start Date">August 2024</span></span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 8pt"><span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zDj9IIabnRz1" title="Estimated End Date">December 2026</span></span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 6%; text-align: center"><span style="font-size: 8pt"><span id="xdx_902_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zrh1OR2gLFo2" title="Number of Patients in Trial">37</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 8pt">Determine RP2D with atezolizumab</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%; text-align: left"><span style="font-size: 8pt">First patient entered August 2024, in total two patients entered</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 8pt"><span id="xdx_904_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zS25rgjPU17f" title="Expected Date">June 2026</span></span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 8pt">NCT06012734</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zcorFI7OWv78" title="Remaining financial contractual commitment"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></span></span><span style="font-size: 8pt">(1</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 8pt"><span id="xdx_901_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z7i2OWVQ7vk8" title="Clinical trial, description">LB-100 combined with doxorubicin in advanced soft
    tissue sarcoma</span> (Phase 1b)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">GEIS</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zdJjLV15myt" title="Estimated Start Date">June 2023</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_901_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zHVmg7al70x1" title="Estimated End Date">Recruitment completed September 2024</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span id="xdx_907_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zCffF5jNIjjh" title="Number of Patients in Trial">9</span>
                                            to <span id="xdx_90B_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zUGXB7TkRXY8" title="Number of Patients in Trial">18</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Determine MTD and RP2D</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Fourteen patients entered</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zT0RXnmH1cL1" title="Expected Date">December 2025</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">NCT05809830</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td id="xdx_982_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zs1b7zL5Cn61" style="text-align: right" title="Remaining financial contractual commitment"><span style="font-size: 8pt">264,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDIp_zaK0ldzzzrnk" title="Clinical trial, description">Doxorubicin with or without LB-100 in advanced soft
    tissue sarcoma </span>(Randomized Phase 2)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">GEIS</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">TBD</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">TBD</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt"><span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zTQUm6J8wsGk" title="Number of Patients in Trial">150</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Determine efficacy: PFS</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical
    trial)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">TBD</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">NCT05809830</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zCxDdXQeHIvi" title="Remaining financial contractual commitment"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></span></span><span style="font-size: 8pt">(1</span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_903_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDIp_zj2xTKkOQkK" title="Clinical trial, description">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma</span> (Phase 1b/2)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">MD Anderson</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_903_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zQMbpJSy59Lj" title="Estimated Start Date">January 2024</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zzCWNGur0Zk7" title="Estimated End Date">December 2027</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zSwqRcECedGi" title="Number of Patients in Trial">21</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 8pt">Determine the OS of patients with recurrent ovarian
    clear cell carcinoma</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt">Nine patients entered</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zUMEVM22olN7" title="Expected Date">December 2026</span></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt">NCT06065462</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zhxbiG9B0Ac5" title="Remaining financial contractual commitment"><span style="-sec-ix-hidden: xdx2ixbrl1432">-</span></span></span><span style="font-size: 8pt">(1</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"><span style="font-size: 8pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td id="xdx_98A_eus-gaap--OtherCommitment_iI_c20250314_zokjzbaUrqnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Remaining financial contractual commitment"><span style="font-size: 8pt">264,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span id="xdx_F06_zXGwjXEDSFLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zndBSHdtJAg4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Subparagraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2025</div></th>
<th class="th"><div>Jun. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 14, 2025</div></th>
<th class="th"><div>Aug. 23, 2024</div></th>
<th class="th"><div>Aug. 19, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity', window );">Minimum net stockholders equity maintaining in nasdaq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stock holders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (827,219)<span></span>
</td>
<td class="num">$ (3,994,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,165,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,585,965<span></span>
</td>
<td class="nump">5,087,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,164,536<span></span>
</td>
<td class="nump">4,293,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,038,952<span></span>
</td>
<td class="nump">4,203,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember', window );">Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member] | Purchasers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="nump">$ 1,050,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stock holders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stock holders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nasdaq listing maintaining minimum net stockholders equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=LIXT_PurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=LIXT_PurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,494,514<span></span>
</td>
<td class="nump">1,433,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">808,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">613,232<span></span>
</td>
<td class="nump">552,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insurance</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CashSIPCInsuredAmount', window );">Cash SIPC insurance</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and filing fees and costs</a></td>
<td class="nump">$ 243,186<span></span>
</td>
<td class="nump">$ 978,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ForeignCurrencyExchangeRateTranslation', window );">Foreign currency average rate</a></td>
<td class="nump">1.0823<span></span>
</td>
<td class="nump">1.0820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and filing fees and costs</a></td>
<td class="nump">$ 1,495,712<span></span>
</td>
<td class="nump">$ 1,718,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">23.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember', window );">General And Administrative [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor And Consultant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember', window );">General And Administrative [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor And Consultant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor And Consultant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">39.20%<span></span>
</td>
<td class="nump">29.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor And Consultant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">25.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor And Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor and Consultant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">15.40%<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=LIXT_DirectorsAndCorporateOfficersMember', window );">Stock Options Granted to Directors and Corporate Officers [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk, percentage</a></td>
<td class="nump">14.70%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_CashSIPCInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash SIPC insured amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_CashSIPCInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ForeignCurrencyExchangeRateTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency exchange rate translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ForeignCurrencyExchangeRateTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=LIXT_GeneralAndAdministrativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorAndConsultantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorAndConsultantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=LIXT_DirectorsAndCorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=LIXT_DirectorsAndCorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Information by segment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CashBasedCompensationToRelatedParties', window );">Cash-based</a></td>
<td class="nump">$ 753,124<span></span>
</td>
<td class="nump">$ 944,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_StockBasedCompensationToRelatedParties', window );">Stock-based</a></td>
<td class="nump">418,422<span></span>
</td>
<td class="nump">773,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_LegalFeesRelatingToPatentsAndLicensing', window );">Patent and licensing legal and filing fees and costs</a></td>
<td class="nump">243,186<span></span>
</td>
<td class="nump">978,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_OtherConsultingAndProfessionalFees', window );">Other consulting and professional fees</a></td>
<td class="nump">735,021<span></span>
</td>
<td class="nump">655,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance expense</a></td>
<td class="nump">434,444<span></span>
</td>
<td class="nump">442,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other costs and expenses, net</a></td>
<td class="nump">262,360<span></span>
</td>
<td class="nump">396,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative costs</a></td>
<td class="nump">2,846,557<span></span>
</td>
<td class="nump">4,192,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">726,232<span></span>
</td>
<td class="nump">898,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,145,503<span></span>
</td>
<td class="nump">4,308,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=LIXT_ResearchAndDevelopmentMember', window );">Research And Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">39,298<span></span>
</td>
<td class="nump">78,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,106,205<span></span>
</td>
<td class="nump">4,230,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">462,566<span></span>
</td>
<td class="nump">359,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">SPAIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">51,022<span></span>
</td>
<td class="nump">295,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">2,282<span></span>
</td>
<td class="nump">17,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">NETHERLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">210,362<span></span>
</td>
<td class="nump">226,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=LIXT_ClinicalAndRelatedOversightCostsMember', window );">Clinical And Related Oversight Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">377,958<span></span>
</td>
<td class="nump">416,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=LIXT_PreclinicalResearchMember', window );">Preclinical Research [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">329,438<span></span>
</td>
<td class="nump">463,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=LIXT_RegulatoryServiceCostsMember', window );">Regulatory Service Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 18,836<span></span>
</td>
<td class="nump">$ 18,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_CashBasedCompensationToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash based compensation to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_CashBasedCompensationToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_LegalFeesRelatingToPatentsAndLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal fees relating to patents and licensing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_LegalFeesRelatingToPatentsAndLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_OtherConsultingAndProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other consulting and professional fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_OtherConsultingAndProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_StockBasedCompensationToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_StockBasedCompensationToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=LIXT_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=LIXT_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=LIXT_ClinicalAndRelatedOversightCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=LIXT_ClinicalAndRelatedOversightCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=LIXT_PreclinicalResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=LIXT_PreclinicalResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=LIXT_RegulatoryServiceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=LIXT_RegulatoryServiceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Ending Balance</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Ending Balance</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">190,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants Outstanding, Ending</a></td>
<td class="nump">$ 16.407<span></span>
</td>
<td class="nump">$ 50.161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">618,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6.034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Shares, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Ending Balance</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">808,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants Outstanding, Ending</a></td>
<td class="nump">$ 16.407<span></span>
</td>
<td class="nump">$ 16.407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Outstanding</a></td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants exercisable</a></td>
<td class="nump">808,365<span></span>
</td>
<td class="nump">808,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable', window );">Weighted Average Exercise Price, Warrants exercisable</a></td>
<td class="nump">$ 16.407<span></span>
</td>
<td class="nump">$ 16.407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Exercisable</a></td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option weighted average exercise price exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">808,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">583,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 37.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">11,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 57.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Shares</a></td>
<td class="nump">149,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 07, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Jun. 02, 2023</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Mar. 17, 2015</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
<td class="nump">2,249,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,137,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">6.60<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant expires date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,499,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,137,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember', window );">Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant expires date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 5.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">403,334<span></span>
</td>
<td class="nump">403,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend', window );">Principal cash obligations and commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares', window );">Annual net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
<td class="nump">72,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from sale of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 0.20833 shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual net revenue divided by converted or redeemed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share tranche of the series a convertible preferred stock receive a per share dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Related Party Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based</a></td>
<td class="nump">$ 418,422<span></span>
</td>
<td class="nump">$ 773,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">2,846,557<span></span>
</td>
<td class="nump">4,192,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Cash-based</a></td>
<td class="nump">753,124<span></span>
</td>
<td class="nump">944,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based</a></td>
<td class="nump">418,422<span></span>
</td>
<td class="nump">773,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 1,171,546<span></span>
</td>
<td class="nump">$ 1,718,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 17, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 09, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 12, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,846,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,192,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,038,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,203,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember', window );">New Independent Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember', window );">Annual Grant of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_SchellensMember', window );">Schellens [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
<td class="nump">&#8364; 104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Annual Grant of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Annual cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember', window );">Independent Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Appointment Grants of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Cash fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember', window );">Chairman of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember', window );">Chairman of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember', window );">Member of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember', window );">Member of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr. Kovach [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr. Kovach [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr.James S. Miser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr.James S. Miser [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Eric J. Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Paid office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Eric J. Forman [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Robert N. Weingarten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Robert N. Weingarten [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | BasvanderBaan [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fee payable for management of fund or trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_SchellensMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_SchellensMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LIXT_AppointmentGrantsOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LIXT_AppointmentGrantsOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrKovachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrKovachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Each Option Award Estimated Assumption (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">4.565%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">125.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.29%<span></span>
</td>
<td class="nump">4.843%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">126.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-based Compensation Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs</a></td>
<td class="nump">$ 418,422<span></span>
</td>
<td class="nump">$ 773,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs</a></td>
<td class="nump">418,422<span></span>
</td>
<td class="nump">773,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity Including Options Form of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the end</a></td>
<td class="nump">552,083<span></span>
</td>
<td class="nump">389,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding, at the end</a></td>
<td class="nump">$ 15.330<span></span>
</td>
<td class="nump">$ 29.183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">92,815<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 2.259<span></span>
</td>
<td class="nump">$ 2.492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5.025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, expired</a></td>
<td class="num">(31,666)<span></span>
</td>
<td class="num">(126,146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="nump">$ 35.368<span></span>
</td>
<td class="nump">$ 28.687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the end</a></td>
<td class="nump">613,232<span></span>
</td>
<td class="nump">552,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding, at the end</a></td>
<td class="nump">$ 12.317<span></span>
</td>
<td class="nump">$ 15.330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), stock options outstanding</a></td>
<td class="text">3 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, stock options exercisable</a></td>
<td class="nump">409,897<span></span>
</td>
<td class="nump">252,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options exercisable</a></td>
<td class="nump">$ 17.100<span></span>
</td>
<td class="nump">$ 28.387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), stock options exercisable</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">613,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">409,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">21,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">21,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">104,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">56,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">26,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 5.025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember', window );">Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 5.880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember', window );">Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 7.400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember', window );">Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember', window );">Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 20.600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember', window );">Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 28.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember', window );">Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 30.300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember', window );">Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 32.100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember', window );">Exercise PriceThirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 60.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">8,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">8,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember', window );">Exercise Price Fourteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 71.400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFifteenMember', window );">Exercise Price Fifteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 120.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">8,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">8,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 20, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Nov. 27, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 17, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 11, 2021</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Jul. 15, 2020</div></th>
<th class="th"><div>Jul. 14, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,232<span></span>
</td>
<td class="nump">552,083<span></span>
</td>
<td class="nump">389,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,897<span></span>
</td>
<td class="nump">252,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,815<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred compensation expense for unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair market value, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Outstanding stock options to acquire shares of common stock not vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember', window );">Five Non Officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,421,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
<td class="nump">38,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsOneMember', window );">Five Non-Officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,310<span></span>
</td>
<td class="nump">94,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember', window );">Four Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,565<span></span>
</td>
<td class="nump">61,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember', window );">Four Non-officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,532<span></span>
</td>
<td class="nump">48,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember', window );">Four Non-officer Directors [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="nump">$ 1.65002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorMember', window );">Four Non Officer Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorMember', window );">Four Non Officer Director [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="nump">16,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_SchellensMember', window );">Schellens [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options vest quarterly over a three-year period commencing on the last day of each calendar quarter
commencing September 30, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember', window );">Eric J. Forman [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesSMiserMember', window );">Dr.James S. Miser [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options vested 25% on August 1, 2020, 2021 and 2022, respectively, with
the final 25% vesting on August 1, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember', window );">Robert N. Weingarten [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August
12, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember', window );">Ms.Regina Brown [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 658,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,114<span></span>
</td>
<td class="nump">$ 35,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrvanderBaanMember', window );">Mrvander Baan [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares avaliable for issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares were available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_FairValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_FairValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourNonOfficerDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_SchellensMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_SchellensMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesSMiserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesSMiserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MrvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Components of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credits</a></td>
<td class="nump">$ 652,000<span></span>
</td>
<td class="nump">$ 612,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">844,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,550,000<span></span>
</td>
<td class="nump">1,631,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">9,515,000<span></span>
</td>
<td class="nump">8,601,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">12,617,000<span></span>
</td>
<td class="nump">11,688,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(12,617,000)<span></span>
</td>
<td class="num">(11,688,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U. S. federal statutory tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Expirations related to stock-based compensation</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset', window );">Adjustment to deferred tax asset</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">17.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Operating loss carryforwards, federal</a></td>
<td class="nump">$ 31,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating loss carryforwards, state</a></td>
<td class="nump">$ 35,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember', window );">New York State Division of Taxation and Finance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating loss carryforwards, state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,141,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Prior net operating loss conversion utilization</a></td>
<td class="text">The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Franchise Tax Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating loss carryforwards, state</a></td>
<td class="nump">$ 16,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Contractual Clinical Trials (Details)<br></strong></div></th>
<th class="th" colspan="2">
<div>Mar. 14, 2025 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment | $</a></td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Phase 1b [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">August 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">December 2026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial | Integer</a></td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedDateOfPreliminaryEfficacySignal', window );">Expected Date</a></td>
<td class="text">June 2026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Phase 1b Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100 combined with doxorubicin in advanced soft
    tissue sarcoma<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">June 2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">Recruitment completed September 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedDateOfPreliminaryEfficacySignal', window );">Expected Date</a></td>
<td class="text">December 2025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment | $</a></td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Phase 1b Two [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial | Integer</a></td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Phase 1b Two [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial | Integer</a></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Randomized Phase 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">Doxorubicin with or without LB-100 in advanced soft
    tissue sarcoma<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial | Integer</a></td>
<td class="nump">150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Clinical Trial Phase MD 1b 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClinicalTrialDescription', window );">Clinical trial, description</a></td>
<td class="text">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodStartDate', window );">Estimated Start Date</a></td>
<td class="text">January 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractualClinicalTrialPeriodEndDate', window );">Estimated End Date</a></td>
<td class="text">December 2027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfPatientInTrial', window );">Number of Patients in Trial | Integer</a></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedDateOfPreliminaryEfficacySignal', window );">Expected Date</a></td>
<td class="text">December 2026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining financial contractual commitment | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ClinicalTrialDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical trial description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ClinicalTrialDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractualClinicalTrialPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual clinical trial period end date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractualClinicalTrialPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractualClinicalTrialPeriodStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual clinical trial period start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractualClinicalTrialPeriodStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedDateOfPreliminaryEfficacySignal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected date of preliminary efficacy signal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedDateOfPreliminaryEfficacySignal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NumberOfPatientInTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patient in trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NumberOfPatientInTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseMD1b2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseMD1b2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 08, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 23, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 14, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 24, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2030 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 11, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 04, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 726,232<span></span>
</td>
<td class="nump">$ 898,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember', window );">GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AmountRelatedToMilestonePayment', window );">Amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember', window );">NDA Consulting Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember', window );">Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember', window );">Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember', window );">Clinical Research Support Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember', window );">Clinical Research Support Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="nump">$ 207,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,019<span></span>
</td>
<td class="nump">69,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">732,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPartsAndComponentsNetOfReserves', window );">Inventory costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">268,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bio Pharma Works LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ReimbursementExpense', window );">Reimbursed expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,200<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember', window );">Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="nump">&#8364; 391,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,362<span></span>
</td>
<td class="nump">226,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember', window );">Clinical Trial Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember', window );">Clinical Trial Research Monitoring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_WorkOrderAgreementCosts', window );">Work order agreement costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember', window );">Clinical Trial Research Monitoring [Member] | MD Anderson Cancer Center Clinical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember', window );">Clinical Trial Research Monitoring [Member] | Theradex Systems, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,642<span></span>
</td>
<td class="nump">20,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | Theradex Systems, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,593<span></span>
</td>
<td class="nump">14,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_EstimatedWorkCost', window );">Work cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,380<span></span>
</td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedPaymentinServices', window );">Percentage of payment through services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ExpectedPaymentThroughSoftware', window );">Percentage of payment through software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Non refundable license issue royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RoyaltyPayable', window );">Minimum annual royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationHealthCareCostsGross', window );">Dosing of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payment for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RoyatiesPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember', window );">License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Non refundable license issue royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember', window );">License Agreement [Member] | Due Each January 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RoyaltyPayable', window );">Minimum annual royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development process costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember', window );">MRI Global [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,308<span></span>
</td>
<td class="nump">$ 32,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Clinical Trial Monitoring Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Collaboration Agreement [Member] | GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Development Collaboration Agreement [Member] | GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AdvanceAmountRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance amount related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AdvanceAmountRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AmountRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AmountRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ConsultingAndAdvisoryCashFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting and advisory quarterly cash fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ConsultingAndAdvisoryCashFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_EstimatedWorkCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated work cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_EstimatedWorkCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedPaymentThroughSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of expected paymen through software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedPaymentThroughSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ExpectedPaymentinServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected payment in services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ExpectedPaymentinServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ReimbursementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ReimbursementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_RoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_RoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_RoyatiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royaties percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_RoyatiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_WorkOrderAgreementCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Work order agreement costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_WorkOrderAgreementCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationHealthCareCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expenses of a HCO before stop-loss insurance recoveries. Costs of services rendered (including costs of services rendered but not yet reported).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478201/954-450-30-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478201/954-450-30-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationHealthCareCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPartsAndComponentsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPartsAndComponentsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MDAndersonCancerCenterClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MDAndersonCancerCenterClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=LIXT_DueEachJanuaryOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=LIXT_DueEachJanuaryOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th">
<div>Feb. 11, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 06, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 20, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 11, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 23, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 19, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 07, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stock holders' equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (827,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,994,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,165,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,137,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | At The Market Sales Agreement [Member] | Wallach Beth Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Description of stock transaction</a></td>
<td class="text">On March 7, 2025, the Company provided a notice
of termination of the Sales Agreement to the Agent, which, pursuant to the terms of the Sales Agreement, will become effective 10 days
after issuance, or March 18, 2025. No shares of common stock were sold under this Sales Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member] | Purchasers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member] | Purchasers [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member] | Purchasers [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ClassOfWarrantOrRightExercisableTerm', window );">Class of warrant or right exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member] | Placement Agent [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Development Collaboration Agreement [Member] | GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stock holders' equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Subsequent Event [Member] | At The Market Sales Agreement [Member] | Wallach Beth Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ClassOfWarrantOrRightExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercisable term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ClassOfWarrantOrRightExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_WallachBethCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_WallachBethCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=LIXT_PurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=LIXT_PurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=LIXT_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=LIXT_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -!#>%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( -!#>%K0(*$J\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( -!#>%J-('=8YPD  -L]   8
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MB\6;Q(L/!9_K=VL?>5'P3!_.& 7SKDZ WR<<O/?R@[K ^GWN\_\ 4$L#!!0
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M\ONW:=FV[738,6ES91(L-@368C1H& W.9K1%(]VJI]=!]K2(%Z24(9PHZ 6
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M(@J&Z/MFC]W=_ER,;;,2MN(/B#%\T2Y_*6_#*/1]'KL;_;T4">=I&P/%8/^
MGE<\V<LZ B:MDC]"^^<2DIQF$@Y58++E$D+U!I7<O'4?IMNM&\<+^BT>"PB*
MZ=*C$^H/]Q("NS7$^R<NDTS5$0 0\^W>'$.,%"R@WRBC#M&12:C8$Q0O)2E:
M1T,I-<&NUPO8V9D'[ :41&5$KIW1?VCV=D;1N).2:(I3+P>P6P]T%:B2XI"9
M9&V^63>RE9S3]TO(C64"Q3ZEX00_T@L%XGVW1EEK$'$*C)?6H$MY&[+LI09Q
M2PV3Q6<1:R5K$1CV=F&SQ-B/8\^?2$4O,XA;9MRRW"@UQ#3:0#TL2[/ 3*&
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M<FD,X/];(?3SBYF@NZ5?_PM02P,$%     @ T$-X6KDH\V-/ @  H04  !@
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6RME&UOTS 0Q[^*91 :$JO3/'1=
M22.M+8A)#%4K@Q>(%VYR;:(Y=K"=9OOVV$X:NJF=$.)-X[/O__/=U7=Q(^2]
MR@$T>B@95U.<:UU-"%%I#B55 U$!-R<;(4NJC2FW1%42:.9$)2.^YXU(20N.
MD]CM+642BUJS@L-2(E67)96/,V"BF>(AWF_<%MM<VPV2Q!7=P@KT7;64QB(]
M)2M*X*H0'$G83/'5<#(/K;]S^%9 HP[6R&:R%N+>&M?9%'LV(&"0:DN@YK.#
M.3!F02:,7QT3]U=:X>%Z3__H<C>YK*F"N6#?BTSG4SS&*(,-K9F^%<TGZ/*)
M+"\53+E?U+2^H8=16BLMRDYL(B@+WG[I0U>' \%P=$+@=P+_N2 \(0@Z0> 2
M;2-S:2VHIDDL18.D]38TNW"U<6J33<'MO[C2TIP61J>3)7U$.X66(-V+X"F@
M1:%2)E0M 9VCN]4"G;U^&Q-M+K,2DG;@60OV3X"'/KH17.<*?> 99$\!Q$39
MA^KO0YWY+Q(7D Y0,'R'?,\/CP0T_WMY\$(X05^YP/%&_U2Y'U_IFL'/8W5K
ML<%QK.W:B:IH"E-LVE*!W %.WKP:CKSWQW+^3[ G%0C["H0OT9,O9LA<\U24
M@,X^"Z6.OI(6$3J$'2F[Y#R(QM'E*(K)[C"3(XZ1-[[P_,O>L8V2'+SV$N36
M#0&%4E%SW;ZF?K>=,S,S9UP_/MLW\^?*M1WY@VF'UPV5VX(KQ&!CD-[@(L)(
MM@.A-;2H7$^MA38=ZI:YF:$@K8,YWPBA]X:]H)_*R6]02P,$%     @ T$-X
M6DC"H!E# @  D 8  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6R=E5UO
MFS 4AO^*Y4F[6LM'OJ8,D))VTR*M4Y1VV\6T"P<.8-78S#:E_?>S#6'9E% I
M-^"/\[Y^SD$^1*V0CZH$T.BY8ES%N-2Z7GJ>2DNHB+H6-7"SDPM9$6VFLO!4
M+8%D3E0Q+_3]N5<1RG$2N;6M3"+1:$8Y;"523541^;(&)MH8!_BPL*-%J>V"
MET0U*> >]+=Z*\W,&UPR6@%75' D(8_Q*EBN%S;>!7RGT*JC,;*9[(5XM)--
M%F/? @&#5%L'8EY/< .,62.#\;OWQ,.15G@\/KA_<KF;7/9$P8U@/VBFRQB_
MQRB#G#1,[T3[&?I\9M8O%4RY)VJ[V&F(4=HH+:I>; @JRKLW>>[K<"0P/J<%
M82\('7=WD*.\)9HDD10MDC;:N-F!2]6I#1SE]J/<:VEVJ='I9&/*FX%$#Y)D
ME!=H)27A!9BR:Q5YVIQ@X[RT=UMW;N$9MPFZ$UR7"GWD&63_ZCU#-N"%![QU
M.&IX"^DUF@3O4.B'TQ&_R9#NQ/G-+T@7_?QBHM%&0Z5^G<J]LYZ<MK:W9ZEJ
MDD*,S?50()\ )V_?!'/_PPCX= "?CKDGNX8!"OS]["HXAD:K3-3Z_U)WN..&
M.6$*1L!F ]ALU.>KX%<7P(V;O@8W'^#F%U7M :2Y2^0,V[CG:VR+@6UQ<>'&
M^<9]S_)Y1UVB EFX7JA0*AJNNX8QK [M=M5UF;_A7:^^([*@7"$&N9'ZUPOS
M.677_[J)%K7K.7NA30=SP]+\,D#: +.?"Z$/$WO \!-*_@!02P,$%     @
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MJ]_;:("I >51%-P$1*:I9=8PA,[:I2R#N8VC6O%'T:DL95EI:2$D-X7R2+?
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MOJY(HCCR MS/C/&;"U;0O" ^_0]02P,$%     @ T$-X6K^UM440#P  !2H
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M)J/<>(NG&NO\Y8]V(VO]FPPJJ@MQ)9UVPJS%>ZN<JCT_>7'BL1>M.,DCW:M
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MNT(J?1S5QM51^]VT%\2GT*J(0?8+HH<H#C0DK':WP2(MT?2 !+1D&+@D=:W
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M46F'2B^:C^BU7=TE1)$05L<F+<H*0$G'[OB^M:XE5!(32A0XE:\/;4EHK:/
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MB3$^GL)NX3W7S>6&E5BZO7.+KOD8E!6&3^J![(_T4)\>@4W0[ ;)_!T8X<,
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MLO0"GJ^-\>F"-NB^_+S\+U!+ P04    " #00WA:2I4=^0H@   ,9   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6S%75MSVSBR?N>O8&4OE531BB7;
MB6<RDRK;27:]E9EQQ<GNJ3IU'B@1DC"A2 U VM'\^M,WW"C*\62WSGE);)(
M&HU&]]<7P#_<M^:S72O5Y5\V=6-_?++NNNWWSY_;Q5IM2CMIMZJ!-\O6;,H.
M?C6KYW9K5%E1HTW]?'9\_.+YIM3-D]<_T+,;\_J'MN]JW:@;D]M^LRG-[E+5
M[?V/3Z9/W(,/>K7N\,'SUS]LRY6Z5=VG[8V!WY[[7BJ]48W5;9,;M?SQR<7T
M^\M3_)X^^*=6]S;Z.<>9S-OV,_YR7?WXY!@)4K5:=-A#"?_=J2M5U]@1D/&;
M]/G$#XD-XY]=[^]H[C"7>6G555O_2U?=^L<GYT_R2BW+ONX^M/=_5S*?,^QO
MT=:6_LWO^=O3DR?YHK==NY'&0,%&-_Q_^47X$#4X/S[08"8-9D0W#T14OBF[
M\O4/IKW/#7X-O>$/-%5J#<3I!A?EMC/P5D.[[O4M+T;>+O-;O6KT4B_*ILLO
M%HNV;SK=K/*;MM8+K>P/SSL8#UL]7TC?E]SW[$#?TUG^4]MT:YN_;2I5I1T\
M!T(]M3-'[>7LP1[?J,4D/YD6^>QX=OI ?R=^]B?4WXL#_8U,,__OB[GM#$C+
M_XS-F/L[&>\/=]#W=ELNU(]/8(M89>[4D]=__=/TQ?&K!Z@]]=2>/M3[O[E6
M#_8]3OELDCU^S/S&Z&:AM[6R&7Q]U386WE0E;;Z/:Y65T&:S+9L=MEKXUZK*
ME[HIH6E9Y[:#![#G.XLC=FL%_5";?%W>J7RN5),#?=O20#.-FWK1F@H:*]@W
MW3K_U&CL\!:[L?E*-<J4=;W#[]06WA 10OC6TYL__>N?SF>SXU=_N[BXH1^G
MKY[E98-#+.J^4D3)(2K?ZR^=RB]UVZG%NFGK=K7+_][6%8QAB_RZ 9&EKN#K
M^W4+U!RU]PV08ONYU94&[A9C?4C3ZZ931A@'^J?&N5KJ$(2TL24I-QNQ1]4:
M] 3Q%1BTB)=ADM^J%=*=73>LS]W:")=Q[M.7KW M%= &7])(5VNMEOG;+VK1
MHP[-?UF"&"B3:QLOD6_,G_^R!=X3HV'7:E+B/Y6?H95C]M4O;WY*F*WNRKK'
MA<N@*=&'ZXIO-M 0>.U[K*1'8,0<+$T.:]PN^!40WO8&>83*NLIA6(TL;&#=
MP@H"/\J<!+WI^*,R%4EHK.TDNU2+LK>\_DAOH#'J+*;V0$_%0)8M3 &(@H6"
M+[IUV8%XR/R@:Q3LW,)L:@7SV;:F*^>URBPO7@%BI!=K&D7;L%,J=0<V=HN?
MX*,RKTP/&ZTNK<T7P"$8Z<: @$'O-^O6;F%4X% ^NX#QUGJNN]8 G22JT !(
M-9H8R+W'<\K"W(&%8/^&NW6"0L4, ^[9E"$-0 W85^U&Y4_KUEI8?)8C^$3E
M&U7:WBCL4.8+Z]0ND3TFQ\^Y;Z-^Z[7!720?Z2#1A6Q;% <;*2WWJ?H"D ;(
M*G"B00A@$7X&]N0GD_R35:C#WMI.;VA%<(^PWN$] R]'U0'O.*1$=SM62:A3
M'+D6)+D!K$-D="W)=:[\*,A[6*U^L^5-38)1+I> 8(A!+ NHQ3:HQ(CK\+WJ
MN&FMR[FN=8?*N.06R'&W-J,$DR*)NLZCKAV?\JHWR,OP':E/971;@87 A:0A
M6I"F7_MJQ3T#RT$A =J;_ZH(>M%8*%>U^E*X@0&#M485B,[Z2)Q 2==57FF8
MN\F1.4:3'E^:=B,C!;;U@"Y,QA^3RHI8"$(#"U)I^FT"&LBS']6#):T<>H*5
M7<.6:@T(3$WS-UHY)00O[TJ8<V]'%LF@]JTU;,$J@X6=(Z=*VS:X<5$JC*I9
M<N#EP<7H0!Q >F$[E&0J@"\T-]Z VBSZ#7R-!J"0Q?";CU4""AZ](:63P:\H
M8KA:85U88U*/I3%DC%&GJ8>DR<^Q:3N<6*71IF[1# ,G:5%:7,Q<=&_,Z,RH
M55^7!EH$Y8G#?U:PGK#NH';V)+]'S0.L$IU&WT<+W@%AOQ.,Z V2@-3<E;H6
M;D>:8+$NFQ58%%@"'(M'&K!R=,E90J-%C,B;Y!?+#F?; \]E4O@<%,H22(9I
M5\@=TX(*!8*+H<1FR,JR^A7@/7Y)& :U/>C-BP?VP9CP3Q)8%E@4@ M^3M+'
M'(VFD1&7@3,L#/6BK[UV Z(,$&)1I,"&Z(;8T^$V!**L,)(7?0M:$R 5O(ED
MAOF'O,%U0O4'"E$W *U[495 "&*_UF0(-S6)S55IU_1/!JIYK6H&>4 </)Z7
MS6?@[K:UFFS"RI2;'/W.KB0S.M^!NV%6H'8 _C4U2->_5%F#!@ZR6*!5U'>,
M1F"6@^]O-ZBP+TO3P"_OWU]E#JJDWSG0,AFVU[AQWUW__.'BB(6>[+]I ?4<
M54"+,F(8!X!IBQ":FI--X!F1:L*)9Q[UD3T)F@.YJ;N>=XPL8PJ J<$:'--\
M ;82V,;XR0JVS04-8VLTNL1#[.6=JA X W)C;E_C:Z0!@*(! \!B\A0_%0Z]
M>W-]%8.YYR VTMDMP$;#>N2ZN5.XUQB(L%]^J,?;ZYNKP.F(;6)Y4"#K7898
M2L1#N(1;_2"/U!?XQ,,5I)IX@8,Q$PC%(81FO?KG?'9V7!P?'^=GQ_S_!\ +
MI5FL,VSW)L)<R8L8C/%^$;B&;@=X5*A $40H('A;:MJ:^ 7L^M+99?B='%&/
MRWB[>;/,-@4-,]N41JU:V(:D^+)*(?0I8D(*,H7]HA-,[4TA$))N<9$<T$);
MPA[M*,[W;="H@QQ5U"_L3!H#%%)%B&^2.<[DXYR!\=K$T^+'M!>:'M4V D(W
MB!@'LJE1MX,).)",FA9L@%FQ7187@CP'4I)H/ZKQ7:E!6!M@/BW4^\NC*2Q^
MH@W1,4#Q([<K(K4"I$E(4=6[T7V9R?;#%V][,!,*E A\0;[*GD^+7]7EO16#
MM!(M3>))%NA7V%X6]H/8IJ_((7(D.,;"FSSE#?P/-@\F?B?@H]9+CR,)DM3.
MBR<)M0A4:MQ8^$&Y6",0$M'*-KK&3=\XU,(0T!D:UP70@/$[_H1=HV",@"DK
MHT2%PQ+P1H@,/?R,"J'S6"4/<)#W"Y";84BSZA$B !!OT08'(ST!G_T>J#8%
M[,<=FRA<;?.P['IDY.;1$ULKM22;!-+1M U8@R5PC6&$4=DXTQ.!_&5>ZQ6_
MR-S3O4T),@<;#"74S:P*Q#-R]'R3+>T7 _?IG7.B#4*$10M XG<FFBFD/6@>
M%B<1XSW=$'M\'N+B8D8S]A[ZOM2P9,>B U3AQ 'JP%:64847Y%RXB2:\R_^#
MO$/8/,8^1G-L21G0@.X!C5#U"")3UNYMK$@"Q:ZE,\T?F"D;!3>"J= QM EN
M?\SBB-W,*89<,)\PA&%P2'2=<)^3.,32<& [\(![X:3'2,,DOQ'V9YL2#,&V
M-[8OV4_V>H9F"^JW8W?0S9M<INJ.[7_;/$0E=Y0[R/D8%F4)BSS3.USD:"L_
MBC7?ME$H0 ) /MNG'RF1 !3JC;<.''C!9UD.'$Q D//VA7FI-.&PAR85*/G_
ME+?LWV!JBBF-NL.$#\>AH$%/[$$0Z'S^@1/$QOB@:G3<IGC@;WUI.K29$E;$
M\"J"OLSC:O\D8%!XP*$I)@I^V6AP6ADMHI*I-"R4]YY;CLG:",4N4,L QJ/W
MV$+,OE^RW=C'NLE2D PR8CK]N[?&9*#;#@.?[+<(:0>P!-A'!;H]77<*3('O
MBDJ>91!M<A03G>\R&==%GAX<DMB,:1M,PAUA<H-9'11MI$!='QS RB^$P4G/
M80-E*6!RW$!;[CN'+4=N;G>OZCMUM,&LEU?G\,%N;U^5+G3!(9=O44/"UQ"1
MHV ?::=@5 +%O##?K()0?G"\;"\"B.D A0%"4/NHZ/ROJ=]#6(\5X0&3+$$"
M<=Z0G5&&(P[JUFJ%T7Q%X8^>0N$.V0+P4M0Y^00!^)<5QP!1A& #'6&@MMQJ
M%*E^*P@$( ?*_;*O!QB5L(@GRQ($C1R+@<#K)0U.&&#0DJ'"'%ZW*.30C4.Z
MJ+MO2HRCD#)Y#WN9,&O^GN:*S][!EH4'[Y1$BIG;;WJ5R;K&L>X>!,5@& $8
M"A+6+C2MKG<HHKD.\@8P]8TR"S:P=YH$77RZ 6(;R%'F=;5:@K1TSF'A,,B6
M)H>B62-0YR6%,?P+"CFZ6==^UDN>]=+-FI<Z"F@-4A^9^* NO) F)B+G#O8&
ME@9@M UW"W!K]\"B)N#\YC$D9P.2[\$;P7#"Z4DQ/7^1?_?RO)B=GF*>%'KH
M>!Q,.GS0]G.<DTO"'9%EH:4$#[5R%B .'P#Q!% !1WFD,.#9D".Q9;P2^.]U
M(.Y^:&2C[B2^CV]*AU<70FS^M-MMA6($RSN0BV<H[L.O38O) =H(I?T\$9FF
M9. >D$%7*_-6$1Y,C_^2_XT5,ZUZ6<%6TI9X>>>B"$(YD6!!4:/^?:,6:C,'
MW>U*"6A$^.'$AR&< T0Q5]$WVFSBL*?C?619LR .)(8L)S!+2ZG3MHG%-XK<
M/$8Z-2VAS![;GD]>_"6?G4Q._I)/SR; B^G)9 K_'D].X=_3R4OX]QQ__DI
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M_ML3_ N@ /I[#_.VZ]H-_;A6L$(&/X#WRQ8TE_R" _@_ /+Z?P%02P,$%
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MO"X"]_LJ)_#Q=#"RK[H5I@T6;$X]_.[\OJ@1'^EZV]=2I0S>6NP:;[-ZU5$
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M&X7@<=AF1&"J7#JMI86':VLL+U-9KIG+!.?TQ.GLS1J0TH>:EG6Q%-J9?5:
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M&(V#AZY>G0OC]^TOWE0N"8[GOU6#$9N'V&DZ@0;1=# .9ZT&ISO]OW08G^C
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MUJK"/68"K*]I =ZO%!1M!K1!]_GOYB]02P,$%     @ T$-X6J[$?%CC"P
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MNDM9INUSM:6KR&NZ3H ;#]_YV[= +%\8O7N##GVIJ<%!%'9"?\.1U)6/0Y/
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M] #N+PSP%7[0!NT?8YS_#U!+ P04    " #00WA:1/@KK7 .  "9,   &0
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M9UG5O%#6FQ,0<40S5X*(S":JMLJI4(ME7JZ4JFW,+5A96&[S>@S4\$59-+7
M5%IJ"'?$Z\+ZO@717LC6Y-K\^:R454IS7_6$;"X4,@4C$ F-T3K!<A+?]2Q=
MY;(0C^GS5U\DON\^XUDTRN_>LR>VN)MGD[FX W]U>U.KWUJLS5>67"ZK\A;
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M98[<F>GNG:Y^*K!8I6VNR,J_)F)^[HBY(&)>:S).F8R+GH33'H3UI@L@5A=
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M68.L56NM?GI[^Q"FF&)'YG4K+*=!-X6A/7TPFR8L^T1=JO%%M/"[CS>LFLR
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M;I?DB-0G[ X[5OF<A!5C;O'5*I_E#6, 0C:-P</8U );<'\_N8)'%LD&'%X
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MI)!"DA=@"66^)!L?O41[!=UQJXY&%*ENZ!'H98<F(D[O0Y70,O&5Q3::@6T
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M$]O56D+J1;(UUY1N.QI?)G_/ZY9.4"X*I[ 0NEN/I#[0\/0"]5O1%3[)]8K
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MY"C*SE06&E%^79<-JGC7_@7(O8A8=BK)\-<+JT)P_0[=R73Y5J$0WP1T,"#
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M7X'RS&S951 M4I(MQXFK)%\FGG(2E>7,;-76/H!$D^P8!!A<)#._?L^M;R
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MX*,LR>L.K$"1-4VR @[!3#<U2#^,?K.MFCW,"AQ*%E<PW]8L35O50"?I$;P
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M ,.*9D=5-&KB?HVC14+([#Y&@(RDHB0HQYT.RH]A4:/0&ZQF:4JR=50*LO$
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MY>S1TK"8G+G#I6IZ[4-2$QHXS@(\C %3?Y_(WP"UF+X!"B+OJ$=M,*3_LV-
M8*(R\;W.4(]XZ%$PD#I'4Q^-[ROX=*&BJ"35)_A.#2],<:\8W[A()6[C,E;6
MAM";(>\I217<J/'5!OL'2+R:NNO+EM9&*FN *_X*[(%P/)T#6K0W[F I_@(^
M70Q)Q-/@SV[M=+VA/RY&';MERW^!RWWJ_H#9%?_9+O\X__4SB)8WZ&4*O897
M3V?/+QXE-?]!,?X%T C]$:]EU;;5CG[<:MB@&A^ []<56%#Y!2=P?];MU?\
M4$L#!!0    ( -!#>%J$&8W*1P,  $H'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;*U538_C-@R]YU<0+E"T@#O^2C*STR1 9G:*]K! L-FVAZ('
MQ:9C863)*\F3V?[ZDG+BS0#9H(=>H@^3C^^1(;4X&/OL&D0/KZW2;ADUWG?W
M2>+*!EOA;DR'FK[4QK;"T]'N$]=9%%5P:E62I^D\:874T6H1[C9VM3"]5U+C
MQH+KVU;8+P^HS&$99='IXJ/<-YXODM6B$WO<HO^]VU@Z)2-*)5O43AH-%NME
MM,[N'Z9L'PS^D'AP9WM@)3MCGOGP6[6,4B:$"DO/"(*6%WQ$I1B(:'P^8D9C
M2'8\WY_0?PG:2<M..'PTZD]9^689W45082UZY3^:PZ]XU#-CO-(H%W[A<+1-
M(RA[YTU[="8&K=3#*EZ/>?@O#OG1(0^\AT"!Y7OAQ6IAS0$L6Q,:;X+4X$WD
MI.:B;+VEKY+\_&H[% -,#5NYU[*6I= >UF5I>NVEWL/&*%E*=/##)[%3Z'Y<
M))X"LWM2'H,\#$'R;P3)<OA@M&\</.D*J[< "3$>:><GV@_Y5<3W6-Y D<60
MI_GT"EXQIJ$(>/-OX%W2^]=ZY[REO\W?EQ0/>,5E/&ZE>]>)$I<1]8I#^X+1
MZOOOLGGZ\Q6VTY'M]!KZ:DNM6?4*N6IK8OU3)57/_V[88ME;Z9G^TVNI>LHV
MU-:T\&C:KO<B= )Y/0FK2:R##5K8-L+B)8U765S6N/83J@VV.\(]U0>$KGA3
MQ. ;#%2$_@)X(LB7-"^<)SNN@/LJ8I@5\A^RVO$ B>'0R+(!)-6>$L"NC5$5
M6L=[BZ3-&^KUS[VT.'&LS+'@TK0M2:=^*I_C(272.RB%*GLUI@5/:>F(?G".
M001D:0'KFD8)39E>5= (RO8.D>;*>0%NX%2;R?]8FTG((F?P37+/KK=H&7=-
M6/H%K9?4J;"A 8?64I@MRX;;/'Z7W1Z7R>-91N @K"4A#N[2N[B8ST[K6RO3
M,4<7@]3,GVMUO +I7$^!I XEX<>"I8RP\ZR(\R*'V2R/T[MB\LEXH2"+I^^F
M\2R;\JXH0N!+[9&<S;<6[3Y,<2H>M^PPZL;;\:%8#_/QJ_GPRGP0=B^)K\*:
M7-.;VUD$=IC<P\&;+DS+G?$T>\.VH<<.+1O0]]H8?SIP@/'Y7/T+4$L#!!0
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MYZ@_S7U#B:R[GS2@ES5H= 0TC."K%";3<"U23%\"^,2PHQFU-"^CDXB?,1E
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M_PA4%D#[I91F,[$)MG^=\3]02P,$%     @ T$-X6JFXN4K+!0  9Q$  !D
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M?8.!ZB!@K&[4:*EM&FKN=MMXOG:<9VKG!0%R/J^,+0VAW^L2?3-',=V/UU3
MR1*=WU*1,TF=2V@S]/'S*ZJ/K]K(&1Q<](M_!27SNU;_ ?ANBO70N7[04N&
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MI@S6$%-YRE-(\,N2BY@J'(J5*5,!-,R#XLAT+,LS8\H2PQ_F<S/A#WFF(I;
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MY1?PZ1W)'@EOU;@5YU2-.P*K41Y6E(?.![BA2_*.P&KDH6]F3M^UG$K$?:'
M<-CM0]0HT;:&?3B  [^]2N'>? _MPYF*+9_M<:JBW=4I^ \\D&="-P3<*:FM
ME"=XVO]Q=ZLG3 U_5/+B9C\DXLE:ZO983KW=KM#JF4,F<\AYN9>0KA+@"*V>
M .-GH-4QC.LW7]405_?_)5@3KD^K@;DU P6F+NBJE/TKV*SW(ZWJ$1L3 NTN
MY VA:L8H1'H;*_N<"%E85_#JLWH2$N3B"G!D7<HT7<((0>.$8->] APYGC(!
ME_!/T!@H:'=0YRF@P(2P5MO^H#NL?9J*:.V%@N" )HRI@G97M=/$[=>:^%8M
M3/+G4L)M8E#-/A(:,YY?2#44ZL%:/UJ^I\2N&&OX)Q>,([1ZLHTIA /WBG%J
M$%VAU1-@+"*TFK S%3-LG0VZ38E<PO\AX_^0W?]];R']M656(=G#/[6.7*'5
MDVUL*X+.A82<ND]7:/4$&/>)K.;N/"&5F(U)! 9-^V6_]KG<C+%$=F/YH# Q
MCU:Y3YLJP:1LG2E6)YNTBTY,=A(GE],EWLXAXXQ1Z%Y/3KVL*[1Z HR714=>
MZYVEIVZ;GH)A\_&]O1W:,WGUJ(T!178#^F,HY>C,8R5Q<J$X0JNGW/AEU'>O
M%*<>UA5:/0'&PR+[F\WSE#)HLW"H^92S:]802O? RUAD?">R^\X?0RA6D3A]
M%>H*K;[29;QPX+M?ZW+J3UVAU1-@_&EP[+7J&2*Q8YZ< =AJ]OP#JS"!L9Z!
MW7I^)RWAQJ2SXL1NT.PT3D[G)3QQL+=X?('58[?+QY=PJ(%QJ,&1%>2S%!6V
M:J ;-N:= ^V"_@&M&%L9V&WE7++H";Q?ZZ %>,-5Y9(82 :F"2>19%R4=<W7
M3"]C@O>+11(1?O&E&'O<)]?&)=[#!L8&!SWWXG!J2EVAU1-@3&E@?XE[GCCZ
MK44?]IOB:&\W:$XDWMZV(S6J+_/=6 +D.X>*73O5V6+'UQV\GN0;HQKG;^'U
M;;[_R3,PQ3:R=Y@O$R6DE"P4I'_55W7'BYU9Q8%DZWQSTR.3:FK)OZX(C@G7
M#=3O"\;D[D!?H-H?-_X?4$L#!!0    ( -!#>%IKOBT=-08  )TB   9
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M/FF=]JJ%^D*KY\)H(>K>G^FNTZ3U*A/',6TNTJUF$6WJT>'!BWZ5XT7U_8-
M&=N4<OOF?']U^XW%!WPVJ3Y%:%P?X[-Q]<7!T,!L/]SXG/)%7@I4P%Q!>N\C
M]>CP[;<0VQ/)UM7G! ],JH&N#I>0SH!K _7[G#'Y<J)OL/\B9?0?4$L#!!0
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MM]8:-"V TBB4QJ T#J7%*)JNR;UGSD+3@@#[V%GL<V>Q#Y[%/GD6^^A9:%J
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M#B,NR'U1RU%Z^^U2)'*@WQP@?_Y0%/7+BZ:"YZ+\W#;[YG]02P,$%     @
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M>/V$ZM]OYO/5TU_6 WR?+_[8G/;%_P-02P,$%     @ T$-X6F$RZDFT P
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MC^(V$/Y7K+2J[J3=)'9(2+: !+L]]1ZN7=VJW8>J#R89(-HDIK:!Y;^OG80
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M0MTB0IN(4$L>H AMI<B]?)2)?9!TP0@%1FB?C- N&*' "'7+"-4P(H:^H28
M$>H6$:HY&3$?:/F@B.]6$;^IB"T/8,1OQ<A-.?EC'2/V>)=>J0=(_#XA\;N
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M_H5*-]6]*P^I4FE</5W+8"&S<H'B\V6:JN.+<@6GNYEF_P%02P,$%     @
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M,DIK9DE5.="_IG+@RBE1M'4 U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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MJG9@\%UJ!\1JYV!!:P=034,U'=4,5#-1S4(U&]6<"[\3+Q<%N.A^>*CFHUJ
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M1Q<U4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+4"U%M8S2FDE1]0&,Q7T
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M<">(W.0Y%:\WP/AN8KG68>$^6ZV57K#C<4E7, ?U6-X)G-F-2IKE4,B,%T3
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M4;0;+TI33T6AD,3/(_'WC!,1D&(G:$SQ5N^%K:)Y;:'5"=U=#>W>&Z5XFW?
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M5>![1TZ!WB.@[5=H^^A05[5E76T]!]8QL99+1VM-4'%C;R]_IV'HTF8"3Z9
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MU N]D31AR[*_3&H!&+N/LY,\YZNWG,U$2LW@6P<<#<C:SYEGDGW3T:!4IMI
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" #00WA:#C5FRED$   /'P  #P   'AL+W=O<FMB;V]K+GAM;,696V\:.12
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MGH^_+Q\G.^_X'6<'?^P6OU!+ P04    " #00WA:)OJ'I[4!  #<&P  $P
M %M#;VYT96YT7U1Y<&5S72YX;6S-F<UNPC 0A%\%Y8J(L9W2'P&7MM>60U_
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M?];]U)M_ E!+ 0(4 Q0    ( -!#>%I&QTU(E0   ,T    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ T$-X6M @H2KR
M    *P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ T$-X6IE<G",0!@  G"<  !,              ( !Y $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #00WA:C2!W6.<)  #;/0
M&               @($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ T$-X6J:'6$TP!0  ,1,  !@              ("!0A(  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( -!#>%I=M-4!K ,
M /H-   8              " @:@7  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " #00WA:SWW'@QD$   &#P  &               @(&*
M&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ T$-X6HK4
M;>QM!0  >1\  !@              ("!V1\  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( -!#>%K/X"JPG04  +$7   8
M  " @7PE  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #0
M0WA:N2CS8T\"  "A!0  &               @(%/*P  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ T$-X6DC"H!E# @  D 8  !@
M         ("!U"T  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( -!#>%JD3QTVI <  "P>   8              " @4TP  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #00WA:O[6U11 /   %*@
M&0              @($G.   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( -!#>%I*E1WY"B    QD   9              " @6Y'  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ T$-X6NK:^!JX
M!0  P@T  !D              ("!KV<  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " #00WA:"DRL\ML'   *%   &0
M@(&>;0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -!#
M>%JNQ'Q8XPL  )@A   9              " @;!U  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ T$-X6D3X*ZUP#@  F3   !D
M         ("!RH$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " #00WA:D=ZW!S\'  "]$   &0              @(%QD   >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -!#>%H3_"=O@"0  &II
M   9              " @>>7  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ T$-X6H&FBGN*#   %R4  !D              ("!GKP
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #00WA:I]ZF
MNV\A  #B;0  &0              @(%?R0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( -!#>%J$&8W*1P,  $H'   9
M  " @07K  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MT$-X6C3=6 /L!   IPL  !D              ("!@^X  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " #00WA:0P($2+4#  "O"0  &0
M            @(&F\P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( -!#>%K&/\C$\@(  ($&   9              " @9+W  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ T$-X6JFXN4K+!0
M9Q$  !D              ("!N_H  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " #00WA:!WM>;Y0#  !T"   &0              @(&]
M  $ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -!#>%HW
MK@A.LP0  ( *   9              " @8@$ 0!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ T$-X6H0?G!+<!P  D58  !D
M     ("!<@D! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -!#>%K[WD*W>0,  %$1   9              "
M@1HF 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ T$-X
M6B71$VKX#0  /Z<  !D              ("!RBD! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " #00WA:=VK93?T"    "@  &0
M        @('Y-P$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( -!#>%H2E/]A?Q4  #J> 0 9              " @2T[ 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ T$-X6F$RZDFT P  ?Q
M !D              ("!XU ! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " #00WA:66-#4>\"  !Y"P  &0              @('.5 $
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -!#>%HXE=_D
M-P0  - 0   9              " @?17 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ T$-X6M8UR0=Q!@  V30  !D
M ("!8EP! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #0
M0WA:6@K7->,M  !=P , &0              @($*8P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( -!#>%JLQH>9#P,  &$)   9
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M970T-2YX;6Q02P$"% ,4    " #00WA:*;;(@K,+  "!H0  &0
M    @(&EO@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M -!#>%I%>\4HA ,  *48   -              "  8_* 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ T$-X6I>*NQS     $P(   L              ( !
M/LX! %]R96QS+RYR96QS4$L! A0#%     @ T$-X6@XU9LI9!   #Q\   \
M             ( !)\\! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -!#
M>%K]+-6EK@$  ,$;   :              "  :W3 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -!#>%HF^H>GM0$  -P;   3
M          "  9/5 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     V #8
*L0X  'G7 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>323</ContextCount>
  <ElementCount>288</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>122</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/SegmentInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Organization and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Organization and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Schedule of Information by segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfInformationBySegmentDetails</Role>
      <ShortName>Schedule of Information by segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails</Role>
      <ShortName>Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquityTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Summary of Related Party Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfRelatedPartyCostsDetails</Role>
      <ShortName>Summary of Related Party Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails</Role>
      <ShortName>Schedule of Fair Value of Each Option Award Estimated Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Summary of Stock-based Compensation Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails</Role>
      <ShortName>Summary of Stock-based Compensation Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Summary of Stock Option Activity Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Schedule of Contractual Clinical Trials (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails</Role>
      <ShortName>Schedule of Contractual Clinical Trials (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/SubsequentEvents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>lixt-20241231.xsd</File>
    <File>lixt-20241231_cal.xml</File>
    <File>lixt-20241231_def.xml</File>
    <File>lixt-20241231_lab.xml</File>
    <File>lixt-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="696">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "LIXT",
   "nsuri": "http://lixte.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "lixt-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lixt-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lixt-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lixt-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lixt-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 241,
   "keyCustom": 47,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 83,
   "hidden": {
    "total": 55,
    "http://fasb.org/us-gaap/2024": 44,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://lixte.com/20241231": 8
   },
   "contextCount": 323,
   "entityCount": 1,
   "segmentCount": 122,
   "elementCount": 623,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 696,
    "http://xbrl.sec.gov/dei/2024": 43,
    "http://xbrl.sec.gov/cyd/2024": 11,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://lixte.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://lixte.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "LIXT:AdvancesOnResearchAndDevelopmentContractServices",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://lixte.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://lixte.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://lixte.com/role/StatementsOfStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://lixte.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentation",
     "longName": "999014 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://lixte.com/role/SegmentInformation",
     "longName": "999016 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://lixte.com/role/StockholdersEquity",
     "longName": "999017 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://lixte.com/role/RelatedPartyTransactions",
     "longName": "999018 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://lixte.com/role/Stock-basedCompensation",
     "longName": "999019 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://lixte.com/role/IncomeTaxes",
     "longName": "999020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://lixte.com/role/CommitmentsAndContingencies",
     "longName": "999021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://lixte.com/role/SubsequentEvents",
     "longName": "999022 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999023 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999024 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://lixte.com/role/SegmentInformationTables",
     "longName": "999025 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://lixte.com/role/StockholdersEquityTables",
     "longName": "999026 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://lixte.com/role/RelatedPartyTransactionsTables",
     "longName": "999027 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://lixte.com/role/Stock-basedCompensationTables",
     "longName": "999028 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://lixte.com/role/IncomeTaxesTables",
     "longName": "999029 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://lixte.com/role/CommitmentsAndContingenciesTables",
     "longName": "999030 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
     "longName": "999031 - Disclosure - Organization and Basis of Presentation (Details Narrative)",
     "shortName": "Organization and Basis of Presentation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-02",
      "name": "LIXT:NasdaqListingMaintainingMinimumNetStockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-02",
      "name": "LIXT:NasdaqListingMaintainingMinimumNetStockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "999032 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://lixte.com/role/ScheduleOfInformationBySegmentDetails",
     "longName": "999034 - Disclosure - Schedule of Information by segment (Details)",
     "shortName": "Schedule of Information by segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "LIXT:CashBasedCompensationToRelatedParties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "LIXT:CashBasedCompensationToRelatedParties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
     "longName": "999035 - Disclosure - Schedule of Warrants Outstanding (Details)",
     "shortName": "Schedule of Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_CommonStockWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "999036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_ExercisePriceOneMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://lixte.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999037 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-08-07_us-gaap_InvestorMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
     "longName": "999038 - Disclosure - Summary of Related Party Costs (Details)",
     "shortName": "Summary of Related Party Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_srt_DirectorMember24650984",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999039 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_SchellensMember",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
     "longName": "999040 - Disclosure - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)",
     "shortName": "Schedule of Fair Value of Each Option Award Estimated Assumption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails",
     "longName": "999041 - Disclosure - Summary of Stock-based Compensation Costs (Details)",
     "shortName": "Summary of Stock-based Compensation Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_RelatedPartyMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
     "longName": "999042 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)",
     "shortName": "Summary of Stock Option Activity Including Options Form of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
     "longName": "999043 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "shortName": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999044 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails",
     "longName": "999045 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)",
     "shortName": "Schedule of Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails",
     "longName": "999046 - Disclosure - Schedule of Effective Income Tax Rate (Details)",
     "shortName": "Schedule of Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://lixte.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999047 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
     "longName": "999048 - Disclosure - Schedule of Contractual Clinical Trials (Details)",
     "shortName": "Schedule of Contractual Clinical Trials (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-14",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember",
      "name": "LIXT:ClinicalTrialDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999049 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-14",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember",
      "name": "LIXT:AmountRelatedToMilestonePayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://lixte.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999050 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-01-06_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses, including $27,500 and $36,250 to related parties at December 31, 2024 and 2023, respectively",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties accounts payable and accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r777"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r777",
      "r1057"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r952",
      "r953",
      "r954",
      "r956",
      "r1004",
      "r1058"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r362"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AdvanceAmountRelatedToMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "AdvanceAmountRelatedToMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance amount related to milestone payment",
        "documentation": "Advance amount related to milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AdvancesOnResearchAndDevelopmentContractServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "AdvancesOnResearchAndDevelopmentContractServices",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances on research and development contract services",
        "documentation": "Advances on research and development contract services."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846",
      "r860",
      "r886"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r863",
      "r889"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r881",
      "r890",
      "r894",
      "r902"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based",
        "label": "Total stock-based compensation costs",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r402"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AmountRelatedToMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "AmountRelatedToMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount related to milestone payment",
        "documentation": "Amount related to milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AnnualGrantOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "AnnualGrantOfOptionsMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Grant of Options [Member]",
        "documentation": "Annual Grant of Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "AnnualNetRevenueDividedByConvertedOrRedeemedShares",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual net revenue",
        "documentation": "Annual net revenue divided by converted or redeemed shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "LIXT_AppointmentGrantsOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "AppointmentGrantsOfOptionsMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Appointment Grants of Options [Member]",
        "documentation": "Appointment Grants of Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r114",
      "r159",
      "r178",
      "r210",
      "r218",
      "r244",
      "r248",
      "r288",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r445",
      "r447",
      "r465",
      "r563",
      "r659",
      "r748",
      "r749",
      "r777",
      "r806",
      "r989",
      "r990",
      "r1016"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_AtTheMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "AtTheMarketSalesAgreementMember",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Sales Agreement [Member]",
        "documentation": "At The Market Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r820",
      "r842"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r820",
      "r842"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r820",
      "r842"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "LIXT_BasvanderBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "BasvanderBaanMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BasvanderBaan [Member]",
        "documentation": "BasvanderBaan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_BioPharmaWorksLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "BioPharmaWorksLLCMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bio Pharma Works LLC [Member]",
        "documentation": "Bio Pharma Works LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r566",
      "r631",
      "r654",
      "r777",
      "r806",
      "r939"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "LIXT_CashBasedCompensationToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "CashBasedCompensationToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash-based",
        "documentation": "Cash based compensation to related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r80",
      "r175"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r80"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC insurance",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_CashSIPCInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "CashSIPCInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash SIPC insurance",
        "documentation": "Cash SIPC insured amount."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ChairmanOfAuditCommitteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ChairmanOfAuditCommitteeMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman of Audit Committee [Member]",
        "documentation": "Chairman of Audit Committee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ChairmanOfOtherCommitteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ChairmanOfOtherCommitteesMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman of Other Committees [Member]",
        "documentation": "Chairman of Other Committees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "srt_ChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefOperatingOfficerMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]",
        "documentation": "Person with designation of chief operating officer."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1014"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_CityOfHopeNationalMedicalCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "CityOfHopeNationalMedicalCenterMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City of Hope [Member]",
        "documentation": "City of Hope [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r160",
      "r161",
      "r162",
      "r178",
      "r201",
      "r202",
      "r204",
      "r206",
      "r212",
      "r213",
      "r288",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r336",
      "r337",
      "r340",
      "r343",
      "r351",
      "r465",
      "r611",
      "r612",
      "r613",
      "r614",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r632",
      "r646",
      "r668",
      "r691",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r921",
      "r945",
      "r957"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r212",
      "r336",
      "r337",
      "r338",
      "r340",
      "r343",
      "r349",
      "r351",
      "r611",
      "r612",
      "r613",
      "r614",
      "r759",
      "r921",
      "r945"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expires date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "LIXT_ClassOfWarrantOrRightExercisableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisableTerm",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant or right exercisable term",
        "documentation": "Class of warrant or right exercisable term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices",
        "verboseLabel": "Exercise price",
        "terseLabel": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "verboseLabel": "Number of warrants issued",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalAndRelatedOversightCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalAndRelatedOversightCostsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical And Related Oversight Costs [Member]",
        "documentation": "Clinical And Related Oversight Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalResearchSupportAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalResearchSupportAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Research Support Agreement [Member]",
        "documentation": "Clinical Research Support Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]",
        "documentation": "Clinical Trial Agreements And Clinical Trial Monitoring Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Agreements [Member]",
        "documentation": "Clinical Trial Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialDescription",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical trial, description",
        "documentation": "Clinical trial description."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialMonitoringAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialMonitoringAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Monitoring Agreements [Member]",
        "documentation": "Clinical Trial Monitoring Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhase1bMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialPhase1bMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b [Member]",
        "documentation": "Phase 1b [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhase1bTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialPhase1bTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1b Two [Member]",
        "documentation": "Phase 1b\tTwo [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialPhaseMD1b2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialPhaseMD1b2Member",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Phase MD 1b 2 [Member]",
        "documentation": "Clinical Trial Phase MD 1b 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialRandomizedPhaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialRandomizedPhaseTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Randomized Phase 2 [Member]",
        "documentation": "Randomized Phase 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialResearchAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Research Agreement [Member]",
        "documentation": "Clinical Trial Research Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ClinicalTrialResearchMonitoringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ClinicalTrialResearchMonitoringMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Research Monitoring [Member]",
        "documentation": "Clinical Trial Research Monitoring [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "LIXT_CollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "CollaborationAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreement [Member]",
        "documentation": "Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r108",
      "r565",
      "r645"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r316",
      "r317",
      "r720",
      "r982",
      "r984"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares were available for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798",
      "r800",
      "r801",
      "r802",
      "r803",
      "r952",
      "r953",
      "r956",
      "r1004",
      "r1055",
      "r1058"
     ]
    },
    "LIXT_CommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "CommonStockOptionsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Options [Member]",
        "documentation": "Common Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "LIXT_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r646"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r646",
      "r665",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; authorized \u2013 100,000,000 shares; issued and outstanding \u2013 2,249,290 shares at December 31, 2024 and 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r568",
      "r777"
     ]
    },
    "LIXT_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r55",
      "r56",
      "r256",
      "r719"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r55",
      "r56",
      "r256",
      "r606",
      "r719"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r55",
      "r56",
      "r256",
      "r719",
      "r926"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r119"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r55",
      "r56",
      "r256"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r55",
      "r56",
      "r256",
      "r719"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r739"
     ]
    },
    "LIXT_ConsultingAndAdvisoryCashFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ConsultingAndAdvisoryCashFee",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting and advisory fee",
        "documentation": "Consulting and advisory quarterly cash fee."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ContractualClinicalTrialPeriodEndDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ContractualClinicalTrialPeriodEndDate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated End Date",
        "documentation": "Contractual clinical trial period end date"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ContractualClinicalTrialPeriodStartDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ContractualClinicalTrialPeriodStartDate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Start Date",
        "documentation": "Contractual clinical trial period start date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual obligation",
        "verboseLabel": "Contractual commitment",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Contractual Clinical Trials",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r951"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock convertible into common stock",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, issuable upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r68",
      "r92",
      "r346"
     ]
    },
    "us-gaap_CorporateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Segment [Member]",
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual cash fee",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r178",
      "r288",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r465",
      "r748",
      "r989"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r183",
      "r333",
      "r338",
      "r488",
      "r509",
      "r562",
      "r736",
      "r738"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r256"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r912"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r912"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r907"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r906"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r909"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r911"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r911"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r912"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r915"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r913"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r910"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation expense for unvested stock options",
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r96"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r940"
     ]
    },
    "LIXT_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs",
        "documentation": "Deferred Offering Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards, federal",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards, state",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DevelopmentCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "DevelopmentCollaborationAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Collaboration Agreement [Member]",
        "documentation": "Development Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r964",
      "r1056"
     ]
    },
    "LIXT_DirectorsAndCorporateOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "DirectorsAndCorporateOfficersMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Granted to Directors and Corporate Officers [Member]",
        "documentation": "Stock Options Granted to Directors and Corporate Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r364",
      "r395",
      "r396",
      "r397",
      "r764"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Stock-based Compensation Costs",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r45"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r820",
      "r842"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r820",
      "r842",
      "r882"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "LIXT_DrJamesSMiserMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "DrJamesSMiserMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr.James S. Miser [Member]",
        "documentation": "Dr.James S. Miser [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DrKovachMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "DrKovachMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Kovach [Member]",
        "documentation": "Dr. Kovach [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_DueEachJanuaryOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "DueEachJanuaryOneMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due Each January 1 [Member]",
        "documentation": "Due Each January 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_ES": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "ES",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r199",
      "r201",
      "r204",
      "r205",
      "r206",
      "r209",
      "r440",
      "r443",
      "r458",
      "r459",
      "r561",
      "r575",
      "r741"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r201",
      "r204",
      "r205",
      "r206",
      "r209",
      "r440",
      "r443",
      "r458",
      "r459",
      "r561",
      "r575",
      "r741"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r208"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r766"
     ]
    },
    "LIXT_EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustment to deferred tax asset",
        "documentation": "Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset.",
        "label": "Domestic federal statutory income tax rate attributable to adjustment to deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "U. S. federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r411",
      "r431",
      "r766"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r766",
      "r947",
      "r999"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r766"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expirations related to stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r999",
      "r1000"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State income taxes, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r766",
      "r947",
      "r999"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r766"
     ]
    },
    "LIXT_EmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "EmploymentAgreementMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreement [Member]",
        "documentation": "Employment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r155",
      "r166",
      "r167",
      "r168",
      "r184",
      "r185",
      "r186",
      "r188",
      "r193",
      "r195",
      "r197",
      "r211",
      "r289",
      "r290",
      "r309",
      "r353",
      "r429",
      "r430",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r573",
      "r600",
      "r601",
      "r602",
      "r620",
      "r691"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "LIXT_EricJFormanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "EricJFormanMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eric J. Forman [Member]",
        "documentation": "Eric J. Forman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846",
      "r860",
      "r886"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r843",
      "r857",
      "r883"
     ]
    },
    "LIXT_EstimatedWorkCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "EstimatedWorkCost",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work cost",
        "documentation": "Estimated work cost."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "LIXT_ExercisePriceEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceEightMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eight [Member]",
        "documentation": "Exercise Price Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceElevenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eleven [Member]",
        "documentation": "Exercise Price Eleven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceFifteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Fifteen [Member]",
        "documentation": "Exercise Price Fifteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Five [Member]",
        "documentation": "Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Four [Member]",
        "documentation": "Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceFourteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Fourteen [Member]",
        "documentation": "Exercise Price Fourteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceNineMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Nine [Member]",
        "documentation": "Exercise Price Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price One [Member]",
        "documentation": "Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceSevenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Seven [Member]",
        "documentation": "Exercise Price Seven [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceSixMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Six [Member]",
        "documentation": "Exercise Price Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceTenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Ten [Member]",
        "documentation": "Exercise Price Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceThirteenMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise PriceThirteen [Member]",
        "documentation": "Exercise PriceThirteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Three [Member]",
        "documentation": "Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceTwelveMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Twelve [Member]",
        "documentation": "Exercise Price Twelve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Two [Member]",
        "documentation": "Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExpectedDateOfPreliminaryEfficacySignal": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExpectedDateOfPreliminaryEfficacySignal",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Date",
        "documentation": "Expected date of preliminary efficacy signal."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExpectedPaymentThroughSoftware": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExpectedPaymentThroughSoftware",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of payment through software",
        "documentation": "Percentage of expected paymen through software."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ExpectedPaymentinServices": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ExpectedPaymentinServices",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of payment through services",
        "documentation": "Expected payment in services."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "LIXT_FairValueOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "FairValueOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of stock options",
        "documentation": "Fair value of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r334",
      "r349",
      "r455",
      "r464",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r574",
      "r755",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r778",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r965",
      "r966",
      "r967",
      "r968",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010"
     ]
    },
    "LIXT_FiveNonOfficerDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "FiveNonOfficerDirectorsMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Non Officer Directors [Member]",
        "documentation": "Five Non Officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_FiveNonOfficerDirectorsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "FiveNonOfficerDirectorsOneMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Non-Officer Directors [Member]",
        "documentation": "Five Non-Officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ForeignCurrencyExchangeRateTranslation": {
     "xbrltype": "pureItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ForeignCurrencyExchangeRateTranslation",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency average rate",
        "documentation": "Foreign currency exchange rate translation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r688"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "LIXT_FourNonOfficerDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "FourNonOfficerDirectorMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Non Officer Director [Member]",
        "documentation": "Four Non Officer Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_FourNonOfficerDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "FourNonOfficerDirectorsMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Non-officer Directors [Member]",
        "documentation": "Four Non-officer Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_FourOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "FourOfficersMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Officers [Member]",
        "documentation": "Four Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails",
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs",
        "verboseLabel": "Total general and administrative costs",
        "terseLabel": "Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r670"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "LIXT_GeneralAndAdministrativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "GeneralAndAdministrativeMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative [Member]",
        "documentation": "General And Administrative [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance expense",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "GrupoEspanolDeInvestigacionEnSarcomasMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEIS [Member]",
        "documentation": "GEIS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationHealthCareCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCareOrganizationHealthCareCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dosing of product",
        "documentation": "Total expenses of a HCO before stop-loss insurance recoveries. Costs of services rendered (including costs of services rendered but not yet reported)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r820",
      "r842"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r312",
      "r313",
      "r461",
      "r462",
      "r463",
      "r597",
      "r599",
      "r675",
      "r732",
      "r769",
      "r1026"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r461",
      "r462",
      "r463",
      "r597",
      "r599",
      "r675",
      "r732",
      "r769",
      "r1026"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r411",
      "r412",
      "r419",
      "r427",
      "r766",
      "r1002"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r411",
      "r412",
      "r419",
      "r427",
      "r766",
      "r1002"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r1002"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r1002"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r407",
      "r411",
      "r416",
      "r417",
      "r418",
      "r420",
      "r425",
      "r432",
      "r434",
      "r435",
      "r436",
      "r616",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r122",
      "r196",
      "r197",
      "r210",
      "r226",
      "r248",
      "r410",
      "r411",
      "r433",
      "r577",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r408",
      "r409",
      "r420",
      "r421",
      "r424",
      "r428",
      "r610"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r174",
      "r426",
      "r427"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advances on research and development contract services",
        "documentation": "Increase decrease in advances on research and development contract services",
        "label": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidInsurance",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid insurance",
        "label": "Increase (Decrease) in Prepaid Insurance",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development contract liabilities",
        "documentation": "Increase decrease in research and development contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_IndependentDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "IndependentDirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Independent Director [Member]",
        "documentation": "Independent Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r881",
      "r890",
      "r894",
      "r902"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r905"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r905"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r905"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and Licensing Legal and Filing Fees and Costs",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r530",
      "r740",
      "r971"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r218",
      "r222",
      "r228",
      "r248",
      "r478",
      "r748",
      "r749"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r172",
      "r173"
     ]
    },
    "us-gaap_InventoryPartsAndComponentsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPartsAndComponentsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory costs",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r941"
     ]
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal and filing fees and costs",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "LIXT_LegalFeesRelatingToPatentsAndLicensing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "LegalFeesRelatingToPatentsAndLicensing",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and licensing legal and filing fees and costs",
        "documentation": "Legal fees relating to patents and licensing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r109",
      "r570",
      "r777",
      "r946",
      "r969",
      "r1011"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r158",
      "r178",
      "r288",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r446",
      "r447",
      "r448",
      "r465",
      "r777",
      "r989",
      "r1016",
      "r1017"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r406",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r998"
     ]
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation settlement expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r323",
      "r403",
      "r758",
      "r985",
      "r986"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r323",
      "r403",
      "r758",
      "r985",
      "r986"
     ]
    },
    "LIXT_MDAndersonCancerCenterClinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "MDAndersonCancerCenterClinicalMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MD Anderson Cancer Center Clinical [Member]",
        "documentation": "MD Anderson Cancer Center Clinical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MRIGlobalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "MRIGlobalMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MRI Global [Member]",
        "documentation": "MRI Global [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r762",
      "r788",
      "r793",
      "r993",
      "r1025",
      "r1027",
      "r1028",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_ManagementFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManagementFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee payable",
        "documentation": "Amount of fee payable for management of fund or trust."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r855"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r856"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r856"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r856"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r856"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r126",
      "r128",
      "r129",
      "r131",
      "r153",
      "r154",
      "r319",
      "r320",
      "r321",
      "r322",
      "r358",
      "r403",
      "r460",
      "r525",
      "r596",
      "r598",
      "r605",
      "r636",
      "r637",
      "r699",
      "r702",
      "r706",
      "r707",
      "r709",
      "r730",
      "r731",
      "r754",
      "r759",
      "r763",
      "r770",
      "r771",
      "r775",
      "r776",
      "r789",
      "r991",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "LIXT_MemberOfAuditCommitteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "MemberOfAuditCommitteeMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member of Audit Committee [Member]",
        "documentation": "Member of Audit Committee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MemberOfOtherCommitteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "MemberOfOtherCommitteesMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member of Other Committees [Member]",
        "documentation": "Member of Other Committees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r126",
      "r128",
      "r129",
      "r131",
      "r153",
      "r154",
      "r319",
      "r320",
      "r321",
      "r322",
      "r358",
      "r403",
      "r460",
      "r525",
      "r596",
      "r598",
      "r605",
      "r636",
      "r637",
      "r699",
      "r702",
      "r706",
      "r707",
      "r709",
      "r730",
      "r731",
      "r754",
      "r759",
      "r763",
      "r770",
      "r771",
      "r775",
      "r789",
      "r991",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "LIXT_MrvanderBaanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "MrvanderBaanMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mrvander Baan [Member]",
        "documentation": "Mrvander Baan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_MsReginaBrownMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "MsReginaBrownMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ms.Regina Brown [Member]",
        "documentation": "Ms.Regina Brown [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "LIXT_NDAConsultingCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "NDAConsultingCorpMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NDA Consulting Corp [Member]",
        "documentation": "NDA Consulting Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_NL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "NL",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r762",
      "r788",
      "r793",
      "r993",
      "r1025",
      "r1027",
      "r1028",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "LIXT_NasdaqListingMaintainingMinimumNetStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "NasdaqListingMaintainingMinimumNetStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum net stockholders equity maintaining in nasdaq",
        "documentation": "Nasdaq listing maintaining minimum net stockholders equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r82",
      "r110",
      "r157",
      "r163",
      "r164",
      "r168",
      "r178",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r203",
      "r288",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r440",
      "r443",
      "r459",
      "r465",
      "r572",
      "r667",
      "r689",
      "r690",
      "r804",
      "r989"
     ]
    },
    "LIXT_NetherlandsCancerInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "NetherlandsCancerInstituteMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Netherlands Cancer Institute [Member]",
        "documentation": "Netherlands Cancer Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_NewIndependentDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "NewIndependentDirectorMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Independent Director [Member]",
        "documentation": "New Independent Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New York State Division of Taxation and Finance [Member]",
        "documentation": "Designated tax department of the government of the state of New York."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r949"
     ]
    },
    "LIXT_NumberOfPatientInTrial": {
     "xbrltype": "integerItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "NumberOfPatientInTrial",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Patients in Trial",
        "documentation": "Number of patient in trial."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal cash obligations and commitments",
        "documentation": "Number of share tranche of the series a convertible preferred stock receive a per share dividend."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash-based",
        "label": "Compensation",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r742",
      "r958",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior net operating loss conversion utilization",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r104",
      "r607",
      "r608"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining financial contractual commitment",
        "verboseLabel": "Aggregate commitments expected",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_OtherConsultingAndProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "OtherConsultingAndProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other consulting and professional fees",
        "documentation": "Other consulting and professional fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other costs and expenses, net",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r576",
      "r748"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r970"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r862",
      "r888"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r851",
      "r865",
      "r891"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r851",
      "r865",
      "r891"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid office rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs of public offering",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "LIXT_PlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "PlacementAgentMember",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent [Member]",
        "documentation": "Placement Agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_PlacementAgentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "PlacementAgentsMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agents [Member]",
        "documentation": "Placement Agents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "LIXT_PreclinicalResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "PreclinicalResearchMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preclinical Research [Member]",
        "documentation": "Preclinical Research [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConversionBasis",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, conversion description",
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r68"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock dividend, percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r700",
      "r703",
      "r705",
      "r710"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r68",
      "r945",
      "r992"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r800",
      "r801",
      "r802",
      "r803",
      "r1055",
      "r1058"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r646"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r646",
      "r665",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, $0.0001 par value; authorized \u2013 10,000,000 shares; issued and outstanding \u2013 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares \u2013 72,917 shares at December 31, 2024 and 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r567",
      "r777"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r756",
      "r970"
     ]
    },
    "LIXT_PrepaidInsurancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "PrepaidInsurancePolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "documentation": "Prepaid Insurance [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassifications",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered direct offering, net of offering costs",
        "verboseLabel": "Proceeds from issuance initial public offering",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale of transaction",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r611"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of common stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of pre-funded common stock warrants",
        "label": "Proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r151",
      "r252",
      "r529",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r733",
      "r760",
      "r787",
      "r789",
      "r790",
      "r794",
      "r795",
      "r937",
      "r987",
      "r988",
      "r993",
      "r1025",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r151",
      "r252",
      "r529",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r733",
      "r760",
      "r787",
      "r789",
      "r790",
      "r794",
      "r795",
      "r937",
      "r987",
      "r988",
      "r993",
      "r1025",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "LIXT_PurchasersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "PurchasersMember",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchasers [Member]",
        "documentation": "Purchasers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r126",
      "r128",
      "r129",
      "r131",
      "r153",
      "r154",
      "r319",
      "r320",
      "r321",
      "r322",
      "r356",
      "r358",
      "r390",
      "r391",
      "r392",
      "r403",
      "r460",
      "r499",
      "r508",
      "r525",
      "r596",
      "r598",
      "r605",
      "r636",
      "r637",
      "r699",
      "r702",
      "r706",
      "r707",
      "r709",
      "r730",
      "r731",
      "r754",
      "r759",
      "r763",
      "r770",
      "r771",
      "r775",
      "r776",
      "r789",
      "r798",
      "r983",
      "r991",
      "r1007",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r126",
      "r128",
      "r129",
      "r131",
      "r153",
      "r154",
      "r319",
      "r320",
      "r321",
      "r322",
      "r356",
      "r358",
      "r390",
      "r391",
      "r392",
      "r403",
      "r460",
      "r499",
      "r508",
      "r525",
      "r596",
      "r598",
      "r605",
      "r636",
      "r637",
      "r699",
      "r702",
      "r706",
      "r707",
      "r709",
      "r730",
      "r731",
      "r754",
      "r759",
      "r763",
      "r770",
      "r771",
      "r775",
      "r776",
      "r789",
      "r798",
      "r983",
      "r991",
      "r1007",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r832",
      "r843",
      "r857",
      "r883"
     ]
    },
    "LIXT_RegulatoryServiceCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "RegulatoryServiceCostsMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Service Costs [Member]",
        "documentation": "Regulatory Service Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ReimbursementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ReimbursementExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursed expense",
        "documentation": "Reimbursement expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r357",
      "r485",
      "r486",
      "r564",
      "r571",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r664",
      "r666",
      "r698"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r485",
      "r486",
      "r487",
      "r488",
      "r564",
      "r571",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r664",
      "r666",
      "r698"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r671",
      "r672",
      "r675"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r357",
      "r485",
      "r486",
      "r564",
      "r571",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r664",
      "r666",
      "r698",
      "r1015"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r486",
      "r489",
      "r617",
      "r618",
      "r619",
      "r673",
      "r674",
      "r675",
      "r695",
      "r697"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r183",
      "r333",
      "r338",
      "r488",
      "r509",
      "r562",
      "r737",
      "r738"
     ]
    },
    "LIXT_ResearchAndDevelopmentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ResearchAndDevelopmentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties research and development contract liabilities",
        "documentation": "Research and development contract liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ResearchAndDevelopmentContractLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development contract liabilities, including $0 and $120,768 to related parties at December 31, 2024 and 2023, respectively",
        "documentation": "Research and development contract liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails",
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "verboseLabel": "Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r732",
      "r748",
      "r1024"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development process costs",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "LIXT_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development [Member]",
        "documentation": "Research And Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r858",
      "r884"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r845",
      "r859",
      "r885"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r852",
      "r866",
      "r892"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r94",
      "r569",
      "r603",
      "r604",
      "r615",
      "r647",
      "r777"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r184",
      "r185",
      "r186",
      "r188",
      "r193",
      "r195",
      "r197",
      "r289",
      "r290",
      "r309",
      "r429",
      "r430",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r449",
      "r451",
      "r452",
      "r454",
      "r457",
      "r479",
      "r480",
      "r600",
      "r602",
      "r620",
      "r1058"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r210",
      "r219",
      "r220",
      "r242",
      "r248",
      "r252",
      "r254",
      "r256",
      "r354",
      "r355",
      "r529"
     ]
    },
    "LIXT_RobertNWeingartenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "RobertNWeingartenMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert N. Weingarten [Member]",
        "documentation": "Robert N. Weingarten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non refundable license issue royalty",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "LIXT_RoyaltyPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "RoyaltyPayable",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum annual royalty payable",
        "documentation": "Royalty payable."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_RoyatiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "RoyatiesPercentage",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage",
        "documentation": "Royaties percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual salary",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of stock",
        "verboseLabel": "Aggregate offering price",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockDescriptionOfTransaction",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of stock transaction",
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r105"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares issued during period",
        "verboseLabel": "Number of shares issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of shares sold",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock price per share",
        "verboseLabel": "Sale of stock, price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r925"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r198",
      "r359",
      "r922",
      "r955"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39",
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://lixte.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r766",
      "r999"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]",
        "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r671",
      "r672",
      "r675"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Related Party Costs",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://lixte.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Information by segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r363",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Stock Option Activity Including Options Form of Warrants",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r97"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Each Option Award Estimated Assumption",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r89",
      "r91",
      "r93",
      "r94",
      "r160",
      "r161",
      "r162",
      "r212",
      "r336",
      "r337",
      "r338",
      "r340",
      "r343",
      "r349",
      "r351",
      "r611",
      "r612",
      "r613",
      "r614",
      "r759",
      "r921",
      "r945"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding and Exercisable",
        "documentation": "Schedule Of Warrants Outstanding And Exercisable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SchellensMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "SchellensMember",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schellens [Member]",
        "documentation": "Schellens [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r210",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r256",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r314",
      "r315",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r745",
      "r748",
      "r749",
      "r757",
      "r792",
      "r1025",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r127",
      "r130",
      "r132",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r254",
      "r255",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r633",
      "r634",
      "r635",
      "r701",
      "r704",
      "r708",
      "r711",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r734",
      "r761",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r791",
      "r798",
      "r993",
      "r1025",
      "r1027",
      "r1028",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r231",
      "r233",
      "r234",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r256",
      "r743",
      "r746",
      "r747",
      "r748",
      "r750",
      "r752",
      "r753"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r251",
      "r254",
      "r744",
      "r745",
      "r751"
     ]
    },
    "LIXT_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense included in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation vesting rights, percentage",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r363",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Warrants exercisable",
        "documentation": "Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Expired",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Issued",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Warrants Outstanding, Ending Balance",
        "periodEndLabel": "Number of Shares, Warrants Outstanding, Ending Balance",
        "label": "Warrants Outstanding Shares",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Issued",
        "documentation": "Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Warrants Outstanding, Ending",
        "periodEndLabel": "Weighted Average Exercise Price, Warrants Outstanding, Ending",
        "documentation": "Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.",
        "label": "Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Warrants exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option weighted average exercise price exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares avaliable for issuable",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, stock options exercisable",
        "verboseLabel": "Number of fully vested option exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, stock options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, granted",
        "verboseLabel": "Number of fully vested option exercisable",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, grants in period, gross",
        "verboseLabel": "Fair value of stock options",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair market value, per share",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, stock options outstanding, at the end",
        "periodEndLabel": "Number of shares, stock options outstanding, at the end",
        "label": "Shares outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options granted to purchase common stock, issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted to purchase common stock, issued",
        "documentation": "Share based compensation arrangement by share based payment award options outstanding period increase decrease value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, stock options outstanding, at the end",
        "periodEndLabel": "Weighted average exercise price, stock options outstanding, at the end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "LIXT_ShareBasedCompensationIncludedInGeneralAndAdministrativeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ShareBasedCompensationIncludedInGeneralAndAdministrativeCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative costs",
        "documentation": "Stock based compensation expense included in research and development costs.",
        "label": "ShareBasedCompensationIncludedInGeneralAndAdministrativeCost"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_ShareBasedCompensationIncludedInResearchAndDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "ShareBasedCompensationIncludedInResearchAndDevelopmentCost",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development costs",
        "documentation": "Stock based compensation expense included in general and administrative costs.",
        "label": "ShareBasedCompensationIncludedInResearchAndDevelopmentCost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r368",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable (Shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding (Shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Prices",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair market value of stock",
        "verboseLabel": "Stock price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment award, award vesting period",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://lixte.com/role/ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in Years), Exercisable",
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), stock options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding stock options to acquire shares of common stock not vested",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), stock options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average recognition period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options fully vested amount, fair value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bid price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r176"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r156",
      "r210",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r256",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r314",
      "r315",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r745",
      "r748",
      "r749",
      "r757",
      "r792",
      "r1025",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r160",
      "r161",
      "r162",
      "r178",
      "r201",
      "r202",
      "r204",
      "r206",
      "r212",
      "r213",
      "r288",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r336",
      "r337",
      "r340",
      "r343",
      "r351",
      "r465",
      "r611",
      "r612",
      "r613",
      "r614",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r632",
      "r646",
      "r668",
      "r691",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r921",
      "r945",
      "r957"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r72",
      "r73",
      "r155",
      "r166",
      "r167",
      "r168",
      "r184",
      "r185",
      "r186",
      "r188",
      "r193",
      "r195",
      "r197",
      "r211",
      "r289",
      "r290",
      "r309",
      "r353",
      "r429",
      "r430",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r573",
      "r600",
      "r601",
      "r602",
      "r620",
      "r691"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r127",
      "r130",
      "r132",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r254",
      "r255",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r633",
      "r634",
      "r635",
      "r701",
      "r704",
      "r708",
      "r711",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r734",
      "r761",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r791",
      "r798",
      "r993",
      "r1025",
      "r1027",
      "r1028",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r211",
      "r480",
      "r529",
      "r609",
      "r632",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r666",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r691",
      "r799"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r198",
      "r359",
      "r922",
      "r923",
      "r955"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r211",
      "r257",
      "r480",
      "r529",
      "r609",
      "r632",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r666",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r691",
      "r799"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r847",
      "r861",
      "r887"
     ]
    },
    "LIXT_StockBasedCompensationToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "StockBasedCompensationToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based",
        "documentation": "Stock based compensation to related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered direct equity offering, net of offering costs, shares",
        "verboseLabel": "Issuance of common stock",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r69",
      "r94",
      "r611",
      "r691",
      "r713"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded common stock warrants, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of restricted stock issued",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options, shares",
        "negatedLabel": "Number of shares, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r69",
      "r94",
      "r374"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of securities in registered direct equity offering, net of offering costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r69",
      "r94",
      "r620",
      "r691",
      "r713",
      "r805"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded common stock warrants",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r72",
      "r73",
      "r94"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "negatedLabel": "Stock holders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72",
      "r73",
      "r86",
      "r648",
      "r665",
      "r692",
      "r693",
      "r777",
      "r806",
      "r946",
      "r969",
      "r1011",
      "r1058"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://lixte.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r177",
      "r335",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r350",
      "r353",
      "r456",
      "r694",
      "r696",
      "r717"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/ScheduleOfContractualClinicalTrialsDetails",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://lixte.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r492"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationRelatedText",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for -",
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "LIXT_TheradexSystemsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "TheradexSystemsIncMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theradex Systems, Inc. [Member]",
        "documentation": "Theradex Systems, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1014"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r334",
      "r349",
      "r455",
      "r464",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r574",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r778",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r965",
      "r966",
      "r967",
      "r968",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "LIXT_TwoThousandTwentyStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Stock Incentive Plan [Member]",
        "documentation": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://lixte.com/role/ScheduleOfInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_UndesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "UndesignatedPreferredStockMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undesignated Preferred Stock [Member]",
        "documentation": "Undesignated Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r117",
      "r118",
      "r120",
      "r121"
     ]
    },
    "LIXT_VendorAndConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "VendorAndConsultantMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor And Consultant [Member]",
        "documentation": "Vendor And Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "VendorAndConsultantOneMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor And Consultant One [Member]",
        "documentation": "Vendor And Consultant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "VendorAndConsultantThreeMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Consultant Three [Member]",
        "documentation": "Vendor and Consultant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_VendorAndConsultantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "VendorAndConsultantTwoMember",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor And Consultant Two [Member]",
        "documentation": "Vendor And Consultant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_WallachBethCapitalLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "WallachBethCapitalLLCMember",
     "presentation": [
      "http://lixte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wallach Beth Capital LLC [Member]",
        "documentation": "Wallach Beth Capital LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r800",
      "r801",
      "r802",
      "r803"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "LIXT_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Warrants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "WarrantsToPurchaseCommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r206"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r206"
     ]
    },
    "LIXT_WorkOrderAgreementCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "WorkOrderAgreementCosts",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work order agreement costs",
        "documentation": "Work order agreement costs"
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_WorkOrderAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20241231",
     "localname": "WorkOrderAgreementMember",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work Order Agreement [Member]",
        "documentation": "Work Order Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "954",
   "SubTopic": "450",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478201/954-450-30-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "954",
   "SubTopic": "450",
   "Section": "30",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478201/954-450-30-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Subparagraph": "(a)",
   "Publisher": "SEC"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001641172-25-000208-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-000208-xbrl.zip
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MQ>B68#Q<"8#.V5CZ8Z8S^F<Y?B92D4]"$<121X(32ME,FC'20T^$;SVT:)W
M.14@T"G&!6PX7[,>V[OM6X[:XY=02\Q5E+3E_E> 571'<[K2+A.P'9 H,8],
M_"@CF@/&GNYU!3B5:31G$R"%4$[HCZ)R:8'C'$'ZD0M(E4"2@0KUR")T '85
M\&7-:NN7S_68A9&:Z0+8RY+*.#UT_L-;%Z*#IRZ\$4&YM-;M[=WC+8?HB:V\
M/+:PP#;+821L:17 Y#"2>DS40WL:@TB)3.E[@)H;*9V!JHAB4Q4Y?$Q2Y8L
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MIS,THM=9C"5'V#::O.ZLO5NLVZ3X1.@&(92.>TUHA# %356 %V&OAH$X^^M
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MDG!U)+.!$Q A,)6"S?F:1#"CB9 *T-A0R!C=J/V%;DG3R,VF/LIL*)% $7,
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MT$)I[(&/#>UD[D?F?D,_.LN?I>E';O\!4$L#!!0    ( -!#>%H#V^\US 0
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M2?Z2!5-V!21VEJUQ*[&3&^SDTN\RUY^[^U5MZ]"J85H!)C''16&:C[H5&,S
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MW8W>-$67#XHEZ./H[1S7B+:_86D>K %-*]>'+6(XA+NU 3AP+5]T<"B!L0W
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MGS2Z@&:O YYQ,TM _7GY[^O>\/NY9_^U%MT-8XFQ&,J. ?-MRL7JR5'Y:*X
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MY:-/GN(SBXV'COV\N/V[>3P3)7O=9=I\+GE8JWX__EH],?PUJ1FIW+%D_V"
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MUSQ9#[QGI-%D!B)AG<O!SX'UPY#1P:(,MM^5WZN@$Q"@#56SK C52;CWF'@
MVER \ 0K#\&N -CQ9ZR[HAKPJSV@1\<NTQDJPFJYHE+=*T]]!^V!RJ%Z@3X$
M@\[!P[]A30M_J/G9L3]HWC11TLMB#N\+JF8;ZKO*>P7GV /%!7[O_04SP.?I
M47@)1R':067.HT'0(#$%^Z2D&MK$VY];.8L3AZC*Q8ONH((/NN&\\EE?+:MR
M?]YVQ^?KR2VOGDP3Z^SQ[)U^QSL$%A*M>NVH4<V@K22!-T2_B&N ],CT?2 "
M9@&T7<=&GYDU4=D]<R<JWJ'@ E(P<^]<\S7U@@NO%'G';22E&>IJBM#5;MD@
MX#<"J)UB5WV'BWST2:U4*_N1-F?2H?TQ'MI?,[$K66+G XYHF'GOIRFTF3G+
M':T#+H,@D-D4JFE?_O&=5O6BLYY,I=J,(BFSQR,I-/>#7XU"R3JR8*!,U70=
M*-35D,P0LR[*IYG?@L)I%V?^X(V M*$7-V3L!06H" 07KL1 ';C.@S\$C(Y@
MMI-]F .C 9$!1E6B/"15S&BLE#[-&Q;]7/X4/O;D V)02C2H< #1@RB'Q<-S
MQAH^&9J(Y4JO6)FI.V\I;-Y:=M?J>2ATV<C:UOL2P4V#FL*ONMZDH/6..\O9
MUS'$-2]M/5Y0&AHMZI:MZ=L(3%:G:L.Y#=BV@>-.9FL^)Q=U\]L7;S+X?2TE
MF[G?F#HGD.BB\ZP+N3:CV%=JM.AM2(G$)/ V%CY9.P8/UT+7:\W#%K(;AS(E
MO_,VV"R\RREXTU3. L^TF3?']#;[?_QQ_SLKM<K6.N ]_XZ%VHRJ3*GQ/7W%
MPJ[SJGR65\WGJ)I":::QI!7GO TU2Z.-%(V&$_E"<VCP*<PY6SW\5KJ]_.X:
M?_762:LS2FG79E2RFCG0IZMIR[CE:P^^U5>@I3E69@'L2VZ]JT^%?="U1@XU
ML!HP_N,[:N!Q:QHFP._(F%%\&:QQ[,N:(+4^F- U=*O:,'P'K?9[TT-'NZYC
M/3X<'][?;6BNX:EX&-XTYAV"JK[3YH22I"MH2UQ!B4"+4+7P^ .Z1C3?9U@0
M 7<:-AVKGT+W&K^S.SQ^JFJ>!XH#?A4"@?7[C#R(J%$H\"6^::)CT=8L8I*N
M8ZD.J #0L:W9NJE9"2V/#J=&$*N5:HF#=AW-[6G0;+']:+$)(DU]5SY0[_8[
M>,/>4>403^6]1RJ*9XFG-Y1QT+. 0R<@WC?=$7?JCJ%O#3VX0 N4'6#0B+7
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MB62[#NYNZ)4P>A>SI=V9<?UW0__]YD]_N&EI-Z,>7'*,2WL1MVO/MAIP>-)
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M'IMC!F-G.(VQ:\(2FU9ZE/;0[)ED%(!*#:_Y#"R"\=#Q8(:^!FITI5Y0R"C
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M0_[T5Y57([NB\58J!3XK.H*+$XZ+((&B QN :=Q&=$9'"]<&C]7 O Q>@B<
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MM@K%\TNSU0GUS@*H?X9K&@7LRX2EP/J*FNM.5(SI:)1!.Z&*E+X% PTKKH-
M=$:P0H8RIC2YUH=62[A88ZDYMD# &LZCXP8]3/M4[[W]U-\\"Q ]J*;K86U@
MF_%3VE%R6]\711C"P@=BW/SP) C-L4,2G=]AD77VT@%#IT=%X)-%J).E247I
M47ZJ6=,GHLI"7X2@Q%12=0M2<\ <Q'B8BA@F3/0\^1 _@C2PG![7;GC9@SZ5
M"^5IDQ2ABBHY+%@!+S(@ZIUNM(^I_A2^L/&A;PS-43$%C2:56.Y4M]@@#0H/
M@JNUDCH!6P85/IRT9?H @;#>PH@G8L:!-CIERLWQ.)%9B743W F7GRA%<X2.
ML?+#9E'6<^JT>7*1*2<S52:C$&\,::'"2$F>]Z+<;8KB*<EB&,F]"T.7VGBL
MN<G,4I['+/*T7UN3DLQ\K3-%[D?'K3759OZ#X_Y$6/!236A7$$,G !!'Y+H_
M9N%Y(BF=._VYX603/3 /D^PP0UG_B=%TL#GHG'2B4 +@E#+T,/?.MIU[\A8H
MX?D$Z 9ICU?119E!47@D-# 65!QQ&)CB%SXD2[50FC,0%-:-CDJZB^ZB^KG9
M)&8-CTWB 0<D3"7L" VI,,U@NHH%Y[D#)^*LM%(\<_^1[F: @94/:$CEHU(<
MV ^#;AGV3$Q&$V?"B8<_.&3.H95#G(?W&"9B)TZ@X^"X9.JQ@19&[;&6LHM#
MXIZ*WS'OH5I"65VI4CUCQIT23&1]\W/V^"COHD)U<!31/F?Y6MAE2F[A]4"T
M_%0M).;60DQ3,3E*[-8&@Q =83(V+VY,QG8XE;#[>(9*/$,J=XW%".BHK&;S
M&A.,JL\7^X"5F >'@N'F(B'?;=@HW%UTU^(\1.0ST0HR9K#< 5^<B=L3GC;_
M'I>BMG^ T5!_&)WM2*V$.PH/DF@6K*[-O6!BI# .[/)H81.D)81V-E9UQHV"
MQWF)#E6CZM# XD6AZV01!C"FHX, O!(XII:8WD]1-VYZ@KU)**/"_>N*4\F(
M1+S=@:MR@,D16?P3D"[A?O#*>BAF#)Y)0P=XTO@_*/UWN*OE4B6L=B[\%USB
M]^D 3-2XZ4653=X"^WT[@J9M*VW==WIX;J%*7*A"%@->:Q(0OXB*PX5Z?GT
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MPO^5\61&MT**U(:8*44NQ H7\=Q2NY]B971%BH=%@4/#*^6HQS"5I@Z#41@
MT48C] F15Q\/L(ZQVW(< CDOEN/:(.')K>@L%_"0+YT_U+&E1V_ WW'0Q'"
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M"<5\K!9$53&G_,.4ON_SDX)8#S.Z<Y[*Q[A,.)/46!P(#AMY/LD?@@@%3C9
M>0!MN< +[IF29)!"?F"2JWE/:?[";9RHM.6:CLM/5_*6*&*E&9CYZO!SZ6G2
M0(?)/[-FQ6$<-ZU@*"@*J">?3IZ/Y)&9,.>5CQ?O9!'Y<#T3X\4CGJ$ ''+
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M(Z9A7!.E0.)2B#0S3XFS.5H3V1&\T%E"UTHJAE(@Y*>BZ0W5MZ ]NS1UAJD
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MG!P<)9V((<,G+@]MS'(/*N@>S,01Q86;?T412'$L&^1>I50M(0J!<(\+<1D
M*O #(BOR6,WV;.W#S -4_<DUDJ5E96&_E>/]L#IK\N"NB#%XB>1@[L6=OW+
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M\$Y2::H6AOR?E<=PJ*SBY'P<.H1=;+=\9?DS0,J0(5%LHX&*Q9=,*!9GE+;
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MW$>B?<S-^#F"@<#^MD73406?WT/ VP-.'<#I<>ZN $%R;%#@2O:CB)$/MRI
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M.T1C0S1V\I3/Y[CWH[%PH E3+-\LVMJ09PL=7CQ$+[>4GC0L!!JJC#*Z6)[
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M,>M4#8HBK,N6"^#HLS7VQ^(5N-7%$F$6@,9UNT&^83@$<QH_AR?LVL#/TOV
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MO8$T?*+M=A_;CZSX/[ER;;5C)C<]9:2'LA?APQXLJZMIDT -+'(KN78=VS$
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MZ=%"[R-6_]C4>3+ONE-L9W-$K'5T9^4YV -5NUI'OI!E^8QE[^BV40C+)$T
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M>6Y!6!^T"VKRTFMC98";]X^1N36QT:#FBVP8I_@H3@.CN>0<01VMN2'6(.3
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M55?U_5B U8I>WEX29^3S</)4S6>J/!YTAT(5,>8H;4GR:YMN+>4 "\G#368
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M] R3-KBZA5YRY 3ZEIU)E)K*KN-(^* TV4#7(2N2LF'K2YW27T<<MB=5FW_
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MF^7"F_%\@F?N#3L2[Y.D"!(BIW4\^,^/P%I=?L-DAKG: D 0U\H%!B'XC0Q
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M-RU13IF.R&\@CP[\V7T9^(.<8[+T#9S]Z[[HH2Y+ZCR'>CG6;HO#6WKVH@"
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M?,& SDJ8 7-WVWS%:67@[7X@"U'VG)M=_5C>5:60K?W %_\O7%P^S><[[AZ
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MIJ_JF7N+E_U ,U;I7D*<*?F?;_6+"5GN+$+?4>QH'#H-<&S_TF:T.%2@PF5
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M.HYDUH3C5P.#TO22P3EY4+<G<F^Y'K3I5#BP45W>\/],)+2,>)*N9'ILDBT
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M+_Y/*$D&T[%Z(U'1JZ\^_QS0I6(G@G^_X^_IC>/7,_JZWNPSR_>#I*W7,WB
M-Q+%9[9A*9?O*%!435B&0U@!)CZ-7\M1/T%9QDP4 D74I!@01"\A,TENYZEY
M0O4F1D>_>_69LB>XFQ_M1+CS](.!_8J!]7YD-I.-1X_YDW* ?O'RBS#+!04U
M=.*^^/Y=71YLIE^_?/E://S?O?XL;'!/D^;Z:^CD+[J-J% :RPD0;$T?''*H
MKJ"*5:TS>69#>;7O#BB0RS G3@^_;'HMN[(#08Y"V4*!1=4XV@9UH#@YZO.
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MTG&UVY6;2I[050,D.V"%C-P$R2JP\H72!SQTB;GIV_[E?9D*IJ%)16MJT_F
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M(GPWEY7T>]J,#F9*9#KX0INKU7^"]DU?K:V@(+&Y4SEC)5O5$!JV#W7*N>1
MKOKL@<8=A15F26M-J4QOSSF$8"3]T[X/7WM*.!Z:XV0QETYIH,Q2B1SE'1^>
MP*%UM?HS=VU46WMQ\\.N>C^W#S02JI6OC-OE80NNI/QQQ?I\@9ASX1V;-^>K
M-_0.0Q[ #S@+R=-(_L?+>=6,H(N)8JNR,I4MWI9 F"C-2H8=GG-^@E>4>H+B
MWA_I&N1!ZR(;.LG82P)'A5^D!!\UVJ6]9O9)(EUN6(2F'>+E:D+IW^3-@Y8
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MM(V[3^Y?10"%VM'M,J>T5. Q"\T-I#(74PN52>D!@I:)5IK\O4HMY;4\"R1
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M\%@8B"IP\[UJ(4NGCZHCY%&VQVD\@UF9NTS:T!9_XX'-=0;TF7/0;.$[STZ
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M,U'^,,[FH'K/PI&JR**AZF-\>IP!+[(J+#Q+4"(I?+J$)4G+>A /*);\**]
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M%W*$![#Z+SA"/J#.S;,&B[A858?_&6*AE7W*::[4W63"SF%O &0T. 310/,
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M=OLFF4BWIQL>=NF&CYIN>-BE&S[A=,,-NQGNVP@-B^D3,-.>Q*6,9X&-(:;
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M[!):.BOW2'VB9$K1OW#6M!?X,=X$RNY*XEG,9N7W@SVNY\6GOI?BWF:4A\G
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M./ZJ[LE2:M=^5#BF-'K>;324_H2^(9G?W66K9P75$M0GHB76+A?Y(SO9"[W
MO<8")1>)EVF[)/"XA5N-*"A""+=!R*\-LFE*>Z-1-FXNCCKU-E9X;.S$CX!\
M&BS6)C""^[[K_?I=OZIG?:NP")S0LO,%W2\7V!IK5?F7WP]V=X+^P?Z=<#0"
M=+RB\ REL?'WAR\.@L'N[EW>WJ&2 ODV)8R_V-D+MO<.*++T8J_7_TO/7P\*
M>1*7^WW@05ZA-CV;A1SZIM+,I@#3)[]T49/TG%%6%LI5+=CD/J2H>I9<:;"
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MIY"-\%#EHRP:0@U#UZ!>N_NPLG!7T\'(QZ37;7/[O-!K/-E.D[RTXS@I>[Z
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M5R'!M*&=/<36'&AS]809D*],GAQQG]6NV'RMV:LM "A?.\4'G$Z#T>Y&:]G
M_3*=9&F_NIU9JYVY+$@+YVF=T-W=;<Y:;<X':0>M0I[:*2EBW29]_F0>3O5X
MC#T^+SGWS?^,_T>WW8> >XDO><AY===[PI%<V<O7]+QCYS60.9=H<L_3>L^.
MANBZ$SCKM4,V4(.9_38/NROAF5T)I^P!5^$&"G?H)\8B^X":!3A\LX5_BK!$
M,%ILX)0N:>3NIEI#.7A^?,63.D>ZZW.0?W?C\/_Q9.&%"6MOH.1X:P+Q&TC[
M<>7^W4CJ3<CN(>7VHTJ!%ISM+_?P;H:\ZXCMB/T28MN283=J AM%;+?:';$=
ML1VQ';$=L1VQ?SAB6YP2FT'X,S'N5OO7EMLM_=?Q\>GIV[=?8P_J7*2#/S_@
M>@@H#=,T2F=#3B'F=,>@4+^G<?1[.0N&R#J?1:,LS9%3'T>%HD]SOM5,%0$
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M,;?O\<D9&60S&2F?:WE AYVX4XD:AY- -\7"8^,MQ^,J(#6M?B1[=9[I/YP
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M5==I?"TI!ZQFA6JNF!=( H7(CA$5C4:5C I<B'1O)SG4:EFZ0"^W2 X2I["
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M@RM)]1!C?NG-M7C\.D-%EW OZT*<IG%[$@C&X7I>#-/W*]>T=TN-N?86M*!
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M3QST4&=]30"XN\\>T[=Q[_2EG2Y]Z4G3EW:Z]*5GD;ZT<>+E2=N#H68:<)S
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M=1^<UHUU @R* O1X+>EMH4Z&RVVBE/'9>9J^6DX0FJ9)G!31U56$V!PK6G<
M'Z@Y]%WMLL)F1 G@)0-1V0!@VF.8XJUI>M.KDIH$%R+O51@K\FB5F85<.@FO
ML8/064X[KY<.3C'=R [>,9Z>9U#@1\IHB>* 6Y+ =C1/O\<I8(Z.Z"KYG(!G
MW80TJ#'66[.LI T=9(AD-_!T;B+&X1[CZ@%2J^L=K(RA)G&;)T$V7':\3SSC
M[7G55EI=]5L4OZS*M@P>L\X2@Q*@0:_DKG6Z* F<X*Z(#^W8,D)C2=QXCG>/
M!VI(+[J2Z+)124.6A$8VN.U2*QIV=0OZNE/(><UV044$/TD]=UYC)2"Y,,FE
MBH1]:G7'?Z\^V@AB@"[B235FY1]"H0FC,C=B!]5Q/7JJHHW.SGHPU7GYS"!*
MRF>&4TK \I72R>KD86^P?0B?C\!N&[\.3*0L%Y/?5:@KK<^SH]_K4#T=/VUX
M-<!W]TF3>-6E23QIFL2K+DWBF:1)&&HV1?:\AP[K7=)'HC%M@EN=(2[3XQ00
M_:.NV&H]+FH46YT<>;0K,+APG1ZGV5QJK-Y7&8Z^A%T'N[<65XVJ41HE^/0-
MO_D-TW0"O^3KVA-7%6J2C7/*%MZ0*8G"JD5E(G(X1MHD6%N,2X.11F(1!5LH
MZC$U09RG5H5-_5%0PNXB,P^:113R<R<9TND3HL$_Z?M_)\7V)])6>_Z[_DF?
MP0100:U,>D?37W7)?3=P#/PCFE2.X- Q>ZX*4H_#JEX:FK/U_%84>PU_F'EL
MU;Q8XV88T41K73J1YYH;L$I!U7]*6AV5Q63O!OF4%75&;A$HT*L50WL6:#,H
MT2>"Y2N'^A-U8\;6K:^@A"5JBPD R;D)!@9)$K&6EBVTZXV[<\%2DJ*=)7:#
M@LAML@(7 I%TN:K2YC;;Y57?Y3G#7+P/-.\<'5VRB6R_HV4NEQ:WKC7QO?>G
MP8Y-2D8O9/S;6/KW;;3LIBULN"QY%I8+"<0W42J]'/^19A]S;M#@G;:PV4!D
MXMZM,O&XZJM #-[P#-:_5(=A6L[%4<F$=(W0J[\ES<$R>-6L&] B.QANU$/@
MA*,!COV["1CTX"='!HKVJ*'R!]V8\RBW-I83-ZT5WG@ZTB\!>PYF%R08)@4'
M*? W*;]#F'Y,^GSZO<_RE3830W.GH=455CK]Q38NX^K13'&LODWL>L;E-H_F
M"BE$WSO3@(<4R?@B>M5H*KY%;4QJ <!NRRQI3-N*=3/3[VMW%X:6VRC*1_#[
M+YKY M]+@8 S<RV:=8$PX[PH;L19!/G'>@9EY09U@M,DN %N;?IC=D[ IY85
M]8/HR?TK;5.)'2 :X*_B=DJ9_V%,;Y*1(EI!;L"!.'^ /0_<>VD+_!/-:;MQ
M3=:5G4;B3%/YX?J2+(*E)_A!*T6/UA.X<CSB0V5UBYM4WUQ\72Y?]O*F4UJD
M<X!,VH.NB*TN:'3&# 2]W*_G].YO2_C;]H!KK_IUJ@SE(]SMLAE)+5;/E\6S
MC?I7*A_B_0U1&@ XI)C&"ZL8#7393UZK7)12XI:$$HP)R/E)JG$PIVD)98L;
M-T:)%T>JK'J3VD_U'3R#=[SAM=@R3C@QB<S+.%,KU^=M^TSK!'M89DR++O1X
M3 ^)Z9*C%IW+= TFX::F6%^EJ*CY72KJ*@[@PK7#WH[547<D!36\'6+2NT-/
M-:%OKJUS<PY6RJM:QD%[AD'>2#'8\.U\%CQY!TB?[5UF0F$';9TX&@JQB]QQ
MJW+,N5C5US4F2@4)T_./9CD-'0:S"LGDEPH>11HPBZR]2;,XM"I<K(+ERGR_
M7IDOT:GWR2@-E>]\\S?2;4?3HN<%NFLS%G^N> ?,$/88R%@];7M7!CS-4V=^
ML,E]KR5IV,!T?82<RHX+]@AYC/S8>=KW!YARIHKT_J,C<09J<".QFUOQA')Y
M&,U5WUW(4,_2F70?9K@2SV(2.G")IHTTNR*JYL,&6Q$M/=-)"1Z4M\M<OL:!
M<E3:H.EJ!4G"1@G)G3CFU/D&53J]?^2T79TI]&V-\IE.KHH71O#I-R-)H368
M+'DCWFFUA7&I4P^65JF'>MX@<1-]6-ZAL\3NX8 %[FF9I;GKCT%'4MN;E?Y)
M2DZCX;-NQ]K^S:Z!VY.$]G?;PI0U>58_>3M&/[RWD".!96Y3S1EYPYOF59>J
MDW!N47^T8]!$WMT"MOL0@7BZU?F)^+HDW^]IMQG) &]/UZ\(+^N)Z@N;SM2P
M#">*!F0+=BQ64#U:WUWI:S")I<25V_#2ZMR]^S7<G9?Y7.X2.Z@G1Z;%2PVW
MAMQ YLZL^;31_A.U(7-36'E+^931.>L@/7RWT$=ATWD0UGAYX#)XQZQK,(E&
M&LE]_.GMN=C:C#(8&[97_)]VR,#?W3<=RTC@#?:66I:Y"2->2YZQ,+A)- Z^
MR":Z7Q9VTT:Z?QKV_N%>[W!PL(%YV)^- ^^MP%UM7&T<*]2VP4>\+S>75KMD
M[R )YLH@NS"]8X'Q8QG1$P!RO<S8^,I-Y"$K@LZ*+[V_1@M_',/;HDUX-R?O
MMX31<RX++CD[@4#-;*8K/M0Y=M<"[&6ORV)ZTBRFO2Z+Z9ED,6V8>'F*PI.+
M,^_'.!VBH3O<:$>Y%*,B%.NJ,%/QX7/*E/&IT+N^O"O!&-K9*&:@6;J,%HP@
MD1>DD4_DY@I1^!4-2Q-4T2X&SKZI];RPRDCM0KI70Z+[MXD5K6NWM[M]($K7
M[@[]^W5#YUK6)\PB? ;Z_^ZK[=[>SLZ]=!X[_(:SUK,X'U=?W@9 ;^/7*IV#
M@]O:AV^2/K;YJ/U7&3Q=/>_TVB:1_I;H3!<XPS9L1L_BA%ZL L70.2DMZ3R<
MHN+C<AHN."TH"1![!HCV'-4>(U902+R;KL@W2M"*V6]?!!_52E/:X S)];@"
MC(CN05HB:) ]B8\@I !#,4F1(51F#*[)E4? 1N+TR'F:1SK'@&&379\]L!]D
MX)*]H9H>#R^OG+[-<N",J$0I'5P9(=RA_'')180"!H+\4MI-Y',YL5^M#V@(
MZ]#'3**DN[;68!)7V OO5JY:P1C"7P(^K>N9ED"J<PV^ BQKH,2J>2%CIP8.
MS+ +0V]IT(B\P;*(-*69$.,XDGP(5S\:X]#!C\%\38\+B$"A# 9%?N?9,:=V
M*(-X#GE5K(!F-(ZLVHH*03YHM6<D/SE.;W(-6GSO;TIF]@@GR0FCP%63C!AP
MIWX*#;Z9@+')PO(HDKR<L;,XCAF0AXDB,43+QXVSV-?76&$B/Q\O9(6326KG
MHK_#?KR>!YH-IKF+L,8@BUPUR9F$*'%#$669K78D,LI2,,M[0BQD@Y3."3\A
M%H/"Z[$?7 =1+ C9VBGF,2:$FD0C3#%BZ,:>M%'P<=V6#%^8F;Q06O,\D*PK
MFSRD0>E'/!D]DV9:5(9,3/H+5D':?' V$L/JL,J6QIZU3'@:$*CN_"L!B*@M
MC==%D]9A$E+NP^E\*/>E'2MS1/"#88K>(%J:,(P<NT&1N!!PVSA=(%^(<N<K
M4>Y0IN_J=L);>!X5_S$S$YMSR+Z@ XI8CE0 >#!NZ93H8\["54-#&;,V,24)
M/3\P2D;$N0\D?O*(SSP7'M/TA2[0HRD#UKD^=+8X16YKA_U!FK=$FK^:M VS
M) S/;I3"#0N(!XO"__DN^-?V8-<Z?<^N3M]YKX_Z_O_[[>C\ZNSJZ.KL[Z?^
MT?D)?O&K^?GD[/+XU_>7OUV<7OI';][_=N6_.[KXY?3*OSB[_.49U( ]"TET
MGA9>E2K\Q)?#UJO^'K/:9NW)HYZR5_53=M#WWYZ='YT?GQW]ZE_2R3I]=WI^
M=<F'[?*W#Q]^Y9^/+O[IGQQ='76G:CTFT>:)JX6FJSO-"5)#0:4[GZ]O3D2T
MT4RN:0$\MQ(K9,R> #>%DBR?*)<4E#F#X'%'C)*A'DB'SV9BGQ0%614Z51".
MOR,I0[C0XR;^6]1##;:W?B$%FQ:0RWDX>WZB_+=;@^[B_08B8:\N$@[[_O%/
M1^<_TK5Z=LZ"@&[:HQ\O3K5H^,?9U4_^T?'Q^]](,. 7[\_-CV?G/_(+E4BI
M+NE.=JS'))[V1MZXY7_4D[;?.&FDXAZ_/[^Z>/^KW+@?+MX?GYY H]T\F?)D
MLO![?QB,/DXR>.@0S$^SOR+;J% //*'3ZR"6O" X04[(B([3');EL;A&Y$+]
M  R]$ Z79S3U)]S+IU>4Z#W2-DQ]!>+;I#FQFP&Q=XOA;< )9O!YT/_X9S]?
MD!;$J:]AQ1 CER'FEB'\%U5+ 4#\7Y3TC<%NL#78>Z&DN_!@+]0_576#E_"1
M<CXY\*^F7&EQ)/T@!X>[K[C40B<EU/ CW8=-M<U+<8.@5YP2H#N/ R2Y]9 X
MP(\UA^=0F1DNP[M9;[@&F.=Q"K2F%+<D8ZT7+FYN;2)1;E&_*@S*$,6<,^(6
MVKU0=\/E\?&3[?K00/.N&D<8DDJ0@)<Q*R1)W+E+GLX*E:^D9>''$5$?"!3F
MJJTUR^E_X7+B4D SO4Q3[GWY8D(3+V>E:/ &NK]$ DEA-''=N2]K.0,]OVJ)
M*C@K]',TAY?L$S&B>/_A2%?9B_RE7@;S2&5F5(^PGY@V*.>22$% X,X<M*K(
MH!R7R4@CD8*1$4:A 1',@$&"K@"\Q_'""VES&; ?UD>0A0*ZK=>T.GZ="K,6
M:9C[71KFDZ9A[G=IF%T:YG,T4,\2#[ZE+.1(,N>.U&Z\"[[C18]RE*@> W%;
MG5W#+,SFL<(U6-V>>3D'S$YN^J;8HF;N<X=[36=D>FT%("LO3O]X&JDQ46HN
MS?=R(TJ5@OW[6WMCZK_W3'V41<Q*D"*G?REJ!J?SV%AK ]_"DG8/A33(JVJL
M')D.=Z/ ZM8\4%$<7+#:^PRL8[1$5JFARO3]-X%N1\8Z3;4UO5;R';4<4#]2
MJ-/L!&_AA.XQ689!J'#(&&0(Y6RB1MC\HT;2PKT4.*VS-:=@=#CH;F&EN]7Y
MK\;+8-+/TH57J<+>7:JPV7C'NL#?+#4,@<?]D6S5_N7IL;$C-DG'VF"_[#M[
M!BRC+WG0SZ! H+Q)NR'\]VAG4<D5>9*8?,.F_RSNKMO]#0]V9=S#;^'5_!8A
M23+!.M+,HX6F]$*IS+C,,(_KN_ ;OHMQS7<Q?KE"N+WL6U[U[OR<1KK0W6VK
M99J3<3 RPJH2[KV: 6[ &UJENK4=/1WIBFR"V[B5%!,4$T@Z>^6VAM1XY3_I
M-:V&F)?9/,VELK6ARWB_]2_[I@L0TFXXLPV6NXVG&0,[5GE[J>?]=S%:Z:GP
M;#9,_<8SAG;;%>VD>T7@:^!EF-PU#.]<X681WZ1H,,C^4[KGBE3@#,R&T1,S
M;_5=S+M0FHYZ[3%-FLXXB #FI>$"5=BEH*W!).[PO 9H.Y/7.^E\ 7\/*Q53
M+=V,/-[.]_CU)&/0N[<96=%<6/P"J,F^_?FE.,A<3Z<&!";6O82@3;G8ZGTV
M"1+=$-.J5%?$P>%-L&C3H8[?7[ZW2E3;8?8JC_(7'^O[R3__-OGG/8#\NT7J
M^9\G]3JUY8D1,Q4#;7LV\6,JC9DK3SA?RO=E3R1E(KETSNGIA;0 +9!RB>-A
MN4<GD,.U))FFQ';$/_I$Y/P.?,?6 *N,.>2<&ZY/DWI!2<7ZM<[0Q-)15M'.
M@ #2T?5MF2$A9L9TY#-B4)4YYZ$"O1T'(S=WW5V>OG\I+_IM+Z(L) 6DY T[
M_,.(""]-[0#F0JL(E<\'#3X:8T>C,F94"[C'&1@\5Z;2+BQAOMW^1<91+Y0T
M0Z7G@0A<]1ZL#EV>C@M._)T'HX_!Q*3VLG,V0%9XFJ4E"2DE33#-T\;F[D[J
M$Y_4HTIONU'!1_85L>X,71W%#J.%U!NXZ&D<KC1_9YRJ*/F,X\P ^$8A0VE%
M[@7N@9,T;;E3)#&\2K5V#_PJQY7&JF4$#[PV:[]KN)8$8F6HC&2A*UW+%FGL
MB-[K$CR"9A#1&7GH3>\8LGEU0 /S5O1:<-RQE8TXMDH8<2'TH[O\@;W5/MHV
M,]J[MQE]MY_Q,TX)7'G5!17DWK<H4>Y,DWM,HO*R>4-2ATF2Y!4#W)U&ZZ)(
M.?[NAAG*,I;NYTH4:B2%O)7=O98JE)[IMUF'E])*@RG#TTY][>B54\(^X55X
M$!T//KUC]ZBD+4UM_H5W3W<NB95-=>?6O/#/0FQ<33EQB3<N3.E5Z"):&##0
M;%' ":O]:":1OOU2N5]BO<^)]94!']W7G=KWER,)AB;<4Z#<@<YW*:^G>MU!
MLK>"9!< 1.)0)OIT>BRB=@[+KG;ENHX,-NEF*Z=0%[R=#?(EO1]?=^DZ3YJN
M\[I+UWDFZ3H;U?OQF,-Q2')]MH'C/TZ^^H/%CZ=!W;NJ^WKKV.V*[);/BQV+
M0068Z&@ID(SLK1?!RUHL^45H?EY*5/':TN#IN9%&C=-M4^H-D'3>\^VFD%")
MU3!6&F(3;,0S\$@FD7;MZ5IX%=K!TO/M3HQ[KUF_13-8\W.WSJZUI<JKUXW*
MJS=]__W53Z<7_MGYV_<7[XZNSMZ?/XK\Z,Q@9T]P^+W!]G!O:^!_B(/D:6JF
MGL$^/"&BNVY%NTID]G!1A#J9@S&(]*73FC"T'VP-;LD0:K9JJ\[LI_#3OPZW
MM_^EU"C<VL)@8)O!498=A2DBQV_C8/*O</CV7R-017KBX%__XG_M[ [^]?OD
MX.!=]-OB[Y^2(2FV<9#G,N1\FA3_NO@Q_OV?.Y^N1[M_7_S?Y5%Q=AJ7HYWX
MX__][]GD[S_]//V_'^/R_Q9OWHR2GZ?#61@/__'W,OSIW=%W/S3I&VCZSM/D
MLTF<'\2O_C&8_/;FYX,')3'Z]-<D3<[+&6WU2$#I/A47:OP_W[W-TAF^OS78
MWMH>R+]VMG8'W_F2 /0_WT6?BK\.TS1603(.XEQ]QW-]&XR*;?I_^WO?^0G9
M-?_S'4WZKRLF_+@4[+L4K%[U[WX(Y(>__:5&S _+/^MCR_]!,.D^+'B5S9+B
MCNT]>*W*__WM:OKQ<O*8''C:SH'WH3!^_\]9_-NKMSN?PDUAP->K&+":[^,2
M<' +_[DT5(TV/X\#_<!4<XK\E*NRR*0Q6I!QWRWC$ML9H(FN#L\N:]IG2"MZ
MM7U FC;D[(5@%\+'=[GU2Q.OV=L=M+6="2.&##'@7I]'&]&@D;;<5AW<'HR,
MD]SJ]UU XNDUL;,D1X]C[TIOWP?DV2XZRW\=+'\V2/4%!AS+*!20Q]L2HOT)
M+$O;'7M>9J1FY<AG"H KR05$#!891KF%S]7Q\^HDZK8M'@@PR.P2ZP1%=)P_
M3:-A5.%Z:W\\1K>OT.ANW7%RK8!Z[V89_T5HY12M7'<+;H^4>*,TFZ>,='JC
MAD2U\E_<W-ST8Q+3JC]*9P]9F++.(N%1;>.#AFU\W'=@>_R+TQ^/+DZ [$.&
M\NG9C^?^S[]=G%V>G!W#9K[TKWXZNO(_7)S^_?3\BJSIRP^G\@=9@L<XGYLC
M0C8/Q.</<PCN7==^T 7*GC10=M %RC8M4+;.0J.^?,*FCWJ;'EKA\N'HXLH[
M.SM[3.WTX2>TB=9,;0=VMNOZS& ;^LP%J27O+RY[_NG_GA[_Q@#"[]^^/3L^
MO1#HM>/W%Q_>7QQ=G?H_OO_[Z07P"Q\5LK#;.&R<K0KTI!B]$<G<M"8RS\T@
M':? 8V*C4DIK4$]"7_51#X+>+I*5#9>8)*'&,>>JEID-$8BANH0E9=)6WW'K
MA('T/-Z3"KGEFE$O$BR/+.)RO[$DB*'Y,/LMT9TFMI 9]L-<,)"KC+Z*Y+18
MH\U_*DS%P4RI0G<H)AMU]'&:QJ'2%-LW(H251ZA+9C8%ID3,\6%^[#\T#L,N
M] 0DOWI)!5D<P>!603%%*F^ANTQP6B_MI/CB4M3OS-!)1"8_S!"S#U4^RJ)Y
MK<QP6.81UWN@HVJ&4@XNV%(!+: -R*Q:;+0+3[CT:!38DA"S4M-HGOM3%7/Y
M8WT\=+EAOT%56N0D#E8H<(@>N9TTG(C/6Q5RU5'E9O#CX$9*=VV#:>F7XP\5
M\1NV,T^KOP6Z<\4P0D.-^32J\@EG[+RLT@NYW0?MQ\@["J^C'(U:JE).=H*4
M7 .&M.H )6@;?DB?1?#Q?9EY=XL+P$NCX!02*?_KYICJ;5M4V16N'=&T,SY[
M3C4S8Z4Y\AT, <?FN._XWVD#HK(]&J;OL&GZ?C;E.P=_?N#K&.9E[3(FTZ@Y
MC<\G\T&I;#!("X$/OLZ#O3\_@5UT-.F6?FD">[L/S>(?M#O_1?Z2J?\)%SE'
MW+0WO;D)[!IX*!EP_P5H\6T\[5[^44A]8D/S*\C_(U+U/$_?FX!4Q2!(F,!K
M&A3:_QOZ17<@'_] [NVN/]NO U4?8'A#S>\Q-2O2YR5:?CP-HHP&-:;ELE/B
MFQ_J!TT S?I,QL\TWD_]=WTRI:=DCJ@D7[=-?,BS^KC'<O_@^:[=0U)U;/TQ
M3(V</AS-=^@_7=6M/*L#=Y$.Z:)@2L[[_C\4&?W(NWZ0^W(]6>:QC]OKG>>[
M=@])U=_I+#$=]CITCEQ+L=BE&F6J"++%LSI_YL*[+-1\JA+_YS[WIGL8A74]
MF>C1#^#^\UV[!V4]K4$^J_-T@7:. 5/R)DMONF/TY6KCX/FN77>,[GDM_;-,
M_']VVN!77$;;SW?MNE-TSU-TH9+__J^=W=WO_3<H.,C"SIO1F5??\D#I?-PU
M3V/;Q$S"-U5RD%=K-_ L$@LW<4?^%E51H7I$*/JA6_YO@M0KFV%Z$] O3&N"
M6LB.(0*#^3P%>HVMY&M"V[1T]JC@;W\N$^4/7G-6YT[?+04[-<]XE^@ P-@2
M._NFX]B[K%\G)5/S.!BMZ!,Q3CG+L.?3?>__G$X3_[+O_Y)>!Z,I-Q=M<W M
MB8*^A[?E+7\><%.* -T<TL1_3_,"@7M"7]^WU-L_6=*Q9AJPU<2,,)K.+ZV^
MT3))6F^O6N\@OT?P:4U+OIY3 C1M4TUN<8DKXS?M;'/C.TX[K9)Q3>.U8906
M:C1-TCB=H%=R2.1F"PUB'?@?U8*^-2IS,%B:C.0Q,&@8!9,DI;F-\K[_D^+O
MH;E&DN.X?$S2FVEZ8[ZB>R6!A!D PJ0]-;)T<2C\<9;._%$<)1Q "=6UBM/Y
M3 -C92J:#<LLKUKUH&6PRN#WU<U-F)]O5!S[C.6EJOY2C)M,7P44=Z)T\G %
MT#T-B'%'JN08N#/[8!2$:L9X#'$<#%'42VS<0SURD47#4GZ*$M.[P6EE0/1)
MQ;!D%M,$=$+VN(P!RA64"1W=A#;6+B>M3EB.T&*B[;#Y3B?#6..=LG X-@MF
MD-1HGD<3E=#.<'M)._XLC4F,H)UQM6G>2)=O2U,:(#!DUU&B>OXQ<L33+(D"
MGLS1#.BI83#K$3<BN3JFWV*5L[2<3$EV$DT#*W*6)A#E.I7; K)6<#QC[TIQ
M9?9E?]X_ZA/1_KLH!K.?%4&\V!+2-#O(_ (_H<6-?9*S!4JT&44ZCOY31B%8
M>9[3 M'F"ZILVV*.TBTMB#'<%<UB-DQ//O6\H#&,61\&7>,[9J3[*]):[6P/
M2)3^OV"F8D4' YU!@CFS4=[3C,V %$(ZMR58)+1X]( ?TYS!Y5DY<=L><'L:
M;P1VRD0J%9D*"LG!QT:\I^W,<73KF\OCN$?&?+QD:9ZC0^>(3SS.!LDH*898
M>J^V7AZO%QTB[N*(+1H%F9+^WX/#P]<^^B8(E=S*,8@+6K$IC@P:A:!E2*[S
M]G]+HEA=<W9]<R&'"__L^ R-UVA!MW>6[QKOWRGP0>1#OV Y%%^6#:EE9NP.
M_*LB4OB;-3+1HY(F(;\C/E=^/A)Y2*-/;)<@]!Z!L*0;$O/H>2?G1P;#H$#J
M/PFQ>,$]&Y:X#'49N%W?!3@X]OH_04<4%KOO['&\E&_G(@!QLO\!(FC?5(*%
MHV7+T:="8QPZYZ\K!5B#2=R_+/NP*\M^TK+LPZXL>]/*LI^O&'IX3P4\QLNY
M;W1_]D](B_HPI?]T?HMOA$U)6V-WI.&;@$569NWI8HX[XJB<$*V^:8#"UG@U
M)./_IM(7E?2FO<JXLP:44W+)=OY,?TKKC&3#](SIHW\6L\J\7_^;B^-<?;BX
M24GE@9F4NVHNQAD"G1,_P,B!FIE[C$&<?52D91ZG6T%93%G_=\8[W-[6+26T
M-HP.Z*1Q;F7J.E(WM'JY+9?T_TW+2 I8WFM9&ZX,C540BK7G&_RHW-,]<UPK
MYIC5;5) B3>*DEL.5P:/[2V)CYS O(-M2J<N)6K$^-HZS8)\1M9Q75F[H'N:
MAV#+&$Q >N.8BW(]=Z.<A5Y I?Z-5/[1M%A6_5RB 7N%QF8P<X,LT?HYCCY1
M!QU3S(6IDFIB0</RA^R4D0I4[KC<SH5$W9L%6OKD_IO^W_NBF)*H*8-L :OG
MT!I^CD.,+3^:*+?QTS0%(H8T29C&A[JQ;71?CS]!ZGJXI//*+VMV9_,TZ"E"
M9Q^\UD=A>;[:,752%F1Z\Y11F^R?VH9?GOBL3%NBP8X[5+5HP!R/,CI<>04"
M5E7Q^K:*5T9[;TPT_>3INZ.^#U!'-A\MYK?IP$0*/OC7W31X+;8*$C@K9 9*
MTM,P"QIK*WO'9J)E9FU,UZQ:US'!?R'35(4>#Y<K?V=8<6I>E.'"?N\D'6UO
M[_\E8U,L%0BU%%731? I2+C^V=C#W%F*\<3)'#)S)L,R"6F)MM+Q%@Q+_^SO
M;#VF\B(9M>E(T5@J[J$7 !JHZ:9ZQ11'B?M;^6(K=PU5OND--X^#!5C5D;@9
MV;?6\4>G%O8LL0'8"XX&/G!2WLYG?3)=V7K(LE\!]'IQKM6[R7LXKG!<Y])J
M6+[JND,8+@&@?!.X\\R D]2,Q[A_R[3EP5@5<)TE:(6E_>*"#QA- MU2%:<"
MD*!>72A%N3[9T0QBTUR_>BR6,$$<5\2L&+97:Y/66*R(! S$P\(_OGAOAB9*
M?E*-%;(#9 *I"OFD%T0<N8W)ZZVH/>+.!F<Y&(D/R0[9E,L>.B9B_](<+0BL
MP[6YP:MZ0J1W[*-L7Z)4V&@5KTQ'S?JL<.N2'I:E- L6':Y<@]M6#V76JI*,
MNG]4YBZ.]?4YGMOE:RF"8T=@([A5= #W;P8G:&;:\=7N]4Z0/;K=I,L8&B4,
M3V(H/0M+]BF"6-7.+$=V63<R9A0J ^Y7%=!B6^VP<;4M[EOGDY%&CC4&5.A9
M()L*B$4 :D39,X$R_5=I#4_R$<1QX(ROCL1M.H>WT5J.-:Z(XT=1GI<J7Z(&
M"\!K&0699X5HU9"%K2U#G]-SLWZ=<G1LB@A=Z,#4U.FI-?0T$[%2K!Y4ESO7
M3TJC6XNN3&(.TC-E<T1OFX3L\L_9JR;ZMM:1Z:X+;L?>O:L3*NOO=/P#BQ)4
M7TAG.V;H,?B@8>M.)GSI)"XC^#$&AZ\/>\WC,17#6AB:@>5;V=@YK0O+T])6
M*AAIO\R(N;%Z/76K:RNSS+2.9NLRK\%2X8<$,/EIF9OFF%58F'CN.J #0G\C
MED3G>NYR;M6;7G5\!60KS2;TIH2WFW+!DUB[&\H/>'AHK*RF<AQ;]TXWOIM;
M MX=HZ_!)-HN/YM"@VW]L41G56*0GU00DY T'I2>?Y:,^GZ.@R*Y3#O;@SWF
MW)M&>@X U%M2H<3+@T@^+D7/N'A,UI"X(1N'CYT]VEFA3T6 OL$]YGI2@DUF
M1H*F#-Q?PAS&"B?=P58?&>2SW)VKUSY7W42-S[PT3>OC>KG& 8L72X*B\JG\
M2F:JLZB)_=!MF6)8'L]Q@KVV3C !!&S5))"P$?%7_3?]HSY[%IW&LR;@ZWB\
MZ)O_",B"3B9%FDBD_?4K]N*\Z^LA/+DOU:KW+],2-UOB)G'(0'L]8ST'_C$"
M1( !]#^(G-*$0;5Y01]@5>FE,5$NV=E"@U=CMO5_VP3]WY"]<:&1*NS34@&Z
M<;-Y%N):;X1G-\*$WY:L%A@KM^:?O@L6_F"WQVYA\23(B#9YBMLRBG.(9#0-
MD$X2SF1A)0 MIKVI(J65(S8C6ABL!#09G9 V!/@H+5>6WJ U1Y+#+5<X CJJ
M7'@<>*%/& ])+3(D+E>HYPJ2KT9L/2]T];Q)MM4G+"ZK4;JEN.V\Y&71'N1:
M)M,#F!N-S/E3Q\CSNUJ:A303BCA9%SL_3-./[,\1XDFQI\W4,:1<FP-3N5Q&
M&MQS+-D^=+,U=X&109'J%\F+OP3%-$;_D'>C\X 6%A<U>R#+*)\JC<<"U_5/
M9EO$D7;W3'P=I3K6$OTGT@O9V,G45'(K3=#JF+,E,'/;(F6JJA"8J .#PX/7
MG7:W!I,X2[P$(+L+_Y7)QVW9Z9[+=TY?&U+22W9FQJSLA]=@1:W3YR59--=H
MSTKWM*2OV8!)7I*0R:S"(<>72T[8BHG3--0^X!GTQGR1HPT7JU7T\5B5']4,
MV:3Q8C;'D>2'9PNR6F9!QU9K,(FCW'--!.SJE<B5,VRI#:A=:(GM_VJRF4E+
MYKQ.="5."BO2(>W8;R5JO1;XD3M83Z>6BB$<5CZ8]"9I<!+= D%1()E-!^M,
MI%)N*N0J)%/\Q;CX#><:T:^'T_$,ZXJ*,L/+H!>A 4GOE+M2Y857=UGU;&)X
M\OMBIDP>K+:(</$Y=YS.2N_YO[[9&FQO]ZJ#*.C1<KL-R60!0#2'IU)#Z+A,
M1MIDIT/DZ5H*.=!56$NO.8(D.NF-K\6K+<X*,R$7.\FM,>(^TD^KP/T5Q-WA
M^_))W)FN>;#=I6L^9;KFP7:7KOF,TS4-A>MOF%9FMD6TZ(SK;W$]T/)[_U1)
M+:.UY[_M'_6/^Q^^R,;6@3]NW3$X$/ONGSK@Y\^GBYQ-1,="A.L\2:^A*O6X
MW\M\BMHD>/[F].=JA/O20A=\DPBQ?.DX*S;K)_2.T[U2F_9^%I']7HYBE1;T
MI)<II!P$:)<9."J(:#215=F,YM=6JQ>YU::G:.U;E*Q&70717$4VS\QQ+KZX
M>O?;RPIKU/M@$AJ-VBGI?O3K219(69:V4]]$E?U[@J(C,I5'\/LN\+B.&=+H
MO=J*8L@C)%/P>[\JI, %J7^:A.F-:V"?5#$4(EA_LEZ/Q<]*[IHIO/G@)EZ>
M(+BH"ZV.:$HC3A&Q:C6FPD9Z;/)SC#+=DT3*=*NI@M])E%VG-FO__/AL*]1-
M5S#5VXS_DQ+>9M<UZ^E:3 Y!L3.B2K+=19)M+:DVP-T3<SB,RY:X8G1_&WHX
MU/ J_N767&),Q-;F,7J:%-,T9'6>PUS7:7R-]BI)D*3S:O1\AHPG#!:#44U)
MHI+\X!X*NCA!&&65;#GPA2N?-_E3H>+(777R.(*',(14]-6/Z,AW0VBY%Y#$
M";'>' '4YLLD3H>56PMS+!-L!<^:%T3W;$%>&W%;%>!SO$4^6$9Q;V@<+@XV
MY/Y2I/!M&:/ S/M1)8IY !^Y"I)K]0EG1%B2PQL;+KPW-#B@,>$8#XZ$QH>C
M#;S\GU-%N[L?7^I4EQJ* 5GC=#9E)&O,!R91A\.2500,\CZ5@M4(^97LK(-8
MS:K,'I8\?''[W$A>EU^(R+P.LH5.1L5\>C;,+L7A2D._C/PXU<4.;IA>Y*-Q
M]]M8*>?UD$ OJB0$+.4_X4*X1#LP__33: I::L7P;0%!DS$$>?5>VF4)Z9PT
M@6H0.&)<=SA*#DA@HSNWQJB91I.I1W(,/HQBRJVZKJ.P9-?Y.R28TQ#NR-/@
M6M4#&1)8R-(\WQ(KRDE@ZB3@&DSBB.Y,Y@ACCNLM#=6<=KP&)D%WMDTPAHM;
M$K)SG6958R6;"QP9YK!N,4F"DS)KE:&Z'P7KGSSKFI2^<%)XK<L*$MV1G4>-
M(Y-$[;20U[E<M2JF@!1>*!3TQ30N)8!$7Y(/5$%Z-Q6-2Y@4'4W3GPZUYKJR
M:"FYG7-PF-=CJ7U(C2YC$3+$^:=#[$&F M8=L]*$IA1GKN4HCG<.C0<J]8R:
M26O<<PS:4.!#=T1%"L09E#"S=49^N?(P<DI<B)P)0@)<GZ%SWED]K83')>LZ
M"W@VZ8JL4NB/8$70!YU:*CRR.M,@MZHER77:7U/S0JL=D![HBY^&]"<PFZO)
M=<+AFWE%VA *-TY'>A;"N7TWOD!-$NRK/8U]Q::5':V1%2"YQX@M<^6FMJ6]
M$<GF*$D!F4%RN<>"C56JSRRW).-)*E=$V$L0BNTH]E/0HF+4BG)375H#4>EY
M]M?B$;$V))2C*)^Q*0;?!V0<24U$J&CP+6T"LCEJ\8Q8G%K$&)2'T'*V88]$
M$IGBRE>$U3RG6#74[@[]C(TS.? _1BJ+:R9HE"U>I MZW%W'(X8GDHPOFQC'
MLM=5L'Y*$](<LX7WKC:<E=3.*$>9EL<6D43W8*V/6!_HW/RZA1S_Q6^71R_[
M_E$81B9QI>=-]?S&"GTQEPG2SA=<H8X#R<8N7QP='5^\;#"I) %S#27M$.]^
M4 3&_";N_C27!KB6<Z#[FA!XLR#IKE#@#7*O)AC$)/X[>;>FK%%"ZHVB+I?+
MS+BYQW68K!QSD^!9&BI48X-.=@DE6E6BF[J[]Y[^WGO+KY*D%=\?PX=MV'7W
MG%P"IR0G/)-MUW9\5]:9O!?;DJ2SJ3/1*<081=)Q%(OX$S42(;>K\1<$V8R'
MPA5IG-.>+@&OU9ES$:!.T-1)/$8_IL=I7;;B@,4>C!OHN.[+/T8HBI_>D+[^
M._T\8:-[%<;C[K:^L;V?2[*B?'=1;@!K11_!:C7)"(-R,BTJ&1[#U;W\Y6AI
M*=E]#C4<^<!)K!;^/R1Y[AWP_*15N"? !*V5O$'.J25D/")93?<C9RQ =",W
MY.G7Z ^DP=#_<JFLHHTKL5G#(&'5(G/.8[\V3VE6CB+VSV*&^FW@*!E+[-!)
MX368Q+V!MPX&72;'DV9R#+I,CF><R;%A8NB!U:AC6Z$$Z^%]JV7=*8??C*5H
M0[P65X<4:$I"P<SJ*GB&C7E3/<WV[G@<1' 5NW6E0R0(D-H&]RK]IZ?=K@GC
M/G#ZJ!U#5X5Y,Z6@7=@Z[!:JV$(L\LK36I6_H8I,3,*@^C.7UE4/6=^OJ;.K
M_M1'HH%\LMY:0,>E4=X!D'*#IOL9E7F,U!IHB[ZG:]"B&3M1\-^>3<-UBOEF
MP<(;.HC,M*0"O\OJ*%/GE'6W+!6;W(D"'@?J[^"P"4, L\K7X&+1Y?,;=/ V
M4?[]+?KA"&SH64&X@=[?;U (^!2"KRD?EC& 2'#-4H1T."I6H,PT_^L&;5S;
MB:DT/%>C:VI\GSVIFL*W4C'\[@N;3JWH#__EG90TN=O]'6*LI]Z'K^H!]=24
M'^Z_/OQ>R'WP'E:/0# C5G$VG>DTC=:V46+\5BZJ/@L 7)<(,8AV(J'E)"GA
M?6;YH)6>-GB4VHY^14NU!^?N#6+GCM35I'8LM9ZD;IA(E,1E(Q)U:YEYFC,^
M,)*G14H"^L>:7RS[.F9<^[W=:%([EEI/4C=:ODG'&;5E%4&MQPFF4K(E/XV5
MSM<PV&;MC+E)W3P[8V]=3*;.V/LV)_\6>$Y.)ZXPE5NM0,Y_+IL0E\ZH9/F-
MQ]T-MO9LL=&D=BRUGJ1NMFB$(+,*$<.9!2.ICQJJX@:E764E "T^:\]@NMI8
M'V"5BU7:4L>Q':F=$'S.^[1A0M &T(T<Y)[*89DIP7SC2C"D3>85].P076 U
ML(13Y2HU<%Q$UG'JVF_\1I/:L=1ZDKIAPH^;'REE1)\MKM4., VZ1P-$8]+N
M%M]#Q>O8<-UW=:-)[5AJ/4G=,,DFK6W<@*: C-:"ETYB%Q<,\F-EK&R($^V$
M,O6?,LJ4QB85M -I- 8[6.>!Z-14*(^?%E7Z1__Q(@;\_U\=S(O[Y,9M[;SB
M)+W-RK/\%@E^&D.6&W<F&FUC[ MFCJ\QC!@G2X ,-?I:WU\N&N^)*[E"A,@U
M0!:WQ0DB>LGFNM<SBE%Z&RJZBF<16KXR:ZI@-#5<65&K4;28_71G/P%KE\Q?
M6B=4BNUL?^\ZLXWKIL=_&WSO\^?&^)8G*<3G01X&_Y&C8(K(Y'@LA!#[O6K<
M4=5^-->9R!< (AML'VWMVE:M&DO'/QH5??]4AC*USWR<.!'6G:#2.>:5QSV.
M:&F"T<*<3&E#98NG*](;>=4K:O;;5ILV30,D_:<$1@<#_N?.>C;9IJ).\ 7=
MM678;XPOA7J\T! ?9\!C>[7]^D7X\L7>2\UFI53@^9=;OS!_M*7><PE]F,ZY
MW,^_R4!" I[*4(%H>BTV2$398R0XU,%U$,4<]4M%B%7IZ3=JB#)"@ S<W-ST
MX^A3H?HT1I<#_NBYT\=.V4&7"KY^-T5[64B7$=XE"6R >= E"7QF) S-@&:D
M6=@6?[7C'V0,3RB:!RY<95LMSVPM7&?6KOV^;S2I'4NM)ZD;)ON6 F B_K1
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MIC: 7^LG3=1![5I#UYOI$![&'N!BHCI[2&F>J%;6+:K9,J):>4Y4ZZ!U&AH
M^;EEM-43K2EEM0$Z&^MQ/"^KBV:19/7KB7@Y/:U-Z6D;34]K4WK:3J2G%2^X
MBJ>L)0?^Y(%;H8.BFEFZ/!%[@R?^=,-XSTXQO.<-_*G#,W-*:Q3%(#J8BYU-
MK,IM\9J9#=Z\4D<<R=NC<RJ#3/Z+M -[XHU363#I7FXF/4#&,Z8VA<7M2GYK
MN&@G>&$G*M;)^H_H9.5U[E-+]->6BE@S#+5];+RDB&6O@F0<LZ8T*>02$!$[
M3]JQFN&J9V.#12?WEHD/6GY!?+#0>=I6?! %0WRFK)3AP>-:@Z*#:XX.:N!I
M-'7TS%HUHZ%E_3(E#0X>GZAZRUA-;#"W$.<'!_,^H+*.X"!6NL*C]8NYG0Y7
M$M1%?F>C&MH-W,QV.W(S4<_KC1-R,ZM)Q%1(<*Y6HY#@.D.">2U%$<%%(H*&
MUE*/8:*$UC$:!=' Y61S$A*<)YJQP/&&Y/(K(X$G#9#+<K/LYY:A'A\?DUBN
M,A%3PMFHA' 6;=;6)9P;6Q#.S5J[3<)YR>V:$UUMGF#"0*/6U@QM==+9*)3.
MS;QTGK]94RB3(P:+D+Q6-*<FLS(KFAMMM=%JD/RM"!%3DK=!DG<;DE>O&<<D
M>9>3O,>&>G+< L&KU=J-DQ6:Q8U"P=N:V2F?(WL;1;(74[NES/TQ@8O;%U,"
M5VNKK4:;!&Y%B%A*X (3_$_2162>Q.5#$#F!%&_  'A45$CAG/PLDIO*7+D9
MVPGP-3B?S9/V,Y)T%4%NY55R<JD@MQ!74_F.V,4S'B/+4>+3\D*%Y0^(XML6
M%?(8I,4G9X\)2XDJ9:83"G$QO?N8'+5[M;9#.0DB'N8MFG!!R,24Y=QR)T_9
MHQO:@!PCR8\XQB/S@<L3&'A0)+ ECKA47WS.)#X!+27?%!\/+%FO.CFBFVQE
MQNVM<V)\&4V@1&'Y.  ^JPWT8[$/B=J@U3RN+Y4R%<?9\TM2GN-VHKO11"G@
MGJR^)/%: B(6;PMX0NE)&TU/.J'TI!U.3R(Q-&WEI761JV+JZ9H*KRF)J0=>
M'9EZI3'UBIBY+/:>?M(J"KL^:^_-6YPYHT^9S8*8-?I6+:Y(E!8XS*838MD1
M/8J!EUV0@L_<:C5+(DC!9S9(D)9%D!9$"V?D:";U;L..<[VN9R2I'/H9-(7I
M88+3Y*-$XEN_[X6RBG],L1)3+#O4%DIF4=LM3ERCD@";+]DB'2,?9 +*QQ'6
M:W$?I8@4-9=&4Z5.X@(C@:MBKP%'LC'6Q3(M.;FX$,$5',S6.)^;7A)UA\LE
MF:R-&ZI6I';U>+&N_<5-]^SNZD8YN_IZW;V\[=Q=7%VRN\[IE^XZBW-L9NQ3
M9S_KW$\[_TO3E//]Y\8(WJ!W_DP@0(:/WD0^?.K^/Q]]@B$KBXT)W(.A'B9[
M5UA.WYJ8]A33L#*AO0;31\BN _UP"N=T'$K<_LBM^U& ,V4/WK.(99*)T;)<
M!W<O-X\1POPKBE;(7R JI]$50"EXWKP@WX_0!LR-8_;K&WTZ2/:C=-Z*3D4?
M>M[;WY2#GP_W@>13;'ZT5Q3?"LNQ@Z;#?A$>=?*9HOQ VPOB+\$KD9T+V$5<
MCHY=VZ:3KP6V3_R 0_(O\#VMH25,X"'WL%->KL].%ZQJ@+E?"Z5CV^P*_>S]
MY8T[#":ME&+<.%K.&)T:L.?LG"(2YM\][V$%PYE]L(>DT7/IN5M_[J)K"3Q#
M6/[WGALZ _0.70^>?M\[T.L-53?:JMYL'LXZ?[,;P]<CR[8F[&.-79OVF _<
MUZY)#*T\M]\O7_>Z=5]T[S/#.[/M3S@(Q\SRR_Y;7F3EPE=1'.L1JDG33G;0
M/ER6X(S8-*HYJ(2#<!".ZN%8KX49;5[HT\F%LU?D+YCSG.8OQ4XL[MS->;#V
M2U$"Y JPO.+!T_#GS1A!)^C/06\9JM&H5Q=_A8>^PM!U3=4:[>KB;S?41OWU
M^']$T?TYL@*^IGAE*7Q, D-@" R!6;,[,/ONVX!/L#OBYQK[*)J<L8.3'XF>
M4-"9<#R'0V^KC1-BDG+B:,+<-$N"Q3#4D_9)&81G$EC^ ;%(067"\1R.1EO5
M#*TD8,HR*&7!H8O:]R4!<UQ76\MRRIKDXH]YX44QXSUG-,*Q2)QUSP>E+#A*
M)17;3;6]+*=00'(W0R@$AL 0F*H&)/\*'?87=]B!06%(PK'&Z!*%(<N*X[A$
MAF6CKIXLRR@4AJP*IQ$."D-6!H<A"M:7!,SQ*SB%PI#58#3"06'(RN HE50\
M>06G4!AR-P,G!(; $)BJAB%_MVQVVQ\]FE[POSWNW?^ >4EA)L)!. C'AG"L
M_71]@T[7$P["03@J@(-"CCLYK3N/@T*.)<:!;3^,LDS.\8EZ<DPA1PJ2$!@"
M0V J''*\X?>68[)3SWUT?L"TI' CX7@.A]%0CQO$).7$<5PBR[*AJ\9QN5(?
MV4&3@H^$@](?]Q!'J1)]*/UQ=QF-<% LLC(X2B45*?V1HB<$AL 0F.K'(IU_
M_*0;QGMVRCU'M#%\O8%)P2;"\:P-HZLZ121+BD,#3[<T)^6;=;5AS)0@WW)(
MLD4A2<)!./8+1ZM,U<]> X:BD=5@-,)!.*J 0S,,M7U<%G/F56@H%+F;P1,"
M0V (3%5#D:>FSQY,APVXQTY-DU(C"0?A(!P5P+'VR.,Q11X)!R5#[B$.K:TV
MCI?<"%D;F%9+;=7+T:J+PH^$8[T+K]E6FWI9FN25953*@D/3U'9K24FT/C#'
M==5X;>WPMX'9L_EOBO)A$M\X=)W@'=/JDX#=66/NLTO^R&[<L>FH\@N5W7+/
M&KYG8].[M^#Q]7Q/[O\)_< :/KWY[8,_ 8<Z\]BCH3FV[*=W+SU87.M;_\LE
MCA0Z/A# 3TH/^$ [5,Y<Q[?\P&?ND-U[IA.P@1EP-C0MCSV8=LCQ!W<26*[#
MS$?3&S!02_W0AHL&;!)Z?HCW!"X+1IR=VJ"?CF[[(]<&(/*NHXEG]2WGGHW=
M ;=K%1J>3<VG?/+_.3IB'RUN#]ZQ:_.>OX?;_QMRIP]P3N#6?^-<O&,Z.SJ*
MUN7 >HC!]%QOP+TC:26\D]/ -(#FN[8UB"$DO[>0N@]B48&ZM^V).1C #/WZ
MIOY&? :"^_'G_!O Z+#-B0] XK_>L[CI?;W^2\$@/F/4!.XD/R12 F3$0_1H
MP_AE$5$C+9<$D-'X!85Q9ESC$7W/[IXF@+#CF3VK_YY=FF,N1_W2Q?$]J6?O
M>AO?AC_-"/=Y$%%VQ8+KPUN8JX)9\[CY[:C'AZX'KY^(28]F"H:F>M.$CUYL
M$+*CB\,NF'HMBRM&4WYI<Z ?*N=>C7UV1PZ[K;%_N@]F?Z0*N3I$BY][*(KQ
MXYD[AK<^J<SGW@.(8=-G9R,0V-BQ/+KDU$51#1_B (G/0B>P;#:R?#;@9C!B
M(-"OX)<>/+>I,@R"U-BU9[F> M+\ED\"/L;?]);\466(3J)BC_!*T_:EU+_V
MN&\-8/&I ,/B0];]SOMA8#UP=C4<6GUXB.D,HM]N^Q9<:<'7R8]YJFJ9]R@#
M:\ <-V!  \?GP>] ],3T4$?UX0;N^*;03;"(!&TX)/!4'P?%9&-)P]Q!(76T
M3HXV#I7.9.):3B"9U&2#.%R7GW/&AT/X'F>X$]X#$M9 IM/:-#_KG)_&:^8'
MS#F;G0B9H(EU/;#@[HPP,>KB1YWF;IUSUWS%W'TUGQAXA6+J:';6.3NM5\S.
MY]#A3&M&BT=HP?B\2:S_X%FVC4] 39=7?YX[SC\!WN*YX?U(^6IZH+$-.>\-
M9CF12>&-\4E]TQ\1+ZR3%XY?S0O'<B95(687,_(R<K@5&W7=[WT[''!?R7%,
MRE+# "TT"7$,QAF^*K'I,J;;K%D'CYDU%(F;ULE-;? 2(J/8#W!NT/#U^!&W
MD74P2!,(WC =)S1M,(!Y@,$78!(_</O?1JX-CH1?8YU^'WQ%^,D&/P+%"3#!
M^ 7V!!]DD#*I$C/:,>G[]<_[R6OUO2$LZ5:59N=#[[</5C)'%F"&+RH%/_5R
ME<[@P?)=[PGG9VP% >?OQ53%@KABQ&UDY41?6@YJ(+BHUK2<51)Q-^)*)A Q
M.T4BP,%]C%Q9_@A67. R$Z_BV:7VCY_:NG;\W@=J'/.>"]TIS"L/GF!ZW/3?
ML5&("GOL@G@.;=-C$S, &>S>(XV HF];#@;;LH] ^T[<U?-,?%PX!LW^7BCB
M,1]@,!VN[X_XV/(#[ZG&O@K]Z\=RX'G"!J[4'1@Y0K! AI)Y=]_$H&+PQ!ZM
M8#05E@D]U"3XW1,WX7U2'YR#'2'T?VQA2BM P)76R\N@^G(3@@\4W&P TT?&
M;63(Z=QT+&ZS\QK[-ZBW3^YPJ+*OM?-U"[1U\^!.+*0K1TGF7\X\ZIN\T0"&
M!; )*"Y80F*F0UN8).8]+!/!=(+7+L\[["S]]<SU)C5AW$2W2*M56,(#C/ E
MC@S&D27?],7" FO(Y\+G$=$)+[QG _[ ;7>"+P/+QX=%Z 7Q<BE"I HT(L I
MOA/K?V3BB@G@[C3>F>-/)<^?47@6C>0BF?'",DT7FS#,T'X+@:0BM#5VEUZF
MS*-)B#0<3UQ?N(#%\$P\]\'"98R_F.R_(8P,]^PGX1>R(1?;?S\WL*Z.?$WA
MHT?F@/4XA^D) ^ ;L7U@/RD>=_AC_.S!P,(9!-$% (X$ (0L7!8<53!8P6;Q
M?!/& ;<@51":OHS\.@$ @LNF6 UCTKU0$N:'/5]LT^"E^%P0DF@I]4"ZA0%:
MPBG:U$!*G9<H:-40[&$B"P&1,8O$ST,&?(9KGGVP*H+[,8=(WNJ#AI"\U>,S
MP>KG^4-8^?@/K$^2A"4@(A5=2BRCQ)3!$O)!60,V.=/NA'N"D_RIW7,1T2E:
MMB ^V<^:CDM0A3]:^(=8N_'?N+SF:65EKE8&%I](;D4/\'%DX;8.OLMR1+@
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MG^+NMZG[BAV]XJ,=:0=?4H:EYXI*0R66*B?4BDG&3A^4/$:;4P,KLH=4L*)
MXLDN4A/7ER6Z,8"-@:0D-5GFGWCLT43?,C[9D1AE3GJ$(Q"? @OCUDX<61-G
MW(I,.BFK?68%(*WYV)<Y>Q,/.RJJTV?4;:R@&(6-?1Y@'%P6'L]):EH_I6?'
M2D,EEBHGU(J)Y&M1"5K*O^Q.ESQG/(S*@"<A??BVQ]/SR[TGT<449>Y[:II0
MA?FN-%1BJ7)"K9C,N\!:-!./IUL80J#YL1TYVR0WVTCWN1/!.Q.VVX$$F3E;
MT9A^XH<^[M.GS@>8\8$M(BFJ/,^35A>,' J\7LQ^DFYGQN7B'T=<[%^;A6EV
M25:*'[7%]$=Q)\Q,CLY0G#</X94'X$A$J04F(ICAO+239I+P<UB+<A3CY)J,
MQX)ND,A1?9*U%8O3&<2-%H:Q96J0$U7CFIOV>N"A<1#U"P'/R8P3#G)7]6WS
ML6?VO\7Y!A+(84VYFTUJF%=G=UZR@W06+0\FQ!8U*OVH!$I/;$GRL6/%63RR
ME6FVV+[P-@-%]L&(LG8SF4( 6TR)&3F7@?F-B]B;*!4L/F!=3$],"V5)O@#X
MY2)J!A51VV@1-8.*J&VUB-KJ%E=Q"<,R2IMETON0?7W,ZIM-O=]C^;J81;AR
M8VJIW'1Q=OI*'@S,]"T! X5E#PUB&J:P,+!EDVSH*$I]QGF_HC;%T/J.Y?CS
M=2G<!V%JR=] ?UNN,!HPTCM[2D(I/B61RSHL" =+PV,F7[Z/[Y:V C?!0,L1
M%-DC,W"%<1-G:V?LLIDGJ*R'!\<Q1#VW*$??=*+CYR*W&0PZ9\D2'4JV1$>^
M/$=LB&5!R2&=I6F6_O@ 2=&)@3@G=6): PR4#T/;5J+*=R)$CT^,WJ$R,&EQ
M8D2N-]9@$B9YW!349#W/_08JP/3%)ND@L3OA2AR4V-1,,./$^*:=-, 3CW-X
MD+Y1R3[?D6PQ!IL>.$N>W7\I3;C&;G,'8I\="VFA1T2*VN7P>E&KJJ9<H)$I
M[G&%N6T_R6&X TWJA]X3N^'WH2W?GA3#K35T_4@_Z!U.]Z7(]YIR7#8&12R9
M9JJ6>RXG7WFIV/H*;=PMB;1]E,R=FYQ 5CIX9GM&#D=YFZKL.IXN2@R$C-T0
MF *,1=..66-@#<$-%,9CCP>/>'YBKCP2LB4Z>92*GSAW'\#$KG)^[>*/:1^"
M0O%:(*"S? MZ HM*2V\]>M>"NB*?\"Y+QEE.WPX3SV\*T$&^MN?2XESY@8I+
M>7$>B8,XX2P>RO@(?S(.MTGL0[X%OE1B>>#,.RJ&+?"<5#ICD %^[\51$=$5
MSQVJ+,K[?R86DXQU;;K$BO(C)5:JNJ3W4#+=) 4:%:%&I\S&F:Z@,O<I$ER)
MY9(RZLSJ$ ?%BF)STC; )9K7@Y&9IL@;PQY&X )L%.Y9_C=\111Y"ST>M?S$
M@SW6T.KGTD0]=N]B4CRN6K GI,C)DE-T($[H>]=+V!S7F)([IP<7XX(6QE0D
MZ8J)\]/%]:(!\\SY8G&L")/ZE>1Q,HEMKOTLDS'27K+34TC+M"1D++5,;__(
M&Q#XA>#M(@-BGL'PDF4PI<+A'>@+^GC^=!B*!2>4G#D,I&6MR,J"S_&O.(^2
M85WX%+US$=Y%*FOL.CHSBT%AU*B 4) OUZZR844I7HW:D?M<2#&8IR%.U4"1
MR4X^[X<XBND)5X$\]&42NLDBO2G-BJ37LCBG!WY"U$@Y/I8GG$PWV@YA]]P!
M062S/KS "ER/%G-)R%AF,5_AU"JYZ)K4M_G#LD+TY]W(@H+)\5E8>#JN?+DK
M(Q?WT'/'T@R-USIJYWBM>/)W,*C1O^6^$B71%5RLQFHR\JUK#'QEC!?+T$FV
MA3=>*( G2E4<884Y",* 9Z^:=PQ=D2>%X07PZW@2NPZN)XT!?$Z\I#*FJ=PQ
MBK8+/?Y@N:$/#GP<#)"Y,MA3'09.#MBC7-E1[(L64DG(6&8AB7;:('?O8)9]
M<(5-63Z&3<>N(VM6<L=S\:%(O.)!@:A74A ]VA,;)1FAW'N2NLWU8G5IFX\B
M; ZKM<\C^W: Q^2M7BC#>9_<1PX:]MFM5;$7/%U(ALF]4JDW(T29_?$,K%T*
M$>TA1Y\)88:B^ P>X[EVCH,OI(0&'L+X("H$$&+(J3)[\"GJ'\F]>RZ$H^0+
ML'&\>].Q_C=*F@!!"NO&-CW)2G*;7<TE.R0K0HG3'J)2(%/9V,D9&&10K*D@
M C.N=.M2''D$J!"PW4ER+[)\I.>$&#^(NJ6 71A83FAFJTP4I&3(' -KF Z&
M'WH/U@-> H,\B<993=NP9#7+E%IY]C5B,R%Y=J1-T,B$Q0H3(#)8X"7P%@RR
MI\4;I52*.AN(G^+ D%"STZ\2QNJ!]7"(,2K<BTVR73+7QC.3#=AG/=>LTRI*
M4Z'IC5DM?N&U/+,%4>#//F?C*Y&-W\?Y$_PYQ#-7TF"-M#.:X9*A\>M0!"&?
MR^NJZEK?0Y'5@34\P'4LW)^[?'I646&8U-8M2(5*-; PSO#9N8I*T_F!4T=-
MAM+-4]"D1;['8JB32%:"_A1[86Y/5'\I"F$BEC&\Q<-XDQD3YJ=[,9BX%'=&
M+,A;\K'C2;Q)Y./6EA?:ZZ_1-<4.,BMQO<D)A:]<(-FH0<E&&TTV:E"RT4XD
M&Q6OM]+JK?4G-/6BAUF#7]^8?]=U_4V<G71QU_VJ:#J8F=VS/VXN[OYB5W]>
M=F]N/UU<LZN/[*Q[<]>YN&2GW<ONQXNSB\Z7Z'?6N3QG7SN7G=^[7[N7=^+C
M3?=+YZY[SF[OKL[^^>GJRWGW!BZYNX/+/[SM[7,^U-92RZ442<]^REXY43C6
M3XJ[68XH!R(,D31=N ?FQ1!L6E3UCV!I^"-K4KAM=2"\  ?LD+X-[D)\S8,K
MS'89@5-$I-<*L !Q%,J:.J]PB*%EN/6KZ8''HS54-%V::#>@CR/R>,!Q\J4?
MDD2G7-Q?^^8 P#1_6GQ(P*-Y%*>3*,U?8G19B[HX)!XY0>+-T4V#-.,[ZE4)
M%T1Q^MSOXF?P:?K@*3WPM(LT)J K]YX;3FJL4T"N*@/MX)[!/[K::C?4^G'C
MN3W#XL$4_B\FYH1!O/\?98GAA3".J#5!!"OIAF1NQ'#"I<T6#;KZ;"W6^"H1
MES=GD^70>T(STOH.DW;0JA^R@?F4DJ\DLYW-Z,G5[E<9>#T8C?)%(6.AK7HB
M5RI.[T^V,2)/7FX-H)/;Q]T='",_.T0B&&P+(]F/=W64.)15?(L\_9 ;U70H
M\XLDW7>4(X-&/.X$BP4)?_1,3/<0N2O9U2=*;UA\H,#03S%<RD,X@Y[EH+=I
M9TUS^9/L3.ZS(1 7[=**%(IT_>%52>%$X9J*&A\U_!(] +&W M2K2AQ[ VJR
M.2\YKD9J8!(B/SC:'@*;Q>-2%,CE(;&K4RM$CE".!!A%'-LT ZSY2]6/*BQE
MRRU.U&)6WW09H6D[3WH'LP<,7W(N!.6/'%<9/L0>S!E:M++%7'=2ECA--<L5
M+IIIZ[K@V='()7BT[&!GS_#!(.#8__I&GS:/7TN*=##0>1>[Q$C+I2EV>#_T
MO+>_Y0F27UW%HF":L@(R"MX_S^TIY[A<2Q&(XW"&^G\5-,^>GUV4;Y\]?""!
M+3H^2SYJC4]>=#A *, <HGWA#% PN-X[YMWW#O1Z0]6-MJHWFX?%9XD76<I7
M60V4A*&>I;V 7NE'ONS7"P6^R(5%#RP1F!^9NS]'5L!7Q^,T&VM>2843<PHV
MT0.8%Q@\/34QM%NZ42D5F"U,4:M=9UW3#\#8A<>8 Y>=NJ'-'\ 3!G,+_%?.
MM':]A&-5*C#KG;C(IFUA(+-P$J]-WQQPQU39&?P$/I5CF>Q$T^K:G.BM_DNQ
MJ305W_RE* Y:/#[Q+:VI>Z)!U5IMM7'2GG=7X8L^@$OXVX%^""X%_/'L:S=.
M3[-VLA0MOY!&+!^8+8C;<P\/HO')B#OL<XU]%+6(2S@TI0)#:I$F;M&)>UD5
MKFE\FKIZK,WHVWE:S2C4:FN"ILTJ*])0M(#F:ZB_0H?]Q4DOE6]V2"]5=.*V
MIY>.U7I[ ?DO]5)CDWI)KRV@+TDOE1#,EO32#7?^\9-N&._9*?<<>72C=&-3
M*C"DHFCB2J^B$&;=6%1%-3?K.C5(1=$"6FQB;OB]Y9CLU',?R7<JW_208JKH
MQ&U-,;7::KVYL&+2ZIMUGIJDF6@%+:B9W!Z\@EW6V)]8F,CT HKNE7":2$-5
M=.*VIJ'TNMHV%M90K4TJJ'IM)MV#%!0MH/G1O<^FPS[5OM;8;7_$;9L[%-TK
MWT21BJKHQ&TONJ<>-^LO#X_44.W-:BC:?Z+UL^#$=#*'^:*B7<EY/CSY*8ZV
MLH.3Z-2C?[CF86O43U3-."[))&H&!<I+, WE6TL+G[ 2YV%OL^=AK^1YV*]X
M'O9.GH<MX?"5"@RMK#*!V8*6^NR.''9;8_]T'[!XPYT'/ZQ;]#=;JJ8OX.M'
M4?)-6GC-#<4@R)G:KV6V-6=JKR>+-%299N/59X*]GNF9[*S&/L5ZBC04:2A:
M9J2A2@&&-%29P&PETL>_F\X =%27%!0I*%IEI*!*!8845)G ;$-!><$HE/5,
M/YL.9S?6_;W/M).3.KOP//[@RDKSFPC^T?2](D:;S)DJYXCS$@Y,J<!L898:
M[:;.;DW+"5C'P?J=K// G9"FJGQ3]<5D_^:>PZ=,B4S:R;KL]N/&,LDMQYNT
MVUNU!=)":4.^A&"VL()^M[GCL"_@[GJ6XW][*N&HE H,.;HT<:5W=+7&L=HX
M6;CTQ\EFHTK+GUZ+^NI4L0Y^J0$?:(?*A=.W0VP@K#4;:EUKS^MY@3ZG_"MN
M2H']*B:AUQ^9/O;M +Z>VV?[,=/DOBA11<&^X0/ .0FXZ-BAZ]@<0VO*/G 3
MSX)!>4K;=7A/29=PO!W;,13M+M8*OY65^6=#O8KLFW$42,_,S[\";QJ9#U$'
MP^\P:#[V@TC:?L3M"_%GR\'^C>-,ST33]WF0?V+5.SRL _#+_>&:U!]N 5F[
MNOYP3>H/MQ/]X5(TY9<V!WI6+6EJO3Y7LZ1:*>J9E%-*6A/MH+DJ+5%+T]7J
MJR>:JV=Z&)DY-HZ;KYO@AJ%J>NO%^<W67I:%EVM@ /@N*&J)0#E6M?H"&.:9
M/O/OS9D^>0SLB^P3+2P@)BP@1=/?:JVW)^UIO&CA1'9)@5GBV@,_;CT7=96?
MN+XE&E9-W$=LLOT0];*?(2SW14R?DH--YLK:5T,CLQJ:JMXRYO;G>X81G[OQ
MI8744IO)O<K4O;7*C6?E !\T,PR@-W] Y1E846W.O;2&USF%K4/E#*;#\J6C
M-W^.9.D&FJ,MS-%QUK*L:\_,@UAGQ[IZHAW/NP+;D J71+2TE!TZ_:BQO=&L
M3RUBQ(1[B>PL;>6I7">M/&]GS85E=ONE_< N0=&+ (K65L65M>RMEI_J\]20
MD*]1%GJ-C,<\3Q2;)DHT=HW:H@X8C$_4__58QGAB D/3>U*TIOBRI3+9EM0Y
MDG:-;#Z+WUGC,1]80"WVWLV\U7)$%(96TF964GM1:2>J )"PV\(4G62%74/5
M6B][2M/;@5-^$I@7AFK,EYFS@5Y8M4H<A(W"KV+-"VFBBM:Y+C8EAN^GWRU_
ME;)*%5V68U&0]6]0+&3BK5$8EAAKK=L&]0QGM8Q7FJJM8[6ADQFT!< ?>M'#
MK,&O;\R_Z[J!L7<!_^*N^U71C!H[Z][<=2XNV4WW2^?NXNKR]M/%]2WK7)[+
M;[KG[+IS<_<7N[OI7-YVSL0EJOC]_.*F>W9W=<,N+L^[UUWXY_*L^^%M[[<*
MC5 5I_3 /%1NN"WLP&O3"YY R)J.;_;%TMO !$1?6LZ XP/KM:;E5&Y2UDW$
M>0C:[5YTF7_BIN<S#F\:L'/>EX:[H:$!K#?$OX:*(A3^T%54J6#]"EO:<4$O
MIE.K,FZ)(AJR, W8Q:X'.C'^I+(>#QXY=UBFM;U0S/A?D+N6,.%FN]7#4TSX
MVD9C&WZ01@#&&.$YEL?D"+"QP(T@OO<YC#[H:5 +?<_J 5G<]OFC &[AZ\$!
M&;C]$#7UN@4\,>,B4B,'_[E]UQ;MNVYTW[5%^ZX[L>^Z$V)HU89*[U YC[0,
MNX"1F: .!/:NF)$(I,3#7WG;ZF[$E=@TZ&-<1Q3B"D9FP#)] 566[70A_+OB
M[DPB4L=ELA7[QT]M7:^_MY*9#A(C0Q6_:>^EU3"T'#Y00@?WX2]-?V#^EWFA
MS675O=X3NX$/@+=S9,2QR^YW\"4=6+Z=?J5V*#?).FOU'!M3GF.CQJYO+B[/
M+JX[7UCG[.SJC\N[SN4=^]CM2N_QMGOS[XNS[FW%"-\)<P]; ("M?J_\PQR#
M1HW6N\JN:YT: V<"#';3SWH)N#JUX_<^RZY=#T2 #V8.7#T)>[;5AUO[;NB(
M](.AY8WAQ3+98&CYH,7G^CD*^CDL\G ,\4=\IX5VE#7&DIJ6.\#W,S\$:9)]
MHMR+&()YX3X*KT28*?[(?90T##&'4TBP1^F ]$.Q*1&%)R,2%7RE"7Z-S*5P
MA2/E<^\!W"&?33SWP1K(F^+18T6C%P-_UJ=+:-U%YV<I*W%Q0A>S)]\LE-N?
MYNW/L>4+:E9&Q"2>BY:E/YL:#[AP.'Y]TYJVA><Z12^4R)3>Q)O?_A(\U9WA
MJ6GT!5 +WO&Z8Q&;&3I]U4.'JVX5PU0!.F<._:V3'5YW2B9:L"U<KZL31ATA
MO#^"M,\724G$4Z&[K/]2/$=3#N4O18[GSW.>J;6F+H_/X^"HU&?.O3S[CF+N
MVP9XO:ZV&C-'71<&O\(CIJMFFJ,X7)XRCU[,/&L[R ;VE5Z>8W6O0+,>B;%*
MS];\GIE?8Z/SJQGJL;9 %:6-3*^AJ^W6 D?6UUQQIE!;KFZZ93GQ=,(;SVN#
MA77W@OIZT?E9YCEQQZ>FVCJ942*%6GY1%!6B?HYP>@7YZ[5QI@'IM::00FY@
MVB^!CZY==@+$;6S@@C/.%]+X2SXE.55LJ*U9:59(Q.M9L.1CT#349GU&B+YJ
M#-9RNCEV^8\V[/-G??SI&,#21.4VBN8& *9]_L6?7["_5-R_8BFX]9J^XB&7
MKDRBMEZ/<,W!46%,"W0BYN;QB<=]#!6*CQ@:FWCND/N8'&W:!=$U2Z1/.USD
M,\!X!B-Y:EIX=E&H?SHD:3I." \;6H[I]"U\; "V/*86^ )*E+,H'HX9#AUY
M_0V?N!XF/,BC54#!T3]%7 [?X?$'"ZB.<B+B(&31*V8>_Z\0>ZMZ]E/\!@$B
M\Y9_R72XF'81F)0YSM[8M.&^YT8#7QP&KB=2.SQ^'X+?@I\P.\.YE\D727*&
MZT?!SQAC-!XLM8UJ.7-H5B-N:2VM45Z5>?W,0MW-*9'>=?GG0P8'/!D<>%:N
MF;X?>B9F9N#BCNXH6.0>-WV0?3U8YO%%@2M$SH1[0W'$LY\<R(C$GI<11_"U
MP#$M! M%$T)Q7-RH04&$FSH]]X$SN:^:1LM(!I2)Y_9&!AC5D %WYO=76#39
MQ6U^QXSVB6WAVE;%9W. ETES SY.;#!B0&?32BS3S._-2FQ48R4*JW7N6DRV
M]86=#+],P&Z.E>NTNKP1J0N>*0SKVU1CQF;Z[9$F%F?TP:BQ0C:(/?;=V+BO
M'!$=VU;2C TS:ZPEDEC*VT0N%Z1V>)BDX2V0VC$0&?MS$EJ4^4D>,NT$F/7(
MG*!O)U\5I>H7<:<TS>#;L16(\[G>5*Y*<N6I:WH#M OC-$J_IF RS.SWXMR<
M.7 GP@[,H $R)JYM]9^DD1HYGWZ2R)*[$IX(+FK&<9=&*T\3=N)L&@ L7><E
M\H6VDPVSWGI(<]; RXGVQY1HO]%$^V-*M*=$^^UE[,*ER?\7I_:L,7FWF23O
MXEE.Y>+?U:5MU8;-?.R;R*IN3655-VNL^Y]/%Z<7=S*)^N/%9>?R[*+SA=W>
M=>"*[N4=NSW[U#W_X\NJ,ZL+!F)+::7[O,44;S *95''O<4X$ZPQ^3Y''L;W
M>#+93]PUO5%97VWRQ8&Y(I=REMZRD/@%;%FYM3-,SK)B'-:6R?,3TXMVK"P_
M"L"^6Y\/N5$I1:NSXJMSE3&XBI"\LAWT\@JDC_$6D" N#6KML-19%7BT7]9.
MP T60T.?4@&-,#8'/ Y.XLG7[_@!ZVBA\RY3D9,=O7Q\$GU&]O%(4YFLIP!/
M\'E& ^$NHXUQEL$*PRE;G^E*ZI<UJI+=UAK;4!"K2DF8):T\NH#=]D=\@">I
M22F40RG@<?N"W WFQQ,E>XWTL&J/*[8#!O"A;X8^CQ+5HFJ:EB.R1\2&%N@7
M3/LP)Q/;$C4[5=Q"P*_B'3/+8>880^\^\T.L^&/!MPJHH.AY\&UO;/EQ$5-\
M4X)(/"R+8>K5V80XN5=2D)HB\8C,&%!B@4NZBG05Z:I-I\Z40E=UOX^LGD5^
M2EE4TBWGRD'O$$2\[3Z27":YO$K)U=M%R;7+@=U*B:Z.@I$/M%AY-#6I@0S&
M;8_/B<_GCH3D3X3 KSX/,+TE&,46;1*PB1E C2I76WYL8?.!,K_DI:QA+TUE
MUX-WBH /7@I7]C S/(H4[9+TK0SXF4W8XZE-V%:-?;RZ^2KYX_:/KU\[-W]M
M:L.\8I.UD55_Z3J\TLD*6\LH>3D+K4U9:!O-0FM3%EK5LM 67F=5D4J[F.'6
M3G7XY7GW/\K=59)(56DJYTW4COBZ4^JE-ZU>9MW U^=^Q,4^DE/\PG;9@EL)
MTQHY%A]ZWELY)I<AGBW(S?.*_>="X9N,A3;'CBMI='<;?+,=3CD7+19$5YTX
M&^T\<C.GN>4'3J^M-@I5HA%<[T;!BP9-N5?1SLYQ:5>"8) M#)%6TV@-;&P-
M_"#U)AMY?/CKFU$03/QW;]\^/C[6?-ZOW;L/;SM>?V0]</\M']R;WMN!&9AO
M-<-H:O7FVWJ]KC5.#*VIZ_6ZKK?T]EO^73O2:J-@G-B"1_"D(\#GF7U $851
M5SGD?^!IRT?/$J?^.O<>YS(D*K/>3-$ +NE>JHLNH'I];NLB]B?W@VO3^\;.
MS(D5F+;*+IQ^3?YD@CG:'YWR8*2R+U_.U#3Z&]E7#/A^WA'A,SQ-[ 330>'V
MT3]%/T+YJ*1"T2WOATA3=,0T:4<@#G%&>11.AJYC25?4M?"%*'!Z^-@LN?PJ
ME90G*;;[<UR>B@QE3@W7UZ?>RT+B>M? %C6VUFCH]4:]5=>/VUK[[4.]<5PW
MFG_S[_JF-?<M-FC-=-J)=7=.=7\.'<[:J-WJ+<PQC HF))441#/@VUK< QCU
MWQ?K>\#9J>4&O#]R7-N]?Y):O$!AZYM5V)]#^XD=Q]0LHJM7J*KW2$"5>O42
ME:2D-S!N!BGIJBOI9ETW6DT=E+2N-UIU4-(&*.G@>[ Y)7V&RV4("R80920O
M$GT%&JU(#YYSVWQ$O0X*T>.!Z8E.P.+$""K K^83DSV(Z^"*#W,XQ7@/>#]Z
M^CM96-*V'/[FMVF];<S7V\6UN+)96+>GK]?@G? >6($9DH0E=3BI\AU;XT0E
MJ?*-J')]_UBC1%2NQ-\V3NH:JO*F 3_]/?&XUNAOUN&>TN4=T(L#J1N'['D]
MG_C-G0E6W[.^L\X\]7N1.;V7:-_7Z]M;/@EDC%L[(;]YKU<A44G*=B/*UM@_
MUB@1E3^^':TUX>]VZ^0M_]XXJF\XJCVE2,^Y#P,AU&%: W=:9^*SX"4=K-@B
MUADF6UX+989'C6X#M_^M('C=J-4W&KW^:L+P,TU$X[5E?5_2P[NR0(E*TL,;
MT<.-_6.-$E&Y CW< C5LZ-I;C%LW2NOKYE1T5)WFE1H9>':>0G[F3'!L%F2Z
M ,@F &RJ"8#6_%'EK4OE34[TOJYJHI*4]T:4=W/_6*-$5*X@IUNO&YK1:+^5
MF\X;5=Y"6Z-F!25UPT69MP$[?;+-1[]0Z6XGZ5JKBZ1KG73IGBXRHI)TZ49T
M:6O_6*-$5*[T?-3&=>D*-GVWK6B7.]U$BG;G5B!128IV(XKV>/]8HT14KD#1
M&G6,;AJE4K2QRGQ&V>(7!<>6V"?7QG'RYYY?VK!*%J>Q6D(;&Z2-]W29$I6D
MC3<P;@TZOU1U;0Q_-EHGQR(/:\/:.%/'"I5K?"C("3))5XG&NTD[B5^'GA^:
M4FO#%>)^34^WA9-[TG/+?>%+:R=&0RA64P:O"_.UYBKKE>P.G_SP[G"3'.V]
M7O-$):GVC:AV.L]4>=4>1[0;1_IF5;M0C:!QK\.>;?79GZ:'>CW7)^P/QPH*
M%;!. >P=E2FE7G!$)>G5C>A5.KI4<;UJU/5F73.VX3+'>A65F#B\Z_:_H3\,
MNLWGL9I=SJU=6PTMO?[C0>BDHU:F0G]AW?V4ZR:+7+Q &Y03:H.RT38H)]0&
M9:MM4!995I5L,;$MXV+K324:&SZ=E>\<08;'R@V/9KT._GR3#(^YAL='WO-"
M+&BF&<+XH!/0^[K<B$IRYS>B8^D05<6U:M:=-[84)@?G49; [-SCO\_I4Z.2
MCCS)D0HO,J*2=.E&="D=HJJX+LUZJ-O:<EY"EVYTJYE\4UIH1"7IT\UU>*Q3
M>G9E%:JL2:T9=:W9:&IO'PRCI=6-O_EWK7ZD-3>K6K^:F'F=Z?X4=V9\^3R4
MT'%WH-?, ?_.;I_@0>/X)]E#ZK/I2*VHBP3I^H^TG$".;ZXU?UO_X=*<(G];
M6]:9)AM@QV0#44DVP&9L ,KCKK@-T*AKQ_43'6R U@GXV9$-T-JT#0 F@&7:
MX!N[[H2C,G[@6/F+"[6&VNR</W#;G42^]RMM!=2GET+3@R*^<&"\@U">QK[D
MH8>WX;IEYY8O\D2DQKT-//<;CPR*JW[@BMI?LHZF4=0#&NR$UEKM!..'SWG)
MYS0H2+"G@H.H) -A,P8"):17U4"(HNZ-NFX<G^!!+S0,-EQ2!3QQH9'OT#IX
MKD-T5(NSD5@$&>6;JGX._WHV? 1#PP35YJ5&P!Q%OO'B*EHC(H14\WXN6:*2
M5/-F5#.UUZBV:L8V5^#$ZU(U;[S/%9Z<Z,7URU[MDL,%UR/3&YM_NMXWGWWY
M<L;X<(B%5QY0;R;-'QMQ_XLB-;W9-E@95-0*:[\7,5%)RGHSRIHRP2NNK$_J
MFG:L'6_'CYZCJS'D#*^X< !^8-V;@>L=73B@ (4.F_*^7Q%KOP4"+'_$;DVO
M#T#9[YX;3A*WW7Y*"I>Q W#& Q,T)JKIM!&7Y<?#P48F& 0]!.".K0#Q]4P?
M_@6"3%"R_PV!!$%0WW6&U@#(0]"!Q\U TBI4/2CD;&1@&<T?C,R /0+X>TSY
MDV^>[DZMG1R6()#0">^!Q66=5AA;,D[V4VA5A,I2$$3LOJ =0EGTU;9#\#A:
M76_K6[%#TIKHEVZ-"9TXSS21$?XHK4V+<MI+8Z^40,E'0].@=/^]E@@5H;(4
M!!&[+ZCDJ0U*Q95\HZ[KQ_63+04;'#^T Z"K8%=@>EO^W*MADCZ[[8^X;7/'
M+X%F%?OPS66VX?\?*=:=6X5$)6G;S6C;]O[Q1HFH7$DM=*VEUZ/0?GW#1].[
MXXGM/LW)BY]6MS>8O [>=XW]"4H,: JX,V=+?:/'UZ.(M=Q/7[1..FG=W5N-
M1"5IW<UHW9/]XXT24;D:K6LT&\VM^+@+Q)2%'I.E3.$S;D<_<*P?,T??3GNX
MZZNXIBW5C&2.DMU>[72M7J?BZ9LLG@ZD4/5TJIY.U=-77#VG3O73=\D<,>H-
M_:39J)PYP@[2GJ5E2%Y+FZ:UEZD,^_\810-V;ED2E10-V) VIF)V%=>_&D;A
MC?I6].]+"6E))9O;<"(TY6RD_LP*GC#-[),[R=2H^<H'X@%GPID3FC!W8?S[
M1S=T!N(F<<W+]D )%'U<FT\7M?ETC5+8]G3Q$Y6DY3>DY:E<7>6UO'Y\W-Q.
MT#];@F[NZ7>YS_Z:NG3/%J?IC+%*[L <J^*&*U"3 YZ]X(_ @U<$*A.6@NB"
M#KH<L,45Z]J1EIU_TJX[[Z3=LF&!?X686.#93P5U[OZ5U+G[;W+5! ;<'43%
M[M(C=8:LZ:.M()80E0=:T,:0BVAJ*9&]L2MBB*@D>V-#]@95OZNXO6'4ZR=&
MNR7M#7WC807?&H#VNO-,I(Y=N[;5?RI6QOI<;;R*DK/Z#Y>FUT^HS]M>+T:B
MDK3NAK0N%;:KN-9MU+5Z0X]KY6RX&#WJ3^[XTK,_L\W''N://:=[UUON73=^
M^)"XU+T-E?+J]W51$I6D?3>D?:E27<6UKU$'^EK;.3R>5H@1M6$<\:9EP^E?
M;R[8[[;; [6:UI+M3#S+CI/?]4U&M*427H4R?XH#V>1&[^OZ)BI)D6](D5.I
MM\HK<JSV9FQ%D6=4VG4(<$V?I]OD9<@^PZ-P.FG3_5YD1"5ITPUI4ZJI5G%M
MVJS76WI[.ZEG9=>F'WG/$\G<V)N4ZI'N\4(C*DFC;DBC4MVTBFM4HVX8;7T[
M&G6ILFFG)@R/"6]^@/_'C*Q3_%#4ITQOQ5%>.7E;U\P9:,?+.+MTG'KWEBQ1
M2;IY0[J9JJM57C<WZIH6Z69CZVU"2G3V"F]X_?FK8F?=V,Q1JA_8?$Z.4E$>
M]W[+%J*2C(C-&!'Z9BNDE8(Y2D3E:AS\XZ:QG0WHO!&A[X81$877C4V<XEY'
M-"*A8ZE8!%D1.R=<B$JR(C9D15!EMXI;$8UZHZV?E*%CJ5%M*R(MK9H<"-NZ
M19 <=M.7:;A6OJ+T&A6EWVQ1>HV*TE-1>BI*OV)C:;,%\J@H_29W<9J;-9WN
MN#>V'&D9V3S ^K6Q/?2IQKYPSKZZPZ$5!+&=DRERFQ3,S9@U.3,ISLZ0;>+C
ML$(C$U5(LS-D__:BS9 BZZ=)6S%EE9 D((A*"J)LQ2Z@0G85MP0:]?KQ<7L[
M[6E C]FA+QK.@'IR O;% D<P>X3AN4C)=(#$C&KC)Z8!:O=+'GIXM:B&?V[Y
MPBF06O0V\-QO?/;^V>@*-\'B,,&!&$]<!U&)/95YK_S$33L8J3.&1G(60C=*
M$V5),;5^/,Q"\K+"HH2H))MA ^.F:S7:=ZFXR9#6OM6UC1]X#'N^-;!,#Q5;
MI(9O^+WEPRL+3SPBPU$%W'T7.Z5>DD0EJ=Y-J%Z#5&\I5"_H32/2FRLM3PN>
ML_1-_P2M 1KJGOW#'$_>QVI/9=>U3@V]Y@&?H"X3OB2J3I$,<!WV;*O/.OV^
M&SH!H&<?+6_\?TG?[!P?$I6D;S8P;@98WH4=D_:&3TI$9:I[#&WUNN=J.+3Z
MW$M#E<CC\)7<Y+T./3\T9>G66PR)PG=&78_=MUO3ZYD.]X^NOMO\"120T&%Z
MO:Z3\MD]1B0J2?EL1OE03\_2*!R=%,XN+[92,R)120IG$PI')V^G-%1FE(]>
M!F_GI-XBY;./C$A4DO+9C/(A;Z<T"J<$W@XIG#UE1**2%,Y&4O^UVL7E[?ZQ
MQRY2>>'8EL,%9?\YO?DBLMDQ!YZ=N_U09.$?#%QXHN,&S)Q,,!7.DK60+_!@
MGBF3W,_-P&0?+1N+"_7-T.?,"GSYP,"\]YGI<8:)<X-!E"B7/ /?+B\<1"\\
MI!5)K$I4TAI87BO=GGW:/_;812JGM=*=^=UUW/$3ZWX/N"-2J&_[(SY.U10M
M&.(DHI+6P/)*XZSS9?_88Q>I7$!IG)EV/[1EZ.R+Y7SKF3ZI$.(KHI)4R(^H
MD"^=T_UCCUVD<@$5\L7L<9N4!W$444G*8Q7*X_JFNW_LL8M4+J \KCV.YS3)
M 2'&(BI)AZQ,AYQW/^X?>^PBE0OHD',^M!R+- BQ%5%)&F0U&J2Q?ZRQBU2>
MN<"S@C#1G*$X0^M@Z'IC$YN_8>VRH@RLN!B9'0Y$HYA,A5*1^5><H17W64F[
M02P^I/-ZK*QX_J>X@-I1/,/321N&QI;:,/S?75^MN!H'@C"L]8=9D;7JZ"Z2
MX63$;(L1_M^N\\"%,\ #/MP7Q)F@'AW0YT(U]^%:U.G,Q:8H3Z(N.3B&9N!Z
M3VQBX\-SEW@>UA[%6XN%2P6T=EY?KPBGWI@[X>)+2]3(>\>.\,+%NKWIU.UM
ML]W>=.KVMM5N;YM=@560*O4\09+75XG]0R]ZF#7X]8WY=UT_0=DD*+F]^/VR
M<_?'3??VP]O>;]4D;W-34\QKHL_>:C6Y8O;[L-S%F2I1(CP^IJO)HM]:\V!P
MF)S734N')V7#HT.[VHG14*=*GC-QUFH@>[Q[LI)YX+(>9SX0"3_ :_ @5H^/
M3'NH])[$_:&#;5#D!=A7EH?8"G80VD_,#(.1ZP'^06V')F%GW/ZU>/A-A+H%
M(_<<#-QW@IZH%+YLU-=<EW$?D[L=:E]V7J?,P]ZT>3A+T=)LV4#BBXRQ+0S(
MEXO_W'7%&)Q>7-UUSSY=7GVY^OTO]NGJR_G%Y>^W*KNX/%M50*3R+N]Z8Q\[
M1U!)>/P@5=6K.M5,G$P$52D"2?Q:-H).G]YMRPS9 K4?K-_>^F^EG=&YO;OH
M="[9O^'_S[LW\$7G\L-;ZS=B]1UE=1$RC.C)!+PJ3M6I"5ZS:3J"C =X**Q7
M=@I?$!_O*!_?68'-GY7:%2,(\^ MC/;(#2YGP,Y&%A^R[G?>#T6^2E3V;C-[
M5J6)2E6:H()8YX(Q3<N/^S".3(Q6<B<.8/:X[3ZR*' Y=&WX!&S))MSS7<?'
M^*:,;<ZV@U2B$E-]$^-[P9/@,E=^-\"]569%NZP4ZZQ&K',# 3)C2['0#[W?
M;H%+S"#T>&[W9CTQ4'V?8Z"MK4VQ4.,TO6N=7GU[*Q@W-*9GMS1F>%E2FW;.
M-B>"B*"M$[12,;/G$<"=8XZ*$_2J6$'%:=ZY210I'H*&HC2/TEA)BX],&=.E
M/[LC&11>]']N:^R?[H/9'V7C!6(X5T@>/',7.'CGEN0.D;)S<[,+6_#;WG"C
M]Y?F_>2>+.2>W%R==F_NV&6-_=F]N/R]<W/7)>^DY 3]&SP/>>(^=E,R+LI'
MRS&=OF7:Y**4GR!R43;@HMRX/>X%2SDI* XY4&=Z 7?6Z:BLWK(FSX<((H+(
M_Z'W[_?[R?]9R/^YO>M>?^I>LL\U]O'JYBMMS92=H'/+X_W );>FQ 3MG%NS
MLI&Y#?ADQ.6."8H<+(OG[-#,[QPK$T'5(VB?!<P>3"\11 156:+LKC-UT[WL
MLM/NS67GYOR6'*ER$T2.5/D)(D=J[J8.=_[QDVX8[V62+?<<TQOX.S3U.\?+
M1%#U"-IG";,'TTL$$4%5EBB[ZTG]]<<E^ZM[R<B)*C=!Y$25GR!RHN:-S%^A
MW(GZB],>%!%$!)75SJG\:!!!1! 15"*)LKN>TTWW]XO+#CN]N?J3W*>R$T3N
M4_D)(O=I_A[4O>68<@/*<Q_)AR*"B*!U6#S[VC R*F6RC@<^VU72H*Z2F^TJ
M:5!7R0IWE:RG('YXL6Z@F:/L@O5\!ZQ,1=$JD-2Y/%=N_SB]O3B_Z-S\52WX
MJ]8?FVX':M23T^<7E^?=_RAW5^SLZO+VZLO%>>>N>\X^@C]^>7;1^<)N[^"+
MK]W+NQ6W"]T R0>P+K[\@6M$N>E>7]W<L:N/#.F][L(_EW<B[G![U[T!@J__
M./UR<<8Z9V=7?US>P2TP!#=?#ZM%<P79\B]N>K[2=09\P,YYGX][W&.&)IS6
MABB1 G\8U9^&2M;6?\\*]/PJ0@"QE:FACU)0<GJKY<9G3..EIZ->:UG.NKD,
M;2)!R66(BV9% 9Z53_G69_=U4-<N%=8P32 !@'/O/3=T!B@%7.\=^^GLK-O]
M^+'$,_C!9"./#W]]\]/#W_6ZAB$ZT>+%';(+4 L3+EJ@1!U;N =ZXCKLV5:?
M=?I]H#0 >0)^@C?^\-;\C1U<GW6N3MG%.;N\JK'4YOD^^/[W2;W[-Q]PZ^BH
M$PZLP/7PKHO!WWU4-76MKOW]-_ZEZ8;V]__Z?_WK_[NY^_T_OW]JXU;%]W>.
MZ\!" QKZ(%8='),;!/W1<\=XUU%=@_\+7/&WIA\9VAOQXH]F/ZC#_[1.WC '
M?,A?WP""=SD ;WYK'NL?WN;>$6N[PRIP]L<C?=-L_3BR EYBIB:QM"6QE!,F
M^BH'ZLQUA#V G:#8J6F+[E6W(\X#G_WCI[:N:>^?M6"C 3;+S0X?CQJTEFDM
MEV\M&VM;R[<!_&<,D^&CS7$UX9X96-@U+E[5PD=E+_NH55GAJ]H,IA5.*WR%
M*[RQH15^&[C];R/7!I_?%TO\^#WK_C?$WH^[NN);M.)IQ9=OQ3<WM.+/3'_$
M/MKNX^[J]&-:X;3"R[?"6ZL<J$L7VS$'+LLM];1X?F;1[^HR;Z\OUZH8_+J3
M)!;(;&J\!Z=,>&3O\#VWO(\?DG0G;:_2G9Y)9I*I-1]?E\XT-YF),I6VD:E$
MF0)3$YKLY$2;1!%TF=>A+)O741W"USM1:["[[EPE&/&<DRWT[*EK>@,TQN/S
M(WZ%B/IB?0^X<FJ! =(?.6! W3^Q3T <R"NXZ\+IUXBCUK=!G'V2>-> ]UT9
MI'W'P*3EGFTYX(M<32P'OE-<AR$+%AF&"=G5GJUD2[NMY[>THR&X TRG-JS
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M0+V1T#IZ5,%613,Q_ HD.723,>^9'/2$Q6_^%NUC70/KDT(YP(4 I@@E@%R
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M^M8007WGB2"*#)GP_QE)QYN.:@;/2@C\8H*OL?F!E1@9T3*_GUJ%8=.N;FX
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MP7;JGKI"^Z9O+M*3HV8FU"P5@[A)<<_K?@KB!_7A(",Z)Q]Y,HWA+,=IFA^
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M]S&BH M+>A( 8=DE5,BB.8K.#"I+>4*[#6NS?\;H(4)*C3C62;)BZ":"1^0
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MV[=3;0=UH')W]D6YNOG]U'H8C/0/GT-'Q;X2>,@\=O+J+27B2FL"D56BQ3P
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MARS?!#Y46' T$5#1\&](]R7I7D% "42T>SDH7UTX5:G &N#-3=']:(,^?PX
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M'9ZE'M3AN*I&/6=>&M^CBI$C7!"]Z4/?/<B<&;Z4]P(Q+ X*:C[9I<"V9FL
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M,VB+V3SK;.S;?J%1BG/.),](K#X3U'-I9555G=T9%[_[X\'K@GJ9'9G-'1H
M]/SX<@YH0ATDQ39>^PK.WR,#.R*MXX4T1<FF3OO3,Z!B_H7)VC'(R:H?F2-
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M7.=N:_E95^[6]^<'9/XI>1A<^H4KG$R79S%)$WC=T6:2,=P#AX4?T+>:+ZB
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MY\:\[/!K8><ZB)ZV\A"*YS/*'!0O?#/"4IM93N-N,&*BSAU/PE&EP?(M..H
M(#KX6)K1'9FX87K$*L0=#75/LYUH4]!C)9+_O:=)>@]S P7I%J:F&Q0\PWW3
M6O<]W'!/6I@#U1,Y$!$M!D*//<E O*0;TPZP#)D;\TSB# ?9H*FQ21_CL:8&
MN-EILWLZ'?^:'>N=9&[6=7<(N-?5E0D0P[?L\9(HM\JX1R^P'EIYB $TPG&6
MN4?T[6<+68D4T=#! Y-%V[>IUY7:#)1= )5J&!ITP!!FD D;H^O7?$CDK<E&
M L*.7&6'VRQ$XEMGK[)R?B^?C!*MA*X/O!@^7?P<\FN:4$F%UV)-]XM%0&XA
M*R(B@=A=GJT+<7'WL)SQ0XS^;KMNP*PDVP*7(A[!TE-&%@;B1-?>%(":0::P
M9K9N%</O&4(LLT?&._B8@4T WC<4SN"RO3>@Q3O>(ED?(%T6Z;D&LI^P>\:P
M#QGMRQIAGQ2Z;:!KA@%+[LIR#^J= N81/,JD1[)DF%%'>C7 G\D#  =.D+2%
M<33M?N)1KXS0/L9OYNRY.KD>O'DNG*/@GOMHS01*P% \0*7K7 OMN0QBX2MB
MI<$+E1!IY.]+PS'U^:;4;B2";Q/,;0*64V$L!W^Y1(\4Q.]ZDDTPCM/1:U$-
MKGYT]N@E/3_^8QX63YN[B4OP"(V$3^F>ABX!1^Q0 N<10G3LRTM8DZTL@N]4
MG>'^V&0@.) 2_HF\.4P>C10#JFV9AHEH'!&B[2THDPX.V#.C9AI\6T^WH31O
M95&M3%A\6SF,PJS;TH9O9G-?O;]4GA?<UL+FE&]C68S#/%X0;M4F8MJ>A +V
M5%9L9KZ=Z#ML'[_(Q*!PH_N(XC0GKK>>.N8'WS[X79<JS_HXD392]</03@\7
MWFFXSW<I.ZV^/O2NVNK%J\)](4TX0;@O%Y0I8Y^)HYB6V2>_G'Y?XYD&5UO"
MO110^[]TN?_&.8KV0$FD[#DFDFGJ2L<R%XTD@@$@ORF:98QFMH^E RX&,Y3:
M(75Q^S!THS-M)9,0P4KN1$;XJY)Y+;9=#XLT8I(J96S^;U&I]%1*XE;8YE&N
MVR:6RZ/D XJ)ZSC*D$3)WO1O?]]UV(.:E\FW[^/]F8)EAXN_WF[O($Q?ST^F
M9R?WDY<%7I\BQ!,7D#F%4.27"\@6N\*XL@Z17\Y8XMAY":9YM(2Y6:=</(8L
MD'+Z(1R>G]^=UL[Z"8CB3S<-O;V9_^TVGHY;U\;#Z*!Y>%7-\/JLI[]TJJO(
MYS,O_:FNY:PV'F?S*>^9$G/GHZPO87=.N@/EICO0\](=#N:QNQ,<;(U!X/TC
MH_-<N]R[NJ_-9W4D7!O%XKE,/N1W"KW;.NNT[YN/9S*7\NZYOB]VL7T[DZU>
M3.W0./_8-[KY]EW/L6_[W0.UUJN*M\_MWTEDN[AS+&'GV6E66,ZT6W!U&?UV
MH26N5/S- 6 L&Q'*]!,N#,#X)2[G]N,9O@)=-3+)YL5883:+WTX9 1O?1QIE
MVV=;2R'#)MHJ=6JI,LTS=%1<R?V^W"5U&/,RVFY\)CB)O$,*I&[(!.\G(\6T
MW9<B$CM/WJ<B O?7!_M=[6BJ=O>'+E.V7V]CGP$+R)+M(>RPX@[+>Y^RAL^%
M2/Y&!I @K7D'$?4.QR9% 1W4*NRP=;(&"D/$J0&*=^Y'@X$^(U+%^?;8^Y+@
MXK,C]9X.[Z640T2 @GBAY&!79V8/T8V<VBY]J=%]F_4@8]5^'9F>2YB*@BL[
M5)EP7[=6*>9A#/E5&HVHZ",[,NP?]WM #[4F3O!>13A"3]%)RJ[&-[)O(AEO
M[KZD,;BV2!Z<HA)V;0<_H>X$/16& */E0IR4ZL@R) ^8NB;AN<&C&2WU@.:=
M7/S^"*<NQ&\%N\_01N#UBM8SO)>4[_1:L\[4/+OM3%UH9^K:MC/UMC/U9BLU
M+2Q98!J[74S+QFDWM@"9YUS"TIH8% >6CE#R"O-;HEBC]>"?#%NY$=B&K=P(
M'%N,<G/S,IQ:LZO.XZOB*C<W?I5:13 A_EPCDSV2;4-)@4GT?PWG$]IB1NVH
MLIR%RC%\['"8N1:'-;$C6O*[K'>A.A,G\I$?[8Q7.\\/ED9^G4JZ+JDFDM,C
M4$HH"=>,6B,3O@PE\X$ GN<87"GF/)"%.U@SN97?9TJEJO[IKS'6!!8=PI@E
M"YBR8(R-&%@&23$)F?[4+#NIPEYQ6\>UO"T;LZZ0RBZ[/QKVKP87<" 5<[ -
M<^^N)E_J#R=>>,6^Q$/T":PGU2^19T<)#HOLQ[I\)X7J+LO'-?X+^65)>!G'
MMW RHIN>BN@\<M*-A-1;>R<.5$HBUKWSCG)VIQ\?7_DK&/S9M-/0"6=(3DO>
M1(%$FGO@E\CP]<1ZT]4:,.NNCGT91>S40A8N'ZN'(3LL10N31K*=0A6H]+==
MO2?JK9=G;A-IC7.(M,87I(L="\^'S?>S\=Z-E_1[Z3I" MI'( 1!][#(M$WU
M5%&[P%Z3:+FVPS6<3WQV-6W)!@7UK/V%PLE@$A%9L;RY$H\&6$+%!EB+.^]J
M?SJ:/AZ?]_M>L<.-7=A UDZ6[0J=!8XVL/XDL;K(X57SZ=A^T2KNSCD]GYM+
MQ06B.WWB*;.%$RYVF5C(V(+V*W-#?7&:AXOJ<A<1BPEM.Z31"(KGPTJ(FP9?
MW$$_7 ['K\;+]?"6#VM5P6UE4Y:7W& AV+"<_EQA!480*DG(0.4CY82 <Z:T
MB>(.>]QYF-V]2)/S,RD<P[TA,5RT("A/(4LBKD4:+8J^R4+C^1,<%CO@(C3I
M!OJ?N00?)7/<Y@LL9Z0]F);M05?4-QEA@ X&M627],B0O-G#9=\(&?HR2$#2
MZRB.=T!:!'ILT(2)12*Q6*NL,+3BA=IY7V\/A%-EG2RSA7!J^>2?K'WN&#N"
M,Q[+/07!'*F&?G,<.V\4NPB0P1('7_^&E%<21?9=39%N)#@8$H-:^$;G!'"T
MJ&^-1MO0\QIL@KB2*!PGQ+HQ,7>)I5 AE@(R%'3-&@SIIC5 JZ)K?@,BS!SV
MRU SZFQLRZ'%683XT!S>=R]&+^?U-58SZHAI9.88RUD,*6I&'#DSJ6Z[A&RZ
M;%I&86?],GO1V).3AQ?0Q#XGP7/!LQ27-R R<']'7_2$ .7QYD5\=F*"SP[O
MKXW]^X8C-#UA7[%] H6=\^]IOVH^/)^,I]XYMWP1AX!^3,(."WGO8K>3;/;S
ME1P'G[N^O9)XUDRP+0+P:D><Q]4;1'*)LL9-2CC1UP.V_3)YO!8M[T1/?&M?
MI-!QN;!)SN-<+ILQC2?/2Q!*5+]Z,K('QHHJ]Z#3!VY"XR,+*-9"G!".9ZN6
MK<$F3E02^$0:A XU=LAJ>8.V*).1U,5$Y81"XZW H&\7H9I&'+R9'$6-%3B*
MK(ZA(*M#G_G\<2&^<$6V?.7L.-)HZ%H>X=9NDF[.? Y98V_F_R7TU!,;0@ZK
M:3X:K7.E?U2]%M98(0R8D F <7X.[C#$F);+8:[6<S$F"CIE.5^Y\7WB;E#0
M.Q2$N1G<#I52W0[Y,?*C?E.97+]TCA_4B%&Q-GZ'^+6'L&/Y6IYL_FND=4K&
M(IX'^7VB &;-\VD[<&FJ/0(87Y;_+1)]</J][IJSH_%PP,T>?SV<7L6Q([2+
MN2G4Q3 ,'PKL&'+WGYZE3S6]9\AJ$%UJD<%$:4?P[6<?>EO/9$DW$O*MP1.A
MRU+?A(B>&CGP:@H/,,P#M%,<<X=VF6%::7EH]M3KI84IEV )QK%T]79D/NRW
M!S$L@2!S3S+EN<>9&DQ,(FH_$<-;$-\UASUI!H"/G*(0/L7EX/KMIS_*7$\X
M9J*L!D6"X6:LSZE@\3B$/ZG,C'D8UGI5S:1\SG!0C)V6!XXLIIO8/4YS#4%@
M<)<#&*&!+OX.UT$W Y[]-W@Y_I+[]X?G%<7N=>C::NG MUSU#"URC"U'"O?0
MZQ'OYXV=*%_Y+OWXSO](7A8\_]I".ZZRXO?.#S#'Q]9H@(,BF%#PG02868!&
MA8$6A)8/4GW<3YKTD/,B"G:3,,,Q[>"W0TC=N]D10#Z,)+A7=A(.G**"F]8^
M7'DAS>P2E\K6R%B#34 D*#E2Y%+C7#-D(*NRCO$QU'<Q3H-K9>BOZ!K63Y,)
M.V%+Y-$G[$E=TN]>3II)25^NO\314B=69X28M .BO/T4W3TNF#R218FK+3#3
MUYY$$!W_S50:#:8A)FKZA./X_(1=S3#==C4>3E%).!5%),R (ACC5_"NI!F>
M0F*?L@/0?7AUZ<ARH%YR)^.CJY,_/9\SV=[THF@Q9R-E8,0".8*)&"'R3",Y
MZ3/D:X1I#7,9P7Y\1M$^4I>1C"12QAX-TVL',LO*/N?+\^/>:W,P:;*>XG;I
MWTZ0,3AI2 ND':5OL@P<6&!B;#)7X(0:PPJ)^0J[]%5(_?'(6QJ0_^HR_INA
M_ ZJ >@@<B_VEDPNJU*"CIF1RFGNYYY $U9N."AU5#^1:\=\];4?L076S<5D
M=[F+W4@0H>K+U9,(60<I19*;,F6H''R2JR@%$WY)U4%K=O7P8JQ5Z<"B1Y\O
ML2WH)A(SICE2V%H&N1+C#:BMAS<@Y=2;TMVT<MVH-L1J";Z ^>>VB">@7OT4
M3\!V_DBI!EZ0KQ@1P]_.CY\;3J*_IV5\I%%B)H8;E_]1B%>U\3CYK;T<RN^]
M_CKQW4!(>5[8IKY\5F VQ[P]WB%>>?,C 16'!'ME(<$R"OW]Z?GT\E)LW/76
M*BDT</99-/AZ$<&9+%+W!YY)Z1O;X9L*@IMC8-L5.PA]S3 0%R)_.5,<W2^0
M!M=1W+G(.C@)#8,,(G:^TO2!I"H?]A<4/%E!'$_2R?P/P^Y2 EI [&3C0!;$
MB4I#)P-X%I.#U<%Q20J$WVW7+V13@$L8?!V^61JV#]B;C6(/Z++]O#!\"]&(
MTL<C%GIR'S(OZ(1G&1CDT!C%3M0)[9""1>G:R!VYBTNBQV/)=/K[DBXW#G.W
M5"^A*Z! >^Y>S8+RZMC9HW@H$6Y*,R% 5$#G1B:*.I I.':$S>@H+,48CIW^
MOS""S,L/M%U"/CN7C"[%F>ND^<?.31?ZN1@X_XY<0GJW8!>\ R\;'$[,V#4?
M=RGP/R5 TW<DBHH;/ACT=^4'5)XC[L'@X2^P20,FH&%CE-S=AY%+N*GZC-CV
M.IDKC%#:F&B&XDQH@BQG0%'$E* H74%_SRC\I3VCTS!DSQGF-CI ]ZKXH6@=
MI-\RND(G0BR # Q<]%W!*R90M_OK8!0(/;8SL_%.038U\;8AG0O7 3A_,;YW
MCS7LYH][J8=3AE>D[VCBKHWJ'H$'GHYEH,,R##^E4Z3+CTJN0+S% -CIX"2V
M)C#+3M9EM'2,-['7T%+WU<*J,5XR(B:5KK+N'%1[!#4>=1<* )&^T_:73@/>
M;;QA#39QTJ?P@2?1K4)&V"3S08<(&)NP 07@#M(W2IH X7NMK,(W.Y,0*7<2
M8D ^.#R4L$9-'<T2^",)4:(-T.9L@JG*Z5X19'G?21,J[W*TO(FFPV\_O%'.
M>$;C7([HN=7'2##!3OW\W7YB2*^G[<X;8/,Y*\/$;5\:/@?*?P[VY,C0./9Y
M4M<!S2[=['8U'0X&^ ZZS?#)7RRY;.D/_>R S_C;R%->=WDCN:$\#CTX[&^J
M(+YK-[0G_;B<T4<3XF0G7[I@@1&Y)"!+7M^#H"8TVX=OR-BLZ)LI\F82'(:(
M[U"&D.@<-/;)9WP'!G=@6>@B7<8<#J,6PK2QU"MR&.>&- [CMHW#"FT<5M\V
M#MLV#MOD"1:T8T*O:)1%V>#/.M[6U/R=FV6C*TV 3>B6'/0#-")9=TAOD'N6
MZQ<)-#R]U$PY[).X10O8&Y&@Y<1UW]0;_KSOW,]\^AAV3_[\'KTV]C^&WS9-
M0VU26&SKLTCHR35!(;$)*P.>"AH;H@S<C7T!T8:ISY8:ZI@:-OQ#F06,T\<$
MKL5IE#3)54N>Y02:AM?]M"./M&GQ6L:ZVSU@P8\D]'Y$BO(*EU\6( *.U_I>
MY>FCR9Y_O-_*0F-<=ZDNL.MO/QV:IA!NN_%G7X:N_7#RICC +R3RLQ].-N7@
M&\CH.>H T0"_V9(<27F_P/=T @S8J0Q,"^X9(172WHRK0W)^>*.[G2?"N@ <
M_]\W/JS8)*JG,:^+:G[??GHMC(BO-KSJF"7&//M;PI[+W&#<;@H4TNXCB]0X
M'C#,$#=L(B1":EY(RZ#7??UN<2L..H16O^CA;_'DR^+)M>,PVK2%[X.;#VE:
MEC3:M*6?*WV9_H[4NT?0SGXL2YQ@J2XE][+2KQ\P> 9XF$EL]'.S@A$I(XAO
M#? $ E!(-!T]?=#YSK,5AA?J#%^M_O! '?(S5$2DI+B*E7^B0\RP53Z,"O9#
M^/_&L]R02^._<:Z/$%=W _/U@&4'"@:>-PJVAJP:V"?<A%4/<&!G;^9=8F<J
M-Y&%T[O45-($@5B!)ZJ!C%.2Q^QME2@R3\J-+WLN=5QR?(, )ZO*ER[O ->)
M[;\=WUD\]WHR8\68;I!$E6)B=5V&WI,13\#>]#UI!/&^;V$85T) MM$L)=%W
M!>"-S2G@@X.*$Z$6\B8LV>2YP3*L$->"(A:Y,Z%M<?3PGQA2$)YD=Q;WTD?E
M.QE'5[!5A4!:R*K(H7MS/;BZ%@_U5U^:4TB'H8/*8RIU+$<5YR>_;PL@B8QP
M+I(N"NCMQ^YRXKJ2QMP')YWQ_)M2W[.,$'X8*I @ZRHYI*'+7*4A1E%($9.M
M<L7D$:ER6 DK:/UI/L\.;MOO,. ^43(Z4_J2=:J5"SL;2$DE,. I]P;TI1(U
M7Q$KC5H]-,FOL5P7#)&K)W3!"!)&&N85A[7%230,?N-$)4V2Y@JU5:#Q^\7)
M+7<MODR->G:)EA>K"Q)6V4%8+I(7TLSCL]$\J[67[8'EF(&N/ZYH><26*X_"
MK?G*(^/7NROI_-7J[;&5.=+(UUMO#NGZG370GF1'>=\9*KV>C*Y!8..5]XX^
M8FLL!X"M\QSO!3$^A3TWBF3/+HC6AD,+4_[NX?#U=Z?=R,ZABSUIX5-/>GTX
M5$A'GNMC;.&ZLUYX<9DC #F\_BET<E NLSO4]+ZLF!;B-$VUA[=/R@U60B7'
M=_?O]Z.;E_&H,9<!XD/)%5-9E&BJ:403&W+,2@V?B$=BD?S6QAJYU];MP\G$
M>,M&IX?7WQ^WXNQ.M8:+,-W585=MK;"KZ)<MX!S)\>J2E-2L@0FA8/VG\HFQ
MAXI+@Y7B:7!HGMW4C@]N^+A)5/-C#RT"_7#@81W\+]F"#5E-TX!)6F.7:U5?
M9^N,(,;UH"E3W8L+(K"?'$0H$Z_;>]+=E7AN_ADL&T,@6/YI?IAE@@;Y\)M;
MOGT_)^Y6V-K6Y[)"K__A:KW^9=+N\?6H^H<_._IS55O.ZY]1S^,^U_3VSK#V
MR3[P,@^UMS=Z[S:?W[2'3J$^\*QGG&HI_B7,Z!,<P,U5.H!+52H^S-%Q]^5\
MHM17Y0#F4FW0%?&FP\]W )=YM!/UZ/CREWDG#19(.BGVI!M;#O4%', E1[O2
M'<!E4LGKT4V_]:?;?SWLK(<#F$^-CVVJ _A@31S 9:*3^?B;TUJ_G]63]70
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MS^^W)XJ74-(,'+B.'\C P3OGL&Z';VK>\0>/MIK599]RM!R_F]B=SF4H(\D
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MHMZPKB#KE\WAU5FN&F#%*?P+1"!*JS1+5AEDF&C&<&[].CF\./S:_EY:*LA
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M:EW6MDY?:-I"#$>-"E802X#M8=FSR&@ @'74K\0NQ,[_\""!&IH6\AWOG7A
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M=;+.!K IIZ\S6#S$@R)BOV40W,C7:[-C&U.1=49?Z31=KE,]> VDP *H%]V
M;.9" \-RG4TAA\M3_??9N%,_/:A[Y!"GW[K28@-I(QG2TV)[<Q''<HV&BE*N
MF"(+?<,H8W;)^)+G%5!&-I$R^MU'<M9XN2Y^G2",.#5J@C#J&T,8DX#.C#"6
M3)3,F##6D$6UZ*R/=Z90W8P,ET[.M/T+:W#\_;Y%9BI4[T6)\K8?(8?EDRJE
M?&.AOMLKZ1I2^8C*40"UVU^Z-\?*Y>'CZ^-\RM%F\/T,%*($1"\ME^U7K&S4
M!(^5VP";J.D$T/S;9;?0E8=JI2+/I^IL!IIGH-XDH?ER@VJD0CDG59=M9+?N
M9KJ+E5B_-_VF;Q+/$FC].G'ZO9O#GW>5CZ/A^ "(T$06@W1**1Q%:V+^L^L'
MWJ..$T3OL^M:^UFY>3Y^['U4+2<1V9>S;RO57*4QN[W/FC"]\2'5G""F#^^_
M'?\:V*7C_H=5=!(Q?;F6O<4L,/W-W#<?+AYV9#BF2Q3&B:V=G1P?[%_U/HQV
MX^\_3 7E+'H(EQH;H]Q\R.A6$+G+4KU\/%:>AB<?U8.3B.I+VK9)&?MO@N>S
M9V>\0]4FB.>E@Y_=@Z\GEZ6!]D$UFT0\7S)VFZLLC>:;X,%9631W8U4<]=G3
M^ZO[S?[!L&7?J=K'47&\_4?H8?F)-1LPHO.#^V^"R%TVC-I0N;W_,E(^JHJ3
MA.K+V;3U7&US0K$?,ALGB.:-HT;YZ^/)R0OYJ I. I97EHO%9H'E;^:XF=VX
M^IUI-=?JBQ>5NK5_%JXN])OOG0^CU'C;CY# \LG+E7R]OC',?O9(T7>HTP10
MN]%[4N^ZSG&SH7Y0E28)T9<S9LL;E79S^!%5F@"67X].'F]?ZY>V^5&C44E8
MON3\H"RP?!-\-BLS;3=6NR'/1'?)X_A<:WQ17ZKC^Z>/H]_X (B0Q/*9Q;5\
M>7-X_^Q&U^]1PPFB]^_G_>^DTJIVK(\:F4I$]NIR%FUEHT)3'])Q$\)T8]@[
M->_5;K,TZ:#\('I.(J8O%X3-!-/?S'FSLJ#MIJHWAXC#+E7\?+F_&3I?2S^.
M9M>AOQ?U)@" "!UDD%1<R&\0UU]9POPFZS<A_";'MY5'U2X-;CZJ?I.,[<O9
MM^6-TF]67B.XB?I-"-/K7QK25ZU0^/52_J#Z33*F+Q>!S<1?N0F>G)6Y.C=5
MU3E7_48*/XS.R4@[T%O-TH?1=/S]APFBED&"<2%?W1SV_R%#54'LOCD^LH\N
M2NW"1>6#ZCF)N+Z<<5O<J&#5RC(--EG-">+Y1>7H^.FX=:CT/FH"3B*>+YEA
M_-9*SE).G.9'TVQN?,=F_V1XT[\>W?:O/T[EU$V\([.V?%9QL;Y)#IR55Y1L
MHEX3P.VG>M<HG)T,CT8?5:U)PO0E"V4WRGGS(5-P EA^4#NW!R_:^/:C>FX2
MD+R^;'^G=^*WF3VT\9UI-X=:* 6G9=X/;^Z^#%H?IVXJ"($(42R?95PJY$N;
MP_T_9'5X&,.O?Y5N7]O2J>(\?5 U9PJ^+V?79I*&N3T)9YNHZ81Q7;*ZOP_5
M+T]''[;-WQ1<W_*4XUWWXKDL@!'1 @6T/PZDSM6/_N%3]<-H.4$(1"AA^4SC
M4C'5E.LU<?Z58?<F:SEA#/]UU7[^^5J[&?6['U3+2<;WQG*FKK116D[](VHY
M85R_;#=O:M\=P_[U4>-44W!]V7[&.[?.EBH\?=6TB6\*#.HOU?U1I]ET/HYC
M)PR#"&$LGW]<W:C\XP_9%2>*Y5_:2OWWEX.+FO11R\BGXOQR)F\]5RJ5-@7=
M/V3_ORBZ?[MJ'4@W5=GN3/;Q_B":SS1T7[89U/+H_F8.GH_7_,]P0J31/OYE
M5;6?Q:;Z<8JMPC ($4.IL'P:<DW:I'KRE6GTFZSO1+'\<B#]_'+4;S\//ZBZ
M,Q7EWU,V\H?T\T31O?GX0VDI)_7"8>>#ZCM3\7W+LY)G^WIB)M.G'8#^X>JQ
MCM1ND'34D56Y;A@_OE=GA[QF@GFKE:0@7"($M'Q*LY2R*#TE)L?/@(ZY>>HT
MZ+9A I"]R_<U(#V\2;0,357F&A'](>>#1DCIL?:]=5#2GP:O_?FTKGG.8;NU
MLBDTMKQ17GZWU/4AQY)&J&NLG7T9?#OY==>;+$.8JN-M!W5EH0,F4Y>T;&?H
M%5'7"OQ@T544\Y5EJ#SF=HXD"]\_]^OG9S/T-E$Q'$"GN3C-FZ?(O-;V][^!
MWG9P<SAGJ&9.0&R+((T0\G*^BZI4 C.J.#<I;QD6K]P'.$M>OM[>C]2!=FAU
MKR9UP?FEU29B\7P"*X+%RS:O;N3JC=IJL-@527_;N+7/@N"^!C9.  J?_QMZ
MF%9OUAY>+YI:[_N+_=RXZ'FGV 5 @  LP*G=J -BB>=D)%X9 UG/L2]RXC4\
MK/NO.)#-G@H+*837U2$ 21,.UAK*>O"I>UUYH&KC?V8]EUYKP;FR9?A[Q ?"
M+H>XLV%FZWT$?43MCOF7*J 2/K"0KZAZEIN@2"P @MM](G8TPT))T)55$]?U
M1&SQ6=8<(AI=\7_LI1Y/*,P.##=-$Q%\ $O?'_N77,IC_*HYDDV%8_H7N-"V
MCO5+6*:AW!,D0J(T07>1>X3^V))M<@3KNL/U/ R'1276 ?2J#B_,6KLA7_WP
M,_&/HOO)B4,""A*N:#%27]G.IOE;;".1_-/Z4XJ)DS4+<1%8BMH^K$2 3HMT
MJ#HLEJ2<B.O)4=11==M4=4OM<(21;?B[[<!61=L028!!PY>P!OX-X%['& P,
M1&;@DZ+!.?I(MD1Y.#2-%UBX3;3Q)/I-M %LSSZD=L(A!5COL;L1>AP22B'%
M" JB;S_/>N1$_W9U5O00[#B\^U0XM9+ESB$QTKH'"F&40<];@ON:88ML3^)(
M?LNYY%NP^A+5\++;0T!)%L+$!@0J=WX[*A!XE,@FK)<EL/;<T)^)!1S!57@8
M\T$*&ZI*D,1.F^>%\9'^[;P0J*8*6"J)RZ=<RD)I%>(JN@%\G[YZU929L,?T
M9%E<LCJ\4$KP+##B] &$3!OW*.OC__=_ZT6I]J\5!EI?5@* 6R]9;YNREOUZ
MPRN%TR0O'<U1R.?__L_>GGBD$DWY1[P$%>)?>,1OA^@=O+4$ZZ*" #Z+>WO<
M*%34Y[2N.[8_[_<J70K5VV&/FL;U?RH4\&]88\?]._R&CJ%I\M""A;B?_A5'
MJF+W<8.%/^)VG.RRLHUAG)&1$"MEAQ%ZW:?/1WM!P+D@^U>\&0]A!4U3;JN=
M?\5S8 8,K.<&PJ]8"][UMWL;_N3;-JYA\]_? .@8D)M$?MIK$Z!J>/:0'AD'
M,^QKBV <@F?4P(L#0A!T"%,&M@ N;S@-O@L#[W9HZ (R>U?C1N9O.9U^6(KF
M@@(!KAV2CDU%*TI JSNF/YM$DU$6\#O;L!&9R^"^:3B]/C,%+,N1D4K@1;+G
M#$&]7P!Y!3_B$V(%]7M4$Z.^CM"?J8T]8G7D(?(Y$TW$D,)0^A3188YU@"FY
MD5]:JH46O6.2&WC'O@80_A1RMA2"8;!IMSV\_NC<CQM&[:G1;63GD^''DJG<
M;'^NY86P&ELO'CR\]AY/!C\?-44MJ)\^L[V*L%EB><?5_OP.T6_K-M$B76*:
M1!%4=D8VGA%PGJX&'(GR%YW8^*U(NEW*I%"9)8.A8<KF6%14^-9$(6V);6*/
M".&N+=DTQV@[R /#T=E=LF41^ 1&A:BIH !HJJW";2"HQ:ZJ PM394TP"3S9
MQCN'CCDT+,)NP&>ZCW+ %J!W^4OV+LZ+UP ]M0NB5K>1V0$[)OS]<2JXPK=/
M'^(NT!+@Z@GMFZX#/I1$=,W(N'!-,T;6/UN. 7%HG#G7K$2YYG6G3Q1'(Q==
M%P.!.S3I 31UY=3'CQO4<Q(8:B/4LGFQ)SZ\]CMGYLE!]^QPO(C_6U&MH28#
MW %@Y*W/,NLG>9#>KSV\5L]Z97GTZ[!RI'EP"NW^TV?W#)#<#D+$YYX)"@&1
MG8J+<JO"Y/ _%*_G4OO3XT Z ^%3)%,@@CGQB0/3ZV16KH2'XU'TZA'UJ>/Z
M-&6U;_9V#N#$;ZD_W47)<J,0"$/T?W6KKU9;KCGM3XFK7;4!@\O9#,AM[)G5
M\<Q*[,PNI>:1\_UN?W_0>-,S*VT&Y%+G$J5C"?&)#3'P39T6Z)UH-75J6LKC
M#.I:J9*R8HYFD:RL-X=D,6M(,A:T/ 2W8)^EC#'%8U*%H%8YH4O"AP/X6[4/
MT,0!,P3#$=85L8AL=OHTNC(L# L/ [EUT_SR.G@&#?/P=/SM[%2^+G]Y^C0=
M(Q<K'^%*1A6=D),^17=M8H>NVXK"C=]=_&-J@I.KR,2^XG\)SY2JD<M3I?O,
M"?,YHCUIX_:H!,+9D)AP;+62%(^-AT LO.))[5T>1"GV(.H9'$1B8'S!@XCE
M!;5IO.!8OS2-#K$\"("AV2+/1#.&&*F,9P;[HZ^]']]MVKIR=;7S!_)0M>$;
M= 6;+@- #X;BKR^32LY%"Q'G!69Z*B\5ED>N1F$#BF3?%+2Q=%M*&RZ? MIZ
MN9QM/:9/K*49@MO][O %<PU(*.= 5_:)3KH@'^-3T X,*X&@ZU\?U0/GY>S\
MI+$2Z3X)")KDND>3(JB/TUWC9F%=!@"?@^C3YI5/P4PI5ZF\)[)?U0'$LX9R
M%@=0!0MP1<Q!FL8<+H;$E#'L<&I85DBYB:?Y9NG6?!Z?7SJ'U=5)\01+ZYS8
MHN&N5]1@P2S<XJ[XS>O^5E6W-L>IS<$XJAEH"[F*E&Y.R'85<&[J0<8SH R,
MNWJN6DC'@):K%4SI:_AB C@>U!N/ ]D>!Z+,Z/QUJ#^" M(L?GN]O75J6%FZ
M%@7DQ@#;(BYXNED"D,)O#E8P1XYVH@@KYJI2[1TI$<DPC*7"<@;&EP1Z0+V^
M*CV@.HWB,)N3:4<8V\>TJ@?UW"4_17T86#[9W5W=V*=*_?($ZP#6K -XZQ1E
M=Z%;+"W^G!,G)T\I/9&7BVLE\I1RXJ_=Z:5C+UF8>>G9RWRG-[\#$53YJ'CG
MS.7UQX_2_NFA/2YUUB+3)_D,KWE&:V.*H$^"U(HJIB?\VPN6&P?CN'L6Z>RI
M+WM]55$(7 /G5E1?VJ8&Z%;!+=2+4C$IO+X=A>;K!EMU)6";K[*Y\O#Z2S$[
M8Z7NG%?*&YU%^RXR28]U 5F#14N:,==R:-CP)A4,!9-@)(+I*T8WCIWD8/&Z
MS&J^4!A8*J"G)8[Z!)X$[-0654L<&"81-?4)ZU/M/BP;ZZ7@ PJG ;[/Q#<(
MAHE*D9OQ&9?A.5+A]S;AZR)*7KR!*QW-IM6O*9:+JU'(D%!8BLZ0%W2[^?RR
M;<NJCI5_7<=V3)JB2C//>,:JXI@>D&B=,CQ0A\VJ'4SI-RR2F&'+;B>* _(*
M'I@7FSR[+BE9-0A8 <M\'9VNQ#;@,38Q!ZH.R^K.A'#:Y-DH:.E"^C*6+, N
ML"A',&$7P'WP)U9T/#15!/OSI$XKRCT I!4K@;!$CA96*'"S]1YK&;9N$]%R
MUFI<O0-W17/?LU?MG=A9TKN1=_JPQZSGEJ]5P<^PO<X!IH>;8[??UK-V:>AG
M=U<7X\F%':1?6,E;6"FCA2F%D45.+AO=8G>6-9ZPMI1=(OE3'F+7$=&KP\XS
ME.VH6X^ 4"VB3ZU/SVX')6\'I05V4%]X!^=&C"$07]'+_Q&Z!.032#9:>V :
MSZJ%6T<^U\82"/J5PLL4D'6.B0SB#.6%,JVR0'$H9\8[T*]/4"YT',KXN,R@
M'(\+C;QP0ZO$ )0=55,9[VP3X)VP &+1U&LJ CT1$JK1")1/F,A_,9)(.TBT
MQ\B7M;$KHV[SUWG1W;%ER[9C&R"9Z$VP=%;N1JM#U.? \^;;>_8,?,6\>AUU
M$Y5"<MW$H0MQC\2N .I7(6R86CQ1B2V>F/^Q#Z\7M9.KP>CJ>_M8SKZ"8DW2
MJK[?>G@]5IKWI1_U8YO4TI0X>+ 2_0HW$<&UXM*&%5=,[$HEWEO:?>TAKG=3
MK]E_:M]W?]Z:C[NBB0T^O?V'&#WTU5#:U5_-WN_7Z^*N?&*;DOXS+Y_X216L
MPPD%:U=*L2NE>)-2BLPQ)2U(YGO2ZAX<&PD*CBY+HV4W[2-F<UV[)E?HX@?U
MG#;R4H;JPT ^/+ZY8JEI%[?*M]MOOSM%4WN#8I/;O!AK++I6X0IJ'J864R05
M/LP(6F9P/HNUEJRD#4_3AF0\Q+D7[#-YZ6"7S:*47[(TXJ\_/OA93;BC(B<U
M5R?K=9Q4+-?9GY/K(( (-DPP8,7>==@W,)[=''XS'EN5BU^JM@B[25W/0I<E
M!IN4Y&AG$K#"@[ZX-G,OKCB%*@.$3 +S@EQCKG[4R;A838&*TSC%.X'W+,I/
MFS*\4FC'4GMA7FJ/S?P_?,%B(;B!>^LOB=FA]6SQ+*!<ZE>T,U,W:[TUY9\>
MO@Q5D_="<[ND8?.T3:R+R?P8%F01:4LNHTAKP5;ATP3VEO+U!;!WU:QB$\YB
M%ON8:U)4BI.0"OG9PVT2CR*6CS0?B#?3*(UZI6"$&7,,;HQHDEL2UY +RM7=
MMZ'U^WB1LKG4BH._-);S$,TC>!O1=7K\XR:=XCH%LHLQ@NI<+8^3I9>4E[9(
M5U@=P&=0>S4C@ZZP$+N=JBPTYE06#OK8EOM83Y<U'TOTS=;]S:74_'WW^%9I
MK=3#QG:"25<Q24=;G(J]O/2;XXP79#]IZT332K]B.1\W2V.A1.X)E\?N[.<X
M^UF<<%$C-5'OJ:70>^8[^07YY $ 0]4=.A"-<,/D0;WA+/!A8/L<L-&Z5&N/
MO9OA]>/JU)[$;/[#B32=-\I(GP/MEQP>EO[$%F1H<PU7GB;@YZ]'24R;G\G(
M/OJQSN)5BUK+:SC4^<H@B@^O)[^J7?-.[_::2S43WZ4[1S;1M(6$\5QN(0 F
MA,K/LJK19"I]1N,&U@J;>[,Q+]**.+W]GMC83CLXKTN8.BYNCGI[-]/6;WL1
M'&WZNW+4OWIMU6^? D,ADS>4<W>384, =X'I*SYK&90D8UN2:E+%)Q_$!0>6
MU2F$O-6Q1_'CX*GQ,C[YWKY/>Q04F3(\B- :YSB-#.IO2Y5<O52==AHY;'HV
M9 )"&^=%'OV+(4'L0 \B@9(7RU0>FD#4=/!5L2#5<U@=@V4PCJVRBA:X2%.)
MF<.Q':I)!'<81[%0JL]X4X_H^ T\!$Q/V7NGV"; QG3:+[]K S>!%]> >3QC
M?K6(_*NK @!(Z$AY%CBO7:*+DUG]DQ\2F\EQ5$NTG/8C[?5O@#$,3W0L45,'
MJLV$YZZN9@,V 2<L,%F0=*#&,Y;+@:3 03^S1CDV,V=*Q9FE,3CJ*5(> _O_
M:9A/]+$ME9507'3A)K<]U1&="D'<NAEU^.O@\-3X>A,829S4"XG"8ZW,KA@I
M69EO=Q$>F44OK49.*B?ULF$2BQ;VC8A)_"H3E96&L&@[,!+$4=Q&WOM$F98F
MCX#!TB& EN#],ATY*9=U.:R*M2$&\KD*_MO&ZA,=S6"BY$+U)S(%A*/).9QY
M:L#?E_1F/'A?WN%Y"0?T";00Y\_+\XO3@[^0M]GNV0\-0\M/3%P,VO;)QW_J
M,\0+_=8B<Y>L98#^/Y^_/3U)OUH7DC^ED<$B#NX^+ *BX5/Z>4@Q961+870U
M6LB2'MB4_WDJ]4 >NZ)8=(:(/-+?4L&M]J7G/G'L.1&@]+]&L9XK2260VW*G
M3S$Q+][JKE@7V*WND!F*N*(K:C&V['0ZA*D%#(GA,E7#EXZY(H#$ SI )2\>
M@W 'FP[?S^R!KJ-IXA0Z"11Z"2JNV;+W&&UX6@GNNTU\+00N\XN+V35Y\=*[
M<?K+^()]S:5<R$]8D9Q+(/ ]X2,DTS<P)".M!#I<D5H\)PD>@!B'9^NJ#+Q1
M[_15"^_8-^!=+M4U#SK?[IZE;J>F;KJ>[1'JS&U%:#.#9LQ2-5=M)+7 "TH;
MV4H6-OZZWT;K='7%M2J)<TX<E7831S.=.%K?31R=2#+=T(FC.XMQOF8LG@;B
MP%M,N)0)HE*]Z&I+QTA'NJR)5^29Z XJ60KEQ%*C7LWAC#L@%RPKRE'O5@<P
M2@:FW3%,]*X8;#JX5_Y.O9),4P#[@/I-9 &NQ48F],UT'3V#CO03L8M(L?"O
M,=)!>>BK0[%#HX_T:^G?'.^&HKH^$PW4".H&P;XA\ "Q!U2'KA+:IJ12^(/?
M3ZT'#.J3G"M?O%>@9T0%W0X-%WLLHMJ"3IB^2<@>=<,PCPI3V0(+]QJ>L!%R
M8U0''8O09PU-LL?>+(+^&/&N(- ,VL#&OTR@F4>V;:IMQR9TYJO1[8(*P!Z'
M"ES'S4Z@?M\!1D-0]:->&:+L/#(;L(FF)<1UQ(E5MJD?;TQL;NBZ&GR.=BD"
MQ'BF/C=?T[=4E$#%0J$*-O8 "2[@HI/]=#9 =.YL%/C<7SI/TT>Z1\=4+47M
ML#S90(<AWYJBFIAN W&Q96-HP:1A"_ZWIZ4-9<L.H5[VA[;MLX'K$]T: ,Q
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MU!&.3CSJ+[9<3QT6LG68QQUL)&S$[?_=98_#!UONDB+;%5PH8S(RRS"($"V
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M%9F[+C8'%M"2(@_P.L G - 0'J/JSP3H W8,(#HG1+,?B7AM$]+K X6?M7)
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M*Y5MVON]2I?B.^B##OFHPS[\!N _FCRT8"'NIY!'/F['R>DI25WZ4HW)90&
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MJ)U8&FI5JNX@J^YB!)5"R U#1,$LM*F3@$83?",=HZ3,1='&(+L":.,&)KP
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M 0;WZC3;C20;UQ9.-B[4<H5".2G9V.?7AF6'.7HD: 2RNZ^"N%,1QZFK1<'
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MCD8?Q*'F6*(2F&+V;.5#?\N:H=.D>I:#IF&2'^;C!4>:\7%F A]GQM?-/$!
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M.K=J$W$SU-YKUL!OBE"3#8#<-BCRLZQJO+620&LV&3V"O6DX9@<7GIBNT\1
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M+P0Z;<FB19FYR=5/IH4%6M3+HH;+-6/B01%<BO+_B5Q8NT]BHC9"<'@W<!_
MK7WOQ ,:A7ONK!>G>_ATR\A:@WP:1W,&0ZDX?L.QN"SV@@)A_,L+5_0D+/\H
M @&U8/MQOPT0=[,_JV#QT4;DNN%G3'K!+[[SR:T !G0PK1V7@VD9?K-T80!X
M:2AT+53C 4&N4A7*39+TNZ,&S\''/)1C R)C!@IR=N_PH@PZ)*(2-"&!#JAF
M^<V^_A14]MY&'W?9]5KY])PIC]5=RF.F*8^E7<KC+N5Q_4I;QIZC_]3/KE-(
M8"E-9X:.QA8*3-\!"&?S&9U%6[2Y=Z%"+U)WA-X\J1)74<&5;U"DB&VS=M!\
ML#8U'F_0V%7("ZWM9EC <O'<PA&B"W/6*<7H:AG4*0ESURF)*ZE3$N:M4Q+C
MZY3@T'@:I11;">.=&QL,19N&>S$<(=W9T?GGDUWV>'D4S2CN]>VI?0K;8Z]B
M9P4U,#O:CVR"#@85 HT$)J@6M6&W'T,<:E!_)Y+K0/;/<T9E>LMO4G$/C[S
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MD-*7)V>2*;R_+L?XP@AT_US\<O?K>'PV5-_4H3X7&E0*"_L%9J#!I,-],_*
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M@&C+"TO@][RP<"'VQJ/Z5>%'N7I[>E!\3C',><M1_?]O[TI[VT:V['?^"B+
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M$/>"]#=RG=!I#>C@RL0']H)5C,XIC,[=8)P-_*)A^/$XT5(XJ/3QYVSUVT/
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MF.!W*2-.]-;7(BJP7NPV.T0B05&.HEC238N#R: $6K]G2UVQ?+"9#$_9U4E
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M_N6^\9+I&GAY!\#+YHK RRK,X<\4#3A0W:@_^QW^.YJ.@]__'U!+ P04
M" #00WA:*TSM@NU,  #T3P  $    &9O<FTQ,"UK7S P,2YJ<&?,NW546U^W
M+AP*Q=T=6J!0I!1W**5X@>).BDL:G.*$0G$M%"A>K$"1%/<$=W=W]V -%CY^
M[_W.>\X]X][/_OI6]AQ[C.RY,M:S]MIS/L]<.P^S#ZL 8A4%904 &AH:P.KQ
M WA8 ,@!T)\\^>=X;!B/QU/LIT\Q,)[B8F%A8N/CXN/CX>+A$1"2$A,0DA#B
MX1%3$I.0D5-04. 345%3DE.3DE.0__,C:.B/?3">XCQ]BD-.@$= _O^Z/;0"
M2+ !OYX8H*,]!SPA04,G07OH!# ! &A/T?[5 /]G0WOR.$9,+&P<7+Q'AQIB
MP!,T=/0G&.C_C/KQJO_C=0 &R5/29WRRF&2:YEC/7<CYOWS+P69Y6]%&H35V
MRBI@X1J$@TM)14U#R_:"G>,EIZ"0L(BHF+C<.WD%125E%6T=73U] T,C2RMK
M&UL[>P<W=X_/GE[>/L%?0T+#PB,B$Q*_)R6G_$A-R\W++_A56%3\N[*JNJ:V
MKKZAL;VCLZN[I[>O?WQB<FIZ9G9N?FU]8W-K>V=W;Q]Q=GYQ>?47>7WS#RXT
M #K:?[3_)2Z21UQ/,##0,;#^P87VQ/,?!Q*,I\_X,$EE-;',7<B>\W_!)G_[
M+:>B#8=%0.N4PL)U#)>257"-#?$/M'\A^W\&+.C_$[)_ _M/7/, ?'2TQYN'
M3@*0 =QKYT9R /Y_:PG1YY$ HY<<[.2 :BWT-", 1_[(4.3;U@]<L;F)1?GL
M3[X\GIV[[;!8!!\=;.*%[= FM6P>NW#D!N+^=WO)\>B42M'O-;"N%[7:V[\T
MLF-FR66/MO3LY@'@[IMVFDU^!T001;R:6FL$<\X+$]!3E@5_&ZV"4)U!@5A)
MZWR-7492<^=BV<2KE2.N3FG^R0\ Z9Y),?*:M64<Y,W8CR-)94I%6<B3!\ N
MZ%YQRVRDT.%S8TNII[ GR>)"?7\?F2-F0X4!)U+,=2IN)$_B[&X&)[4CG4@"
M5O+[FK(H-VVHVNI42LTYJW[_?>2JI#G"]_VHWP"(H3'I= -[I4D.-0&1-=/F
M[822#)24Y]SG[C&OOLG[^\8'?')WL'JN+C# W_\[3B #"GU5>WT$8?5G)'K6
M;?GLB'3+E'?FYMB?1]Z[YZLT_]Y-6^R"CNZ$$Q%:W_U MN6=3-R.660L _H3
MW"Q9+.:92>OK+#+!@J,_2>0IZRUZNPB$J I2[%8<486J99 G[[-28O%FM7[W
MQC U%H!>S%[C$\9\P[7E% NL*PRYPW!TS\;L88KRV.P7:I?F!B_<%]+W*N:Z
MH$:A\=QP$#3RRDS4B9R)0LW%]0' M7?.(?Q"<F> ^$*S;]-O^7)7JW6JA!'<
MHFZX;HX%'IF.Y-K._@*I8_HJS9[NS]4I(<FR+M(>?FSU 'A7[W1C^W)7XZ\Q
MUN+,^.^VP(^R6/&*/AO%ZNX% T(V3C3=#@B+,7F*5'-Y\@]H_[)G>T!IKZKU
MNICJ>Q;]='E?WR65A9ZQW=JKA/:?&K9;W2=.6<.M]?J2H5Q9G!M4[%:JGZ6#
MAVB@)(BZ'KP6A8/6"B2G0=:$)FSB50VH86-ITV!QL12/<.*OS;>!:$8=>79G
M3@WL.[NF"L1(7/4*U>+"PFZMYU^U/" &3BT>R,ML&X=O:L;[FX:>@M,Q;<"P
M7GU#T@@H'YIU0125)3@IV+2PI-$_P9[8??,Y\VE*?--1]4%(K4?H^\OO^9U5
M'OB=A$$M5%TH[LD+: 2*:NRH4&<"6MVBOKW.0ILP+K?I;<6W:>GKLB(YNCKQ
MQXV]>&4L[3I*]OZGGU8 #M6,36T58G7\L 8D,6L.9-&J2C/XDB8HB:7QNN<Y
M! ]LWE'FPU:P$HEB]\KK0G^/> \C':V6."^090C)(#-94O^6U\==QB^J,_A%
MET+VF2KE=2#ZKXWZE^P5!V)YSV&N"-OH9E=I.J\>32 %[-LZ+Z8)+-/U!IS4
M-._ $YX?ZYJ05TE&/]! \8?.4S-RWT]V0TU[32/&CRD?1(LJ69>2T K33-X&
M'A9DK:7QX81CU'PUUW<[K\LX\]$\7.X5^W:8REAMY3,S#.-#[I1HY-X9PD=/
M7AWR7- 1\!W2GBA[V08II\D*A/]Z,V[UM%LG.AK_W&BGZR8K9967X4!/FA?Q
MHL*[8'=BT?@7_"=;M'-_T6 E[XV@<2]7;Q]C;IPMEP/][E_).".C4PT\Y*UV
M)<(IZ!,WBED>@77[B7]?W#/)SKHR^HW5K9*OE6ED.05VXK/FMN!O0RL$=^:3
M'KP1Q9)_KYQ6P0YG_D1*$9)POE=E?YFD?M!7#O<Y1Q*A]T7'77[W%</BEZIC
MF8Z>&:+MZ2(P&YY8)X2R=][Z<VF/"8$6P!(=;L:&??0#E"LOR*@UJL7B$6>P
MDW26\49_Q?61B#MV;Y><_<_2GN'-\N3ZC&1?-EKY>W^_J/E1U',C0,;"M]DU
MPJ;&."P['.>26VPW7:=GI)O9<KDWZ601H>5;1=NS(\HD<&1&Q<Z.7F!:.O#?
M Z+ Y4))% \E:GU:AG^;@V']O:W;4U9\?Q#1VU-4.EM!;.XKF\8&YX3[YD7A
M/8/5\^'7&J<71Y'[[&D27G-;'C'DUH\1X"9M>V.B^27!;I/<Q\22Z\"(T-&5
M9;P,])-(QN>9; -BKG =-_6O^VKJ?(W L-0XZ]_[%4B(@4'U3D.$33.>RU6!
M=LS)['G/Q6^+935%S;%OI4QZFKGOM@AZ4FJB_(\U6!\ *H?KS:.KM<G+$B5"
MH5J'NR],^"Q4/4\2=7@%'P!X0#HW[F2K-N(@_CHTE6YQ7H+Q,LO3OTZIO-EW
M9 D&N,<O':Y6IN_A$JE&]8WC'F"20XL$$I ]=Z4!US%AJNG>\1O6X'VI_9<>
M366JG91I!>E-L^F@I,JO9+6N13CQL=>.6'^D:\:-E-=N6=!"M\>,,.PV+$79
M=#*^)?C+OW>J5LC"B9G*3@=81WPM.7ORVF6DABVN UJ=%>/8/."%>WP%?C%1
MV\)S;[04:\'PO-T)I[SF1<[K%N$'@!WX@_I"$B(KM1MMPX9O@8*\41Y64()T
M  UH</J_Q;%NBO(%C&P5M]$<*I<AJX'XIOO/#?(JT[:RAV83,)\V'L\2"JR(
MELU]XMEI"-I:U\LB6-;.*JDWK[CL M&_?P%5UU\YFXTK5K7/K[V>.X%>;KOZ
MF%[E6)>#_ACN#?EC>&+_5FO_*;L%!0A];'TQ^4F2B[XVKD@P&\1O+'CK*N?Y
MZ3SRHHC[8VV:MT4T:^(?;P,(#0 _NQ4WQVU-ZL7Q\C(.=WR7HT$G>=*LP=8?
MV1.C[FKMA9LJT[XLTOP\:ZZ3POOF;,>!LF%+D^J@_A[9NFSUY/EEU:OS3SEN
M+V6:$NF#1YAI(WM,U&A[S)HK8K<EJ/N-Y^=-CGFOLF1QP[C)MT2O6'$/P9)2
MA;/Y. 1_GN"\'SNVZ#()R@_2R&%!%,)"S-E.%FBG"(:W( +TQQ_>R'S H2DX
ML@0)09"^4?M)W@WKXY!3'EA6;:6HFHP.I8]P2W[!U.#")ZO&(-^OW^@3"@<!
M]5AA.[%?6H^T[-,^Z<<5O$BUA-A%U\.2P7MDG9;,L1K<!L48^'%&Q]#J*"FE
MXL8ZY<B2W&0&=/S7-R1Z+"'/8ECD<<.?_(YM_7!0(L%CL!&4-/Z]VMAS^0%P
M*D4HHV3Z]@&@8_K\6/&UW3&M\E\WCRSS82FJY$MF?9NG<A31Q"8C+O0J56IU
M@RY3?UX+7%!(F8NY-4$/&I84$O/3'!\ 6Q.GCX]GE?B32(Z?_[;X#-S([6TN
M)3/[ @,+V63/CQ2*#5 V!+2G"<3+/]$Q%C5W0]>G>/S] 5 I7G=6WBQ,6OO*
MY+LEI/><;RZ6ZE7A$9] 78K^;MS[F6;57TB;OO(:KOHC<P:1+(,;CGV-\6:)
M;C@#]-*)?^:MWD09$>;6 V!&] IU<@X5G19*/R$&"FWG>; MM:'$B  ^:*-$
MYCHEQZ=B%/12A<#EE+4' ,9=BM!ZLSK_Q1]X4QCJ/<I?&NBUXYFLX$V3_VW8
M<''KQTWB<D(DU][AM].RVN/VFCNA]2/]=A$+_U='/_L&.@/L-A\ WI"^TFC*
MO8D6#N;7Z-M_A4XSU+KF> G'0'QIW[-&C?KN&GV:F%PZ)'DR=J8FSV9%"YJ7
MOP&E89$[HXQ,R,M",WM7Y6(C-; _];JHPN8_$^$;(-3ME;TN7;5!,SW,?OLT
MHYP$O/Z)LJ]U>>D!D.02_OJGC_9ZTFHJ6_31-VK^NARLY_!8 91@YPY%!@?4
M4A8>(@7>?@"HQ1W29X>QI'R(FV8_ K$AA*PAK X&2+VSF_E]N_?&//E>LP(D
M"7GL])8_3]2K3UNZAGXO-H_-=^*0>O>W]L34]_;X#T0ZW;&E_20-21.]FWZU
MP"Q[3A*D@(41//U[_D!DFI,2KYA$EB=Z)P$@-F(6? ;]KMV_P7%;"3*^65%O
MB7-*86+C]>&J6S2:DN1SRU^03"%]9_4VUX \H9<Z/O^*^4BH8$TFO!'^=8XE
M$E@S9YMN&,$,:?0I<Y%^C0RS7P/3#<]<NCC9E#6P?*L\$Y'DC#4X\P\%;4/"
MLZN3H>LD;"EAEOZ4K:>.&G=^O=(MQ/YB?Z%EO?R2(P+="C!%&JV@95<?2-O%
MS*;7=:SYU_8/[E4O"MFK]?Y9ZQJ-DI!;:R^LM>W(\64-J>6FZ%<A#N@:34R=
M*Q[ZB]FM,^T0.H@#G/X.G&!L/  _U""LN'8'2_7G$2Z#+N-OZ7EKO,Z;^E@D
M8T=8Z*OX!O@N62]_K</+G&E\.[0B.U6S<HV:#$4V&YDB+5PX2[<.9[A]>!X
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M_1JY8B,'7:+ERPWLH_H3C(1(N3RD-)_;\\<5M__,[2JU!QLR:Q9\, T#-SX
MX@;B;O8? #<DT)TX4J]SAN^CA7(O_6#C>\/S>TYAM;?'$#EGIK!9$VM#_6$J
M$9ZT(!_0W0@T=_1+PZHM^19]Y$M%36"/!X*B0I?!X=PU<:GN,^H3JB0GK" D
MOV@T*%JOCXOM3)CJ9R&9&A:>*?1K ,7^\HLYR=6]:8*1=,Z[0YDYX#YHIG6K
MOG2XKJ)=M@]E!LW97'=Q=W:^2MJR<CF5Y9G<PR=IGA!K[Z%-Z-E]JH'@6@OK
M+!-H/2E":JA4P:?$>*VYX? 8OK_? @[J;EE1_EQ[O/A>+"JG&72?P#T9BB,N
M[/PB&PN[7)[4T,7*5T\ZS.E!V\#FE+/[I(,IE.*.6!RI'M3'2\-5ZN8!T"I#
MYJ<+*7.@O9SP"E7MF2;I5V,XY>)6O"W06+JQJ/3Y"YV!1T.JLH-@(K-),Q=C
ME+]*:AF,1DB6Y/?.+;>9#FOE P+\7.YC[\"G'H7PNB_-:FO?'\6IO8'"^WCH
MO7"X%?2V@^L"NG+JE2'^U:Z=$^=3<M1F@'UXGF;?9.+V^;[7&^H\P<BVP+:E
M+$RQ(9^X0!C:@30'R=)^0;6IT!^%R\$SHBM]9$#A6>FYR0Y:PH>;;O'?7R%4
MNW76'ROO],QUM3H>9Q!O*LNI<&\FK>7P<[+P^-*2DG-\>]./F0*U6S%DL2!;
MLQQ8Z%I,W$+F!'#EU&A\GW9#U!Z /79'8?LH1(? '6@PMW/5EY<V!TCW\J!G
M$3D/@/*HNX/K%4$$D,J8"GO+?=*>_:K&]0' M@=-O8$1?=E]^[4@)MT-]"L"
MDGH:<Q\RG0B1BKFOGM;_PZ<,+B?N807O]GM3$ 0TW9G<9]Y1(3I4WB$PT\BT
M#%J#]:H[/35=>D;B?D JYRBN'P"(GBMQ1%U;E70.&,\KNT,Y&356$7W][[EC
MV0..(3_YB^^YV8WT[J\5:.C^EGR>6/#\M4N\+..DC,K%L-QOI"="H@N"XU$S
MY<?[>W%/!".._S5.D,O]'(L,%]',Z,SR"IJ,XPF1W[NL@;<(/YRU;)+A WSM
M5T;#>WVMN$N6%BYG=8R79SM'6,5J;JM,3SNMJQOPH]@&%$OO<PT*Y^)X#V\7
M+-#&SCPA5>/-Z6M%#X"HN+5G#P#-*(U[^IKMR3P-"HTLE<&#&&7-%$Y/Q2,>
M'N8352"W[SM](.*(]S;L6K_G,VVD_1D0JSKT8%@QVOMG9H.,6=*58/&V0E\&
M)H9^HLCA3GY5%00$Q$_P84?J;YM8)]B(5?\Y'QAWI)]I4O7UE(8S#SK_H- 3
M+9G76^C?B=CKQJR$UZ6M@=\O:RIXV&"!2!71EVO<[U6ZIZ5>-]>63UO(>[X6
M2W\ZNRTP2L\H,'H)?>3EH2[CD%U>_VMVI.8# '^C #)J=GNF<0H=WG4.(S8_
M&E"A4EFARGP ".R#;!MT0>?J>HZWWL9GDBK#^\OH+YZ]WIXVJ*JOO;)N'2E<
M,^HK-S3:%Q$/ZI](;WCN5/7U60ZNK!A[D,+K^GNNJ0? 6H8[] 9O)4 910[I
M$-T#7E#![A+O. K:)>65V6B=)X 13O=\.B/\:3%U+T&_>F)8DT_90C)$9#X]
M_SLB\(D3\W/@:^^^;@W'I*LG%Q2;IP'#\SID71Q3T(B8CL"W;L'9*I?QKY\&
M)+5=2\MPZBZ+<THNUE;!(@3]DOWC.BQ->4N$KYU\2QR/><@U@7G9G.2:\H#_
M*].>O!CPM^CWE>C5\S5,L?HFH\ 8V@!'ZL!('@ _": '**%931.A4U$3G>\E
MX]%IQXEW0WOK7)IZA2(4F_.B#X#_XBD(:2\XC;L'@"% 1'E[Y#:J=P"^^RA#
M\2&],P?UT.M;WCN<!T!JSP/@/_WR4!2\7R&[Z*#'>!3SF5SS/BX%,BHI<TK]
M (A'-44^ +(K'P-5]G7&<N+I24<CQ9UG+>U[RCJ7(%*=87T6+'B!^\>/6F.F
MDZ\GG2LV<YY2S+'"6=(*C)* 0LK"=TN/7*8\\?7_9B<%C4CE&K(!O/ONKXIJ
MZ'K$,#.)5> '1Y2@5*0+4)O &P)_1<('0,O '>^Y8IM+]EW4!HKMFD]0W^.4
M9U=5HMXTS^6J(_6Y>9:"P)DS]K"8U$&D8_">Z71RC$R0B51783QX2:42FB9<
M]0=P>3LK$^-L*Z'@SW7HK'Y>@F(Y.^SF>1OR /A^%1<"Q!9< BI5S0CIBY2(
M\C)D*\U@,8E\WILH\+5N:=;[D_^A\]N[8-SP>ERI$%<@MLQFIAW\L@]^P6*:
M%.#VPX)SIE--)^EP'NA]&ZH:W+'F[+Y$S;I%OK"_8-K[J-1U5N2 -*:0GJV>
M>P_(-NCPD8E-B8S.=#\^H-<N#P!3X'4:RALAL=I^,W"F>-A,AYBYB-N7UYIO
MG1'Y\#8?,UD^FFR4]$W1[^5OPQ6%#X"90<@-,;2C2%Z]U.(*'&"[EV2UH:YE
M2B:=<!K6[L_582%V3.X@LI$MK'E6_ "P]M%W!CSY,JHG$\W[XL_IT>*IDGG2
M9[3GEQ],9>]QH$>2A.@$*6,ZSG\TXU(.%E$>T(B2R/1B(WV;>%@MJ+:&BH0N
MR;2;>,.+L<EGO3Z.87%OHSN M"9%_Y;G[B^&HD4=9QSG*_KZ]YN!'UXR,U+'
M7GYS^6G_YP[\16M5D<5.K;%3122)[.16+^"4$_D^<?@!X#![RO[%3\+%DBJ"
M=>+HDL!3KRK&\=(W\$5]*E]\EOEM$9&\"<"[&S0F%GOBO%3'\ED@^CQ2ZV<0
M-@8C=KG,VE%LI@/O_(!)HHG%0,.V_Q%U6QO&>>A!3[]+*_V,Y1M&D?6X.<M6
M\?(:MW4&";F:L3M9]D''LHW[.<>F:(@[V6(@@9?6(FM"_Y?038O"?4*9 O\R
MD9M?-TQ;0)S%:+/%>"5IMS.992&D3(270\ $$?!(9:^I):GL.KOX5*= 2ZBH
M+K<**+$X5ZB(:N3].W,];0W[V=>9$6=VF>/$/\#*7<CB\P#@ T9J1>E:[L,%
M+E1&7;Y"9V_55U!2&P\ =^U>#&(%V8TT:_C-(ZM;HF"#.$T@->_&_]H.0JIY
M#PU75YCV;E+"!=\!<;V".++6-JNC_=,VB[C]>NL!&?Y;;9=# 19[-S6P8D?&
MI;/9+:)E8#O<6=+X ?"\O.H!8*8-V:T"CBRJCS[OHZL4I>?/H+TI+=<NP7DI
M%<="A=VM7-!PY7E$Y![6NDSX![7B&]6$8> DZ"E\FY<R,))Q:V4O%_^&\XYP
M=L],[70&I:+Q%7[(9_\ R$MN@L3!>":>(_U7K7U+>!0_-,:P-\&K)BT:Q<Y.
MR:2UE%\ KO-9BR3Q-X3:_7BS).+"LT@2V V)]Z]^6(LQ'20W%O,NPE-'I&SB
MYK^H*L=6UR!VFA\CXTLDT49V7,T#@!$Y#+I-[U@;(7*8KZFOJSV=_K05-&7P
M6SAGQR^!'@U5>OYE.5"Z-!<FC_ \BEF7@(?<3-UG?SV69"H;6FMR(MMU&W$C
M.*VO]?V1ZV$%P(!D![J^;MTD?G/D"''PEU/],W-8HX'9E8]L4IKDX5:/\R[M
M)%US_&B?ZU7PSN*HQICO-RFV5,-/HAP[Z(^5J_%T[3'W>]6.;**3FB*KTT'4
M2YBR$#5X?G@99YXN'/71LYYCP>5OQ?SC'%QE0,A -W%75%\=G>[8\[W1]6;8
M8*$X/&G&N@W7/.G;W[D_-;1A)%_+?5Q%7WHI 'RUNU(G5%ZX!FIQU4!W^+8P
M! )YY/W8T8N]/2(K)>Y@+?T=WV\X%<X6:)+9&<15B#1%6'8M\[0@QZ@BP H1
M(J&%D71JTM-*A:#7GTCU%EZ;**>PM9FW?L2F[@+X;E&<*23=6CF8T9]*Q0QX
MR>@BK&M3UY:X#*=J(IR.<NKG/JNP'[?_;DX/>_:YG-]5G+%RYPHZ=?C+GQ$2
MYOER P-!S\@@SC%E_A+FJ^V&G^O?]/F0VCPZB%#@2SQ1[BXTU9UI07Q',W9Z
M0Q/I[Y\_NVQT@#G]>=+\>Y_GK\X3-QQ=&AUI8T[EQ5@=O91(&= !D&!WP"^+
MNGZ2H9FKP"L3G-,<+8%W4%VKZJS4O0J4B,-B:!S%&B/7'Y$YG6H,6E)=VY/$
MDC23?@!\#?0*8""H46H.BY_W_Z/B6'N$_6S_2?+B:[0#@QNL(\-U)D;DA/+$
M!2^>G'WNLI>3]F3Y3E.CMINYA[T[N* 5(_];?B ^6LHR-3%Y).#&)_*:J36[
M]E=>SIW 1(U,N!E54^0-$(\]G =Z9!,26A)A^24LN9Z8C+4BGE!ANH\%0U\?
M?&NT[_EA]\K%3Q*6TFF4W"S(42J_&[LT8-32FR6V*4]$K?-QA8.Y>!413Y1G
M!TU]]0  ITL).U&QC83J68]5^PXYC(,E=&*WN6:/?AE8QWF]*;K-( G:",+!
ML*BVO"]G&Z^9G)#47IWS$T<,%2I[RUQ]UW\];[!"I>I;Z $ L&G2%7<OM7TQ
M'P+X4\@_9@=<:6:1+B:,>62J>Y]["=>>C;#F\&IS[0$+MS9)7,J@+B&6Y.OM
M)EP 1V[DOVT3Q;-LLK>"VVSK:2U8.Q-O5U?9(8@1P>+QI;_R6R]SH&*+G_GI
MP,:+JK638)&;X^#U!5.G[C+,,'1YWW6\)3OYJZBBG#3ELH)WQ+56D@I#PPK.
M7">-;WY^)D=#V$9(@A%<G3#1T\)0&P1%-..+4=@SC;P7->#"/H:"09X\J5Y[
M\-=LX977Y2*KE<6EV90!<]*2HS F+U]]Y4,RTZ#Q&]];]O&K!0>;&4U?N2VE
M<RXN\6[C@1@KZZ7$5FBC'2<.#7KL=[2SC < 0P"KL9\*+/TH[=TR20TRPFFU
M(C]3J&LP?LB)/ @B,]C*:;6QU=;61S'0=JOG=8=DZ1)?!^Y1+;/6A,Q#GG;E
MFO#,A+UI(DZU_0YCTXE.X7Q[O!I<309T^ # R'#U&<7J!MVJ>R&13AT:D'*D
MY[MQ(0:SJ[%FUT\Q1R7R^)R(=Z<=SY2VOLTE/NM])FVFS@5:^]M%1(9DNB([
M+8QTOP#+&5DI[< GGR>O?5I/0"2H-EAB#7I$X( ;A@'# *'+Y+'HCY;CR8'2
M')/-GAMQ5,B_K3,P"F1$WO[?BMTLYOB#/W;GO[)=XUL:/H"C?PJ<UPWBZ],L
MJ-?<E\%8O<(Z W!B1]3&W3VF+LH8400B']"H#'Q+_7,L4A?)Y_J+=%VIGR Q
M].<# 0!T@&:UE;/HWALF!KMLV@!^K\+.1H*"7RUK!W@:I,ALL].CHFRY!,6)
M\:Y"J\SP'S@TR8N_5I("/KK-__&06<!;)_.2ZYC/4\M#^AS=2;PJQ->GU?F+
MMZZFP%7,+"Q\:^#-O:R5X3>(W[IA-^3?$XF-14_(@;XZ$@$D\?-WP^HZ8M=!
MJ!KMQSO,/YU.S)%JZF+[KJUL,Z>G-_"V=)L=_82_H7<82W^#:%YFW?;+D8<_
MWH>F\9WF"4DM05\XI7RAM][5U8A5'8E !VL.1>I(4D/^ A(!M +3#&/ZV 3]
M*^MW!TJ_C;H*0Z8*R'I 7/+M/XM#OD#6."83U<97M'R+WT_(TP1_B@KY6*&D
MLQE-DN'7D59W7R[IBJ)PJ@;-,T3);=#QD&J0JA5&_*34IR0U27WO\K[7D.;M
M%GVL6#>!?X]!P+-3LYCUIC+2#9U*X^)JXZG)3]15O(G.)*.B;3375B[!WX8
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M"R8I;VO\#:'K4P1S6-Z-L63XKI>W S2<4C$>U1^PZ"Q/?=O20'ME3FL+' ^
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M=*;#'[3$71%Y.>3O>Y\-JL^NDDMDS\SF]G\ G#P 6DZF?[BGOZ!Z,[?P[9_
M#NB$PX[.$><!@FB(K;"CD/4E8/LR RC]!-]+_MC)PU<53GY >0;+&+'J?1ZA
MR=;>QP\[N8Q^'5?E\KQI"&OC)/I2(S+-MJ.G>L)FZJ2\[#+\4@)D'Y*?Q0AR
M81E,C_4;D:3&A#27*FH"Y83C/EZMV(+H;.H6F?KY7JIUY'3S98G/2*VMA, 8
M3N'10MGD<T;#-U>EPB9F2TNJS@.,ZR@=\]GPO$753^_QKU8_8!G_;_:W_L/0
M@05^(?_4]$+K'M,8V0- OLS?9XEKDS<&>*;C,7*SFWW# SI  N_/@&N/S(4N
M"KYHCF*[YE\.L^I9.]I\/KR'FHP1:SC_$B'LR(*MV!\@ER"V*S#D0CDS'(A)
MEW)9#E>>DLQ&,YGW_[7$[O$Y]D6LZS9?YEU<8KG8KL0,07W@:WE_&";/<)W,
M.5/Z-BY9"#G\^\W$:E93X;XT^D09N'PC>7\.=PC;*9-P8Q)B=($?#,2QOTG:
M_N;-L!0SF)S"EU'ZIT*/XI@1[3X/L37OE2LC3_L5[Y'D_$19GD%CAT0#FMDY
MD1!O$5\/X'9 <*++"X:)4#J28\$$C;RZ3=^6OW?>(Z@-""=2#3ZMBKJ%B-^&
M\FA-&(PM'_=O<Y78L[!9AP2_W)B&,3I=)D!@*\/PY&95-4E.R/(#8$%C3QW#
MP6RIL+#I)I!-72?>7][!KK%R85_/R?5S#_WN(2J2FA3$]3P^ =,-F+AE:"8A
MW/4V%"@_F3D=$>"?DOZHJ(5[5ET/N4ML*'2>@1?NFN LQYE<>E73I7E-?QHB
MC^=EDY)?+!(8#_DIKSG1@ACQ6F[5$[VFK\42R :U(,TM,HPU%[R! 3)[C&QG
MAY<?&Z7S5SA>K33$WXHXY4"/>C=3?S'AX,XV@K*6SZ):4N\R"9D'^$13QSJ&
MSE:67/4:I<R:)[IN" L9BW\![5+TKF@94UB$SDSDD]]=R]54$7\F8?HA)6UI
MEE#.(/<$FX4Y-C0'5AFL59DUOLTG5(VHUNI>HC'X&'R)V5RUS&4'+I2*/>*W
M*^<9J+6.U'@M$!S*5NGJ*E9&F)2>M]MH&^(^4FD_?;IW15+5MU78'VF0;'F4
MH SE1_P]POEE9P;."B73@P._#V4O*@3 NY !'IO;8K^(. N.*CS(]=?OJ;3A
M6%\Z-_9]N07IL[?V;QASR@[TQ"DS>99S/"D**M%3V3X1=4S.=/S%9VW(G-PR
MTO_H+VLA;X>,ZS*"1IVH+9?YLBVF7NMD//?EO*!(%H7N,'*N&^Q</J/]L/65
M%W1\ K[]%+#4,4=>Z:6NR^ZM/E/;O_)#._>1"8=##AY/XF!Q7B0R#-7(>TZ!
M$(1$,.E>9QOJ(UTO;)=J'P#[+/]4#V]TN5KT!MZ-L\(G7ZW^J:B+&DS;WI:E
M=RFBK^)C1CL&K<K,6Z)P6WYZ:1\9$;5+&#1KEI1;0HA-BVG]L'Y9FM%:2'D!
MW8#S%U/K<5N&0I3'_DD(^'K*5QBYG]14C0SEP;0/0T;M60=)0R*18/17C!BL
MP4-E>@XAI )6+]JU$L-!-C($(=.53=5LX">W(>5SWDE;'<LGM+!E07-;\?/:
M$FC]I/$EE;/HOC]HWS7);F33VZ#837#D$9R]FHS\:#/)VJVOE/3Q@FZ++ZBX
MO.(S^-@%W3L!*UDQHD,B5"W,^6F=I2B4"2D_TC6"_@"8_=SS % L\!GI87#M
MZ69Z*LE2NN=S>9?FH H&4P:QUE(FNW+C5_(FD88JDUD$GB48 F-#F]/7B.Z2
M_FMO':=#T[MA0S_[[):!E8/_P0I/=QY9X9T,FB06N 1D%"W-%$L78\,5[I0@
M$9%,D^Q2Z[:%-5NZ<<)?Q#[=\B02L%H.PT"2WG1O#T,(%_K +C_90[:B^U[0
MO7]_5'N[XNXH>7_L,RDB4[73,3!"$4>JMN:K+!3SA=;B[%,B";6<I&^M!':?
MVF!!13=H=/<G$4_E_0]IZEE[G]A,JA!F7ZFWTWA<X3OU629MZ"E?R)L2@H19
M?XT+7W59F*+Z44S9769X67A?:TZS0QP7="M/D;6D OL$<!%24PG!:!QG%<8"
M\L1NK@6[G__32YG_M[8A3=^W49?8"3]-[\KKH=VO(J"[?9:1_&>C7\#Q 9"<
MZ1;+-01VE-3\Y8TP-#DH99X\W(9-!W0YGYF\G> ?(*E+-2#XK9-<UQ\O$U8
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M&_4O'>L]HQ8I)^: T"^%!RLE+A=;(>&>N[RD,D/4[Y()RH3>3_;VRJ ?OZU
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M8?DUV5L'<Z1M.7'!5^)I"+*C!)ST2]"\X!; 34$[GNK,62!GN"(+(%<"K&
M\NJ<X>9;C3D]$G:Q<A1[T%IY=B#AS:V*8T=,WQKMMW1-KL@&)4$J83 >,7,%
M*2KX7L2( K++614%,6\E4#/OFLJ$3SS@9YE(;MJJN1UZBKJ(3W4I8I%6+#5
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M+P^HNB#D$SM#188GU]K.:2[W*K8]L4>^#ZMD$&\DN)*@+-!S;IPO-NNU_,T
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M>52X?//,P.93/77*Y-&_%8.&>698-<U&&\[*-&E7U*=$.*96.2^PWX0$V9#
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M)?XAADF*7U^]/]5^4-FU(I*]BT-FE7'\\>2CG)<)8C%\,N8CA7_-:5R;.<!
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M2+I_=M@DF?]P_Q#,$# 6XO=F<5JW0,5IFMQI\-F+14DBU-%(4R*#VF_MT\7
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MT#OIOB/CX]_>4L+W.Q$7 S#7A%4&JBY_<;,L-YN^^.^9^22P-@D(10C^;6]
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M<^+WQ5J82*8>[%6XZFNO!#QSSQ#/I4>R'E[D1!/Z%%W5K42@=M1@?LYZ+8?
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M.Z &W!],(Y.Q?O7^H'$,[_]B[KVCFGR;=>$GM #2"=*+]"("2@D]B/3>1(J
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M[&_7V/$^&GQ^Q5&@#8(Q<>2,R%C7LUDR$;7+?=??)?/1RTD4_M?3 O^'Z*3
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M_@E]]^;+F<O @O(OD%[,N@L-M62W7JA9BNP0T197?0&?LMMU>@DERE"J/&I
MB0/Q&$NK:_9UP;]$ C F5JKXO#62+@GF%-EGE^C/,2;.Z/!#20IQKKV*S LN
M-.3.VP/="/Y[L/3?RNV;(H5>I-K82X5RF-5:_FXH*;(>6,OD;!87D@HV=%>9
M,O09Q0!VEIOQ;*\9F.?*B7ME'ACZ[*$HS"::M0MQ@@6:K <E'X^"4> R8OF2
M<L]B4(INSF,X]S\[X?U_5\:A$& >*RWKTW7MZ&XRP[=^0"-'1'F=;\ H)$LI
MQ;A^>K024)/CMHYZO& ^DG/F5J_XFG@3QJ;PA(_]_4%P::79MWCSNJ-/?R?3
M\.4DD'&(:G2=E<P4II#1QAT#A >>S\U#,)Q:]K7#%3?8Q)P4G<@G^\.*J(@@
MHFTJBZG]8Q,-YU,JK*U#+3S/JHTU$T7F_>[0D%?3@P>2?+T!W!S\FKO+U,\4
M"!4^YZG8S 7@:/\B,)R4D.!1K#SZAF*2C&J&QKWSJL&P7QOG1M-9WIY(DQ[>
ML'M.LF,%[ TFSK<&SL(^U^F5^R%OU7,XL46;CCF,7%]N;/!.T6Q\*<,579(K
MH?T9\WC&$48ALSN_F8L7]0(31#;%9[IW1=@C+[V\(W9^\T<!X>&YAYP.KTVZ
M0*"$TD3"6FOM!")S1[/A C#)SUJSOR[^H;$A<WWA:.=K5VVM]0</W(.H)F/P
M.KC-?JK@#@%#9-7'\\J80U*(56;+#;@6N3"!G>B89YP+NM)]_&@Y^C5V5RW-
MBY65M7IB/K9%+*F[A>;C&.^3K'@R%0**IC!Q82015HKS*" QZTCK8X$ Q^[/
M@HH7F#?LE<-_Y*,QU>W]U+\K;/4JOY<\<=@A!4+#/V)SA6['-\_^-DF9K.NW
M'#X-?;OA?'5BNV8/^- ?KAWT"F?Y2LG=V[FA!2DAO81R['I\[]0 KQ5;-;(R
M:)H]Q=?HB8L^'@)O,GSP)N>)'D+XAWT[X0T?4=W&H/U&982ZRRGA%DE"B&-3
M'=TEFN92(C=1*4%SSX51/<D'B7G%<,%W-3?V-V]^U3<*9I![ZW/W.D;LOJ[R
M04UAQP\;*.J*G[D#D[SRVMG?'\$I4C%98G;O,9P52DV/DZ\0,!)/<KQ/=E/2
MG=L$EN8-18%HEMO7W8+Z%K@RK&6_(#[%D5,#AG%"D&U?DSO!*T6FBD,D!46B
M7-K%8AS8W*$5./]_62GZ?X$4]QVZAICIS B#*E2L'65)Y0?5_JH%O^%M8.D=
M+%]F]7G,8-<WQY@T^"5+\?2U3)/]0J3^[EWIC)GE4F)]$7(1XQW7O=?_.U=&
MZ;WS[4OT8V P#>,2.-$^'_S<RNZ7SA\9Z-G:J+QKG\--%TY!Z%G\@Q%(&17(
MFP]@@!6NM#H2D0XHCC^N6:R4NW^'^2#%Z,/251,D<.KQB7 ?M_D0R^[B1_%%
MMUWON1+E&=E96L3C>^'LKI)N4Q6A^SJ  \M3S%Y&\<N2G\([XM?TJ8CHG'?+
M%>$.4DEN0!I4:5MLB78:US$AE\>L5X>38-O1WK2W^R#PU#V3\'+AC?T+.^:&
MT1O&#.NWTR:Q<%6VZ_EA07^:'E9,5)[:GF6>&BUPAJRX!_'G]<]D4%)@FU9Z
MVNSXQZI'!I1O+%H-@,1@+"G0+*M/&+M'&5&EG#K]X37G_0H"XY';#=WLA2)\
MP@ZT(RTF9SF7AXU>GY*Z>P4A4U"$&)QPSZ^]/QQN8]7CZL[4I,L '1.-G 0A
M #G.HTU3^B9\UXWO\0%%/^-#C$G=5R3OS4 7WJ?2+MJG1V"*2V0Q>%F]5W$W
MFSQA?;^IPS]^8^AG[+X _"/)6F4B/%5CL^Q8\+4'_9C&EKR>ZVW>PL2K3,;K
M\NVJ1=<$6.+#53#6<P=SFX'7HX4^*(OLS*E[MC:E:"H\ABM['>A._&F2PGLJ
MOK@"3?F2P6U]=O]S_N9=;T-+,@V2B17FWSH+'NJ=$8PM<QYO?I.K[9(?N>^3
MTMUYR?*K  )(&C?F+$CP3_1? .BM39V2TULC>3UZN<YC]^@L#+6K44HFI3=R
M%Z=/TGH3>=UW&'%V%7E\A.P(;\Y<N0]3.GR5@%QG/GN8%[9\M<' 5)M^X+>G
M:H9?*VV$ZSQS&+0N?G:N+Y">C^>S;W_P\SLBHF2D#-V?1*P GKU!*(IVG/;G
M":XRKML Q!^3M6E2O<7<'+(?_N0":%?9[T 1ON[,].J;X3_D6Y\)F-41_SMT
M?U93.5:LE6S5(6\65<9 2:"^8XO"U35S'/0IYK%$.A+ L*X4V]G(V,F<B@9U
M&[H0&6$A6"G$ QPRPL&%2%>X$ *@_R/QP[\,@OQGE]+]6TD(,<]@VT.1J<Y#
MY'2YMQ!:?!X #)<_@DI>#"JG4F/MMWB=)S4"%_TNV6H],H*=S-ZO.!K\JNS^
ML//A[#,7HJY_A%1E\/%L_AI*+ZD,^!,P$*>T-1AEM-MVT'YQC:;-5M6SWNK,
M5I>D:<J.-M.^PE]5M7(1_MG!76%UJA[<5ZGUOL\+91KZ(($SO<=?G'RG"NYZ
M0MNKX\^)PZ?I-HZ;K.\VA65F?"Z7JWR6]LB?YNV3+$EM_I?=%G'J,/KYM;O6
M%8]N;.)R:0\G9++ D=)7=#)=]B:)JWEBF.HZTVI1^R7"W6HK< 8H[J4/&XE=
MOG"7GLG[W+FQLP[HUJ7*2#<D%L/;#E%@2R$\[>) "EY,[8WNCP>6+R^ %_$I
M>U6E3WV1[KDSE !!%0L^91Q7U,,)Q18ZOQSP#K7P(HIH5W$:P] 2RNZ_^ZR>
MK!5R,O_]FJ&B:45AE4\_X)-/U<+XRY[2SWP4_1HBS')I68EB'T7JZ&=&ET@B
M(_L!/Q0E,C'_:F7QX",YJ:^--OCJOL&I@K;-[4,L9JJ=*G9X,KD]:'"\U48W
M]V>U%*%OF_$VH;GX==5BHF+^T69BA )PFF;U_"-UH9<23FDL4.X5E3JWXMZ4
MO,R^4-(%X+!IK_Y#ZT IP9>8PV> U)_[2L1"?GSMT+K"C_;IW&[!OU@KH@](
M"6HA7G_"U,HTAZ<_S-(]B$>>[%$!RF*,7^P@'[<]7WF5W+O]L8L!M\Q2^?4?
M@FI1^5A'Z?/TN QI$-S2:<G\JXVJ-6*!J6[)?#@'"Q>*KA+]'D2-J*3OL'@.
M#1LBJ1Q%0+9%*+ Y"I1 )@+VY3]B)H5"EU9I1@67%>F,A%W1T5S4MJ79 ]#H
M;$AD^Y;N+](U;>H;BQN7#XN?_R$N+69L+()RB<#_0W;\?U&8V/9*\M*[UF#4
M645W<**B5@KF'H<N1#5O+P!5W9ANTPJ=0^MR^:]L0*QZ76EEN<D+C0=EL\)D
MM2B6EW^=1'__8] A=JJGY'JH%UKC%.)39/M67F:P-5L6!65M6BV$7@"L88H-
MLO+]: \^T-@0>%G/]OX&6]'^P5N^;XI?N_1D?=+,1)^ E9"53W;%EV=,$Q(X
M8G3S"J,1-:U4"FDPIEQ]2Y/9Z48-7T;J0@Y?Y)G%6>JIT[DPP>H!Y_>Y1S-Z
ML?Q+V%:Q&\8S,UHDZK?JOY1NY$RLS?_V7;!II0XBFONSK:!4EEO9#@'MW=[K
M*1(&3$5F!Z0,421"D!YBE;T5*&0T'C\.9V/.\7]OG==8[/+MS49O9>,Y_J.=
M\PDLS'_TG#;(TSF0>^I&?H/MOLQ1/2YIBKN;FQY#(=!0GRGVV!$MYH@ SAY^
MPJ_&843NW)W"H#]Q$97OVE!5"%"5+,D06HO#8'B)6 Q)$[HU=UF]CFB5K.7@
M+/4"<!O&7^/;/F\5['\$L^#?1]&66T7E@')&/R(3C#)G=O-B,V4>7!-ZBZ(H
MDT)8_T]FUG^O5IJ^P53X"S97!\92V\,(?^;*>S*V:0SR5EZ[QBV,HOBRRG1S
MNZY80C?]V?!?U0%FIJ ,)K:DK U34"2,(MX\NDBS)]*(DQ100.C_K5]00T#\
M;Z[$61K]+UF@.(2U/O:_VTOA@##(I;"?M0L0A\2-QT?_Y0&?'QN#1A+?9293
M&9-H2MH(YFBZ/ P\,38JTI@.OZW;1LY9UGC+:#9Q+][(#9+Q.\X]P9G29VPH
MJ(?3E1Q8&F[U6=-=7_1#,WMW46GI:EC,3J7,KW31UQ T]R>]-]K+F.<K[^3@
M(-L=*GOW:YWX\TTO=1+]SX2[H"IOD9)E>VLK!3/[(D JZ9O)*L]8XM,,EF47
M(E9:DE"+A\&\E:VS[YVWD$ 4UPU8591$@UC^JW.5&#_Z9\,PVG_TZO<-&?$A
MN3%=A052WV-80MEJ<D;O^_8#X0'A0ZT? QKR>.O'3H7 ;Q@_)K]#')VI4 :=
MK83:_^Z1T_5):'8_T+'A(_&QZH&-,FP-GG#<?NC;Z+ !X\[GKI'X[57M%BX0
M;86/^5B;^#/Z^A-)=K)6M2I/Z2URET>%(A[.'MQ##I2CMZ5B6)CPX,UY_"OC
M$>QYVVB)"\77EM'X(=(+ &%?B[;CGEC^.(2U>14T69;&*G\\(;!831"^6D"&
M*@_U9)N=3NV 5B=Z;*I+O+DFP7?:GY9GH.^!2W<H XS!&SU?6A/M. B5CHRN
M6;J'-D_Q$7X3J*_Z)MIGVJ8^!,NEN-^#>"+<8DFGGO9B@$@PCW&V<O^S,IS7
M](UO;5R2GX9E%/W5%,JN=WS<@G%+GD^K2-7CG9-,*?3XO66'<D%=053!26XQ
M7VA:?NQ-; 8NCN+6*INL%E]YH>_1M[CR+4E4N:^PNQ=F4SDM'DLJL0'9]>D+
MIQGC8;1CR]M;7>QBY7=YS7B3LBI]/LUH>;#>703+5]\_2U,"1> D7AX<EKF-
MK)6V9>OF^*-HQRX ZCGV0=I)6YW#.9Z>#6N7KOI-8VMK\=QTV;4OW42(%!LO
MHLM \U_:?_]/SN?G3L-Z,):&]LZUO=)1*(FOJ3OW1D$I5E48=86>P>#>;5J[
M##N^_GMJ*4E?X(+QP?#-TW48*X0&LWR)C0,[^U1HP@1_-)F0/-;Z9'"B%:YZ
M_&/'Z'?&!4 J:!_?<E.!# -\"O2:S5)V(=ZC$W$>= L-:TKK>LH-"7,(8[I$
MX#8OO$Z4!-62BMT[6QTCIF*-I@3%O0;BOLG>?-VFT@U7R9X!RZOJ!FQ+NNH[
M0O+LM)1=0'J<,WX% ;>0KNJUK"@QICT4J?.5L1$JQO;!\92W,\'*(K*;7KJ
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MEM]XIA2KY9GA>*<P-]K/)P6[MT$&PJ ["LYAOM0BS/U$PU9$.V<:[(R4G2"
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M^:PERB A5GK" 5 Y5.?T(72%J[%6J^FZYTJ+0N E +=Z-I0&K+B_-5X;%3D
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M12HZ_=20K*VAV(9<F2J>@5EZ*$N@)O=RT*[G_/L,'."+\/6\L@0#81A5S\F
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M.$'_Y+UT^:/_$ZD%)7W>0=!>Z?9\VC@PNGG99 RT%7(*N%+H[]1AC+E_? K
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M^_L;-1/K]V[!")57.JB0L"]Y(T]G5T=_<W)>C-G\0&15H-3G^/N.T2\_SG+
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M-CCP/B)3$.[= &?6 [AIK37VTPIQA0D*4=<P\$=Y98&^O4CL4C#96@;\*#I
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M+7&:A_!J>':="T.%P?(,.Y*A201L3URA<B7B?*U+142XQYRQ]P6=@=3>^ZU
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ME>:* ),%#OHV9K3!IEQNHS1>/YDZTKFC264W7U!I-Y/[+I?E2'%@RFA)/(S
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M8[R,;<O"0W5;XI+>;M$1(XIX0]9,GG0KRT<(S;[Q.W#-V\#0)-0H]X CN[M
MV8D$0XEN^6+Z3^I.GQ6XYW).X%0VKAYQRF7HR#N1"L3]VPZS (<R.1\]Q8 J
MJ_D<9FR8B]+'(4EO!>%53O1+HV(JUXXYT3G]C9,GVL3<5P&6+Q(//&=A\KIJ
M5UED:'A;IN_M\D%?CCE2@#$%0[FA&!B%PW8%0QY3 7&#6V?!7R$7ZYB\B;90
MFGZ6A@ZA]:\%+T!^(+]>Q[?&-T^.YET;V#+%C3*_,+"K<%WN)[J0E"_%5U9/
M]]5;&XI]&7\_AXC(SQA-5"> 7![$&<(H$#=D!'R#-)FD2.%UQ7R'X&E_/<FV
M.=NJZF6JB,N]4'4JT.P&4Z4"B%E2 01301&PHT#>K+_?YE!EK,P;WSL>TV=/
M!P7'C[EBQN!?B:Q-M=(1T#+08Y2H38=;YF3 \)%!0X-W)A)E"I8G_:YN\3</
M);_C?[9@?# AM>5[$/OK3LD_7,/_BV>(+J4\4\4?\G1LTJ<%'EO,M:\D!$V#
M(J@ O[PTF[^%49#N981LOA*R)V86Y4[.I2@YH8])G^VSZ\L:)%WRYG:Z,U9=
MR+ \&'NGJ/>G.;H"T2)V?F4FI:E5^![O<RE/+]M$G.IV MZQ)0@VLCC*71+"
M7QN%K2O<MB),@(4(A3?ZU2YA?$MK8Y_%"<?SD26&*<=A3KV^W5&6Z"?G>K/Z
MBE?X'@=5_;!)MI!Q'C-;N.:_E2W"$-H>J-W(Y_OAXAU4RT.VG#ICH;@3[/8E
MV#J15DB%3JB:](>./+V V:]LR\^19PQ!%8[QJR@!TMEJ5)DWWSI_:$J%:R?<
MP6,DI3E8D."S1P4BSR>:H08SY1A3WK\0$]WB=78*4IV2CN11;'&3]"A[E)1^
M5E9#+6I1<<]B;JZ!Y<':U%H[V:QI]J&*S;><,\_2GG!CT1H<E6<3QAW*7+Y@
MA[8%OFDLQ5B\)D1LA^&0$3!'T)-5CVF5TN-J&>,Q V@>BN@MDBRN++%36,KQ
MT!F3@9(%:(JEU!,L"W0[O1(O_<SA-0_VGE-OY$_O5D-(H#/'.:<-N:U5HE5%
MOT_;@-2YFRLW'G+:A4;A5LRV!W#"KXLOI@T+O72+/3W#1+-:W="\/YS0#,N;
M15(.88O+VK4OIZ;P.DUK(U:-M)8V+#EOL:@9%MF,!13YM,^RQ/1LWI?,!*?B
MT%&;:UQ..!=+ZP7UNL+GESJ*GH]P(Y]"[JQQ+*KHM'1S$(37?\Z4?7S^@:G]
M-!,QV*K*[7I95_Z15>?-JV^6[AH@TB?VCQ4G8!P$M[-OPZM<%R-]B:S"QI.Y
MP!;R99V@+\ODBNX:,Z--1$(G_3JX.9N>O?DT(W<KPS6&!Z('],5E1 7S<S88
M\S,L0%IRWP0RXR\$1AV8GL\-"!\PF64UT; .8N^F%:DU+HHRQV>^IA7IO%+7
MHO/:--LOVJ\H!8YRI!4)W-YB/]0BPE\00Y\E\>"##,$TF7LIU=FW2\[D_8 \
M.) 02>3QM\.>JI3*\Y*X)!];E60Y%[%\""/34?\\_:W$HM=I-4>0I77\&M-2
MG/![\ZMS/F*5?O%)$$R(FKA1\(@(><. "AREQT!W28F47>3[.AIYZ549XZ4;
MCZ*_FSE^R=JFPR$?=4#64FE58&)4 /(B^"RJX =EF-T#-,$>Y(#TW*N7F^DT
MV&;$?>"!K:9\DL@\Q2@P. 7Y9!0A$@YQ^@&_4EGE6/&D(BYH:3/:MGM;8:'+
M^.4/<-(NAJBJ"\$4UEWU'J0"18%<@2\*C*S;.6Z*>UOGS6_:G7GPZ'K^A:K\
M&TWO#VA[&=^RX#MAJ_"V^\;]2*!54ON>0&:HJ#R[WK])]]!_(KOVWJNTHBP:
M5$C5GE@ZK8C6!]<X_SNZY?]0_P] K3,;;Z(K?-2K,<.^S)0^(96N$_C[[][(
M7@UM!:=.^H6<===FY 8EP43P SI3W:.5S7L3Z&,K,G<@"R>/MJ'-H'X7_04_
M=L*01%.8+LY@\8*_56O-U7[F)V?<$V2/![D>@=$,KNH9T%&PM+_LY/:SP?+X
M%5>N\T<?%S+0N1HTJ-1!V&D^X!A9I[G7_=-36/V X$]X6S6:F=(ZR0RSR)<<
M>EO4>E2.?\+BS=-95 ]!!F?0#&(LNU'9<\9\''#>2][I]!/SE4M;W=+)<1L%
MU*9,R?VZK/*J]T(XXG9.C8'.PQLUL<Y@9AG@4V3H&>U'PSF4;XIZD$9I5O$+
MJN>'WRVT>I"<"&Z<K9!#-O-]M^4.7$M_C8R"<>+EVB=+:US2.=!]J\A,1Z<B
MH5CF0_SOSRA\N*DGG+C(R4(N)-ZZXA;Q^J<U[.<C[PGTY9]5IU+A:<W/^KU
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M+O1\:N$6?5QM:*U9^EDRXF2=2DUKMH/$0V[K/8L&: 6H 7[*]005:-+$JBZ
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M,FVR\5<^S(ZR^YW+C!+['W,RZ[_U8X#[2>O?W!<X4R@58-%#7%?8:OWKD #
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M:VZ+"Y^SJI!?XV/,_",PPRO<\.+1A0U#UK=ULN\$BP)OJEKJE7YKK54JW33
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MXR%B;]:9K!_4O.1:LG?8?T6?)3@(WOS _PUHG:FVF^PM#V_V(OS*4 &T0\I
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MH: *KXZ,X9>//C#N*#I=B]'J=V/N^,!()VUM,<@X!6^E;E''8L8,26-+=S:
M7]0N>VB5&6\*?E?,G;NW-'$9_:Q$Q0^(H7/#S\41B:*K:OTSA7/W7E?;@Y=1
MX*]&,-?O.%(B_#W :DYC/>>XGAP2P4PG@(6;<9A^X $ACG3(2A'@Q?,Q#K],
M+JYY @BB ]=>AJVBP$<_#$YCQIY^!,^D@'=PP.-=,=)L^0D 'GD"V/Z@QE%K
MV%!X GAJ=@(8ZH+M#^<</460H.=)LK_5%C_Q2>L$$/>2^$/Y#U0</H8-12>
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M_3SYV2=._VC_8)G_ERM%_W,2$7?*.M7CU"W)"C!B>%-E0&F;0AYH2FOJF.L
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M^8RLTFCH5G5<SOC0%/IFW4B3(73[K ;7ZVNJ&VOA@'/1@ -W(@TA"GY ?P)
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M;1*1A#B<XTV"A7VM^==^9H4;C=0U@7RH&3 /P7O!]+/KQ"35,R:CTO%A!;M
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M._N<Q\ 5Y(8.6CC[;2X\3P2E=U4X^UW=B&R8J?"B?QH@,;H,'^9.62>\VU[
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M%S@?5N?G\1\YC]QWV\J87(V+;!'QS4$A>O@@G0F6KR0L1$3D_>1#!_P+VC:
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M6A=BGM?04+BXH]<2/!Z7'Q%95>GNVKTI>15M\RAMV%3#<LEUKVRH#\1#M*C
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M\L=\0]]=_<"[.OK24XK3<L6+,R9RZ@W3W\B77CW5'A=5.3Z*[6(16OEL2M$
M8[^S1IQ \HZ94'C=UPM9Y58.C\YT9-J(.7XNJ/O^E+0!V-Q0_ZGW$25YQ/A]
M )7(TC9;U&\8(@CI5NP]U5^S(]K8.W"LV=9^5L4"9\#D?L<R5=C!'28(;3K4
M=W#VN)"E::W,2T$%\_9JL1YWU(:G/ RB.%=CK>3GRI\#($F6U[5'&7,:K4)Q
M,2_N4>V!\(/L3-C6H'USCD;JLD#ZQSXCI,]/I/)B^U:*+%:\.5Y-VPB:V*%5
MN?8VY7W2H5UP(V6LE[_[CI;)'EU/#+.\:R#Q->39F?I['E*]J0-504#U-F7J
MPKCC//,RD %K^T A_;Y;;BN/\4[:TQ]O,STNG^]\66M?7P\?9 (AR#X7P)[V
M?U=J,6;N3%UO=4:F>I4;R'M1)R!)*EIH;?"TJ@\9WN:^?3O?9WT'>N?>.A.E
M.Z4)7"8 5\Z%-NGI7J'^2"?)=4W]M:)QB.I,%;"/_1<Y,3KC0F7YD"?:=CLV
M1.YQ& D9;<6NRV,F4<6ZB8+CRCR#UR<-BI272&[8FY@GTSS<$%;ZX_C(KOJ2
M<" SF#K#:'%0>/$8;X[VG9MI0[%I];<2(Q/^I0SAA,#'WQ1:PLO',SB3EJEB
M 0;3YD1NS!)H]9Q7L6Z/B#I+BAXK,7*9RAQRM]KB]26JRE-VRTV6FQK*>SV4
M?^&LL%=<5=-=N(_4F1EPH_"71!U4I4TB?NYYQMEA<LE.B1D27?"S*5TALM2M
MA(7'ZS8LO<3ZOP(%K\OY_<777HY(N9<DR&[*X<PF>XY3M $SM0  =]RBU^KT
M4'[Z7<=I#=]F1MB/)I:F[.K$JKG=='A0JM1"1&_RJ'J &4+* 1LBVSA-1'F2
M\ES7T$BUP"2Q_K-[R;3=((SJB8H546RS?5*&RW(8KJI+]U8S2TP0:>4-.U8/
MK/IYA?N.)<;^:+?01A)EQ\O4?1PTO]]'GQMR)<J772;(PEO#?'+UN$,6,["B
MTR1@\JIV0'/)0B-#"9F7I$=4&ER#-/5!0&)$<OC0QAEO/H4;1.HE,*Y3::[X
M$EN-6]2%32X<H/,,I+ME=@V:@#BHZ^FJ9ZWNSXZ&198UUS70N;'N7;AV#\WV
M]+E(M/D"K7Y6BZ[> @9Y!=>0T+W=-C7/_IBR45ML@]P,KT85D,G;251!G>_!
MSQ\OY3^ ZCD^>;#0V>IEZ'TI8EW&^PAJ,[H%/ A\MN O.8UD;=-,VNS%YR@&
M=]2V1EW >2+FW\6]N4_KRN6OY+QD(XAJZA8)(I/D<BR!*]8TAB4O5=11]@T*
M75@RQ.?DRE,"= G'*"^L//+PQ;I[Z*AB/58#B&YVC$=*I$\\%E_K99\=>%*[
M+?Z05IJN&?L.27EZW0BJ]T J]*E,CORH3?WFI3M()7KP\J7Q1>\RG.$>GI9"
M3=Y.!52#)M'T"<IF/76L?[@D#$Q=SQD4U=%@GV%GKWY!)L5)(%0?;*XC]S<^
MA_M"U#))H[[Y]XG,OG*;$T&ROS]6E::_@^C)'YBDW.0LH'1&U81R5IUVCR<:
MM"E]N"5W7+T.;VQW6??CQ[-3]_,<$D,H[X$9I+'I-CX(AEC?@$8,^I."-W[$
MP0&I27;13(KH1+T7>65YT.>8:3.KJ-XA^?H(Q>,LSK7.=]-=CJK6,X5&4D+#
MC@\=;!CC.L"+-\S^FE.!;+8*%R/IOGS;,8R)T)<B]:1+7S>6Z;%LP!JT1D"0
MH1R[BW(G[S4.Y!M1J!9@E03 ,^K_" W61!-$\9TJ+."ADF,2"(&INZS;\+A@
M<O1LKCJ3W0SGG2C.<D#A/QCN!(M=7A=/.&RW&I6QZF7=9YEL#HH&T0M!0@V#
MLKWUE!D.\\7888FV9HVO1.F3@FQWMV8']'I_+1)]GO)BT-,'YLO?:V:ZJ\3#
M(PUS])<OZ@FP84TBE#8?<C/\5F3TY&6^;4$4_E_ _D(F4<TBM0<W,2KQ0I>0
M07%;ZZSU;LM)26P@T9)=%[ECNWH^+N.)\E>5<[JM#I2!?.GNASX_^B$BP-Y,
MO_?4VF$V(M9T2MVDSOC7)5&<4K&_.G:BZ$I@O*"ME8>]CM,ZVDMH$4+)GBMH
M8V2QND2CG#7L:,6HD[M&;)!+?7IY;=;3).)KX0R4:=H\A="BNI#Q-GX5[!*Q
MD?6-*<&UXMT;L&;OMD&1&Q94$GB"-6>NU"4DAY2BQ41#=96E5ZR3T:[.>*BY
MLW5+QQ=6_? 'U2_LPT%JH,0DQ?&D_*+B:/#UE(E8M_C1KOI2@6X;8]_C4%I*
MW S#![U_%M4=W PPY],L?&ZN]^1W1GI+?PIE-JZ*V++E"#($#WFS3E/[OBG.
M>9L7:C5FTH!@>7@+L!\F(]CG+30P"FC<#<1,_:@R"^VJKTY?K^B?JK:Z?+)^
MGRI>B.-7/:DV,K_6>U<E$%L,#9.669V,;^>VS#Z[H\)94'DG <5EFW>O[^&T
MOOCZV+T%[V'IYIIFZ9[I53^8YFMA$PTF[DG5R#ENUE'ELLE5[['N+H"]&=E9
MA^SRA]Z>R../JT1G'?J]%WJU"Y!GD^_WTPPW_)G0EL,#] W(=I4RID8W#BO3
M #0#IKH&5=PDDFKAP&\=@6AD7,OZXN!7G5LX;R?P!<EJ0,,$@'K'0YU#6]/[
MS:AZ2#YF:NB1!(A5_=6 JF?.1#.;U;165:TR#@QFP&&!///>SE#R79A]!6,6
MH>!R6J/^W>G]=H&"/L3(_<E>//CW/$,XT]W7C2UQQW"N-?.===9XE48)HGQ6
M-J%Z;>G>O\QV-5"%G6J@18*]HACE@'FYP2G3B,)'K_&^9I1>N(_;]K#%PY&L
M0QXCZMEQ>._C4#R7N&"B$U!D$$O[2Q1<R;*U.?;PB>-'4:_JJ1Y3SGAH*R-]
MC+1#RCOS&8Y?GT\]WV\9>=[[(055DB"2F<U6^T>& 2=*EN!IMG*.O9DTFS7K
M^W;P>DG/SI4SHVACS1J&+:&ORD_&R<4X*+Z3U0#+/#C2PCWJ^^A(YQRGB[1^
M(9KL'GSWXE-:$A5<SJN* Z41SONSV1'()N+69EN)@U;H'>Y968 ]LOQ<O=H"
M]6[O:O1HF6D<+*:N68I_*6E9;[3#X1Y?*%RZS/38H(J&M,F^' .AP :@#-?X
M(W2P\6_N+K!7'\[L >FPL278P5YDQ1R5QYN?:EMU5W\LV0>5J,RP&:8:8FG+
M42<$>XK6[*B&TC)Q*1HZW4%K$@A+21O^32%E+'%-:^&9NS.5-^87&]I';BY)
MUW%\(YF!C\PVM*GCCQI5M.AQ)GI1#"1[WFG,1DAQ*"=T5*6X"!S24%7],/,]
M)B,)G,A@B;[2?AI?TJKZ6(28ZQQBIK>([STFK#>EQ:X=S&6'\Z.H\%^6#;'\
M-QW^-CS%\)&_Y89>;*"#[376$D8^)4@>0YGP*JA)M?QF%,C&<9GW6O6U<,L&
MR_?<$'^& -2,39?!DQ96IQ.#=WJ*2 0BZ)XM,^WW]G$2K?V(^4ASE]S)=@A&
M%:N]=@L@]P8:5;TX5$+.?:"J,5WZ=O.#_BA&4MW:;\WO)WMC@[GLRW?TRS^%
M71\OM$H.8R*:VV>ZWD'")_>?]7HFOLK$BD&*NVS& %A\Y[ ,*\J&-(5(U2.+
MK%7]A%M CV+]%R&6T$"FB<H$>0J)068I<"96 *4ZZ+5"ABRJZTRU?*?3;+6K
ME9G::RCT+G F0R,> 8JYP+LA]C!1&LV?Q/\QX+.K?&DOPUR&]D.\V'\FG38B
MN;3H-N!F.H5JPLBTAP]Z+G.@)9$>0HH?%!U.3)_< NX^JFV>[I3P9M"LO5XL
M )2%*.\DR1N> R=03<% %A82@X]WOY4D%2;U2?&LB7 AS. MCNT,CT1TEI"9
M0P[!@DC3S )_ FR("Z*".NS"G%X@F/84ZNO<33:O 0J_V.ADG5E!2J2,=&UO
MA+R>V2RCL<^>K6QPO!0:K/:WS.UOG76J-'U6+K#NR3/8Y>1(T)=#W3B>CYH&
M.U<3IRXF,F:][XS#GJ$OU;':WUKEN4?*?H@H4F0EK*C\7E_=[AD!KP?%Z0\
M>5X02U^NQ1F?K 3;6_FHH.?IV9/.FP2[''!<1 ]@B&\5%-6/8VJ 6?KU_@SA
MB* K;A")\$0#&49HI3EFFQ&6$]2C_$S+GZ=V*N^.V'@Y)V;$TEL.HS'KD?O)
M]\E,7-Z^4*/JXX*N!EE[Y9_I3_P8<Y'ACHA]")VWN_=C8;\I;NNJ4>D-7_VY
M94KZ-7^*VHBPF]GG=\\9]7MN 779[:9$6-C3D/5C4_=,QS8-;TGT;)?FP219
M+73#\=@S-L_U7H6O[HN.$JOCBO7SWA7RG4#0^)5\U6(;G3/-/:/&O6M95.HO
MSQO"B:W$QKSZF*2@)2KT-O*T>Q](J]TMROD<V'!6'%[26(1:4&W4ZY-*,2>_
M0=H0>#.HFQ2/L5^7!MDR\?0$D4"J3X=/_; ;;XBJ?IQ5K02O, H%T7J3J63L
M:VDV#H5P&V7!AG(;5@[FRVW-[I])F2$U'PMU'Y#F%+="YL,QX!F&'E_J[[#J
M1*3^G ;W[M[9B](6O? E >,G_2KHK++MQT5THVY0G4D'>)_F)_R77VGP+F96
MGW,%6PD%KV6K#7 ]I^,.ERUAA.5BF[J!I%-5U0W9.KV2G'R',SM/O-R6.YVN
MFR5]EZFQVCX6CJQQF!U'#1_QRD+AQ=_?NE=(A"!P,LSGC#WX='%BD?&1 NXF
MJ_X.)KU8IG!.SN;.Y[ G1'E_?'Q0#5GP8Q2L-YI7SP!=:EK]FS'F8<8%",2G
M:3C?6)"8<\P<0E<R[9+D.YU"3?D95U4>\'1"N3%;G@=G/;=^I?\C:@%Q=?X(
M([3:WZ5KK'G@L7I>CT*.=GB3I.M7OE.TFCLQAEQ1AJTI==+OYIAZ7I<)QE?Y
ME1S\IM2ZXD!AH_,;95U.R\/*HIQ3GWJ#D,ZKSM38X]%-WI(D7BG*0[@+U'4%
MI2'%54_<16XWNJ40B4[R@\% U&]HN@UKN@E^.KF8<0?V4#BAPZ-;QHXR?T^H
MRK._OMYGWK[4]KXKJ;P*[M 1B,X&LKUXCJETGAM>DUR6Q+HT'CN_V)O_9:V\
MC1MU%A0UQ((8BY"+3X$KYPYUJMT"/@4MJO&=V>H^7?SS1:/AN;XCD4ZMXJ*,
MO$0"D>$_@J54##%9KU,I*U^CI9D=T;> ?D$L&#&;[^%4E/6-C\ T]3?Z4@K\
MW,X,E62V;$>A-OEK+*GER*S@%D#C7)\)(AR"C[-8684M&8_UC85UXK6B%D:^
M0?'&C1_9L!'0466Y^T-?SC/"#A;0+#TYS^)4'8'SSQJ41IG(\#(NJ("_:=>Z
M1!WRS  W,[,89D;7V>1%\N<Q&_S F0L9'%YZ@?WZ]XV^%5\]:H0IM;6BB3@+
MOI 4IZZ>E^AJZIY6;G[W4!P -9#%'K;KKV?S]U+K9.]_:)O1U%ZN#P+[;6/=
M4(+R4^Z-Q^Q?$]E9USVE1WS.EIUN 0[S;,V@5@*>MGV3HRM*BI^#P?61B5Y0
MQMVI[VME/+KR4D\]NNX&XG@[!7TF-UZ>?P9KFKT!J_B&1!UKSLN9M**<!YS)
MO5W??JTT]8P3X@@6A'<68'G*#9>NZ">+E+4*/0T" W<7S)Y>X2O @NR87/V<
M+,(V:Q79JISO^AS7,=L,_QHMP<2&F7U>H94$5>R.CB\L+W)]"8$][>Q#'4*H
M6[X9FLI>3JP3L.V:<=XLV^8+Z:_^J!3QW18^-*MKZ)^Z>CY%\GOY@<>%GO;L
MLQ8.ZJ][Y.Y"5VX9[VSPM@KS+/YY\,5.!DOJKY-UVP(Y[;6-35O W@;B,5DV
M5"<V2)MJ+(L"2@C(,/EL%F80.T/]9N_>6F<_[(9S)^-I;:O\6:^,T KGXMR^
MF7C@-*@N,+H,^_X(2FZ"]Q7D'R[)?);;]]ZV8?$L=QXX>C&%T/CB7"SH'$/)
MOHU+A>RHV R:TQQLRN%!.=YDNGY^FK$FMC*M/P,PUW]U+H[X7J\M_][V[XH3
M^ D( //TM_;:2C MYW/A/(II$BX3Z(TZN07$OY $$0ECXE]"6P8WWTY[RO..
M?;W!:[LRQ%Y6V=-_M#O@_>B=DB-HO *E>X+-O-1>\-98DW5OLP1YY(A5#V*(
M(^E-#"V# KL/F2Y@5!_V\P,7D!ZN_LU%JX(?R(0]M5.TJ@_F=X,:@GH<:92Q
M9J0#\0Z\SKR>:Z_6Q:J3,1XS@U#0I]K=C$3!CG9\R5P+(Y:&Y1KGDBN>-,54
M 8XEAG!QJM' _@S_M&5 6W9"H9MU2L[IM%/A)?Y$]-XH#P:,KEPFQI95>9N>
M_0C=X"$2.%_K'-,H"I?E.=E^DP /G$GC<0A\^_0WYAI\2@TZ$[@LS7\)?0A^
M8;VKJJZVGN&!2R0W/CG)G (8]RZ'Q[:9O!TFRA(LHZM@Z16'ZG>UJQ(K\[$<
M/DX3)C6V_7VSO]H5YD\',?4NZ?]0-6ZN00O[12TQFKT&@=,_0>5?LA.RWJ5$
MQ\ 61'W'PCN?][D4%.Z9R)#@NO*L0:(Z<<(QGMBOCN4[)X0Y=MT"(<D_"[*G
MD^32!G<&$AD&BXW8LD<?O+N<@>K<!Q-T2U3L=Y)-0@IU()+<&\R#5)U&66^&
M7:G[2O_IO&EJL8%FVW$QW['!-[2HE+2TR9263"* Y(GI+0"6ZXMMPLQD6*VI
MB[ ETGQI.:>L\GE4Y)?-$7*ZC=+O5AVCX),_^V4=?;YK##G(1QUI8F,#2K'1
M1N'(>,'GO_>G)?5MM@.'=RF)FXD# 1?Z@I?W[1M_(H8S\3U4(Y8B93_(VRYM
MP*Q$X)],;;Y<R4V.]:S$B:0;BC^'CXCI!*-PA ^"Z@\_8KK",<R/ZN[R=2O3
M2P?1'^?"[?=XC=8&OMHXK=GI( B)SR#Y-P*&I5C6Q!\ ZT9:@FMXYG*&P^1L
M=B(88X\^NGK:21#)=#YB?T< 8L$$W@B:>^JS,2GYBIV#V"5T), EZ\W/MTE-
M^+O2NXJ&AHFA?^O;+#+ZT#;PN&C71I^3H>SFJA8)795/+^2Y'&CJ%+?(D#2H
MNOY)[^(IO9E#8Z.OQQ$&ZU4!ZY<OJ6X!H=;%=[?M+=O=,//<S^IK>N/%@B0P
M9//]VXBT;)7D<[IL=?NGOGE%A4Q<]K'_).3W9:D"?MT_*^R.LWNE+=B$HVB(
M[5H'11WZ>Z$K5%#3KLGV!Z(XDW^VN$FR<BO7L -HJ),*!;[^AOD26:WQ]MU+
MF8M9E_/B<&?WO2[[Z)_MPGEVP(=U;O02Y=^9CGF:4$'=N??'4 (DLRHPI(/Q
MD.\A],,MH#&+C"#*/7.6X*=LBU-OQU%/:T<9EH5T+I7$[-U^KOV\46H-DG,P
M_^3\P*_:^"WV%F" 2AW^RDO.6/GNVBZ0U405E;SN+Q'C8%F?W8L\< 6+8C1#
M(8&@?=$)BME-1GPF'CG,VF,I795$\60D3_?^M$[&+'L1VH?EG:U$Q*R0G^K$
MCXSGMX BVR)7%J)"'R"SK?4 P\'P5<5W  Y4I/*GX=_ @OQ=-D8B0UE!:5)+
MU\#4U=QZTY U38J=)NI6X[@:*M;44X@_S]L<UC?T\LN;>/<6&/WT7+E?YF;E
MUJY\.I)\A';U/BJVX[ 37UP^N]"F_65W"OD,9/B9&T]#*W9]KCG0B9*[K!]D
M)-K)/"=G<4PJ6:+<DQG7F;7ZEZP:_Q,E-QL'7A0: E_I\<H!8;DJ=V8)MXQ'
M8LM?PNH?D,I)"HPV)\J1R7()E%AM=\TM(#!%J!/$GMU%C*E:WGV>'>OU8*[O
M"X,$Y'G:2)W3$@[/B*B&L=1;@%/\YPL(E)=,OFGJD:#00P('/WJ,\R=FQA94
M5Q]28F#',4UL1NF*ISUGEB<)KY31+\K?Y9EJC3Z1!!%U9![X-6X&M@U3B^6H
MPIZO'X6<[=\C26M4PDT0VS>S=X3J9XS2%9*@PRS&$R=#OZE5;Y+=-Q(."[7&
M)<L02U4Z7:LVE4Q\J[%_WIN=YSN3&L,G(%?*$^.QKV)Z\FYP27%S98 _]!;P
MH%T=/;FNWQIEYQY1R$]OGN #L42=]YNQV.G8P0.JLU#P1Z\=2Q6I,)6M3)^1
MK:H&63F;]E2HY12&#[6?R<</2JA7*Z,"3]J YM<50 8PB#J0;G<?_%!J;FZT
M^6BYXQ: H$YT0=P"PDR9IJJ;<^ 3;.:*>=4-E7G'O;0P\YU[9=]BM65+ ??G
M2C?U/1D<Y[ KF)_7F<Z2)I6[R[RH15E>A8F^[]&?!H$SIQS=X&S#H'!#UWU[
MO1NA>Y>MIQ"9G.67H3R/*R#YA4T-47.68C,$>16J2W4/5<Z!^M>0SH?V?T9X
M9H)O(L+V>&&T<N/^/-5I5^@S>%\OW*0.A5HH$)TFFDR#BZ,[<*UR[%]IE0-H
M<1M4]/08O,3-(IGQF["AB*_NT7GT=+0"^%58T3YRK&+?+-Q8[$'WG5*J\8]1
M]P@:J \>44E3[G$6!W-5$NYJ%'PAW\X[^TNC%HHJ,<0FKJF3/K.RXV6S?H$S
M515@*<TX_0+>)X[_ZKZB6I2(%^Y7K&->+HFWH-I4Q#V+&"[<!@_>:=TTX3<
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MBM[NWNQ AQ9W%%OSQ>3]K+>*PH"-S-VQB!1GG#O?V:IT9SCF3-ZBGI8A@B)
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M/YC25/[\=[Z+"OZ_Z^G^NTI2K5/Q9]:S,L[";@M97^VFW-Y<^>>T0TIW4B#
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M71"C<?[N8Y%D^2./>9> ??=>I>(LSZW$<Z/@'WP^!,"*..?49'MAG 0@ ;P
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ME(7BK>=NGWSC>&(52I34<U<Y DVR_)GUHP4HCK[K%I*JWN?\$=)AAZ/ EG[
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MSS+:&E?V61S89$&"IR;41V3!;)(?Q9Q\Z*&.E*DNRSJ"40T1/X+DN_R1>/K
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MJ7?86V/C=4>6+W]W\O8>8;CE877A,H[Z [V8. C/0D^+#['PP5-T$8 .0P)
M'19* -2*%0D Z2(!0.63/8PBUKQHNT$ /HRG$8#G;@0 <Q?>^N C?!!ZFP T
MUQ( ["=@,I,8E\C+@X@5V3SX@A4<=P^$?N, V>,>0: EP7BQH&NB17#L+1FI
M8WK'>2P'B "P:>&$N3E.*2NW<;1$:A7U@3[J=SB_P_D7@;,S/TV+5^4G;JIE
M6;H$8#BT9/W/\9F^A<$PMV-50I!N_*5Y#5*1>]7R]?%!DAPBQ8#G71-7G."Q
MU"FEYS:.[E>/67CF9QSXD.L^>$HM8N,[YCD:CXDYB4$F 1BT_P6]^Q=T,%)D
M"+XB343]B(@:<#0T1Z 35Q![7$3D5XG(X[$Z>Y!CNM5Y+-<OU*K<_\=Q*%^S
MI1(-J4+,(M72B(8D$_AE2*(1,S2(1OSVRXBO?AF1Y'\,C]CIS^-Q^S^7RH&P
MK#2$XVY[;B%VCT#802J1OV)-NU+!30)#*/2MEGT79>IQ+]NPAAA>OAL+<01@
M6?;[7T,'AC,KX'\&'_1GT(-D\HOF_QR^UI^#^K6\ROTY?,._-B69;E3_7YL3
M_L^"0SKW]VF%\SPV0^/ZLT'\Y$C/#@0/$<"O'I:8+DQ$ROCBF7S/6YJ.#'5&
M/J*IFKT?\D/$QH%L<.5?T4IDNDE>;&__ZGZ!5N2>53SV_6]]$Z-0"FV/O]E7
M>L+@1#2F6VW)4N/$PC+14C@^S])"L_/7YXJ>3KC%,60]U8+?"GS8\*\P.__B
MF;&<O\)RKQUW#R,<+YR!_/SN2P@32EDV;J;V&U7Z5?]!JNQ_Q?7J=SR_X_D=
MSW\?GC\>,(C_21U>=@PK<+=B5*#^6DKR88 9Y8Z0^94N&(OJV[%?3XFR?5N;
M9U02+YU77LI#IH$,&^^SE4AN7$B^006PVXE$K>1_8-##LW$\AZ_HHK?Q-!^(
M2HH2@%"-!<@Q<R-1[>!\,#9JW>%WJ=^E?I?ZYTB)#ZA(PR30UKD92&FJ%YZ<
M>MB,6[&]CB]+?DH'W47Z\Z.^M#8N+OK@0G#$I<36Y-=CVJ1!UQ!(0U\._(M2
M!@*P\(D1?R$>>]>&@@!\%&]#8,5""$!$2744\.-WJ7]("B,5#*)5XO!;\/N1
MT7),-W!:4YB[*M/-N<D=VTR6M ( _B0VOWYS%=V,V!/R]2$ %'?@&+97:![\
M3?'X$X9U\+%[7>G-_Q>"ZO\5*1$CK-:"W4A)!!H2_IQ) 801"SG).XWZ@:?!
MB:'OS;?,DP[(A>Q1YR;>*/-)T)>DM+<E9=81[Y%=Y\[#A4C^^ZD/Z'G&C@:,
MR-[NTS*>BN@"-7_I!%9X:R9:ZI3:AH\ M-P%X32\*N]0"?W_0"H*QXXU7RA$
M4'Y7FF,<%'8K@5+7[=52T\B*!U%=' 2 /=*&^;\,]2+$<\2.H#61"P=8$("1
MM'Y_>L =@LYOI"4 -TS#X>A[5 2 20LG)D5*S'I>(^=Q;&H$H-W44N/_8V)6
MC)V@T'3:RA$EF4&LNMH+1,3>J"W_6T!(OS68@>5C*;14"3M" ,Z5$EM-]A,Y
MWNJ-0<J:O^S;\*]F_/B0*F_*[V*_B_TN]KO8/T',I"04R<?8NBXZ5&D-UF9^
M^8C]6EDS;]R+#3+YXC_^@I^$RD*,-C7?^:.C_>OSD6XIKX+S<?KLAX;6K0EM
M%_I8W$O"GX)OB"DL]O<\T[*')@X_@UZ'GUU-'JYT7V,?ZLZCB[T:S/B1JS#Y
M\.F<IF#PW7?20UGWM9;$Y<?S%-P[=1"&M3KBE?J#=T2[R10^):XE)T\PM<E^
MO:(O,AL[2^GZ8=M"URVX,>U%8@ [ =!5R']<&W7FG0Z?;:RF7EDSV>R8);W/
M[3&^X6\'M+F0QO,OKX!>Y7LY=NHRZ&Y_&!6<N&IQ@0" =0V'\YVXES)RV#AJ
M/ELDKPB_E(1+FQ1O7:B+?12FD7R-RT3]96!8Q%C>1?F+PA.J;@E6_0[Z&JPF
M[7__B;Q[R@8FY4.7[+Z,NI[[7!'Q6"^ZP$1^,*#B+ 5@E5G6*+?(1]5I$NOU
M >KO7><<3G\MU8>O]>*>$#4_XK7S((F&B*X%(/JI/BX+FFTV$/#,@S[M_1D;
MR^A(<K?.K$)I7H"J(&_&6OV9"WU'8]F JUBD0+(P75SVH\L"P6<ZZ0$##6%'
M!R SH4Q)9S&>P5?AH0L<,KPGFX22+K#1<D6\=_L2YD#F'K5<91#!SS7D^471
M&(&A?.N8YR1WQ=S<NL\[6/SM#_DX^7GYQ[;-9(E1*Z(D#MG]7/V !*O1XR#V
MJ*5L;"*2LZHE$Q'E>7><U@4_X'+CO-O[17Z;S:F!*L\THGB1*[-OPTVT5U5.
M9T.A^0K:^KN&'7E-19'>I1U>+>9D@4M=05F)&J71>WKS+!!?[WG3BE2;LC#%
MU.)K"J.S:BS+MO7V8L4AP5KR,B05-FZ8!KP:GI$ E!7^.AUZ;A-/O(7 J\W]
M\98JW[>"0@N':B,;R.WD\9[8X;IF+GE0 5NPRD6L,3XD.>/PNSW.<0 GGF:@
M!!N"KXR5OH&+X<*C:_O8VB8G'^0;QR1&)=<T;>/BJ[MW:!1*^.]]TL]-JZRQ
MP]N/$0!T)>XB 5#K,SC9BL=:!+(2@ \_\TX/(:+VJYJ!K]'S&-8R K"[!(X_
MRM#"YSU +&\@R-8(P)^(:N$DP#3P0?<1_$EIDO1>%E@7C+IH2P"6V^&@7<9]
M17IB)-IA0:8$H'4$G7=*)0'>K@<C'?\W=MC'C!RN8^+,9=(C$C25\U@"\ 9>
M,.EZ="+5?(S LV>$@E<4' G LR$"0&O0FK''6TD FM9_TIV*#@S'8Z/,", 1
MAK$+UW9ZNPT^,!5(]7]2*@G>;M1%  8B L%+H#5O'GQ@'UJEE)A^YR$-CADL
MX/.>\#\"/5('ZQ)UPE](!N-A6A@"<)D &'^>WSV /-^'_U'QK#_!.=%+5"<C
M!_0'RZ% \4?AQVEA!""C',=82 #^J#GH3V VW1D8CCDEDH"(G'BBZ%D<_"MX
M=$,.=YJR$-#50@!X5RP80W*K1F7E)9[PF(W9,W5/"@DBTK5G5KI[VR:C-O^T
M7]C'HS^._\MS\;^9IN<?,XW4OY+GU/\IGGMF ,<HMHZ8S69"O8OZ>41Y3E!U
MI2\"E='X<'1>2[WWQT^6T_,6#N/>NRT"#[)>/="P4UF(,1UH]*?Y=^!=_P;\
MZ?\L<,B?>FSE3RSLM1,6F&2_JH73N 3'8<,7\0_^T44!_*>+@H4Y3!,]E^7#
M5]54 ;TTG)8?K):L$EQ_:ZE)U$2L.>[,#R:;370JJGL4EL9CGD3[F;3%?3D2
M/F5[NKV\7UJ)3 >'N4#6)E<^N<-I+<$B'LN[3[B2:3*JV^0$:YKP>65#.K5&
M$QOV;;_V+?YG:#G\S6C$"2,4<NQ15ZI6JH+E(0 7-.9/PZM*3Q5F)SX,_LVW
M/-CX8?+P:C8<Q 4Y5>_7"7ZI^M_@/50?AS2,QKP"^&AZ]?IU#^8-*N)YMB1S
MS+*LWM-5G*6\+4JZR4;'P62MSCO8G:AQ(5Q'0/%UTLX9@7Q968#U+L@Y9&/;
M;;GKQSFAG+EK^7PZRO(M_1JY3M46WV/DZKU^<!P8TP]9S6B7:YW;-S%2 ZFK
M<HAF)LI_H,@LVT.PK[R;JRITY XLM@_XM$K/[<1^YW:I1-;U+36QD*1+C3'[
M;&7$7?M%$+4(V\ D[@:ZI- _V=M&:&AKFW?3,B  FW[C&6E8/^ I\^NU!D;V
M,I6 H<:=5,N1XGUMF1[7S8>C3YBRP_J7#&4^(?Q>2R>3U9%% 0@-M8,^-[(!
M(N1.:C^YV$]45NDAO$N9P_M0"?=6\<WK._-WRM\\5DPU-S&;M><B8EY6IB>F
M!XD*63) Y:^![AH9\&JP_;@KZ9UO&]LUZ#]*'-9\O=0QMK Z29;'N* H$&I.
M/3% ?8IZ^ST>YI.Y#1F1.;TQWKEN6%G=5#\PM9F;9F1>-O$P,1E' 3@86IT2
M@'C<E1PG1ML E/Z%;\?2X=6U39%"1II^1LUQ]"YM,CY,V677>WB">E?<.?E?
M< /)4;=?W^BR&9%5[&NP5-8<WUH;JK9J(5_;)O-HRU<P;EDXOD,9RIKT*ROH
M'(=!,GU]C(8]3XU-*T:VJ_S>S1M4UZ49Z=6Q^5S5S/X98?-4T:330Y7V#T&3
M] <5_\'R-(.["V>99AR'@:]T%."9X3V*0W4$(%F+R,EE U <X4^43)%Z_5>G
M;T8Y1K$Y>E0^:%D&CKF1>Q RG.K@ID31IM>ZZ :RF8G\&X>"4E(_C%]2OD@R
M8+_;,&EA-7_5Y:ATK"1\R- 3:M?4>H_U4=XSUZKB(>F@<61E"LH^PF1;MW9<
M8/=1QY>R\R%N8=V;>-DA&">&/B/,<^#L@)_'A0CO;N?@A.X/"]6,L)>,P]6E
M@9S8S)E.[N2:;"<3[V+OS=B%9!JW%A[M34LX8Q.G'C+MQJ'QF"O+G5$IUL)-
MR$M2=_]]P>?336"I7NGKYI]*N9^H[&OY0(4DTN.VA]+G1$ OTFFG%"#?PR(;
MOC^I,K')'T(C.I1Y.J;?C&P$#DK2/3:8TZIZ>B7=8TO\*\P N0H#8RQ569Q8
MU@R45D4#0GH9I;?B']CLLKW^TO DZLPB_-X=>C_^&O1 I\4<@J%0LC"OJJ-B
MZ?MGS4$>\5<U[XYA)Q2QA2]RN#K&"KARWWOJ"*?6.^]<W=#D3_.K;=*6KRJI
M<5$I8,8/FNZ6I&:;">;*2]H)WP%' _=!)^M[)3[M%O0U;0A^7^N]8'1D]:7H
MVNJ-SR8#991?R#H0C*XP1R0/C^5)-Z*Z.!!>F9DAD?J1<S&DZZ?9M%SK=Q]#
MC%!8'LI:ER?G,\V%N+,Z+GGBZ52!SS V*H[)MFYF1_="V6=/4V,J#UD#!?>'
MCODFE1[SQW'=N,=L:&QD<3(Q52Q[]'X\_.,,3!T;C7+=3-O-)E7C?B)>0U\%
M/P>^O@*V[YMJZBEVW!;0H:CLM25?YIIE &]GC.>-XSF@U38B36.-TOEMC@<_
M'USR(-O9.IE<B&L\,=5!#S1#T,&KQAJ74$L[R,/^"S$,;VBD!_B;]OTT[\6V
M+7DN&R7&7_JD8*"GHX=<A^^PR_&$%X0D"2A^5].\?E+L>NJE:#AH-,R05'4\
MA'G^]]Z; ^&%W4/GQ&^RG'BN0A@:'X4;HD$O8()*FC+4;Z)=;AQ;QE^T>41.
MS<9*1_:2(8"9<7)_=[DK8^JP(_ "-A59&D7<G!K5\GP#4,+1]L(I,M='I833
M"LT:7*_M;AQ-0.U>IXB(3)XE^3'/CV?'VA\\P$Z@]8AI [U,-/R,%31=K :=
M7I?C,'3&Q4M1+PG&$?HT9U%4^[YT O6*^#",Y40?LL)_$;N-) "1FKW#R\CU
MM,?# =I?+VQK)+ (2@7?7F4M%&#J1&6QI7V$D6$+,):H[1<P-TR%.?JKA6O(
M$O0[2VLZL\[<[-SK:<DGPJET7]/NJ38?+'O!I_L.9$;A#N (/#.&,KI4[8.Y
M#)DFQI/!&G)OF.*K*2G%=-XE_FLG[71@F\NJ"L7V!\^Q*0].%&'7,351@>=]
M&9'7"E#G9??G#[929=N.F!]LGJ^I,2=3C.B^"C+AI8$W@V<8VQ%GFWA@[M"9
M38[VZQ-M?2Q^MBAZ:8/:BJK15YMV[X2ACI]7[F6>#U-56(PS@)ZHXD@PXQ68
MZ&8P"YX;1&N]-L<Y4B*3L2'%KB5:P:2KQG(#0VK[RBWN?0EE@ FX;7LJ$?6(
MZB!X3,D-Q4BWID+T1HZE^4QU--W@C(4.W_MQI+D5^V330Z"YXK*1-CDJ2%XQ
M/@K"U^AQ(@9%L"BYYN 45<[4H_6_91& ,X=36Y)Y7SQ<FBX*]Y&?Z0]^2!4J
M__W=>M-%G/TXGA\FC#6$Y\)TT(RM^E*&@R[9R?-FPS\;WVE=;C=25'28!4FH
MW?=?%!,?D@P$H(F!'5H+DZ,RQ Q$FS&D*[QIUD+-<?DTHW<^K:':/J/AO7>I
M(L9THQ\#;B4 9YMXB8EJ,X<*P[C7*5G+9]\;N[<Q%@,'9E$/FL:<,05V#]T9
M5(4T%=$DL>B)@P$,)!K\V""VZ6*R/L==C%S;B =?;JFMG1*[14(1J=GC:SLH
M[9X>NA=Q(6ST\UT9TV3(N5AT!4HD]@F,Y=G" (?3N\=O_9"G_-^\ZLKC]K52
MKLXJOMRBIDAYHM#<O52SQS@%1BG-T\ =]'DZ H702UFHTLBB836_O#;9+]D,
MXX4,$S=R7JMQ<E[2!M)OB]=B:TZN0^?/!E+BKJ+UD[/R+-=4.$;W%-<+H\->
MJHN9N^S>]#5RGU1TIVH2)5O1X=7BN<(U+1UO@?4YN(:56IB?-FBQF.^$1$[3
MI\3!3%'%-D=WH)^CW^SU:>?Y9E:%B?1VLEX4(0/+V8AOZ1Z)ZYQFX&7P X$"
MF*LPM@DE@4]8'BM$ZET#>M\>25L7L27CMRH#EQ2^<REM.MO6* B2)9WFXRFQ
M<@NF;?$DJWCJ84293+$QZMOS?)V\#G&9L[V/)N>,RA19-Z@<%@4766'W3RNK
M&+'6@5)HS6B,>/,\C<PV=:5)^;QO^;A>7YK)YB+SU0[N[F!YX_-ZS&8)3\6K
M,9"-;4P(*OS7VU>FL>N=Z?QC,#V[Q6+I#H;J:^669E-3EF<MQAF3&LK.1]AW
MZKD[=44VD<&,L'Z8Z$X5.:P.',FGIX^)5O<H] WH-+Q=0/_#+:*CHW$P.-".
MS/UR%Q7?9Y)^+/R@<@(O&-@S#CDK@;->R B_WE]2)IE8"+68[G'+!2=]*SJ(
MX+)0%]GZSIH>6H_*/'T-AWX)0$$Z#-A]J>YAA$,6)R_)D)2NXD4&]U+3KCPB
M-61I$Y3>/U?^V5-1>\M 'QP%J4CI(.;<<\Q8OQ(G[H%@6:F(.08,^?2LOU6R
MM-:'V<[ULOL";^4T%<S/?--9':]J8L?18"OG*X6+,0:HVV5(+J$F=(#O$WJI
M-K?9"U,95=1)C]7>4LT)]5!)!-4"@Y1R&Z\PD(.PTP]*%Q?@_-#(!6N>%KE6
M=1]RIEF5K,"H89$W[X^>XGH_7+RD;2*X0^$U7W/8SN>#W-X8*!E -AS)I%F:
M-%0,V8YF=@?<K$NS3=!X$)Q]_CY/F0#OA/W)1=B%,16RP($Y!C1[E8\C_)-#
M]4Z'<L=S6[+D=SJ4PVO%0\T_&-2*!^(( .6>:_P\C1<!(%TOUZ-(+CQSKS[D
MU*ZRMP7U5GEHS)(/$[='LE0-^LS1'*%$Q1$F&<B_:MJL*I!B^DX*^Z;OO)7,
MTH_ W:\B$B]G6;IX35_#;$\_96/=,&8P+O1$.R,-[.I(HTB6>2J""?N-H^G=
MFF:,GPGZ9LGSB!AQI9BI/H#"*SF0_K2T$L&@AA2'<^)D:X,YFWK3I>LJ&UWT
M>D%BW>,$8"UFLN7':Y$2_[%2UL!O")9&+HQADR!,=J)1MAA:WQ1KGX--O84)
M;8QTS>]W3K5MB-)6<\A64+!R^3%(%8R=/XAJ./W81.)K],SDF?").7JYDYY#
MLVYT[\+\_=%[(O1\HR21=J8F)]EHM5(XUH, 7*3'$F/W85PT ?C8=PL3WPR.
MAK,W\3I<XY<9;^3CB+BDY)*+C5'_.#- __K+ZPIQF3-?N7XDI75Y "K.3RG\
M.4)5Z-:F.38U%DLC$VW,=;+6C_DS<BVG.R&;3#UD"MY/[TJ.U-J29SQ0Y>_Y
MV]\K_?DM50X560+0(S]* .:(D#2+80C('1R4 "2X%1" +QSX6(NCD#CQ(WC[
M3]A<!I9C66#_5VNW#"SBYK68"01. JT94H2EZ5PB /HUM;5)O<72I5_AOLT>
MZ\-EC6SHZ8E;&'QA]EIU9 "4#Y'J/"*I?O$^R?$!6!>SV%P[-=(Z'C,A\2AM
M__!)28FW7N1ES&L'7<D] L"CZ.#;S[;61(YULT/%<T#=K<]SWPMMZSRG7JDP
M^U0EB'&\LE3)%KU#?UO_2N/U>"B/G[[W*\G9/4&/VOC JCZ]%T(;*F71[9I)
MEDY*$X=%FW!UI[=K!^F]H1?ULU-K]/!Y,88V_1^=YLAJ)RX,G4=CZZ[>?ABW
MDO_HO@&5X'*NN%Z7G,H9M#[.VY2?2R<G64I&Z4H)T,/7O1RU'D]IG,QM5EK2
MEB#9OYZU6?:B-EBW/&O?ST/6LW(2'9AD6N4;T*8"0H>W=>.TBE9[\F=OLVO$
M=C[EQ$5]0,LK"'\@DOD7>\JVS4^Q>>H5UDI(:Y1:T-WW9U47SQVRQ=ZF:5>G
M61<;\F)5.))%2'F88>@OFMX] HFG2,GI'2BY1QTRTN*4AF'*2)YGMG>'ER9D
M:5^;ZFD/-LG1A=*.Y!E!XS&XY/J<SK=V]L@4],]UO<]%KT*9P\XQJ"Z3C\NG
M,Y:^:.EBLLDT3M#7[-^&6F^\]?18,XM1S]&E[[#9J5_]^24>G/EEVWRD\3RZ
M=T2WXLM0XIWTC4V_-/7+9#SOEV?WV+["[F%=77.A[W2&4&?5"VI?W%!94]$\
ML\<)SG&)62BZS?[BTXTB>WGW78TG==72;1AZ[C%6.RK.7ESQQF;=3T_300X5
MQD$8M1W4E2/LB9)>_O4M/W)+S)J.DM1G7HQ-8&3>>@:KYPJ'!OYKI1^S@K.P
M?JV\0O<A*HNK9>RIRC<VJ)2C'!M466H9ZCCJ"\-SIBC<2/T9]>308J;W4 D?
M=<S2P:["A>Y8>(&] ,6V4IUH5-4^XI_J]_V&$,J+:+S5=G,D?5P\S Q924-"
M'\-/&3"AXM9:WNM"97[;9>:U"+Q[1NI;LG+-QNS#UUO392%S(1 -7SDD/'QO
M4Z'(=7-S7\)&AGDVF:>Q?*J9/R2^BZM4$FN_(-_HB+*,V**VI#5(OZ<>/"5(
M057]%"XVP]+BNZ&$KJQ+3(.N-/47!QQ[26>U<SJ5%2O*<GM/?#DH:S.,.K1V
MJ>0[:]5"%50B>>DC!?WA5"<U7Z>?P.Q$NB^M"7K\%3WN>#_^X,6\:$V$\,;^
M]]'%D6*[&*3O0ID,>LSMBM5$@V-V\5K53ID9;,DL2KJ81F)ZW%2_X5A9:<NM
MTK0QGA%KB0(%2\E*@'7TQ7Q#0KWNA)IK^G61FX8PN-G8^+T<$#HP.HC*%A/O
M*.EZ8OFVZ_)RO$#,AXT1&M',IKL'_YE?'0'W^?V-0UR<0X(5NI6B7-@JQ>1E
M77H<]30#$*VNT9!I4CX>BR3:T@:*OO=^B(V:$YM3?-6&;3H4%:3[4NW</KFW
M[%8&==,E N#@=_U:Q;4G77T4(Z!]Q$89_A !+X9KHB'<8KT*WK92 0X]^SN!
M]C_-B5O_B3@*'?U]K<&O5&!*--LFJ>KDU='4\CP9_(=V P'X?%!% /(4W^UQ
M[V[_]2G]WWR)XW(&-_P'&Q)^PE6).!6UV+N^.Q +WJ%!(TYCIB&_W@O@SP>S
M/7&?6X&SX45@4EB.$JC)-#C<R]P>PQ$I7-N@]_32YE#RF<,RWL;^9@)@JURX
M,3+<Y%QY&E\)YX6Y8",7MZ.O@\-A3]Y5)E>G@S[75Y_HKE9?_LAYX2:@O?&U
MOT9@=I J#?\57OFZI@TRB>A(L=AOM]C*0\=N[8E75::964=[SS@8M@@X1PR)
M/M&B*A&O0^L%CM9OEH2BQ$^AR T3B_8;EFD4GC.OA%-X7R7R7)ISW$VCUN^]
M$1+6LFI6D_$Y+@VZ:! Y[1JN^1I9&JH")A(5EX/PO)L/DP>,(N-?>] ]@'UI
MN*W=+=1@JH]N:X54UH27X"2(!(@)&][,P<\ZE"Y?LA_-$Y [NJ_HT#FFSO.<
M]W8S_5?J'VZJ_.(G5).PVR$+_#GY:_SGT.,?%^3S)G"GW/K"QCXRK8YMCVTE
MYR_U)-;8?Y?_YE<2CM3:I"HE4IF)C:Z"ZO@/*_,,C0ZQ66O)QW:I:OQIST0?
M5UZ!M0L^02:%I+M[6&>T@(,RV)L86E &),)92'H]Y+/-S@(O.W\"X*AO :[R
MBWMU=:$C]-61\_L2MWZBK\-N(481#Y45%YIR"J9$(F4VKXINRD*-\+<XT(A4
M\F[=\&E>R=NSBSZL),8=&56Y>4@$".8\FC \O8X<:#UE%ZQS&#S-/#%S0_28
M>U3=NYMY>5K[,95R8;NGZ\QR^[1*WD(_]"[V+7JF\]J[@SQ'NP)?J;;Q"JV
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MCTB]4ZKM!VG4N3JJ5EP!BAIM5!O>=GYTLN.BU<+76\,O?OPNU!?[NG.9OA4
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MG#-^RU,UA1(\>\,J(^^P(W/-2=&)@CU[FC85'89R=+E.[ G^\*T0J6^HK=$
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MP<PQ,8FV#Z<4P[9Q@D6PI]'+U]L#)4J-.:W';0DCEG;GJU)N^J?8*1EYL/P
M*<4.R@E/IAM(504PCVZ4[I9("VY@.I<-6BP/LC<&R-Y&@]3^D;S*8[UHJ?VY
MUB8Y?1)2-MKXU5G$/6RR4R-2ZJ4LG@%Z.@F!JX9OW<9CO/T+G)1%_ V*KCED
M9.F]K<C2@!YES9>"YL;GV^J?L['<"WITJ:$.\FDG2_G %F(UK_I(T7A'F_!F
MN]G=>1EB/H2VY^UB$X;?9IC:_<1U<GP%6B9#JU#B@0J!?6FN.63%X_-FEEI#
MW:TJE0(_2O7I7GN'HSS?V-1+=Y@LFXA*IKXI^N3OT^>*K33(W_4SYDT/Z@'K
MT_(I<QTX,0"^=6@P-JP&J= 1A2LUN;W^MM?M*7Y1Z49"1E?*]U?<5YS91X'\
MJ7G8XVHZ%V*R,? BWLT[%MGNS>%?1]9473"3>L2S%UM?S.U7S*W]#)N]^GVF
MB&"GV&EP+*U69Z*$%D")88"$9@'+*G,[2NI-MZV4EZ.JR65=)U"%\]OWS<3F
MEF6S1P+[5="L<8E(0D4;>M3\#B?:D6.F_JV$1EF(1)X?4'<?./X1445G%\,
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M#I:%/*CW*#[^#%!'03.."*-*[;,JXE;7_S2S^W-_]+=:  .$2L/:TT^GV#!
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M(<A$7*,6M(=L3:'GD(LNS-T=KK!C_9UW=_"NAK.$?+;(?9G75_0\\AX-3D"
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MQ>(WIV3:9P7JU/C2?MBK"0];5HZ]F81=(5P9S.^)[C)V$IEE]+E/,Z& 8V\
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MAJ*(:I)>F[FX&>*)52+>16W0RK!29V<SHGP>S:4S7V(DNE(2-S0??(>9\XN
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MV&EL6:QW//LU$Y2.7=\E^QB;$14HVM7^R'4JRV/0IQ4SC9D&SSJY-JFL&,&
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MF1.;\+U@(40B^$AT!DU1@$.'R1<P-^I(&>$T(;-4KU)RS#L7ZIC?/5KZ*2P
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M7^7(Z=J# O-D>4*O[VV:_X*:S<B4HN54;*R7TOVTT]*IX\(G=6XT8U.]537
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M4T;JCVY:+5;VPHR^E[G*NLEFO'C=673W2W:K,=,M"B84S(Z3<MX6P,8BN7,
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M#YL1KF-S]6LKD]3"UH.+D/,C!X* E>E8[)_XHFFGLWI7:Q=ZVH+L.DQ[O9,
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M-3J1J9?L<>JGV0SS$2'AAA3X2V0HR"4@7-KS7898#N6540X&:_>T&>MM\QO
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M[/K%V]?,<I1Q(B(4+YP4Q(^OZNM*5NXFV+E#\6&YW7[NVIR;7A6O0@<Q1JY
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M*6R%#MK6UER?_D06#PZU? J[872UM3L[(#^1V<.DDJ+5;\ZR%_+!]_RE?6_
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MIE:"J<T"ZG,,-@UQ^/^('CM[/HNDXYOI$X^LHG6M)YBGB3"U TTXWB "W5]
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M4TV)=N'IKI&ZW,9&H0,7"9%L\8&X7Z:(TEM[4MDH3=XOGSP:\FO,P?=R\M=
MYQ]_WOWW;\["GQ*$C_\%4$L#!!0    ( -!#>%J?Y;8#@0X  /:H   5
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MG1H"A*[71>5LII5HB4P.;-^,KUNN#0XW [.<PCOLT\@G(4FM,K[" >R?P'V
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M*Q5X]H"MKFT?I"TA'IP'MF;!-9Z@\!*+,M^MFO1!_O4T@YNY,Y=BM\PP9;]
M$WS4X%:LU*M'X,C9 #=NO2O2):$XF$1G*:4X\A87+]Z4I^NZ8UM89H:$4%XR
MWENM<Q]@:<J-@H_>0A*R$J>GB_O<XA0D%GLO2BQ6&FOPN!@4]JOM-&$7$6-@
M\3WP<8F^(KZ&O]2]8)*A$0J7SH<*X#4UW]L/:?L):%/2V6FBF!,\/O<>TZ?
MP['RLU&MGW/FJ>G.*@4^1.T 'CN/5R4W50710UJ0#-_7UK=TP,'5!51$PK89
M0U@-NS(7HEM&07/S][Q"L5:D#[-H^Z97%P9.^K<TX&3TKG=9QXU147ARAKQ
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M;PP#-W-3:2ABLDKN)"]CLM5T],'AS%5"HB$</EA;X H'JPR#C6:C(UMY;!L
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M2G!FQ$T#;[J]=H@+00G6)_5Q>P&Y#A9!A; 885-_P;;R@36_;UQU[06LBER
MR%GS&17)]I9\+FD_(['(6!+UZ@=>4@9 J*QYA4JF^AG;W -&3I9&L0C&\X>-
M3YWR87H!9@N.0'3MEO"&:ADO&5VUZ0<N6^2"0K?FQZD]$*E=4$EZ]@(@-29
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M[!F$*MR %H6%0SNTXZJ4KOFR?7;?/+"7AW.G=,WA!'\XP?]\)_@'-O9P7"K
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M%G$=R:3Z!0S, W@G;3NM_26A=Z6] LYD7S3L&R2UY(,&CUOV3E.+I6_8B+@
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M.)/75Y\R@9E_->%A)QNP)&G%'><!3G%8^K,#@06Z@"!U_)EQ7JO (4H@LM'
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MPJ&':O7$-E\/[1>W51"["DY]VK9VA:I?V]<.<#JZC=W@Y_\F],=]PET+P5/
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MK5KK-NIA$VW&M;1QMIVNT#U)6]8-N84!6MM V]F<M8R;PJ1L76Q&!97=IIY
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M$E]?GPDE#;0>O;<4=J(F:2'5H*1;']E;I=C(Z@?P??#>PQ&B 8$3'0%-';>
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ME^2R7L0+8OC_/3(IL=_\?U!+ P04    " #00WA:FWW)=6A_   M4 < %0
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M71A9R#OK?6Q@-YV/3M@[46P1"M$N\!?4T4&S+[(.#W[^)2#1ZE7[QO% QFF
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MYDS0]ZG=08=#$,_IIA_0>6?=)+@F%IK=E"$=B_3WO.X"LB3\;EC$U^YWF/!
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M IKDPA<51 63G)4?.0[?;K+G;W$85=0(HY81])=?[YYW*^9G.S"A_\E%K<O
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M\G9=.2E):8?,CX=PRLZ&K#NQD6FXY-PD\[HD')4 &%9.02U<UVS3X+X3O52
M]H]6=IMZS+&)@..SME<=E\)I,=IX UE':>_D?=@_YOBW/8MJ\&RQ?: 6=WH:
M8 #=V_Q7R((AF0&@Z&91BZ-2'E)7.+3%>-JDEO?))_UIDDH8+*/,GCL#2GGG
M4<\]D[L-O9H'4)V*V^'2#+X_.*KEP7#* N205G<DIF/<+L'<^;67@'>"#;U
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MYP:<Z\QLINA>W%"U)D-CN@'DA#.YG)@_^D_,#WV1Y_MMN?*^C_//5P3CZ[3
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M$^8:H7/.EHLZ?898 [;WAK!$SCNO+, )8>H;4<1EP;AD#VRX,3ADJ\4]LD<
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M4C8E4M_XT4K#JC<;J*KIWC_]PP]_]GWYASGVLQNGC".8U/O2JM6L5AI6Q=A
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M0DO%LH&M0*C*:PQB3<P-G47C=D]"KO<!GWG2[2/SHL3S09.#KMY02+T1BY-
M+#L)_P:(/76U 3K&C4*\(H_>LU[;6XH.T $NUXJF^>S"1_U%G \=OO8'##]
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M4H_V@+3]@$M;;\#Z$FFX MRM.A]YB^T+P.,20!9LD2!?F.Q(:/08!=8S_OU
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M69J2I,!/'A*A*@]E!'>KK9<8+5L+'\JK](JQF%W$W+[Z:BH@]:"4N)$Q2H\
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M17$P+U9<$!W&DDYR?(LGW0S+RH(YL.**&,2>83I =W;4@ EM)3 E5MP2YI0
M44"/S[;ZWL8["]=X(4ZB]DXW$,?-B]'A %\Z?-I+@EFR^2Y*"P.*XWL\LY6O
M)D2LAP[KUH)@J&V^+Z*$6B$?AJ=4>4AP7 *,K<V4?$ILVR0:_]A1'MZS_R,8
M2FLWTG10UN08&45MH%2G\"@+=\9(U^ T!\*DXN@#5X2R(Y<D\1G-W<VZ."E
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MHI!B['/HTSP<U>N-_HATQ#S KT>D&)<VBN'(/R#1[+)<K1@^W'#E;I=@T!"
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MVG1>[4U)RD6<I$G^J-93Y5$MP*#LVR[.D 7WNOK$&&27UKMAY*$]C)K4!OY
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MM+S12(UN<:\\%G%1DAEAN;J!#:^V(EX&H:[C#8@%.F?7,2-T$5UD?%1'_G'
M7!3D_PQSF.'NEAY-XB7ZZ<IS;_SP-<"C[!<OS$CEDAG?SJ8L6QW<20JV8=7Q
M<O%T9M8$%W06[\B7BH0LCOB//JGT%#Q\S5N"<NN RZ:SC([0/&,T9GQ.H7%P
M3_S02Y+]^P1GP;^R)(_QN"2)S^BZ&@O<I-F\)2C-#CB#.LMX2J?[CR+M0.O9
M?N/:OLG9?M'LZ\E^GPVJOR1!)M+*GO%^!33,Q-;JH4@DP?MW]>R'&=>%:Z[A
M8CN6[6YYUU>-D--E"]\ZM2@">WBC6X+&C5[YJ&]>G6_>ZT4>WB_@@N]>U>H]
MJZ!\OBW_:#1^#1O$CJ@SO C<#S?T<=BXE2D?A\W[]=(KPLC#\<3N"A]4J/6.
M[,X]-F7W(G4_*&"U>Y,G<9>X+V*6CJT/_=KW($N3U(N"(NOVU3-A/DW$T,C'
MA\[!VZ,][*@[-8\]A7/#=LINULHM:"/)@OR:.+(%?7GWQ0_JIN3-R+A"6SK-
MF^-=$<,>EY+KX_)AV<C>(+M$CCPH7V^32Y9-]5O,9U\\%N0D%@?!B?!W%Z,M
M2;+5NN-P'^8[+_&NN1TNT+W25:S: PW.Q,JE>)\@X;N\5N$-$Q@,\B'LY9_U
MC 8#TH&N9FVCIRI5=?2<\9EWL]NF=[1>IFUC7_<8S61U ]U]_1&_3<ZR=!DS
M^CL)1$)G5I$OCXTZWY8;+C)CU"?W8AP-H5\#?!O[ @N._@U&&O9ZO)+!1;X&
M;R1RJN9Q05YWOY2$+@>5VUTHX-TKHM+/HN"6>D\TS,^5S"<7PP9/+@U,3^@<
MFB*N\E?0Z8;L0;CG1NR>^''D<QD.6V4C_KNTBKU&[:,%W5'$ML:*E"E2Z_Q#
M(\N6,F40LKD^^=Q!"4LK<O)_'63D_Q#W=/)O9EXX?0KI(M>):]XE+_PG\=A'
M\2P77ZSNE%4[F'F;/9L\Y4Q"_:5W8USK'T*Y)*E'P^1.G+8(T]4VT!NYP6 /
MHTS^HVQ\LF\=:?"_/I8"601<Q"&7+2Z8JCI-N!AW? J3_+GA^X<L#8;[EL[,
M- :B%6MC\]T4&ZA5[VQA72SM+0LWC>2&8ZA(4C+L5]S0-7LCMG'Q=4CP]@Y!
M-)7;C[@B#D$X5N(HE^>9*G1(4^TK4PH-&I7]&=*]O.-N7<8KCRIN!DB*.T(J
M1&'K=_':!3JLMO'RF9;^\X]D]428>H]5*XKM%5 J54OZT59)[?A[-/O"W/LK
ML6_\[Y4_.Z+RUNW8L=258ZJ129$.@UT'H<IOF9ACO-JQW'75BI71@/F11G25
MK51PUHJ@'5W6X6J V2H+OI_X.$'L(_^49L4DJ_"UV!@=#I7#26<HU:V4%%4<
MH56MIGIN7%DKU;JF6R])BF,GQ=*JF)H0QVR@Z/YT7K$!:@LH*>[(0!G+_DE0
MJ*27Q"&S*:G7+IQNZ!DWY(8"*)6YQJ&QB#VMI^P6S?Y^ZRQC_M)+R-F"D;P3
M4I+R"R7Z>MB&LJ,V'EV;@:)CZ8[3!2]"?2]\9-0+]Y_.#]ZJ?_D81Y0W*:[R
M[,LHV1N@7?1T@_W9'0Q=% _$A;C>3MA:W!.Y\U8*9T1[23=,YBA^B78 *CF
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MS"?0;OP,H$!#@GRZ:I/_SR\D$1=KB@2\7#)?<+C0)>T>_G- =;*6N'AL=8*
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M)4E\1M="M*,I":0,\LK8">2ZJX .$/P)M[*0R,12@/]#&*SD)DDR<575E$5
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M? ,  /<,   *              "  0    !E>#(S+3$N:'1M4$L! A0#%
M  @ T$-X6H_E<'GV!P  '3    H              ( !I ,  &5X,S$M,2YH
M=&U02P$"% ,4    " #00WA:AC:=) 4(  #'+P  "@              @ '"
M"P  97@S,2TR+FAT;5!+ 0(4 Q0    ( -!#>%HLFNENR@0  'D;   *
M          "  >\3  !E>#,R+3$N:'1M4$L! A0#%     @ T$-X6@/;[S7,
M!   FQ\   H              ( !X1@  &5X,S(M,BYH=&U02P$"% ,4
M" #00WA:TDU^420-! #DHRD #               @ '5'0  9F]R;3$P+6LN
M:'1M4$L! A0#%     @ T$-X6BM,[8+M3   ]$\  !               ( !
M(RL$ &9O<FTQ,"UK7S P,2YJ<&=02P$"% ,4    " #00WA::E*OKL8> 0"I
M8 $ $               @ $^> 0 9F]R;3$P+6M?,# R+FIP9U!+ 0(4 Q0
M   ( -!#>%HG]<WP& 0! .U4 0 0              "  3*7!0!F;W)M,3 M
M:U\P,#,N:G!G4$L! A0#%     @ T$-X6A,-GQDH$P$ IFT! !
M     ( !>)L& &9O<FTQ,"UK7S P-"YJ<&=02P$"% ,4    " #00WA:U^U#
M?_X1   _R0  $0              @ '.K@< ;&EX="TR,#(T,3(S,2YX<V10
M2P$"% ,4    " #00WA:G^6V X$.  #VJ   %0              @ '[P <
M;&EX="TR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @ T$-X6F.6F4+70@
MU6D$ !4              ( !K\\' &QI>'0M,C R-#$R,S%?9&5F+GAM;%!+
M 0(4 Q0    ( -!#>%J;?<EU:'\  "U0!P 5              "  ;D2" !L
M:7AT+3(P,C0Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #00WA:CE;^ZE)9  !*
MX04 %0              @ %4D@@ ;&EX="TR,#(T,3(S,5]P<F4N>&UL4$L%
3!@     /  \ E0,  -GK"     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LIXT="http://lixte.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lixt-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-06-022023-06-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-02</startDate>
            <endDate>2023-06-02</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2023-06-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2024-08-19_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-19</instant>
        </period>
    </context>
    <context id="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:GeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VendorAndConsultantMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">LIXT:DirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorAndConsultantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ClinicalAndRelatedOversightCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalAndRelatedOversightCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:ClinicalAndRelatedOversightCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PreclinicalResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PreclinicalResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:PreclinicalResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RegulatoryServiceCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RegulatoryServiceCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">LIXT:RegulatoryServiceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LIXT:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">LIXT:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-17</instant>
        </period>
    </context>
    <context id="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-16</startDate>
            <endDate>2015-03-17</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UndesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_UndesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember24649234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember24649234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-03-092023-03-10_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="From2023-03-092023-03-10_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-10_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="From2023-07-192023-07-20_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-08-07_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="From2023-07-242023-08-07_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-07-20_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_PlacementAgentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-07-192023-07-20_custom_PlacementAgentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-19</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-07_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="AsOf2023-08-07_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2023-06-02_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-02</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SchellensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NewIndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:AppointmentGrantsOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_DirectorMember24650984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_DirectorMember24650984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-06</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-27</instant>
        </period>
    </context>
    <context id="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-26</startDate>
            <endDate>2023-11-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-01</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesSMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-12</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2021-06-282021-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-28</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-28</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-06-302022-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="AsOf2022-11-06_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-06-302023-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="From2023-09-252023-09-26_custom_MrvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MrvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-06-302024-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-06-302024-06-30_custom_FourNonOfficerDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-07-01_custom_SchellensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-01_custom_SchellensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SchellensMember24651765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SchellensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-09-302024-09-30_custom_FourNonOfficerDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-202025-01-20_custom_FourNonOfficerDirectorMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-20</startDate>
            <endDate>2025-01-20</endDate>
        </period>
    </context>
    <context id="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-20</startDate>
            <endDate>2025-01-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourNonOfficerDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-20</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialMonitoringAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="From2024-07-072024-07-08_custom_ClinicalResearchSupportAgreementMember_custom_CityOfHopeNationalMedicalCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-07</startDate>
            <endDate>2024-07-08</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-11_us-gaap_SubsequentEventMember_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-11</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ClinicalTrialResearchMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember_custom_MDAndersonCancerCenterClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MDAndersonCancerCenterClinicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ClinicalTrialMonitoringAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialMonitoringAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-04</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-08-252023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-25</startDate>
            <endDate>2023-08-27</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchMonitoringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-232024-02-23_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-23</startDate>
            <endDate>2024-02-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-23_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="AsOf2030-01-31_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2030-01-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-04-30_custom_LicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">LIXT:DueEachJanuaryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-23</startDate>
            <endDate>2013-12-24</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-12</startDate>
            <endDate>2015-09-14</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2024-10-04_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhase1bTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialRandomizedPhaseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialRandomizedPhaseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseMD1b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">LIXT:ClinicalTrialPhaseMD1b2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="AsOf2024-08-23_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="AsOf2025-01-06_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:WallachBethCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-06</instant>
        </period>
    </context>
    <context id="From2025-01-062025-01-06_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:WallachBethCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="From2025-03-072025-03-07_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:WallachBethCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">LIXT:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Integer">
        <measure>LIXT:Integer</measure>
    </unit>
    <unit id="Segment">
        <measure>LIXT:Segment</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001335105</dei:EntityCentralIndexKey>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0119"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationIncludedInResearchAndDevelopmentCost
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781"
      id="xdx2ixbrl0701"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781"
      id="xdx2ixbrl0703"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781"
      id="xdx2ixbrl0705"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781"
      id="xdx2ixbrl0707"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812"
      id="xdx2ixbrl0713"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812"
      id="xdx2ixbrl0715"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812"
      id="xdx2ixbrl0717"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812"
      id="xdx2ixbrl0719"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812"
      id="xdx2ixbrl0721"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812"
      id="xdx2ixbrl0723"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl1161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl1162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1193"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1195"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember"
      id="xdx2ixbrl1400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember"
      id="xdx2ixbrl1420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member"
      id="xdx2ixbrl1432"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000014">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000015">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000016">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000017">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000018">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000020">001-39717</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000021">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000023">20-2903526</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000024">680     East Colorado Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000025">Suite 180</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000026">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000027">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000028">91101</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000029">631</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000030">830-7092</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000031">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000032">LIXT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="Fact000034">Warrants     to Purchase Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="Fact000035">LIXTW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="Fact000036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000037">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000038">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000039">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000040">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000041">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000042">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000043">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000044">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000045">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000046">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000047"
      unitRef="USD">5195000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-14"
      decimals="INF"
      id="Fact000048"
      unitRef="Shares">2684074</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000049">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000052">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Risk
Management and Strategy&lt;/b&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zJXUajnDerac"&gt;We
have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z2cccSJvoRY3"&gt;integrated&lt;/span&gt;
these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats,
including any potential unauthorized occurrence on or conducted through our information and email systems that may result in adverse
effects on the confidentiality, integrity, or availability of our information and email systems or any information residing therein.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zb8js64TZvA7"&gt;We
conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our
business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include
identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such
risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;


    &lt;div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 33%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 34%"&gt;-53-&lt;/td&gt;&lt;td style="width: 33%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
    &lt;div style="break-before: page; margin-top: 6pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 100%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
these risk assessments, we intend to take any steps necessary to redesign, implement, and maintain reasonable safeguards to minimize
identified risks; to reasonably address any identified gaps in existing safeguards; and to regularly monitor the effectiveness of our
safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with an IT consultant, who reports
to our Chief Executive Officer and Chief Financial Officer, to manage the risk assessment and mitigation process. As part of our overall
risk management system, we monitor and periodically evaluate our safeguards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
may engage consultants, or other &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zDtwoLnAn6sl"&gt;third parties&lt;/span&gt; in connection with our risk assessment processes. These service providers can assist us
to design and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, we have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zVBe9V9MMel6"&gt;not&lt;/span&gt; encountered cybersecurity challenges that have materially impaired our operations or financial condition. Additional
information regarding risks from cybersecurity threats is provided at &#x201c;Item 1A. Risk Factors&#x201d;.&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000053">We
have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z2cccSJvoRY3"&gt;integrated&lt;/span&gt;
these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats,
including any potential unauthorized occurrence on or conducted through our information and email systems that may result in adverse
effects on the confidentiality, integrity, or availability of our information and email systems or any information residing therein.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000054">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2024-01-01to2024-12-31" id="Fact000055">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000057">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000060">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Governance&lt;/b&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zNsi1iNNlH3k"&gt;One
of the functions of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats.
Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible
for the day-to-day management of the material risks that we face. Our Board of Directors administers its cybersecurity risk oversight
function directly as a whole, as well as through the audit committee.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_z9c24LgH3xW9"&gt;Our
Chief Executive Officer and Chief Financial Officer are primarily responsible to assess and manage our material risks from cybersecurity
threats with assistance from third-party service providers.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zDME1MjQBUV"&gt;Our
Chief Executive Officer and Chief Financial Officer interact with our IT consultant and oversee our cybersecurity policies and processes,
including those described above at &#x201c;Risk Management and Strategy&#x201d;. The cybersecurity risk management program includes tools
and activities to prevent, detect, and analyze current and emerging cybersecurity threats, and plans and strategies to address threats
and incidents.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_z1pZM2QgKpL9"&gt;Our
Chief Executive Officer and Chief Financial Officer provide periodic briefings to the audit committee regarding the Company&#x2019;s cybersecurity
risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of
third parties, and similar issues.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000061">One
of the functions of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats.
Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible
for the day-to-day management of the material risks that we face. Our Board of Directors administers its cybersecurity risk oversight
function directly as a whole, as well as through the audit committee.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000062">Our
Chief Executive Officer and Chief Financial Officer are primarily responsible to assess and manage our material risks from cybersecurity
threats with assistance from third-party service providers.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000063">Our
Chief Executive Officer and Chief Financial Officer interact with our IT consultant and oversee our cybersecurity policies and processes,
including those described above at &#x201c;Risk Management and Strategy&#x201d;. The cybersecurity risk management program includes tools
and activities to prevent, detect, and analyze current and emerging cybersecurity threats, and plans and strategies to address threats
and incidents.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000064">Our
Chief Executive Officer and Chief Financial Officer provide periodic briefings to the audit committee regarding the Company&#x2019;s cybersecurity
risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of
third parties, and similar issues.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000065">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000066">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000067">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000068">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000069">572</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000070">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying consolidated balance sheets of Lixte Biotechnology Holdings, Inc. and subsidiary (the &#x201c;Company&#x201d;)
as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders&#x2019; equity and cash flows for
the years then ended, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023,
and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted
in the United States of America.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000071">Weinberg &amp; Company, P.A</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000072">Los Angeles, California</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">1038952</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">4203488</us-gaap:Cash>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">78016</LIXT:AdvancesOnResearchAndDevelopmentContractServices>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">20898</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">17116</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">85653</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">10000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">1145503</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">4308620</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000104"
      unitRef="USD">27500</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000106"
      unitRef="USD">36250</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">83206</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">156758</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilities
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000111"
      unitRef="USD">0</LIXT:ResearchAndDevelopmentContractLiabilities>
    <LIXT:ResearchAndDevelopmentContractLiabilities
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000113"
      unitRef="USD">120768</LIXT:ResearchAndDevelopmentContractLiabilities>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">235078</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">157100</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">318284</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">313858</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000127"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000129"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000135"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000143"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000145"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">72917</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">3500000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">3500000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000154"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000156"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">225</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">225</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">49394687</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">48976265</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">-52067693</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">-48481728</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">827219</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">3994762</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">1145503</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">4308620</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">726232</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">898100</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">2846557</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">4192136</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">3572789</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">5090236</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">-3572789</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">-5090236</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">7048</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">17486</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">16821</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">16233</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">-3403</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">1954</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">-3585965</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-5087029</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000212"
      unitRef="USDPShares">-1.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000214"
      unitRef="USDPShares">-1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000216"
      unitRef="USDPShares">-2.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000218"
      unitRef="USDPShares">-2.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000220"
      unitRef="Shares">2249290</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000222"
      unitRef="Shares">2249290</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000224"
      unitRef="Shares">1915838</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000226"
      unitRef="Shares">1915838</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000234"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000228"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000236"
      unitRef="Shares">1664706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000229"
      unitRef="USD">166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000230"
      unitRef="USD">45059760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-43394699</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">5165227</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000244"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000239"
      unitRef="USD">18</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000240"
      unitRef="USD">3137021</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000242"
      unitRef="USD">3137039</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000252"
      unitRef="Shares">403334</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000247"
      unitRef="USD">41</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">41</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000260"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000256"
      unitRef="USD">6281</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">6281</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000264"
      unitRef="USD">773203</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000266"
      unitRef="USD">773203</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000271"
      unitRef="USD">-5087029</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000272"
      unitRef="USD">-5087029</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000280"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000274"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000282"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000276"
      unitRef="USD">48976265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">-48481728</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000278"
      unitRef="USD">3994762</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000284"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000292"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">48976265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">-48481728</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000288"
      unitRef="USD">3994762</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">418422</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">418422</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">-3585965</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000304"
      unitRef="USD">-3585965</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000312"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000306"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000314"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000308"
      unitRef="USD">49394687</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">-52067693</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000310"
      unitRef="USD">827219</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000316"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000324"
      unitRef="Shares">2249290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">49394687</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-52067693</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000320"
      unitRef="USD">827219</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-3585965</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-5087029</us-gaap:NetIncomeLoss>
    <LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000338"
      unitRef="USD">418422</LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost>
    <LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000339"
      unitRef="USD">773203</LIXT:ShareBasedCompensationIncludedInGeneralAndAdministrativeCost>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000350"
      unitRef="USD">-78016</LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000351"
      unitRef="USD">-69001</LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000353"
      unitRef="USD">3782</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000354"
      unitRef="USD">-32108</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">75653</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-1350</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">-73552</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000363"
      unitRef="USD">-73976</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000365"
      unitRef="USD">77978</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000366"
      unitRef="USD">-7922</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000368"
      unitRef="USD">-3164536</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000369"
      unitRef="USD">-4293265</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">3137039</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000378"
      unitRef="USD">41</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000381"
      unitRef="USD">6281</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000384"
      unitRef="USD">3143361</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000389"
      unitRef="USD">-3164536</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">-1149904</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000392"
      unitRef="USD">4203488</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000393"
      unitRef="USD">5353392</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000395"
      unitRef="USD">1038952</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000396"
      unitRef="USD">4203488</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000404"
      unitRef="USD">16821</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">16233</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000410">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z8O7RSmNuSJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_82B_z0atKDIVjeI3"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lixte
Biotechnology Holdings, Inc., a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (collectively,
the &#x201c;Company&#x201d;), is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development
and developing and commercializing cancer therapies. The Company&#x2019;s corporate office is located in Pasadena, California.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents,
radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase
inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic access to equity capital to fund its
operating requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On June 2, 2023, the Company effected a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztceidAmV8wa" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; reverse split of
its outstanding shares of common stock. The authorized number of shares of common stock and the par value per share were not affected
by the reverse stock split. No fractional shares were issued in connection with the reverse stock split, with all fractional shares being
rounded up to the next whole share. All share and per share amounts and information presented herein have been retroactively adjusted
to reflect the reverse stock split for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nasdaq
Compliance&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s common stock and the warrants are traded on the Nasdaq Capital Market under the symbols &#x201c;LIXT&#x201d; and &#x201c;LIXTW&#x201d;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 2, 2023, the Company effected a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF9lnpadEeQb" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; reverse split of its outstanding shares of common stock in order to remain in compliance
with the $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zYaEmCqxk1w7" title="Bid price"&gt;1.00&lt;/span&gt; minimum closing bid price requirement of Nasdaq. However, there can be no assurances that the Company will be able to
remain in compliance with the $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zSfQVo5UkKQd" title="Bid price"&gt;1.00&lt;/span&gt; minimum closing bid price requirement of Nasdaq over time. In addition, Nasdaq has other continued
listing requirements, one of which is maintaining a minimum net stockholders&#x2019; equity of $&lt;span id="xdx_90E_ecustom--NasdaqListingMaintainingMinimumNetStockholdersEquity_iI_c20230602_zdhgrYF8ztb9" title="Minimum net stockholders equity maintaining in nasdaq"&gt;2,500,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 23, 2024, the Company received a letter from the Listing Qualifications Department (the &#x201c;Staff&#x201d;) of the Nasdaq Stock
Market LLC (&#x201c;Nasdaq&#x201d;) on August 19, 2024 indicating that the Company was not in compliance with the minimum stockholders&#x2019;
equity requirement of $&lt;span id="xdx_90D_eus-gaap--StockholdersEquity_iNI_di_c20240819__srt--RangeAxis__srt--MinimumMember_z5EJ6mu2gCf5" title="Stock holders' equity"&gt;2,500,000&lt;/span&gt; for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &#x201c;Stockholders&#x2019;
Equity Requirement&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders&#x2019; Equity Requirement, which
outlined the Company&#x2019;s proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 21, 2024, the Staff provided notice (the &#x201c;Notice&#x201d;) to the Company that it had granted an extension through February
18, 2025 to regain compliance with the Stockholders&#x2019; Equity Requirement, which required that the Company complete its capital raising
initiatives and evidence compliance with the Stockholders&#x2019; Equity Requirement through filing a Current Report on Form 8-K with
the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) providing certain required information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of February 18, 2025, the Company had not gained compliance with the Stockholders&#x2019; Equity Requirement. Accordingly, on February
19, 2025, the Company received a Staff determination letter from the Staff stating that the Company did not meet the terms of the extension
because it did not complete its proposed financing initiatives to regain compliance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company timely filed an appeal and requested a Hearing before a Nasdaq Hearings Panel (the &#x201c;Panel&#x201d;), which has been granted.
The Hearing request automatically stayed Nasdaq&#x2019;s delisting of the Company&#x2019;s common shares and warrants pending the Panel&#x2019;s
decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension through no
later than August 18, 2025. At the upcoming hearing, the Company will present its plan for regaining and sustaining compliance with the
Stockholders&#x2019; Equity Requirement for continued listing. However, there can be no assurances that the Hearings Panel will grant
the Company an extension of time to regain compliance, or that the Company will be able to regain compliance during any extension period.
During the appeal process the Company&#x2019;s common shares and warrants will continue to trade on The Nasdaq Capital Market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company intends to take reasonable measures available to regain compliance under Nasdaq&#x2019;s listing rules and to remain listed on
Nasdaq. However, there can be no assurances that the Company will ultimately regain compliance with the Stockholders&#x2019; Equity Rule,
or be able to maintain compliance with all other applicable requirements for continued listing on Nasdaq. If the Company does not regain
compliance with Nasdaq&#x2019;s continued listing requirements within the time period permitted by Nasdaq, then the Company&#x2019;s securities
will be delisted from Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2024, the Company recorded a net loss of $&lt;span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20240101__20241231_zawoyi7IHt16" title="Net loss"&gt;3,585,965&lt;/span&gt; and used cash in operations of $&lt;span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zzy26qFGPpwd" title="Net cash used in operations"&gt;3,164,536&lt;/span&gt;. At December
31, 2024, the Company had cash of $&lt;span id="xdx_90A_eus-gaap--Cash_iI_pp0p0_c20241231_zhtTYjk1UZtl" title="Cash"&gt;1,038,952&lt;/span&gt; available to fund its operations. Subsequently, the Company completed a securities offering
that generated gross proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember_z3yZNr8Wi3Bk" title="Gross proceeds"&gt;1,050,003&lt;/span&gt; during February 2025 before deducting the placement agent&#x2019;s fees and related offering
expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
the Company is currently engaged in various early-stage clinical trials, it is expected that it will take a significant amount of time
and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#x2019;s
business is unlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company
is able to generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance
that the Company will be able to achieve and maintain positive earnings and operating cash flows. At March 14, 2025, the Company&#x2019;s
remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not yet incurred
aggregated approximately $&lt;span id="xdx_90A_eus-gaap--ContractualObligation_iI_pp0p0_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_zGsjk7dkI0H7" title="Contractual obligation"&gt;526,000&lt;/span&gt; (see Note 8), which are currently scheduled to be incurred through approximately December 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements also
do not reflect any adjustments relating to the recoverability of assets and liabilities that might be necessary if the Company is unable
to continue as a going concern. The Company has no recurring source of revenues and has experienced negative operating cash flows since
inception. The Company has financed its working capital requirements through the recurring sale of its equity securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern
within one year after the date that the consolidated financial statements are being issued. In addition, our independent registered public
accounting firm has included an explanatory paragraph in their report with respect to this uncertainty that accompanies our audited consolidated
financial statements as of and for the year ended December 31, 2024. The Company&#x2019;s consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#x2019;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on current operating plans, the Company estimates that its existing cash resources at December 31, 2024, and the funds raised subsequent
to December 31, 2024, will provide sufficient working capital to fund the current clinical trial program with respect to the development
of the Company&#x2019;s lead anti-cancer clinical compound LB-100 through approximately&#160;September 30, 2025. However, existing cash
resources will not be sufficient to complete the development of and obtain regulatory approval for the Company&#x2019;s product candidate,
which will require that the Company raise significant additional capital. The Company estimates that it will need to raise additional
capital to fund its operations by mid-2025 to be able to proactively manage its current business plan during the remainder of 2025 and
during 2026. In addition, the Company&#x2019;s operating plans may change as a result of many factors that are currently unknown and/or
outside of the control of the Company, and additional funds may be needed sooner than planned. The Company is considering various strategies
and alternatives to obtain the required additional capital. However, as market conditions present uncertainty as to the Company&#x2019;s
ability to secure additional funds, there can be no assurance that the Company will be able to secure additional financing on acceptable
terms, as and when necessary, to continue to conduct operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
cash resources are insufficient to satisfy the Company&#x2019;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances, joint ventures or other transaction structures that could require
the Company to relinquish rights to and/or control of LB-100, or to curtail or discontinue operations entirely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="Fact000412">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="Fact000414">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000416"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-06-02_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000418"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <LIXT:NasdaqListingMaintainingMinimumNetStockholdersEquity
      contextRef="AsOf2023-06-02"
      decimals="0"
      id="Fact000420"
      unitRef="USD">2500000</LIXT:NasdaqListingMaintainingMinimumNetStockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-08-19_srt_MinimumMember"
      decimals="0"
      id="Fact000422"
      unitRef="USD">-2500000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000424"
      unitRef="USD">-3585965</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-3164536</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000428"
      unitRef="USD">1038952</us-gaap:Cash>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember"
      decimals="INF"
      id="Fact000430"
      unitRef="USD">1050003</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-12-31_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="Fact000432"
      unitRef="USD">526000</us-gaap:ContractualObligation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000434">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z3Dj4EoSrzlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_828_zCRrJMw2c0r1"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zcsIdVU2V1Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zEuemcl2zLm9"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zYvjq1FPqv17" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zoX5utclQqPk"&gt;Segment
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s President and Chief Executive Officer is the Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and evaluates
performance and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis.
Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates in a single reportable
segment, which consists of the development of a drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated
financial results of the Company. The CODM uses consolidated net income (loss) as the sole measure of segment profit or loss. The required
segment information, including significant segment expenses, is presented at Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--UseOfEstimates_zmvnkG6QTX85" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zUoSEeUK3TB8"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zG0A1VClo8q1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zOSF5nRCfQi3"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20241231_zuPcV34pXhV8" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_zZmG3YrZbOKd" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOkDrS9BPgeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zbpnMn2tEvs1"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--PrepaidInsurancePolicyTextBlock_z3h6e4ZR1uuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zBPYZfM44O72"&gt;Prepaid
Insurance&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--DeferredOfferingCostsPolicyTextBlock_zmXv6jpx1Dw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z5vbovG3uAmb"&gt;Offering
Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFKb0Ge7Xzcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zkvflM1oU2r9"&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20240101__20241231_z8kzl53Ud9r7" title="Legal and filing fees and costs"&gt;243,186&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--LegalFees_pp0p0_c20230101__20231231_z5i9qWOZxyQb" title="Legal and filing fees and costs"&gt;978,244&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively. Patent and licensing legal and
filing fees and costs are included in general and administrative costs in the Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zLGgas8MCWyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zGdRUYxAvfhl"&gt;Concentration
of Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9cCd0QpT6ze"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zD825rhACgR9"&gt;10%&lt;/span&gt;&lt;/span&gt; or more of general and administrative costs or research and development costs for the years ended December 31, 2024 and
2023 are described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the years ended December 31, 2024 and 2023 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwUSECDxAlwj" title="Concentration risk percentage"&gt;8.6%&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQXrAfWQzf68" title="Concentration risk percentage"&gt;23.3%&lt;/span&gt; of total general
and administrative costs, respectively. General and administrative costs for the year ended December 31, 2024 also include charges from
two vendors and consultants representing &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRJHqxTpIgMk" title="Concentration of risk, percentage"&gt;15.0%&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyddusgTwf8k" title="Concentration of risk, percentage"&gt;13.1%&lt;/span&gt;, respectively, of total general and administrative costs. General and administrative
costs for the year ended December 31, 2023 also include charges from a vendor and consultant representing &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z30MQm4Fjg0k" title="Concentration of risk, percentage"&gt;10.4%&lt;/span&gt; of total general and
administrative costs. General and administrative costs for the years ended December 31, 2024 and 2023 also included charges for the fair
value of stock options granted to directors and corporate officers representing &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_z9paTxDZXXX1" title="Concentration risk percentage"&gt;14.7%&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_zbM2PsTnRHK2" title="Concentration risk percentage"&gt;18.4%&lt;/span&gt;, respectively, of total general and administrative
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the year ended December 31, 2024 include charges from three vendors and consultants representing &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zHjn8TgPM1eh" title="Concentration of risk, percentage"&gt;39.2%&lt;/span&gt;, &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zoCCNC5i5Ujg" title="Concentration of risk, percentage"&gt;29.0%&lt;/span&gt;
and &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVdSOUKz5uX2" title="Concentration of risk, percentage"&gt;15.4%&lt;/span&gt;, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2023
include charges from three vendors and consultants representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNvRjDIHroyd" title="Concentration of risk, percentage"&gt;29.9%&lt;/span&gt;, &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zKJgDKbflNyh" title="Concentration of risk, percentage"&gt;25.2%&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5iMhCrmN43g" title="Concentration of risk, percentage"&gt;13.7%&lt;/span&gt;, respectively, of total research and development
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_z4Stpixsnnd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_z8gALVTKeQ5h"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#x2019;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at December 31, 2024 and 2023. In the event the Company was to determine that it would be able
to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be
credited to operations in the period such determination was made. Should the Company determine that it would not be able to realize all
or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period
such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2024 or 2023
and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.
Subsequent to December 31, 2024, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJ2AhX4EeRW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_znLUEeLScyNc"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#x2019;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zArJkAjk1hQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zh6QqgtvV183"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities
from Equity (&#x201c;ASC 480&#x201d;), and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#x2019;s own common stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance
outside of the Company&#x2019;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance
sheet date. At December 31, 2024 and 2023, the Company did not have any liability-classified warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zbaux3PEnad8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zonN5FB7w03a"&gt;Earnings
(Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkOy0A0pBYfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024 and 2023, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zHPj4DF7oZe6" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_z4VI50AUQvL9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zNebEdGefqK9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zSbnaTJ2wWQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z3WBLs00WJ0a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zmgHoDjTCpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;613,232&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zywad6fWeD06" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,494,514&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,433,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z3OYOmZ6i7Sh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzjL7LzueeNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z6jwXI0Q6Frk"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of &lt;span id="xdx_906_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20241231_zqKinyWzaDg6" title="Foreign currency average rate"&gt;1.0823&lt;/span&gt; and &lt;span id="xdx_905_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20230101__20231231_z5eezjnOYcmf" title="Foreign currency average rate"&gt;1.0820&lt;/span&gt; Euros per United States dollar, respectively. As of December 31,
2024 and 2023, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was not a party
to any foreign currency forward or exchange contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzbdSNTg8JPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zr6DQNoj1sf6"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments, which consists of accounts payable and accrued expenses is considered to be representative of
their respective fair values due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWV5z0CNHuEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zoYAQW06qCIj"&gt;Recent
Accounting Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-03,
Presentation of Financial Statements (Topic 205), Income Statement &#x2014; Reporting Comprehensive Income (Topic 220), Distinguishing
Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#x2014; Stock Compensation (Topic 718) (&#x201c;ASU 2023-03&#x201d;).
ASU 2023-03 amends the FASB Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting
Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting
Series Release 280 &#x2014; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide
any new guidance, there was no transition or effective date associated with its adoption. The Company adopted ASU 2023-03 immediately
upon its issuance in July 2023. The adoption of ASU 2023-03 did not have any impact on the Company&#x2019;s consolidated financial statement
presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure.&#160; ASU 2023-07
amends the FASB Accounting Standards Codification to require additional reportable segment disclosures of a public entity by requiring
disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, requiring other new disclosures,
and requiring enhanced interim disclosures.&#160; ASU 2023-07 requires public entities with a single reportable segment to provide all
the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280 on an interim and annual basis.&#160; ASU 2023-07
is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, and is applied
retrospectively.&#160;The Company adopted ASU 2023-07 effective January 1, 2024 for the 2024 annual period on a retrospective basis.&#160;The
adoption of ASU 2023-07 resulted in additional required segment-related disclosures (see Note 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures
(Subtopic 220-40). ASU 2024-03 amends the FASB Accounting Standards Codification to require specified information about certain costs
and expenses in the notes to the financial statements at each interim and annual reporting period, including disclosure of the amounts
of purchases of inventory; employee compensation; depreciation; intangible asset amortization; and depreciation, depletion, and amortization
included in each relevant expense caption on the face of the income statement within continuing operations that contains any of the expense
categories previously listed. Disclosure will also be required of the total amount of selling expenses and an entity&#x2019;s definition
of selling expenses in annual reporting periods. ASU 2024-03 does not change or remove current expense disclosure requirements, but does
affect where and how this information is presented in the notes to the financial statements. ASU 2024-03 is effective for annual reporting
periods beginning January 1, 2027, and interim periods within annual reporting periods beginning January 1, 2028. Early adoption is permitted.
The Company is in the process of evaluating ASU 2024-03 to determine its impact on the Company&#x2019;s consolidated financial statement
presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5bzgaVIIWQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zu3j216Ka7K9"&gt;Reclassifications&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the adoption of ASU 2023-07 effective January 1, 2024, certain reclassifications have been made to the prior year statement
of operations to conform it to the current year presentation. In presenting general and administrative costs on the Company&#x2019;s consolidated
statement of operations for the year ended December 31, 2023, $&lt;span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zeb3o5LTx6ah" title="Legal and filing fees and costs"&gt;1,718,180&lt;/span&gt; of compensation to related parties, $&lt;span id="xdx_902_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zPz4cLHRxZo1" title="Legal and filing fees and costs"&gt;978,244&lt;/span&gt; of patent and licensing
legal and filing fees and costs, and $&lt;span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSvkEDE7wNU9" title="Legal and filing fees and costs"&gt;1,495,712&lt;/span&gt; of other costs and expenses were shown separately. In presenting the Company&#x2019;s
consolidated statement of operations for the year ended December 31, 2024, the Company has combined these categories into general and
administrative costs in the accompanying consolidated statement of operations for the year ended December 31, 2023. These reclassifications
had no effect on the reported results of operations, including loss from operations and net loss.&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_858_zyhV3J125Fw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000436">&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zcsIdVU2V1Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zEuemcl2zLm9"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted
accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned
subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000438">&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zYvjq1FPqv17" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zoX5utclQqPk"&gt;Segment
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s President and Chief Executive Officer is the Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) and evaluates
performance and makes operating decisions about allocating resources based on internal financial data presented on a consolidated basis.
Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates in a single reportable
segment, which consists of the development of a drug class called Protein Phosphatase 2A inhibitors, and is comprised of the consolidated
financial results of the Company. The CODM uses consolidated net income (loss) as the sole measure of segment profit or loss. The required
segment information, including significant segment expenses, is presented at Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000440">&lt;p id="xdx_840_eus-gaap--UseOfEstimates_zmvnkG6QTX85" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zUoSEeUK3TB8"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for
services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000442">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zG0A1VClo8q1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zOSF5nRCfQi3"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions in the United States with high credit ratings and in accounts insured by the Federal Deposit Insurance
Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically
has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20241231_zuPcV34pXhV8" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20241231_zZmG3YrZbOKd" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan
Stanley Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not
experienced any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <LIXT:CashSIPCInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000446"
      unitRef="USD">500000</LIXT:CashSIPCInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000448">&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOkDrS9BPgeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zbpnMn2tEvs1"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development, conduct and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate.
Research and development costs also include the costs to manufacture compounds used in research and clinical trials, which are charged
to operations as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <LIXT:PrepaidInsurancePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000450">&lt;p id="xdx_845_ecustom--PrepaidInsurancePolicyTextBlock_z3h6e4ZR1uuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zBPYZfM44O72"&gt;Prepaid
Insurance&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</LIXT:PrepaidInsurancePolicyTextBlock>
    <LIXT:DeferredOfferingCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000452">&lt;p id="xdx_84C_ecustom--DeferredOfferingCostsPolicyTextBlock_zmXv6jpx1Dw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z5vbovG3uAmb"&gt;Offering
Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offering
costs consist of costs incurred with respect to equity financing transactions, including legal fees. Such costs are deferred and charged
to additional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings
are abandoned or terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</LIXT:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000454">&lt;p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFKb0Ge7Xzcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zkvflM1oU2r9"&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20240101__20241231_z8kzl53Ud9r7" title="Legal and filing fees and costs"&gt;243,186&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--LegalFees_pp0p0_c20230101__20231231_z5i9qWOZxyQb" title="Legal and filing fees and costs"&gt;978,244&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively. Patent and licensing legal and
filing fees and costs are included in general and administrative costs in the Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:LegalFees
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">243186</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000458"
      unitRef="USD">978244</us-gaap:LegalFees>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000460">&lt;p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zLGgas8MCWyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zGdRUYxAvfhl"&gt;Concentration
of Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that
represented &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9cCd0QpT6ze"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zD825rhACgR9"&gt;10%&lt;/span&gt;&lt;/span&gt; or more of general and administrative costs or research and development costs for the years ended December 31, 2024 and
2023 are described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the years ended December 31, 2024 and 2023 include charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwUSECDxAlwj" title="Concentration risk percentage"&gt;8.6%&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQXrAfWQzf68" title="Concentration risk percentage"&gt;23.3%&lt;/span&gt; of total general
and administrative costs, respectively. General and administrative costs for the year ended December 31, 2024 also include charges from
two vendors and consultants representing &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRJHqxTpIgMk" title="Concentration of risk, percentage"&gt;15.0%&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyddusgTwf8k" title="Concentration of risk, percentage"&gt;13.1%&lt;/span&gt;, respectively, of total general and administrative costs. General and administrative
costs for the year ended December 31, 2023 also include charges from a vendor and consultant representing &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z30MQm4Fjg0k" title="Concentration of risk, percentage"&gt;10.4%&lt;/span&gt; of total general and
administrative costs. General and administrative costs for the years ended December 31, 2024 and 2023 also included charges for the fair
value of stock options granted to directors and corporate officers representing &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_z9paTxDZXXX1" title="Concentration risk percentage"&gt;14.7%&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__custom--DirectorsAndCorporateOfficersMember_zbM2PsTnRHK2" title="Concentration risk percentage"&gt;18.4%&lt;/span&gt;, respectively, of total general and administrative
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the year ended December 31, 2024 include charges from three vendors and consultants representing &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zHjn8TgPM1eh" title="Concentration of risk, percentage"&gt;39.2%&lt;/span&gt;, &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zoCCNC5i5Ujg" title="Concentration of risk, percentage"&gt;29.0%&lt;/span&gt;
and &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20241231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVdSOUKz5uX2" title="Concentration of risk, percentage"&gt;15.4%&lt;/span&gt;, respectively, of total research and development costs. Research and development costs for the year ended December 31, 2023
include charges from three vendors and consultants representing &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNvRjDIHroyd" title="Concentration of risk, percentage"&gt;29.9%&lt;/span&gt;, &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zKJgDKbflNyh" title="Concentration of risk, percentage"&gt;25.2%&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5iMhCrmN43g" title="Concentration of risk, percentage"&gt;13.7%&lt;/span&gt;, respectively, of total research and development
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      id="Fact000461"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      id="Fact000462"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="Fact000464"
      unitRef="Pure">0.086</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="Fact000466"
      unitRef="Pure">0.233</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      id="Fact000468"
      unitRef="Pure">0.150</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_custom_GeneralAndAdministrativeMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      id="Fact000470"
      unitRef="Pure">0.131</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      id="Fact000472"
      unitRef="Pure">0.104</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember"
      decimals="INF"
      id="Fact000474"
      unitRef="Pure">0.147</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_DirectorsAndCorporateOfficersMember"
      decimals="INF"
      id="Fact000476"
      unitRef="Pure">0.184</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000478"
      unitRef="Pure">0.392</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000480"
      unitRef="Pure">0.290</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000482"
      unitRef="Pure">0.154</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000484"
      unitRef="Pure">0.299</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantTwoMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000486"
      unitRef="Pure">0.252</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_VendorAndConsultantThreeMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="Fact000488"
      unitRef="Pure">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000490">&lt;p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_z4Stpixsnnd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_z8gALVTKeQ5h"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due
to the uncertainty of the Company&#x2019;s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are
fully offset by a valuation allowance at December 31, 2024 and 2023. In the event the Company was to determine that it would be able
to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be
credited to operations in the period such determination was made. Should the Company determine that it would not be able to realize all
or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period
such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2024 or 2023
and does not anticipate any material amount of unrecognized tax benefits through December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.
Subsequent to December 31, 2024, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000492">&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJ2AhX4EeRW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_znLUEeLScyNc"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, contractors and consultants for services
rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally
time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, contractors, and consultants by measuring the cost of services
received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense
on the straight-line basis in the Company&#x2019;s financial statements over the vesting period of the awards. Recognition of compensation
expense for non-employees is in the same period and manner as if the Company had paid cash for the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <LIXT:WarrantsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000494">&lt;p id="xdx_84B_ecustom--WarrantsPolicyTextBlock_zArJkAjk1hQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zh6QqgtvV183"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities
from Equity (&#x201c;ASC 480&#x201d;), and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company&#x2019;s own common stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance
outside of the Company&#x2019;s control, among other conditions for equity classification. The Company has determined that the warrants
issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This assessment, which requires
the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the
warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required
to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet
all of the criteria for equity classification, the warrants are required to be liability-classified and recorded at their initial fair
value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value
of the warrants that are liability-classified are recognized as a non-cash gain or loss in the statement of operations at each balance
sheet date. At December 31, 2024 and 2023, the Company did not have any liability-classified warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

</LIXT:WarrantsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000496">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zbaux3PEnad8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zonN5FB7w03a"&gt;Earnings
(Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkOy0A0pBYfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024 and 2023, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zHPj4DF7oZe6" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_z4VI50AUQvL9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zNebEdGefqK9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zSbnaTJ2wWQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z3WBLs00WJ0a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zmgHoDjTCpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;613,232&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zywad6fWeD06" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,494,514&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,433,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z3OYOmZ6i7Sh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000498">&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkOy0A0pBYfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024 and 2023, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zHPj4DF7oZe6" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_z4VI50AUQvL9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zNebEdGefqK9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zSbnaTJ2wWQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;72,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_z3WBLs00WJ0a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zmgHoDjTCpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;613,232&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;552,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zywad6fWeD06" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,494,514&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,433,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000500"
      unitRef="Shares">72917</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000501"
      unitRef="Shares">72917</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000503"
      unitRef="Shares">808365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000504"
      unitRef="Shares">808365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_CommonStockOptionsMember"
      decimals="INF"
      id="Fact000506"
      unitRef="Shares">613232</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_CommonStockOptionsMember"
      decimals="INF"
      id="Fact000507"
      unitRef="Shares">552083</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000509"
      unitRef="Shares">1494514</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000510"
      unitRef="Shares">1433365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000512">&lt;p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzjL7LzueeNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z6jwXI0Q6Frk"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required
foreign currency to pay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for
financial statement purposes based on the foreign currency conversion rate in effect on the transaction date. The Company purchases the
requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss resulting from the purchase of the foreign
currency is included as foreign currency gain (loss) in the consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company incurred various costs and expenses denominated in Euros, which were converted
into United States dollars at the average rate of &lt;span id="xdx_906_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20240101__20241231_zqKinyWzaDg6" title="Foreign currency average rate"&gt;1.0823&lt;/span&gt; and &lt;span id="xdx_905_ecustom--ForeignCurrencyExchangeRateTranslation_pid_uPure_c20230101__20231231_z5eezjnOYcmf" title="Foreign currency average rate"&gt;1.0820&lt;/span&gt; Euros per United States dollar, respectively. As of December 31,
2024 and 2023, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was not a party
to any foreign currency forward or exchange contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <LIXT:ForeignCurrencyExchangeRateTranslation
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000514"
      unitRef="Pure">1.0823</LIXT:ForeignCurrencyExchangeRateTranslation>
    <LIXT:ForeignCurrencyExchangeRateTranslation
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000516"
      unitRef="Pure">1.0820</LIXT:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000518">&lt;p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzbdSNTg8JPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zr6DQNoj1sf6"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments, which consists of accounts payable and accrued expenses is considered to be representative of
their respective fair values due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000520">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWV5z0CNHuEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zoYAQW06qCIj"&gt;Recent
Accounting Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-03,
Presentation of Financial Statements (Topic 205), Income Statement &#x2014; Reporting Comprehensive Income (Topic 220), Distinguishing
Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation &#x2014; Stock Compensation (Topic 718) (&#x201c;ASU 2023-03&#x201d;).
ASU 2023-03 amends the FASB Accounting Standards Codification to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting
Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting
Series Release 280 &#x2014; General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide
any new guidance, there was no transition or effective date associated with its adoption. The Company adopted ASU 2023-03 immediately
upon its issuance in July 2023. The adoption of ASU 2023-03 did not have any impact on the Company&#x2019;s consolidated financial statement
presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure.&#160; ASU 2023-07
amends the FASB Accounting Standards Codification to require additional reportable segment disclosures of a public entity by requiring
disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, requiring other new disclosures,
and requiring enhanced interim disclosures.&#160; ASU 2023-07 requires public entities with a single reportable segment to provide all
the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280 on an interim and annual basis.&#160; ASU 2023-07
is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, and is applied
retrospectively.&#160;The Company adopted ASU 2023-07 effective January 1, 2024 for the 2024 annual period on a retrospective basis.&#160;The
adoption of ASU 2023-07 resulted in additional required segment-related disclosures (see Note 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures
(Subtopic 220-40). ASU 2024-03 amends the FASB Accounting Standards Codification to require specified information about certain costs
and expenses in the notes to the financial statements at each interim and annual reporting period, including disclosure of the amounts
of purchases of inventory; employee compensation; depreciation; intangible asset amortization; and depreciation, depletion, and amortization
included in each relevant expense caption on the face of the income statement within continuing operations that contains any of the expense
categories previously listed. Disclosure will also be required of the total amount of selling expenses and an entity&#x2019;s definition
of selling expenses in annual reporting periods. ASU 2024-03 does not change or remove current expense disclosure requirements, but does
affect where and how this information is presented in the notes to the financial statements. ASU 2024-03 is effective for annual reporting
periods beginning January 1, 2027, and interim periods within annual reporting periods beginning January 1, 2028. Early adoption is permitted.
The Company is in the process of evaluating ASU 2024-03 to determine its impact on the Company&#x2019;s consolidated financial statement
presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statements, including their presentation and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2024-01-01to2024-12-31" id="Fact000522">&lt;p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5bzgaVIIWQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zu3j216Ka7K9"&gt;Reclassifications&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the adoption of ASU 2023-07 effective January 1, 2024, certain reclassifications have been made to the prior year statement
of operations to conform it to the current year presentation. In presenting general and administrative costs on the Company&#x2019;s consolidated
statement of operations for the year ended December 31, 2023, $&lt;span id="xdx_90F_eus-gaap--LegalFees_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zeb3o5LTx6ah" title="Legal and filing fees and costs"&gt;1,718,180&lt;/span&gt; of compensation to related parties, $&lt;span id="xdx_902_eus-gaap--LegalFees_pp0p0_c20230101__20231231_zPz4cLHRxZo1" title="Legal and filing fees and costs"&gt;978,244&lt;/span&gt; of patent and licensing
legal and filing fees and costs, and $&lt;span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSvkEDE7wNU9" title="Legal and filing fees and costs"&gt;1,495,712&lt;/span&gt; of other costs and expenses were shown separately. In presenting the Company&#x2019;s
consolidated statement of operations for the year ended December 31, 2024, the Company has combined these categories into general and
administrative costs in the accompanying consolidated statement of operations for the year ended December 31, 2023. These reclassifications
had no effect on the reported results of operations, including loss from operations and net loss.&lt;/span&gt;&lt;/p&gt;
</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000524"
      unitRef="USD">1718180</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000526"
      unitRef="USD">978244</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000528"
      unitRef="USD">1495712</us-gaap:LegalFees>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000530">&lt;p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zkaepRb4dZIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_825_zU5STFEyee65"&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Company&#x2019;s President and Chief Executive Officer
(&#x201c;CEO&#x201d;).&#160; The Company&#x2019;s CODM evaluates performance and makes operating decisions about allocating resources based on financial
data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined
that it has a single operating segment composed of the consolidated financial results of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zP5EFrePXqoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#x2019;s
CODM and included in general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zPIJcxJyNOLl"&gt;Schedule
of Information by segment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zETcYSt7bFzi" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_z8UO2HUZbS84" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Compensation to related parties:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--CashBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_zCLm9UfEApc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: 13.5pt"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;753,124&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;944,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--StockBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_z46vrHQtW378" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 13.5pt"&gt;Stock-based&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;418,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maOEzto3_maGAAEzrRU_zbZOsPQhxxmd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Patent and licensing legal and filing fees and costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;978,244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--OtherConsultingAndProfessionalFees_i02_maOEzto3_maGAAEzrRU_zJT7l41PW0Q1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other consulting and professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;735,021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;655,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_zq1M5KBNuWJh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Insurance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434,444&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;442,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherCostAndExpenseOperating_i02_maOEzto3_maGAAEzrRU_zjykiRH4hWb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other costs and expenses, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;262,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;396,882&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02_mtGAAEzrRU_zzKr2726wAD8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total general and administrative costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,846,557&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,192,136&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#x2019;s
CODM, and included in research and development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zULItvwWvFu6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zDe9RiimY82h" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zXVQc8HCrOXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Clinical and related oversight costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;377,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;416,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zT0k6nIKot1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Preclinical research focused on development of additional novel anti-cancer compounds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329,438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;463,093&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_zmyzxwrGY0c3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Regulatory service costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,836&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,738&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zlssANikio66" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total research and development costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;726,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;898,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents a summary of research and development costs for the years ended December 31, 2024 and 2023 based on the respective
geographical regions where such costs were incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zgS3gpVgf6ac" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zQuUutuOvKPh" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zhI62rfIJFwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;462,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;359,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zi2qV338Hpf9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Spain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;295,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zO57OxTVorqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zBd5NB5odKhd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;210,362&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;226,150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_z4TX9qz5HvAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;726,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;898,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s total assets by segment at December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zgNLEZyDoDz1" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zAtd3ap42RPc" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zKvNy7KVPQK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Research and development assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;39,298&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;78,369&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zXnyYYYbrMg9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Corporate assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,106,205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,230,251&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Assets_iI_zIs5kCZrKhMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,145,503&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,308,620&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_znCrEZGWeial" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000532">&lt;p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zP5EFrePXqoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#x2019;s
CODM and included in general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zPIJcxJyNOLl"&gt;Schedule
of Information by segment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zETcYSt7bFzi" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_z8UO2HUZbS84" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Compensation to related parties:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--CashBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_zCLm9UfEApc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: 13.5pt"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;753,124&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;944,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--StockBasedCompensationToRelatedParties_i02_maOEzto3_maGAAEzrRU_z46vrHQtW378" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 13.5pt"&gt;Stock-based&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;418,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LegalFeesRelatingToPatentsAndLicensing_i02_maOEzto3_maGAAEzrRU_zbZOsPQhxxmd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Patent and licensing legal and filing fees and costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;978,244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--OtherConsultingAndProfessionalFees_i02_maOEzto3_maGAAEzrRU_zJT7l41PW0Q1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other consulting and professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;735,021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;655,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--GeneralInsuranceExpense_maGAAEzrRU_zq1M5KBNuWJh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Insurance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434,444&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;442,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherCostAndExpenseOperating_i02_maOEzto3_maGAAEzrRU_zjykiRH4hWb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other costs and expenses, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;262,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;396,882&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i02_mtGAAEzrRU_zzKr2726wAD8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total general and administrative costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,846,557&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,192,136&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company&#x2019;s
CODM, and included in research and development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zULItvwWvFu6" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zDe9RiimY82h" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalAndRelatedOversightCostsMember_zXVQc8HCrOXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Clinical and related oversight costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;377,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;416,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PreclinicalResearchMember_zT0k6nIKot1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Preclinical research focused on development of additional novel anti-cancer compounds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329,438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;463,093&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryServiceCostsMember_zmyzxwrGY0c3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Regulatory service costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,836&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,738&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_zlssANikio66" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total research and development costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;726,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;898,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents a summary of research and development costs for the years ended December 31, 2024 and 2023 based on the respective
geographical regions where such costs were incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zgS3gpVgf6ac" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zQuUutuOvKPh" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zhI62rfIJFwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;462,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;359,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zi2qV338Hpf9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Spain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;295,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zO57OxTVorqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_zBd5NB5odKhd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;210,362&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;226,150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_z4TX9qz5HvAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;726,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;898,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s total assets by segment at December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zgNLEZyDoDz1" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zAtd3ap42RPc" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ResearchAndDevelopmentMember_zKvNy7KVPQK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Research and development assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;39,298&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;78,369&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zXnyYYYbrMg9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Corporate assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,106,205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,230,251&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Assets_iI_zIs5kCZrKhMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,145,503&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,308,620&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <LIXT:CashBasedCompensationToRelatedParties
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000534"
      unitRef="USD">753124</LIXT:CashBasedCompensationToRelatedParties>
    <LIXT:CashBasedCompensationToRelatedParties
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000535"
      unitRef="USD">944977</LIXT:CashBasedCompensationToRelatedParties>
    <LIXT:StockBasedCompensationToRelatedParties
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">418422</LIXT:StockBasedCompensationToRelatedParties>
    <LIXT:StockBasedCompensationToRelatedParties
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000538"
      unitRef="USD">773203</LIXT:StockBasedCompensationToRelatedParties>
    <LIXT:LegalFeesRelatingToPatentsAndLicensing
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">243186</LIXT:LegalFeesRelatingToPatentsAndLicensing>
    <LIXT:LegalFeesRelatingToPatentsAndLicensing
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000541"
      unitRef="USD">978244</LIXT:LegalFeesRelatingToPatentsAndLicensing>
    <LIXT:OtherConsultingAndProfessionalFees
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">735021</LIXT:OtherConsultingAndProfessionalFees>
    <LIXT:OtherConsultingAndProfessionalFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000544"
      unitRef="USD">655854</LIXT:OtherConsultingAndProfessionalFees>
    <us-gaap:GeneralInsuranceExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">434444</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000547"
      unitRef="USD">442976</us-gaap:GeneralInsuranceExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">262360</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000550"
      unitRef="USD">396882</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">2846557</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000553"
      unitRef="USD">4192136</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ClinicalAndRelatedOversightCostsMember"
      decimals="0"
      id="Fact000555"
      unitRef="USD">377958</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ClinicalAndRelatedOversightCostsMember"
      decimals="0"
      id="Fact000556"
      unitRef="USD">416269</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_PreclinicalResearchMember"
      decimals="0"
      id="Fact000558"
      unitRef="USD">329438</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_PreclinicalResearchMember"
      decimals="0"
      id="Fact000559"
      unitRef="USD">463093</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_RegulatoryServiceCostsMember"
      decimals="0"
      id="Fact000561"
      unitRef="USD">18836</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_RegulatoryServiceCostsMember"
      decimals="0"
      id="Fact000562"
      unitRef="USD">18738</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000564"
      unitRef="USD">726232</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000565"
      unitRef="USD">898100</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_country_US"
      decimals="0"
      id="Fact000567"
      unitRef="USD">462566</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_country_US"
      decimals="0"
      id="Fact000568"
      unitRef="USD">359589</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_country_ES"
      decimals="0"
      id="Fact000570"
      unitRef="USD">51022</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_country_ES"
      decimals="0"
      id="Fact000571"
      unitRef="USD">295163</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_country_CN"
      decimals="0"
      id="Fact000573"
      unitRef="USD">2282</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_country_CN"
      decimals="0"
      id="Fact000574"
      unitRef="USD">17198</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_country_NL"
      decimals="0"
      id="Fact000576"
      unitRef="USD">210362</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_country_NL"
      decimals="0"
      id="Fact000577"
      unitRef="USD">226150</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000579"
      unitRef="USD">726232</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000580"
      unitRef="USD">898100</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_ResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000582"
      unitRef="USD">39298</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_custom_ResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000583"
      unitRef="USD">78369</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_us-gaap_CorporateMember"
      decimals="0"
      id="Fact000585"
      unitRef="USD">1106205</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_us-gaap_CorporateMember"
      decimals="0"
      id="Fact000586"
      unitRef="USD">4230251</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000588"
      unitRef="USD">1145503</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000589"
      unitRef="USD">4308620</us-gaap:Assets>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000591">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zTRFqv7VKJWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_82E_z46kftVfLe16"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zt9egMKEwHuf" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_z03YNqldrtk6" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#x2019;s certificate of incorporation. The Company has designated a total of &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zW0XETcgPNP4" title="Preferred stock, shares authorized"&gt;350,000&lt;/span&gt; shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The
holders of each tranche of &lt;span id="xdx_903_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zvAAN9XOS7Kd" title="Principal cash obligations and commitments"&gt;175,000&lt;/span&gt; shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to &lt;span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20150316__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYUIr7kuHtga" title="Preferred stock dividend, percentage"&gt;1&lt;/span&gt;% of the annual net revenue of the Company divided by &lt;span id="xdx_90B_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3UNnUqr0kpc" title="Annual net revenue"&gt;175,000&lt;/span&gt;, until converted or redeemed. As of December 31, 2024 and 2023, the
Company had &lt;span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zFQDS2gcNL9a" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zHAlDEbStNb2" title="Preferred stock, shares authorized"&gt;9,650,000&lt;/span&gt;&lt;/span&gt; shares of undesignated preferred stock, which may be issued with such rights and powers as the Board of Directors
may designate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockConversionBasis_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJAcJwmQyHrb" title="Preferred stock, conversion description"&gt;Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into &lt;span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2EKqeiLVeIl" title="Preferred stock convertible into common stock"&gt;0.20833&lt;/span&gt; shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zmvtyj5pRgvd" title="Gross proceeds from sale of transaction"&gt;21,875,000&lt;/span&gt;.&lt;/span&gt; The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have any cash liquidation preference rights or any registration rights. The &lt;span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zD0Ks7ts2Or2" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zohvtACnVNij" title="Preferred stock, shares outstanding"&gt;350,000&lt;/span&gt;&lt;/span&gt; outstanding shares of Series A Convertible
Preferred Stock were convertible into a total of &lt;span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z2ODX8a4jrmj" title="Preferred stock convertible into common stock"&gt;&lt;span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5qWdPOnMqi1" title="Preferred stock convertible into common stock"&gt;72,917&lt;/span&gt;&lt;/span&gt; shares of common stock at December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_z0SfTXUb0D76" title="Common stock, shares authorized"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z3wqLIwKIVpk" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zz3FLLUJ7Kf" title="Common stock, par value"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zmERsWlDAFP5" title="Common stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. As of December 31, 2024 and
2023, the Company had &lt;span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zCGsbj7NBPV7" title="Common stock, shares issued"&gt;&lt;span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zuKbOVAYKe17" title="Common stock, shares outstanding"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zQktoFsLzCsc" title="Common stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zgn7d56TjOX5" title="Common stock, shares outstanding"&gt;2,249,290&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of common stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 2, 2023, the Company effected a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRDCcoGwncCh" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reverse
split of its outstanding shares of common stock. The authorized number of shares of common stock and the par value per share were
not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split, with all
fractional shares being rounded up to the next whole share. All share and per share amounts and information presented herein have
been retroactively adjusted to reflect the reverse stock split for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 10, 2023, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkhwuyPbYqi" title="Stock issued new issue shares"&gt;1,250&lt;/span&gt; shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpTexyi45nZf" title="Stock issued new issue shares"&gt;1,250&lt;/span&gt; shares exercisable at $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9tBU7eNrWI6" title="Warrant exercise price"&gt;5.025&lt;/span&gt; per share for total cash proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBLbiKUrHHPb" title="Proceeds from warrant exercises"&gt;6,281&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
July 20, 2023, the Company sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230719__20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH3jFAxKmBS2" title="Number of common stock shares issued during period"&gt;180,000&lt;/span&gt; shares of common stock at a price of $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5fwlwYHLffd" title="Sale of stock price per share"&gt;6.00&lt;/span&gt; per share and pre-funded warrants to purchase &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWNhmqskRhT2" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt;
shares of common stock at a price of $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmbWyUkapLKa" title="Common Stock, Par or Stated Value Per Share"&gt;5.9999&lt;/span&gt; per pre-funded warrant to an institutional investor in a registered direct offering. The
pre-funded warrants had an exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z237LfrOg3Ji" title="Warrant exercise price"&gt;0.0001&lt;/span&gt; per share, were immediately exercisable upon issuance, and were valid and exercisable
until all pre-funded warrants were exercised in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period from July 24, 2023 through August 7, 2023, the &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6WAhVcMlkL8" title="Warrants to purchase shares"&gt;403,334&lt;/span&gt; pre-funded warrants, exercisable at $&lt;span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkyko0IIWk53" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per common share, were
exercised for total cash proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXwf5tWjImw3" title="Exercise of common stock options"&gt;41&lt;/span&gt;, resulting in the issuance of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230724__20230807__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqD0OkpYR6u3" title="Issuance of common stock"&gt;403,334&lt;/span&gt; shares of common stock. The pre-funded warrants were determined
to be common stock equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
a concurrent private placement to the institutional investor, the Company also sold warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zAYsELifG5R3" title="Warrants to purchase shares"&gt;583,334&lt;/span&gt; shares of common stock.
Each common warrant had an initial exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z8S4pRkbHWn8" title="Warrant exercise price"&gt;6.00&lt;/span&gt; per share, was immediately exercisable upon issuance, and expires &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmhg1yYQWJP3" title="Warrants term"&gt;five years&lt;/span&gt;
thereafter on &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsHaPvGtWCOg" title="Warrant expires date"&gt;July 20, 2028&lt;/span&gt;. The common warrants and the shares of common stock issuable upon exercise of the common warrants were not
registered under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon
exercise of the warrants were registered for resale on a registration statement on Form S-3 declared effective by the SEC on May 2, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
registered direct offering and the concurrent private placement generated gross proceeds of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zI0I8arUkIAb" title="Proceeds from issuance initial public offering"&gt;3,499,964&lt;/span&gt;. The total cash costs of the registered
direct offering and the private placement were $&lt;span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDnN1ImGPIZd" title="Costs of public offering"&gt;362,925&lt;/span&gt;, resulting in net proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNLHdqAgpA0g" title="Net proceeds from issuance of stock"&gt;3,137,039&lt;/span&gt;. Pursuant to the placement agent agreement,
the Company granted the placement agent warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zG8Ie7H25qfg" title="Warrants to purchase shares"&gt;35,000&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zQa5gEyPWks6" title="Warrant exercise price"&gt;6.60&lt;/span&gt; per share and
expiring on &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20230719__20230720__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zAaUw4R95965" title="Warrant expires date"&gt;July 20, 2028&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise prices of the warrants issued to the institutional investor (exercisable at $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230807__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z9YpXokFexdf" title="Warrant exercise price"&gt;6.00&lt;/span&gt; per share) and to the placement agent (exercisable
at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230807__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVJLwNN69Udi" title="Warrant exercise price"&gt;6.60&lt;/span&gt; per share) are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications, reorganizations,
or similar events affecting the Company&#x2019;s common stock. In addition, the warrants issued to the institutional investor contain
a &#x201c;fundamental transaction&#x201d; provision which provides that if any defined fundamental transactions are within the Company&#x2019;s
control and are consummated, the holder of the unexercised common stock warrants would be entitled to receive, at its option, in exchange
for extinguishment of such warrants, cash consideration equal to a Black-Scholes valuation amount, as defined in the warrant agreement.
The fundamental transaction provision includes (i) a sale, lease, assignment, transfer, conveyance or other disposition of all or substantially
all of the assets of the Company in one or a series of related transactions, or (ii) a change in control of the Company by which it,
directly or indirectly, in one or more related transactions, consummates a stock or share purchase agreement or other business combination
with another person or group, whereby such other person or group acquires more than 50% of the voting power of the common equity of the
Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
such fundamental transaction is not within the Company&#x2019;s control, including not being approved by the Company&#x2019;s Board of
Directors, the warrant holder would only be entitled to receive the same type or form of consideration (and in the same proportion) equal
to the Black-Scholes valuation amount of the remaining unexercised portion of the warrant on the date of consummation of such fundamental
transaction as the holders of the Company&#x2019;s common stock receive. Accordingly, these warrants are classified as a component of
permanent stockholders&#x2019; equity. The Company will account for any cash payment for a warrant redemption as a distribution from stockholders&#x2019;
equity, as and when a fundamental transaction is consummated and such cash payment is required to be made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhcIZXlq9Czh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#x2019;s
public offering, during the years ended December 31, 2024 and 2023 is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zA0LzxTe39m8" style="display: none"&gt;Schedule
of Warrants Outstanding&lt;/span&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvHUu21qIy06" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;190,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcSRgPR6Frqf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;50.161&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEZAjyDTOxd1" style="text-align: right" title="Number of Shares, Issued"&gt;618,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxMIT1R6kws8" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;6.034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqUPaLqudB04" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3w2UWFqXbO9" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHUVxVlSkml9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWqXzT6yUnuh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhtKS7HDS22" style="text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOBaUP6LtZg" style="text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;16.407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHRl5Z2KGZP7" style="text-align: right" title="Number of Shares, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0713"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdBlxcAjvoWb" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOztlHckLpi8" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0717"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpnGHNQtUagf" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0719"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqGSfEZcfqFb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0721"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYX1oEXjnIh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0723"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXeuv9vUD975" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPW2Yq38twX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXLrtH3fCSbe" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGs6rbVFADM5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zB8XJIi0ChUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjX90tWAUER5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAxpK8s0Bnv2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwQvuPayTsh" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zuJwvDR6Wpk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zJW3jkC8sjVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zlNz7iDJy66f" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants &lt;br/&gt; Outstanding (Shares)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 46%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BLW3JZyeU6" title="Exercise Prices"&gt;6.000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAv0MNL8T0Va" style="width: 45%; text-align: right" title="Warrants Outstanding Shares"&gt;583,334&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxcR0ejaDVdh" title="Exercise Prices"&gt;6.600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7JUSpnp3An2" style="text-align: right" title="Warrants Outstanding Shares"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOveWcXkvlOc" title="Exercise Prices"&gt;20.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zJfWm6ToHzy6" style="text-align: right" title="Warrants Outstanding Shares"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zZYsk5xZFzP" title="Exercise Prices"&gt;37.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvZQLxqzHFYb" style="text-align: right" title="Warrants Outstanding Shares"&gt;11,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zDjqAiGL4Xsg" title="Exercise Prices"&gt;57.000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zg9Z0wMJ1m7g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;149,700&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231_zCEMOz6bI6Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zh1iXQquaTbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants exercisable at $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrf3uLcQTI52" title="Warrants exercisable"&gt;57.00&lt;/span&gt; per share at December 31, 2024 consist of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyYYovZIwzWf" title="Warrants outstanding"&gt;1,497,000&lt;/span&gt; publicly-traded warrants, described herein on a pre-split
&lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20230602__20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF2HT8ouHQFj" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; basis, that were issued as part of the Company&#x2019;s November 2020 public offering of units, and are exercisable for a period
of five years thereafter. As a result of the 1-for-10 reverse split of the Company&#x2019;s common stock effective June 2, 2023, each
such publicly-traded warrant currently now represents the right to purchase 1/10th of a share of common stock at the original exercise
price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfw68oB2krba" title="Exercise price"&gt;5.70&lt;/span&gt; per share. Accordingly, the exercise of 10 warrants, each exercisable at $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4GkiwIoNwzf" title="Warrants exercisable"&gt;5.70&lt;/span&gt;, are required to acquire one share of post-split
common stock, which is equivalent to a purchase price of $&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20230602__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyJ17QWMjMJ8" title="Warrants and rights outstanding"&gt;57.00&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the closing fair market value of $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEMybhi9NBei" title="Fair market value of stock"&gt;2.03&lt;/span&gt; per share on December 31, 2024, there was no intrinsic value attributed to exercisable but
unexercised common stock warrants at December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000593"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000595"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000597"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesAuthorized>
    <LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000599"
      unitRef="Shares">175000</LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000601"
      unitRef="Pure">0.01</us-gaap:PreferredStockDividendRatePercentage>
    <LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000603"
      unitRef="Shares">175000</LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_UndesignatedPreferredStockMember"
      decimals="INF"
      id="Fact000605"
      unitRef="Shares">9650000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_UndesignatedPreferredStockMember"
      decimals="INF"
      id="Fact000607"
      unitRef="Shares">9650000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockConversionBasis
      contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember"
      id="Fact000609">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 0.20833 shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000.</us-gaap:PreferredStockConversionBasis>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000611"
      unitRef="Shares">0.20833</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember24649234"
      decimals="0"
      id="Fact000613"
      unitRef="USD">21875000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000615"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000617"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-01-012024-12-31_custom_SeriesAConvertiblePreferredStockMember24649234"
      decimals="INF"
      id="Fact000619"
      unitRef="Shares">72917</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-12-31_custom_SeriesAConvertiblePreferredStockMember24649234"
      decimals="INF"
      id="Fact000621"
      unitRef="Shares">72917</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000623"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000625"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000627"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000629"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000631"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000637"
      unitRef="Shares">2249290</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="Fact000639">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-092023-03-10_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000641"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-10_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000645"
      unitRef="USDPShares">5.025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000647"
      unitRef="USD">6281</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-192023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000649"
      unitRef="Shares">180000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000651"
      unitRef="USDPShares">6.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000653"
      unitRef="Shares">403334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000655"
      unitRef="USDPShares">5.9999</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000657"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-07_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000659"
      unitRef="Shares">403334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-08-07_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000661"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">41</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-242023-08-07_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">403334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000667"
      unitRef="Shares">583334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000669"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-07-20_us-gaap_PrivatePlacementMember_us-gaap_InvestorMember"
      id="Fact000671">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      id="Fact000673">2028-07-20</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000675"
      unitRef="USD">3499964</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000677"
      unitRef="USD">362925</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-07-192023-07-20_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000679"
      unitRef="USD">3137039</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">35000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-20_custom_PlacementAgentsMember"
      decimals="INF"
      id="Fact000683"
      unitRef="USDPShares">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2023-07-192023-07-20_custom_PlacementAgentsMember"
      id="Fact000685">2028-07-20</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-07_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000687"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-07_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000689"
      unitRef="USDPShares">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000691">&lt;p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhcIZXlq9Czh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company&#x2019;s
public offering, during the years ended December 31, 2024 and 2023 is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zA0LzxTe39m8" style="display: none"&gt;Schedule
of Warrants Outstanding&lt;/span&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvHUu21qIy06" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;190,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcSRgPR6Frqf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;50.161&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEZAjyDTOxd1" style="text-align: right" title="Number of Shares, Issued"&gt;618,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxMIT1R6kws8" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;6.034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqUPaLqudB04" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3w2UWFqXbO9" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHUVxVlSkml9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWqXzT6yUnuh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWhtKS7HDS22" style="text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOBaUP6LtZg" style="text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;16.407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHRl5Z2KGZP7" style="text-align: right" title="Number of Shares, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0713"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdBlxcAjvoWb" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zOztlHckLpi8" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0717"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpnGHNQtUagf" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0719"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqGSfEZcfqFb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0721"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_ztYX1oEXjnIh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0723"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXeuv9vUD975" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPW2Yq38twX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXLrtH3fCSbe" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zGs6rbVFADM5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zB8XJIi0ChUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zjX90tWAUER5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAxpK8s0Bnv2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable"&gt;16.407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwQvuPayTsh" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000693"
      unitRef="Shares">190031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000695"
      unitRef="USDPShares">50.161</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781"
      decimals="INF"
      id="Fact000697"
      unitRef="Shares">618334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CommonStockWarrantsMember24649781"
      decimals="INF"
      id="Fact000699"
      unitRef="USDPShares">6.034</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000709"
      unitRef="Shares">808365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000711"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">808365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000727"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812"
      id="Fact000729">P2Y11M26D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000731"
      unitRef="Shares">808365</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable
      contextRef="AsOf2023-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000733"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000735"
      unitRef="Shares">808365</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000737"
      unitRef="USDPShares">16.407</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageExercisePriceExercisable>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-12-31_custom_CommonStockWarrantsMember24649812"
      id="Fact000739">P2Y11M26D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm>
    <LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000741">&lt;p id="xdx_892_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zJW3jkC8sjVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zlNz7iDJy66f" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants &lt;br/&gt; Outstanding (Shares)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 46%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6BLW3JZyeU6" title="Exercise Prices"&gt;6.000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAv0MNL8T0Va" style="width: 45%; text-align: right" title="Warrants Outstanding Shares"&gt;583,334&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxcR0ejaDVdh" title="Exercise Prices"&gt;6.600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7JUSpnp3An2" style="text-align: right" title="Warrants Outstanding Shares"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOveWcXkvlOc" title="Exercise Prices"&gt;20.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zJfWm6ToHzy6" style="text-align: right" title="Warrants Outstanding Shares"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zZYsk5xZFzP" title="Exercise Prices"&gt;37.000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvZQLxqzHFYb" style="text-align: right" title="Warrants Outstanding Shares"&gt;11,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zDjqAiGL4Xsg" title="Exercise Prices"&gt;57.000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zg9Z0wMJ1m7g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;149,700&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20241231_zCEMOz6bI6Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;808,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact000743"
      unitRef="USDPShares">6.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact000745"
      unitRef="Shares">583334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact000747"
      unitRef="USDPShares">6.600</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact000749"
      unitRef="Shares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact000751"
      unitRef="USDPShares">20.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact000753"
      unitRef="Shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact000755"
      unitRef="USDPShares">37.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact000757"
      unitRef="Shares">11331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact000759"
      unitRef="USDPShares">57.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact000761"
      unitRef="Shares">149700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000763"
      unitRef="Shares">808365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000765"
      unitRef="USDPShares">57.00</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000767"
      unitRef="Shares">1497000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-06-022023-06-02_us-gaap_CommonStockMember"
      id="Fact000769">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-02_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000771"
      unitRef="USDPShares">5.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-02_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000773"
      unitRef="USDPShares">5.70</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-06-02_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000775"
      unitRef="USD">57.00</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact000777"
      unitRef="USDPShares">2.03</us-gaap:SharePrice>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000779">&lt;p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFqZGgdkYFwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_82E_zQhu5H8QRTr7"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related
party transactions include transactions with the Company&#x2019;s officers, directors and affiliates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment
Agreements with Officers&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting
of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment
agreements were automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice
prior to the end of the applicable one-year period, or by death, or by termination for cause. Except as noted below, these employment
agreements were automatically renewed for additional one-year periods in July and August 2021, 2022, 2023 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach
to continue to act as the Company&#x2019;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $&lt;span id="xdx_903_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zW9TkZvKIlTc" title="Annual salary"&gt;250,000&lt;/span&gt;.
The employment agreement with Dr. Kovach terminated upon his death on October 5, 2023. During the year ended December 31, 2023, the Company
paid $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ziKxBrQLEGEg" title="Compensation"&gt;190,860&lt;/span&gt; to Dr. Kovach under this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s
consolidated statement of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020, to act as the Company&#x2019;s Chief
Medical Officer, with an annual salary of $&lt;span id="xdx_90F_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember_zQn1R3EceS9e" title="Annual salary"&gt;150,000&lt;/span&gt;. Effective May 1, 2021, Dr. Miser&#x2019;s annual salary was increased to $&lt;span id="xdx_90F_eus-gaap--SalariesAndWages_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zb47GQ3wa3Mb" title="Increase in annual salary"&gt;175,000&lt;/span&gt;.
Dr. Miser was required to devote at least 50% of his business time to the Company&#x2019;s activities. On May 29, 2024, the Company elected
not to renew its employment agreement with Dr. Miser, as a result of which such employment agreement expired on July 31, 2024. During
the years ended December 31, 2024 and 2023, the Company paid $&lt;span id="xdx_900_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zhbwHRsbKls2" title="Compensation"&gt;102,083&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z9UDO1Trlt4g" title="Compensation"&gt;175,000&lt;/span&gt;, respectively, to Dr. Miser under this employment
agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations
for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#x2019;s Chief Administrative Officer, with an annual salary of $&lt;span id="xdx_901_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zrXKmKSzmK8a" title="Annual salary"&gt;120,000&lt;/span&gt;. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#x2019;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#x2019;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#x2019;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#x2019;s
annual salary was increased to $&lt;span id="xdx_901_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zaXTh3eb5yMg" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $&lt;span id="xdx_902_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zFsiOp3dbLX3" title="Compensation"&gt;200,000&lt;/span&gt;. Effective October 1, 2022, Mr. Forman was provided a monthly office rent allowance,
pursuant to which the Company paid $&lt;span id="xdx_90B_eus-gaap--PaymentsForRent_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zpX57SQlVGZk" title="Paid office rent"&gt;16,435&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zF30Nql6zjN6" title="Paid office rent"&gt;15,571&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively, on Mr. Forman&#x2019;s
behalf. The employment agreement with Mr. Forman terminated upon his resignation as an officer of the Company effective December 31,
2024. During the years ended December 31, 2024 and 2023, the Company paid $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAFmPNuuaDp2" title="Compensation"&gt;200,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z13pky0hmBs4" title="Compensation"&gt;200,000&lt;/span&gt;, respectively, to Mr. Forman under this
employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of
operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#x2019;s Vice President
and Chief Financial Officer, with an annual salary of $&lt;span id="xdx_905_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zWhgFA4Tr6G6" title="Annual salary"&gt;120,000&lt;/span&gt;. Effective May 1, 2021, Mr. Weingarten&#x2019;s annual salary was increased
to $&lt;span id="xdx_90A_eus-gaap--SalariesAndWages_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_z8H0NhtRJfth" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. During the years ended December 31, 2024 and 2023, the Company paid $&lt;span id="xdx_90D_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWa0gxkPCAAd" title="Compensation"&gt;175,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqGD2IbxApRd" title="Compensation"&gt;175,000&lt;/span&gt;, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements
of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company&#x2019;s President
and Chief Executive Officer and as Vice Chairman of the Board of Directors, with an annual salary of $&lt;span id="xdx_904_eus-gaap--SalariesAndWages_c20230925__20230926__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z4Oae3txdtd8" title="Annual salary"&gt;150,000&lt;/span&gt;. Effective October 6, 2023,
Mr. van der Baan was appointed as Chairman of the Board of Directors upon the death of Dr. Kovach on October 5, 2023. Mr. van der Baan&#x2019;s
annual salary may be increased from time to time at the sole discretion of the Board of Directors. In addition, Mr. van der Baan is eligible
to receive an annual bonus as determined at the sole discretion of the Board of Directors. The term of the employment agreement is for
three years and is automatically renewable for additional one-year periods unless terminated by either party, subject to early termination
provisions as described in the employment agreement. During the years ended December 31, 2024 and 2023, the Company paid $&lt;span id="xdx_904_eus-gaap--OfficersCompensation_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0V0iOHZR8s8" title="Compensation"&gt;153,495&lt;/span&gt; and
$&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zOq4r0L3xQwl" title="Compensation"&gt;40,639&lt;/span&gt;, respectively, to Mr. van der Baan under this employment agreement, which costs are included in general and administrative costs
in the Company&#x2019;s consolidated statement of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 31, 2024, the Company entered into a consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D. Pursuant to the agreement, effective
July 1, 2024, the Company engaged Dr. Schellens as a consultant, and, effective August 1, 2024, as the Company&#x2019;s Chief Medical
Officer. The term of the agreement is in effect from July 1, 2024 until the earliest of (i) termination by either party upon sixty days&#x2019;
notice, (ii) Dr. Schellens&#x2019; death or disability, or (iii) termination by the Company for breach as provided in the agreement. Under
the agreement, Dr. Schellens provides his services for two days per week with the specific days in each week based on arrangements agreed
to from time to time between Dr. Schellens and the Company&#x2019;s Chief Executive Officer. The Company pays Dr. Schellens an annual
compensation of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_uEUR_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zaBAXretHULa" title="Annual compensation"&gt;104,000&lt;/span&gt; Euros (approximately $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zHlqimYpTB59" title="Annual compensation"&gt;108,000&lt;/span&gt; as of December 31, 2024), payable on a monthly basis. During the year ended December
31, 2024, the Company paid $&lt;span id="xdx_908_eus-gaap--OfficersCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchellensMember_zuto7JslNzs" title="Compensation"&gt;56,226&lt;/span&gt; to Dr. Schellens under this consulting agreement, which costs are included in general and administrative
costs in the Company&#x2019;s consolidated statement of operations for such periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
as of June 15, 2022, Dr. Ren&#xe9; Bernards was appointed to the Company&#x2019;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. Upon
his appointment, it was agreed that Dr. Bernards would receive annual compensation for his services on the Board only in the form of
cash, in lieu of the annual June 30 grant of stock options as provided to the Company&#x2019;s other non-officer directors. During the
years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement
of operations of $&lt;span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_zWHf65OHqPsc" title="General administrative expense"&gt;10,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zL73ks6RIMkb" title="General administrative expense"&gt;40,000&lt;/span&gt;, respectively, with respect to his annual cash board compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the Company&#x2019;s efforts to preserve cash, effective with the quarter ended June 30, 2024, Dr. Bernards agreed to
receive equity-based compensation for his services on the Board, for the quarters ended June 30, 2024, September 30, 2024 and December
31, 2024. In order to reconcile his Board compensation with that of the other non-officer directors, Dr. Bernards has agreed to receive
the same Board compensation, both in form and amount, as the other non-officer directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Previously,
on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands
Cancer Institute, Amsterdam, one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations (see Note
8).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Compensatory
Arrangements for Members of the Board of Directors&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for
their services on the Board of Directors (the &#x201c;Board Plan&#x201d;), which was subsequently amended effective May 25, 2022 and July
9, 2024. Officers who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
compensation for directors, payable quarterly, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Base
director compensation - $&lt;span id="xdx_901_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zualF1oz72h4" title="Compensation"&gt;20,000&lt;/span&gt; per year (except for Dr. Bernards, who was paid an additional annual cash fee of $&lt;span id="xdx_90C_eus-gaap--Cash_iI_c20210409_zBw7KjuliqO7" title="Cash"&gt;40,000&lt;/span&gt;, in lieu of
the annual June &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_znivQYyz6Fkc" title="Stock option grant"&gt;30&lt;/span&gt; grant of stock option as described below, through March 31, 2024)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of audit committee &#x2013; additional $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_z58VxW5ZvtVl" title="Compensation"&gt;10,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of any other committees &#x2013; additional $&lt;span id="xdx_904_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zT083QGWGz6d" title="Compensation"&gt;5,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of audit committee &#x2013; additional $&lt;span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zbHC4xLPQtb1" title="Compensation"&gt;5,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of any other committees &#x2013; additional $&lt;span id="xdx_907_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_z9KzKYYgZmyg" title="Compensation"&gt;2,500&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the Company&#x2019;s efforts to preserve cash, the Board approved an amendment to the Board Plan, such that for the quarters
ended June 30, 2024, September 30, 2024 and December 31, 2024, the non-officer directors (including Dr. Bernards) received, in lieu of
cash compensation, stock options exercisable for a period of five years, vesting immediately, to purchase common stock at an exercise
price based on the closing market price upon issuance, with the amount of such stock options equal to the cash payment such director
would otherwise have been entitled to receive for such quarter, divided by their quarterly value as determined pursuant to the Black-Scholes
option-pricing model. The Board may extend this amendment to the Board Plan for additional quarterly periods subsequent to December 31,
2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
compensation for directors is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Appointment
of new directors &#x2013; The Company grants options to purchase &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zZjbuZOTbD8" title="Options, grants in period, gross"&gt;25,000&lt;/span&gt; shares of common stock, exercisable for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_zCDT3JB8W5wb" title="Options exercisable period"&gt;five years&lt;/span&gt;,
at the closing market price on the date of grant, vesting 50% on the grant date and the remaining &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_z3fzU7LrDJXi" title="Share-based payment award, award vesting period"&gt;50&lt;/span&gt;% vesting &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20240101__20241231_zt4jYsjxTIi7" title="Award vesting rights, percentage"&gt;12.5&lt;/span&gt;% on the last day of
each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued
service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution
or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company may elect to pay a one-time
cash fee of $&lt;span id="xdx_90C_eus-gaap--ManagementFeePayable_iI_c20241231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__custom--AppointmentGrantsOfOptionsMember_z2FvsVsl72b1" title="Cash fee payable"&gt;100,000&lt;/span&gt; to such director, payable upfront.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
grant of options to directors &#x2013; Effective on the last business day of the month of June, the Company grants options to purchase
&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zCqqL8u4SMV7" title="Options, grants in period, gross"&gt;10,000&lt;/span&gt; shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_znEBEdBWU0u1" title="Share-based payment award, award vesting period"&gt;12.5&lt;/span&gt;%
on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested, subject
to continued service. If any director has served for less than 12 full calendar months on the grant date, the amount of such stock option
grant is prorated based on the length of service of such director. At the discretion of the Board of Directors, for a nominee to the
Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of
the grant of such stock options, the Company may elect to pay an annual cash fee of $&lt;span id="xdx_907_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_za6dyUtxOLUl" title="Annual cash fee"&gt;40,000&lt;/span&gt; to such director, payable quarterly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
cash compensation paid to non-officer directors was $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zKYwGrzOEVCh" title="Stock based compensation"&gt;38,819&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_z783IsZNd8Mf" title="Stock based compensation"&gt;163,479&lt;/span&gt;, respectively, for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation granted to members of the Company&#x2019;s Board of Directors, officers and affiliates is described at Note 6.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zCkUAaQ2qT4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2024 and 2023, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_z0855uu1EIeb" style="display: none"&gt;Summary
of Related Party Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_zqFSlMulDgNa" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zV6VaY1AgAHb" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years
Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Related party costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zawWesLCRlSe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;753,124&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;944,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zl3IsGzqtrfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Stock-based&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;418,422&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zcTgqVL3cSRg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,171,546&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,718,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zBGjUe6mo7u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      id="Fact000781"
      unitRef="USD">250000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrKovachMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000783"
      unitRef="USD">190860</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember"
      decimals="0"
      id="Fact000785"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000787"
      unitRef="USD">175000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000789"
      unitRef="USD">102083</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000791"
      unitRef="USD">175000</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="Fact000793"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="Fact000795"
      unitRef="USD">175000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember"
      decimals="0"
      id="Fact000797"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="Fact000799"
      unitRef="USD">16435</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      id="Fact000801"
      unitRef="USD">15571</us-gaap:PaymentsForRent>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000803"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_EricJFormanMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000805"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      id="Fact000807"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      id="Fact000809"
      unitRef="USD">175000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000811"
      unitRef="USD">175000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000813"
      unitRef="USD">175000</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2023-09-252023-09-26_custom_EmploymentAgreementMember_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact000815"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000817"
      unitRef="USD">153495</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000819"
      unitRef="USD">40639</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_SchellensMember"
      decimals="0"
      id="Fact000821"
      unitRef="EUR">104000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_SchellensMember"
      decimals="0"
      id="Fact000823"
      unitRef="USD">108000</us-gaap:ShareBasedCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-12-31_custom_SchellensMember"
      decimals="0"
      id="Fact000825"
      unitRef="USD">56226</us-gaap:OfficersCompensation>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_srt_DirectorMember"
      decimals="0"
      id="Fact000827"
      unitRef="USD">10000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_srt_DirectorMember"
      decimals="0"
      id="Fact000829"
      unitRef="USD">40000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_srt_DirectorMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">20000</us-gaap:OfficersCompensation>
    <us-gaap:Cash
      contextRef="AsOf2021-04-09"
      decimals="0"
      id="Fact000833"
      unitRef="USD">40000</us-gaap:Cash>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Shares">30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember"
      decimals="0"
      id="Fact000837"
      unitRef="USD">10000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember"
      decimals="0"
      id="Fact000839"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember"
      decimals="0"
      id="Fact000841"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember"
      decimals="0"
      id="Fact000843"
      unitRef="USD">2500</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_NewIndependentDirectorMember"
      decimals="INF"
      id="Fact000845"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2024-01-012024-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember"
      id="Fact000847">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2024-01-012024-12-31_custom_NewIndependentDirectorMember"
      decimals="INF"
      id="Fact000849"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000851"
      unitRef="Pure">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ManagementFeePayable
      contextRef="AsOf2024-12-31_srt_DirectorMember_custom_AppointmentGrantsOfOptionsMember"
      decimals="0"
      id="Fact000853"
      unitRef="USD">100000</us-gaap:ManagementFeePayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember"
      decimals="INF"
      id="Fact000855"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember"
      decimals="INF"
      id="Fact000857"
      unitRef="Pure">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000859"
      unitRef="USD">40000</us-gaap:CostOfRevenue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">38819</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_IndependentDirectorMember"
      decimals="0"
      id="Fact000863"
      unitRef="USD">163479</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000865">&lt;p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zCkUAaQ2qT4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the years ended December 31, 2024 and 2023, is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_z0855uu1EIeb" style="display: none"&gt;Summary
of Related Party Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_zqFSlMulDgNa" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zV6VaY1AgAHb" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years
Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Related party costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zawWesLCRlSe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;753,124&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;944,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zl3IsGzqtrfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Stock-based&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;418,422&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zcTgqVL3cSRg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,171,546&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,718,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="From2024-01-012024-12-31_srt_DirectorMember24650984"
      decimals="0"
      id="Fact000867"
      unitRef="USD">753124</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-12-31_srt_DirectorMember24650984"
      decimals="0"
      id="Fact000868"
      unitRef="USD">944977</us-gaap:OfficersCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_srt_DirectorMember24650984"
      decimals="0"
      id="Fact000870"
      unitRef="USD">418422</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_srt_DirectorMember24650984"
      decimals="0"
      id="Fact000871"
      unitRef="USD">773203</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_srt_DirectorMember24650984"
      decimals="0"
      id="Fact000873"
      unitRef="USD">1171546</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_srt_DirectorMember24650984"
      decimals="0"
      id="Fact000874"
      unitRef="USD">1718180</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000876">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zAS0EvzUnC36" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_821_z5QSJ2YgHftl"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_z5GuizCV97Fi" title="Number of restricted stock issued"&gt;233,333&lt;/span&gt; shares of the Company&#x2019;s common stock, under terms
and conditions as determined by the Company&#x2019;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zTSz8EKwHV1c" title="Common shares avaliable for issuable"&gt;180,000&lt;/span&gt; shares, to a total of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zE4A1Cd4OWN8" title="Shares total"&gt;413,333&lt;/span&gt; shares.
On November 27, 2023, the stockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares
issuable thereunder by &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zbEgVAQBJBbd" title="Common shares avaliable for issuable"&gt;336,667&lt;/span&gt; shares, to a total of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231126__20231127__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zmDhV4NvBWMg" title="Shares total"&gt;750,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, unexpired stock options for &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zKgsl5FF78e7" title="Shares outstanding"&gt;613,232&lt;/span&gt; shares were issued and outstanding under the 2020 Plan and &lt;span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zDvSZPRmRuh9" title="Shares were available for issuance"&gt;136,768&lt;/span&gt; shares were
available for issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#x2019;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zavaGoiujWQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2024, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zNrDkvVspYj8" style="display: none"&gt;Schedule
of Fair Value of Each Option Award Estimated Assumption&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zClvD3qZD5I6" title="Risk-free interest rate"&gt;3.550&lt;/span&gt;%
    to &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zUtnvCVi5V68" title="Risk-free interest rate"&gt;4.290&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20241231_zpklP1HcI7Y8" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zD3o1Bin2H01" title="Expected volatility"&gt;125.59&lt;/span&gt;%
    to &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zWMs3o2xMUVa" title="Expected volatility"&gt;126.45&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zaKQpP0zrOp5" title="Expected life"&gt;2.5&lt;/span&gt;
    to &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zMg6pH8a5QH" title="Expected life"&gt;3.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zEV5Y5uG5HB8" title="Risk-free interest rate"&gt;4.565&lt;/span&gt;%
    to &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z08wtOj4FW7f" title="Risk-free interest rate"&gt;4.843&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_z9iTTxDtBjG1" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zlA1ii6t9nk3" title="Expected volatility"&gt;138.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zsz1Kn08Z9bl" title="Expected life"&gt;4.0&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zPslbr6NUISf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement with Eric J. Forman, Mr. Forman was granted
stock options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zMyTuv7VS1Y1" title="Stock options granted to purchase common stock, issued"&gt;5,833&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4G2aMjjXozc" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4pV6DzAFmV8" title="Stock options are exercisable price per share"&gt;71.40&lt;/span&gt; per share, which was equal to the closing market price of the
Company&#x2019;s common stock on the grant date. &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zgTKt8iooZE9" title="Stock option vested exercisable term"&gt;The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_90B_ecustom--FairValueOfStockOptions_pp0p0_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zkuoPl0FLrZ" title="Fair value of stock options"&gt;400,855&lt;/span&gt; ($&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVcsG7G5wyy1" title="Stock price per share"&gt;68.718&lt;/span&gt; per share), of which $&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zqdb3DKObyTj" title="Stock options fully vested amount, fair value"&gt;100,214&lt;/span&gt; was attributable to the portion of the stock options fully vested
on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock
options was charged to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded a charge to general and
administrative costs in the consolidated statement of operations for the year ended December 31, 2023 of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbAo5RYKuya1" title="Stock based compensation"&gt;61,501&lt;/span&gt; with respect to these
stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2020, in connection with an employment agreement with Dr. James S. Miser, M.D., Dr. Miser was granted stock options to purchase
&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zACfU2SfE6Wc" title="Stock options granted to purchase common stock, issued"&gt;8,333&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are exercisable for a
period of &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRJ9nhBgNAte" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z70Ro5BHCZ15" title="Stock options are exercisable price per share"&gt;71.40&lt;/span&gt; per share, which was equal to the closing market price of the Company&#x2019;s common
stock on the effective date of the employment agreement. &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zm28jaOS3r2" title="Stock options description"&gt;The options vested 25% on August 1, 2020, 2021 and 2022, respectively, with
the final 25% vesting on August 1, 2023.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $&lt;span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zmK0KxNHtiHj" title="Fair value of stock options"&gt;572,650&lt;/span&gt; ($&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zotTW5RlPWy8" title="Stock price per share"&gt;68.718&lt;/span&gt; per share), of which $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKieuDW6iOC" title="Stock options fully vested amount, fair value"&gt;143,163&lt;/span&gt; was attributable to the portion of the stock options fully
vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the
stock options was charged to operations ratably from August 1, 2020 through August 1, 2023. The Company recorded a charge to general
and administrative costs in the consolidated statement of operations for the year ended December 31, 2023 of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesSMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zvPSOWfDCLhc" title="Stock based compensation"&gt;83,544&lt;/span&gt; with respect to
these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 12, 2020, in connection with the employment agreement with Robert N. Weingarten, Mr. Weingarten was granted stock options to purchase
&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVsW0NWHhm51" title="Number of fully vested option exercisable"&gt;5,833&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are exercisable for a
period of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zvISUkkFWlC3" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zCiUPBIwy8sc" title="Stock options are exercisable price per share"&gt;71.40&lt;/span&gt; per share, which was equal to the closing market price of the Company&#x2019;s common
stock on the grant date. &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z8m4schk1qAc" title="Stock options description"&gt;The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August
12, 2023.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to
be $&lt;span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0Pzdq0hflf1" title="Fair value of stock options"&gt;400,855&lt;/span&gt; ($&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrRIMcEAWTe1" title="Stock price per share"&gt;68.718&lt;/span&gt; per share), of which $&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zE7V0Ey14iub" title="Stock options fully vested amount, fair value"&gt;100,214&lt;/span&gt; was attributable to the portion of the stock options fully vested on August 12, 2020
and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged
to operations ratably from August 12, 2020 through August 12, 2023. The Company recorded a charge to general and administrative costs
in the consolidated statement of operations for the year ended December 31, 2023 of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0ug49ODV8jc" title="Stock based compensation"&gt;61,501&lt;/span&gt; with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zzh6JhtbRQK3" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z1xkGjQa3fv9" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt;
at an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zeogJ2T3kR1e" title="Stock options are exercisable price per share"&gt;28.00&lt;/span&gt; per share (the closing market price on the grant date), &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_za37kSpZdctd" title="Stock options description"&gt;vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.&lt;/span&gt; The fair value of these stock options, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_ztzMK6qv9hjl" title="Fair value of stock options"&gt;658,363&lt;/span&gt; ($&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z9fgbPAnBtm4" title="Stock price per share"&gt;26.335&lt;/span&gt; per share), of which $&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zM1RVyhmbw31" title="Stock options fully vested amount, fair value"&gt;329,188&lt;/span&gt; was attributable
to the portion of the stock options fully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining
unvested portion of the fair value of the stock options was charged to operations ratably from May 11, 2021 through June 30, 2023. The
Company recorded a charge to general and administrative costs in the consolidated statement of operations for the year ended December
31, 2023 of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zrvzJ6LDjU1l" title="Stock based compensation"&gt;76,388&lt;/span&gt; with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2021, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember_zwOHHv1bIhF5" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zMlcx5RYY0S6" title="Number of fully vested option exercisable"&gt;50,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zfygF6b8UFc2" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zMSYmHmSxYQb" title="Stock options are exercisable price per share"&gt;30.30&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zxhvTON12Tne" title="Stock options description"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.&lt;/span&gt;
The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zin5rP0MyYVb" title="Fair value of stock options"&gt;1,421,095&lt;/span&gt;
($&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zMsdvsDDo0z1" title="Stock price per share"&gt;28.423&lt;/span&gt; per share), which was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded a charge to
general and administrative costs in the consolidated statement of operations for the year ended December 31, 2023 of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z8jzQPKUfMUg" title="Stock based compensation"&gt;211,413&lt;/span&gt; with respect
to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Mr. van der Baan was granted stock options to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zIE3nq5lOfMc" title="Number of fully vested option exercisable"&gt;25,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of
&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z7hpvadKEowh" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zsAaB0CFkOx2" title="Stock options are exercisable price per share"&gt;7.40&lt;/span&gt; per share (the closing market price on the grant date), &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zRZQNRPemM1l" title="Stock options description"&gt;vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.&lt;/span&gt; The
fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zJiFnELwH7y4" title="Fair value of stock options"&gt;158,525&lt;/span&gt; ($&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z1nn1O4rlXfj" title="Stock price per share"&gt;6.341&lt;/span&gt;
per share), of which $&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zPfqCoQheYTc" title="Stock options granted to purchase common stock, issued"&gt;79,263&lt;/span&gt; was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from
June 17, 2022 through June 30, 2024. During the years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative
costs in the consolidated statement of operations of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zeTkbZxU9gsg" title="Stock based compensation"&gt;19,390&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zj0OTRT68Mii" title="Stock based compensation"&gt;38,885&lt;/span&gt;, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2022, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zhGWiPw0bW5g" title="Fair value of stock options"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp5d_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z2ADy4wM81gd" title="Stock price per share"&gt;50,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dc_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zG5wpfh4aXq9" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z6ahBUqJVBCi" title="Stock options are exercisable price per share"&gt;7.40&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_z9vLLybWDl5c" title="Stock options description"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_909_ecustom--FairValueOfStockOptions_pp0p0_c20220630__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zeNHdbd3Njw3" title="Fair value of stock options"&gt;316,700&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zWZPbCZ69Vd2" title="Stock price per share"&gt;6.334&lt;/span&gt; per share), which was charged to operations ratably from July 1, 2022 through June 30, 2024. During
the years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement
of operations of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zPbQ2VaJBnM5" title="Stock based compensation"&gt;47,310&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsOneMember_zxZbwBXmbDF9" title="Stock based compensation"&gt;94,881&lt;/span&gt;, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zNzhFeiDs7G1" title="Number of fully vested option exercisable"&gt;20,000&lt;/span&gt; shares
(a total of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zx7DjRwuqfx7" title="Number of fully vested option exercisable"&gt;80,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zd9I7E8Ermw6" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zf0lZSyktps4" title="Share price"&gt;20.00&lt;/span&gt;
per share, &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zP6s0urCCtu4" title="Stock options description"&gt;vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.&lt;/span&gt; The
total fair value of the &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zmjp9j9IwPJ1" title="Stock options granted to purchase common stock, issued"&gt;80,000&lt;/span&gt; stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$&lt;span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_znEf26e1q3Rd" title="Fair value of stock options"&gt;262,560&lt;/span&gt; ($&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z6yEW44TiIGb" title="Stock price per share"&gt;3.282&lt;/span&gt; per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the
years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement
of operations of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zUJV4XJcERx8" title="Stock based compensation"&gt;42,565&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zhkFQvPLdmAd" title="Stock based compensation"&gt;61,448&lt;/span&gt;, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2023, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__srt--DirectorMember_zUVmBb1944ac" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z66LSaKS7KYk" title="Number of fully vested option exercisable"&gt;40,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zCg5ynPtkov9" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zUCPAZNtCWqc" title="Exercise price"&gt;5.88&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zxgGWCzODHLh" title="Share based compensation vesting rights, percentage"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_908_ecustom--FairValueOfStockOptions_pp0p0_c20230630__20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zHbluKpuIore" title="Fair value of stock options"&gt;192,593&lt;/span&gt; ($&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pp4d_c20230630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zvnHSF4cmcR6" title="Stock price per share"&gt;4.8131&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025.
During the years ended December 31, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z2N2fdJcahqb" title="Stock based compensation"&gt;96,532&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zsTC1wZp8nmg" title="Stock based compensation"&gt;48,464&lt;/span&gt;, respectively, with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted stock
options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zra8WHrxR603" title="Options, grants in period, gross"&gt;250,000&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zrnnqKn9guA6" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z6JFikwDG9Y7" title="Stock options are exercisable price per share"&gt;1.95&lt;/span&gt; per share, which was equal to the closing market price of the
Company&#x2019;s common stock on the grant date. &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zJ2jJ1RO191k" title="Options vesting term"&gt;The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service.&lt;/span&gt; The fair value of these stock options,
as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_904_ecustom--FairValueOfStockOptions_pp0p0_c20230925__20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKATwL4QezPd" title="Fair value of stock options"&gt;403,066&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20230926__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zAuqBnWIHYLl" title="Stock price per share"&gt;1.612&lt;/span&gt; per share), which is being charged
to operations ratably from September 26, 2023 through September 30, 2026. During the years ended December 31, 2024 and 2023, the Company
recorded charges to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zIsz7mX8F6Aa" title="Stock based compensation"&gt;134,114&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BasvanderBaanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRanRFYcfPV4" title="Stock based compensation"&gt;35,178&lt;/span&gt;, respectively,
with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2024, the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the four non-officer directors of the Company stock options to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zIcLW1DcpXff" title="Number of fully vested option exercisable"&gt;10,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zY05fABykAe7" title="Number of fully vested option exercisable"&gt;40,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_z9uginQJ5ym4" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zdAow8K7fJzg" title="Exercise price"&gt;2.37&lt;/span&gt; per share
(the closing market price on the grant date), &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zmoEUrdG4Kt7" title="Share based compensation vesting rights, percentage"&gt;vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_90A_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zB463LtqCsJ2" title="Fair value of stock options"&gt;73,976&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__srt--DirectorMember_zkI1jrMrewl1" title="Stock price per share"&gt;1.8494&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2026.
During the year ended December 31, 2024, the Company record a charge general and administrative costs in the consolidated statement of
operations of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_zpoC8URmx8J4" title="Stock based compensation"&gt;18,648&lt;/span&gt; with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2024, the Board of Directors, in conjunction with the Company&#x2019;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_z2wpVDiIz68d" title="Fair value of stock options"&gt;16,598&lt;/span&gt; stock options to purchase shares of the Company&#x2019;s common stock, exercisable for a period
of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zY6AOdCPTgD3" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_z9fiqbloed59" title="Exercise price"&gt;2.37&lt;/span&gt; per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_ziKDphPSejHf" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended June 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $&lt;span id="xdx_905_ecustom--FairValueOfStockOptions_pp0p0_c20240630__20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zrGK7aE3H0y2" title="Fair value of stock options"&gt;27,500&lt;/span&gt; ($&lt;span id="xdx_905_eus-gaap--SharePrice_iI_pp4d_c20240630__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zqU48oqYeWP" title="Stock price per share"&gt;1.6570&lt;/span&gt; per share), which was charged to operations on June 30, 2024, the date on which the
stock options were fully vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 1, 2024, in connection with the consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D., Dr. Schellens was granted stock options
to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zniZHl3nv6a1" title="Fair value of stock options"&gt;15,000&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zwpIisoII6s7" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise e price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zXVyoKcihSA9" title="Exercise price"&gt;2.39&lt;/span&gt; per share, which was equal to the closing market price of the Company&#x2019;s
common stock on the grant date. &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_pid_dp_uPure_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zoIJuGIjF7te" title="Share based compensation vesting rights, percentage"&gt;The options vest quarterly over a three-year period commencing on the last day of each calendar quarter
commencing September 30, 2024.&lt;/span&gt; The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_906_ecustom--FairValueOfStockOptions_pp0p0_c20240701__20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_z53mJUW80PCh" title="Fair value of stock options"&gt;29,074&lt;/span&gt; ($&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20240701__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_z4EBCzcjLuVi" title="Stock price per share"&gt;1.9382&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2027.
During the year ended December 31, 2024, the Company record a charge general and administrative costs in the consolidated statement of
operations of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SchellensMember_zfRHcERCYs68" title="Stock based compensation"&gt;4,863&lt;/span&gt; with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 30, 2024, the Board of Directors, in conjunction with the Company&#x2019;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember_zf3hl42bOGB" title="Fair value of stock options"&gt;21,217&lt;/span&gt; stock options to purchase shares of the Company&#x2019;s common stock, exercisable for a period
of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zLTWU4TpCZJf" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zIsLNLDLwf29" title="Exercise price"&gt;1.87&lt;/span&gt; per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zWPM7wwnj2Df" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended September 30, 2024, divided by their quarterly value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $&lt;span id="xdx_901_ecustom--FairValueOfStockOptions_pp0p0_c20240930__20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zZ61bb60kkW5" title="Fair value of stock options"&gt;27,500&lt;/span&gt; ($&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20240930__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zkO5iVOtult7" title="Stock price per share"&gt;1.2961&lt;/span&gt; per share), which was charged to operations on September 30, 2024, the date on which
the stock options were fully vested.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 20, 2025, the Board of Directors, in conjunction with the Company&#x2019;s efforts to preserve cash, granted to the four non-officer
directors of the Company a total of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCT6jE6OTBNc" title="Fair value of stock options"&gt;16,665&lt;/span&gt; stock options to purchase shares of the Company&#x2019;s common stock, exercisable for a period
of &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSOKuGRsLkcc" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; at an exercise price of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsw1EgAHQWXb" title="Exercise price"&gt;2.33&lt;/span&gt; per share (the closing market price on the grant date) The stock options were granted in
lieu of cash compensation, are exercisable for a period of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dc_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpqM61ZhgShj" title="Stock option vested exercisable term"&gt;five years&lt;/span&gt; and were immediately vested. The number of stock options granted
to each of the four non-officer directors of the Company was equal to the cash payment such director would otherwise have been entitled
to receive for the quarter ended December 31, 2024, divided by their grant date value as determined pursuant to the Black-Scholes option-pricing
model, and was determined to be $&lt;span id="xdx_90E_ecustom--FairValueOfStockOptions_pp0p0_c20250120__20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJ7qnbKysjw9" title="Fair value of stock options"&gt;27,500&lt;/span&gt; ($&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pp5d_c20250120__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfvM0U1tg9g5" title="Stock price per share"&gt;1.65002&lt;/span&gt; per share). The grant date value of the stock options of $&lt;span id="xdx_907_ecustom--FairValueOfStockOptions_pp0p0_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FourNonOfficerDirectorsMember_zp2wV1mNfFc2" title="Fair value of stock options"&gt;27,500&lt;/span&gt; was accrued at December
31, 2024 and charged to operations at that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#x2019;s Board of Directors at the
Company&#x2019;s annual meeting of stockholders held on October 7, 2022. Gil Schwartzberg, a former director of the Company, died on October
30, 2022. Dr. John S. Kovach, the Chairman of the Board of Directors and the Company&#x2019;s President and Chief Executive Officer, and
Chief Scientific Officer, died on October 5, 2023, the employment agreement of the Company&#x2019;s Chief Medical Officer, Dr. James S.
Miser expired on July 31, 2024, and the employment agreement of the Company&#x2019;s Vice President and Chief Operating Officer, Eric
J. Forman, terminated upon his resignation from the Company on December 31, 2024. Accordingly, the unvested stock options for each such
person ceased vesting effective as of the respective dates that their services to the Company terminated. Furthermore, the expiration
date of all vested stock options owned by each such person contractually expire one year from the respective dates that their services
to the Company terminate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zLmHfiQDu9Vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the years ended December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zgC3DbVUULNd" style="display: none"&gt;Summary
of Stock-based Compensation Costs&lt;/span&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zCPUK4slL2Rf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zD7ueh03xcgj" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zw41nmCfHsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Related parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;418,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zRIWM6L1xRA2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Non-related parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1161"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_zC9hb6zYcjhj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total stock-based compensation costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;418,422&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zNtVSvWUGJ02" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWFBvOWESuj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2024 and 2023
is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z8jCAeDDOI2f" style="display: none"&gt;Summary
of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                                                                                                                                                                                                                                                               Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual Life&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(in Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zEqJTGSvK8w6" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;389,479&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zFVS6abLMYZj" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;29.183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zNz0eVZiNNlb" style="text-align: right" title="Number of shares, granted"&gt;290,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zhUt0lVuxo7f" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zyMcabLTWXEj" style="text-align: right" title="Number of shares, exercised"&gt;(1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zoZSsYFi1C96" style="text-align: right" title="Weighted average exercise price, exercised"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvzjbhKsNVA4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired"&gt;(126,146&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z3eDmD362pL5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;28.687&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zNsZKEOEHbQ3" style="text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;552,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zdAC1ThDecti" style="text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;15.330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231_z5nJTobYUYk5" style="text-align: right" title="Number of shares, granted"&gt;92,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zUaVZz4zovPa" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_ziyRLtF7njf2" style="text-align: right" title="Number of shares, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zgg5FRnlwTeb" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1195"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231_zmUY0rVkgze3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired"&gt;(31,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_z2fVu7X2tNAd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;35.368&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zisLJpd1Xp63" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;613,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zniAOJtrgp25" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;12.317&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_z3FMT0xDwTD1" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_zrlZMuvw59Tf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;252,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zW8Vuv6cQ5Pc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;28.387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zcFNdfHDkKz9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;409,897&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z4GpV6jBnfXd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;17.100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zqqRxBwPm26a" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zp7zS8mJVt6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $&lt;span id="xdx_909_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20240101__20241231_zNusLmbTe0Ca" title="Deferred compensation expense for unvested stock options"&gt;375,000&lt;/span&gt; at December 31, 2024, which
will be recognized subsequent to December 31, 2024 over a weighted-average period of approximately &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20240101__20241231_z7hrdWB2apc1" title="Weighted-average recognition period"&gt;19&lt;/span&gt; months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxCENmtaZDP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zATPZYEZtqe7" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options &lt;br/&gt; Outstanding (Shares)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zUdjPHIoTpU1" style="width: 29%; text-align: right" title="Exercise Prices"&gt;1.870&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zPLnqMyc8LC8" style="width: 29%; text-align: right" title="Options Outstanding (Shares)"&gt;21,217&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhfjeM9xS2H" style="width: 28%; text-align: right" title="Options Exercisable (Shares)"&gt;21,217&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zMlBOsmIQWDe" style="text-align: right" title="Exercise Prices"&gt;1.950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbGfTIdPEjzj" style="text-align: right" title="Options Outstanding (Shares)"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zJPf0fapi55a" style="text-align: right" title="Options Exercisable (Shares)"&gt;104,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zDZKuhgTEYV5" style="text-align: right" title="Exercise Prices"&gt;2.370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zMS7bvdTvIjg" style="text-align: right" title="Options Outstanding (Shares)"&gt;56,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWJIZmt3Iha" style="text-align: right" title="Options Exercisable (Shares)"&gt;26,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zoKtlMKICBRg" style="text-align: right" title="Exercise Prices"&gt;2.390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z4184IydkpKj" style="text-align: right" title="Options Outstanding (Shares)"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3CYfCHKP3ml" style="text-align: right" title="Options Exercisable (Shares)"&gt;2,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z6BAhCpDtVil" style="text-align: right" title="Exercise Prices"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4oo7pdUWGwd" style="text-align: right" title="Options Outstanding (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z9F94HjKKxe" style="text-align: right" title="Options Exercisable (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zDUtY0ROnTQc" style="text-align: right" title="Exercise Prices"&gt;5.880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z9gkiVfuIA9i" style="text-align: right" title="Options Outstanding (Shares)"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSwKjUz8Ptra" style="text-align: right" title="Options Exercisable (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zINl9Gix6yWk" style="text-align: right" title="Exercise Prices"&gt;7.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqvBQe5D6csj" style="text-align: right" title="Options Outstanding (Shares)"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zopgLrWifA3d" style="text-align: right" title="Options Exercisable (Shares)"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zYxWTpuH3XF1" style="text-align: right" title="Exercise Prices"&gt;20.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zeIU5jit3mTj" style="text-align: right" title="Options Outstanding (Shares)"&gt;45,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8G91Hl00Zx4" style="text-align: right" title="Options Exercisable (Shares)"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zXocKwlCnDA3" style="text-align: right" title="Exercise Prices"&gt;20.600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zTIFtFO3b0O5" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO5FIkIDEdge" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zhKpThSwUhSg" style="text-align: right" title="Exercise Prices"&gt;28.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zk8fo0MKpFw5" style="text-align: right" title="Options Outstanding (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zC7NtmxlyU4" style="text-align: right" title="Options Exercisable (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zIDrWpTVGmDl" style="text-align: right" title="Exercise Prices"&gt;30.300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSZ3Uzb1Lduk" style="text-align: right" title="Options Outstanding (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1sfqEiGkF5a" style="text-align: right" title="Options Exercisable (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z4XC1cRXhEk6" style="text-align: right" title="Exercise Prices"&gt;32.100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZRbvYz7Twhf" style="text-align: right" title="Options Outstanding (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zPbAT7QuotZe" style="text-align: right" title="Options Exercisable (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zm8x6BwcAAul" style="text-align: right" title="Exercise Prices"&gt;60.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zGbd8qGCO71i" style="text-align: right" title="Options Outstanding (Shares)"&gt;8,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zJRDC1T6atcg" style="text-align: right" title="Options Exercisable (Shares)"&gt;8,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zbIZs6lY2Ai1" style="text-align: right" title="Exercise Prices"&gt;71.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPm1YGFhbvp" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zAjXdDdK80Ec" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_ziws5S9oXQ66" style="padding-bottom: 1pt; text-align: right" title="Exercise Prices"&gt;120.000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj7QDC3nkmzh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;8,334&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zylMGmJKZVg5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;8,334&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_z7BBJromCTEi" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"&gt;613,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231_zUWwimlEsfRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;409,897&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zOAlgQxtv9Og" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the closing fair market value of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20240101__20241231_zipOr7b9aRXa" title="Fair market value, per share"&gt;2.03&lt;/span&gt; per share on December 31, 2024, the intrinsic value attributed to exercisable but unexercised
common stock options was approximately $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_do_c20241231_zJYMgeKnJRM2" title="Intrinsic value"&gt;12,000&lt;/span&gt; at December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
stock options to acquire &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231_zLAN0yFnJN0a" title="Outstanding stock options to acquire shares of common stock not vested"&gt;203,334&lt;/span&gt; shares of the Company&#x2019;s common stock had not vested at December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the exercise of such stock options, the Company expects to satisfy the related stock obligations through the issuance of authorized but
unissued shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Shares">233333</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact000880"
      unitRef="Shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">413333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">336667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-11-262023-11-27_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact000886"
      unitRef="Shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">613232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact000890"
      unitRef="Shares">136768</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000892">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zavaGoiujWQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2024, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zNrDkvVspYj8" style="display: none"&gt;Schedule
of Fair Value of Each Option Award Estimated Assumption&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zClvD3qZD5I6" title="Risk-free interest rate"&gt;3.550&lt;/span&gt;%
    to &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zUtnvCVi5V68" title="Risk-free interest rate"&gt;4.290&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20240101__20241231_zpklP1HcI7Y8" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zD3o1Bin2H01" title="Expected volatility"&gt;125.59&lt;/span&gt;%
    to &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zWMs3o2xMUVa" title="Expected volatility"&gt;126.45&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zaKQpP0zrOp5" title="Expected life"&gt;2.5&lt;/span&gt;
    to &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zMg6pH8a5QH" title="Expected life"&gt;3.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options requiring an assessment of value during the year ended December 31, 2023, the fair value of each stock option award was
estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zEV5Y5uG5HB8" title="Risk-free interest rate"&gt;4.565&lt;/span&gt;%
    to &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z08wtOj4FW7f" title="Risk-free interest rate"&gt;4.843&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_z9iTTxDtBjG1" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20231231_zlA1ii6t9nk3" title="Expected volatility"&gt;138.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zsz1Kn08Z9bl" title="Expected life"&gt;4.0&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact000894"
      unitRef="Pure">0.03550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000896"
      unitRef="Pure">0.04290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000898"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Pure">1.2559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000902"
      unitRef="Pure">1.2645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact000904">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact000906">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact000908"
      unitRef="Pure">0.04565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000910"
      unitRef="Pure">0.04843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000912"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000914"
      unitRef="Pure">1.3805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-12-31" id="Fact000916">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="Fact000918"
      unitRef="Shares">5833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      id="Fact000920">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="2"
      id="Fact000922"
      unitRef="USDPShares">71.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      id="Fact000924">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000926"
      unitRef="USD">400855</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="4"
      id="Fact000928"
      unitRef="USDPShares">68.718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000930"
      unitRef="USD">100214</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000932"
      unitRef="USD">61501</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="Fact000934"
      unitRef="Shares">8333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      id="Fact000936">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="2"
      id="Fact000938"
      unitRef="USDPShares">71.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      id="Fact000940">The options vested 25% on August 1, 2020, 2021 and 2022, respectively, with
the final 25% vesting on August 1, 2023.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000942"
      unitRef="USD">572650</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="4"
      id="Fact000944"
      unitRef="USDPShares">68.718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-07-302020-08-01_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">143163</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_DrJamesSMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000948"
      unitRef="USD">83544</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="Fact000950"
      unitRef="Shares">5833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      id="Fact000952">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="2"
      id="Fact000954"
      unitRef="USDPShares">71.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      id="Fact000956">The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August
12, 2023.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000958"
      unitRef="USD">400855</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="4"
      id="Fact000960"
      unitRef="USDPShares">68.718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000962"
      unitRef="USD">100214</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact000964"
      unitRef="USD">61501</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="INF"
      id="Fact000966"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      id="Fact000968">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="2"
      id="Fact000970"
      unitRef="USDPShares">28.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      id="Fact000972">vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="0"
      id="Fact000974"
      unitRef="USD">658363</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="4"
      id="Fact000976"
      unitRef="USDPShares">26.335</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2021-05-102021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="0"
      id="Fact000978"
      unitRef="USD">329188</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      id="Fact000980"
      unitRef="USD">76388</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-06-282021-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact000984"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember"
      id="Fact000986">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact000988"
      unitRef="USDPShares">30.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember"
      id="Fact000990">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      id="Fact000992"
      unitRef="USD">1421095</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="5"
      id="Fact000994"
      unitRef="USDPShares">28.423</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      id="Fact000996"
      unitRef="USD">211413</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      id="Fact001000">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="2"
      id="Fact001002"
      unitRef="USDPShares">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      id="Fact001004">vesting 50% on the grant date and the
remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact001006"
      unitRef="USD">158525</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="4"
      id="Fact001008"
      unitRef="USDPShares">6.341</us-gaap:SharePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact001010"
      unitRef="USD">79263</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact001012"
      unitRef="USD">19390</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember"
      decimals="0"
      id="Fact001014"
      unitRef="USD">38885</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-302022-06-30_srt_DirectorMember"
      decimals="0"
      id="Fact001016"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="5"
      id="Fact001018"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      id="Fact001020">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="INF"
      id="Fact001022"
      unitRef="USDPShares">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      id="Fact001024">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-302022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="0"
      id="Fact001026"
      unitRef="USD">316700</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-30_custom_FiveNonOfficerDirectorsOneMember"
      decimals="5"
      id="Fact001028"
      unitRef="USDPShares">6.334</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_FiveNonOfficerDirectorsOneMember"
      decimals="0"
      id="Fact001030"
      unitRef="USD">47310</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_FiveNonOfficerDirectorsOneMember"
      decimals="0"
      id="Fact001032"
      unitRef="USD">94881</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="Fact001034"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="Fact001036"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      id="Fact001038">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_srt_DirectorMember"
      decimals="INF"
      id="Fact001040"
      unitRef="USDPShares">20.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      id="Fact001042">vesting 25% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      id="Fact001044"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="0"
      id="Fact001046"
      unitRef="USD">262560</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="4"
      id="Fact001048"
      unitRef="USDPShares">3.282</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_FourOfficersMember"
      decimals="0"
      id="Fact001050"
      unitRef="USD">42565</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_FourOfficersMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">61448</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-06-302023-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001054"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001056"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001058">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001060"
      unitRef="USDPShares">5.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001062">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2023-06-302023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001064"
      unitRef="USD">192593</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="4"
      id="Fact001066"
      unitRef="USDPShares">4.8131</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001068"
      unitRef="USD">96532</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001070"
      unitRef="USD">48464</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="Fact001072"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      id="Fact001074">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      id="Fact001076"
      unitRef="USDPShares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2023-09-252023-09-26_custom_MrvanderBaanMember_custom_EmploymentAgreementMember"
      id="Fact001078">The options vest in equal increments quarterly over a three-year period commencing on
the last day of each calendar quarter commencing October 1, 2023, subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2023-09-252023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact001080"
      unitRef="USD">403066</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-26_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="4"
      id="Fact001082"
      unitRef="USDPShares">1.612</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact001084"
      unitRef="USD">134114</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_BasvanderBaanMember_custom_EmploymentAgreementMember"
      decimals="0"
      id="Fact001086"
      unitRef="USD">35178</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001088"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001090"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      id="Fact001092">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_srt_DirectorMember"
      decimals="INF"
      id="Fact001094"
      unitRef="USDPShares">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      id="Fact001096">vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-06-302024-06-30_srt_DirectorMember"
      decimals="0"
      id="Fact001098"
      unitRef="USD">73976</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_srt_DirectorMember"
      decimals="4"
      id="Fact001100"
      unitRef="USDPShares">1.8494</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_srt_DirectorMember"
      decimals="0"
      id="Fact001102"
      unitRef="USD">18648</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorMember"
      decimals="0"
      id="Fact001104"
      unitRef="Shares">16598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001106">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001108"
      unitRef="USDPShares">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001110">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-06-302024-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001112"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_FourNonOfficerDirectorsMember"
      decimals="4"
      id="Fact001114"
      unitRef="USDPShares">1.6570</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-07-012024-07-01_custom_SchellensMember"
      decimals="0"
      id="Fact001116"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012024-07-01_custom_SchellensMember"
      id="Fact001118">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-07-01_custom_SchellensMember"
      decimals="INF"
      id="Fact001120"
      unitRef="USDPShares">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2024-07-012024-07-01_custom_SchellensMember"
      id="Fact001122">The options vest quarterly over a three-year period commencing on the last day of each calendar quarter
commencing September 30, 2024.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-07-012024-07-01_custom_SchellensMember"
      decimals="0"
      id="Fact001124"
      unitRef="USD">29074</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-07-01_custom_SchellensMember"
      decimals="4"
      id="Fact001126"
      unitRef="USDPShares">1.9382</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_SchellensMember24651765"
      decimals="0"
      id="Fact001128"
      unitRef="USD">4863</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorMember"
      decimals="0"
      id="Fact001130"
      unitRef="Shares">21217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001132">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="INF"
      id="Fact001134"
      unitRef="USDPShares">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember"
      id="Fact001136">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-09-302024-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001138"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-09-30_custom_FourNonOfficerDirectorsMember"
      decimals="4"
      id="Fact001140"
      unitRef="USDPShares">1.2961</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001142"
      unitRef="Shares">16665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember"
      id="Fact001144">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001146"
      unitRef="USDPShares">2.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember"
      id="Fact001148">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <LIXT:FairValueOfStockOptions
      contextRef="From2025-01-202025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001150"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2025-01-20_custom_FourNonOfficerDirectorsMember_us-gaap_SubsequentEventMember"
      decimals="5"
      id="Fact001152"
      unitRef="USDPShares">1.65002</us-gaap:SharePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2024-01-012024-12-31_custom_FourNonOfficerDirectorsMember"
      decimals="0"
      id="Fact001154"
      unitRef="USD">27500</LIXT:FairValueOfStockOptions>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001156">&lt;p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zLmHfiQDu9Vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the years ended December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zgC3DbVUULNd" style="display: none"&gt;Summary
of Stock-based Compensation Costs&lt;/span&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zCPUK4slL2Rf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zD7ueh03xcgj" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zw41nmCfHsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Related parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;418,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zRIWM6L1xRA2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Non-related parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1161"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_zC9hb6zYcjhj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total stock-based compensation costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;418,422&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;773,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001158"
      unitRef="USD">418422</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001159"
      unitRef="USD">773203</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001164"
      unitRef="USD">418422</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001165"
      unitRef="USD">773203</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001167">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWFBvOWESuj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2024 and 2023
is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z8jCAeDDOI2f" style="display: none"&gt;Summary
of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                                                                                                                                                                                                                                                               Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual Life&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(in Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zEqJTGSvK8w6" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;389,479&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zFVS6abLMYZj" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;29.183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231_zNz0eVZiNNlb" style="text-align: right" title="Number of shares, granted"&gt;290,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zhUt0lVuxo7f" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zyMcabLTWXEj" style="text-align: right" title="Number of shares, exercised"&gt;(1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zoZSsYFi1C96" style="text-align: right" title="Weighted average exercise price, exercised"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231_zvzjbhKsNVA4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired"&gt;(126,146&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z3eDmD362pL5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;28.687&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zNsZKEOEHbQ3" style="text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;552,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zdAC1ThDecti" style="text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;15.330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231_z5nJTobYUYk5" style="text-align: right" title="Number of shares, granted"&gt;92,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zUaVZz4zovPa" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_ziyRLtF7njf2" style="text-align: right" title="Number of shares, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zgg5FRnlwTeb" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1195"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231_zmUY0rVkgze3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, expired"&gt;(31,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_z2fVu7X2tNAd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;35.368&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zisLJpd1Xp63" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;613,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zniAOJtrgp25" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;12.317&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_z3FMT0xDwTD1" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_zrlZMuvw59Tf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;252,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231_zW8Vuv6cQ5Pc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;28.387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zcFNdfHDkKz9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable"&gt;409,897&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_z4GpV6jBnfXd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;17.100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zqqRxBwPm26a" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001169"
      unitRef="Shares">389479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001171"
      unitRef="USDPShares">29.183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001173"
      unitRef="Shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001175"
      unitRef="USDPShares">2.492</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001177"
      unitRef="Shares">1250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001179"
      unitRef="USDPShares">5.025</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001181"
      unitRef="Shares">126146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001183"
      unitRef="USDPShares">28.687</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001185"
      unitRef="Shares">552083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001187"
      unitRef="USDPShares">15.330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">92815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001191"
      unitRef="USDPShares">2.259</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001197"
      unitRef="Shares">31666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001199"
      unitRef="USDPShares">35.368</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001201"
      unitRef="Shares">613232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001203"
      unitRef="USDPShares">12.317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-12-31" id="Fact001205">P3Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001207"
      unitRef="Shares">252292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001209"
      unitRef="USDPShares">28.387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001211"
      unitRef="Shares">409897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001213"
      unitRef="USDPShares">17.100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact001215">P2Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001217"
      unitRef="USD">375000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact001219">P19M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001221">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxCENmtaZDP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following
prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zATPZYEZtqe7" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options &lt;br/&gt; Outstanding (Shares)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable (Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zUdjPHIoTpU1" style="width: 29%; text-align: right" title="Exercise Prices"&gt;1.870&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zPLnqMyc8LC8" style="width: 29%; text-align: right" title="Options Outstanding (Shares)"&gt;21,217&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zhfjeM9xS2H" style="width: 28%; text-align: right" title="Options Exercisable (Shares)"&gt;21,217&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zMlBOsmIQWDe" style="text-align: right" title="Exercise Prices"&gt;1.950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbGfTIdPEjzj" style="text-align: right" title="Options Outstanding (Shares)"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zJPf0fapi55a" style="text-align: right" title="Options Exercisable (Shares)"&gt;104,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zDZKuhgTEYV5" style="text-align: right" title="Exercise Prices"&gt;2.370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zMS7bvdTvIjg" style="text-align: right" title="Options Outstanding (Shares)"&gt;56,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpWJIZmt3Iha" style="text-align: right" title="Options Exercisable (Shares)"&gt;26,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zoKtlMKICBRg" style="text-align: right" title="Exercise Prices"&gt;2.390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z4184IydkpKj" style="text-align: right" title="Options Outstanding (Shares)"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z3CYfCHKP3ml" style="text-align: right" title="Options Exercisable (Shares)"&gt;2,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z6BAhCpDtVil" style="text-align: right" title="Exercise Prices"&gt;5.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4oo7pdUWGwd" style="text-align: right" title="Options Outstanding (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z9F94HjKKxe" style="text-align: right" title="Options Exercisable (Shares)"&gt;8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zDUtY0ROnTQc" style="text-align: right" title="Exercise Prices"&gt;5.880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z9gkiVfuIA9i" style="text-align: right" title="Options Outstanding (Shares)"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSwKjUz8Ptra" style="text-align: right" title="Options Exercisable (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zINl9Gix6yWk" style="text-align: right" title="Exercise Prices"&gt;7.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqvBQe5D6csj" style="text-align: right" title="Options Outstanding (Shares)"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zopgLrWifA3d" style="text-align: right" title="Options Exercisable (Shares)"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zYxWTpuH3XF1" style="text-align: right" title="Exercise Prices"&gt;20.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zeIU5jit3mTj" style="text-align: right" title="Options Outstanding (Shares)"&gt;45,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8G91Hl00Zx4" style="text-align: right" title="Options Exercisable (Shares)"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zXocKwlCnDA3" style="text-align: right" title="Exercise Prices"&gt;20.600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zTIFtFO3b0O5" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO5FIkIDEdge" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zhKpThSwUhSg" style="text-align: right" title="Exercise Prices"&gt;28.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zk8fo0MKpFw5" style="text-align: right" title="Options Outstanding (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zC7NtmxlyU4" style="text-align: right" title="Options Exercisable (Shares)"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zIDrWpTVGmDl" style="text-align: right" title="Exercise Prices"&gt;30.300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSZ3Uzb1Lduk" style="text-align: right" title="Options Outstanding (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1sfqEiGkF5a" style="text-align: right" title="Options Exercisable (Shares)"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z4XC1cRXhEk6" style="text-align: right" title="Exercise Prices"&gt;32.100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZRbvYz7Twhf" style="text-align: right" title="Options Outstanding (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zPbAT7QuotZe" style="text-align: right" title="Options Exercisable (Shares)"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zm8x6BwcAAul" style="text-align: right" title="Exercise Prices"&gt;60.000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zGbd8qGCO71i" style="text-align: right" title="Options Outstanding (Shares)"&gt;8,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zJRDC1T6atcg" style="text-align: right" title="Options Exercisable (Shares)"&gt;8,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zbIZs6lY2Ai1" style="text-align: right" title="Exercise Prices"&gt;71.400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPm1YGFhbvp" style="text-align: right" title="Options Outstanding (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zAjXdDdK80Ec" style="text-align: right" title="Options Exercisable (Shares)"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_ziws5S9oXQ66" style="padding-bottom: 1pt; text-align: right" title="Exercise Prices"&gt;120.000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj7QDC3nkmzh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;8,334&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zylMGmJKZVg5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;8,334&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_z7BBJromCTEi" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding (Shares)"&gt;613,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231_zUWwimlEsfRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;409,897&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001223"
      unitRef="USDPShares">1.870</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001225"
      unitRef="Shares">21217</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001227"
      unitRef="Shares">21217</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001229"
      unitRef="USDPShares">1.950</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001231"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001233"
      unitRef="Shares">104165</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001235"
      unitRef="USDPShares">2.370</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001237"
      unitRef="Shares">56598</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001239"
      unitRef="Shares">26598</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001241"
      unitRef="USDPShares">2.390</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001243"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001245"
      unitRef="Shares">2500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001247"
      unitRef="USDPShares">5.025</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001249"
      unitRef="Shares">8750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001251"
      unitRef="Shares">8750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001253"
      unitRef="USDPShares">5.880</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001255"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001257"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001259"
      unitRef="USDPShares">7.400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001261"
      unitRef="Shares">55000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001263"
      unitRef="Shares">55000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001265"
      unitRef="USDPShares">20.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001267"
      unitRef="Shares">45000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001269"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001271"
      unitRef="USDPShares">20.600</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001273"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001275"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001277"
      unitRef="USDPShares">28.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001279"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001281"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001283"
      unitRef="USDPShares">30.300</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001285"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001287"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001289"
      unitRef="USDPShares">32.100</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001291"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001293"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001295"
      unitRef="USDPShares">60.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001297"
      unitRef="Shares">8333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001299"
      unitRef="Shares">8333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceFourteenMember"
      decimals="INF"
      id="Fact001301"
      unitRef="USDPShares">71.400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourteenMember"
      decimals="INF"
      id="Fact001303"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourteenMember"
      decimals="INF"
      id="Fact001305"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceFifteenMember"
      decimals="INF"
      id="Fact001307"
      unitRef="USDPShares">120.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceFifteenMember"
      decimals="INF"
      id="Fact001309"
      unitRef="Shares">8334</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceFifteenMember"
      decimals="INF"
      id="Fact001311"
      unitRef="Shares">8334</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001313"
      unitRef="Shares">613232</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001315"
      unitRef="Shares">409897</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="2"
      id="Fact001317"
      unitRef="USDPShares">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001319"
      unitRef="USD">12000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001321"
      unitRef="Shares">203334</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001323">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zXcWy9o7k9f9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_82C_zgjKmYjldi0i"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets as
of December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhcMrKCfMEyg" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z6Mg4awZE5Fl" style="display: none"&gt;Schedule of Components of Deferred Tax Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zhZf6zsba7ub" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zP1AFuQVBBm9" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_zELyJMLaS4Gk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research credits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;652,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;612,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zBwHgXQtF5a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_z8HjiCuxMNK9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,631,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zA3UrvyNPuE6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,515,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,601,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_z8A2JzUUu7g5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,617,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,688,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_zVRTtLd8PKe1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,617,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11,688,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zzXX3BLEty3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zZdrcyd8uN54" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining
future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2024 and 2023, management
was unable to determine if it is more likely than not that the Company&#x2019;s deferred tax assets will be realized and has therefore
recorded an appropriate valuation allowance against deferred tax assets at such dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_do_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zvlPonMVROy"&gt;&lt;span id="xdx_90C_eus-gaap--IncomeTaxExpenseBenefit_do_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zd0wseKP9f2f"&gt;No&lt;/span&gt;&lt;/span&gt;
federal tax provision has been provided for the years ended December 31, 2024 and 2023 due to the losses incurred during such periods.
The reconciliation below presents the difference between the income tax rate computed by applying the U.S. federal statutory rate and
the effective tax rate for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zO7KRmwRQbIa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zIdAW3X8Ite7" style="display: none"&gt;Schedule of Effective Income Tax Rate&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zgAhkbWfYUrj" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zodb6ZAgqzS2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zOUdJUJqc2rl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;U. S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_zEJojD5OZill" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_z43h5lMrnr7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expirations related to stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_za0dRVJpsqI9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Adjustment to deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zADWTP1AqVjc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_z9DPi7jgTpSj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zKZ6frVnfgA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately
$&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20241231_z7q5FhRzD8Uk" title="Operating loss carryforwards, federal"&gt;31,067,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20241231_zXCk9xyKQbWk" title="Operating loss carryforwards, state"&gt;35,836,000&lt;/span&gt;, respectively. Federal net operating losses from tax years preceding 2018, if not utilized earlier, expire
through 2038. Federal net operating losses generated in a tax year beginning after 2017 have an indefinite carryforward period. The utilization
of federal net operating loss carryforwards is subject to various limitations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
state net operating loss carryovers include approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zipZCELoHTRh" title="Net operating loss carryovers"&gt;19,141,000&lt;/span&gt; that were incurred in the State of New York. New York tax law requires
New York net operating loss carryovers from years prior to 2015 to be converted, by applying a formula, into a Prior Net Operating Loss
Conversion (PNOLC) subtraction pool. &lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--NewYorkStateDivisionOfTaxationAndFinanceMember_zYvJkk1ZDO1a" title="Prior net operating loss conversion utilization"&gt;The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.&lt;/span&gt; The state net
operating loss carryovers also include approximately $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zACcJVv1fc7i" title="Operating loss carryforwards, state"&gt;16,695,000&lt;/span&gt; that was incurred in the State of California.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and certain corresponding provisions of state law, if a
corporation undergoes an &#x201c;ownership change&#x201d;, which is generally defined as a greater than 50% change, by value, in the ownership
of its equity over a three-year period, the corporation&#x2019;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income might be limited.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company&#x2019;s net operating losses have yet to be utilized, all previous tax years since 2006 remain subject to adjustment by Federal
authorities and other jurisdictions in which the Company currently operates or has operated in the past.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001325">&lt;p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhcMrKCfMEyg" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z6Mg4awZE5Fl" style="display: none"&gt;Schedule of Components of Deferred Tax Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zhZf6zsba7ub" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zP1AFuQVBBm9" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzmvk_zELyJMLaS4Gk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research credits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;652,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;612,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzmvk_zBwHgXQtF5a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzmvk_z8HjiCuxMNK9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,631,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzmvk_zA3UrvyNPuE6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,515,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,601,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzmvk_maDTANzpnj_z8A2JzUUu7g5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,617,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,688,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzpnj_zVRTtLd8PKe1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,617,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11,688,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzpnj_zzXX3BLEty3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001327"
      unitRef="USD">652000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001328"
      unitRef="USD">612000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001330"
      unitRef="USD">900000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001331"
      unitRef="USD">844000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001333"
      unitRef="USD">1550000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001334"
      unitRef="USD">1631000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001336"
      unitRef="USD">9515000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001337"
      unitRef="USD">8601000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001339"
      unitRef="USD">12617000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001340"
      unitRef="USD">11688000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001342"
      unitRef="USD">12617000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001343"
      unitRef="USD">11688000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001347"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001348"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001350">&lt;p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zO7KRmwRQbIa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zIdAW3X8Ite7" style="display: none"&gt;Schedule of Effective Income Tax Rate&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zgAhkbWfYUrj" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zodb6ZAgqzS2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maEITRzmvk_zOUdJUJqc2rl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;U. S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_maEITRzmvk_zEJojD5OZill" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_iN_pid_dpi_maEITRzmvk_z43h5lMrnr7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expirations related to stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset_iN_pid_dpi_maEITRzmvk_za0dRVJpsqI9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Adjustment to deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_pid_dpi_maEITRzmvk_zADWTP1AqVjc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtEITRzmvk_z9DPi7jgTpSj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001352"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001353"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001355"
      unitRef="Pure">0.060</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001356"
      unitRef="Pure">0.060</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001358"
      unitRef="Pure">-0.038</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001359"
      unitRef="Pure">-0.104</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001361"
      unitRef="Pure">0.011</LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset>
    <LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001362"
      unitRef="Pure">0.008</LIXT:EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001364"
      unitRef="Pure">-0.243</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001365"
      unitRef="Pure">-0.174</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001367"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001368"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001370"
      unitRef="USD">31067000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001372"
      unitRef="USD">35836000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2022-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"
      decimals="0"
      id="Fact001374"
      unitRef="USD">19141000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="From2024-01-012024-12-31_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"
      id="Fact001376">The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized
PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred
in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember"
      decimals="0"
      id="Fact001378"
      unitRef="USD">16695000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001380">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zDBhwmoYf2Ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_822_zuyoCltX3Ayc"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal
Claims&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of December 31, 2024 and
2023, the Company was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
Commitments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 14, 2025, the Company&#x2019;s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial
monitoring agreements not yet incurred, as described below, aggregated $&lt;span id="xdx_908_eus-gaap--ContractualObligation_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember_z1tqH4drcJU3" title="Clinical trial contractual commitment"&gt;526,000&lt;/span&gt;, including clinical trial agreements of $&lt;span id="xdx_900_eus-gaap--ContractualObligation_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialAgreementsMember_zqWnh1Y3vhH4" title="Contractual commitment"&gt;264,000&lt;/span&gt; and
clinical trial monitoring agreements of $&lt;span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_zJvmGUJ4tmLb" title="Contractual commitment"&gt;262,000&lt;/span&gt;, which, based on current estimates, are currently scheduled to be incurred through approximately
December 31, 2027. The Company&#x2019;s ability to conduct and fund these contractual commitments is subject to the timely availability
of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds to the Company&#x2019;s
current or future clinical trial programs. The Company expects that the full amount of these expenditures will be incurred only if such
clinical trial programs are conducted as originally designed and their respective enrollments and duration are not modified or reduced.
Clinical trial programs, such as the types that the Company is engaged in, can be highly variable and can frequently involve a series
of changes and modifications over time as clinical data is obtained and analyzed, and is frequently modified, suspended or terminated,
in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial endpoint is reached.
Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current clinical assumptions
and conditions and are typically subject to significant modifications and revisions over time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zbNYDSNxOP0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the Company&#x2019;s ongoing contractual clinical trials described below as of March 14, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zyV50Cq5DUUh" style="display: none"&gt;Schedule
of Contractual Clinical Trials&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Description
    of Clinical Trial&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Institution&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Start Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Projected End Date&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Number
                                            of Patients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;in
                                            Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Study Objective&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Clinical Update&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Expected&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Date
                                            of Preliminary Efficacy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Signal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;NCT No.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Financial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Commitment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 19%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_906_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zXixyQiSU8ni" title="Clinical trial, description"&gt;LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer&lt;/span&gt; (Phase 1b)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Netherlands Cancer Institute (NKI)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 8%"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zuV8mTERxdwj" title="Estimated Start Date"&gt;August 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 8%"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zDj9IIabnRz1" title="Estimated End Date"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_902_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zrh1OR2gLFo2" title="Number of Patients in Trial"&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Determine RP2D with atezolizumab&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;First patient entered August 2024, in total two patients entered&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 8%"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_904_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zS25rgjPU17f" title="Expected Date"&gt;June 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%"&gt;&lt;span style="font-size: 8pt"&gt;NCT06012734&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zcorFI7OWv78" title="Remaining financial contractual commitment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1400"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_901_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z7i2OWVQ7vk8" title="Clinical trial, description"&gt;LB-100 combined with doxorubicin in advanced soft
    tissue sarcoma&lt;/span&gt; (Phase 1b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;GEIS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zdJjLV15myt" title="Estimated Start Date"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_901_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zHVmg7al70x1" title="Estimated End Date"&gt;Recruitment completed September 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;span id="xdx_907_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zCffF5jNIjjh" title="Number of Patients in Trial"&gt;9&lt;/span&gt;
                                            to &lt;span id="xdx_90B_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zUGXB7TkRXY8" title="Number of Patients in Trial"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Determine MTD and RP2D&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Fourteen patients entered&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zT0RXnmH1cL1" title="Expected Date"&gt;December 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;NCT05809830&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zs1b7zL5Cn61" style="text-align: right" title="Remaining financial contractual commitment"&gt;&lt;span style="font-size: 8pt"&gt;264,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDIp_zaK0ldzzzrnk" title="Clinical trial, description"&gt;Doxorubicin with or without LB-100 in advanced soft
    tissue sarcoma &lt;/span&gt;(Randomized Phase 2)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;GEIS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;TBD&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;TBD&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zTQUm6J8wsGk" title="Number of Patients in Trial"&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Determine efficacy: PFS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical
    trial)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;TBD&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;NCT05809830&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zCxDdXQeHIvi" title="Remaining financial contractual commitment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1420"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_903_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDIp_zj2xTKkOQkK" title="Clinical trial, description"&gt;LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma&lt;/span&gt; (Phase 1b/2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;MD Anderson&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_903_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zQMbpJSy59Lj" title="Estimated Start Date"&gt;January 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zzCWNGur0Zk7" title="Estimated End Date"&gt;December 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zSwqRcECedGi" title="Number of Patients in Trial"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;Determine the OS of patients with recurrent ovarian
    clear cell carcinoma&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;Nine patients entered&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zUMEVM22olN7" title="Expected Date"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;NCT06065462&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zhxbiG9B0Ac5" title="Remaining financial contractual commitment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1432"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OtherCommitment_iI_c20250314_zokjzbaUrqnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Remaining financial contractual commitment"&gt;&lt;span style="font-size: 8pt"&gt;264,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span id="xdx_F06_zXGwjXEDSFLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zndBSHdtJAg4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A7_zA6RA5e8Ptxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Netherlands
Cancer Institute. &lt;/b&gt;Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute
(&#x201c;NKI&#x201d;) (see Note 5) to conduct a Phase 1b clinical trial of the Company&#x2019;s protein phosphatase inhibitor, LB-100, combined
with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (&#x201c;Roche&#x201d;), for patients with microsatellite
stable metastatic colorectal cancer. Under the agreement, the Company will provide its lead compound, LB-100, and under a separate agreement
between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to
and will not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement,
the clinical trial will be conducted by NKI at NKI&#x2019;s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and
NKI will be responsible for the recruitment of patients. The agreement provides for the protection of the respective intellectual property
rights of each of the Company, NKI and Roche.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&#x2019;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. A total of two patients have been enrolled to date. Patient accrual
is expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&#x201c;SAEs&#x201d;) observed in the clinical trial. The Investigational Review Board (IRB) of the Netherlands Cancer
Institute has requested additional information with respect to these SAEs and the study has been paused for enrollment until the IRB&#x2019;s
questions have been satisfactorily addressed (see &#x201c;Specific Risks Associated with the Company&#x2019;s Business Activities - Serious
Adverse Events&#x201d; below for additional information).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has no financial contractual commitment associated with this clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the &#x201c;Agreement&#x201d;) with
the City of Hope National Medical Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively,
&#x201c;City of Hope&#x201d;), to carry out a Phase 1b clinical trial of LB-100, the Company&#x2019;s first-in-class protein phosphatase
inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung cancer (&#x201c;ED-SCLC&#x201d;).
LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously
untreated ED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended
Phase 2 dose (&#x201c;RP2D&#x201d;). Patient entry was to be expanded so that a total of 12 patients would be evaluable at the RP2D to
confirm the safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration
of overall response, progression-free survival, and overall survival.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient
accrual was slower than expected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (&#x201c;SCRI&#x201d;),
Nashville, Tennessee, to the ongoing Phase 1b clinical trial. The Company and City of Hope continued efforts to increase patient accrual
by adding additional sites and by modifying the protocol to increase the number of patients eligible for the clinical trial. The impact
of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms
of the Agreement, the Company provided notice to City of Hope of the Company&#x2019;s intent to terminate the Agreement effective as of
July 8, 2024. Upon closure, the Company incurred a prorated charge of $&lt;span id="xdx_90D_eus-gaap--LitigationSettlementExpense_c20240707__20240708__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_z5acQ9n9FrKd" title="Litigation settlement expense"&gt;207,004&lt;/span&gt; for the cost of patients enrolled to date, which is included
in accounts payable and accrued expenses at December 31, 2024 .&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024 and 2023, the Company incurred costs of $&lt;span id="xdx_901_eus-gaap--LitigationSettlementExpense_c20240101__20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zerFstXrgqWh" title="Litigation settlement expense"&gt;285,019&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--LitigationSettlementExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zWPnrIWmoQ0j" title="Litigation settlement expense"&gt;69,001&lt;/span&gt;, respectively, pursuant to this Agreement.
As of December 31, 2024, total costs of $&lt;span id="xdx_90A_eus-gaap--DeferredCosts_iI_c20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zhtmO9ywpI37" title="Total costs"&gt;732,532&lt;/span&gt; had been incurred pursuant to this Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GEIS.
&lt;/b&gt;Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#xf1;ol de Investigaci&#xf3;n en Sarcomas or &#x201c;GEIS&#x201d;), Madrid, Spain, to carry out a
study entitled &#x201c;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#x201d;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#x201c;ASTS&#x201d;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding
cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the
anti-tumor activity of doxorubicin without apparent increases in toxicity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended
Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase
2 portion of the study assumes a median progression-free survival (&#x201c;PFS&#x201d;), no evidence of disease progression or death from
any cause, of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate
a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#x2019;s existing LB-100 inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practice (GMP) of the active pharmaceutical ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $&lt;span id="xdx_907_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zrrPgDwaZoHa" title="Inventory costs"&gt;1,144,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#xf1;ola de Medicamentos
y Productos Sanitarios or &#x201c;AEMPS&#x201d;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#x2019;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of ASTS. Consequently, this
clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a report prepared by December 31,
2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#xf3;n Jim&#xe9;nez
D&#xed;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b
portion of the protocol was extended with two patients and was completed during the quarter ended September 30, 2024. The Company expects
to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, the Company entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved
the Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $&lt;span id="xdx_905_eus-gaap--OtherCommitment_iI_uEUR_c20250311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zfFDQYq8Va3k" title="Aggregate commitments expected"&gt;3,095,000&lt;/span&gt;. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s agreement with GEIS provided for various payments based on achieving specific milestones over the term of the agreement.
During the years ended December 31, 2024 and 2023, the Company incurred costs of $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zaia5Nyr86Kc" title="Research and development costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zfaifKZ1ugng" title="Research and development costs"&gt;268,829&lt;/span&gt;, respectively, pursuant to this agreement.
Through December 31, 2024, the Company has incurred charges of $&lt;span id="xdx_902_ecustom--AmountRelatedToMilestonePayment_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zPbDmT63fws6" title="Amount related to milestone payment"&gt;684,652&lt;/span&gt; for work done under this agreement through the fourth milestone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_901_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_z3ayU8lepmxg" title="Aggregate commitments expected"&gt;264,000&lt;/span&gt;
for the Phase 1b portion of this clinical trial as of March 14, 2025, which is scheduled to be incurred through December 31, 2025. As
the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations between the
United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign currency gain
or loss, as appropriate, and have not been significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MD
Anderson Cancer Center Clinical Trial&lt;/b&gt;. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative
clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (&#x201c;PD-1&#x201d;) blocking antibody of GSK plc
(&#x201c;GSK&#x201d;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma
(&#x201c;OCCC&#x201d;). The study objective is to determine the overall survival (&#x201c;OS&#x201d;) of patients with OCCC. The clinical
trial is being sponsored by The University of Texas MD Anderson Cancer Center (&#x201c;MD Anderson&#x201d;) and is being conducted at The
University of Texas - MD Anderson Cancer Center. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial
support for the clinical trial. On January 29, 2024, the Company announced the entry of the first patient into this clinical trial. The
Company currently expects that this clinical trial will be completed by December 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 25, 2025, the Company announced that it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&#x2019;s proprietary compound LB-100 with GSK&#x2019;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida (&#x201c;Moffitt&#x201d;), effective for a term of five years. Pursuant to the Clinical Trial Research
Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of the Company&#x2019;s
lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic
syndrome (&#x201c;MDS&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (&#x201c;IND&#x201d;)
Application to conduct a Phase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and
intermediate-1 risk MDS who had failed or were intolerant of standard treatment. This Phase 1b/2 clinical trial utilized LB-100 as a
single agent in the treatment of patients with low and intermediate-1 risk MDS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the
year ended December 31, 2023, the clinical trial was closed. Although the maximum tolerated dose (&#x201c;MTD&#x201d;) was not achieved,
there was no dose-limiting toxicity noted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company incurred costs of $&lt;span id="xdx_90F_eus-gaap--LitigationSettlementExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zob6CNqPjDLa" title="Litigation settlement expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--LitigationSettlementExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zqwFN48l7781" title="Litigation settlement expense"&gt;16,165&lt;/span&gt;, respectively, pursuant to this agreement. As
of December 31, 2024, total costs of $&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zq3iBSb06mGk" title="Research and development costs"&gt;147,239&lt;/span&gt; had been incurred pursuant to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
September 2023, the Company decided not to pursue further studies in MDS, as other, more promising, opportunities had become available
(see &#x201c;Patent and License Agreements - Moffitt&#x201d; below).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;National
Cancer Institute Pharmacologic Clinical Trial. &lt;/b&gt;In May 2019, the National Cancer Institute (&#x201c;NCI&#x201d;) initiated a glioblastoma
(&#x201c;GBM&#x201d;) pharmacologic clinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and
Development Agreement, with the Company responsible for providing the LB-100 clinical compound.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#x2019;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Monitoring Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MD
Anderson Cancer Center Clinical Trial&lt;/b&gt;. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen
investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1
(&#x201c;PD-1&#x201d;) blocking antibody of GSK plc (&#x201c;GSK&#x201d;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy
in the treatment of ovarian clear cell carcinoma (&#x201c;OCCC&#x201d;). On August 19, 2024, the Company signed a work order agreement
with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
under this letter of intent and related work order agreement are estimated to be approximately $&lt;span id="xdx_90D_ecustom--WorkOrderAgreementCosts_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zwEqjo3bJZ4i" title="Work order agreement costs"&gt;95,000&lt;/span&gt;. During the year ended December
31, 2024, the Company incurred costs of $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_zJXSCxsY3QLl" title="Research and development process costs"&gt;26,763&lt;/span&gt; pursuant to this letter of intent and subsequent work order. As of December 31, 2024,
total costs of $&lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MDAndersonCancerCenterClinicalMember_z6u3aHzZVgW9" title="Research and development costs"&gt;26,763&lt;/span&gt; have been incurred pursuant to this letter of intent and subsequent work order.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialMonitoringAgreementsMember_z7s91UCce1F1" title="Remaining financial contractual commitment"&gt;70,000&lt;/span&gt;
as of December 31, 2024, which is expected to be incurred through December 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement were estimated to be approximately $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zuwqhvVoEij5" title="Research and development expense"&gt;335,000&lt;/span&gt;. During the years December 31, 2024 and 2023, the Company incurred costs
of $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zxUpJtMbc5Me" title="Research and development expense"&gt;10,642&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zoWlzMGxETc8" title="Research and development expense"&gt;20,240&lt;/span&gt;, respectively, pursuant to this work order. As of December 31, 2024, total costs of $&lt;span id="xdx_908_eus-gaap--DeferredCosts_iI_c20241231__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zy7awQEgtZC5" title="Total costs incurred"&gt;89,323&lt;/span&gt; had been incurred
pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see &#x201c;Clinical Trial Agreements &#x2013; City
of Hope&#x201d; above), the work order agreement with Theradex to monitor this clinical trial was concurrently terminated, although nominal
oversight trailing costs subsequent to July 8, 2024 are expected to be incurred relating to the closure of this study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GEIS.
&lt;/b&gt;On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study
oversight is expected to be completed by December 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
under this work order agreement are estimated to be approximately $&lt;span id="xdx_908_ecustom--EstimatedWorkCost_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zHPObUbzIjvl" title="Work cost"&gt;153,000&lt;/span&gt;, with such payments expected to be allocated approximately
&lt;span id="xdx_90A_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zSs29Oasw99d" title="Percentage of payment through services"&gt;72%&lt;/span&gt; to Theradex for services and approximately &lt;span id="xdx_909_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230620__20230622__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zVJsW386BqG1" title="Percentage of payment through software"&gt;28%&lt;/span&gt; for payments for pass-through software costs. During the years ended December 31,
2024 and 2023, the Company incurred costs of $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zvrFtEs5QRhl" title="Research and development costs"&gt;34,593&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zt7Etgvjyxx8" title="Research and development costs"&gt;14,862&lt;/span&gt;, respectively, pursuant to this work order. As of December 31, 2024,
total costs of $&lt;span id="xdx_905_eus-gaap--DeferredCosts_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zosVXaEv71r8" title="Total costs"&gt;49,455&lt;/span&gt; have been incurred pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $&lt;span id="xdx_90F_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zYMs96711Ewa" title="Aggregate commitments expected"&gt;104,000&lt;/span&gt; as of December 31, 2024, which is expected to be incurred through December 31, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Netherlands
Cancer Institute. &lt;/b&gt;On August 27, 2024, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical
trial of LB-100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colorectal cancer.
The study oversight is expected to be completed by May 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
under this work order agreement are estimated to be approximately $&lt;span id="xdx_90B_ecustom--EstimatedWorkCost_c20230825__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zTDQMn6kiTjj" title="Work cost"&gt;106,380&lt;/span&gt;, with such payments expected to be allocated approximately
&lt;span id="xdx_90D_ecustom--ExpectedPaymentinServices_pid_dp_uPure_c20230825__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zPhBSyHe1mcb" title="Percentage of payment through services"&gt;47%&lt;/span&gt; to Theradex for services and approximately &lt;span id="xdx_908_ecustom--ExpectedPaymentThroughSoftware_pid_dp_uPure_c20230825__20230827__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zEtdN6DvHa5i" title="Percentage of payment through software"&gt;53%&lt;/span&gt; for payments for pass-through software costs. During the year ended December 31, 2024,
the Company incurred costs of $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zAWEsj9qaw03" title="Research and development costs"&gt;20,191&lt;/span&gt; pursuant to this work order. As of December 31, 2024, total costs of $&lt;span id="xdx_90B_eus-gaap--DeferredCosts_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zWv2GVZIyMpi" title="Total costs"&gt;20,191&lt;/span&gt; have been incurred
pursuant to this work order agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled
approximately $&lt;span id="xdx_901_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchMonitoringMember_z6OTPaC8QIS7" title="Aggregate commitments expected"&gt;88,000&lt;/span&gt; as of December 31, 2024, which is expected to be incurred through May 31, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Patent
and License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;National
Institute of Health.&lt;/b&gt; Effective February 23, 2024, the Company entered into a Patent License Agreement (the &#x201c;License Agreement&#x201d;)
with the National Institute of Neurological Disorders and Stroke (&#x201c;NINDS&#x201d;) and the National Cancer Institute (&#x201c;NCI&#x201d;),
each an institute or center of the National Institute of Health (&#x201c;NIH&#x201d;). Pursuant to the License Agreement, the Company has
licensed on an exclusive basis the NIH&#x2019;s intellectual property rights claimed for a Cooperative Research and Development Agreement
(&#x201c;CRADA&#x201d;) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer
activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors,
immunotherapy, and radiation for the treatment of cancer. The License Agreement is effective, and shall extend, on a licensed product,
licensed process, and country basis, until the expiration of the last-to-expire valid claim of the jointly owned licensed patent rights
in each such country in the licensed territory, estimated at twenty years, unless sooner terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, the Company would be expected to commercialize the licensed products in markets where regulatory approval
has been obtained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $&lt;span id="xdx_906_eus-gaap--RoyaltyExpense_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zptXwdPPvFr4" title="Non refundable license issue royalty"&gt;50,000&lt;/span&gt; and a first minimum annual royalty
within sixty days from the effective date of the Agreement. The first minimum annual royalty of $&lt;span id="xdx_902_ecustom--RoyaltyPayable_iI_c20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_zCqN7oWazy69" title="Minimum annual royalty payable"&gt;25,643&lt;/span&gt; was prorated from the effective
date of the License Agreement to the next subsequent January 1. Thereafter, the minimum annual royalty of $&lt;span id="xdx_90F_ecustom--RoyaltyPayable_iI_c20300131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_z3Gc6lfxHH3i" title="Minimum annual royalty payable"&gt;30,000&lt;/span&gt; is due each January
1 and may be credited against any earned royalties due for sales made in that year. The license issue royalty of $&lt;span id="xdx_900_eus-gaap--RoyaltyExpense_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z0r7EDgcW52d" title="Non refundable license issue royalty"&gt;50,000&lt;/span&gt; and the first
minimum annual royalty of $&lt;span id="xdx_907_ecustom--RoyaltyPayable_iI_c20240430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--StatementScenarioAxis__custom--DueEachJanuaryOneMember_z5XWMqrKPmve" title="Minimum annual royalty payable"&gt;25,643&lt;/span&gt;, were paid in April 2024. The second minimum annual royalty for 2025 of $&lt;span id="xdx_909_ecustom--RoyaltyPayable_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zTsgb8AqqnTa" title="Minimum annual royalty payable"&gt;30,000&lt;/span&gt;, was paid in December
2024 and is included in other prepaid expenses at December 31, 2024 in the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product
and process, subject to reduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but
not less than 1%. The Company&#x2019;s obligation to pay earned royalties under the License Agreement commences on the date of the first
commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim of the licensed product
or licensed process expires in such country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such
benchmark. The License Agreement defines four such benchmarks, which the Company is required to pursue based on &#x201c;commercially reasonable
efforts&#x201d; as defined in the License Agreement, with deadlines of October 1, 2024, 2027, 2029 and 2031, respectively, each with a
different specified benchmark payment amount payable within thirty days of achieving such benchmark. The October 1, 2024 benchmark of
$&lt;span id="xdx_90B_eus-gaap--HealthCareOrganizationHealthCareCostsGross_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zmWKH5089rna" title="Dosing of product"&gt;100,000&lt;/span&gt; was defined as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed product
in the licensed fields of use. The Company had not commenced a Phase 2 clinical study as of December 31, 2024. The total of all such
benchmark payments is $&lt;span id="xdx_90F_eus-gaap--PaymentsForRoyalties_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zDrlkfevcfV6" title="Payment for royalties"&gt;1,225,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to provide annual reports to the NIH on its progress toward the development and commercialization of products under
the licensed patents. These reports, due within sixty days following the end of each calendar year, must include updates on research
and development activities, regulatory submissions, manufacturing efforts, sublicensing, and sales initiatives. If any deviations from
the established commercial development plan or agreed-upon benchmarks occur, the Company is obligated to provide explanation and may
amend the commercial development plan and the benchmarks, which, subject to certain conditions, the NIH shall not unreasonably withhold,
condition, or delay approval of any request of the Company to amend the commercial development plan and/or the benchmarks and to extend
the time periods of the benchmarks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is obligated to pay the NIH sublicensing royalties of &lt;span id="xdx_90D_ecustom--RoyatiesPercentage_pid_dp_c20240223__20240223__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zmpeM7Wasmi7" title="Royalty percentage"&gt;5%&lt;/span&gt; on sublicensing revenue received for granting each sublicense within
sixty days of receipt of such sublicensing revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company incurred costs of $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zKLGUFOwBJmj" title="Research and development process costs"&gt;75,643&lt;/span&gt; in connection with its obligations under the License Agreement.
Such costs when incurred have been included in general and administrative costs in the Company&#x2019;s consolidated statement of operations.
As of December 31, 2024, total costs of $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zR0X46ULC2v9" title="Research and development process costs"&gt;75,643&lt;/span&gt; have been incurred pursuant to this agreement. The Company&#x2019;s aggregate commitment
pursuant to this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_901_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zBK6C61HFLq4" title="Aggregate commitments expected"&gt;1,795,000&lt;/span&gt; as of December 31, 2024, which is
expected to be incurred over approximately the next twenty years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#x201c;Licensed Patents&#x201d;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License
Agreement dated August 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no
termination fee was due or payable by the Company, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company recorded a credit to operations of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zYQRKdDADNGl" title="Stock based compensation"&gt;9,109&lt;/span&gt; representing the reversal of obligations previously
recorded with respect to the Exclusive License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Significant Agreements and Contracts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NDA
Consulting Corp.&lt;/b&gt; On December 24, 2013, the Company entered into a consulting agreement with NDA Consulting Corp. for consultation
and advice in the field of oncology research and drug development. As part of the consulting agreement, NDA also agreed to have its president,
Dr. Daniel D. Von Hoff, M.D., serve on the Company&#x2019;s Scientific Advisory Committee during the term of such consulting agreement.
The term of the consulting agreement was for one year and provided for a quarterly cash fee of $&lt;span id="xdx_908_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zZZVADBV9pRa" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt;. The consulting agreement had been
automatically renewed for additional one-year terms on its anniversary date, most recently on December 24, 2023, but was subsequently
terminated by mutual agreement effective September 30, 2024. Consulting and advisory fees charged to operations pursuant to this consulting
agreement were $&lt;span id="xdx_906_ecustom--ConsultingAndAdvisoryCashFee_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_z46HHK3xWhk8" title="Consulting and advisory fee"&gt;12,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zw8m0P3OayKc" title="Consulting and advisory fee"&gt;16,000&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BioPharmaWorks&lt;/b&gt;.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#x2019;s
product pipeline; assisting in preparing technical presentations concerning the Company&#x2019;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $&lt;span id="xdx_90A_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zkwYA3IcTSi9" title="Consulting and advisory fee"&gt;10,000&lt;/span&gt;, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly fee. Effective March 1, 2024, the compensation payable under the Collaboration Agreement was converted to an hourly
rate structure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded charges to operations pursuant to this Collaboration Agreement of $&lt;span id="xdx_90A_ecustom--ReimbursementExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_ziEGFH02FsQd" title="Reimbursed expense"&gt;39,200&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--ReimbursementExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zKkEIJpFnvAl" title="Reimbursed expense"&gt;120,000&lt;/span&gt; during the years ended December
31, 2024 and 2023, respectively, which were included in research and development costs in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Netherlands
Cancer Institute&lt;/b&gt;. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (&#x201c;NKI&#x201d;) (see Note 5), one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, for a term of three years. The Development Collaboration Agreement was subsequently
modified by Amendment No. 1 thereto.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. The Company agreed to fund the preclinical study, at an approximate cost of &lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_uEUR_c20211008__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zoVVWKBXOnP7" title="Aggregate commitments expected"&gt;391,000&lt;/span&gt; Euros and provide a
sufficient supply of LB-100 to conduct the preclinical study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional
research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added
&lt;span id="xdx_902_eus-gaap--OtherCommitment_iI_uEUR_c20231003__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zxvXEhvSBEni" title="Aggregate commitments expected"&gt;500,000&lt;/span&gt; Euros to the operating budget being funded by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 4, 2024, the Company entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment
No. 2 and provided for a new study term of one year and starts upon the dosing of the first patient in the trial at a project cost of
&lt;span id="xdx_90C_eus-gaap--OtherCommitment_iI_uEUR_c20241004__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zvjNsJGVi2Z6" title="Aggregate commitments expected"&gt;100,000&lt;/span&gt; Euros.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company incurred charges in the amount of $&lt;span id="xdx_908_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zuma1q5Sg1rl" title="Advance amount related to milestone payment"&gt;210,362&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zklbAAnirwS1" title="Advance amount related to milestone payment"&gt;226,150&lt;/span&gt;, respectively, with respect
to this agreement, which amounts are included in research and development costs in the Company&#x2019;s consolidated statements of operations.
As of December 31, 2024, total costs of $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zAdVNb4vM5Nj" title="Research and development costs"&gt;695,918&lt;/span&gt; have been incurred pursuant to this agreement. The Company&#x2019;s aggregate commitment
pursuant to this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_902_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zlf9PRipJmid" title="Aggregate commitments expected"&gt;104,000&lt;/span&gt; as of December 31, 2024, which is expected
to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to
foreign currency fluctuations between the United States Dollar and the Euro.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MRI
Global. &lt;/b&gt;As amended, the Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical
trials in the United States. During the years ended December 31, 2024 and 2023, the Company incurred costs of $&lt;span id="xdx_907_ecustom--AdvanceAmountRelatedToMilestonePayment_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zCMROx1V97V2" title="Advance amount related to milestone payment"&gt;23,308&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zgRbDfMAeETe" title="Advance amount related to milestone payment"&gt;32,307&lt;/span&gt;, respectively,
pursuant to this contract. As of December 31, 2024, total costs of $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zbFiOeixeyIc" title="Research and development costs"&gt;340,522&lt;/span&gt; have been incurred pursuant to this contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_906_eus-gaap--OtherCommitment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zPHuGQJrNYj4" title="Aggregate commitments expected"&gt;118,000&lt;/span&gt;
as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Specific
Risks Associated with the Company&#x2019;s Business Activities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Serious
Adverse Events&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of
these trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to the Company&#x2019;s drug
candidate or to another company&#x2019;s drug used in combination in one of the Company&#x2019;s clinical trials. It is possible that the
SAEs could be attributable to the Company&#x2019;s drug candidate and could include, but not be limited to, unexpected severe side effects,
treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting
toxicity (DLT). When two DLTs occur at the same dose-level, that dose-level is considered too high and unsafe. Further treatment is only
allowed at lower dose-levels that have previously been found safe.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving the Company&#x2019;s drug candidate, the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring
the Company to pause or discontinue further enrollment and dosing in its clinical trial. It is also possible that the clinical trial
could be terminated. Any of these actions could delay or halt the development of the Company&#x2019;s drug candidate, increase development
costs, and negatively impact the Company&#x2019;s ability to ultimately achieve regulatory approval. Additionally, if an SAE is confirmed
to be drug-related, the Company may be required to conduct additional studies, modify the study design, or abandon further development
of the drug candidate altogether, which could materially impact the Company&#x2019;s business, financial condition, and prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
occurrence of an SAE and any resulting clinical hold could also harm the Company&#x2019;s reputation with patients, physicians, health
institutions, and investors, diminish its ability to attract clinical trial participants, and damage its ability to interest investors
and obtain financing in the future. There can be no assurance that the Company will not experience such SAEs in the future or that any
related clinical hold will be lifted in a timely manner, or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Netherlands Cancer Institute (&#x201c;NKI&#x201d;) Institutional
Review Board (the &#x201c;IRB&#x201d;) has put the colorectal cancer study on hold. The adverse reactions that developed in the two patients
were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and atezolizumab in
one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second patient. The
patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea. The patient
with fever and aphasia fully recovered from the adverse events with supportive medication.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator is preparing a response to the IRB
detailing the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab.
Doxorubicin is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related
to that of atezolizumab.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through February 2025, a total of 78 patient have received or are receiving experimental treatment
with LB-100. It is expected that it will take at least two months to prepare a detailed response to the IRB, during which time the Company
intends to update the safety overview of LB-100.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
Business Risks&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Covid-19
Virus&lt;/b&gt;. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak
has subsided, the extent to which the coronavirus or any other pandemics may reappear and impact the Company&#x2019;s clinical trial programs
and capital raising efforts in the future is uncertain and cannot be predicted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Inflation
and Interest Rate Risk. &lt;/b&gt;The Company does not believe that inflation or increasing interest rates have had a material effect on its
operations to date, other than their impact on the general economy. However, there is a risk that the Company&#x2019;s operating costs
could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company&#x2019;s
operating costs (including, specifically, clinical trial costs), and which would put additional stress on the Company&#x2019;s working
capital resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Supply
Chain Issues. &lt;/b&gt;The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Potential
Recession. &lt;/b&gt;There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear
at this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Geopolitical
Risk.&lt;/b&gt; The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of
the Company. In the event of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may
adversely affect the Company&#x2019;s ability to conduct research, develop, test and manufacture products, and distribute them globally.
This could lead to delays in product development, interruptions in the supply of critical materials, and delays in clinical trials, thereby
impeding the Company&#x2019;s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial
markets may result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company&#x2019;s
publicly-traded shares. Investor confidence, market sentiment, and access to capital could all be negatively influenced. Such geopolitical
risks are outside the control of the Company, and the actual effects on the Company&#x2019;s business, financial condition and results
of operations may differ from current estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Risks. &lt;/b&gt;The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity
threats, and has integrated these processes into its overall risk management systems and processes. The Company routinely assesses material
risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through its information and email systems
that may result in adverse effects on the confidentiality, integrity, or availability of the Company&#x2019;s information and email systems
or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as assessments
in the event of a material change in the Company&#x2019;s business practices that may affect information systems that are vulnerable to
such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the
likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems and
safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges to date that have materially impaired
its operations or financial condition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information becomes available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="Fact001382"
      unitRef="USD">526000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialAgreementsMember"
      decimals="0"
      id="Fact001384"
      unitRef="USD">264000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="Fact001386"
      unitRef="USD">262000</us-gaap:ContractualObligation>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001388">&lt;p id="xdx_89A_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zbNYDSNxOP0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the Company&#x2019;s ongoing contractual clinical trials described below as of March 14, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zyV50Cq5DUUh" style="display: none"&gt;Schedule
of Contractual Clinical Trials&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Description
    of Clinical Trial&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Institution&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Start Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Projected End Date&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Number
                                            of Patients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;in
                                            Trial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Study Objective&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Clinical Update&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Expected&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Date
                                            of Preliminary Efficacy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Signal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;NCT No.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Financial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Commitment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 19%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_906_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zXixyQiSU8ni" title="Clinical trial, description"&gt;LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer&lt;/span&gt; (Phase 1b)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Netherlands Cancer Institute (NKI)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 8%"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90B_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zuV8mTERxdwj" title="Estimated Start Date"&gt;August 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 8%"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_909_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zDj9IIabnRz1" title="Estimated End Date"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_902_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zrh1OR2gLFo2" title="Number of Patients in Trial"&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Determine RP2D with atezolizumab&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;First patient entered August 2024, in total two patients entered&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 8%"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_904_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_zS25rgjPU17f" title="Expected Date"&gt;June 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%"&gt;&lt;span style="font-size: 8pt"&gt;NCT06012734&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bMember_fKDEp_zcorFI7OWv78" title="Remaining financial contractual commitment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1400"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_901_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_z7i2OWVQ7vk8" title="Clinical trial, description"&gt;LB-100 combined with doxorubicin in advanced soft
    tissue sarcoma&lt;/span&gt; (Phase 1b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;GEIS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_904_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zdJjLV15myt" title="Estimated Start Date"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_901_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zHVmg7al70x1" title="Estimated End Date"&gt;Recruitment completed September 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;span id="xdx_907_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MinimumMember_zCffF5jNIjjh" title="Number of Patients in Trial"&gt;9&lt;/span&gt;
                                            to &lt;span id="xdx_90B_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember__srt--RangeAxis__srt--MaximumMember_zUGXB7TkRXY8" title="Number of Patients in Trial"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Determine MTD and RP2D&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Fourteen patients entered&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zT0RXnmH1cL1" title="Expected Date"&gt;December 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;NCT05809830&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhase1bTwoMember_zs1b7zL5Cn61" style="text-align: right" title="Remaining financial contractual commitment"&gt;&lt;span style="font-size: 8pt"&gt;264,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90B_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDIp_zaK0ldzzzrnk" title="Clinical trial, description"&gt;Doxorubicin with or without LB-100 in advanced soft
    tissue sarcoma &lt;/span&gt;(Randomized Phase 2)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;GEIS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;TBD&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;TBD&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_906_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_zTQUm6J8wsGk" title="Number of Patients in Trial"&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Determine efficacy: PFS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical
    trial)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;TBD&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;NCT05809830&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialRandomizedPhaseTwoMember_fKDEp_zCxDdXQeHIvi" title="Remaining financial contractual commitment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1420"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_903_ecustom--ClinicalTrialDescription_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDIp_zj2xTKkOQkK" title="Clinical trial, description"&gt;LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma&lt;/span&gt; (Phase 1b/2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;MD Anderson&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_903_ecustom--ContractualClinicalTrialPeriodStartDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zQMbpJSy59Lj" title="Estimated Start Date"&gt;January 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90F_ecustom--ContractualClinicalTrialPeriodEndDate_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zzCWNGur0Zk7" title="Estimated End Date"&gt;December 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_908_ecustom--NumberOfPatientInTrial_uInteger_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zSwqRcECedGi" title="Number of Patients in Trial"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;Determine the OS of patients with recurrent ovarian
    clear cell carcinoma&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;Nine patients entered&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_90E_ecustom--ExpectedDateOfPreliminaryEfficacySignal_c20250314__20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_zUMEVM22olN7" title="Expected Date"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;NCT06065462&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--OtherCommitment_iI_c20250314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--OtherCommitmentsAxis__custom--ClinicalTrialPhaseMD1b2Member_fKDEp_zhxbiG9B0Ac5" title="Remaining financial contractual commitment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1432"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;&lt;span style="font-size: 8pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OtherCommitment_iI_c20250314_zokjzbaUrqnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Remaining financial contractual commitment"&gt;&lt;span style="font-size: 8pt"&gt;264,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span id="xdx_F06_zXGwjXEDSFLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zndBSHdtJAg4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <LIXT:ClinicalTrialDescription
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember"
      id="Fact001390">LB-100 combined with atezolizumab in microsatellite
    stable metastatic colorectal cancer</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember"
      id="Fact001392">August 2024</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember"
      id="Fact001394">December 2026</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember"
      decimals="INF"
      id="Fact001396"
      unitRef="Integer">37</LIXT:NumberOfPatientInTrial>
    <LIXT:ExpectedDateOfPreliminaryEfficacySignal
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bMember"
      id="Fact001398">June 2026</LIXT:ExpectedDateOfPreliminaryEfficacySignal>
    <LIXT:ClinicalTrialDescription
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember"
      id="Fact001402">LB-100 combined with doxorubicin in advanced soft
    tissue sarcoma</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember"
      id="Fact001404">June 2023</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember"
      id="Fact001406">Recruitment completed September 2024</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001408"
      unitRef="Integer">9</LIXT:NumberOfPatientInTrial>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001410"
      unitRef="Integer">18</LIXT:NumberOfPatientInTrial>
    <LIXT:ExpectedDateOfPreliminaryEfficacySignal
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember"
      id="Fact001412">December 2025</LIXT:ExpectedDateOfPreliminaryEfficacySignal>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhase1bTwoMember"
      decimals="0"
      id="Fact001414"
      unitRef="USD">264000</us-gaap:OtherCommitment>
    <LIXT:ClinicalTrialDescription
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember"
      id="Fact001416">Doxorubicin with or without LB-100 in advanced soft
    tissue sarcoma</LIXT:ClinicalTrialDescription>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialRandomizedPhaseTwoMember"
      decimals="INF"
      id="Fact001418"
      unitRef="Integer">150</LIXT:NumberOfPatientInTrial>
    <LIXT:ClinicalTrialDescription
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member"
      id="Fact001422">LB-100 combined with dostarlimab
    in ovarian clear cell carcinoma</LIXT:ClinicalTrialDescription>
    <LIXT:ContractualClinicalTrialPeriodStartDate
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member"
      id="Fact001424">January 2024</LIXT:ContractualClinicalTrialPeriodStartDate>
    <LIXT:ContractualClinicalTrialPeriodEndDate
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member"
      id="Fact001426">December 2027</LIXT:ContractualClinicalTrialPeriodEndDate>
    <LIXT:NumberOfPatientInTrial
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member"
      decimals="INF"
      id="Fact001428"
      unitRef="Integer">21</LIXT:NumberOfPatientInTrial>
    <LIXT:ExpectedDateOfPreliminaryEfficacySignal
      contextRef="From2025-03-142025-03-14_us-gaap_SubsequentEventMember_custom_ClinicalTrialPhaseMD1b2Member"
      id="Fact001430">December 2026</LIXT:ExpectedDateOfPreliminaryEfficacySignal>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-03-14"
      decimals="0"
      id="Fact001434"
      unitRef="USD">264000</us-gaap:OtherCommitment>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2024-07-072024-07-08_custom_ClinicalResearchSupportAgreementMember_custom_CityOfHopeNationalMedicalCenterMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">207004</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2024-01-012024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">285019</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">69001</us-gaap:LitigationSettlementExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="Fact001443"
      unitRef="USD">732532</us-gaap:DeferredCosts>
    <us-gaap:InventoryPartsAndComponentsNetOfReserves
      contextRef="AsOf2024-12-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="Fact001445"
      unitRef="USD">1144000</us-gaap:InventoryPartsAndComponentsNetOfReserves>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-03-11_us-gaap_SubsequentEventMember_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="Fact001447"
      unitRef="EUR">3095000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact001449"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact001451"
      unitRef="USD">268829</us-gaap:ResearchAndDevelopmentExpense>
    <LIXT:AmountRelatedToMilestonePayment
      contextRef="From2024-01-012024-12-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="Fact001453"
      unitRef="USD">684652</LIXT:AmountRelatedToMilestonePayment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-03-14_us-gaap_SubsequentEventMember_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="Fact001455"
      unitRef="USD">264000</us-gaap:OtherCommitment>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2024-01-012024-12-31_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="Fact001457"
      unitRef="USD">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2023-01-012023-12-31_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      id="Fact001459"
      unitRef="USD">16165</us-gaap:LitigationSettlementExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-12-31_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      id="Fact001461"
      unitRef="USD">147239</us-gaap:OtherCommitment>
    <LIXT:WorkOrderAgreementCosts
      contextRef="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember"
      decimals="0"
      id="Fact001463"
      unitRef="USD">95000</LIXT:WorkOrderAgreementCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ClinicalTrialResearchMonitoringMember"
      decimals="0"
      id="Fact001465"
      unitRef="USD">26763</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember_custom_MDAndersonCancerCenterClinicalMember"
      decimals="0"
      id="Fact001467"
      unitRef="USD">26763</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-12-31_custom_ClinicalTrialMonitoringAgreementsMember"
      decimals="0"
      id="Fact001469"
      unitRef="USD">70000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact001471"
      unitRef="USD">335000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact001473"
      unitRef="USD">10642</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact001475"
      unitRef="USD">20240</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact001477"
      unitRef="USD">89323</us-gaap:DeferredCosts>
    <LIXT:EstimatedWorkCost
      contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact001479"
      unitRef="USD">153000</LIXT:EstimatedWorkCost>
    <LIXT:ExpectedPaymentinServices
      contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      id="Fact001481"
      unitRef="Pure">0.72</LIXT:ExpectedPaymentinServices>
    <LIXT:ExpectedPaymentThroughSoftware
      contextRef="From2023-06-202023-06-22_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      id="Fact001483"
      unitRef="Pure">0.28</LIXT:ExpectedPaymentThroughSoftware>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact001485"
      unitRef="USD">34593</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact001487"
      unitRef="USD">14862</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact001489"
      unitRef="USD">49455</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-12-31_custom_WorkOrderAgreementMember"
      decimals="0"
      id="Fact001491"
      unitRef="USD">104000</us-gaap:OtherCommitment>
    <LIXT:EstimatedWorkCost
      contextRef="From2023-08-252023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact001493"
      unitRef="USD">106380</LIXT:EstimatedWorkCost>
    <LIXT:ExpectedPaymentinServices
      contextRef="From2023-08-252023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      id="Fact001495"
      unitRef="Pure">0.47</LIXT:ExpectedPaymentinServices>
    <LIXT:ExpectedPaymentThroughSoftware
      contextRef="From2023-08-252023-08-27_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="INF"
      id="Fact001497"
      unitRef="Pure">0.53</LIXT:ExpectedPaymentThroughSoftware>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ClinicalTrialResearchMonitoringMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact001499"
      unitRef="USD">20191</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      id="Fact001501"
      unitRef="USD">20191</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-12-31_custom_ClinicalTrialResearchMonitoringMember"
      decimals="0"
      id="Fact001503"
      unitRef="USD">88000</us-gaap:OtherCommitment>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001505"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2024-02-23_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember"
      decimals="0"
      id="Fact001507"
      unitRef="USD">25643</LIXT:RoyaltyPayable>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2030-01-31_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember"
      decimals="0"
      id="Fact001509"
      unitRef="USD">30000</LIXT:RoyaltyPayable>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-04-012024-04-30_custom_LicenseAgreementMember_srt_MinimumMember"
      decimals="0"
      id="Fact001511"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2024-04-30_custom_LicenseAgreementMember_custom_DueEachJanuaryOneMember"
      decimals="0"
      id="Fact001513"
      unitRef="USD">25643</LIXT:RoyaltyPayable>
    <LIXT:RoyaltyPayable
      contextRef="AsOf2024-12-31_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001515"
      unitRef="USD">30000</LIXT:RoyaltyPayable>
    <us-gaap:HealthCareOrganizationHealthCareCostsGross
      contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001517"
      unitRef="USD">100000</us-gaap:HealthCareOrganizationHealthCareCostsGross>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001519"
      unitRef="USD">1225000</us-gaap:PaymentsForRoyalties>
    <LIXT:RoyatiesPercentage
      contextRef="From2024-02-232024-02-23_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact001521"
      unitRef="Pure">0.05</LIXT:RoyatiesPercentage>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact001523"
      unitRef="USD">75643</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact001525"
      unitRef="USD">75643</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact001527"
      unitRef="USD">1795000</us-gaap:OtherCommitment>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact001529"
      unitRef="USD">9109</us-gaap:ShareBasedCompensation>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember"
      decimals="0"
      id="Fact001531"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2024-01-012024-12-31_custom_NDAConsultingCorpMember"
      decimals="0"
      id="Fact001533"
      unitRef="USD">12000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2023-01-012023-12-31_custom_NDAConsultingCorpMember"
      decimals="0"
      id="Fact001535"
      unitRef="USD">16000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="Fact001537"
      unitRef="USD">10000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ReimbursementExpense
      contextRef="From2024-01-012024-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="Fact001539"
      unitRef="USD">39200</LIXT:ReimbursementExpense>
    <LIXT:ReimbursementExpense
      contextRef="From2023-01-012023-12-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      id="Fact001541"
      unitRef="USD">120000</LIXT:ReimbursementExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2021-10-08_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact001543"
      unitRef="EUR">391000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-10-03_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact001545"
      unitRef="EUR">500000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-10-04_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact001547"
      unitRef="EUR">100000</us-gaap:OtherCommitment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2024-01-012024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact001549"
      unitRef="USD">210362</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact001551"
      unitRef="USD">226150</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact001553"
      unitRef="USD">695918</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-12-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      id="Fact001555"
      unitRef="USD">104000</us-gaap:OtherCommitment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2024-01-012024-12-31_custom_MRIGlobalMember"
      decimals="0"
      id="Fact001557"
      unitRef="USD">23308</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-12-31_custom_MRIGlobalMember"
      decimals="0"
      id="Fact001559"
      unitRef="USD">32307</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_MRIGlobalMember"
      decimals="0"
      id="Fact001561"
      unitRef="USD">340522</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-12-31_custom_MRIGlobalMember"
      decimals="0"
      id="Fact001563"
      unitRef="USD">118000</us-gaap:OtherCommitment>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001565">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zvgSFNEAHlnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_82A_zoBAb5jgYfWe"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
Other than as described below, there were no material subsequent events which affected, or could affect, the amounts or disclosures in
the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nasdaq
Compliance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 23, 2024, the Company received a letter from the Listing Qualifications Department (the &#x201c;Staff&#x201d;) of the Nasdaq Stock
Market LLC (&#x201c;Nasdaq&#x201d;) on August 19, 2024 indicating that the Company was not in compliance with the minimum net stockholders&#x2019;
equity requirement of $&lt;span id="xdx_903_eus-gaap--StockholdersEquity_iNI_di_c20240823__srt--RangeAxis__srt--MinimumMember_ziiVLvi279f4" title="Stock holders' equity"&gt;2,500,000&lt;/span&gt; for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &#x201c;Stockholders&#x2019;
Equity Requirement&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders&#x2019; Equity Requirement, which
outlined the Company&#x2019;s proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 21, 2024, the Staff provided notice (the &#x201c;Notice&#x201d;) to the Company that it had granted an extension through February
18, 2025 to regain compliance with the Stockholders&#x2019; Equity Requirement, which required that the Company complete its capital raising
initiatives and evidence compliance with the Stockholders&#x2019; Equity Requirement through filing a Current Report on Form 8-K with
the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) providing certain required information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of February 18, 2025, the Company had not gained compliance with the Stockholders&#x2019; Equity Requirement. Accordingly, on February
19, 2025, the Company received a Staff determination letter from the Staff stating that the Company did not meet the terms of the extension
because it did not complete its proposed financing initiatives to regain compliance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company timely filed an appeal and requested a Hearing before a Nasdaq Hearings Panel (the &#x201c;Panel&#x201d;), which has been granted.
The Hearing request automatically stayed Nasdaq&#x2019;s delisting of the Company&#x2019;s common shares and warrants pending the Panel&#x2019;s
decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension through no
later than August 18, 2025. At the upcoming hearing, the Company will present its plan for regaining and sustaining compliance with the
Stockholders&#x2019; Equity Requirement for continued listing. However, there can be no assurances that the Hearings Panel will grant
the Company an extension of time to regain compliance, or that the Company will be able to regain compliance during any extension period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company intends to take reasonable measures available to regain compliance under Nasdaq&#x2019;s listing rules and to remain listed on
Nasdaq. However, there can be no assurances that the Company will ultimately regain compliance with the Stockholders&#x2019; Equity Rule,
or be able to maintain compliance with all other applicable requirements for continued listing on Nasdaq. If the Company does not regain
compliance with Nasdaq&#x2019;s continued listing requirements within the time period permitted by Nasdaq, then the Company&#x2019;s securities
will be delisted from Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Termination
of At-the-Market Sales Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;WallachBeth
Capital, LLC.&lt;/b&gt; Effective January 6, 2025, the Company entered into an At-the-Market Sales Agreement (the &#x201c;Sales Agreement&#x201d;)
with WallachBeth Capital, LLC (the &#x201c;Agent&#x201d;) pursuant to which the Company may offer and sell from time to time through the
Agent, acting as agent, shares of its common stock, $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_zLWWLbiydgya" title="Sale of stock, price per share"&gt;0.0001&lt;/span&gt; par value per share, having an aggregate offering price of up to $&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20250106__20250106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember__srt--RangeAxis__srt--MaximumMember_zPx8pQU8fwx8" title="Aggregate offering price"&gt;1,700,000&lt;/span&gt;,
subject to the terms and conditions of the Agreement. The issuance and sale, if any, of shares of common stock through the Agent under
the Sales Agreement was to be made pursuant to the Company&#x2019;s effective shelf registration statement on Form S-3 (File No. 333-278874)
(the &#x201c;Registration Statement&#x201d;) filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on April 23, 2024,
and declared effective on May 2, 2024.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
offering of shares of the Company&#x2019;s common stock pursuant to the Sales Agreement was scheduled to terminate upon the earliest of
(i) the sale of the maximum dollar amount of shares of common stock subject to the Sales Agreement, (ii) the termination of the Sales
Agreement by the Company or the Agent, and (iii) the expiration of the shelf registration statement on Form S-3 (File No. 333-278874)
on the third anniversary of the initial effective date of such registration statement. &lt;span id="xdx_90F_eus-gaap--SaleOfStockDescriptionOfTransaction_pid_c20250307__20250307__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_zGF1KYdEYA0g" title="Description of stock transaction"&gt;On March 7, 2025, the Company provided a notice
of termination of the Sales Agreement to the Agent, which, pursuant to the terms of the Sales Agreement, will become effective 10 days
after issuance, or March 18, 2025. No shares of common stock were sold under this Sales Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Sale
of Securities Pursuant to Securities Purchase Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 11, 2025, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain purchasers
named therein (the &#x201c;Purchasers&#x201d;), pursuant to which the Company agreed to issue and sell, (a) in a registered direct offering
(the &#x201c;Registered Offering&#x201d;), an aggregate of &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zh9s9g5sJ1ib" title="Number of shares issued"&gt;434,784&lt;/span&gt; shares (the &#x201c;Shares&#x201d;) of the Company&#x2019;s common stock,
par value $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zDoTMOUdUI4f" title="Sale of stock, price per share"&gt;0.0001&lt;/span&gt; per share (the &#x201c;Common Stock&#x201d;), at an offering price of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zD18FKAYQFy8" title="Sale of stock, price per share"&gt;2.415&lt;/span&gt; per share, and (b) in a concurrent private
placement (the &#x201c;Private Offering&#x201d;), warrants (the &#x201c;Common Stock Warrants&#x201d;) to purchase an aggregate of &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzki4rINDy5h" title="Number of warrants issued"&gt;434,784&lt;/span&gt;
shares of Common Stock. The Common Stock Warrants were immediately exercisable for a term of &lt;span id="xdx_905_ecustom--ClassOfWarrantOrRightExercisableTerm_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zXGCQqEqDC1a" title="Class of warrant or right exercisable term"&gt;five years&lt;/span&gt; from issuance at an exercise
price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zm7giliVbI3g" title="Exercise price per share"&gt;2.29&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Common Stock Warrants and the shares of Common Stock underlying the Common Stock Warrants have not been registered under the Securities
Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), and have been issued in reliance on an exemption from the registration requirements
of the Securities Act afforded by Section 4(a)(2) thereof. The Common Stock Warrants and the shares of the Company&#x2019;s Common Stock
underlying the Common Stock Warrants may not be offered or sold in the United States in the absence of an effective registration statement
or exemption from applicable registration requirements. The Company has agreed to file a registration statement to cover the resale of
any share of Common Stock issuable upon the exercise of the Common Stock Warrants by April 4, 2025. The Registered Offering and Private
Offering are referred to herein as the &#x201c;Offering&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Offering resulted in gross proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PurchasersMember_zIxauiAYnN4l" title="Gross proceeds"&gt;1,050,003&lt;/span&gt; before deducting the placement agent&#x2019;s fees and related offering expenses. The
Shares were offered by the Company pursuant to a prospectus supplement to the Company&#x2019;s effective shelf registration statement
on Form S-3 (Registration No. 333-278874), which was initially filed with the Securities and Exchange Commission (the &#x201c;Commission&#x201d;)
on April 23, 2024, and was declared effective by the Commission on May 2, 2024. The Offering closed on February 13, 2025 (the &#x201c;Closing
Date&#x201d;). H.C. Wainwright &amp;amp; Co., LLC acted as the exclusive placement agent for the offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
a Fundamental Transaction (as defined in the Common Stock Warrants) occurs, then the successor entity will succeed to, and be substituted
for the Company, and may exercise every right and power that the Company may exercise and will assume all of the Company&#x2019;s obligations
under the Common Stock Warrants with the same effect as if such successor entity had been named in the Common Warrant itself. If holders
of shares of the Company&#x2019;s Common Stock are given a choice as to the securities, cash or property to be received in such a Fundamental
Transaction, then the holder of the Common Stock Warrants shall be given the same choice as to the consideration it would receive upon
any exercise of the Common Stock Warrants following such a Fundamental Transaction. Additionally, as more fully described in the Common
Stock Warrants, in the event of certain Fundamental Transactions, the holders of such Common Stock Warrants will be entitled to receive
cash consideration in an amount equal to the Black-Scholes value of the Common Stock Warrants on the date of consummation of such Fundamental
Transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date, the Company issued to the Placement Agent, or its designees, warrants (the &#x201c;Placement Agent&#x2019;s Warrants&#x201d;)
to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSOkkSC5AQS6" title="Number of warrants issued"&gt;32,609&lt;/span&gt; shares of Common Stock, which represents &lt;span id="xdx_909_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20250211__20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlWEAF5LECRi" title="Percentage of shares sold"&gt;7.5%&lt;/span&gt; of the Shares sold in the Registered Offering. The Placement Agent&#x2019;s
Warrants have an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zI6NXxN1Imbk" title="Exercise price per share"&gt;3.0188&lt;/span&gt; per share, and a term of five years form the commencement of the sales pursuant to the Offering
and otherwise have the same terms as the Common Stock Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Placement Agent&#x2019;s Warrants and the shares of Common Stock underlying the Placement Agent&#x2019;s Warrants have not been registered
under the Securities Act and have been issued in reliance on an exemption from the registration requirements of the Securities Act afforded
by Section 4(a)(2) thereof. The Placement Agent&#x2019;s Warrants and the shares of the Company&#x2019;s Common Stock underlying the Placement
Agent&#x2019;s Warrants may not be offered or sold in the United States in the absence of an effective registration statement or exemption
from applicable registration requirements. As soon as practicable (and in any event by April 4, 2025), the Company has agreed to file
a registration statement on Form S-1 providing for the resale by the Purchasers of the Common Warrant Shares issued and issuable upon
exercise of the Common Warrants. The Company is obligated to use commercially reasonable efforts to cause such registration statement
to become effective within 120 days following the Closing Date and to keep such registration statement effective at all times until no
Purchaser owns any Common Warrants or Common Warrant Shares issuable upon exercise thereof.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
Significant Developments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 11, 2025, the Company entered into Amendment No. 1 to the Collaboration Agreement between the Company and GEIS that relieved the
Company of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration
Agreement of approximately $&lt;span id="xdx_90D_eus-gaap--OtherCommitment_iI_uEUR_c20250311__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zQVvdMliOe9j" title="Aggregate commitments expected"&gt;3,095,000&lt;/span&gt; (see Note 8).&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-08-23_srt_MinimumMember"
      decimals="0"
      id="Fact001567"
      unitRef="USD">-2500000</us-gaap:StockholdersEquity>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-01-06_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember"
      decimals="INF"
      id="Fact001569"
      unitRef="USDPShares">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-01-062025-01-06_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001571"
      unitRef="USD">1700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockDescriptionOfTransaction
      contextRef="From2025-03-072025-03-07_us-gaap_SubsequentEventMember_custom_AtTheMarketSalesAgreementMember_custom_WallachBethCapitalLLCMember"
      id="Fact001573">On March 7, 2025, the Company provided a notice
of termination of the Sales Agreement to the Agent, which, pursuant to the terms of the Sales Agreement, will become effective 10 days
after issuance, or March 18, 2025. No shares of common stock were sold under this Sales Agreement.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001575"
      unitRef="Shares">434784</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001577"
      unitRef="USDPShares">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001579"
      unitRef="USDPShares">2.415</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001581"
      unitRef="Shares">434784</us-gaap:ClassOfWarrantOrRightOutstanding>
    <LIXT:ClassOfWarrantOrRightExercisableTerm
      contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember"
      id="Fact001583">P5Y</LIXT:ClassOfWarrantOrRightExercisableTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001585"
      unitRef="USDPShares">2.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PurchasersMember"
      decimals="INF"
      id="Fact001587"
      unitRef="USD">1050003</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001589"
      unitRef="Shares">32609</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2025-02-112025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001591"
      unitRef="Pure">0.075</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-11_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_PlacementAgentMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001593"
      unitRef="USDPShares">3.0188</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:OtherCommitment
      contextRef="AsOf2025-03-11_us-gaap_SubsequentEventMember_custom_DevelopmentCollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      id="Fact001595"
      unitRef="EUR">3095000</us-gaap:OtherCommitment>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl1400"
          xlink:label="xdx2ixbrl1400"
          xlink:type="locator"/>
        <link:footnote id="Footnote001435" xlink:label="Footnote001435" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1400"
          xlink:to="Footnote001435"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1420"
          xlink:label="xdx2ixbrl1420"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1420"
          xlink:to="Footnote001435"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1432"
          xlink:label="xdx2ixbrl1432"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1432"
          xlink:to="Footnote001435"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
